@prefix schema: <http://schema.org/> .
@prefix adms: <http://www.w3.org/ns/adms#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix org: <http://www.w3.org/ns/org#> .
@prefix xls2rdf: <https://xls2rdf.sparna.fr/vocabulary#> .
@prefix this: <http://www.limics.org/remiames_ontology/thesaurus_interactions#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .
@prefix skosthes: <http://purl.org/iso25964/skos-thes#> .
@prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> .
@prefix adm: <http://www.limics.org/remiames_ontology/administrations#> .
@prefix qb: <http://purl.org/linked-data/cube#> .
@prefix r: <http://www.limics.org/remiames_ontology#> .
@prefix dct: <http://purl.org/dc/terms/> .
@prefix doap: <http://usefulinc.com/ns/doap#> .
@prefix sh: <http://www.w3.org/ns/shacl#> .
@prefix rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#> .
@prefix dcat: <http://www.w3.org/ns/dcat#> .
@prefix euvoc: <http://publications.europa.eu/ontology/euvoc#> .
@prefix prov: <http://www.w3.org/ns/prov#> .
@prefix foaf: <http://xmlns.com/foaf/0.1/> .
@prefix dc: <http://purl.org/dc/elements/1.1/> .
@prefix skos: <http://www.w3.org/2004/02/skos/core#> .
@prefix skosxl: <http://www.w3.org/2008/05/skos-xl#> .

<http://www.limics.org/remiames_ontology/thesaurus_interactions> a owl:Ontology;
  owl:imports <http://www.limics.org/remiames_ontology>, <http://www.limics.org/remiames_ontology/classes_et_groupes_substances>,
    <http://www.limics.org/remiames_ontology/administrations> .

this:IAM_10454-1 a owl:Class;
  rdfs:label "BÊTA-BLOQUANTS (SAUF ESMOLOL) <-> LIDOCAINE"@fr;
  dct:identifier "IAM_10454";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b198656;
  r:natureDuRisque "Avec la lidocaïne utilisée par voie IV : augmentation des concentrations plasmatiques de lidocaïne avec possibilité d'effets indésirables neurologiques et cardiaques (diminution de la clairance hépatique de la lidocaïne)."@fr;
  r:conduiteATenir "Surveillance clinique, ECG et éventuellement contrôle des concentrations plasmatiques de lidocaïne pendant l'association et après l'arrêt du bêta-bloquant. Adaptation si besoin de la posologie de la lidocaïne."@fr;
  rdfs:comment "De nombreuses publications, souvent anciennes, évoquent une diminution de la clairance de la lidocaïne lorsque les bêta-bloquants sont pris conjointement, vraisemblablement en raison de la diminution du flux sanguin hépatique. De fait, ces publications ne"@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b198665, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b198656 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b198657 .

_:79f295ad32df4ce8a18a92539c6e8a3b198657 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b198658;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b198659 .

_:79f295ad32df4ce8a18a92539c6e8a3b198658 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10054 .

_:79f295ad32df4ce8a18a92539c6e8a3b198659 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b198660;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b198661 .

_:79f295ad32df4ce8a18a92539c6e8a3b198660 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10523 .

_:79f295ad32df4ce8a18a92539c6e8a3b198661 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b198662;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b198662 a owl:Restriction;
  owl:onProperty r:patient;
  owl:someValuesFrom _:79f295ad32df4ce8a18a92539c6e8a3b198663 .

_:79f295ad32df4ce8a18a92539c6e8a3b198663 a owl:Restriction;
  owl:onProperty r:diabete;
  owl:hasValue r:Oui .

_:79f295ad32df4ce8a18a92539c6e8a3b198665 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10454-XXX a owl:Class;
  rdfs:label "BÊTA-BLOQUANTS (SAUF ESMOLOL) <-> LIDOCAINE"@fr;
  dct:identifier "IAM_10454";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b198667;
  r:natureDuRisque "Avec la lidocaïne utilisée par voie IV : augmentation des concentrations plasmatiques de lidocaïne avec possibilité d'effets indésirables neurologiques et cardiaques (diminution de la clairance hépatique de la lidocaïne)."@fr;
  r:conduiteATenir "Surveillance clinique, ECG et éventuellement contrôle des concentrations plasmatiques de lidocaïne pendant l'association et après l'arrêt du bêta-bloquant. Adaptation si besoin de la posologie de la lidocaïne."@fr;
  rdfs:comment "De nombreuses publications, souvent anciennes, évoquent une diminution de la clairance de la lidocaïne lorsque les bêta-bloquants sont pris conjointement, vraisemblablement en raison de la diminution du flux sanguin hépatique. De fait, ces publications ne"@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b198682, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b198667 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b198668 .

_:79f295ad32df4ce8a18a92539c6e8a3b198668 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b198669;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b198670 .

_:79f295ad32df4ce8a18a92539c6e8a3b198669 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10054 .

_:79f295ad32df4ce8a18a92539c6e8a3b198670 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b198671;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b198672 .

_:79f295ad32df4ce8a18a92539c6e8a3b198671 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10523 .

_:79f295ad32df4ce8a18a92539c6e8a3b198672 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b198673;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b198673 a owl:Restriction;
  owl:onProperty r:patient;
  owl:someValuesFrom _:79f295ad32df4ce8a18a92539c6e8a3b198674 .

_:79f295ad32df4ce8a18a92539c6e8a3b198674 a owl:Class;
  owl:unionOf _:79f295ad32df4ce8a18a92539c6e8a3b198675 .

_:79f295ad32df4ce8a18a92539c6e8a3b198675 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b198676;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b198677 .

_:79f295ad32df4ce8a18a92539c6e8a3b198676 a owl:Restriction;
  owl:onProperty r:diabete;
  owl:hasValue r:Inconnu .

_:79f295ad32df4ce8a18a92539c6e8a3b198677 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b198678;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b198679 .

_:79f295ad32df4ce8a18a92539c6e8a3b198678 a owl:Restriction;
  owl:onProperty r:diabete;
  owl:hasValue r:Oui .

_:79f295ad32df4ce8a18a92539c6e8a3b198679 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b198680;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b198680 a owl:Restriction;
  owl:onProperty r:diabete;
  owl:hasValue r:Possible .

_:79f295ad32df4ce8a18a92539c6e8a3b198682 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10443-1 a owl:Class;
  rdfs:label "BENZODIAZÉPINES ET APPARENTÉS <-> CLOZAPINE"@fr;
  dct:identifier "IAM_10443";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b198684;
  r:natureDuRisque "Risque accru de collapsus avec arrêt respiratoire et / ou cardiaque."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b198692, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b198684 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b198685 .

_:79f295ad32df4ce8a18a92539c6e8a3b198685 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b198686;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b198687 .

_:79f295ad32df4ce8a18a92539c6e8a3b198686 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10049 .

_:79f295ad32df4ce8a18a92539c6e8a3b198687 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b198688;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b198689 .

_:79f295ad32df4ce8a18a92539c6e8a3b198688 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10220 .

_:79f295ad32df4ce8a18a92539c6e8a3b198689 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b198690;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b198690 a owl:Restriction;
  owl:onProperty r:administration;
  owl:minQualifiedCardinality "2"^^xsd:nonNegativeInteger;
  owl:onClass adm:Administration_GS_IAM_10220 .

_:79f295ad32df4ce8a18a92539c6e8a3b198692 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10444-1 a owl:Class;
  rdfs:label "BENZODIAZÉPINES ET APPARENTÉS <-> MORPHINIQUES"@fr;
  dct:identifier "IAM_10444";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b198694;
  r:natureDuRisque "Risque majoré de dépression respiratoire, pouvant être fatale en cas de surdosage."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b198700, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b198694 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b198695 .

_:79f295ad32df4ce8a18a92539c6e8a3b198695 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b198696;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b198697 .

_:79f295ad32df4ce8a18a92539c6e8a3b198696 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10049 .

_:79f295ad32df4ce8a18a92539c6e8a3b198697 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b198698;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b198698 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10109 .

_:79f295ad32df4ce8a18a92539c6e8a3b198700 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10445-1 a owl:Class;
  rdfs:label "BÊTA-2 MIMÉTIQUES <-> HALOTHANE"@fr;
  dct:identifier "IAM_10445";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b198702;
  r:natureDuRisque "En cas d'intervention obstétricale, majoration de l'inertie utérine avec risque hémorragique ; par ailleurs, troubles du rythme ventriculaires graves, par augmentation de la réactivité cardiaque."@fr;
  r:conduiteATenir "Interrompre le traitement par bêta-2 mimétiques si l'anesthésie doit se faire sous halothane."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b198708, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b198702 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b198703 .

_:79f295ad32df4ce8a18a92539c6e8a3b198703 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b198704;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b198705 .

_:79f295ad32df4ce8a18a92539c6e8a3b198704 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10052 .

_:79f295ad32df4ce8a18a92539c6e8a3b198705 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b198706;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b198706 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10427 .

_:79f295ad32df4ce8a18a92539c6e8a3b198708 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10446-1 a owl:Class;
  rdfs:label "BÊTA-2 MIMÉTIQUES <-> INSULINE"@fr;
  dct:identifier "IAM_10446";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b198710;
  r:natureDuRisque "Elévation de la glycémie par le bêta-2 mimétique."@fr;
  r:conduiteATenir "Renforcer la surveillance sanguine et urinaire."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b198716, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b198710 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b198711 .

_:79f295ad32df4ce8a18a92539c6e8a3b198711 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b198712;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b198713 .

_:79f295ad32df4ce8a18a92539c6e8a3b198712 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10052 .

_:79f295ad32df4ce8a18a92539c6e8a3b198713 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b198714;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b198714 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10105 .

_:79f295ad32df4ce8a18a92539c6e8a3b198716 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10447-1 a owl:Class;
  rdfs:label "BÊTA-2 MIMÉTIQUES <-> SULFAMIDES HYPOGLYCÉMIANTS"@fr;
  dct:identifier "IAM_10447";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b198718;
  r:natureDuRisque "Elévation de la glycémie par le bêta-2 mimétique."@fr;
  r:conduiteATenir "Renforcer la surveillance sanguine et urinaire. Passer éventuellement à l'insuline, le cas échéant."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b198724, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b198718 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b198719 .

_:79f295ad32df4ce8a18a92539c6e8a3b198719 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b198720;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b198721 .

_:79f295ad32df4ce8a18a92539c6e8a3b198720 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10052 .

_:79f295ad32df4ce8a18a92539c6e8a3b198721 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b198722;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b198722 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10147 .

_:79f295ad32df4ce8a18a92539c6e8a3b198724 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10448-1 a owl:Class;
  rdfs:label "BÊTA-BLOQUANTS (SAUF ESMOLOL) <-> DIHYDROPYRIDINES"@fr;
  dct:identifier "IAM_10448";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b198726;
  r:natureDuRisque "Hypotension, défaillance cardiaque chez les patients en insuffisance cardiaque latente ou non contrôlée (addition des effets inotropes négatifs). Le bêta-bloquant peut par ailleurs minimiser la réaction sympathique réflexe mise en jeu en cas de répercussi"@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b198732, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b198726 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b198727 .

_:79f295ad32df4ce8a18a92539c6e8a3b198727 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b198728;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b198729 .

_:79f295ad32df4ce8a18a92539c6e8a3b198728 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10054 .

_:79f295ad32df4ce8a18a92539c6e8a3b198729 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b198730;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b198730 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10062 .

_:79f295ad32df4ce8a18a92539c6e8a3b198732 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10449-1 a owl:Class;
  rdfs:label "BÊTA-BLOQUANTS (SAUF ESMOLOL) <-> DILTIAZEM"@fr;
  dct:identifier "IAM_10449";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b198734;
  r:natureDuRisque "Troubles de l'automatisme (bradycardie excessive, arrêt sinusal), troubles de la conduction sino-auriculaire et auriculo-ventriculaire et défaillance cardiaque."@fr;
  r:conduiteATenir "Une telle association ne doit se faire que sous surveillance clinique et ECG étroite, en particulier chez le sujet âgé ou en début de traitement."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b198740, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b198734 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b198735 .

_:79f295ad32df4ce8a18a92539c6e8a3b198735 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b198736;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b198737 .

_:79f295ad32df4ce8a18a92539c6e8a3b198736 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10054 .

_:79f295ad32df4ce8a18a92539c6e8a3b198737 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b198738;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b198738 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10290 .

_:79f295ad32df4ce8a18a92539c6e8a3b198740 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10450-1 a owl:Class;
  rdfs:label "BÊTA-BLOQUANTS (SAUF ESMOLOL) <-> DIPYRIDAMOLE"@fr;
  dct:identifier "IAM_10450";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b198742;
  r:natureDuRisque "Avec le dipyridamole par voie injectable : majoration de l'effet antihypertenseur."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b198748, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b198742 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b198743 .

_:79f295ad32df4ce8a18a92539c6e8a3b198743 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b198744;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b198745 .

_:79f295ad32df4ce8a18a92539c6e8a3b198744 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10054 .

_:79f295ad32df4ce8a18a92539c6e8a3b198745 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b198746;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b198746 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10297 .

_:79f295ad32df4ce8a18a92539c6e8a3b198748 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10451-1 a owl:Class;
  rdfs:label "BÊTA-BLOQUANTS (SAUF ESMOLOL) <-> GLINIDES"@fr;
  dct:identifier "IAM_10451";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b198750;
  r:natureDuRisque "Tous les bêta-bloquants peuvent masquer certains symptômes de l'hypoglycémie : palpitations et tachycardie."@fr;
  r:conduiteATenir "Prévenir le patient et renforcer, surtout en début de traitement, l'autosurveillance glycémique."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b198756, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b198750 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b198751 .

_:79f295ad32df4ce8a18a92539c6e8a3b198751 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b198752;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b198753 .

_:79f295ad32df4ce8a18a92539c6e8a3b198752 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10054 .

_:79f295ad32df4ce8a18a92539c6e8a3b198753 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b198754;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b198754 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10078 .

_:79f295ad32df4ce8a18a92539c6e8a3b198756 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10394-1 a owl:Class;
  rdfs:label "ATORVASTATINE <-> OMBITASVIR + PARITAPRÉVIR"@fr;
  dct:identifier "IAM_10394";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b198758;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de l'atorvastatine par diminution de son métabolisme hépatique par la bithérapie."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b198764, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b198758 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b198759 .

_:79f295ad32df4ce8a18a92539c6e8a3b198759 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b198760;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b198761 .

_:79f295ad32df4ce8a18a92539c6e8a3b198760 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10128 .

_:79f295ad32df4ce8a18a92539c6e8a3b198761 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b198762;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b198762 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10089 .

_:79f295ad32df4ce8a18a92539c6e8a3b198764 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10453-1 a owl:Class;
  rdfs:label "BÊTA-BLOQUANTS (SAUF ESMOLOL) <-> INSULINE"@fr;
  dct:identifier "IAM_10453";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b198766;
  r:natureDuRisque "Tous les bêtabloquants peuvent masquer certains symptômes de l'hypoglycémie : palpitations et tachycardie."@fr;
  r:conduiteATenir "Prévenir le patient et renforcer, surtout en début de traitement, l'autosurveillance glycémique."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b198772, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b198766 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b198767 .

_:79f295ad32df4ce8a18a92539c6e8a3b198767 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b198768;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b198769 .

_:79f295ad32df4ce8a18a92539c6e8a3b198768 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10054 .

_:79f295ad32df4ce8a18a92539c6e8a3b198769 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b198770;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b198770 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10458 .

_:79f295ad32df4ce8a18a92539c6e8a3b198772 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10440-1 a owl:Class;
  rdfs:label "BÉDAQUILINE <-> MILLEPERTUIS"@fr;
  dct:identifier "IAM_10440";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b198774;
  r:natureDuRisque "Risque de diminution des concentrations plasmatiques de bédaquiline par augmentation de son métabolisme par l’inducteur."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b198780, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b198774 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b198775 .

_:79f295ad32df4ce8a18a92539c6e8a3b198775 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b198776;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b198777 .

_:79f295ad32df4ce8a18a92539c6e8a3b198776 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10105 .

_:79f295ad32df4ce8a18a92539c6e8a3b198777 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b198778;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b198778 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10588 .

_:79f295ad32df4ce8a18a92539c6e8a3b198780 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10455-1 a owl:Class;
  rdfs:label "BÊTA-BLOQUANTS (SAUF ESMOLOL) <-> PROPAFENONE"@fr;
  dct:identifier "IAM_10455";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b198782;
  r:natureDuRisque "Troubles de la contractilité, de l'automatisme et de la conduction (suppression des mécanismes sympathiques compensateurs)."@fr;
  r:conduiteATenir "Surveillance clinique et ECG."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b198788, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b198782 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b198783 .

_:79f295ad32df4ce8a18a92539c6e8a3b198783 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b198784;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b198785 .

_:79f295ad32df4ce8a18a92539c6e8a3b198784 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10054 .

_:79f295ad32df4ce8a18a92539c6e8a3b198785 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b198786;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b198786 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10765 .

_:79f295ad32df4ce8a18a92539c6e8a3b198788 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10456-1 a owl:Class;
  rdfs:label "BÊTA-BLOQUANTS (SAUF ESMOLOL) <-> SULFAMIDES HYPOGLYCÉMIANTS"@fr;
  dct:identifier "IAM_10456";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b198790;
  r:natureDuRisque "Tous les bêta-bloquants peuvent masquer certains symptômes de l'hypoglycémie : palpitations et tachycardie."@fr;
  r:conduiteATenir "Prévenir le patient et renforcer, surtout en début de traitement, l'autosurveillance glycémique."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b198796, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b198790 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b198791 .

_:79f295ad32df4ce8a18a92539c6e8a3b198791 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b198792;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b198793 .

_:79f295ad32df4ce8a18a92539c6e8a3b198792 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10054 .

_:79f295ad32df4ce8a18a92539c6e8a3b198793 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b198794;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b198794 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10147 .

_:79f295ad32df4ce8a18a92539c6e8a3b198796 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10457-1 a owl:Class;
  rdfs:label "BÊTA-BLOQUANTS (SAUF ESMOLOL) <-> VERAPAMIL"@fr;
  dct:identifier "IAM_10457";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b198798;
  r:natureDuRisque "Troubles de l'automatisme (bradycardie excessive, arrêt sinusal), trouble de la conduction sino-auriculaire et auriculo-ventriculaire et défaillance cardiaque."@fr;
  r:conduiteATenir "Une telle association ne doit se faire que sous surveillance clinique et ECG étroite, en particulier chez le sujet âgé ou en début de traitement."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b198804, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b198798 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b198799 .

_:79f295ad32df4ce8a18a92539c6e8a3b198799 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b198800;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b198801 .

_:79f295ad32df4ce8a18a92539c6e8a3b198800 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10054 .

_:79f295ad32df4ce8a18a92539c6e8a3b198801 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b198802;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b198802 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10980 .

_:79f295ad32df4ce8a18a92539c6e8a3b198804 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10458-1 a owl:Class;
  rdfs:label "BÊTA-BLOQUANTS DANS L'INSUFFISANCE CARDIAQUE <-> DIGOXINE"@fr;
  dct:identifier "IAM_10458";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b198806;
  r:natureDuRisque "Troubles de l’automatisme (bradycardie, arrêt sinusal) et troubles de la conduction sino-auriculaire et auriculo-ventriculaire."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b198812, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b198806 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b198807 .

_:79f295ad32df4ce8a18a92539c6e8a3b198807 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b198808;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b198809 .

_:79f295ad32df4ce8a18a92539c6e8a3b198808 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10055 .

_:79f295ad32df4ce8a18a92539c6e8a3b198809 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b198810;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b198810 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10286 .

_:79f295ad32df4ce8a18a92539c6e8a3b198812 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10459-1 a owl:Class;
  rdfs:label "BÊTA-BLOQUANTS DANS L'INSUFFISANCE CARDIAQUE <-> DIHYDROPYRIDINES"@fr;
  dct:identifier "IAM_10459";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b198814;
  r:natureDuRisque "Hypotension, défaillance cardiaque chez les malades en insuffisance cardiaque latente ou non contrôlée (effet inotrope négatif in vitro des dihydropyridines plus ou moins marqué et susceptibles de s'additionner aux effets inotropes négatifs des bêta-bloqu"@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b198820, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b198814 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b198815 .

_:79f295ad32df4ce8a18a92539c6e8a3b198815 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b198816;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b198817 .

_:79f295ad32df4ce8a18a92539c6e8a3b198816 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10055 .

_:79f295ad32df4ce8a18a92539c6e8a3b198817 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b198818;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b198818 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10062 .

_:79f295ad32df4ce8a18a92539c6e8a3b198820 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10460-1 a owl:Class;
  rdfs:label "BÊTA-BLOQUANTS DANS L'INSUFFISANCE CARDIAQUE <-> DILTIAZEM"@fr;
  dct:identifier "IAM_10460";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b198822;
  r:natureDuRisque "Effet inotrope négatif avec risque de décompensation de l’insuffisance cardiaque, troubles de l'automatisme (bradycardie, arrêt sinusal) et troubles de la conduction sino-auriculaire et auriculo-ventriculaire."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b198828, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b198822 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b198823 .

_:79f295ad32df4ce8a18a92539c6e8a3b198823 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b198824;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b198825 .

_:79f295ad32df4ce8a18a92539c6e8a3b198824 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10055 .

_:79f295ad32df4ce8a18a92539c6e8a3b198825 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b198826;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b198826 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10290 .

_:79f295ad32df4ce8a18a92539c6e8a3b198828 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10461-1 a owl:Class;
  rdfs:label "BÊTA-BLOQUANTS DANS L'INSUFFISANCE CARDIAQUE <-> GLINIDES"@fr;
  dct:identifier "IAM_10461";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b198830;
  r:chapeau """A l’heure actuelle, 4 bêta-bloquants ont l'indication \"insuffisance cardiaque\" : le carvédilol, le bisoprolol, le métoprolol et le névibolol.
Les interactions médicamenteuses des bêta-bloquants, lorsqu’ils sont prescrits dans l’insuffisance cardiaque, pe"""@fr;
  r:natureDuRisque "Tous les bêtabloquants peuvent masquer certains symptômes de l'hypoglycémie : palpitations et tachycardie."@fr;
  r:conduiteATenir "Prévenir le patient et renforcer, surtout en début de traitement, l'autosurveillance glycémique."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b198836, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b198830 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b198831 .

_:79f295ad32df4ce8a18a92539c6e8a3b198831 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b198832;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b198833 .

_:79f295ad32df4ce8a18a92539c6e8a3b198832 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10055 .

_:79f295ad32df4ce8a18a92539c6e8a3b198833 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b198834;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b198834 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10078 .

_:79f295ad32df4ce8a18a92539c6e8a3b198836 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10462-1 a owl:Class;
  rdfs:label "BÊTA-BLOQUANTS DANS L'INSUFFISANCE CARDIAQUE <-> INSULINE"@fr;
  dct:identifier "IAM_10462";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b198838;
  r:natureDuRisque "Tous les bêtabloquants peuvent masquer certains symptômes de l'hypoglycémie : palpitations et tachycardie."@fr;
  r:conduiteATenir "Prévenir le patient et renforcer, surtout en début de traitement, l'autosurveillance glycémique."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b198844, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b198838 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b198839 .

_:79f295ad32df4ce8a18a92539c6e8a3b198839 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b198840;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b198841 .

_:79f295ad32df4ce8a18a92539c6e8a3b198840 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10055 .

_:79f295ad32df4ce8a18a92539c6e8a3b198841 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b198842;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b198842 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10458 .

_:79f295ad32df4ce8a18a92539c6e8a3b198844 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10463-1 a owl:Class;
  rdfs:label "BÊTA-BLOQUANTS DANS L'INSUFFISANCE CARDIAQUE <-> LIDOCAINE"@fr;
  dct:identifier "IAM_10463";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b198846;
  r:natureDuRisque "Effet inotrope négatif avec risque de décompensation cardiaque."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b198852, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b198846 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b198847 .

_:79f295ad32df4ce8a18a92539c6e8a3b198847 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b198848;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b198849 .

_:79f295ad32df4ce8a18a92539c6e8a3b198848 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10055 .

_:79f295ad32df4ce8a18a92539c6e8a3b198849 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b198850;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b198850 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10523 .

_:79f295ad32df4ce8a18a92539c6e8a3b198852 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10452-1 a owl:Class;
  rdfs:label "BÊTA-BLOQUANTS (SAUF ESMOLOL) <-> GLIPTINES"@fr;
  dct:identifier "IAM_10452";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b198854;
  r:natureDuRisque "Tous les bêtabloquants peuvent masquer certains symptômes de l'hypoglycémie : palpitations et tachycardie."@fr;
  r:conduiteATenir "Prévenir le patient et renforcer, surtout en début de traitement, l'autosurveillance glycémique."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b198860, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b198854 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b198855 .

_:79f295ad32df4ce8a18a92539c6e8a3b198855 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b198856;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b198857 .

_:79f295ad32df4ce8a18a92539c6e8a3b198856 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10054 .

_:79f295ad32df4ce8a18a92539c6e8a3b198857 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b198858;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b198858 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10079 .

_:79f295ad32df4ce8a18a92539c6e8a3b198860 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10430-1 a owl:Class;
  rdfs:label "AZITHROMYCINE <-> DIGOXINE"@fr;
  dct:identifier "IAM_10430";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b198862;
  r:natureDuRisque "Augmentation de la digoxinémie par augmentation de son absorption."@fr;
  r:conduiteATenir "Surveillance clinique et éventuellement de la digoxinémie pendant le traitement par l'azithromycine et après son arrêt."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b198868, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b198862 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b198863 .

_:79f295ad32df4ce8a18a92539c6e8a3b198863 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b198864;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b198865 .

_:79f295ad32df4ce8a18a92539c6e8a3b198864 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10100 .

_:79f295ad32df4ce8a18a92539c6e8a3b198865 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b198866;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b198866 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10286 .

_:79f295ad32df4ce8a18a92539c6e8a3b198868 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10521-1 a owl:Class;
  rdfs:label "CAFEINE <-> CIPROFLOXACINE"@fr;
  dct:identifier "IAM_10521";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b198870;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de caféine, par diminution de son métabolisme hépatique."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b198876, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b198870 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b198871 .

_:79f295ad32df4ce8a18a92539c6e8a3b198871 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b198872;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b198873 .

_:79f295ad32df4ce8a18a92539c6e8a3b198872 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10147 .

_:79f295ad32df4ce8a18a92539c6e8a3b198873 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b198874;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b198874 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10200 .

_:79f295ad32df4ce8a18a92539c6e8a3b198876 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10396-1 a owl:Class;
  rdfs:label "ATORVASTATINE <-> POSACONAZOLE"@fr;
  dct:identifier "IAM_10396";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b198878;
  r:natureDuRisque "Risque majoré d'effets indésirables (concentration-dépendants) à type de rhabdomyolyse (diminution du métabolisme hépatique de l’inhibiteur de l’HMG-CoA reductase)."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b198884, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b198878 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b198879 .

_:79f295ad32df4ce8a18a92539c6e8a3b198879 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b198880;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b198881 .

_:79f295ad32df4ce8a18a92539c6e8a3b198880 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10089 .

_:79f295ad32df4ce8a18a92539c6e8a3b198881 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b198882;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b198882 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10741 .

_:79f295ad32df4ce8a18a92539c6e8a3b198884 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10397-1 a owl:Class;
  rdfs:label "ATORVASTATINE <-> RANOLAZINE"@fr;
  dct:identifier "IAM_10397";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b198886;
  r:natureDuRisque "Risque majoré d'effets indésirables (concentration-dépendants) à type de rhabdomyolyse par inhibition du métabolisme de l'atorvastatine par la ranolazine."@fr;
  r:conduiteATenir "Utiliser des doses plus faibles d’hypocholestérolémiant ou une autre statine non concernée par ce type d’interaction."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b198892, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b198886 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b198887 .

_:79f295ad32df4ce8a18a92539c6e8a3b198887 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b198888;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b198889 .

_:79f295ad32df4ce8a18a92539c6e8a3b198888 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10089 .

_:79f295ad32df4ce8a18a92539c6e8a3b198889 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b198890;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b198890 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10786 .

_:79f295ad32df4ce8a18a92539c6e8a3b198892 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10398-1 a owl:Class;
  rdfs:label "ATORVASTATINE <-> RIFAMPICINE"@fr;
  dct:identifier "IAM_10398";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b198894;
  r:natureDuRisque "Diminution très importante des concentrations plasmatiques d'atorvastatine, par augmentation de son métabolisme hépatique par la rifampicine."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b198900, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b198894 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b198895 .

_:79f295ad32df4ce8a18a92539c6e8a3b198895 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b198896;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b198897 .

_:79f295ad32df4ce8a18a92539c6e8a3b198896 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10089 .

_:79f295ad32df4ce8a18a92539c6e8a3b198897 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b198898;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b198898 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:79f295ad32df4ce8a18a92539c6e8a3b198900 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10399-1 a owl:Class;
  rdfs:label "ATORVASTATINE <-> ROXITHROMYCINE"@fr;
  dct:identifier "IAM_10399";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b198902;
  r:natureDuRisque "Risque majoré d'effets indésirables (concentration-dépendants) à type de rhabdomyolyse."@fr;
  r:conduiteATenir "Utiliser des doses plus faibles d’hypocholestérolémiant."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b198908, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b198902 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b198903 .

_:79f295ad32df4ce8a18a92539c6e8a3b198903 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b198904;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b198905 .

_:79f295ad32df4ce8a18a92539c6e8a3b198904 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10089 .

_:79f295ad32df4ce8a18a92539c6e8a3b198905 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b198906;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b198906 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10817 .

_:79f295ad32df4ce8a18a92539c6e8a3b198908 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10400-1 a owl:Class;
  rdfs:label "ATORVASTATINE <-> STIRIPENTOL"@fr;
  dct:identifier "IAM_10400";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b198910;
  r:natureDuRisque "Risque majoré d’effets indésirables (dose-dépendants) à type de rhabdomyolyse (diminution du métabolisme hépatique de l’hypocholestérolémiant)."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b198916, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b198910 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b198911 .

_:79f295ad32df4ce8a18a92539c6e8a3b198911 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b198912;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b198913 .

_:79f295ad32df4ce8a18a92539c6e8a3b198912 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10089 .

_:79f295ad32df4ce8a18a92539c6e8a3b198913 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b198914;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b198914 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10859 .

_:79f295ad32df4ce8a18a92539c6e8a3b198916 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10401-1 a owl:Class;
  rdfs:label "ATORVASTATINE <-> TELAPREVIR"@fr;
  dct:identifier "IAM_10401";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b198918;
  r:natureDuRisque "Risque majoré d'effets indésirables (concentration-dépendants) à type de rhabdomyolyse (diminution du métabolisme hépatique de l'atorvastatine)."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b198924, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b198918 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b198919 .

_:79f295ad32df4ce8a18a92539c6e8a3b198919 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b198920;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b198921 .

_:79f295ad32df4ce8a18a92539c6e8a3b198920 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10089 .

_:79f295ad32df4ce8a18a92539c6e8a3b198921 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b198922;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b198922 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10887 .

_:79f295ad32df4ce8a18a92539c6e8a3b198924 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10402-1 a owl:Class;
  rdfs:label "ATORVASTATINE <-> TELITHROMYCINE"@fr;
  dct:identifier "IAM_10402";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b198926;
  r:natureDuRisque "Risque majoré d’effets indésirables (dose-dépendants) à type de rhabdomyolyse (diminution du métabolisme hépatique de l’hypocholestérolémiant)."@fr;
  rdfs:comment """La télithromycine est un inhibiteur du CYP3A4. Par conséquent, son administration est contre-indiquée avec des médicaments qui sont métabolisés par le CYP3A4 et qui ont un index thérapeutique étroit. 
L’association de la télithromycine avec la simvastatin"""@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b198932, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b198926 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b198927 .

_:79f295ad32df4ce8a18a92539c6e8a3b198927 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b198928;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b198929 .

_:79f295ad32df4ce8a18a92539c6e8a3b198928 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10089 .

_:79f295ad32df4ce8a18a92539c6e8a3b198929 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b198930;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b198930 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10889 .

_:79f295ad32df4ce8a18a92539c6e8a3b198932 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10412-1 a owl:Class;
  rdfs:label "AUTRES CORTICOÏDES, NOTAMMENT INHALÉS <-> VORICONAZOLE"@fr;
  dct:identifier "IAM_10412";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b198934;
  r:natureDuRisque """En cas d’utilisation prolongée par voie orale ou inhalée : 
augmentation des concentrations plasmatiques du corticoïde par diminution de son métabolisme hépatique par le voriconazole, avec risque d’apparition d’un syndrome cushingoïde voire d’une insuffis"""@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b198940, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b198934 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b198935 .

_:79f295ad32df4ce8a18a92539c6e8a3b198935 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b198936;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b198937 .

_:79f295ad32df4ce8a18a92539c6e8a3b198936 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10047 .

_:79f295ad32df4ce8a18a92539c6e8a3b198937 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b198938;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b198938 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10998 .

_:79f295ad32df4ce8a18a92539c6e8a3b198940 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10442-1 a owl:Class;
  rdfs:label "BENZODIAZÉPINES ET APPARENTÉS <-> BUPRENORPHINE"@fr;
  dct:identifier "IAM_10442";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b198942;
  r:natureDuRisque "Avec la buprénorphine utilisée en traitement de substitution : risque majoré de dépression respiratoire, pouvant être fatale."@fr;
  r:conduiteATenir "Evaluer attentivement le rapport bénéfice/risque de cette association. Informer le patient de la nécessité de respecter les doses prescrites."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b198948, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b198942 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b198943 .

_:79f295ad32df4ce8a18a92539c6e8a3b198943 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b198944;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b198945 .

_:79f295ad32df4ce8a18a92539c6e8a3b198944 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10049 .

_:79f295ad32df4ce8a18a92539c6e8a3b198945 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b198946;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b198946 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10139 .

_:79f295ad32df4ce8a18a92539c6e8a3b198948 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10429-1 a owl:Class;
  rdfs:label "AZITHROMYCINE <-> CICLOSPORINE"@fr;
  dct:identifier "IAM_10429";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b198950;
  r:natureDuRisque "Risque d'augmentation des concentrations sanguines de ciclosporine et de la créatininémie."@fr;
  r:conduiteATenir "Dosage des concentrations sanguines de la ciclosporine, contrôle de la fonction rénale et adaptation de la posologie pendant l'association et après l'arrêt du macrolide."@fr;
  rdfs:comment """En 2001, une publication évoquant une interaction entre azithromycine et ciclosporine n’avait pas été prise en compte car aucune autre observation n'allait dans ce sens.
Depuis, huit nouvelles observations ont été évaluées. Six d’entre elles sont bien doc"""@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b198956, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b198950 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b198951 .

_:79f295ad32df4ce8a18a92539c6e8a3b198951 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b198952;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b198953 .

_:79f295ad32df4ce8a18a92539c6e8a3b198952 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10100 .

_:79f295ad32df4ce8a18a92539c6e8a3b198953 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b198954;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b198954 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10193 .

_:79f295ad32df4ce8a18a92539c6e8a3b198956 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10441-1 a owl:Class;
  rdfs:label "BÉLATACEPT <-> VACCINS VIVANTS ATTÉNUÉS"@fr;
  dct:identifier "IAM_10441";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b198958;
  r:natureDuRisque "Risque de maladie vaccinale généralisée, éventuellement mortelle."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b198964, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b198958 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b198959 .

_:79f295ad32df4ce8a18a92539c6e8a3b198959 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b198960;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b198961 .

_:79f295ad32df4ce8a18a92539c6e8a3b198960 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10159 .

_:79f295ad32df4ce8a18a92539c6e8a3b198961 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b198962;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b198962 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10106 .

_:79f295ad32df4ce8a18a92539c6e8a3b198964 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10431-1 a owl:Class;
  rdfs:label "AZITHROMYCINE <-> IVABRADINE"@fr;
  dct:identifier "IAM_10431";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b198966;
  r:natureDuRisque "Risque majoré de troubles du rythme ventriculaires, notamment de torsades de pointes. De plus, augmentation des concentrations plasmatiques de l’ivabradine par diminution de son métabolisme par l’azithromycine."@fr;
  r:conduiteATenir "Surveillance clinique et ECG pendant l’association."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b198972, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b198966 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b198967 .

_:79f295ad32df4ce8a18a92539c6e8a3b198967 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b198968;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b198969 .

_:79f295ad32df4ce8a18a92539c6e8a3b198968 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10100 .

_:79f295ad32df4ce8a18a92539c6e8a3b198969 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b198970;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b198970 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10497 .

_:79f295ad32df4ce8a18a92539c6e8a3b198972 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10432-1 a owl:Class;
  rdfs:label "AZITHROMYCINE <-> SIMVASTATINE"@fr;
  dct:identifier "IAM_10432";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b198974;
  r:natureDuRisque "Risque majoré d'effets indésirables (concentration-dépendants) à type de rhabdomyolyse, par diminution du métabolisme hépatique de l'hypocholestérolémiant."@fr;
  r:conduiteATenir "Utiliser des doses plus faibles d’hypocholestérolémiant ou une autre statine non concernée par ce type d’interaction."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b198980, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b198974 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b198975 .

_:79f295ad32df4ce8a18a92539c6e8a3b198975 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b198976;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b198977 .

_:79f295ad32df4ce8a18a92539c6e8a3b198976 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10100 .

_:79f295ad32df4ce8a18a92539c6e8a3b198977 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b198978;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b198978 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10838 .

_:79f295ad32df4ce8a18a92539c6e8a3b198980 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10433-1 a owl:Class;
  rdfs:label "AZITHROMYCINE <-> SUBSTANCES SUSCEPTIBLES DE DONNER DES TORSADES DE POINTES"@fr;
  dct:identifier "IAM_10433";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b198982;
  r:natureDuRisque """Risque majoré de troubles du rythme ventriculaire, notamment de
torsades de pointes."""@fr;
  r:conduiteATenir "Surveillance clinique et électrocardiographique pendant l'association."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b198988, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b198982 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b198983 .

_:79f295ad32df4ce8a18a92539c6e8a3b198983 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b198984;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b198985 .

_:79f295ad32df4ce8a18a92539c6e8a3b198984 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10143 .

_:79f295ad32df4ce8a18a92539c6e8a3b198985 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b198986;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b198986 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10100 .

_:79f295ad32df4ce8a18a92539c6e8a3b198988 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10434-1 a owl:Class;
  rdfs:label "AZTREONAM <-> VALPROÏQUE (ACIDE) ET, PAR EXTRAPOLATION, VALPROMIDE"@fr;
  dct:identifier "IAM_10434";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b198990;
  r:natureDuRisque "Risque de survenue de crises convulsives, par diminution des concentrations plasmatiques de l'acide valproïque."@fr;
  r:conduiteATenir "Surveillance clinique, dosages plasmatiques et adaptation éventuelle de la posologie de l'anticonvulsivant pendant le traitement par l'anti-infectieux et après son arrêt."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b198996, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b198990 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b198991 .

_:79f295ad32df4ce8a18a92539c6e8a3b198991 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b198992;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b198993 .

_:79f295ad32df4ce8a18a92539c6e8a3b198992 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10160 .

_:79f295ad32df4ce8a18a92539c6e8a3b198993 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b198994;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b198994 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10101 .

_:79f295ad32df4ce8a18a92539c6e8a3b198996 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10435-1 a owl:Class;
  rdfs:label "BACLOFENE <-> LEVODOPA"@fr;
  dct:identifier "IAM_10435";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b198998;
  r:natureDuRisque "Risque d’aggravation du syndrome parkinsonien ou d’effets indésirables centraux (hallucinations visuelles, état confusionnel, céphalées)."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b199004, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b198998 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b198999 .

_:79f295ad32df4ce8a18a92539c6e8a3b198999 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199000;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b199001 .

_:79f295ad32df4ce8a18a92539c6e8a3b199000 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10102 .

_:79f295ad32df4ce8a18a92539c6e8a3b199001 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199002;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b199002 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10517 .

_:79f295ad32df4ce8a18a92539c6e8a3b199004 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10436-1 a owl:Class;
  rdfs:label "BARBITURIQUES <-> BENZODIAZÉPINES ET APPARENTÉS"@fr;
  dct:identifier "IAM_10436";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b199006;
  r:natureDuRisque "Risque majoré de dépression respiratoire, pouvant être fatale en cas de surdosage."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b199012, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b199006 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b199007 .

_:79f295ad32df4ce8a18a92539c6e8a3b199007 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199008;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b199009 .

_:79f295ad32df4ce8a18a92539c6e8a3b199008 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10048 .

_:79f295ad32df4ce8a18a92539c6e8a3b199009 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199010;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b199010 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10049 .

_:79f295ad32df4ce8a18a92539c6e8a3b199012 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10437-1 a owl:Class;
  rdfs:label "BARBITURIQUES <-> MORPHINIQUES"@fr;
  dct:identifier "IAM_10437";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b199014;
  r:natureDuRisque "Risque majoré de dépression respiratoire, pouvant être fatale en cas de surdosage."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b199020, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b199014 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b199015 .

_:79f295ad32df4ce8a18a92539c6e8a3b199015 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199016;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b199017 .

_:79f295ad32df4ce8a18a92539c6e8a3b199016 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10048 .

_:79f295ad32df4ce8a18a92539c6e8a3b199017 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199018;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b199018 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10109 .

_:79f295ad32df4ce8a18a92539c6e8a3b199020 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10438-1 a owl:Class;
  rdfs:label "BÉDAQUILINE <-> INDUCTEURS ENZYMATIQUES"@fr;
  dct:identifier "IAM_10438";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b199022;
  r:natureDuRisque "Diminution des concentrations plasmatiques de bédaquiline par augmentation de son métabolisme par l’inducteur."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b199028, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b199022 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b199023 .

_:79f295ad32df4ce8a18a92539c6e8a3b199023 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199024;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b199025 .

_:79f295ad32df4ce8a18a92539c6e8a3b199024 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10094 .

_:79f295ad32df4ce8a18a92539c6e8a3b199025 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199026;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b199026 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10105 .

_:79f295ad32df4ce8a18a92539c6e8a3b199028 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10439-1 a owl:Class;
  rdfs:label "BÉDAQUILINE <-> INHIBITEURS PUISSANTS DU CYP3A4"@fr;
  dct:identifier "IAM_10439";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b199030;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de bédaquiline par diminution de son métabolisme hépatique par l’inhibiteur."@fr;
  r:conduiteATenir "Si l’association est nécessaire, une surveillance ECG plus fréquente et une surveillance des transaminases sont recommandées."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b199036, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b199030 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b199031 .

_:79f295ad32df4ce8a18a92539c6e8a3b199031 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199032;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b199033 .

_:79f295ad32df4ce8a18a92539c6e8a3b199032 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10103 .

_:79f295ad32df4ce8a18a92539c6e8a3b199033 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199034;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b199034 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10105 .

_:79f295ad32df4ce8a18a92539c6e8a3b199036 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10466-1 a owl:Class;
  rdfs:label "BÊTA-BLOQUANTS DANS L'INSUFFISANCE CARDIAQUE <-> SULFAMIDES HYPOGLYCÉMIANTS"@fr;
  dct:identifier "IAM_10466";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b199038;
  r:natureDuRisque "Tous les bêta-bloquants peuvent masquer certains symptômes de l'hypoglycémie : palpitations et tachycardie."@fr;
  r:conduiteATenir "Prévenir le malade et renforcer, surtout au début du traitement, l'autosurveillance sanguine."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b199044, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b199038 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b199039 .

_:79f295ad32df4ce8a18a92539c6e8a3b199039 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199040;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b199041 .

_:79f295ad32df4ce8a18a92539c6e8a3b199040 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10055 .

_:79f295ad32df4ce8a18a92539c6e8a3b199041 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199042;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b199042 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10147 .

_:79f295ad32df4ce8a18a92539c6e8a3b199044 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10428-1 a owl:Class;
  rdfs:label "AVANAFIL <-> PAMPLEMOUSSE (JUS ET FRUIT)"@fr;
  dct:identifier "IAM_10428";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b199046;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de l'avanafil, avec risque d’hypotension."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b199052, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b199046 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b199047 .

_:79f295ad32df4ce8a18a92539c6e8a3b199047 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199048;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b199049 .

_:79f295ad32df4ce8a18a92539c6e8a3b199048 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10130 .

_:79f295ad32df4ce8a18a92539c6e8a3b199049 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199050;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b199050 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10093 .

_:79f295ad32df4ce8a18a92539c6e8a3b199052 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10499-1 a owl:Class;
  rdfs:label "BUPROPION <-> DESIPRAMINE"@fr;
  dct:identifier "IAM_10499";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b199054;
  r:natureDuRisque "Risque d'augmentation des effets indésirables de la désipramine par diminution de son métabolisme hépatique par le bupropion."@fr;
  r:conduiteATenir "Surveillance clinique. Si besoin, adaptation de la posologie de la désipramine pendant le traitement par le bupropion."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b199060, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b199054 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b199055 .

_:79f295ad32df4ce8a18a92539c6e8a3b199055 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199056;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b199057 .

_:79f295ad32df4ce8a18a92539c6e8a3b199056 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10140 .

_:79f295ad32df4ce8a18a92539c6e8a3b199057 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199058;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b199058 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10268 .

_:79f295ad32df4ce8a18a92539c6e8a3b199060 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10464-1 a owl:Class;
  rdfs:label "BÊTA-BLOQUANTS DANS L'INSUFFISANCE CARDIAQUE <-> NEUROLEPTIQUES"@fr;
  dct:identifier "IAM_10464";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b199062;
  r:natureDuRisque "Effet vasodilatateur et risque d'hypotension, notamment orthostatique (effet additif)."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b199068, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b199062 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b199063 .

_:79f295ad32df4ce8a18a92539c6e8a3b199063 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199064;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b199065 .

_:79f295ad32df4ce8a18a92539c6e8a3b199064 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10055 .

_:79f295ad32df4ce8a18a92539c6e8a3b199065 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199066;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b199066 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10124 .

_:79f295ad32df4ce8a18a92539c6e8a3b199068 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10408-1 a owl:Class;
  rdfs:label "AUTRES BRADYCARDISANTS <-> BRADYCARDISANTS"@fr;
  dct:identifier "IAM_10408";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b199070;
  r:natureDuRisque "Risque de bradycardie excessive (addition des effets)."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b199072, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b199070 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10051 .

_:79f295ad32df4ce8a18a92539c6e8a3b199072 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10491-1 a owl:Class;
  rdfs:label "BRADYCARDISANTS <-> FINGOLIMOD"@fr;
  dct:identifier "IAM_10491";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b199074;
  r:natureDuRisque "Potentialisation des effets bradycardisants pouvant avoir des conséquences fatales. Les bêta-bloquants sont d’autant plus à risque qu’ils empêchent les mécanismes de compensation adrénergique."@fr;
  r:conduiteATenir "Surveillance clinique et ECG continu pendant les 24 heures suivant la première dose."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b199080, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b199074 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b199075 .

_:79f295ad32df4ce8a18a92539c6e8a3b199075 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199076;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b199077 .

_:79f295ad32df4ce8a18a92539c6e8a3b199076 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10051 .

_:79f295ad32df4ce8a18a92539c6e8a3b199077 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199078;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b199078 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10379 .

_:79f295ad32df4ce8a18a92539c6e8a3b199080 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10492-1 a owl:Class;
  rdfs:label "BRADYCARDISANTS <-> SUBSTANCES SUSCEPTIBLES DE DONNER DES TORSADES DE POINTES"@fr;
  dct:identifier "IAM_10492";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b199082;
  r:chapeau "Ce trouble du rythme cardiaque grave peut être provoqué par un certain nombre de médicaments, antiarythmiques ou non. L'hypokaliémie (cf. médicaments hypokaliémiants) est un facteur favorisant, de même que la bradycardie (cf. médicaments bradycardisants)"@fr;
  r:natureDuRisque "Risque majoré de troubles du rythme ventriculaire, notamment de torsades de pointes."@fr;
  r:conduiteATenir "Surveillance clinique et électrocardiographique pendant l'association."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b199088, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b199082 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b199083 .

_:79f295ad32df4ce8a18a92539c6e8a3b199083 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199084;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b199085 .

_:79f295ad32df4ce8a18a92539c6e8a3b199084 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10051 .

_:79f295ad32df4ce8a18a92539c6e8a3b199085 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199086;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b199086 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10143 .

_:79f295ad32df4ce8a18a92539c6e8a3b199088 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10493-1 a owl:Class;
  rdfs:label "BRENTUXIMAB <-> INHIBITEURS PUISSANTS DU CYP3A4"@fr;
  dct:identifier "IAM_10493";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b199090;
  r:natureDuRisque "Augmentation des concentrations du métabolite actif du brentuximab, avec risque de neutropénie."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b199096, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b199090 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b199091 .

_:79f295ad32df4ce8a18a92539c6e8a3b199091 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199092;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b199093 .

_:79f295ad32df4ce8a18a92539c6e8a3b199092 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10103 .

_:79f295ad32df4ce8a18a92539c6e8a3b199093 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199094;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b199094 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10133 .

_:79f295ad32df4ce8a18a92539c6e8a3b199096 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10494-1 a owl:Class;
  rdfs:label "BUPRENORPHINE <-> FOSAMPRENAVIR"@fr;
  dct:identifier "IAM_10494";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b199098;
  r:natureDuRisque "Risque de majoration ou de diminution des effets de la A prendre en compte buprénorphine, à la fois par inhibition et accélération de son métabolisme par l’inhibiteur de protéases."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b199104, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b199098 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b199099 .

_:79f295ad32df4ce8a18a92539c6e8a3b199099 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199100;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b199101 .

_:79f295ad32df4ce8a18a92539c6e8a3b199100 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10139 .

_:79f295ad32df4ce8a18a92539c6e8a3b199101 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199102;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b199102 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10400 .

_:79f295ad32df4ce8a18a92539c6e8a3b199104 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10495-1 a owl:Class;
  rdfs:label "BUPRENORPHINE <-> INHIBITEURS DE PROTÉASES BOOSTÉS PAR RITONAVIR"@fr;
  dct:identifier "IAM_10495";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b199106;
  r:natureDuRisque "Risque de majoration ou de diminution des effets de la buprénorphine, à la fois par inhibition et accélération de son métabolisme par l’inhibiteur de protéases."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b199112, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b199106 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b199107 .

_:79f295ad32df4ce8a18a92539c6e8a3b199107 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199108;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b199109 .

_:79f295ad32df4ce8a18a92539c6e8a3b199108 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10100 .

_:79f295ad32df4ce8a18a92539c6e8a3b199109 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199110;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b199110 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10139 .

_:79f295ad32df4ce8a18a92539c6e8a3b199112 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10496-1 a owl:Class;
  rdfs:label "BUPRENORPHINE <-> ITRACONAZOLE"@fr;
  dct:identifier "IAM_10496";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b199114;
  r:natureDuRisque "Augmentation des concentrations de buprénorphine par diminution de son métabolisme hépatique, avec risque de majoration de ses effets indésirables."@fr;
  r:conduiteATenir "Surveillance clinique et adaptation de la posologie de la buprénorphine pendant le traitement par l'inhibiteur et, le cas échéant, après son arrêt."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b199120, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b199114 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b199115 .

_:79f295ad32df4ce8a18a92539c6e8a3b199115 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199116;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b199117 .

_:79f295ad32df4ce8a18a92539c6e8a3b199116 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10139 .

_:79f295ad32df4ce8a18a92539c6e8a3b199117 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199118;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b199118 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10496 .

_:79f295ad32df4ce8a18a92539c6e8a3b199120 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10497-1 a owl:Class;
  rdfs:label "BUPRENORPHINE <-> KETOCONAZOLE"@fr;
  dct:identifier "IAM_10497";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b199122;
  r:natureDuRisque "Augmentation des concentrations de buprénorphine par diminution de son métabolisme hépatique, avec risque de majoration de ses effets indésirables."@fr;
  r:conduiteATenir "Surveillance clinique et adaptation de la posologie de la buprénorphine pendant le traitement par l'inhibiteur et, le cas échéant, après son arrêt."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b199128, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b199122 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b199123 .

_:79f295ad32df4ce8a18a92539c6e8a3b199123 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199124;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b199125 .

_:79f295ad32df4ce8a18a92539c6e8a3b199124 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10139 .

_:79f295ad32df4ce8a18a92539c6e8a3b199125 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199126;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b199126 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10501 .

_:79f295ad32df4ce8a18a92539c6e8a3b199128 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10489-1 a owl:Class;
  rdfs:label "BOSENTAN <-> PROGESTATIFS NON CONTRACEPTIFS, ASSOCIÉS OU NON À UN ESTROGÈNE"@fr;
  dct:identifier "IAM_10489";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b199130;
  r:natureDuRisque "Risque de diminution de l’efficacité du progestatif."@fr;
  r:conduiteATenir "Surveillance clinique et adaptation éventuelle de la posologie du traitement hormonal pendant l’administration du bosentan et après son arrêt."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b199136, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b199130 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b199131 .

_:79f295ad32df4ce8a18a92539c6e8a3b199131 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199132;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b199133 .

_:79f295ad32df4ce8a18a92539c6e8a3b199132 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10135 .

_:79f295ad32df4ce8a18a92539c6e8a3b199133 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199134;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b199134 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10129 .

_:79f295ad32df4ce8a18a92539c6e8a3b199136 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10498-1 a owl:Class;
  rdfs:label "BUPROPION <-> CLOMIPRAMINE"@fr;
  dct:identifier "IAM_10498";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b199138;
  r:natureDuRisque "Risque d'augmentation des effets indésirables de la clomipramine par diminution de son métabolisme hépatique par le bupropion."@fr;
  r:conduiteATenir "Surveillance clinique. Si besoin, adaptation de la posologie de la clomipramine pendant le traitement par le bupropion."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b199144, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b199138 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b199139 .

_:79f295ad32df4ce8a18a92539c6e8a3b199139 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199140;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b199141 .

_:79f295ad32df4ce8a18a92539c6e8a3b199140 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10140 .

_:79f295ad32df4ce8a18a92539c6e8a3b199141 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199142;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b199142 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10212 .

_:79f295ad32df4ce8a18a92539c6e8a3b199144 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10488-1 a owl:Class;
  rdfs:label "BOSENTAN <-> PROGESTATIFS CONTRACEPTIFS"@fr;
  dct:identifier "IAM_10488";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b199146;
  r:natureDuRisque "Risque de diminution de l'efficacité du contraceptif hormonal par augmentation de son métabolisme hépatique."@fr;
  r:conduiteATenir "Utiliser une méthode contraceptive fiable, additionnelle ou alternative, pendant la durée de l'association et un cycle suivant."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b199152, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b199146 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b199147 .

_:79f295ad32df4ce8a18a92539c6e8a3b199147 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199148;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b199149 .

_:79f295ad32df4ce8a18a92539c6e8a3b199148 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10134 .

_:79f295ad32df4ce8a18a92539c6e8a3b199149 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199150;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b199150 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10129 .

_:79f295ad32df4ce8a18a92539c6e8a3b199152 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10511-1 a owl:Class;
  rdfs:label "BUSPIRONE <-> ERYTHROMYCINE"@fr;
  dct:identifier "IAM_10511";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b199154;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de la buspirone par diminution de son métabolisme hépatique, avec majoration importante de la sédation."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b199160, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b199154 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b199155 .

_:79f295ad32df4ce8a18a92539c6e8a3b199155 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199156;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b199157 .

_:79f295ad32df4ce8a18a92539c6e8a3b199156 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10141 .

_:79f295ad32df4ce8a18a92539c6e8a3b199157 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199158;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b199158 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10338 .

_:79f295ad32df4ce8a18a92539c6e8a3b199160 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10512-1 a owl:Class;
  rdfs:label "BUSPIRONE <-> ITRACONAZOLE"@fr;
  dct:identifier "IAM_10512";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b199162;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de la buspirone par diminution de son métabolisme hépatique, avec majoration importante de la sédation."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b199168, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b199162 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b199163 .

_:79f295ad32df4ce8a18a92539c6e8a3b199163 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199164;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b199165 .

_:79f295ad32df4ce8a18a92539c6e8a3b199164 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10141 .

_:79f295ad32df4ce8a18a92539c6e8a3b199165 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199166;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b199166 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10496 .

_:79f295ad32df4ce8a18a92539c6e8a3b199168 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10513-1 a owl:Class;
  rdfs:label "BUSPIRONE <-> PAMPLEMOUSSE (JUS ET FRUIT)"@fr;
  dct:identifier "IAM_10513";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b199170;
  r:natureDuRisque "Risque de majoration des effets indésirables de la buspirone par diminution de son métabolisme par le pamplemousse."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b199176, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b199170 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b199171 .

_:79f295ad32df4ce8a18a92539c6e8a3b199171 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199172;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b199173 .

_:79f295ad32df4ce8a18a92539c6e8a3b199172 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10130 .

_:79f295ad32df4ce8a18a92539c6e8a3b199173 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199174;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b199174 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10141 .

_:79f295ad32df4ce8a18a92539c6e8a3b199176 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10514-1 a owl:Class;
  rdfs:label "BUSPIRONE <-> RIFAMPICINE"@fr;
  dct:identifier "IAM_10514";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b199178;
  r:natureDuRisque "Diminution des concentrations plasmatiques de la buspirone par augmentation de son métabolisme hépatique par la rifampicine."@fr;
  r:conduiteATenir "Surveillance clinique et adaptation éventuelle de la posologie de la buspirone pendant le traitement par rifampicine et après son arrêt."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b199184, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b199178 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b199179 .

_:79f295ad32df4ce8a18a92539c6e8a3b199179 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199180;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b199181 .

_:79f295ad32df4ce8a18a92539c6e8a3b199180 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10141 .

_:79f295ad32df4ce8a18a92539c6e8a3b199181 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199182;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b199182 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:79f295ad32df4ce8a18a92539c6e8a3b199184 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10515-1 a owl:Class;
  rdfs:label "BUSPIRONE <-> VERAPAMIL"@fr;
  dct:identifier "IAM_10515";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b199186;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de la buspirone par diminution de son métabolisme hépatique par le vérapamil, avec augmentation de ses effets indésirables."@fr;
  r:conduiteATenir "Surveillance clinique et adaptation de la posologie de la buspirone si nécessaire."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b199192, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b199186 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b199187 .

_:79f295ad32df4ce8a18a92539c6e8a3b199187 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199188;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b199189 .

_:79f295ad32df4ce8a18a92539c6e8a3b199188 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10141 .

_:79f295ad32df4ce8a18a92539c6e8a3b199189 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199190;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b199190 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10980 .

_:79f295ad32df4ce8a18a92539c6e8a3b199192 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10516-1 a owl:Class;
  rdfs:label "BUSULFAN <-> DEFERASIROX"@fr;
  dct:identifier "IAM_10516";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b199194;
  r:natureDuRisque "Risque d’augmentation de la toxicité du busulfan par diminution de sa clairance par le déférasirox."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b199200, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b199194 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b199195 .

_:79f295ad32df4ce8a18a92539c6e8a3b199195 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199196;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b199197 .

_:79f295ad32df4ce8a18a92539c6e8a3b199196 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10142 .

_:79f295ad32df4ce8a18a92539c6e8a3b199197 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199198;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b199198 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10259 .

_:79f295ad32df4ce8a18a92539c6e8a3b199200 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10517-1 a owl:Class;
  rdfs:label "BUSULFAN <-> ITRACONAZOLE"@fr;
  dct:identifier "IAM_10517";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b199202;
  r:natureDuRisque "Avec le busulfan à fortes doses : doublement des concentrations de busulfan par l’itraconazole."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b199208, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b199202 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b199203 .

_:79f295ad32df4ce8a18a92539c6e8a3b199203 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199204;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b199205 .

_:79f295ad32df4ce8a18a92539c6e8a3b199204 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10142 .

_:79f295ad32df4ce8a18a92539c6e8a3b199205 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199206;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b199206 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10496 .

_:79f295ad32df4ce8a18a92539c6e8a3b199208 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10518-1 a owl:Class;
  rdfs:label "BUSULFAN <-> METRONIDAZOLE"@fr;
  dct:identifier "IAM_10518";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b199210;
  r:natureDuRisque "Avec le busulfan à fortes doses : doublement des concentrations de busulfan par le métronidazole."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b199216, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b199210 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b199211 .

_:79f295ad32df4ce8a18a92539c6e8a3b199211 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199212;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b199213 .

_:79f295ad32df4ce8a18a92539c6e8a3b199212 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10142 .

_:79f295ad32df4ce8a18a92539c6e8a3b199213 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199214;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b199214 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10580 .

_:79f295ad32df4ce8a18a92539c6e8a3b199216 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10519-1 a owl:Class;
  rdfs:label "CABAZITAXEL <-> INDUCTEURS ENZYMATIQUES"@fr;
  dct:identifier "IAM_10519";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b199218;
  r:natureDuRisque "Diminution des concentrations du cytotoxique par augmentation de son métabolisme par l’inducteur, avec risque de moindre efficacité."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b199224, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b199218 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b199219 .

_:79f295ad32df4ce8a18a92539c6e8a3b199219 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199220;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b199221 .

_:79f295ad32df4ce8a18a92539c6e8a3b199220 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10094 .

_:79f295ad32df4ce8a18a92539c6e8a3b199221 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199222;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b199222 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10143 .

_:79f295ad32df4ce8a18a92539c6e8a3b199224 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10714-1 a owl:Class;
  rdfs:label "DACLATASVIR <-> DEXAMETHASONE"@fr;
  dct:identifier "IAM_10714";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b199226;
  r:natureDuRisque "Avec la dexaméthasone à usage systémique, risque de diminution significative des concentrations plasmatiques de daclatasvir par augmentation de son métabolisme hépatique par l’inducteur."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b199232, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b199226 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b199227 .

_:79f295ad32df4ce8a18a92539c6e8a3b199227 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199228;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b199229 .

_:79f295ad32df4ce8a18a92539c6e8a3b199228 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10243 .

_:79f295ad32df4ce8a18a92539c6e8a3b199229 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199230;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b199230 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10272 .

_:79f295ad32df4ce8a18a92539c6e8a3b199232 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10501-1 a owl:Class;
  rdfs:label "BUPROPION <-> IMAO-B"@fr;
  dct:identifier "IAM_10501";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b199234;
  r:natureDuRisque "Risque de crises hypertensives."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b199240, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b199234 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b199235 .

_:79f295ad32df4ce8a18a92539c6e8a3b199235 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199236;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b199237 .

_:79f295ad32df4ce8a18a92539c6e8a3b199236 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10004 .

_:79f295ad32df4ce8a18a92539c6e8a3b199237 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199238;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b199238 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10140 .

_:79f295ad32df4ce8a18a92539c6e8a3b199240 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10477-1 a owl:Class;
  rdfs:label "BOCEPREVIR <-> PROGESTATIFS CONTRACEPTIFS"@fr;
  dct:identifier "IAM_10477";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b199242;
  r:natureDuRisque "En dehors de l’association éthinylestradiol (0,035mg)/noréthistérone (1mg), risque de diminution de l'efficacité contraceptive par augmentation du métabolisme hépatique du contraceptif hormonal par le bocéprévir"@fr;
  r:conduiteATenir "Utiliser une méthode contraceptive fiable, additionnelle ou alternative, pendant la durée de l'association."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b199248, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b199242 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b199243 .

_:79f295ad32df4ce8a18a92539c6e8a3b199243 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199244;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b199245 .

_:79f295ad32df4ce8a18a92539c6e8a3b199244 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10134 .

_:79f295ad32df4ce8a18a92539c6e8a3b199245 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199246;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b199246 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10126 .

_:79f295ad32df4ce8a18a92539c6e8a3b199248 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10393-1 a owl:Class;
  rdfs:label "ATORVASTATINE <-> KETOCONAZOLE"@fr;
  dct:identifier "IAM_10393";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b199250;
  r:natureDuRisque "Risque majoré d'effets indésirables (concentration-dépendants) à type de rhabdomyolyse (diminution du métabolisme hépatique de l'atorvastatine)."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b199256, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b199250 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b199251 .

_:79f295ad32df4ce8a18a92539c6e8a3b199251 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199252;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b199253 .

_:79f295ad32df4ce8a18a92539c6e8a3b199252 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10089 .

_:79f295ad32df4ce8a18a92539c6e8a3b199253 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199254;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b199254 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10501 .

_:79f295ad32df4ce8a18a92539c6e8a3b199256 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10467-1 a owl:Class;
  rdfs:label "BÊTA-BLOQUANTS DANS L'INSUFFISANCE CARDIAQUE <-> VERAPAMIL"@fr;
  dct:identifier "IAM_10467";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b199258;
  r:natureDuRisque "Effet inotrope négatif avec risque de décompensation de l’insuffisance cardiaque, troubles de l'automatisme (bradycardie, arrêt sinusal) et troubles de la conduction sino-auriculaire et auriculo-ventriculaire."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b199264, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b199258 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b199259 .

_:79f295ad32df4ce8a18a92539c6e8a3b199259 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199260;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b199261 .

_:79f295ad32df4ce8a18a92539c6e8a3b199260 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10055 .

_:79f295ad32df4ce8a18a92539c6e8a3b199261 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199262;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b199262 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10980 .

_:79f295ad32df4ce8a18a92539c6e8a3b199264 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10468-1 a owl:Class;
  rdfs:label "BISPHOSPHONATES <-> CALCIUM"@fr;
  dct:identifier "IAM_10468";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b199266;
  r:natureDuRisque "Pour les sels de calcium administrés par voie orale : diminution de l'absorption digestive des bisphosphonates."@fr;
  r:conduiteATenir "Prendre les sels de calcium et antiacides à distance des bisphosphonates (de 30 minutes au minimum à plus de 2 heures, si possible, selon le bisphosphonate)."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b199272, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b199266 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b199267 .

_:79f295ad32df4ce8a18a92539c6e8a3b199267 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199268;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b199269 .

_:79f295ad32df4ce8a18a92539c6e8a3b199268 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10050 .

_:79f295ad32df4ce8a18a92539c6e8a3b199269 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199270;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b199270 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10150 .

_:79f295ad32df4ce8a18a92539c6e8a3b199272 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10469-1 a owl:Class;
  rdfs:label "BISPHOSPHONATES <-> FER"@fr;
  dct:identifier "IAM_10469";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b199274;
  r:natureDuRisque "Pour les sels de fer administrés par voie orale : diminution de l'absorption digestive des bisphosphonates."@fr;
  r:conduiteATenir "Prendre les sels de fer à distance des bisphosphonates (de 30 minutes au minimum à plus de 2 heures, si possible, selon le bisphosphonate)."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b199280, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b199274 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b199275 .

_:79f295ad32df4ce8a18a92539c6e8a3b199275 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199276;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b199277 .

_:79f295ad32df4ce8a18a92539c6e8a3b199276 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10050 .

_:79f295ad32df4ce8a18a92539c6e8a3b199277 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199278;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b199278 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10375 .

_:79f295ad32df4ce8a18a92539c6e8a3b199280 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10470-1 a owl:Class;
  rdfs:label "BLEOMYCINE <-> BRENTUXIMAB"@fr;
  dct:identifier "IAM_10470";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b199282;
  r:natureDuRisque "Risque de majoration de la toxicité pulmonaire."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b199288, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b199282 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b199283 .

_:79f295ad32df4ce8a18a92539c6e8a3b199283 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199284;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b199285 .

_:79f295ad32df4ce8a18a92539c6e8a3b199284 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10123 .

_:79f295ad32df4ce8a18a92539c6e8a3b199285 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199286;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b199286 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10133 .

_:79f295ad32df4ce8a18a92539c6e8a3b199288 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10471-1 a owl:Class;
  rdfs:label "BOCEPREVIR <-> DROSPIRENONE"@fr;
  dct:identifier "IAM_10471";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b199290;
  r:natureDuRisque "Augmentation de plus du double des concentrations de drospérinone en association avec le bocéprévir."@fr;
  r:conduiteATenir "Préférer une contraception avec un autre progestatif, a fortiori en cas d’hyperkaliémie."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b199296, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b199290 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b199291 .

_:79f295ad32df4ce8a18a92539c6e8a3b199291 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199292;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b199293 .

_:79f295ad32df4ce8a18a92539c6e8a3b199292 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10126 .

_:79f295ad32df4ce8a18a92539c6e8a3b199293 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199294;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b199294 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10313 .

_:79f295ad32df4ce8a18a92539c6e8a3b199296 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10472-1 a owl:Class;
  rdfs:label "BOCEPREVIR <-> ESTROGÈNES NON CONTRACEPTIFS"@fr;
  dct:identifier "IAM_10472";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b199298;
  r:natureDuRisque "Diminution de l'efficacité de l'estrogène."@fr;
  r:conduiteATenir "Surveillance clinique et adaptation éventuelle de la posologie du traitement hormonal pendant l'administration du bocéprévir."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b199304, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b199298 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b199299 .

_:79f295ad32df4ce8a18a92539c6e8a3b199299 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199300;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b199301 .

_:79f295ad32df4ce8a18a92539c6e8a3b199300 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10072 .

_:79f295ad32df4ce8a18a92539c6e8a3b199301 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199302;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b199302 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10126 .

_:79f295ad32df4ce8a18a92539c6e8a3b199304 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10473-1 a owl:Class;
  rdfs:label "BOCEPREVIR <-> ESTROPROGESTATIFS CONTRACEPTIFS"@fr;
  dct:identifier "IAM_10473";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b199306;
  r:natureDuRisque "En dehors de l’association éthinylestradiol (0,035mg)/noréthistérone (1mg), risque de diminution de l'efficacité contraceptive par augmentation du métabolisme hépatique du contraceptif hormonal par le bocéprévir"@fr;
  r:conduiteATenir "Utiliser une méthode contraceptive fiable, additionnelle ou alternative, pendant la durée de l'association."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b199312, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b199306 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b199307 .

_:79f295ad32df4ce8a18a92539c6e8a3b199307 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199308;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b199309 .

_:79f295ad32df4ce8a18a92539c6e8a3b199308 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10073 .

_:79f295ad32df4ce8a18a92539c6e8a3b199309 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199310;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b199310 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10126 .

_:79f295ad32df4ce8a18a92539c6e8a3b199312 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10474-1 a owl:Class;
  rdfs:label "BOCEPREVIR <-> IMMUNOSUPPRESSEURS"@fr;
  dct:identifier "IAM_10474";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b199314;
  r:natureDuRisque "Augmentation des concentrations sanguines de l'immunosuppresseur (notable pour la ciclosporine, extrêmement importante pour le tacrolimus)."@fr;
  r:conduiteATenir "Dosage des concentrations sanguines de l'immunosuppresseur, contrôle de la fonction rénale et adaptation de sa posologie pendant l'association et après son arrêt."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b199320, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b199314 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b199315 .

_:79f295ad32df4ce8a18a92539c6e8a3b199315 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199316;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b199317 .

_:79f295ad32df4ce8a18a92539c6e8a3b199316 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10093 .

_:79f295ad32df4ce8a18a92539c6e8a3b199317 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199318;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b199318 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10126 .

_:79f295ad32df4ce8a18a92539c6e8a3b199320 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10490-1 a owl:Class;
  rdfs:label "BOSENTAN <-> RIFAMPICINE"@fr;
  dct:identifier "IAM_10490";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b199322;
  r:natureDuRisque "Risque de diminution, importante pour la rifampicine, des concentrations plasmatiques de bosentan."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b199328, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b199322 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b199323 .

_:79f295ad32df4ce8a18a92539c6e8a3b199323 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199324;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b199325 .

_:79f295ad32df4ce8a18a92539c6e8a3b199324 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10129 .

_:79f295ad32df4ce8a18a92539c6e8a3b199325 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199326;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b199326 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:79f295ad32df4ce8a18a92539c6e8a3b199328 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10476-1 a owl:Class;
  rdfs:label "BOCEPREVIR <-> METHADONE"@fr;
  dct:identifier "IAM_10476";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b199330;
  r:natureDuRisque "Diminution des concentrations plasmatiques de méthadone, avec risque d'apparition d'un syndrome de sevrage, par augmentation de son métabolisme hépatique par le bocéprévir."@fr;
  r:conduiteATenir "Surveillance clinique régulière et adaptation éventuelle de la posologie de méthadone."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b199336, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b199330 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b199331 .

_:79f295ad32df4ce8a18a92539c6e8a3b199331 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199332;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b199333 .

_:79f295ad32df4ce8a18a92539c6e8a3b199332 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10126 .

_:79f295ad32df4ce8a18a92539c6e8a3b199333 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199334;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b199334 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10567 .

_:79f295ad32df4ce8a18a92539c6e8a3b199336 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10465-1 a owl:Class;
  rdfs:label "BÊTA-BLOQUANTS DANS L'INSUFFISANCE CARDIAQUE <-> SUBSTANCES SUSCEPTIBLES DE DONNER DES TORSADES DE POINTES"@fr;
  dct:identifier "IAM_10465";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b199338;
  r:chapeau "Ce trouble du rythme cardiaque grave peut être provoqué par un certain nombre de médicaments, antiarythmiques ou non. L'hypokaliémie (cf. médicaments hypokaliémiants) est un facteur favorisant, de même que la bradycardie (cf. médicaments bradycardisants)"@fr;
  r:natureDuRisque "Risque majoré de troubles du rythme ventriculaire, notamment de torsades de pointes."@fr;
  r:conduiteATenir "Surveillance clinique et électrocardiographique."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b199344, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b199338 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b199339 .

_:79f295ad32df4ce8a18a92539c6e8a3b199339 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199340;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b199341 .

_:79f295ad32df4ce8a18a92539c6e8a3b199340 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10055 .

_:79f295ad32df4ce8a18a92539c6e8a3b199341 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199342;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b199342 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10143 .

_:79f295ad32df4ce8a18a92539c6e8a3b199344 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10478-1 a owl:Class;
  rdfs:label "BOCEPREVIR <-> RIFAMPICINE"@fr;
  dct:identifier "IAM_10478";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b199346;
  r:natureDuRisque "Risque de diminution des concentrations plasmatiques de bocéprévir."@fr;
  r:conduiteATenir "Si l’association ne peut être évitée, surveillance clinique et biologique régulière, notamment en début d'association."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b199352, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b199346 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b199347 .

_:79f295ad32df4ce8a18a92539c6e8a3b199347 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199348;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b199349 .

_:79f295ad32df4ce8a18a92539c6e8a3b199348 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10126 .

_:79f295ad32df4ce8a18a92539c6e8a3b199349 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199350;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b199350 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:79f295ad32df4ce8a18a92539c6e8a3b199352 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10479-1 a owl:Class;
  rdfs:label "BOCEPREVIR <-> SIMVASTATINE"@fr;
  dct:identifier "IAM_10479";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b199354;
  r:natureDuRisque "Risque majoré d'effets indésirables (concentration-dépendants) à type de rhabdomyolyse par diminution du métabolisme de la simvastatine."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b199360, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b199354 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b199355 .

_:79f295ad32df4ce8a18a92539c6e8a3b199355 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199356;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b199357 .

_:79f295ad32df4ce8a18a92539c6e8a3b199356 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10126 .

_:79f295ad32df4ce8a18a92539c6e8a3b199357 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199358;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b199358 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10838 .

_:79f295ad32df4ce8a18a92539c6e8a3b199360 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10480-1 a owl:Class;
  rdfs:label "BOCEPREVIR <-> TÉNOFOVIR ALAFÉNAMIDE"@fr;
  dct:identifier "IAM_10480";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b199362;
  r:natureDuRisque "Risque de diminution de l'efficacité du ténofovir alafénamide par diminution de son activité intracellulaire par le bocéprevir."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b199368, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b199362 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b199363 .

_:79f295ad32df4ce8a18a92539c6e8a3b199363 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199364;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b199365 .

_:79f295ad32df4ce8a18a92539c6e8a3b199364 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10126 .

_:79f295ad32df4ce8a18a92539c6e8a3b199365 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199366;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b199366 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10895 .

_:79f295ad32df4ce8a18a92539c6e8a3b199368 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10481-1 a owl:Class;
  rdfs:label "BORTEZOMIB <-> INDUCTEURS ENZYMATIQUES"@fr;
  dct:identifier "IAM_10481";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b199370;
  r:natureDuRisque "Diminution des concentrations du cytotoxique par augmentation de son métabolisme par l’inducteur, avec risque de moindre efficacité."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b199376, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b199370 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b199371 .

_:79f295ad32df4ce8a18a92539c6e8a3b199371 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199372;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b199373 .

_:79f295ad32df4ce8a18a92539c6e8a3b199372 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10094 .

_:79f295ad32df4ce8a18a92539c6e8a3b199373 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199374;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b199374 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10128 .

_:79f295ad32df4ce8a18a92539c6e8a3b199376 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10482-1 a owl:Class;
  rdfs:label "BORTEZOMIB <-> INHIBITEURS PUISSANTS DU CYP3A4"@fr;
  dct:identifier "IAM_10482";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b199378;
  r:natureDuRisque "Risque de majoration des effets indésirables, notamment neurologiques, du bortezomib par diminution de son métabolisme."@fr;
  r:conduiteATenir "Surveillance clinique et adaptation éventuelle de la posologie du bortezomib pendant la durée du traitement par l’inhibiteur enzymatique."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b199384, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b199378 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b199379 .

_:79f295ad32df4ce8a18a92539c6e8a3b199379 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199380;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b199381 .

_:79f295ad32df4ce8a18a92539c6e8a3b199380 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10103 .

_:79f295ad32df4ce8a18a92539c6e8a3b199381 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199382;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b199382 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10128 .

_:79f295ad32df4ce8a18a92539c6e8a3b199384 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10483-1 a owl:Class;
  rdfs:label "BOSENTAN <-> CICLOSPORINE"@fr;
  dct:identifier "IAM_10483";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b199386;
  r:natureDuRisque "Diminution importante des concentrations sanguines de la ciclosporine et augmentation des concentrations plasmatiques de bosentan."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b199392, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b199386 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b199387 .

_:79f295ad32df4ce8a18a92539c6e8a3b199387 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199388;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b199389 .

_:79f295ad32df4ce8a18a92539c6e8a3b199388 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10129 .

_:79f295ad32df4ce8a18a92539c6e8a3b199389 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199390;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b199390 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10193 .

_:79f295ad32df4ce8a18a92539c6e8a3b199392 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10484-1 a owl:Class;
  rdfs:label "BOSENTAN <-> CYPROTERONE"@fr;
  dct:identifier "IAM_10484";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b199394;
  r:natureDuRisque "Risque de diminution de l'efficacité de la cyprotérone."@fr;
  r:conduiteATenir """Dans ses indications comme anti-androgène, surveillance clinique et si possible adaptation de la posologie de la cyprotérone pendant l'administration avec le bosentan et après son arrêt.

Dans son utilisation comme contraceptif hormonal, utiliser une méth"""@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b199400, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b199394 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b199395 .

_:79f295ad32df4ce8a18a92539c6e8a3b199395 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199396;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b199397 .

_:79f295ad32df4ce8a18a92539c6e8a3b199396 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10129 .

_:79f295ad32df4ce8a18a92539c6e8a3b199397 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199398;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b199398 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10238 .

_:79f295ad32df4ce8a18a92539c6e8a3b199400 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10485-1 a owl:Class;
  rdfs:label "BOSENTAN <-> ESTROPROGESTATIFS CONTRACEPTIFS"@fr;
  dct:identifier "IAM_10485";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b199402;
  r:natureDuRisque "Risque de diminution de l'efficacité contraceptive par augmentation du métabolisme hépatique du contraceptif hormonal."@fr;
  r:conduiteATenir "Utiliser une méthode contraceptive fiable, additionnelle ou alternative, pendant la durée de l'association et un cycle suivant."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b199408, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b199402 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b199403 .

_:79f295ad32df4ce8a18a92539c6e8a3b199403 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199404;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b199405 .

_:79f295ad32df4ce8a18a92539c6e8a3b199404 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10073 .

_:79f295ad32df4ce8a18a92539c6e8a3b199405 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199406;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b199406 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10129 .

_:79f295ad32df4ce8a18a92539c6e8a3b199408 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10486-1 a owl:Class;
  rdfs:label "BOSENTAN <-> GLIBENCLAMIDE"@fr;
  dct:identifier "IAM_10486";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b199410;
  r:natureDuRisque "Risque de moindre efficacité du glibenclamide par diminution de ses concentrations plasmatiques, en raison de l'effet inducteur du bosentan. Par ailleurs, des cas d'hépatotoxicité ont été rapportés lors de l'association."@fr;
  r:conduiteATenir "Surveillance de la glycémie, adaptation du traitement si besoin, et surveillance des constantes biologiques hépatiques."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b199416, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b199410 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b199411 .

_:79f295ad32df4ce8a18a92539c6e8a3b199411 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199412;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b199413 .

_:79f295ad32df4ce8a18a92539c6e8a3b199412 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10129 .

_:79f295ad32df4ce8a18a92539c6e8a3b199413 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199414;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b199414 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10414 .

_:79f295ad32df4ce8a18a92539c6e8a3b199416 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10487-1 a owl:Class;
  rdfs:label "BOSENTAN <-> INHIBITEURS PUISSANTS DU CYP3A4"@fr;
  dct:identifier "IAM_10487";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b199418;
  r:natureDuRisque "Risque majoré des effets indésirables du bosentan, notamment d’atteintes hépatiques, par diminution de son métabolisme par l'inhibiteur."@fr;
  r:conduiteATenir "Surveillance clinique et biologique pendant l’association."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b199424, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b199418 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b199419 .

_:79f295ad32df4ce8a18a92539c6e8a3b199419 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199420;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b199421 .

_:79f295ad32df4ce8a18a92539c6e8a3b199420 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10103 .

_:79f295ad32df4ce8a18a92539c6e8a3b199421 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199422;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b199422 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10129 .

_:79f295ad32df4ce8a18a92539c6e8a3b199424 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10475-1 a owl:Class;
  rdfs:label "BOCEPREVIR <-> INHIBITEURS DE PROTÉASES BOOSTÉS PAR RITONAVIR"@fr;
  dct:identifier "IAM_10475";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b199426;
  r:natureDuRisque "Diminution des concentrations du bocéprévir et du lopinavir (ou darunavir ou fosamprénavir), avec risque d’échec thérapeutique."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b199432, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b199426 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b199427 .

_:79f295ad32df4ce8a18a92539c6e8a3b199427 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199428;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b199429 .

_:79f295ad32df4ce8a18a92539c6e8a3b199428 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10100 .

_:79f295ad32df4ce8a18a92539c6e8a3b199429 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199430;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b199430 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10126 .

_:79f295ad32df4ce8a18a92539c6e8a3b199432 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10321-1 a owl:Class;
  rdfs:label "ANTIVITAMINES K <-> CEFTRIAXONE"@fr;
  dct:identifier "IAM_10321";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b199434;
  r:chapeau """ANTI-INFECTIEUX ET INR
De nombreux cas d’augmentation de l’activité des antivitamines K ont été rapportés chez des patients recevant des antibiotiques. Le contexte infectieux ou inflammatoire marqué, l’âge et l’état général du patient apparaissent comme d"""@fr;
  r:natureDuRisque "Augmentation de l'effet de l'antivitamine K et du risque hémorragique."@fr;
  r:conduiteATenir "Contrôle plus fréquent de l'INR. Adaptation éventuelle de la posologie de l'antivitamine K pendant le traitement par la céphalosporine et après son arrêt."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b199440, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b199434 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b199435 .

_:79f295ad32df4ce8a18a92539c6e8a3b199435 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199436;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b199437 .

_:79f295ad32df4ce8a18a92539c6e8a3b199436 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10046 .

_:79f295ad32df4ce8a18a92539c6e8a3b199437 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199438;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b199438 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10172 .

_:79f295ad32df4ce8a18a92539c6e8a3b199440 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10311-1 a owl:Class;
  rdfs:label "ANTI-TNF ALPHA <-> CANAKINUMAB"@fr;
  dct:identifier "IAM_10311";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b199442;
  r:natureDuRisque "Risque de majoration des infections graves."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b199448, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b199442 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b199443 .

_:79f295ad32df4ce8a18a92539c6e8a3b199443 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199444;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b199445 .

_:79f295ad32df4ce8a18a92539c6e8a3b199444 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10021 .

_:79f295ad32df4ce8a18a92539c6e8a3b199445 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199446;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b199446 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10152 .

_:79f295ad32df4ce8a18a92539c6e8a3b199448 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10312-1 a owl:Class;
  rdfs:label "ANTI-TNF ALPHA <-> VACCINS VIVANTS ATTÉNUÉS"@fr;
  dct:identifier "IAM_10312";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b199450;
  r:natureDuRisque "Risque de maladie vaccinale généralisée éventuellement mortelle."@fr;
  r:conduiteATenir "Et pendant les 3 mois suivant l'arrêt du traitement."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b199456, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b199450 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b199451 .

_:79f295ad32df4ce8a18a92539c6e8a3b199451 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199452;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b199453 .

_:79f295ad32df4ce8a18a92539c6e8a3b199452 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10021 .

_:79f295ad32df4ce8a18a92539c6e8a3b199453 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199454;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b199454 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10159 .

_:79f295ad32df4ce8a18a92539c6e8a3b199456 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10313-1 a owl:Class;
  rdfs:label "ANTITUSSIFS MORPHINE-LIKE <-> METHADONE"@fr;
  dct:identifier "IAM_10313";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b199458;
  r:natureDuRisque "Risque majoré de dépression respiratoire, pouvant être fatale en cas de surdosage."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b199464, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b199458 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b199459 .

_:79f295ad32df4ce8a18a92539c6e8a3b199459 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199460;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b199461 .

_:79f295ad32df4ce8a18a92539c6e8a3b199460 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10044 .

_:79f295ad32df4ce8a18a92539c6e8a3b199461 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199462;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b199462 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10567 .

_:79f295ad32df4ce8a18a92539c6e8a3b199464 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10314-1 a owl:Class;
  rdfs:label "ANTITUSSIFS MORPHINIQUES VRAIS <-> METHADONE"@fr;
  dct:identifier "IAM_10314";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b199466;
  r:natureDuRisque "Risque majoré de dépression respiratoire, pouvant être fatale en cas de surdosage."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b199472, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b199466 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b199467 .

_:79f295ad32df4ce8a18a92539c6e8a3b199467 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199468;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b199469 .

_:79f295ad32df4ce8a18a92539c6e8a3b199468 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10045 .

_:79f295ad32df4ce8a18a92539c6e8a3b199469 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199470;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b199470 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10567 .

_:79f295ad32df4ce8a18a92539c6e8a3b199472 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10315-1 a owl:Class;
  rdfs:label "ANTITUSSIFS MORPHINIQUES VRAIS <-> MORPHINIQUES AGONISTES-ANTAGONISTES"@fr;
  dct:identifier "IAM_10315";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b199474;
  r:natureDuRisque "Diminution de l'effet antalgique ou antitussif du morphinique, par blocage compétitif des récepteurs, avec risque d'apparition d'un syndrome de sevrage."@fr;
  rdfs:comment "L’association d’agonistes-antagonistes morphiniques (buprénorphine, nalbuphine, pentazocine) avec des analgésiques morphiniques agonistes a été contre-indiquée jusqu'à présent, et ce, quel que soit leur niveau (palier II ou III de la classification de l'O"@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b199480, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b199474 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b199475 .

_:79f295ad32df4ce8a18a92539c6e8a3b199475 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199476;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b199477 .

_:79f295ad32df4ce8a18a92539c6e8a3b199476 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10045 .

_:79f295ad32df4ce8a18a92539c6e8a3b199477 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199478;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b199478 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10110 .

_:79f295ad32df4ce8a18a92539c6e8a3b199480 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10076-1 a owl:Class;
  rdfs:label "ALCOOL (BOISSON OU EXCIPIENT) <-> ANTIVITAMINES K"@fr;
  dct:identifier "IAM_10076";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b199482;
  r:natureDuRisque "Variations possibles de l'effet anticoagulant, avec augmentation en cas d'intoxication aiguë ou diminution en cas d'alcoolisme chronique (métabolisme augmenté)."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b199488, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b199482 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b199483 .

_:79f295ad32df4ce8a18a92539c6e8a3b199483 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199484;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b199485 .

_:79f295ad32df4ce8a18a92539c6e8a3b199484 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10046 .

_:79f295ad32df4ce8a18a92539c6e8a3b199485 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199486;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b199486 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_11013 .

_:79f295ad32df4ce8a18a92539c6e8a3b199488 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10316-1 a owl:Class;
  rdfs:label "ANTIVITAMINES K <-> APREPITANT"@fr;
  dct:identifier "IAM_10316";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b199490;
  r:natureDuRisque "Risque de diminution de l’effet de l’antivitamine K par augmentation de son métabolisme hépatique par l’aprépitant."@fr;
  r:conduiteATenir "Contrôle plus fréquent de l’INR. Adaptation de la posologie de l’antivitamine K pendant et après l’association."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b199496, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b199490 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b199491 .

_:79f295ad32df4ce8a18a92539c6e8a3b199491 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199492;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b199493 .

_:79f295ad32df4ce8a18a92539c6e8a3b199492 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10046 .

_:79f295ad32df4ce8a18a92539c6e8a3b199493 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199494;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b199494 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10080 .

_:79f295ad32df4ce8a18a92539c6e8a3b199496 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10317-1 a owl:Class;
  rdfs:label "ANTIVITAMINES K <-> BOSENTAN"@fr;
  dct:identifier "IAM_10317";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b199498;
  r:natureDuRisque "Diminution de l'effet de l'antivitamine K par augmentation de son métabolisme hépatique."@fr;
  r:conduiteATenir "Contrôle plus fréquent de l'INR. Adaptation éventuelle de la posologie de l'antivitamine K."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b199504, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b199498 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b199499 .

_:79f295ad32df4ce8a18a92539c6e8a3b199499 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199500;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b199501 .

_:79f295ad32df4ce8a18a92539c6e8a3b199500 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10046 .

_:79f295ad32df4ce8a18a92539c6e8a3b199501 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199502;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b199502 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10129 .

_:79f295ad32df4ce8a18a92539c6e8a3b199504 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10318-1 a owl:Class;
  rdfs:label "ANTIVITAMINES K <-> CEFAMANDOLE"@fr;
  dct:identifier "IAM_10318";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b199506;
  r:chapeau """ANTI-INFECTIEUX ET INR
De nombreux cas d’augmentation de l’activité des antivitamines K ont été rapportés chez des patients recevant des antibiotiques. Le contexte infectieux ou inflammatoire marqué, l’âge et l’état général du patient apparaissent comme d"""@fr;
  r:natureDuRisque "Augmentation de l'effet de l'antivitamine K et du risque hémorragique."@fr;
  r:conduiteATenir "Contrôle plus fréquent de l'INR. Adaptation éventuelle de la posologie de l'antivitamine K pendant le traitement par la céphalosporine et après son arrêt."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b199512, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b199506 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b199507 .

_:79f295ad32df4ce8a18a92539c6e8a3b199507 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199508;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b199509 .

_:79f295ad32df4ce8a18a92539c6e8a3b199508 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10046 .

_:79f295ad32df4ce8a18a92539c6e8a3b199509 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199510;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b199510 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10169 .

_:79f295ad32df4ce8a18a92539c6e8a3b199512 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10395-1 a owl:Class;
  rdfs:label "ATORVASTATINE <-> PAMPLEMOUSSE (JUS ET FRUIT)"@fr;
  dct:identifier "IAM_10395";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b199514;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de l'hypolipémiant, avec risque de survenue d'effets indésirables, notamment musculaires."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b199520, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b199514 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b199515 .

_:79f295ad32df4ce8a18a92539c6e8a3b199515 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199516;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b199517 .

_:79f295ad32df4ce8a18a92539c6e8a3b199516 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10130 .

_:79f295ad32df4ce8a18a92539c6e8a3b199517 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199518;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b199518 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10089 .

_:79f295ad32df4ce8a18a92539c6e8a3b199520 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10320-1 a owl:Class;
  rdfs:label "ANTIVITAMINES K <-> CEFOTETAN"@fr;
  dct:identifier "IAM_10320";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b199522;
  r:chapeau """ANTI-INFECTIEUX ET INR
De nombreux cas d’augmentation de l’activité des antivitamines K ont été rapportés chez des patients recevant des antibiotiques. Le contexte infectieux ou inflammatoire marqué, l’âge et l’état général du patient apparaissent comme d"""@fr;
  r:natureDuRisque "Augmentation de l'effet de l'antivitamine K et du risque hémorragique."@fr;
  r:conduiteATenir "Contrôle plus fréquent de l'INR. Adaptation éventuelle de la posologie de l'antivitamine K pendant le traitement par la céphalosporine et après son arrêt."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b199528, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b199522 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b199523 .

_:79f295ad32df4ce8a18a92539c6e8a3b199523 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199524;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b199525 .

_:79f295ad32df4ce8a18a92539c6e8a3b199524 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10046 .

_:79f295ad32df4ce8a18a92539c6e8a3b199525 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199526;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b199526 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10171 .

_:79f295ad32df4ce8a18a92539c6e8a3b199528 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10308-1 a owl:Class;
  rdfs:label "ANTISÉCRÉTOIRES INHIBITEURS DE LA POMPE À PROTONS <-> ULIPRISTAL"@fr;
  dct:identifier "IAM_10308";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b199530;
  r:natureDuRisque "Risque de diminution de l’effet de l’ulipristal, par diminution de son absorption."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b199536, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b199530 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b199531 .

_:79f295ad32df4ce8a18a92539c6e8a3b199531 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199532;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b199533 .

_:79f295ad32df4ce8a18a92539c6e8a3b199532 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10043 .

_:79f295ad32df4ce8a18a92539c6e8a3b199533 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199534;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b199534 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10964 .

_:79f295ad32df4ce8a18a92539c6e8a3b199536 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10322-1 a owl:Class;
  rdfs:label "ANTIVITAMINES K <-> CIMETIDINE"@fr;
  dct:identifier "IAM_10322";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b199538;
  r:natureDuRisque "Avec la cimétidine utilisée à des doses supérieures ou égales à 800 mg/j : augmentation de l'effet de l'antivitamine K et du risque hémorragique (diminution de son métabolisme hépatique)."@fr;
  r:conduiteATenir "Contrôle plus fréquent de l'INR. Adaptation éventuelle de la posologie de l'antivitamine K pendant le traitement par la cimétidine et 8 jours après son arrêt."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b199544, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b199538 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b199539 .

_:79f295ad32df4ce8a18a92539c6e8a3b199539 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199540;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b199541 .

_:79f295ad32df4ce8a18a92539c6e8a3b199540 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10046 .

_:79f295ad32df4ce8a18a92539c6e8a3b199541 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199542;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b199542 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10196 .

_:79f295ad32df4ce8a18a92539c6e8a3b199544 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10323-1 a owl:Class;
  rdfs:label "ANTIVITAMINES K <-> CLINDAMYCINE"@fr;
  dct:identifier "IAM_10323";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b199546;
  r:natureDuRisque "Augmentation de l’effet de l’antivitamine K et du risque hémorragique."@fr;
  r:conduiteATenir "Contrôle plus fréquent de l’INR. Adaptation éventuelle de la posologie de l’antivitamine K pendant le traitement par clindamycine et après son arrêt."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b199552, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b199546 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b199547 .

_:79f295ad32df4ce8a18a92539c6e8a3b199547 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199548;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b199549 .

_:79f295ad32df4ce8a18a92539c6e8a3b199548 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10046 .

_:79f295ad32df4ce8a18a92539c6e8a3b199549 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199550;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b199550 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10209 .

_:79f295ad32df4ce8a18a92539c6e8a3b199552 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10324-1 a owl:Class;
  rdfs:label "ANTIVITAMINES K <-> COLCHICINE"@fr;
  dct:identifier "IAM_10324";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b199554;
  r:natureDuRisque "Augmentation de l'effet de l'antivitamine K et du risque hémorragique."@fr;
  r:conduiteATenir "Contrôle plus fréquent de l'INR. Adaptation éventuelle de la posologie de l'antivitamine K pendant le traitement par la colchicine et 8 jours après son arrêt."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b199560, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b199554 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b199555 .

_:79f295ad32df4ce8a18a92539c6e8a3b199555 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199556;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b199557 .

_:79f295ad32df4ce8a18a92539c6e8a3b199556 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10046 .

_:79f295ad32df4ce8a18a92539c6e8a3b199557 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199558;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b199558 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10225 .

_:79f295ad32df4ce8a18a92539c6e8a3b199560 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10325-1 a owl:Class;
  rdfs:label "ANTIVITAMINES K <-> CYCLINES"@fr;
  dct:identifier "IAM_10325";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b199562;
  r:chapeau """ANTI-INFECTIEUX ET INR
De nombreux cas d’augmentation de l’activité des antivitamines K ont été rapportés chez des patients recevant des antibiotiques. Le contexte infectieux ou inflammatoire marqué, l’âge et l’état général du patient apparaissent comme d"""@fr;
  r:natureDuRisque "Augmentation de l'effet de l'antivitamine K et du risque hémorragique."@fr;
  r:conduiteATenir "Contrôle plus fréquent de l'INR. Adaptation éventuelle de la posologie de l'antivitamine K pendant le traitement par la cycline et après son arrêt."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b199568, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b199562 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b199563 .

_:79f295ad32df4ce8a18a92539c6e8a3b199563 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199564;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b199565 .

_:79f295ad32df4ce8a18a92539c6e8a3b199564 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10046 .

_:79f295ad32df4ce8a18a92539c6e8a3b199565 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199566;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b199566 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10059 .

_:79f295ad32df4ce8a18a92539c6e8a3b199568 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10326-1 a owl:Class;
  rdfs:label "ANTIVITAMINES K <-> CYTOTOXIQUES"@fr;
  dct:identifier "IAM_10326";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b199570;
  r:chapeau """ANTI-INFECTIEUX ET INR
De nombreux cas d’augmentation de l’activité des antivitamines K ont été rapportés chez des patients recevant des antibiotiques. Le contexte infectieux ou inflammatoire marqué, l’âge et l’état général du patient apparaissent comme d"""@fr;
  r:natureDuRisque "Augmentation du risque thrombotique et hémorragique au cours des affections tumorales. De surcroit, possible interaction entre les AVK et la chimiothérapie."@fr;
  r:conduiteATenir "Contrôle plus fréquent de l'INR."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b199576, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b199570 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b199571 .

_:79f295ad32df4ce8a18a92539c6e8a3b199571 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199572;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b199573 .

_:79f295ad32df4ce8a18a92539c6e8a3b199572 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10046 .

_:79f295ad32df4ce8a18a92539c6e8a3b199573 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199574;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b199574 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10060 .

_:79f295ad32df4ce8a18a92539c6e8a3b199576 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10327-1 a owl:Class;
  rdfs:label "ANTIVITAMINES K <-> DANAZOL"@fr;
  dct:identifier "IAM_10327";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b199578;
  r:natureDuRisque "Augmentation du risque hémorragique par effet direct sur la coagulation et/ou les systèmes fibrinolytiques."@fr;
  r:conduiteATenir "Contrôle plus fréquent de l’INR. Adaptation de la posologie de l’antivitamine K pendant le traitement par le danazol et après son arrêt."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b199584, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b199578 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b199579 .

_:79f295ad32df4ce8a18a92539c6e8a3b199579 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199580;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b199581 .

_:79f295ad32df4ce8a18a92539c6e8a3b199580 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10046 .

_:79f295ad32df4ce8a18a92539c6e8a3b199581 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199582;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b199582 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10248 .

_:79f295ad32df4ce8a18a92539c6e8a3b199584 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10328-1 a owl:Class;
  rdfs:label "ANTIVITAMINES K <-> DEFERASIROX"@fr;
  dct:identifier "IAM_10328";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b199586;
  r:natureDuRisque "Majoration du risque ulcérogène et hémorragique digestif."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b199592, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b199586 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b199587 .

_:79f295ad32df4ce8a18a92539c6e8a3b199587 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199588;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b199589 .

_:79f295ad32df4ce8a18a92539c6e8a3b199588 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10046 .

_:79f295ad32df4ce8a18a92539c6e8a3b199589 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199590;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b199590 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10259 .

_:79f295ad32df4ce8a18a92539c6e8a3b199592 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10329-1 a owl:Class;
  rdfs:label "ANTIVITAMINES K <-> DISULFIRAME"@fr;
  dct:identifier "IAM_10329";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b199594;
  r:natureDuRisque "Augmentation de l'effet de l'antivitamine K et du risque hémorragique."@fr;
  r:conduiteATenir "Contrôle plus fréquent de l'INR. Adaptation de la posologie de l'antivitamine K pendant le traitement par le disulfirame et 8 jours après son arrêt."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b199600, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b199594 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b199595 .

_:79f295ad32df4ce8a18a92539c6e8a3b199595 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199596;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b199597 .

_:79f295ad32df4ce8a18a92539c6e8a3b199596 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10046 .

_:79f295ad32df4ce8a18a92539c6e8a3b199597 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199598;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b199598 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10299 .

_:79f295ad32df4ce8a18a92539c6e8a3b199600 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10330-1 a owl:Class;
  rdfs:label "ANTIVITAMINES K <-> DRONEDARONE"@fr;
  dct:identifier "IAM_10330";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b199602;
  r:natureDuRisque "Augmentation de l’effet de l’antivitamine K et du risque hémorragique."@fr;
  r:conduiteATenir "Contrôle plus fréquent de l’INR. Adaptation éventuelle de la posologie de l’antivitamine K pendant le traitement par la dronédarone et 8 jours après son arrêt."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b199608, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b199602 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b199603 .

_:79f295ad32df4ce8a18a92539c6e8a3b199603 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199604;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b199605 .

_:79f295ad32df4ce8a18a92539c6e8a3b199604 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10046 .

_:79f295ad32df4ce8a18a92539c6e8a3b199605 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199606;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b199606 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10311 .

_:79f295ad32df4ce8a18a92539c6e8a3b199608 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10319-1 a owl:Class;
  rdfs:label "ANTIVITAMINES K <-> CEFOPERAZONE"@fr;
  dct:identifier "IAM_10319";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b199610;
  r:chapeau """ANTI-INFECTIEUX ET INR
De nombreux cas d’augmentation de l’activité des antivitamines K ont été rapportés chez des patients recevant des antibiotiques. Le contexte infectieux ou inflammatoire marqué, l’âge et l’état général du patient apparaissent comme d"""@fr;
  r:natureDuRisque "Augmentation de l'effet de l'antivitamine K et du risque hémorragique."@fr;
  r:conduiteATenir "Contrôle plus fréquent de l'INR. Adaptation éventuelle de la posologie de l'antivitamine K pendant le traitement par la céphalosporine et après son arrêt."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b199616, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b199610 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b199611 .

_:79f295ad32df4ce8a18a92539c6e8a3b199611 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199612;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b199613 .

_:79f295ad32df4ce8a18a92539c6e8a3b199612 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10046 .

_:79f295ad32df4ce8a18a92539c6e8a3b199613 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199614;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b199614 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10170 .

_:79f295ad32df4ce8a18a92539c6e8a3b199616 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11222-1 a owl:Class;
  rdfs:label "KETOCONAZOLE <-> VENLAFAXINE"@fr;
  dct:identifier "IAM_11222";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b199618;
  r:natureDuRisque "Augmentation des concentrations de venlafaxine avec risque de surdosage."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b199624, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b199618 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b199619 .

_:79f295ad32df4ce8a18a92539c6e8a3b199619 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199620;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b199621 .

_:79f295ad32df4ce8a18a92539c6e8a3b199620 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10501 .

_:79f295ad32df4ce8a18a92539c6e8a3b199621 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199622;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b199622 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10979 .

_:79f295ad32df4ce8a18a92539c6e8a3b199624 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11080-1 a owl:Class;
  rdfs:label "IMMUNOSUPPRESSEURS <-> STIRIPENTOL"@fr;
  dct:identifier "IAM_11080";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b199626;
  r:natureDuRisque "Augmentation des concentrations sanguines de l’immunosuppresseur (diminution de son métabolisme hépatique)."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b199632, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b199626 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b199627 .

_:79f295ad32df4ce8a18a92539c6e8a3b199627 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199628;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b199629 .

_:79f295ad32df4ce8a18a92539c6e8a3b199628 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10093 .

_:79f295ad32df4ce8a18a92539c6e8a3b199629 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199630;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b199630 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10859 .

_:79f295ad32df4ce8a18a92539c6e8a3b199632 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11082-1 a owl:Class;
  rdfs:label "IMMUNOSUPPRESSEURS <-> TELITHROMYCINE"@fr;
  dct:identifier "IAM_11082";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b199634;
  r:natureDuRisque "Augmentation très importante des concentrations sanguines de l'immunosuppresseur par inhibition de son métabolisme hépatique."@fr;
  r:conduiteATenir "En cas d’association, contrôle strict de la fonction rénale, dosage des concentrations sanguines de l'immunosuppresseur et adaptation éventuelle de la posologie."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b199640, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b199634 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b199635 .

_:79f295ad32df4ce8a18a92539c6e8a3b199635 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199636;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b199637 .

_:79f295ad32df4ce8a18a92539c6e8a3b199636 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10093 .

_:79f295ad32df4ce8a18a92539c6e8a3b199637 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199638;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b199638 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10889 .

_:79f295ad32df4ce8a18a92539c6e8a3b199640 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11083-1 a owl:Class;
  rdfs:label "IMMUNOSUPPRESSEURS <-> VACCINS VIVANTS ATTÉNUÉS"@fr;
  dct:identifier "IAM_11083";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b199642;
  r:natureDuRisque "Risque de maladie vaccinale généralisée éventuellement mortelle."@fr;
  r:conduiteATenir "Et pendant les 3 mois suivant l'arrêt du traitement."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b199648, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b199642 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b199643 .

_:79f295ad32df4ce8a18a92539c6e8a3b199643 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199644;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b199645 .

_:79f295ad32df4ce8a18a92539c6e8a3b199644 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10093 .

_:79f295ad32df4ce8a18a92539c6e8a3b199645 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199646;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b199646 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10159 .

_:79f295ad32df4ce8a18a92539c6e8a3b199648 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11084-1 a owl:Class;
  rdfs:label "IMMUNOSUPPRESSEURS <-> VÉMURAFÉNIB"@fr;
  dct:identifier "IAM_11084";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b199650;
  r:natureDuRisque "Risque de diminution des concentrations des immunosuppresseurs, avec pour conséquence un risque d’inefficacité."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b199656, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b199650 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b199651 .

_:79f295ad32df4ce8a18a92539c6e8a3b199651 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199652;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b199653 .

_:79f295ad32df4ce8a18a92539c6e8a3b199652 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10093 .

_:79f295ad32df4ce8a18a92539c6e8a3b199653 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199654;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b199654 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10978 .

_:79f295ad32df4ce8a18a92539c6e8a3b199656 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11085-1 a owl:Class;
  rdfs:label "IMMUNOSUPPRESSEURS <-> VORICONAZOLE"@fr;
  dct:identifier "IAM_11085";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b199658;
  r:natureDuRisque "Augmentation des concentrations sanguines de l'immunosuppresseur par inhibition de son métabolisme hépatique par le voriconazole."@fr;
  r:conduiteATenir """Association déconseillée
- avec l'évérolimus, le sirolimus, et le temsirolimus.

Précaution d'emploi
- avec la ciclosporine et le tacrolimus :
dosage des concentrations sanguines de l'immunosuppresseur, contrôle de la fonction rénale et adaptation de la p"""@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b199664, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b199658 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b199659 .

_:79f295ad32df4ce8a18a92539c6e8a3b199659 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199660;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b199661 .

_:79f295ad32df4ce8a18a92539c6e8a3b199660 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10093 .

_:79f295ad32df4ce8a18a92539c6e8a3b199661 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199662;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b199662 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10998 .

_:79f295ad32df4ce8a18a92539c6e8a3b199664 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11086-1 a owl:Class;
  rdfs:label "INDINAVIR <-> NEVIRAPINE"@fr;
  dct:identifier "IAM_11086";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b199666;
  r:natureDuRisque "Risque de baisse de l'efficacité de l'indinavir."@fr;
  r:conduiteATenir "Surveillance clinique et biologique régulière, notamment en début d'association."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b199672, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b199666 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b199667 .

_:79f295ad32df4ce8a18a92539c6e8a3b199667 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199668;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b199669 .

_:79f295ad32df4ce8a18a92539c6e8a3b199668 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10455 .

_:79f295ad32df4ce8a18a92539c6e8a3b199669 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199670;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b199670 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10628 .

_:79f295ad32df4ce8a18a92539c6e8a3b199672 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11088-1 a owl:Class;
  rdfs:label "INDUCTEURS ENZYMATIQUES <-> IRINOTECAN"@fr;
  dct:identifier "IAM_11088";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b199674;
  r:natureDuRisque """Diminution probable des concentrations plasmatiques du métabolite actif de l'irinotécan, avec risque d'échec du traitement
cytotoxique."""@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b199680, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b199674 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b199675 .

_:79f295ad32df4ce8a18a92539c6e8a3b199675 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199676;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b199677 .

_:79f295ad32df4ce8a18a92539c6e8a3b199676 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10094 .

_:79f295ad32df4ce8a18a92539c6e8a3b199677 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199678;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b199678 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10486 .

_:79f295ad32df4ce8a18a92539c6e8a3b199680 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11089-1 a owl:Class;
  rdfs:label "INDUCTEURS ENZYMATIQUES <-> ISAVUCONAZOLE"@fr;
  dct:identifier "IAM_11089";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b199682;
  r:natureDuRisque "Diminution des concentrations plasmatiques d’isavuconazole par augmentation de son métabolisme hépatique par l’inducteur."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b199688, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b199682 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b199683 .

_:79f295ad32df4ce8a18a92539c6e8a3b199683 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199684;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b199685 .

_:79f295ad32df4ce8a18a92539c6e8a3b199684 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10094 .

_:79f295ad32df4ce8a18a92539c6e8a3b199685 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199686;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b199686 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10487 .

_:79f295ad32df4ce8a18a92539c6e8a3b199688 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11090-1 a owl:Class;
  rdfs:label "INDUCTEURS ENZYMATIQUES <-> ITRACONAZOLE"@fr;
  dct:identifier "IAM_11090";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b199690;
  r:natureDuRisque "Diminution des concentrations plasmatiques d’itraconazole, avec risque de perte d’efficacité, par augmentation de son métabolisme hépatique par l’inducteur."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b199696, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b199690 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b199691 .

_:79f295ad32df4ce8a18a92539c6e8a3b199691 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199692;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b199693 .

_:79f295ad32df4ce8a18a92539c6e8a3b199692 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10094 .

_:79f295ad32df4ce8a18a92539c6e8a3b199693 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199694;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b199694 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10496 .

_:79f295ad32df4ce8a18a92539c6e8a3b199696 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10310-1 a owl:Class;
  rdfs:label "ANTISPASMODIQUES URINAIRES <-> INHIBITEURS PUISSANTS DU CYP3A4"@fr;
  dct:identifier "IAM_10310";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b199698;
  r:chapeau "Certains médicaments possèdent la capacité d’inhiber fortement le CYP3A4, une enzyme qui intervient dans le métabolisme de nombreux médicaments. Lorsque l’activité de cette enzyme est inhibée, elle n’est plus en mesure de métaboliser le médicament qui va"@fr;
  r:natureDuRisque "Risque de majoration des effets indésirables."@fr;
  r:conduiteATenir """Contre-indication :
- avec la darifénacine
- avec la fésotérodine et la solifénacine, en cas d'insuffisance rénale ou hépatique, modérée à sévère.

Association déconseillée : 
- avec la toltérodine

Précaution d'emploi:
- avec la fésotérodine ou la solifé"""@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b199704, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b199698 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b199699 .

_:79f295ad32df4ce8a18a92539c6e8a3b199699 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199700;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b199701 .

_:79f295ad32df4ce8a18a92539c6e8a3b199700 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10041 .

_:79f295ad32df4ce8a18a92539c6e8a3b199701 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199702;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b199702 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10103 .

_:79f295ad32df4ce8a18a92539c6e8a3b199704 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11092-1 a owl:Class;
  rdfs:label "INDUCTEURS ENZYMATIQUES <-> LURASIDONE"@fr;
  dct:identifier "IAM_11092";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b199706;
  r:natureDuRisque "Diminution des concentrations plasmatiques de la lurasidone par augmentation de son métabolisme hépatique par l’inducteur."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b199712, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b199706 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b199707 .

_:79f295ad32df4ce8a18a92539c6e8a3b199707 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199708;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b199709 .

_:79f295ad32df4ce8a18a92539c6e8a3b199708 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10094 .

_:79f295ad32df4ce8a18a92539c6e8a3b199709 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199710;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b199710 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10542 .

_:79f295ad32df4ce8a18a92539c6e8a3b199712 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10309-1 a owl:Class;
  rdfs:label "ANTISEPTIQUES MERCURIELS <-> POVIDONE IODÉE"@fr;
  dct:identifier "IAM_10309";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b199714;
  r:natureDuRisque """Erythèmes, phlyctènes, voire nécrose cutanéo-muqueuse 
(formation d'un complexe caustique en cas d'utilisation
concomitante d'antiseptiques iodés et mercuriels). L'interaction
dépend de la stabilité de l'organo-mercuriel au niveau cutané et de la sensibil"""@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b199720, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b199714 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b199715 .

_:79f295ad32df4ce8a18a92539c6e8a3b199715 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199716;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b199717 .

_:79f295ad32df4ce8a18a92539c6e8a3b199716 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10040 .

_:79f295ad32df4ce8a18a92539c6e8a3b199717 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199718;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b199718 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10745 .

_:79f295ad32df4ce8a18a92539c6e8a3b199720 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11224-1 a owl:Class;
  rdfs:label "LAMIVUDINE <-> ZALCITABINE"@fr;
  dct:identifier "IAM_11224";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b199722;
  r:natureDuRisque "Risque de diminution de l'efficacité de chaque antiviral par antagoniste compétitif de la réaction de phosphorylation à l'origine des métabolites actifs."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b199728, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b199722 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b199723 .

_:79f295ad32df4ce8a18a92539c6e8a3b199723 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199724;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b199725 .

_:79f295ad32df4ce8a18a92539c6e8a3b199724 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10506 .

_:79f295ad32df4ce8a18a92539c6e8a3b199725 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199726;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b199726 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_11002 .

_:79f295ad32df4ce8a18a92539c6e8a3b199728 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11225-1 a owl:Class;
  rdfs:label "LAMOTRIGINE <-> OXCARBAZEPINE"@fr;
  dct:identifier "IAM_11225";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b199730;
  r:natureDuRisque "Diminution des concentrations de la lamotrigine avec risque de moindre efficacité, par augmentation de son métabolisme hépatique par l'oxcarbazépine."@fr;
  r:conduiteATenir "Surveillance clinique et contrôle des concentrations plasmatiques, avec adaptation de la posologie de la lamotrigine si besoin."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b199736, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b199730 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b199731 .

_:79f295ad32df4ce8a18a92539c6e8a3b199731 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199732;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b199733 .

_:79f295ad32df4ce8a18a92539c6e8a3b199732 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10507 .

_:79f295ad32df4ce8a18a92539c6e8a3b199733 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199734;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b199734 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10674 .

_:79f295ad32df4ce8a18a92539c6e8a3b199736 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11226-1 a owl:Class;
  rdfs:label "LAMOTRIGINE <-> VALPROÏQUE (ACIDE) ET, PAR EXTRAPOLATION, VALPROMIDE"@fr;
  dct:identifier "IAM_11226";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b199738;
  r:natureDuRisque "Risque majoré de réactions cutanées graves (syndrome de Lyell). Par ailleurs, augmentation des concentrations plasmatiques de lamotrigine (diminution de son métabolisme hépatique par le valproate de sodium)."@fr;
  r:conduiteATenir "Si l'association s'avère nécessaire, surveillance clinique étroite."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b199744, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b199738 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b199739 .

_:79f295ad32df4ce8a18a92539c6e8a3b199739 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199740;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b199741 .

_:79f295ad32df4ce8a18a92539c6e8a3b199740 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10160 .

_:79f295ad32df4ce8a18a92539c6e8a3b199741 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199742;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b199742 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10507 .

_:79f295ad32df4ce8a18a92539c6e8a3b199744 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11227-1 a owl:Class;
  rdfs:label "LANSOPRAZOLE <-> TACROLIMUS"@fr;
  dct:identifier "IAM_11227";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b199746;
  r:natureDuRisque "Augmentation des concentrations sanguines du tacrolimus."@fr;
  r:conduiteATenir "Dosage des concentrations sanguines du tacrolimus, contrôle de la fonction rénale et adaptation de la posologie pendant l'association et après son arrêt."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b199752, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b199746 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b199747 .

_:79f295ad32df4ce8a18a92539c6e8a3b199747 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199748;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b199749 .

_:79f295ad32df4ce8a18a92539c6e8a3b199748 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10509 .

_:79f295ad32df4ce8a18a92539c6e8a3b199749 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199750;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b199750 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10880 .

_:79f295ad32df4ce8a18a92539c6e8a3b199752 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11228-1 a owl:Class;
  rdfs:label "LÉDIPASVIR <-> MILLEPERTUIS"@fr;
  dct:identifier "IAM_11228";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b199754;
  r:natureDuRisque "Risque de diminution importante des concentrations plasmatiques du lédipasvir par augmentation de son métabolisme hépatique par le millepertuis."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b199760, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b199754 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b199755 .

_:79f295ad32df4ce8a18a92539c6e8a3b199755 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199756;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b199757 .

_:79f295ad32df4ce8a18a92539c6e8a3b199756 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10512 .

_:79f295ad32df4ce8a18a92539c6e8a3b199757 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199758;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b199758 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10588 .

_:79f295ad32df4ce8a18a92539c6e8a3b199760 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10304-1 a owl:Class;
  rdfs:label "ANTISÉCRÉTOIRES INHIBITEURS DE LA POMPE À PROTONS <-> MILLEPERTUIS"@fr;
  dct:identifier "IAM_10304";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b199762;
  r:natureDuRisque "Risque d’inefficacité du traitement antisécrétoire par augmentation de son métabolisme par le millepertuis."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b199768, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b199762 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b199763 .

_:79f295ad32df4ce8a18a92539c6e8a3b199763 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199764;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b199765 .

_:79f295ad32df4ce8a18a92539c6e8a3b199764 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10043 .

_:79f295ad32df4ce8a18a92539c6e8a3b199765 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199766;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b199766 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10588 .

_:79f295ad32df4ce8a18a92539c6e8a3b199768 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10305-1 a owl:Class;
  rdfs:label "ANTISÉCRÉTOIRES INHIBITEURS DE LA POMPE À PROTONS <-> MYCOPHENOLATE MOFETIL"@fr;
  dct:identifier "IAM_10305";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b199770;
  r:natureDuRisque "Diminution des concentrations de l’acide mycophénolique d’environ un tiers, avec risque potentiel de baisse d’efficacité."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b199776, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b199770 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b199771 .

_:79f295ad32df4ce8a18a92539c6e8a3b199771 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199772;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b199773 .

_:79f295ad32df4ce8a18a92539c6e8a3b199772 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10043 .

_:79f295ad32df4ce8a18a92539c6e8a3b199773 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199774;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b199774 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10609 .

_:79f295ad32df4ce8a18a92539c6e8a3b199776 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10306-1 a owl:Class;
  rdfs:label "ANTISÉCRÉTOIRES INHIBITEURS DE LA POMPE À PROTONS <-> POSACONAZOLE"@fr;
  dct:identifier "IAM_10306";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b199778;
  r:natureDuRisque "Diminution de l'absorption de l'azolé antifongique, par augmentation du pH intragastrique par l'antisécrétoire."@fr;
  r:conduiteATenir """Association déconseillée:
- uniquement avec la forme suspension buvable de posaconazole."""@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b199784, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b199778 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b199779 .

_:79f295ad32df4ce8a18a92539c6e8a3b199779 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199780;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b199781 .

_:79f295ad32df4ce8a18a92539c6e8a3b199780 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10043 .

_:79f295ad32df4ce8a18a92539c6e8a3b199781 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199782;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b199782 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10741 .

_:79f295ad32df4ce8a18a92539c6e8a3b199784 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10307-1 a owl:Class;
  rdfs:label "ANTISÉCRÉTOIRES INHIBITEURS DE LA POMPE À PROTONS <-> RILPIVIRINE"@fr;
  dct:identifier "IAM_10307";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b199786;
  r:natureDuRisque "Diminution des concentrations plasmatiques de rilpivirine par l’inhibiteur de la pompe à protons (absorption diminuée en raison de l’augmentation du pH gastrique)."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b199792, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b199786 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b199787 .

_:79f295ad32df4ce8a18a92539c6e8a3b199787 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199788;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b199789 .

_:79f295ad32df4ce8a18a92539c6e8a3b199788 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10043 .

_:79f295ad32df4ce8a18a92539c6e8a3b199789 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199790;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b199790 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10803 .

_:79f295ad32df4ce8a18a92539c6e8a3b199792 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10333-1 a owl:Class;
  rdfs:label "ANTIVITAMINES K <-> FIBRATES"@fr;
  dct:identifier "IAM_10333";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b199794;
  r:natureDuRisque "Augmentation de l'effet de l'antivitamine K et du risque hémorragique."@fr;
  r:conduiteATenir "Contrôle plus fréquent de l'INR. Adaptation éventuelle de la posologie de l'antivitamine K pendant le traitement par le fibrate et 8 jours après son arrêt."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b199800, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b199794 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b199795 .

_:79f295ad32df4ce8a18a92539c6e8a3b199795 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199796;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b199797 .

_:79f295ad32df4ce8a18a92539c6e8a3b199796 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10046 .

_:79f295ad32df4ce8a18a92539c6e8a3b199797 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199798;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b199798 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10074 .

_:79f295ad32df4ce8a18a92539c6e8a3b199800 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11091-1 a owl:Class;
  rdfs:label "INDUCTEURS ENZYMATIQUES <-> IVACAFTOR"@fr;
  dct:identifier "IAM_11091";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b199802;
  r:natureDuRisque "Diminution importante des concentrations de l’ivacaftor, avec risque de perte d’efficacité."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b199808, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b199802 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b199803 .

_:79f295ad32df4ce8a18a92539c6e8a3b199803 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199804;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b199805 .

_:79f295ad32df4ce8a18a92539c6e8a3b199804 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10094 .

_:79f295ad32df4ce8a18a92539c6e8a3b199805 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199806;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b199806 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10498 .

_:79f295ad32df4ce8a18a92539c6e8a3b199808 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10382-1 a owl:Class;
  rdfs:label "ATAZANAVIR <-> EFAVIRENZ"@fr;
  dct:identifier "IAM_10382";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b199810;
  r:natureDuRisque "Risque de baisse de l’efficacité de l’atazanavir par augmentation de son métabolisme hépatique."@fr;
  r:conduiteATenir "Si l’association s’avère nécessaire, adaptation posologique de l’atazanavir avec surveillance clinique et biologique régulière, notamment en début d’association."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b199816, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b199810 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b199811 .

_:79f295ad32df4ce8a18a92539c6e8a3b199811 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199812;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b199813 .

_:79f295ad32df4ce8a18a92539c6e8a3b199812 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10087 .

_:79f295ad32df4ce8a18a92539c6e8a3b199813 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199814;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b199814 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10318 .

_:79f295ad32df4ce8a18a92539c6e8a3b199816 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10331-1 a owl:Class;
  rdfs:label "ANTIVITAMINES K <-> ECONAZOLE"@fr;
  dct:identifier "IAM_10331";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b199818;
  r:natureDuRisque "Quelle que soit la voie d'administration de l'éconazole : augmentation de l'effet de l'antivitamine K et du risque hémorragique."@fr;
  r:conduiteATenir "Contrôle plus fréquent de l'INR. Adaptation éventuelle de la posologie de l'antivitamine K pendant le traitement par éconazole et après son arrêt."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b199824, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b199818 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b199819 .

_:79f295ad32df4ce8a18a92539c6e8a3b199819 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199820;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b199821 .

_:79f295ad32df4ce8a18a92539c6e8a3b199820 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10046 .

_:79f295ad32df4ce8a18a92539c6e8a3b199821 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199822;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b199822 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10317 .

_:79f295ad32df4ce8a18a92539c6e8a3b199824 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10372-1 a owl:Class;
  rdfs:label "APREPITANT <-> CYPROTERONE"@fr;
  dct:identifier "IAM_10372";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b199826;
  r:natureDuRisque "Risque de diminution des concentrations de la cyprotérone avec risque de moindre efficacité contraceptive."@fr;
  r:conduiteATenir """Dans son utilisation comme contraceptif hormonal : 
Utiliser une méthode de contraception fiable, additionnelle ou alternative, pendant la durée de l'association."""@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b199832, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b199826 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b199827 .

_:79f295ad32df4ce8a18a92539c6e8a3b199827 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199828;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b199829 .

_:79f295ad32df4ce8a18a92539c6e8a3b199828 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10080 .

_:79f295ad32df4ce8a18a92539c6e8a3b199829 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199830;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b199830 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10238 .

_:79f295ad32df4ce8a18a92539c6e8a3b199832 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10373-1 a owl:Class;
  rdfs:label "APREPITANT <-> ESTROPROGESTATIFS CONTRACEPTIFS"@fr;
  dct:identifier "IAM_10373";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b199834;
  r:natureDuRisque "Diminution des concentrations de l’estroprogestatif ou du progestatif, avec risque de moindre efficacité contraceptive."@fr;
  r:conduiteATenir "Utiliser de préférence une autre méthode contraceptive, en particulier de type mécanique, pendant la durée de l'association et un cycle suivant."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b199840, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b199834 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b199835 .

_:79f295ad32df4ce8a18a92539c6e8a3b199835 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199836;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b199837 .

_:79f295ad32df4ce8a18a92539c6e8a3b199836 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10073 .

_:79f295ad32df4ce8a18a92539c6e8a3b199837 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199838;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b199838 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10080 .

_:79f295ad32df4ce8a18a92539c6e8a3b199840 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10374-1 a owl:Class;
  rdfs:label "APREPITANT <-> IFOSFAMIDE"@fr;
  dct:identifier "IAM_10374";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b199842;
  r:natureDuRisque "Risque d’augmentation de la neurotoxicité de l’ifosfamide."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b199848, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b199842 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b199843 .

_:79f295ad32df4ce8a18a92539c6e8a3b199843 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199844;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b199845 .

_:79f295ad32df4ce8a18a92539c6e8a3b199844 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10080 .

_:79f295ad32df4ce8a18a92539c6e8a3b199845 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199846;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b199846 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10445 .

_:79f295ad32df4ce8a18a92539c6e8a3b199848 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10375-1 a owl:Class;
  rdfs:label "APREPITANT <-> ITRACONAZOLE"@fr;
  dct:identifier "IAM_10375";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b199850;
  r:natureDuRisque "Augmentation des concentrations d’aprépitant par diminution de son métabolisme hépatique par l’itraconazole."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b199856, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b199850 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b199851 .

_:79f295ad32df4ce8a18a92539c6e8a3b199851 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199852;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b199853 .

_:79f295ad32df4ce8a18a92539c6e8a3b199852 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10080 .

_:79f295ad32df4ce8a18a92539c6e8a3b199853 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199854;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b199854 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10496 .

_:79f295ad32df4ce8a18a92539c6e8a3b199856 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10376-1 a owl:Class;
  rdfs:label "APREPITANT <-> PIMOZIDE"@fr;
  dct:identifier "IAM_10376";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b199858;
  r:natureDuRisque "Risque majoré de troubles du rythme ventriculaire, notamment de torsades de pointes."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b199864, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b199858 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b199859 .

_:79f295ad32df4ce8a18a92539c6e8a3b199859 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199860;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b199861 .

_:79f295ad32df4ce8a18a92539c6e8a3b199860 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10080 .

_:79f295ad32df4ce8a18a92539c6e8a3b199861 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199862;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b199862 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10721 .

_:79f295ad32df4ce8a18a92539c6e8a3b199864 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10377-1 a owl:Class;
  rdfs:label "APREPITANT <-> PROGESTATIFS CONTRACEPTIFS"@fr;
  dct:identifier "IAM_10377";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b199866;
  r:natureDuRisque "(Sauf stérilet), diminution des concentrations du progestatif, avec risque de moindre efficacité contraceptive."@fr;
  r:conduiteATenir "Utiliser de préférence une autre méthode contraceptive, en particulier de type mécanique, pendant la durée de l'association et un cycle suivant."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b199872, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b199866 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b199867 .

_:79f295ad32df4ce8a18a92539c6e8a3b199867 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199868;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b199869 .

_:79f295ad32df4ce8a18a92539c6e8a3b199868 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10134 .

_:79f295ad32df4ce8a18a92539c6e8a3b199869 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199870;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b199870 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10080 .

_:79f295ad32df4ce8a18a92539c6e8a3b199872 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10378-1 a owl:Class;
  rdfs:label "APREPITANT <-> RIFAMPICINE"@fr;
  dct:identifier "IAM_10378";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b199874;
  r:natureDuRisque "Diminution très importante des concentrations d'aprépitant."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b199880, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b199874 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b199875 .

_:79f295ad32df4ce8a18a92539c6e8a3b199875 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199876;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b199877 .

_:79f295ad32df4ce8a18a92539c6e8a3b199876 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10080 .

_:79f295ad32df4ce8a18a92539c6e8a3b199877 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199878;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b199878 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:79f295ad32df4ce8a18a92539c6e8a3b199880 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10379-1 a owl:Class;
  rdfs:label "ARIPIPRAZOLE <-> INDUCTEURS ENZYMATIQUES"@fr;
  dct:identifier "IAM_10379";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b199882;
  r:natureDuRisque "Diminution des concentrations plasmatiques de l’aripiprazole."@fr;
  r:conduiteATenir "Surveillance clinique et adaptation éventuelle de la posologie de l’aripiprazole pendant l’association et 1 à 2 semaines après l’arrêt de l’inducteur."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b199888, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b199882 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b199883 .

_:79f295ad32df4ce8a18a92539c6e8a3b199883 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199884;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b199885 .

_:79f295ad32df4ce8a18a92539c6e8a3b199884 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10094 .

_:79f295ad32df4ce8a18a92539c6e8a3b199885 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199886;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b199886 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10082 .

_:79f295ad32df4ce8a18a92539c6e8a3b199888 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10370-1 a owl:Class;
  rdfs:label "APIXABAN <-> RIFAMPICINE"@fr;
  dct:identifier "IAM_10370";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b199890;
  r:natureDuRisque "Diminution des concentrations plasmatiques de l’apixaban par la rifampicine, avec risque de diminution de l’effet thérapeutique."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b199896, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b199890 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b199891 .

_:79f295ad32df4ce8a18a92539c6e8a3b199891 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199892;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b199893 .

_:79f295ad32df4ce8a18a92539c6e8a3b199892 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10078 .

_:79f295ad32df4ce8a18a92539c6e8a3b199893 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199894;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b199894 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:79f295ad32df4ce8a18a92539c6e8a3b199896 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10381-1 a owl:Class;
  rdfs:label "ATAZANAVIR <-> CLARITHROMYCINE"@fr;
  dct:identifier "IAM_10381";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b199898;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de clarithromycine et inhibition de la formation de son métabolite actif."@fr;
  r:conduiteATenir "Surveillance clinique et biologique régulière, notamment en début d'association."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b199904, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b199898 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b199899 .

_:79f295ad32df4ce8a18a92539c6e8a3b199899 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199900;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b199901 .

_:79f295ad32df4ce8a18a92539c6e8a3b199900 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10087 .

_:79f295ad32df4ce8a18a92539c6e8a3b199901 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199902;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b199902 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10206 .

_:79f295ad32df4ce8a18a92539c6e8a3b199904 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10369-1 a owl:Class;
  rdfs:label "APIXABAN <-> INHIBITEURS PUISSANTS DU CYP3A4"@fr;
  dct:identifier "IAM_10369";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b199906;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de l’apixaban par l'inhibiteur, avec majoration du risque de saignement."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b199912, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b199906 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b199907 .

_:79f295ad32df4ce8a18a92539c6e8a3b199907 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199908;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b199909 .

_:79f295ad32df4ce8a18a92539c6e8a3b199908 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10103 .

_:79f295ad32df4ce8a18a92539c6e8a3b199909 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199910;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b199910 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10078 .

_:79f295ad32df4ce8a18a92539c6e8a3b199912 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10383-1 a owl:Class;
  rdfs:label "ATAZANAVIR <-> NEVIRAPINE"@fr;
  dct:identifier "IAM_10383";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b199914;
  r:natureDuRisque "Risque de baisse de l’efficacité de l’atazanavir par augmentation de son métabolisme hépatique."@fr;
  r:conduiteATenir "Si l’association s’avère nécessaire, adaptation posologique de l’atazanavir avec surveillance clinique et biologique régulière, notamment en début d’association."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b199920, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b199914 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b199915 .

_:79f295ad32df4ce8a18a92539c6e8a3b199915 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199916;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b199917 .

_:79f295ad32df4ce8a18a92539c6e8a3b199916 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10087 .

_:79f295ad32df4ce8a18a92539c6e8a3b199917 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199918;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b199918 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10628 .

_:79f295ad32df4ce8a18a92539c6e8a3b199920 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10384-1 a owl:Class;
  rdfs:label "ATAZANAVIR <-> TENOFOVIR DISOPROXIL"@fr;
  dct:identifier "IAM_10384";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b199922;
  r:natureDuRisque "Diminution d’environ un tiers de l’exposition à l’atazanavir chez le patient en cas d’association au ténofovir, comparativement au sujet sain recevant la même association."@fr;
  r:conduiteATenir "Ne pas administrer l’atazanavir avec le ténofovir sans ritonavir."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b199928, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b199922 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b199923 .

_:79f295ad32df4ce8a18a92539c6e8a3b199923 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199924;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b199925 .

_:79f295ad32df4ce8a18a92539c6e8a3b199924 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10087 .

_:79f295ad32df4ce8a18a92539c6e8a3b199925 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199926;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b199926 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10896 .

_:79f295ad32df4ce8a18a92539c6e8a3b199928 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10385-1 a owl:Class;
  rdfs:label "ATORVASTATINE <-> AZITHROMYCINE"@fr;
  dct:identifier "IAM_10385";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b199930;
  r:natureDuRisque "Risque majoré d'effets indésirables (concentration-dépendants) à type de rhabdomyolyse, par diminution du métabolisme hépatique de l'hypocholestérolémiant."@fr;
  r:conduiteATenir "Utiliser des doses plus faibles d’hypocholestérolémiant ou une autre statine non concernée par ce type d’interaction."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b199936, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b199930 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b199931 .

_:79f295ad32df4ce8a18a92539c6e8a3b199931 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199932;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b199933 .

_:79f295ad32df4ce8a18a92539c6e8a3b199932 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10089 .

_:79f295ad32df4ce8a18a92539c6e8a3b199933 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199934;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b199934 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10100 .

_:79f295ad32df4ce8a18a92539c6e8a3b199936 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10386-1 a owl:Class;
  rdfs:label "ATORVASTATINE <-> BOCEPREVIR"@fr;
  dct:identifier "IAM_10386";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b199938;
  r:natureDuRisque "Risque majoré d'effets indésirables (concentration-dépendants) à type de rhabdomyolyse, par diminution du métabolisme hépatique de l'atorvastatine."@fr;
  r:conduiteATenir "Ne pas dépasser la posologie de 20mg/jour d'atorvastatine. Si l'objectif thérapeutique n'est pas atteint à cette posologie, utiliser une autre statine non concernée par ce type d'interaction."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b199944, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b199938 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b199939 .

_:79f295ad32df4ce8a18a92539c6e8a3b199939 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199940;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b199941 .

_:79f295ad32df4ce8a18a92539c6e8a3b199940 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10089 .

_:79f295ad32df4ce8a18a92539c6e8a3b199941 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199942;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b199942 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10126 .

_:79f295ad32df4ce8a18a92539c6e8a3b199944 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10387-1 a owl:Class;
  rdfs:label "ATORVASTATINE <-> CICLOSPORINE"@fr;
  dct:identifier "IAM_10387";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b199946;
  r:natureDuRisque "Risque majoré d'effets indésirables (concentration-dépendants) à type de rhabdomyolyse (diminution du métabolisme de l'hypocholestérolémiant)."@fr;
  r:conduiteATenir "Ne pas dépasser la posologie de 10mg/jour d'atorvastatine. Si l'objectif thérapeutique n'est pas atteint à cette posologie, utiliser une autre statine non concernée par ce type d'interaction."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b199952, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b199946 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b199947 .

_:79f295ad32df4ce8a18a92539c6e8a3b199947 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199948;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b199949 .

_:79f295ad32df4ce8a18a92539c6e8a3b199948 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10089 .

_:79f295ad32df4ce8a18a92539c6e8a3b199949 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199950;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b199950 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10193 .

_:79f295ad32df4ce8a18a92539c6e8a3b199952 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10388-1 a owl:Class;
  rdfs:label "ATORVASTATINE <-> CLARITHROMYCINE"@fr;
  dct:identifier "IAM_10388";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b199954;
  r:natureDuRisque "Risque majoré d'effets indésirables (concentration-dépendants) à type de rhabdomyolyse, par diminution du métabolisme hépatique de l'hypocholesterolémiant."@fr;
  r:conduiteATenir "Utiliser des doses plus faibles d'hypocholestérolémiant. Si l'objectif thérapeutique n'est pas atteint, utiliser une autre statine non concernée par ce type d'interaction."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b199960, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b199954 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b199955 .

_:79f295ad32df4ce8a18a92539c6e8a3b199955 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199956;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b199957 .

_:79f295ad32df4ce8a18a92539c6e8a3b199956 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10089 .

_:79f295ad32df4ce8a18a92539c6e8a3b199957 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199958;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b199958 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10206 .

_:79f295ad32df4ce8a18a92539c6e8a3b199960 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10389-1 a owl:Class;
  rdfs:label "ATORVASTATINE <-> DILTIAZEM"@fr;
  dct:identifier "IAM_10389";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b199962;
  r:natureDuRisque "Risque majoré d'effets indésirables (concentration-dépendants) à type de rhabdomyolyse, par diminution du métabolisme hépatique de l'hypocholestérolémiant."@fr;
  r:conduiteATenir "Utiliser des doses plus faibles d’hypocholestérolémiant ou une autre statine non concernée par ce type d’interaction."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b199968, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b199962 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b199963 .

_:79f295ad32df4ce8a18a92539c6e8a3b199963 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199964;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b199965 .

_:79f295ad32df4ce8a18a92539c6e8a3b199964 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10089 .

_:79f295ad32df4ce8a18a92539c6e8a3b199965 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199966;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b199966 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10290 .

_:79f295ad32df4ce8a18a92539c6e8a3b199968 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10390-1 a owl:Class;
  rdfs:label "ATORVASTATINE <-> ERYTHROMYCINE"@fr;
  dct:identifier "IAM_10390";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b199970;
  r:natureDuRisque "Risque majoré d'effets indésirables (concentration-dépendants) à type de rhabdomyolyse, par diminution du métabolisme hépatique de l'hypocholesterolémiant."@fr;
  r:conduiteATenir "Utiliser des doses plus faibles d'hypocholestérolémiant. Si l'objectif thérapeutique n'est pas atteint, utiliser une autre statine non concernée par ce type d'interaction."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b199976, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b199970 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b199971 .

_:79f295ad32df4ce8a18a92539c6e8a3b199971 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199972;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b199973 .

_:79f295ad32df4ce8a18a92539c6e8a3b199972 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10089 .

_:79f295ad32df4ce8a18a92539c6e8a3b199973 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199974;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b199974 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10338 .

_:79f295ad32df4ce8a18a92539c6e8a3b199976 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10391-1 a owl:Class;
  rdfs:label "ATORVASTATINE <-> INHIBITEURS DE PROTÉASES BOOSTÉS PAR RITONAVIR"@fr;
  dct:identifier "IAM_10391";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b199978;
  r:natureDuRisque "Risque majoré d'effets indésirables (concentration-dépendants) à type de rhabdomyolyse (diminution du métabolisme hépatique de l'atorvastatine)."@fr;
  r:conduiteATenir "Utiliser des doses plus faibles d'atorvastatine. Si l'objectif thérapeutique n'est pas atteint, utiliser une autre statine non concernée par ce type d'interaction."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b199984, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b199978 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b199979 .

_:79f295ad32df4ce8a18a92539c6e8a3b199979 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199980;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b199981 .

_:79f295ad32df4ce8a18a92539c6e8a3b199980 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10100 .

_:79f295ad32df4ce8a18a92539c6e8a3b199981 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199982;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b199982 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10089 .

_:79f295ad32df4ce8a18a92539c6e8a3b199984 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10392-1 a owl:Class;
  rdfs:label "ATORVASTATINE <-> ITRACONAZOLE"@fr;
  dct:identifier "IAM_10392";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b199986;
  r:natureDuRisque "Risque majoré d'effets indésirables (concentration-dépendants) à type de rhabdomyolyse (diminution du métabolisme hépatique de l'atorvastatine)."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b199992, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b199986 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b199987 .

_:79f295ad32df4ce8a18a92539c6e8a3b199987 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199988;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b199989 .

_:79f295ad32df4ce8a18a92539c6e8a3b199988 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10089 .

_:79f295ad32df4ce8a18a92539c6e8a3b199989 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199990;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b199990 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10496 .

_:79f295ad32df4ce8a18a92539c6e8a3b199992 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10380-1 a owl:Class;
  rdfs:label "ATAZANAVIR <-> BUPRENORPHINE"@fr;
  dct:identifier "IAM_10380";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b199994;
  r:natureDuRisque "Risque de majoration ou de diminution des effets de la buprénorphine, à la fois par inhibition et accélération de son métabolisme par l’inhibiteur de protéases."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b200000, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b199994 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b199995 .

_:79f295ad32df4ce8a18a92539c6e8a3b199995 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199996;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b199997 .

_:79f295ad32df4ce8a18a92539c6e8a3b199996 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10087 .

_:79f295ad32df4ce8a18a92539c6e8a3b199997 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b199998;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b199998 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10139 .

_:79f295ad32df4ce8a18a92539c6e8a3b200000 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10358-1 a owl:Class;
  rdfs:label "ANTIVITAMINES K <-> ROPINIROLE"@fr;
  dct:identifier "IAM_10358";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b200002;
  r:natureDuRisque "Augmentation du risque hémorragique."@fr;
  r:conduiteATenir "Contrôle plus fréquent de l’INR. Adaptation éventuelle de la posologie de l’antivitamine K pendant le traitement par ropinirole et après son arrêt."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b200008, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b200002 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b200003 .

_:79f295ad32df4ce8a18a92539c6e8a3b200003 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200004;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b200005 .

_:79f295ad32df4ce8a18a92539c6e8a3b200004 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10046 .

_:79f295ad32df4ce8a18a92539c6e8a3b200005 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200006;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b200006 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10813 .

_:79f295ad32df4ce8a18a92539c6e8a3b200008 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10522-1 a owl:Class;
  rdfs:label "CAFEINE <-> DIPYRIDAMOLE"@fr;
  dct:identifier "IAM_10522";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b200010;
  r:natureDuRisque "Avec le dipyridamole par voie injectable : réduction de l’effet vasodilatateur du dipyridamole par la caféine."@fr;
  r:conduiteATenir "Interrompre un traitement à base de caféine au moins 5 jours avant une imagerie myocardique avec le dipyridamole et éviter la consommation de café, thé, chocolat ou cola dans les 24 heures qui précèdent le test."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b200016, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b200010 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b200011 .

_:79f295ad32df4ce8a18a92539c6e8a3b200011 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200012;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b200013 .

_:79f295ad32df4ce8a18a92539c6e8a3b200012 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10147 .

_:79f295ad32df4ce8a18a92539c6e8a3b200013 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200014;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b200014 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10297 .

_:79f295ad32df4ce8a18a92539c6e8a3b200016 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10334-1 a owl:Class;
  rdfs:label "ANTIVITAMINES K <-> FLUCONAZOLE"@fr;
  dct:identifier "IAM_10334";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b200018;
  r:natureDuRisque "Augmentation de l'effet de l'antivitamine K et du risque hémorragique."@fr;
  r:conduiteATenir "Contrôle plus fréquent de l'INR. Adaptation éventuelle de la posologie de l'antivitamine K pendant le traitement par le fluconazole et 8 jours après son arrêt."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b200024, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b200018 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b200019 .

_:79f295ad32df4ce8a18a92539c6e8a3b200019 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200020;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b200021 .

_:79f295ad32df4ce8a18a92539c6e8a3b200020 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10046 .

_:79f295ad32df4ce8a18a92539c6e8a3b200021 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200022;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b200022 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10381 .

_:79f295ad32df4ce8a18a92539c6e8a3b200024 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10335-1 a owl:Class;
  rdfs:label "ANTIVITAMINES K <-> FLUOROQUINOLONES"@fr;
  dct:identifier "IAM_10335";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b200026;
  r:chapeau """ANTI-INFECTIEUX ET INR
De nombreux cas d’augmentation de l’activité des antivitamines K ont été rapportés chez des patients recevant des antibiotiques. Le contexte infectieux ou inflammatoire marqué, l’âge et l’état général du patient apparaissent comme d"""@fr;
  r:natureDuRisque "Augmentation de l'effet de l'antivitamine K et du risque hémorragique."@fr;
  r:conduiteATenir "Contrôle plus fréquent de l'INR. Adaptation éventuelle de la posologie de l'antivitamine K pendant le traitement par la fluoroquinolone et après son arrêt."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b200032, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b200026 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b200027 .

_:79f295ad32df4ce8a18a92539c6e8a3b200027 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200028;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b200029 .

_:79f295ad32df4ce8a18a92539c6e8a3b200028 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10046 .

_:79f295ad32df4ce8a18a92539c6e8a3b200029 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200030;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b200030 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10075 .

_:79f295ad32df4ce8a18a92539c6e8a3b200032 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10336-1 a owl:Class;
  rdfs:label "ANTIVITAMINES K <-> FLUOROURACILE (ET, PAR EXTRAPOLATION, AUTRES FLUOROPYRIMIDINES)"@fr;
  dct:identifier "IAM_10336";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b200034;
  r:natureDuRisque "Augmentation importante de l'effet de l'antivitamine K et du risque hémorragique."@fr;
  r:conduiteATenir "Si elle ne peut être évitée, contrôle plus fréquent de l'INR. Adaptation de la posologie de l'antivitamine K pendant le traitement par le cytotoxique et 8 jours après son arrêt."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b200040, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b200034 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b200035 .

_:79f295ad32df4ce8a18a92539c6e8a3b200035 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200036;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b200037 .

_:79f295ad32df4ce8a18a92539c6e8a3b200036 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10046 .

_:79f295ad32df4ce8a18a92539c6e8a3b200037 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200038;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b200038 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10076 .

_:79f295ad32df4ce8a18a92539c6e8a3b200040 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10337-1 a owl:Class;
  rdfs:label "ANTIVITAMINES K <-> GLUCOSAMINE"@fr;
  dct:identifier "IAM_10337";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b200042;
  r:natureDuRisque "Augmentation du risque hémorragique."@fr;
  r:conduiteATenir "Contrôle plus fréquent de l’INR. Adapation éventuelle de la posologie de l’antivitamine K."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b200048, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b200042 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b200043 .

_:79f295ad32df4ce8a18a92539c6e8a3b200043 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200044;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b200045 .

_:79f295ad32df4ce8a18a92539c6e8a3b200044 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10046 .

_:79f295ad32df4ce8a18a92539c6e8a3b200045 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200046;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b200046 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10418 .

_:79f295ad32df4ce8a18a92539c6e8a3b200048 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10339-1 a owl:Class;
  rdfs:label "ANTIVITAMINES K <-> HÉPARINES NON FRACTIONNÉES (DOSES CURATIVES ET/OU SUJET ÂGÉ)"@fr;
  dct:identifier "IAM_10339";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b200050;
  r:natureDuRisque "Augmentation du risque hémorragique."@fr;
  r:conduiteATenir "Lors du relais de l'héparine par l'antivitamine K, renforcer la surveillance clinique."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b200056, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b200050 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b200051 .

_:79f295ad32df4ce8a18a92539c6e8a3b200051 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200052;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b200053 .

_:79f295ad32df4ce8a18a92539c6e8a3b200052 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10046 .

_:79f295ad32df4ce8a18a92539c6e8a3b200053 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200054;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b200054 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10091 .

_:79f295ad32df4ce8a18a92539c6e8a3b200056 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10338-1 a owl:Class;
  rdfs:label "ANTIVITAMINES K <-> GRISEOFULVINE"@fr;
  dct:identifier "IAM_10338";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b200058;
  r:natureDuRisque "Diminution de l'effet de l'antivitamine K par augmentation de son métabolisme hépatique par la griséofulvine."@fr;
  r:conduiteATenir "Contrôle plus fréquent de l'INR. Adaptation éventuelle de la posologie de l'antivitamine K pendant le traitement par la griséofulvine et 8 jours après son arrêt."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b200064, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b200058 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b200059 .

_:79f295ad32df4ce8a18a92539c6e8a3b200059 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200060;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b200061 .

_:79f295ad32df4ce8a18a92539c6e8a3b200060 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10046 .

_:79f295ad32df4ce8a18a92539c6e8a3b200061 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200062;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b200062 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10422 .

_:79f295ad32df4ce8a18a92539c6e8a3b200064 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10340-1 a owl:Class;
  rdfs:label "ANTIVITAMINES K <-> IMATINIB"@fr;
  dct:identifier "IAM_10340";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b200066;
  r:natureDuRisque "Augmentation du risque hémorragique."@fr;
  r:conduiteATenir "Si l'association ne peut être évitée, surveillance clinique étroite et mesure fréquente de l'INR."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b200072, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b200066 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b200067 .

_:79f295ad32df4ce8a18a92539c6e8a3b200067 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200068;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b200069 .

_:79f295ad32df4ce8a18a92539c6e8a3b200068 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10046 .

_:79f295ad32df4ce8a18a92539c6e8a3b200069 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200070;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b200070 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10448 .

_:79f295ad32df4ce8a18a92539c6e8a3b200072 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10341-1 a owl:Class;
  rdfs:label "ANTIVITAMINES K <-> INHIBITEURS DE L'HMG-COA RÉDUCTASE (STATINES)"@fr;
  dct:identifier "IAM_10341";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b200074;
  r:natureDuRisque "Augmentation de l'effet de l'antivitamine K et du risque hémorragique."@fr;
  r:conduiteATenir "Contrôle plus fréquent de l'INR. Adaptation éventuelle de la posologie de l'antivitamine K."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b200080, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b200074 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b200075 .

_:79f295ad32df4ce8a18a92539c6e8a3b200075 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200076;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b200077 .

_:79f295ad32df4ce8a18a92539c6e8a3b200076 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10046 .

_:79f295ad32df4ce8a18a92539c6e8a3b200077 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200078;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b200078 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10095 .

_:79f295ad32df4ce8a18a92539c6e8a3b200080 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10371-1 a owl:Class;
  rdfs:label "APOMORPHINE <-> ONDANSETRON"@fr;
  dct:identifier "IAM_10371";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b200082;
  r:natureDuRisque "Des hypotensions sévères et des pertes de connaissance ont été rapportées lors de l’association d’ondansetron avec l’apomorphine."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b200088, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b200082 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b200083 .

_:79f295ad32df4ce8a18a92539c6e8a3b200083 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200084;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b200085 .

_:79f295ad32df4ce8a18a92539c6e8a3b200084 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10079 .

_:79f295ad32df4ce8a18a92539c6e8a3b200085 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200086;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b200086 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10665 .

_:79f295ad32df4ce8a18a92539c6e8a3b200088 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10357-1 a owl:Class;
  rdfs:label "ANTIVITAMINES K <-> RIFAMPICINE"@fr;
  dct:identifier "IAM_10357";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b200090;
  r:natureDuRisque "Diminution de l'effet de l'antivitamine K par augmentation de son métabolisme hépatique par la rifampicine."@fr;
  r:conduiteATenir "Contrôle plus fréquent de l'INR. Adaptation éventuelle de la posologie de l'antivitamine K pendant le traitement par la rifampicine et 8 jours après son arrêt."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b200096, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b200090 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b200091 .

_:79f295ad32df4ce8a18a92539c6e8a3b200091 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200092;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b200093 .

_:79f295ad32df4ce8a18a92539c6e8a3b200092 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10046 .

_:79f295ad32df4ce8a18a92539c6e8a3b200093 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200094;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b200094 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:79f295ad32df4ce8a18a92539c6e8a3b200096 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10332-1 a owl:Class;
  rdfs:label "ANTIVITAMINES K <-> EFAVIRENZ"@fr;
  dct:identifier "IAM_10332";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b200098;
  r:chapeau """ANTI-INFECTIEUX ET INR
De nombreux cas d’augmentation de l’activité des antivitamines K ont été rapportés chez des patients recevant des antibiotiques. Le contexte infectieux ou inflammatoire marqué, l’âge et l’état général du patient apparaissent comme d"""@fr;
  r:natureDuRisque "Diminution de l'effet de l'antivitamine K par augmentation de son métabolisme hépatique."@fr;
  r:conduiteATenir "Contrôle plus fréquent de l'INR. Adaptation éventuelle de la posologie de l'antivitamine K."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b200104, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b200098 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b200099 .

_:79f295ad32df4ce8a18a92539c6e8a3b200099 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200100;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b200101 .

_:79f295ad32df4ce8a18a92539c6e8a3b200100 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10046 .

_:79f295ad32df4ce8a18a92539c6e8a3b200101 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200102;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b200102 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10318 .

_:79f295ad32df4ce8a18a92539c6e8a3b200104 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10359-1 a owl:Class;
  rdfs:label "ANTIVITAMINES K <-> SUCRALFATE"@fr;
  dct:identifier "IAM_10359";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b200106;
  r:natureDuRisque "Diminution de l'absorption digestive de l'antivitamine K."@fr;
  r:conduiteATenir "Prendre le sucralfate à distance de l'antivitamine K (plus de 2 heures, si possible)."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b200112, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b200106 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b200107 .

_:79f295ad32df4ce8a18a92539c6e8a3b200107 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200108;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b200109 .

_:79f295ad32df4ce8a18a92539c6e8a3b200108 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10046 .

_:79f295ad32df4ce8a18a92539c6e8a3b200109 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200110;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b200110 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10864 .

_:79f295ad32df4ce8a18a92539c6e8a3b200112 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10360-1 a owl:Class;
  rdfs:label "ANTIVITAMINES K <-> SULFAFURAZOL"@fr;
  dct:identifier "IAM_10360";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b200114;
  r:natureDuRisque "Augmentation de l'effet de l'antivitamine K et du risque hémorragique."@fr;
  r:conduiteATenir "Contrôle plus fréquent de l'INR. Adaptation éventuelle de la posologie de l'antivitamine K pendant le traitement anti-infectieux et 8 jours après son arrêt."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b200120, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b200114 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b200115 .

_:79f295ad32df4ce8a18a92539c6e8a3b200115 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200116;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b200117 .

_:79f295ad32df4ce8a18a92539c6e8a3b200116 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10046 .

_:79f295ad32df4ce8a18a92539c6e8a3b200117 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200118;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b200118 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10868 .

_:79f295ad32df4ce8a18a92539c6e8a3b200120 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10361-1 a owl:Class;
  rdfs:label "ANTIVITAMINES K <-> SULFAMETHIZOL"@fr;
  dct:identifier "IAM_10361";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b200122;
  r:natureDuRisque "Augmentation de l'effet de l'antivitamine K et du risque hémorragique."@fr;
  r:conduiteATenir "Contrôle plus fréquent de l'INR. Adaptation éventuelle de la posologie de l'antivitamine K pendant le traitement anti-infectieux et 8 jours après son arrêt."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b200128, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b200122 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b200123 .

_:79f295ad32df4ce8a18a92539c6e8a3b200123 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200124;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b200125 .

_:79f295ad32df4ce8a18a92539c6e8a3b200124 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10046 .

_:79f295ad32df4ce8a18a92539c6e8a3b200125 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200126;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b200126 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10870 .

_:79f295ad32df4ce8a18a92539c6e8a3b200128 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10362-1 a owl:Class;
  rdfs:label "ANTIVITAMINES K <-> SULFAMETHOXAZOLE"@fr;
  dct:identifier "IAM_10362";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b200130;
  r:natureDuRisque "Augmentation importante de l’effet de l’antivitamine K et du risque hémorragique."@fr;
  r:conduiteATenir "Si l’association ne peut être évitée, contrôle plus fréquent de l’INR et adaptation de la posologie de l’antivitamine K pendant le traitement par cotrimoxazole et après son arrêt."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b200136, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b200130 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b200131 .

_:79f295ad32df4ce8a18a92539c6e8a3b200131 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200132;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b200133 .

_:79f295ad32df4ce8a18a92539c6e8a3b200132 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10046 .

_:79f295ad32df4ce8a18a92539c6e8a3b200133 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200134;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b200134 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10871 .

_:79f295ad32df4ce8a18a92539c6e8a3b200136 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10363-1 a owl:Class;
  rdfs:label "ANTIVITAMINES K <-> TAMOXIFENE"@fr;
  dct:identifier "IAM_10363";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b200138;
  r:natureDuRisque "Risque d'augmentation de l'effet de l'antivitamine K et du risque hémorragique."@fr;
  r:conduiteATenir "Contrôle plus fréquent de l'INR. Adaptation éventuelle de la posologie de l'antivitamine K."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b200144, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b200138 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b200139 .

_:79f295ad32df4ce8a18a92539c6e8a3b200139 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200140;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b200141 .

_:79f295ad32df4ce8a18a92539c6e8a3b200140 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10046 .

_:79f295ad32df4ce8a18a92539c6e8a3b200141 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200142;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b200142 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10882 .

_:79f295ad32df4ce8a18a92539c6e8a3b200144 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10364-1 a owl:Class;
  rdfs:label "ANTIVITAMINES K <-> THROMBOLYTIQUES"@fr;
  dct:identifier "IAM_10364";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b200146;
  r:chapeau """ANTI-INFECTIEUX ET INR
De nombreux cas d’augmentation de l’activité des antivitamines K ont été rapportés chez des patients recevant des antibiotiques. Le contexte infectieux ou inflammatoire marqué, l’âge et l’état général du patient apparaissent comme d"""@fr;
  r:natureDuRisque "Augmentation du risque hémorragique."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b200152, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b200146 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b200147 .

_:79f295ad32df4ce8a18a92539c6e8a3b200147 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200148;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b200149 .

_:79f295ad32df4ce8a18a92539c6e8a3b200148 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10046 .

_:79f295ad32df4ce8a18a92539c6e8a3b200149 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200150;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b200150 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10151 .

_:79f295ad32df4ce8a18a92539c6e8a3b200152 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10365-1 a owl:Class;
  rdfs:label "ANTIVITAMINES K <-> TIBOLONE"@fr;
  dct:identifier "IAM_10365";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b200154;
  r:chapeau """ANTI-INFECTIEUX ET INR
De nombreux cas d’augmentation de l’activité des antivitamines K ont été rapportés chez des patients recevant des antibiotiques. Le contexte infectieux ou inflammatoire marqué, l’âge et l’état général du patient apparaissent comme d"""@fr;
  r:natureDuRisque "Augmentation de l'effet de l'antivitamine K et du risque hémorragique."@fr;
  r:conduiteATenir "Contrôle plus fréquent de l'INR. Adaptation éventuelle de la posologie de l'antivitamine K pendant le traitement par la tibolone et après son arrêt."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b200160, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b200154 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b200155 .

_:79f295ad32df4ce8a18a92539c6e8a3b200155 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200156;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b200157 .

_:79f295ad32df4ce8a18a92539c6e8a3b200156 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10046 .

_:79f295ad32df4ce8a18a92539c6e8a3b200157 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200158;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b200158 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10925 .

_:79f295ad32df4ce8a18a92539c6e8a3b200160 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10366-1 a owl:Class;
  rdfs:label "ANTIVITAMINES K <-> TRAMADOL"@fr;
  dct:identifier "IAM_10366";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b200162;
  r:natureDuRisque "Risque d’augmentation de l’effet de l’antivitamine K et du risque hémorragique."@fr;
  r:conduiteATenir "Contrôle plus fréquent de l’INR. Adaptation éventuelle de la posologie de l’antivitamine K pendant le traitement par le tramadol et après son arrêt."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b200168, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b200162 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b200163 .

_:79f295ad32df4ce8a18a92539c6e8a3b200163 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200164;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b200165 .

_:79f295ad32df4ce8a18a92539c6e8a3b200164 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10046 .

_:79f295ad32df4ce8a18a92539c6e8a3b200165 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200166;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b200166 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10945 .

_:79f295ad32df4ce8a18a92539c6e8a3b200168 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10367-1 a owl:Class;
  rdfs:label "ANTIVITAMINES K <-> VORICONAZOLE"@fr;
  dct:identifier "IAM_10367";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b200170;
  r:natureDuRisque "Augmentation de l'effet de l'antivitamine K et du risque hémorragique par diminution de son métabolisme hépatique."@fr;
  r:conduiteATenir "Contrôle plus fréquent de l'INR. Adaptation éventuelle de la posologie de l'antivitamine K pendant le traitement par voriconazole et 8 jours après son arrêt."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b200176, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b200170 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b200171 .

_:79f295ad32df4ce8a18a92539c6e8a3b200171 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200172;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b200173 .

_:79f295ad32df4ce8a18a92539c6e8a3b200172 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10046 .

_:79f295ad32df4ce8a18a92539c6e8a3b200173 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200174;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b200174 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10998 .

_:79f295ad32df4ce8a18a92539c6e8a3b200176 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10368-1 a owl:Class;
  rdfs:label "APIXABAN <-> FLUCONAZOLE"@fr;
  dct:identifier "IAM_10368";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b200178;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de l'apixaban par le fluconazole, avec majoration du risque de saignement."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b200184, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b200178 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b200179 .

_:79f295ad32df4ce8a18a92539c6e8a3b200179 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200180;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b200181 .

_:79f295ad32df4ce8a18a92539c6e8a3b200180 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10078 .

_:79f295ad32df4ce8a18a92539c6e8a3b200181 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200182;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b200182 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10381 .

_:79f295ad32df4ce8a18a92539c6e8a3b200184 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10342-1 a owl:Class;
  rdfs:label "ANTIVITAMINES K <-> INHIBITEURS DE PROTÉASES BOOSTÉS PAR RITONAVIR"@fr;
  dct:identifier "IAM_10342";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b200186;
  r:chapeau "Le ritonavir est désormais utilisé à la dose de 100 mg 2 fois par jour en association à un autre inhibiteur de protéase, dans le but d'augmenter de façon très significative la biodisponibilité de l'inhibiteur de protéase associé (ou boosté), ce qui permet"@fr;
  r:natureDuRisque "Variation de l'effet de l'antivitamine K, le plus souvent dans le sens d'une diminution."@fr;
  r:conduiteATenir "Contrôle plus fréquent de l'INR. Adaptation éventuelle de la posologie de l'antivitamine K pendant la durée du traitement."@fr;
  rdfs:comment """Il existe une interaction au niveau \"précaution d'emploi\" évoquant une modification de l'effet de l'anticoagulant oral, « le plus souvent dans le sens d’une diminution ». 
Il existe en effet une disproportion importante entre les cas rapportés : un seul c"""@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b200192, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b200186 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b200187 .

_:79f295ad32df4ce8a18a92539c6e8a3b200187 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200188;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b200189 .

_:79f295ad32df4ce8a18a92539c6e8a3b200188 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10046 .

_:79f295ad32df4ce8a18a92539c6e8a3b200189 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200190;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b200190 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10100 .

_:79f295ad32df4ce8a18a92539c6e8a3b200192 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10641-1 a owl:Class;
  rdfs:label "CLARITHROMYCINE <-> GLIMEPIRIDE"@fr;
  dct:identifier "IAM_10641";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b200194;
  r:natureDuRisque "Risque d'hypoglycémie par augmentation de l’absorption et des concentrations plasmatiques de l’antidiabétique."@fr;
  r:conduiteATenir "Prévenir le patient, renforcer l'autosurveillance glycémique et adapter éventuellement la posologie du sulfamide hypoglycémiant pendant le traitement par la clarithromycine."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b200200, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b200194 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b200195 .

_:79f295ad32df4ce8a18a92539c6e8a3b200195 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200196;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b200197 .

_:79f295ad32df4ce8a18a92539c6e8a3b200196 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10206 .

_:79f295ad32df4ce8a18a92539c6e8a3b200197 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200198;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b200198 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10416 .

_:79f295ad32df4ce8a18a92539c6e8a3b200200 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10632-1 a owl:Class;
  rdfs:label "CIPROFLOXACINE <-> THÉOPHYLLINE (ET, PAR EXTRAPOLATION, AMINOPHYLLINE)"@fr;
  dct:identifier "IAM_10632";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b200202;
  r:natureDuRisque "Augmentation de la théophyllinémie avec risque de surdosage, par diminution de son métabolisme hépatique par la ciprofloxacine."@fr;
  r:conduiteATenir "Surveillance clinique et éventuellement de la théophyllinémie."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b200208, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b200202 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b200203 .

_:79f295ad32df4ce8a18a92539c6e8a3b200203 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200204;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b200205 .

_:79f295ad32df4ce8a18a92539c6e8a3b200204 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10152 .

_:79f295ad32df4ce8a18a92539c6e8a3b200205 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200206;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b200206 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10200 .

_:79f295ad32df4ce8a18a92539c6e8a3b200208 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10633-1 a owl:Class;
  rdfs:label "CLADRIBINE <-> LAMIVUDINE"@fr;
  dct:identifier "IAM_10633";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b200210;
  r:natureDuRisque "Risque de diminution de l’efficacité de la cladribine par la lamivudine."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b200216, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b200210 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b200211 .

_:79f295ad32df4ce8a18a92539c6e8a3b200211 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200212;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b200213 .

_:79f295ad32df4ce8a18a92539c6e8a3b200212 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10205 .

_:79f295ad32df4ce8a18a92539c6e8a3b200213 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200214;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b200214 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10506 .

_:79f295ad32df4ce8a18a92539c6e8a3b200216 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10656-1 a owl:Class;
  rdfs:label "CLARITHROMYCINE <-> VINCA-ALCALOÏDES CYTOTOXIQUES"@fr;
  dct:identifier "IAM_10656";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b200218;
  r:natureDuRisque "Risque de majoration de la toxicité de l'antimitotique par diminution de son métabolisme hépatique par la clarithromycine."@fr;
  r:conduiteATenir "Surveillance clinique et biologique étroite. Eventuellement, utiliser un autre antibiotique."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b200224, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b200218 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b200219 .

_:79f295ad32df4ce8a18a92539c6e8a3b200219 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200220;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b200221 .

_:79f295ad32df4ce8a18a92539c6e8a3b200220 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10161 .

_:79f295ad32df4ce8a18a92539c6e8a3b200221 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200222;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b200222 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10206 .

_:79f295ad32df4ce8a18a92539c6e8a3b200224 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10645-1 a owl:Class;
  rdfs:label "CLARITHROMYCINE <-> LUMEFANTRINE"@fr;
  dct:identifier "IAM_10645";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b200226;
  r:natureDuRisque "Risque majoré de troubles du rythme ventriculaire, notamment de torsades de pointes."@fr;
  r:conduiteATenir "Si cela est possible, interrompre le torsadogène associé. Si l'association ne peut être évitée, contrôle préalable du QT et surveillance ECG monitorée."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b200232, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b200226 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b200227 .

_:79f295ad32df4ce8a18a92539c6e8a3b200227 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200228;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b200229 .

_:79f295ad32df4ce8a18a92539c6e8a3b200228 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10206 .

_:79f295ad32df4ce8a18a92539c6e8a3b200229 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200230;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b200230 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10541 .

_:79f295ad32df4ce8a18a92539c6e8a3b200232 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10634-1 a owl:Class;
  rdfs:label "CLARITHROMYCINE <-> DEXAMETHASONE"@fr;
  dct:identifier "IAM_10634";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b200234;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de la dexaméthasone par diminution de son métabolisme hépatique par l'inhibiteur enzymatique, avec risque d’apparition d’un syndrome cushingoïde."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b200240, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b200234 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b200235 .

_:79f295ad32df4ce8a18a92539c6e8a3b200235 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200236;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b200237 .

_:79f295ad32df4ce8a18a92539c6e8a3b200236 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10206 .

_:79f295ad32df4ce8a18a92539c6e8a3b200237 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200238;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b200238 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10272 .

_:79f295ad32df4ce8a18a92539c6e8a3b200240 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10635-1 a owl:Class;
  rdfs:label "CLARITHROMYCINE <-> DIGOXINE"@fr;
  dct:identifier "IAM_10635";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b200242;
  r:natureDuRisque "Augmentation de la digoxinémie par augmentation de son absorption."@fr;
  r:conduiteATenir "Surveillance clinique et éventuellement de la digoxinémie pendant le traitement par la clarithromycine et après son arrêt."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b200248, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b200242 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b200243 .

_:79f295ad32df4ce8a18a92539c6e8a3b200243 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200244;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b200245 .

_:79f295ad32df4ce8a18a92539c6e8a3b200244 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10206 .

_:79f295ad32df4ce8a18a92539c6e8a3b200245 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200246;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b200246 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10286 .

_:79f295ad32df4ce8a18a92539c6e8a3b200248 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10636-1 a owl:Class;
  rdfs:label "CLARITHROMYCINE <-> EBASTINE"@fr;
  dct:identifier "IAM_10636";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b200250;
  r:natureDuRisque "Risque majoré de troubles du rythme ventriculaire chez les sujets prédisposés (syndrome du QT long congénital)."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b200256, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b200250 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b200251 .

_:79f295ad32df4ce8a18a92539c6e8a3b200251 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200252;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b200253 .

_:79f295ad32df4ce8a18a92539c6e8a3b200252 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10206 .

_:79f295ad32df4ce8a18a92539c6e8a3b200253 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200254;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b200254 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10316 .

_:79f295ad32df4ce8a18a92539c6e8a3b200256 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10637-1 a owl:Class;
  rdfs:label "CLARITHROMYCINE <-> ÉRIBULINE"@fr;
  dct:identifier "IAM_10637";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b200258;
  r:natureDuRisque "Augmentation des concentrations plasmatiques d’éribuline par la clarithromycine."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b200264, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b200258 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b200259 .

_:79f295ad32df4ce8a18a92539c6e8a3b200259 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200260;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b200261 .

_:79f295ad32df4ce8a18a92539c6e8a3b200260 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10206 .

_:79f295ad32df4ce8a18a92539c6e8a3b200261 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200262;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b200262 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10335 .

_:79f295ad32df4ce8a18a92539c6e8a3b200264 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10638-1 a owl:Class;
  rdfs:label "CLARITHROMYCINE <-> ETRAVIRINE"@fr;
  dct:identifier "IAM_10638";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b200266;
  r:natureDuRisque "Dans le traitement des infections à Mycobacterium avium complex, risque de diminution de l’efficacité de la clarithromycine par augmentation de son métabolisme hépatique par l’étravirine."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b200272, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b200266 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b200267 .

_:79f295ad32df4ce8a18a92539c6e8a3b200267 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200268;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b200269 .

_:79f295ad32df4ce8a18a92539c6e8a3b200268 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10206 .

_:79f295ad32df4ce8a18a92539c6e8a3b200269 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200270;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b200270 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10360 .

_:79f295ad32df4ce8a18a92539c6e8a3b200272 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10607-1 a owl:Class;
  rdfs:label "CICLOSPORINE <-> TÉNOFOVIR ALAFÉNAMIDE"@fr;
  dct:identifier "IAM_10607";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b200274;
  r:natureDuRisque "Augmentation des concentrations plasmatiques du ténofovir alafénamide par augmentation de son absorption."@fr;
  r:conduiteATenir "En cas de co-administration avec la ciclosporine, la dose de ténofovir alafénamide doit être limitée à 10 mg par jour."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b200280, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b200274 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b200275 .

_:79f295ad32df4ce8a18a92539c6e8a3b200275 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200276;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b200277 .

_:79f295ad32df4ce8a18a92539c6e8a3b200276 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10193 .

_:79f295ad32df4ce8a18a92539c6e8a3b200277 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200278;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b200278 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10895 .

_:79f295ad32df4ce8a18a92539c6e8a3b200280 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10640-1 a owl:Class;
  rdfs:label "CLARITHROMYCINE <-> GLIBENCLAMIDE"@fr;
  dct:identifier "IAM_10640";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b200282;
  r:natureDuRisque "Risque d'hypoglycémie par augmentation de l’absorption et des concentrations plasmatiques de l’antidiabétique."@fr;
  r:conduiteATenir "Prévenir le patient, renforcer l'autosurveillance glycémique et adapter éventuellement la posologie du sulfamide hypoglycémiant pendant le traitement par la clarithromycine."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b200288, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b200282 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b200283 .

_:79f295ad32df4ce8a18a92539c6e8a3b200283 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200284;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b200285 .

_:79f295ad32df4ce8a18a92539c6e8a3b200284 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10206 .

_:79f295ad32df4ce8a18a92539c6e8a3b200285 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200286;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b200286 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10414 .

_:79f295ad32df4ce8a18a92539c6e8a3b200288 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10629-1 a owl:Class;
  rdfs:label "CIPROFLOXACINE <-> PHÉNYTOÏNE (ET, PAR EXTRAPOLATION, FOSPHÉNYTOÏNE)"@fr;
  dct:identifier "IAM_10629";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b200290;
  r:natureDuRisque """Variation, éventuellement importante, des concentrations de
phénytoïne en cas de traitement par la ciprofloxacine."""@fr;
  r:conduiteATenir "Surveillance clinique et contrôle des concentrations plasmatiques de l’anticonvulsivant pendant le traitement par ciprofloxacine et après son arrêt."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b200296, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b200290 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b200291 .

_:79f295ad32df4ce8a18a92539c6e8a3b200291 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200292;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b200293 .

_:79f295ad32df4ce8a18a92539c6e8a3b200292 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10132 .

_:79f295ad32df4ce8a18a92539c6e8a3b200293 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200294;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b200294 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10200 .

_:79f295ad32df4ce8a18a92539c6e8a3b200296 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10642-1 a owl:Class;
  rdfs:label "CLARITHROMYCINE <-> IMMUNOSUPPRESSEURS"@fr;
  dct:identifier "IAM_10642";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b200298;
  r:natureDuRisque "Augmentation très importante des concentrations sanguines de l'immunosuppresseur par inhibition de son métabolisme hépatique."@fr;
  r:conduiteATenir "En cas d’association, contrôle strict de la fonction rénale, dosage des concentrations sanguines de l'immunosuppresseur et adaptation éventuelle de la posologie."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b200304, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b200298 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b200299 .

_:79f295ad32df4ce8a18a92539c6e8a3b200299 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200300;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b200301 .

_:79f295ad32df4ce8a18a92539c6e8a3b200300 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10093 .

_:79f295ad32df4ce8a18a92539c6e8a3b200301 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200302;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b200302 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10206 .

_:79f295ad32df4ce8a18a92539c6e8a3b200304 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10643-1 a owl:Class;
  rdfs:label "CLARITHROMYCINE <-> INHIBITEURS DE PROTÉASES BOOSTÉS PAR RITONAVIR"@fr;
  dct:identifier "IAM_10643";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b200306;
  r:natureDuRisque "Augmentation des concentrations de la clarithromycine et de son métabolite actif par diminution de son métabolisme hépatique par l'inhibiteur de protéases."@fr;
  r:conduiteATenir "Surveillance clinique et biologique régulière, notamment en début d'association."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b200312, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b200306 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b200307 .

_:79f295ad32df4ce8a18a92539c6e8a3b200307 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200308;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b200309 .

_:79f295ad32df4ce8a18a92539c6e8a3b200308 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10100 .

_:79f295ad32df4ce8a18a92539c6e8a3b200309 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200310;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b200310 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10206 .

_:79f295ad32df4ce8a18a92539c6e8a3b200312 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10644-1 a owl:Class;
  rdfs:label "CLARITHROMYCINE <-> LINEZOLIDE"@fr;
  dct:identifier "IAM_10644";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b200314;
  r:natureDuRisque "Risque de majoration des effets indésirables du linézolide par la clarithromycine, par augmentation de son absorption."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b200320, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b200314 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b200315 .

_:79f295ad32df4ce8a18a92539c6e8a3b200315 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200316;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b200317 .

_:79f295ad32df4ce8a18a92539c6e8a3b200316 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10206 .

_:79f295ad32df4ce8a18a92539c6e8a3b200317 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200318;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b200318 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10526 .

_:79f295ad32df4ce8a18a92539c6e8a3b200320 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10646-1 a owl:Class;
  rdfs:label "CLARITHROMYCINE <-> MIZOLASTINE"@fr;
  dct:identifier "IAM_10646";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b200322;
  r:natureDuRisque "Risque de troubles du rythme ventriculaire, notamment de torsades de pointes."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b200328, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b200322 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b200323 .

_:79f295ad32df4ce8a18a92539c6e8a3b200323 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200324;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b200325 .

_:79f295ad32df4ce8a18a92539c6e8a3b200324 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10206 .

_:79f295ad32df4ce8a18a92539c6e8a3b200325 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200326;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b200326 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10597 .

_:79f295ad32df4ce8a18a92539c6e8a3b200328 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10647-1 a owl:Class;
  rdfs:label "CLARITHROMYCINE <-> PRAVASTATINE"@fr;
  dct:identifier "IAM_10647";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b200330;
  r:natureDuRisque "Augmentation de la concentration plasmatique de la pravastatine par la clarithromycine."@fr;
  r:conduiteATenir "Surveillance clinique et biologique pendant le traitement par l'antibiotique."@fr;
  rdfs:comment "La clarithromycine et l’érythromycine sont des inhibiteurs puissants du CYP3A4 et de la P-gp intestinale, transporteur qui intervient dans l’efflux de nombreux médicaments au niveau de la lumière intestinale et qui limite donc leur absorption digestive. L"@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b200336, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b200330 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b200331 .

_:79f295ad32df4ce8a18a92539c6e8a3b200331 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200332;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b200333 .

_:79f295ad32df4ce8a18a92539c6e8a3b200332 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10206 .

_:79f295ad32df4ce8a18a92539c6e8a3b200333 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200334;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b200334 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10748 .

_:79f295ad32df4ce8a18a92539c6e8a3b200336 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10648-1 a owl:Class;
  rdfs:label "CLARITHROMYCINE <-> REPAGLINIDE"@fr;
  dct:identifier "IAM_10648";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b200338;
  r:natureDuRisque "Risque d'hypoglycémie par augmentation des concentrations plasmatiques du répaglinide."@fr;
  r:conduiteATenir "Prévenir le patient, renforcer l'autosurveillance glycémique et adapter éventuellement la posologie de l'hypoglycémiant pendant le traitement par la clarithromycine."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b200344, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b200338 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b200339 .

_:79f295ad32df4ce8a18a92539c6e8a3b200339 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200340;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b200341 .

_:79f295ad32df4ce8a18a92539c6e8a3b200340 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10206 .

_:79f295ad32df4ce8a18a92539c6e8a3b200341 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200342;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b200342 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10791 .

_:79f295ad32df4ce8a18a92539c6e8a3b200344 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10649-1 a owl:Class;
  rdfs:label "CLARITHROMYCINE <-> RIFABUTINE"@fr;
  dct:identifier "IAM_10649";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b200346;
  r:natureDuRisque "Risque d'augmentation des effets indésirables de la rifabutine (uvéites) par augmentation de ses concentrations et de celle de son métabolite actif par la clarithromycine. De plus, augmentation du métabolisme de la clarithromycine par la rifabutine, avec"@fr;
  r:conduiteATenir "Surveillance clinique et biologique régulière, notamment en début d'association."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b200352, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b200346 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b200347 .

_:79f295ad32df4ce8a18a92539c6e8a3b200347 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200348;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b200349 .

_:79f295ad32df4ce8a18a92539c6e8a3b200348 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10206 .

_:79f295ad32df4ce8a18a92539c6e8a3b200349 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200350;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b200350 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10800 .

_:79f295ad32df4ce8a18a92539c6e8a3b200352 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10650-1 a owl:Class;
  rdfs:label "CLARITHROMYCINE <-> RIFAMPICINE"@fr;
  dct:identifier "IAM_10650";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b200354;
  r:natureDuRisque "Diminution des concentrations plasmatiques et risque de baisse de l'efficacité de la clarithromycine, notamment chez le patient HIV, par augmentation de son métabolisme hépatique par la rifampicine."@fr;
  r:conduiteATenir "Surveillance clinique et biologique régulière."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b200360, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b200354 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b200355 .

_:79f295ad32df4ce8a18a92539c6e8a3b200355 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200356;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b200357 .

_:79f295ad32df4ce8a18a92539c6e8a3b200356 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10206 .

_:79f295ad32df4ce8a18a92539c6e8a3b200357 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200358;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b200358 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:79f295ad32df4ce8a18a92539c6e8a3b200360 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10651-1 a owl:Class;
  rdfs:label "CLARITHROMYCINE <-> SIMVASTATINE"@fr;
  dct:identifier "IAM_10651";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b200362;
  r:natureDuRisque "Risque majoré d'effets indésirables (concentration-dépendants) à type de rhabdomyolyse, par diminution du métabolisme hépatique de l'hypocholestérolémiant."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b200368, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b200362 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b200363 .

_:79f295ad32df4ce8a18a92539c6e8a3b200363 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200364;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b200365 .

_:79f295ad32df4ce8a18a92539c6e8a3b200364 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10206 .

_:79f295ad32df4ce8a18a92539c6e8a3b200365 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200366;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b200366 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10838 .

_:79f295ad32df4ce8a18a92539c6e8a3b200368 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10639-1 a owl:Class;
  rdfs:label "CLARITHROMYCINE <-> FIDAXOMICINE"@fr;
  dct:identifier "IAM_10639";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b200370;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de la fidaxomicine."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b200376, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b200370 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b200371 .

_:79f295ad32df4ce8a18a92539c6e8a3b200371 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200372;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b200373 .

_:79f295ad32df4ce8a18a92539c6e8a3b200372 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10206 .

_:79f295ad32df4ce8a18a92539c6e8a3b200373 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200374;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b200374 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10378 .

_:79f295ad32df4ce8a18a92539c6e8a3b200376 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10619-1 a owl:Class;
  rdfs:label "CIMETIDINE <-> PHÉNYTOÏNE (ET, PAR EXTRAPOLATION, FOSPHÉNYTOÏNE)"@fr;
  dct:identifier "IAM_10619";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b200378;
  r:natureDuRisque "Avec la cimétidine utilisée à des doses supérieures ou égales à 800 mg/j : augmentation des concentrations plasmatiques de phénytoïne avec possibilité d'apparition des signes habituels de surdosage."@fr;
  r:conduiteATenir "Si l'association ne peut être évitée, surveillance clinique étroite, dosage des concentrations plasmatiques de phénytoïne et adaptation éventuelle de sa posologie pendant le traitement par la cimétidine et après son arrêt."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b200384, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b200378 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b200379 .

_:79f295ad32df4ce8a18a92539c6e8a3b200379 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200380;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b200381 .

_:79f295ad32df4ce8a18a92539c6e8a3b200380 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10132 .

_:79f295ad32df4ce8a18a92539c6e8a3b200381 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200382;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b200382 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10196 .

_:79f295ad32df4ce8a18a92539c6e8a3b200384 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10520-1 a owl:Class;
  rdfs:label "CABAZITAXEL <-> INHIBITEURS PUISSANTS DU CYP3A4"@fr;
  dct:identifier "IAM_10520";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b200386;
  r:natureDuRisque "Risque de majoration des effets indésirables dose-dépendants du cabazitaxel par inhibition de son métabolisme par l’inhibiteur enzymatique."@fr;
  r:conduiteATenir "Surveillance clinique et adaptation éventuelle de la posologie du cabazitaxel pendant le traitement par l’inhibiteur enzymatique."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b200392, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b200386 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b200387 .

_:79f295ad32df4ce8a18a92539c6e8a3b200387 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200388;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b200389 .

_:79f295ad32df4ce8a18a92539c6e8a3b200388 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10103 .

_:79f295ad32df4ce8a18a92539c6e8a3b200389 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200390;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b200390 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10143 .

_:79f295ad32df4ce8a18a92539c6e8a3b200392 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10609-1 a owl:Class;
  rdfs:label "CICLOSPORINE <-> TICLOPIDINE"@fr;
  dct:identifier "IAM_10609";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b200394;
  r:natureDuRisque "Diminution des concentrations sanguines de ciclosporine."@fr;
  r:conduiteATenir "Augmentation de la posologie de la ciclosporine sous contrôle des concentrations sanguines. Réduction de la posologie en cas d'arrêt de la ticlopidine."@fr;
  rdfs:comment """L'essentiel des publications repose sur des cas isolés, trois d'entre eux comportant la notion d'une réintroduction positive. 
Dans une étude chez 20 patients transplantés cardiaques recevant de la ticlopidine, les ciclosporinémies n'ont en moyenne pas va"""@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b200400, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b200394 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b200395 .

_:79f295ad32df4ce8a18a92539c6e8a3b200395 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200396;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b200397 .

_:79f295ad32df4ce8a18a92539c6e8a3b200396 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10193 .

_:79f295ad32df4ce8a18a92539c6e8a3b200397 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200398;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b200398 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10928 .

_:79f295ad32df4ce8a18a92539c6e8a3b200400 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10610-1 a owl:Class;
  rdfs:label "CICLOSPORINE <-> TRIMETHOPRIME"@fr;
  dct:identifier "IAM_10610";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b200402;
  r:natureDuRisque """Avec le triméthoprime (seul ou associé) par voie orale : augmentation de la créatininémie avec diminution possible des concentrations sanguines de ciclosporine.

Avec le trimethoprime (seul ou associé) par voie IV : la diminution des concentrations sangui"""@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b200408, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b200402 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b200403 .

_:79f295ad32df4ce8a18a92539c6e8a3b200403 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200404;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b200405 .

_:79f295ad32df4ce8a18a92539c6e8a3b200404 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10193 .

_:79f295ad32df4ce8a18a92539c6e8a3b200405 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200406;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b200406 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10955 .

_:79f295ad32df4ce8a18a92539c6e8a3b200408 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10611-1 a owl:Class;
  rdfs:label "CICLOSPORINE <-> VERAPAMIL"@fr;
  dct:identifier "IAM_10611";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b200410;
  r:natureDuRisque "Augmentation des concentrations sanguines de la ciclosporine (diminution de son métabolisme hépatique), et majoration du risque de gingivopathies."@fr;
  r:conduiteATenir "Dosage des concentrations sanguines de la ciclosporine, contrôle de la fonction rénale et adaptation de la posologie pendant l’association et après son arrêt."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b200416, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b200410 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b200411 .

_:79f295ad32df4ce8a18a92539c6e8a3b200411 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200412;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b200413 .

_:79f295ad32df4ce8a18a92539c6e8a3b200412 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10193 .

_:79f295ad32df4ce8a18a92539c6e8a3b200413 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200414;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b200414 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10980 .

_:79f295ad32df4ce8a18a92539c6e8a3b200416 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10612-1 a owl:Class;
  rdfs:label "CIMETIDINE <-> DIAZEPAM"@fr;
  dct:identifier "IAM_10612";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b200418;
  r:natureDuRisque "Avec la cimétidine utilisée à des doses supérieures ou égales à 800 mg/j : risque accru de somnolence."@fr;
  r:conduiteATenir "Avertir les patients de l'augmentation du risque en cas de conduite automobile ou d'utilisation de machines."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b200424, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b200418 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b200419 .

_:79f295ad32df4ce8a18a92539c6e8a3b200419 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200420;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b200421 .

_:79f295ad32df4ce8a18a92539c6e8a3b200420 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10196 .

_:79f295ad32df4ce8a18a92539c6e8a3b200421 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200422;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b200422 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10280 .

_:79f295ad32df4ce8a18a92539c6e8a3b200424 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10613-1 a owl:Class;
  rdfs:label "CIMETIDINE <-> LIDOCAINE"@fr;
  dct:identifier "IAM_10613";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b200426;
  r:natureDuRisque "Avec la cimétidine utilisée à des doses supérieures ou égales à 800 mg/j : augmentation des concentrations plasmatiques de lidocaïne avec risque d'effets indésirables neurologiques et cardiaques (inhibition du métabolisme hépatique de la lidocaïne)."@fr;
  r:conduiteATenir "Surveillance clinique, ECG et éventuellement des concentrations plasmatiques de la lidocaïne ; s'il y a lieu, adaptation de la posologie de la lidocaïne pendant le traitement par la cimétidine et après son arrêt."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b200432, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b200426 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b200427 .

_:79f295ad32df4ce8a18a92539c6e8a3b200427 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200428;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b200429 .

_:79f295ad32df4ce8a18a92539c6e8a3b200428 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10196 .

_:79f295ad32df4ce8a18a92539c6e8a3b200429 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200430;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b200430 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10523 .

_:79f295ad32df4ce8a18a92539c6e8a3b200432 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10614-1 a owl:Class;
  rdfs:label "CIMETIDINE <-> LOMUSTINE"@fr;
  dct:identifier "IAM_10614";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b200434;
  r:natureDuRisque "Avec la cimétidine utilisée à des doses supérieures ou égales à 800 mg/j : toxicité médullaire accrue (inhibition du métabolisme de la lomustine)."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b200440, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b200434 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b200435 .

_:79f295ad32df4ce8a18a92539c6e8a3b200435 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200436;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b200437 .

_:79f295ad32df4ce8a18a92539c6e8a3b200436 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10196 .

_:79f295ad32df4ce8a18a92539c6e8a3b200437 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200438;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b200438 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10534 .

_:79f295ad32df4ce8a18a92539c6e8a3b200440 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10615-1 a owl:Class;
  rdfs:label "CIMETIDINE <-> METHADONE"@fr;
  dct:identifier "IAM_10615";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b200442;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de méthadone avec surdosage et risque majoré d’allongement de l’intervalle QT et de troubles du rythme ventriculaire, notamment de torsades de pointes."@fr;
  r:conduiteATenir "Surveillance clinique et électrocardiographique renforcée ; si besoin, adaptation de la posologie de la méthadone pendant le traitement par la cimétidine et après son arrêt."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b200448, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b200442 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b200443 .

_:79f295ad32df4ce8a18a92539c6e8a3b200443 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200444;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b200445 .

_:79f295ad32df4ce8a18a92539c6e8a3b200444 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10196 .

_:79f295ad32df4ce8a18a92539c6e8a3b200445 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200446;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b200446 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10567 .

_:79f295ad32df4ce8a18a92539c6e8a3b200448 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10616-1 a owl:Class;
  rdfs:label "CIMETIDINE <-> METOPROLOL"@fr;
  dct:identifier "IAM_10616";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b200450;
  r:natureDuRisque "Avec le métoprolol utilisé dans l'insuffisance cardiaque, et la cimétidine utilisée à des doses supérieures ou égales à 800 mg/j : augmentation des concentrations du métoprolol, pouvant être préjudiciables dans le cas du traitement de l'insuffisance cardi"@fr;
  r:conduiteATenir "Surveillance clinique. Si besoin, adaptation de la posologie du métoprolol pendant le traitement par la cimétidine."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b200456, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b200450 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b200451 .

_:79f295ad32df4ce8a18a92539c6e8a3b200451 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200452;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b200453 .

_:79f295ad32df4ce8a18a92539c6e8a3b200452 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10196 .

_:79f295ad32df4ce8a18a92539c6e8a3b200453 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200454;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b200454 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10579 .

_:79f295ad32df4ce8a18a92539c6e8a3b200456 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10631-1 a owl:Class;
  rdfs:label "CIPROFLOXACINE <-> SUBSTANCES SUSCEPTIBLES DE DONNER DES TORSADES DE POINTES"@fr;
  dct:identifier "IAM_10631";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b200458;
  r:natureDuRisque "Risque majoré de troubles du rythme ventriculaire, notamment de torsades de pointes."@fr;
  r:conduiteATenir """Surveillance clinique et électrocardiographique pendant
l'association."""@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b200464, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b200458 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b200459 .

_:79f295ad32df4ce8a18a92539c6e8a3b200459 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200460;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b200461 .

_:79f295ad32df4ce8a18a92539c6e8a3b200460 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10143 .

_:79f295ad32df4ce8a18a92539c6e8a3b200461 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200462;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b200462 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10200 .

_:79f295ad32df4ce8a18a92539c6e8a3b200464 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10618-1 a owl:Class;
  rdfs:label "CIMETIDINE <-> NIFEDIPINE"@fr;
  dct:identifier "IAM_10618";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b200466;
  r:natureDuRisque "Avec la cimétidine utilisée à des doses supérieures ou égales à 800 mg/j : augmentation de l'effet hypotenseur de la nifédipine par inhibition de son métabolisme hépatique par la cimétidine."@fr;
  r:conduiteATenir "Surveillance clinique accrue : adapter la posologie de la nifédipine pendant le tratiement par la cimétidine et après son arrêt."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b200472, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b200466 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b200467 .

_:79f295ad32df4ce8a18a92539c6e8a3b200467 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200468;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b200469 .

_:79f295ad32df4ce8a18a92539c6e8a3b200468 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10196 .

_:79f295ad32df4ce8a18a92539c6e8a3b200469 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200470;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b200470 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10633 .

_:79f295ad32df4ce8a18a92539c6e8a3b200472 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10630-1 a owl:Class;
  rdfs:label "CIPROFLOXACINE <-> ROPINIROLE"@fr;
  dct:identifier "IAM_10630";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b200474;
  r:natureDuRisque "Augmentation des concentrations de ropinirole avec risque de surdosage, par diminution de son métabolisme hépatique par la ciprofloxacine."@fr;
  r:conduiteATenir "Surveillance clinique et réduction éventuelle de la posologie du ropinirole pendant le traitement par la ciprofloxacine et après son arrêt."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b200480, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b200474 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b200475 .

_:79f295ad32df4ce8a18a92539c6e8a3b200475 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200476;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b200477 .

_:79f295ad32df4ce8a18a92539c6e8a3b200476 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10200 .

_:79f295ad32df4ce8a18a92539c6e8a3b200477 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200478;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b200478 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10813 .

_:79f295ad32df4ce8a18a92539c6e8a3b200480 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10620-1 a owl:Class;
  rdfs:label "CIMETIDINE <-> THÉOPHYLLINE (ET, PAR EXTRAPOLATION, AMINOPHYLLINE)"@fr;
  dct:identifier "IAM_10620";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b200482;
  r:natureDuRisque "Avec la cimétidine utilisée à des doses supérieures ou égales à 800 mg/j : augmentation de la théophyllinémie avec risque de surdosage (diminution du métabolisme de la théophylline)."@fr;
  r:conduiteATenir "Surveillance clinique et éventuellement de la théophyllinémie. S'il y a lieu, adaptation de la théophylline pendant le traitement par la cimétidine et après son arrêt."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b200488, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b200482 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b200483 .

_:79f295ad32df4ce8a18a92539c6e8a3b200483 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200484;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b200485 .

_:79f295ad32df4ce8a18a92539c6e8a3b200484 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10152 .

_:79f295ad32df4ce8a18a92539c6e8a3b200485 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200486;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b200486 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10196 .

_:79f295ad32df4ce8a18a92539c6e8a3b200488 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10621-1 a owl:Class;
  rdfs:label "CINACALCET <-> DEXTROMETHORPHANE"@fr;
  dct:identifier "IAM_10621";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b200490;
  r:natureDuRisque "Augmentation très importante des concentrations plasmatiques de dextrométhorphane avec risque de surdosage, par diminution de son métabolisme hépatique par le cinacalcet."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b200496, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b200490 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b200491 .

_:79f295ad32df4ce8a18a92539c6e8a3b200491 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200492;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b200493 .

_:79f295ad32df4ce8a18a92539c6e8a3b200492 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10197 .

_:79f295ad32df4ce8a18a92539c6e8a3b200493 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200494;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b200494 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10278 .

_:79f295ad32df4ce8a18a92539c6e8a3b200496 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10622-1 a owl:Class;
  rdfs:label "CINACALCET <-> FLECAINIDE"@fr;
  dct:identifier "IAM_10622";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b200498;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de flécaïnide avec risque de surdosage, par diminution de son métabolisme hépatique par le cinacalcet."@fr;
  r:conduiteATenir "Surveillance clinique et réduction de la posologie du flécaïnide pendant le traitement par cinacalcet."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b200504, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b200498 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b200499 .

_:79f295ad32df4ce8a18a92539c6e8a3b200499 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200500;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b200501 .

_:79f295ad32df4ce8a18a92539c6e8a3b200500 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10197 .

_:79f295ad32df4ce8a18a92539c6e8a3b200501 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200502;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b200502 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10380 .

_:79f295ad32df4ce8a18a92539c6e8a3b200504 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10624-1 a owl:Class;
  rdfs:label "CINACALCET <-> METOPROLOL"@fr;
  dct:identifier "IAM_10624";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b200506;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de métroprolol avec risque de surdosage, par diminution de son métabolisme hépatique par le cinacalcet."@fr;
  r:conduiteATenir "Surveillance clinique et réduction de la posologie du métroprolol pendant le traitement par cinacalcet."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b200512, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b200506 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b200507 .

_:79f295ad32df4ce8a18a92539c6e8a3b200507 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200508;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b200509 .

_:79f295ad32df4ce8a18a92539c6e8a3b200508 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10197 .

_:79f295ad32df4ce8a18a92539c6e8a3b200509 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200510;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b200510 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10579 .

_:79f295ad32df4ce8a18a92539c6e8a3b200512 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10623-1 a owl:Class;
  rdfs:label "CINACALCET <-> MEQUITAZINE"@fr;
  dct:identifier "IAM_10623";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b200514;
  r:natureDuRisque "Risque de majoration des effets indésirables de la méquitazine, par inhibition de son métabolisme par l’inhibiteur enzymatique."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b200520, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b200514 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b200515 .

_:79f295ad32df4ce8a18a92539c6e8a3b200515 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200516;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b200517 .

_:79f295ad32df4ce8a18a92539c6e8a3b200516 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10197 .

_:79f295ad32df4ce8a18a92539c6e8a3b200517 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200518;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b200518 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10561 .

_:79f295ad32df4ce8a18a92539c6e8a3b200520 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10625-1 a owl:Class;
  rdfs:label "CINACALCET <-> PROPAFENONE"@fr;
  dct:identifier "IAM_10625";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b200522;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de propafénone avec risque de surdosage, par diminution de son métabolisme hépatique par le cinacalcet."@fr;
  r:conduiteATenir "Surveillance clinique et réduction de la posologie de la propafénone pendant le traitement par cinacalcet."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b200528, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b200522 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b200523 .

_:79f295ad32df4ce8a18a92539c6e8a3b200523 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200524;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b200525 .

_:79f295ad32df4ce8a18a92539c6e8a3b200524 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10197 .

_:79f295ad32df4ce8a18a92539c6e8a3b200525 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200526;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b200526 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10765 .

_:79f295ad32df4ce8a18a92539c6e8a3b200528 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10626-1 a owl:Class;
  rdfs:label "CINACALCET <-> VORTIOXÉTINE"@fr;
  dct:identifier "IAM_10626";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b200530;
  r:natureDuRisque "Risque d’augmentation des effets indésirables de la vortioxétine par diminution importante de son métabolisme hépatique."@fr;
  r:conduiteATenir "Surveillance clinique et adaptation éventuelle de la posologie de la vortioxétine pendant le traitement par le cinacalcet et après son arrêt."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b200536, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b200530 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b200531 .

_:79f295ad32df4ce8a18a92539c6e8a3b200531 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200532;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b200533 .

_:79f295ad32df4ce8a18a92539c6e8a3b200532 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10197 .

_:79f295ad32df4ce8a18a92539c6e8a3b200533 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200534;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b200534 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10999 .

_:79f295ad32df4ce8a18a92539c6e8a3b200536 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10627-1 a owl:Class;
  rdfs:label "CIPROFLOXACINE <-> CLOZAPINE"@fr;
  dct:identifier "IAM_10627";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b200538;
  r:natureDuRisque "Augmentation des concentrations de clozapine avec risque de surdosage, par diminution de son métabolisme hépatique par la ciprofloxacine."@fr;
  r:conduiteATenir "Surveillance clinique et réduction éventuelle de la posologie de la clozapine pendant le traitement par la ciprofloxacine et après son arrêt."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b200544, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b200538 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b200539 .

_:79f295ad32df4ce8a18a92539c6e8a3b200539 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200540;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b200541 .

_:79f295ad32df4ce8a18a92539c6e8a3b200540 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10200 .

_:79f295ad32df4ce8a18a92539c6e8a3b200541 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200542;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b200542 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10220 .

_:79f295ad32df4ce8a18a92539c6e8a3b200544 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10628-1 a owl:Class;
  rdfs:label "CIPROFLOXACINE <-> METHOTREXATE"@fr;
  dct:identifier "IAM_10628";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b200546;
  r:natureDuRisque "Augmentation de la toxicité du méthotrexate par inhibition de sa sécrétion tubulaire rénale par la ciprofloxacine."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b200552, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b200546 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b200547 .

_:79f295ad32df4ce8a18a92539c6e8a3b200547 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200548;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b200549 .

_:79f295ad32df4ce8a18a92539c6e8a3b200548 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10200 .

_:79f295ad32df4ce8a18a92539c6e8a3b200549 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200550;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b200550 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10569 .

_:79f295ad32df4ce8a18a92539c6e8a3b200552 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10654-1 a owl:Class;
  rdfs:label "CLARITHROMYCINE <-> THÉOPHYLLINE (ET, PAR EXTRAPOLATION, AMINOPHYLLINE)"@fr;
  dct:identifier "IAM_10654";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b200554;
  r:natureDuRisque "Risque d'augmentation de la théophyllinémie, particulièrement chez l'enfant."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b200560, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b200554 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b200555 .

_:79f295ad32df4ce8a18a92539c6e8a3b200555 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200556;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b200557 .

_:79f295ad32df4ce8a18a92539c6e8a3b200556 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10152 .

_:79f295ad32df4ce8a18a92539c6e8a3b200557 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200558;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b200558 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10206 .

_:79f295ad32df4ce8a18a92539c6e8a3b200560 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10617-1 a owl:Class;
  rdfs:label "CIMETIDINE <-> MOCLOBEMIDE"@fr;
  dct:identifier "IAM_10617";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b200562;
  r:natureDuRisque "Avec la cimétidine utilisée à des doses supérieures ou égales à 800 mg/j : augmentation des concentrations du moclobémide, par diminution de son métabolisme hépatique."@fr;
  r:conduiteATenir "Surveillance clinique avec adaptation éventuelle de la posologie de moclobémide."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b200568, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b200562 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b200563 .

_:79f295ad32df4ce8a18a92539c6e8a3b200563 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200564;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b200565 .

_:79f295ad32df4ce8a18a92539c6e8a3b200564 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10196 .

_:79f295ad32df4ce8a18a92539c6e8a3b200565 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200566;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b200566 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10598 .

_:79f295ad32df4ce8a18a92539c6e8a3b200568 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10703-1 a owl:Class;
  rdfs:label "CYTOTOXIQUES <-> PHÉNYTOÏNE (ET, PAR EXTRAPOLATION, FOSPHÉNYTOÏNE)"@fr;
  dct:identifier "IAM_10703";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b200570;
  r:natureDuRisque "Risque de survenue de convulsions par diminution de l'absorption digestive de la seule phénytoïne par le cytotoxique, ou bien risque de majoration de la toxicité ou de perte d'efficacité du cytotoxique par augmentation de son métabolisme hépatique par la"@fr;
  rdfs:comment "Deux niveaux de contrainte distincts avaient été retenus entre les cytotoxiques et la phénytoïne, selon que l'anticonvulsivant était administré antérieurement à la chimiothérapie (conduisant alors à une précaution d’emploi) ou qu'il aurait pu être donné à"@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b200576, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b200570 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b200571 .

_:79f295ad32df4ce8a18a92539c6e8a3b200571 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200572;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b200573 .

_:79f295ad32df4ce8a18a92539c6e8a3b200572 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10060 .

_:79f295ad32df4ce8a18a92539c6e8a3b200573 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200574;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b200574 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10132 .

_:79f295ad32df4ce8a18a92539c6e8a3b200576 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10652-1 a owl:Class;
  rdfs:label "CLARITHROMYCINE <-> SUBSTANCES SUSCEPTIBLES DE DONNER DES TORSADES DE POINTES"@fr;
  dct:identifier "IAM_10652";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b200578;
  r:natureDuRisque """Risque majoré de troubles du rythme ventriculaire, notamment de
torsades de pointes."""@fr;
  r:conduiteATenir "Surveillance clinique et électrocardiographique pendant l'association."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b200584, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b200578 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b200579 .

_:79f295ad32df4ce8a18a92539c6e8a3b200579 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200580;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b200581 .

_:79f295ad32df4ce8a18a92539c6e8a3b200580 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10143 .

_:79f295ad32df4ce8a18a92539c6e8a3b200581 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200582;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b200582 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10206 .

_:79f295ad32df4ce8a18a92539c6e8a3b200584 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10693-1 a owl:Class;
  rdfs:label "CYCLINES <-> VITAMINE A"@fr;
  dct:identifier "IAM_10693";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b200586;
  r:natureDuRisque "En cas d'apport de 10,000 UI/j et plus : risque d’hypertension intracrânienne."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b200592, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b200586 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b200587 .

_:79f295ad32df4ce8a18a92539c6e8a3b200587 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200588;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b200589 .

_:79f295ad32df4ce8a18a92539c6e8a3b200588 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10059 .

_:79f295ad32df4ce8a18a92539c6e8a3b200589 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200590;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b200590 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10997 .

_:79f295ad32df4ce8a18a92539c6e8a3b200592 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10694-1 a owl:Class;
  rdfs:label "CYCLINES <-> ZINC"@fr;
  dct:identifier "IAM_10694";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b200594;
  r:natureDuRisque "Diminution de l'absorption digestive des cyclines."@fr;
  r:conduiteATenir "Prendre les sels de zinc à distance des cyclines (plus de 2 heures si possible)."@fr;
  rdfs:comment """Le zinc est utilisé dans le traitement de l’acné inflammatoire macrokystique et/ou nodulaire ainsi que dans le traitement des acrodermatites entéropathiques. Comme le fer et le calcium, il peut chélater les tétracyclines et diminuer leur efficacité. 
Cett"""@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b200600, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b200594 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b200595 .

_:79f295ad32df4ce8a18a92539c6e8a3b200595 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200596;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b200597 .

_:79f295ad32df4ce8a18a92539c6e8a3b200596 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10059 .

_:79f295ad32df4ce8a18a92539c6e8a3b200597 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200598;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b200598 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_11005 .

_:79f295ad32df4ce8a18a92539c6e8a3b200600 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10695-1 a owl:Class;
  rdfs:label "CYCLOPHOSPHAMIDE <-> PENTOSTATINE"@fr;
  dct:identifier "IAM_10695";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b200602;
  r:natureDuRisque "Majoration du risque de toxicité pulmonaire pouvant être fatale."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b200608, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b200602 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b200603 .

_:79f295ad32df4ce8a18a92539c6e8a3b200603 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200604;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b200605 .

_:79f295ad32df4ce8a18a92539c6e8a3b200604 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10235 .

_:79f295ad32df4ce8a18a92539c6e8a3b200605 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200606;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b200606 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10704 .

_:79f295ad32df4ce8a18a92539c6e8a3b200608 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10696-1 a owl:Class;
  rdfs:label "CYPROHEPTADINE <-> INHIBITEURS SÉLECTIFS DE LA RECAPTURE DE LA SÉROTONINE"@fr;
  dct:identifier "IAM_10696";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b200610;
  r:natureDuRisque "Risque de diminution de l'efficacité de l'antidépresseur."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b200616, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b200610 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b200611 .

_:79f295ad32df4ce8a18a92539c6e8a3b200611 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200612;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b200613 .

_:79f295ad32df4ce8a18a92539c6e8a3b200612 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10104 .

_:79f295ad32df4ce8a18a92539c6e8a3b200613 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200614;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b200614 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10237 .

_:79f295ad32df4ce8a18a92539c6e8a3b200616 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10697-1 a owl:Class;
  rdfs:label "CYPROTERONE <-> INDUCTEURS ENZYMATIQUES"@fr;
  dct:identifier "IAM_10697";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b200618;
  r:natureDuRisque "Risque de diminution de l'efficacité de la cyprotérone."@fr;
  r:conduiteATenir """Association déconseillée:
- dans son utilisation comme contraceptif hormonal: utiliser de préférence une autre méthode de contraception en particulier de type mécanique, pendant la durée de l'association et un cycle suivant.

Précaution d'emploi
- dans se"""@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b200624, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b200618 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b200619 .

_:79f295ad32df4ce8a18a92539c6e8a3b200619 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200620;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b200621 .

_:79f295ad32df4ce8a18a92539c6e8a3b200620 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10094 .

_:79f295ad32df4ce8a18a92539c6e8a3b200621 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200622;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b200622 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10238 .

_:79f295ad32df4ce8a18a92539c6e8a3b200624 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10698-1 a owl:Class;
  rdfs:label "CYPROTERONE <-> INHIBITEURS DE PROTÉASES BOOSTÉS PAR RITONAVIR"@fr;
  dct:identifier "IAM_10698";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b200626;
  r:natureDuRisque "Risque de diminution de l'efficacité de la cyprotérone."@fr;
  r:conduiteATenir """Association déconseillée
- dans son utilisation comme contraceptif hormonal: utiliser de préférence une autre méthode de contraception en particulier de type mécanique, pendant la durée de l'association et un cycle suivant.

Précaution d'emploi
- dans ses"""@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b200632, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b200626 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b200627 .

_:79f295ad32df4ce8a18a92539c6e8a3b200627 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200628;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b200629 .

_:79f295ad32df4ce8a18a92539c6e8a3b200628 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10100 .

_:79f295ad32df4ce8a18a92539c6e8a3b200629 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200630;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b200630 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10238 .

_:79f295ad32df4ce8a18a92539c6e8a3b200632 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10699-1 a owl:Class;
  rdfs:label "CYPROTERONE <-> MILLEPERTUIS"@fr;
  dct:identifier "IAM_10699";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b200634;
  r:natureDuRisque "Risque de diminution de l'efficacité de la cyprotérone, par augmentation de son métabolisme hépatique par le millepertuis."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b200640, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b200634 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b200635 .

_:79f295ad32df4ce8a18a92539c6e8a3b200635 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200636;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b200637 .

_:79f295ad32df4ce8a18a92539c6e8a3b200636 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10238 .

_:79f295ad32df4ce8a18a92539c6e8a3b200637 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200638;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b200638 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10588 .

_:79f295ad32df4ce8a18a92539c6e8a3b200640 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10700-1 a owl:Class;
  rdfs:label "CYPROTERONE <-> PÉRAMPANEL"@fr;
  dct:identifier "IAM_10700";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b200642;
  r:natureDuRisque "Pour des doses de pérampanel > ou = à 12 mg/jour, risque de diminution de l'efficacité de la cyprotérone."@fr;
  r:conduiteATenir "Dans son utilisation comme contraceptif hormonal: utiliser de préférence une autre méthode de contraception en particulier de type mécanique, pendant la durée de l'association et un cycle suivant."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b200648, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b200642 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b200643 .

_:79f295ad32df4ce8a18a92539c6e8a3b200643 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200644;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b200645 .

_:79f295ad32df4ce8a18a92539c6e8a3b200644 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10238 .

_:79f295ad32df4ce8a18a92539c6e8a3b200645 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200646;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b200646 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10706 .

_:79f295ad32df4ce8a18a92539c6e8a3b200648 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10691-1 a owl:Class;
  rdfs:label "CYCLINES <-> RÉTINOÏDES"@fr;
  dct:identifier "IAM_10691";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b200650;
  r:natureDuRisque "Risque d'hypertension intracrânienne."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b200656, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b200650 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b200651 .

_:79f295ad32df4ce8a18a92539c6e8a3b200651 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200652;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b200653 .

_:79f295ad32df4ce8a18a92539c6e8a3b200652 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10059 .

_:79f295ad32df4ce8a18a92539c6e8a3b200653 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200654;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b200654 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10141 .

_:79f295ad32df4ce8a18a92539c6e8a3b200656 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10702-1 a owl:Class;
  rdfs:label "CYTOTOXIQUES <-> IMMUNOSUPPRESSEURS"@fr;
  dct:identifier "IAM_10702";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b200658;
  r:natureDuRisque "Immunodépression excessive avec risque de syndrome lympho-prolifératif."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b200664, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b200658 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b200659 .

_:79f295ad32df4ce8a18a92539c6e8a3b200659 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200660;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b200661 .

_:79f295ad32df4ce8a18a92539c6e8a3b200660 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10060 .

_:79f295ad32df4ce8a18a92539c6e8a3b200661 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200662;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b200662 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10093 .

_:79f295ad32df4ce8a18a92539c6e8a3b200664 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10690-1 a owl:Class;
  rdfs:label "CYCLINES <-> FER"@fr;
  dct:identifier "IAM_10690";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b200666;
  r:natureDuRisque "Avec les cyclines utilisées par voie orale : diminution de l'absorption digestive des cyclines (formation de complexes)."@fr;
  r:conduiteATenir "Prendre les sels de fer à distance des cyclines (plus de 2 heures, si possible)."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b200672, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b200666 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b200667 .

_:79f295ad32df4ce8a18a92539c6e8a3b200667 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200668;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b200669 .

_:79f295ad32df4ce8a18a92539c6e8a3b200668 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10059 .

_:79f295ad32df4ce8a18a92539c6e8a3b200669 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200670;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b200670 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10375 .

_:79f295ad32df4ce8a18a92539c6e8a3b200672 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10704-1 a owl:Class;
  rdfs:label "CYTOTOXIQUES <-> VACCINS VIVANTS ATTÉNUÉS"@fr;
  dct:identifier "IAM_10704";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b200674;
  r:natureDuRisque "Risque de maladie vaccinale généralisée éventuellement mortelle."@fr;
  r:conduiteATenir """- Et pendant les 6 mois suivant l'arrêt de la chimiothérapie.

- Et, à l'exception de l'hydroxycarbamide dans son indication chez le patient drépanocytaire."""@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b200680, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b200674 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b200675 .

_:79f295ad32df4ce8a18a92539c6e8a3b200675 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200676;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b200677 .

_:79f295ad32df4ce8a18a92539c6e8a3b200676 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10060 .

_:79f295ad32df4ce8a18a92539c6e8a3b200677 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200678;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b200678 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10159 .

_:79f295ad32df4ce8a18a92539c6e8a3b200680 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10705-1 a owl:Class;
  rdfs:label "DABIGATRAN <-> DRONEDARONE"@fr;
  dct:identifier "IAM_10705";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b200682;
  r:natureDuRisque "Doublement des concentrations plasmatiques de dabigatran, avec majoration du risque de saignement."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b200688, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b200682 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b200683 .

_:79f295ad32df4ce8a18a92539c6e8a3b200683 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200684;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b200685 .

_:79f295ad32df4ce8a18a92539c6e8a3b200684 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10240 .

_:79f295ad32df4ce8a18a92539c6e8a3b200685 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200686;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b200686 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10311 .

_:79f295ad32df4ce8a18a92539c6e8a3b200688 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10706-1 a owl:Class;
  rdfs:label "DABIGATRAN <-> ITRACONAZOLE"@fr;
  dct:identifier "IAM_10706";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b200690;
  r:natureDuRisque "Augmentation de plus du double des concentrations plasmatiques de dabigatran, avec majoration du risque de saignement."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b200696, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b200690 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b200691 .

_:79f295ad32df4ce8a18a92539c6e8a3b200691 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200692;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b200693 .

_:79f295ad32df4ce8a18a92539c6e8a3b200692 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10240 .

_:79f295ad32df4ce8a18a92539c6e8a3b200693 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200694;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b200694 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10496 .

_:79f295ad32df4ce8a18a92539c6e8a3b200696 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10707-1 a owl:Class;
  rdfs:label "DABIGATRAN <-> KETOCONAZOLE"@fr;
  dct:identifier "IAM_10707";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b200698;
  r:natureDuRisque "Augmentation de plus du double des concentrations plasmatiques de dabigatran, avec majoration du risque de saignement."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b200704, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b200698 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b200699 .

_:79f295ad32df4ce8a18a92539c6e8a3b200699 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200700;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b200701 .

_:79f295ad32df4ce8a18a92539c6e8a3b200700 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10240 .

_:79f295ad32df4ce8a18a92539c6e8a3b200701 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200702;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b200702 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10501 .

_:79f295ad32df4ce8a18a92539c6e8a3b200704 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10708-1 a owl:Class;
  rdfs:label "DABIGATRAN <-> QUINIDINE"@fr;
  dct:identifier "IAM_10708";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b200706;
  r:natureDuRisque """Augmentation des concentrations plasmatiques de dabigatran,
avec majoration du risque de saignement."""@fr;
  r:conduiteATenir "Dans l'indication post-chirurgicale : surveillance clinique et adaptation de la posologie du dabigatran à 150 mg/j en une prise."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b200712, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b200706 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b200707 .

_:79f295ad32df4ce8a18a92539c6e8a3b200707 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200708;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b200709 .

_:79f295ad32df4ce8a18a92539c6e8a3b200708 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10240 .

_:79f295ad32df4ce8a18a92539c6e8a3b200709 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200710;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b200710 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10776 .

_:79f295ad32df4ce8a18a92539c6e8a3b200712 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10709-1 a owl:Class;
  rdfs:label "DABIGATRAN <-> RIFAMPICINE"@fr;
  dct:identifier "IAM_10709";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b200714;
  r:natureDuRisque "Diminution des concentrations plasmatiques de dabigatran, avec risque de diminution de l'effet thérapeutique."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b200720, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b200714 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b200715 .

_:79f295ad32df4ce8a18a92539c6e8a3b200715 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200716;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b200717 .

_:79f295ad32df4ce8a18a92539c6e8a3b200716 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10240 .

_:79f295ad32df4ce8a18a92539c6e8a3b200717 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200718;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b200718 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:79f295ad32df4ce8a18a92539c6e8a3b200720 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10710-1 a owl:Class;
  rdfs:label "DABIGATRAN <-> TACROLIMUS"@fr;
  dct:identifier "IAM_10710";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b200722;
  r:natureDuRisque "Risque d'augmentation des concentrations plasmatiques de dabigatran."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b200728, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b200722 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b200723 .

_:79f295ad32df4ce8a18a92539c6e8a3b200723 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200724;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b200725 .

_:79f295ad32df4ce8a18a92539c6e8a3b200724 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10240 .

_:79f295ad32df4ce8a18a92539c6e8a3b200725 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200726;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b200726 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10880 .

_:79f295ad32df4ce8a18a92539c6e8a3b200728 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10711-1 a owl:Class;
  rdfs:label "DABIGATRAN <-> TICAGRELOR"@fr;
  dct:identifier "IAM_10711";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b200730;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de dabigatran, avec majoration du risque de saignement."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b200736, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b200730 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b200731 .

_:79f295ad32df4ce8a18a92539c6e8a3b200731 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200732;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b200733 .

_:79f295ad32df4ce8a18a92539c6e8a3b200732 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10240 .

_:79f295ad32df4ce8a18a92539c6e8a3b200733 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200734;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b200734 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10926 .

_:79f295ad32df4ce8a18a92539c6e8a3b200736 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10712-1 a owl:Class;
  rdfs:label "DABIGATRAN <-> VERAPAMIL"@fr;
  dct:identifier "IAM_10712";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b200738;
  r:natureDuRisque """Augmentation des concentrations plasmatiques de dabigatran,
avec majoration du risque de saignement."""@fr;
  r:conduiteATenir """Dans l'indication post-chirurgicale : surveillance clinique et adaptation de la posologie du dabigatran à 150 mg/j en une prise, voire 75 mg/j en cas d'insuffisance rénale modérée.

Dans l'indication fibrillation auriculaire : surveillance clinique et ada"""@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b200744, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b200738 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b200739 .

_:79f295ad32df4ce8a18a92539c6e8a3b200739 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200740;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b200741 .

_:79f295ad32df4ce8a18a92539c6e8a3b200740 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10240 .

_:79f295ad32df4ce8a18a92539c6e8a3b200741 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200742;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b200742 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10980 .

_:79f295ad32df4ce8a18a92539c6e8a3b200744 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10001-1 a owl:Class;
  rdfs:label "ABATACEPT <-> ANTI-TNF ALPHA"@fr;
  dct:identifier "IAM_10001";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b200746;
  r:natureDuRisque "Majoration de l’immunodépression."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b200752, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b200746 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b200747 .

_:79f295ad32df4ce8a18a92539c6e8a3b200747 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200748;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b200749 .

_:79f295ad32df4ce8a18a92539c6e8a3b200748 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10021 .

_:79f295ad32df4ce8a18a92539c6e8a3b200749 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200750;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b200750 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10002 .

_:79f295ad32df4ce8a18a92539c6e8a3b200752 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10701-1 a owl:Class;
  rdfs:label "CYPROTERONE <-> ULIPRISTAL"@fr;
  dct:identifier "IAM_10701";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b200754;
  r:natureDuRisque """Dans l'indication contraception d'urgence de l'ulipristal :
Antagonisme des effets de l’ulipristal en cas de reprise d’un contraceptif hormonal moins de 5 jours après la prise de la contraception d’urgence.

Dans l’indication fibrome de l'ulipristal :
Ant"""@fr;
  r:conduiteATenir """Association déconseillée 
Dans l'utilisation à visée contraceptive de la cyprotérone

- Dans l'indication contraception d'urgence de l'ulipristal
Dans le cas où la (re)prise d’une contraception hormonale est envisagée, utiliser une contraception additionn"""@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b200760, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b200754 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b200755 .

_:79f295ad32df4ce8a18a92539c6e8a3b200755 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200756;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b200757 .

_:79f295ad32df4ce8a18a92539c6e8a3b200756 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10238 .

_:79f295ad32df4ce8a18a92539c6e8a3b200757 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200758;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b200758 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10964 .

_:79f295ad32df4ce8a18a92539c6e8a3b200760 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10666-1 a owl:Class;
  rdfs:label "CLOZAPINE <-> PHÉNYTOÏNE (ET, PAR EXTRAPOLATION, FOSPHÉNYTOÏNE)"@fr;
  dct:identifier "IAM_10666";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b200762;
  r:natureDuRisque "Risque d'inefficacité du traitement antipsychotique (diminution des concentrations plasmatiques de clozapine par augmentation de son métabolisme hépatique)."@fr;
  r:conduiteATenir "Surveillance clinique et augmentation éventuelle de la posologie de la clozapine durant le traitement par la phénytoïne."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b200768, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b200762 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b200763 .

_:79f295ad32df4ce8a18a92539c6e8a3b200763 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200764;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b200765 .

_:79f295ad32df4ce8a18a92539c6e8a3b200764 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10132 .

_:79f295ad32df4ce8a18a92539c6e8a3b200765 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200766;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b200766 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10220 .

_:79f295ad32df4ce8a18a92539c6e8a3b200768 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10606-1 a owl:Class;
  rdfs:label "CICLOSPORINE <-> SULFINPYRAZONE"@fr;
  dct:identifier "IAM_10606";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b200770;
  r:natureDuRisque "Diminution des concentrations sanguines de ciclosporine par augmentation de son métabolisme par la sulfinpyrazone."@fr;
  r:conduiteATenir "Contrôle des concentrations sanguines de ciclosporine et adaptation éventuelle de sa posologie pendant le traitement par sulfinpyrazone et après son arrêt."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b200776, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b200770 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b200771 .

_:79f295ad32df4ce8a18a92539c6e8a3b200771 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200772;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b200773 .

_:79f295ad32df4ce8a18a92539c6e8a3b200772 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10193 .

_:79f295ad32df4ce8a18a92539c6e8a3b200773 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200774;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b200774 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10873 .

_:79f295ad32df4ce8a18a92539c6e8a3b200776 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10655-1 a owl:Class;
  rdfs:label "CLARITHROMYCINE <-> VENLAFAXINE"@fr;
  dct:identifier "IAM_10655";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b200778;
  r:natureDuRisque "Augmentation des concentrations de venlafaxine avec risque de surdosage."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b200784, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b200778 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b200779 .

_:79f295ad32df4ce8a18a92539c6e8a3b200779 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200780;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b200781 .

_:79f295ad32df4ce8a18a92539c6e8a3b200780 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10206 .

_:79f295ad32df4ce8a18a92539c6e8a3b200781 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200782;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b200782 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10979 .

_:79f295ad32df4ce8a18a92539c6e8a3b200784 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10657-1 a owl:Class;
  rdfs:label "CLINDAMYCINE <-> TACROLIMUS"@fr;
  dct:identifier "IAM_10657";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b200786;
  r:natureDuRisque "Diminution des concentrations sanguines de l'immunosuppresseur, avec risque de perte de l'activité immunosuppressive."@fr;
  r:conduiteATenir "Contrôle renforcé des dosages sanguins de tacrolimus et augmentation éventuelle de sa posologie."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b200792, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b200786 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b200787 .

_:79f295ad32df4ce8a18a92539c6e8a3b200787 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200788;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b200789 .

_:79f295ad32df4ce8a18a92539c6e8a3b200788 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10209 .

_:79f295ad32df4ce8a18a92539c6e8a3b200789 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200790;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b200790 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10880 .

_:79f295ad32df4ce8a18a92539c6e8a3b200792 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10658-1 a owl:Class;
  rdfs:label "CLOBAZAM <-> STIRIPENTOL"@fr;
  dct:identifier "IAM_10658";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b200794;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de ces anticonvulsivants, avec risque de surdosage, par inhibition de leur métabolisme hépatique."@fr;
  r:conduiteATenir "Surveillance clinique, dosage plasmatique, lorsque cela est possible, de l'anticonvulsivant associé au stiripentol et éventuelle adaptation posologique de l'anticonvulsivant associé."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b200800, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b200794 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b200795 .

_:79f295ad32df4ce8a18a92539c6e8a3b200795 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200796;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b200797 .

_:79f295ad32df4ce8a18a92539c6e8a3b200796 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10210 .

_:79f295ad32df4ce8a18a92539c6e8a3b200797 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200798;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b200798 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10859 .

_:79f295ad32df4ce8a18a92539c6e8a3b200800 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10659-1 a owl:Class;
  rdfs:label "CLONIDINE <-> DILTIAZEM"@fr;
  dct:identifier "IAM_10659";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b200802;
  r:natureDuRisque "Troubles de l'automatisme (troubles de la conduction auriculo-ventriculaire par addition des effets négatifs sur la conduction)."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b200808, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b200802 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b200803 .

_:79f295ad32df4ce8a18a92539c6e8a3b200803 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200804;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b200805 .

_:79f295ad32df4ce8a18a92539c6e8a3b200804 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10214 .

_:79f295ad32df4ce8a18a92539c6e8a3b200805 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200806;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b200806 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10290 .

_:79f295ad32df4ce8a18a92539c6e8a3b200808 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10660-1 a owl:Class;
  rdfs:label "CLONIDINE <-> VERAPAMIL"@fr;
  dct:identifier "IAM_10660";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b200810;
  r:natureDuRisque "Troubles de l'automatisme (troubles de la conduction auriculo-ventriculaire par addition des effets négatifs sur la conduction)."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b200816, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b200810 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b200811 .

_:79f295ad32df4ce8a18a92539c6e8a3b200811 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200812;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b200813 .

_:79f295ad32df4ce8a18a92539c6e8a3b200812 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10214 .

_:79f295ad32df4ce8a18a92539c6e8a3b200813 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200814;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b200814 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10980 .

_:79f295ad32df4ce8a18a92539c6e8a3b200816 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10661-1 a owl:Class;
  rdfs:label "CLONIDINE <-> YOHIMBINE"@fr;
  dct:identifier "IAM_10661";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b200818;
  r:natureDuRisque "Inhibition possible de l’activité antihypertensive par antagonisme au niveau des récepteurs."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b200824, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b200818 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b200819 .

_:79f295ad32df4ce8a18a92539c6e8a3b200819 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200820;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b200821 .

_:79f295ad32df4ce8a18a92539c6e8a3b200820 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10214 .

_:79f295ad32df4ce8a18a92539c6e8a3b200821 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200822;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b200822 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_11001 .

_:79f295ad32df4ce8a18a92539c6e8a3b200824 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10662-1 a owl:Class;
  rdfs:label "CLOPIDOGREL <-> PACLITAXEL"@fr;
  dct:identifier "IAM_10662";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b200826;
  r:natureDuRisque "Augmentation des concentrations du paclitaxel par le clopidogrel, avec risque de majoration des effets indésirables."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b200832, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b200826 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b200827 .

_:79f295ad32df4ce8a18a92539c6e8a3b200827 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200828;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b200829 .

_:79f295ad32df4ce8a18a92539c6e8a3b200828 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10216 .

_:79f295ad32df4ce8a18a92539c6e8a3b200829 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200830;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b200830 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10685 .

_:79f295ad32df4ce8a18a92539c6e8a3b200832 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10663-1 a owl:Class;
  rdfs:label "CLOPIDOGREL <-> PHÉNYTOÏNE (ET, PAR EXTRAPOLATION, FOSPHÉNYTOÏNE)"@fr;
  dct:identifier "IAM_10663";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b200834;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de phénytoïne avec signes de surdosage (inhibition du métabolisme de la phénytoïne)."@fr;
  r:conduiteATenir "Surveillance clinique et contrôle des concentrations plasmatiques de phénytoïne."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b200840, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b200834 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b200835 .

_:79f295ad32df4ce8a18a92539c6e8a3b200835 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200836;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b200837 .

_:79f295ad32df4ce8a18a92539c6e8a3b200836 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10132 .

_:79f295ad32df4ce8a18a92539c6e8a3b200837 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200838;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b200838 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10216 .

_:79f295ad32df4ce8a18a92539c6e8a3b200840 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10692-1 a owl:Class;
  rdfs:label "CYCLINES <-> STRONTIUM"@fr;
  dct:identifier "IAM_10692";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b200842;
  r:natureDuRisque "Diminution de l'absorption digestive du strontium."@fr;
  r:conduiteATenir "Prendre le strontium à distance des cyclines (plus de deux heures, si possible)."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b200848, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b200842 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b200843 .

_:79f295ad32df4ce8a18a92539c6e8a3b200843 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200844;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b200845 .

_:79f295ad32df4ce8a18a92539c6e8a3b200844 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10059 .

_:79f295ad32df4ce8a18a92539c6e8a3b200845 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200846;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b200846 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10863 .

_:79f295ad32df4ce8a18a92539c6e8a3b200848 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10665-1 a owl:Class;
  rdfs:label "CLOZAPINE <-> FLUVOXAMINE"@fr;
  dct:identifier "IAM_10665";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b200850;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de clozapine avec signes de surdosage."@fr;
  r:conduiteATenir "Surveillance clinique accrue ; si besoin, adaptation de la posologie de la clozapine pendant le traitement par la fluvoxamine et après son arrêt."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b200856, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b200850 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b200851 .

_:79f295ad32df4ce8a18a92539c6e8a3b200851 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200852;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b200853 .

_:79f295ad32df4ce8a18a92539c6e8a3b200852 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10220 .

_:79f295ad32df4ce8a18a92539c6e8a3b200853 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200854;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b200854 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10398 .

_:79f295ad32df4ce8a18a92539c6e8a3b200856 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10653-1 a owl:Class;
  rdfs:label "CLARITHROMYCINE <-> SULFAMIDES HYPOGLYCÉMIANTS"@fr;
  dct:identifier "IAM_10653";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b200858;
  r:natureDuRisque "Risque d'hypoglycémie par augmentation des concentrations plasmatiques de l’antidiabétique."@fr;
  r:conduiteATenir "Prévenir le patient, renforcer l'autosurveillance glycémique et adapter éventuellement la posologie du sulfamide hypoglycémiant pendant le traitement par la clarithromycine."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b200864, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b200858 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b200859 .

_:79f295ad32df4ce8a18a92539c6e8a3b200859 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200860;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b200861 .

_:79f295ad32df4ce8a18a92539c6e8a3b200860 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10147 .

_:79f295ad32df4ce8a18a92539c6e8a3b200861 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200862;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b200862 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10206 .

_:79f295ad32df4ce8a18a92539c6e8a3b200864 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10667-1 a owl:Class;
  rdfs:label "CLOZAPINE <-> RIFAMPICINE"@fr;
  dct:identifier "IAM_10667";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b200866;
  r:natureDuRisque "Risque d'inefficacité du traitement antipsychotique (diminution des concentrations plasmatiques de clozapine par augmentation de son métabolisme hépatique)."@fr;
  r:conduiteATenir "Surveillance clinique et augmentation éventuelle de la posologie de la clozapine durant le traitement par la rifampicine."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b200872, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b200866 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b200867 .

_:79f295ad32df4ce8a18a92539c6e8a3b200867 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200868;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b200869 .

_:79f295ad32df4ce8a18a92539c6e8a3b200868 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10220 .

_:79f295ad32df4ce8a18a92539c6e8a3b200869 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200870;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b200870 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:79f295ad32df4ce8a18a92539c6e8a3b200872 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10675-1 a owl:Class;
  rdfs:label "COBICISTAT <-> VINCA-ALCALOÏDES CYTOTOXIQUES"@fr;
  dct:identifier "IAM_10675";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b200874;
  r:natureDuRisque "Majoration de la neurotoxicité de l’antimitotique par diminution de son métabolisme hépatique par le cobicistat."@fr;
  r:conduiteATenir "Surveillance clinique étroite et adaptation éventuelle de la posologie de l’antimitotique."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b200880, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b200874 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b200875 .

_:79f295ad32df4ce8a18a92539c6e8a3b200875 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200876;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b200877 .

_:79f295ad32df4ce8a18a92539c6e8a3b200876 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10161 .

_:79f295ad32df4ce8a18a92539c6e8a3b200877 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200878;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b200878 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10221 .

_:79f295ad32df4ce8a18a92539c6e8a3b200880 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10668-1 a owl:Class;
  rdfs:label "COBICISTAT <-> INHIBITEURS PUISSANTS DU CYP3A4"@fr;
  dct:identifier "IAM_10668";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b200882;
  r:natureDuRisque "Risque d’augmentation des concentrations plasmatiques du cobicistat ou de l’inhibiteur du CYP3A4."@fr;
  r:conduiteATenir "Pour connaître les risques et les niveaux de contrainte de chaque interaction, il convient de se reporter aux AMM specifiques à chaque spécialité."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b200888, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b200882 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b200883 .

_:79f295ad32df4ce8a18a92539c6e8a3b200883 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200884;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b200885 .

_:79f295ad32df4ce8a18a92539c6e8a3b200884 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10103 .

_:79f295ad32df4ce8a18a92539c6e8a3b200885 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200886;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b200886 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10221 .

_:79f295ad32df4ce8a18a92539c6e8a3b200888 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10669-1 a owl:Class;
  rdfs:label "COBICISTAT <-> ITRACONAZOLE"@fr;
  dct:identifier "IAM_10669";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b200890;
  r:natureDuRisque "Risque d’augmentation des concentrations d’itraconazole par le cobicistat."@fr;
  r:conduiteATenir "Surveillance clinique lors de l’association. L’administration de doses élevées d’itraconazole (>200 mg par jour) n’est pas recommandée."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b200896, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b200890 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b200891 .

_:79f295ad32df4ce8a18a92539c6e8a3b200891 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200892;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b200893 .

_:79f295ad32df4ce8a18a92539c6e8a3b200892 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10221 .

_:79f295ad32df4ce8a18a92539c6e8a3b200893 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200894;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b200894 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10496 .

_:79f295ad32df4ce8a18a92539c6e8a3b200896 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10670-1 a owl:Class;
  rdfs:label "COBICISTAT <-> MILLEPERTUIS"@fr;
  dct:identifier "IAM_10670";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b200898;
  r:natureDuRisque "Risque de diminution de l’efficacité du cobicistat par augmentation de son métabolisme par l’inducteur."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b200904, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b200898 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b200899 .

_:79f295ad32df4ce8a18a92539c6e8a3b200899 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200900;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b200901 .

_:79f295ad32df4ce8a18a92539c6e8a3b200900 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10221 .

_:79f295ad32df4ce8a18a92539c6e8a3b200901 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200902;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b200902 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10588 .

_:79f295ad32df4ce8a18a92539c6e8a3b200904 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10671-1 a owl:Class;
  rdfs:label "COBICISTAT <-> QUINIDINE"@fr;
  dct:identifier "IAM_10671";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b200906;
  r:natureDuRisque "Risque de majoration des effets indésirables de la quinidine par diminution de son métabolisme par le cobicistat."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b200912, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b200906 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b200907 .

_:79f295ad32df4ce8a18a92539c6e8a3b200907 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200908;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b200909 .

_:79f295ad32df4ce8a18a92539c6e8a3b200908 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10221 .

_:79f295ad32df4ce8a18a92539c6e8a3b200909 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200910;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b200910 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10776 .

_:79f295ad32df4ce8a18a92539c6e8a3b200912 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10672-1 a owl:Class;
  rdfs:label "COBICISTAT <-> RIFABUTINE"@fr;
  dct:identifier "IAM_10672";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b200914;
  r:natureDuRisque "Augmentation très importante du métabolite de la rifabutine, avec risque de majoration de sa toxicité (uvéites, neutropénies). Par ailleurs, possible diminution des concentrations de cobicistat."@fr;
  r:conduiteATenir "Adaptation de la posologie de la rifabutine (en principe, réduction des doses de moitié)."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b200920, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b200914 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b200915 .

_:79f295ad32df4ce8a18a92539c6e8a3b200915 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200916;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b200917 .

_:79f295ad32df4ce8a18a92539c6e8a3b200916 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10221 .

_:79f295ad32df4ce8a18a92539c6e8a3b200917 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200918;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b200918 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10800 .

_:79f295ad32df4ce8a18a92539c6e8a3b200920 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10687-1 a owl:Class;
  rdfs:label "CURARES <-> LINCOSANIDES"@fr;
  dct:identifier "IAM_10687";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b200922;
  r:chapeau """Certaines substances peuvent modifier l'intensité et/ou la durée de l'effet des curares non dépolarisants. 
Les médicaments susceptibles de potentialiser l'action des curares non dépolarisants sont :
- les anesthésiques volatils tels que isoflurane, enflu"""@fr;
  r:natureDuRisque "Potentialisation des curares lorque l'antibiotique est administré par voie parentérale et/ou péritonéale avant, pendant ou après l'agent curarisant."@fr;
  r:conduiteATenir "Surveiller le degré de curarisation en fin d'anesthésie."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b200928, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b200922 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b200923 .

_:79f295ad32df4ce8a18a92539c6e8a3b200923 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200924;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b200925 .

_:79f295ad32df4ce8a18a92539c6e8a3b200924 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10057 .

_:79f295ad32df4ce8a18a92539c6e8a3b200925 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200926;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b200926 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10106 .

_:79f295ad32df4ce8a18a92539c6e8a3b200928 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10688-1 a owl:Class;
  rdfs:label "CURARES <-> POLYMYXINE B"@fr;
  dct:identifier "IAM_10688";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b200930;
  r:natureDuRisque "Potentialisation des curares lorque l'antibiotique est administré par voie parentérale et/ou péritonéale avant, pendant ou après l'agent curarisant."@fr;
  r:conduiteATenir "Surveiller le degré de curarisation en fin d'anesthésie."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b200936, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b200930 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b200931 .

_:79f295ad32df4ce8a18a92539c6e8a3b200931 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200932;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b200933 .

_:79f295ad32df4ce8a18a92539c6e8a3b200932 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10057 .

_:79f295ad32df4ce8a18a92539c6e8a3b200933 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200934;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b200934 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10739 .

_:79f295ad32df4ce8a18a92539c6e8a3b200936 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10689-1 a owl:Class;
  rdfs:label "CURARES NON DÉPOLARISANTS <-> GLUCOCORTICOÏDES (SAUF HYDROCORTISONE)"@fr;
  dct:identifier "IAM_10689";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b200938;
  r:natureDuRisque "Avec les glucocorticoïdes par voie IV : risque de myopathie sévère, réversible après un délai éventuellement long (plusieurs mois)."@fr;
  rdfs:comment """Une interaction entre l'hydrocortisone et les curares non dépolarisants a été retenue en raison de l’existence de plusieurs cas de myopathie aiguë avec l’utilisation de corticoïdes injectables.
La Myopathie Aiguë de Réanimation (MAR) est une atteinte musc"""@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b200944, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b200938 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b200939 .

_:79f295ad32df4ce8a18a92539c6e8a3b200939 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200940;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b200941 .

_:79f295ad32df4ce8a18a92539c6e8a3b200940 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10058 .

_:79f295ad32df4ce8a18a92539c6e8a3b200941 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200942;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b200942 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10081 .

_:79f295ad32df4ce8a18a92539c6e8a3b200944 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10664-1 a owl:Class;
  rdfs:label "CLOPIDOGREL <-> REPAGLINIDE"@fr;
  dct:identifier "IAM_10664";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b200946;
  r:natureDuRisque "Augmentation des concentrations du répaglinide par le clopidogrel, avec risque de majoration des effets indésirables."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b200952, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b200946 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b200947 .

_:79f295ad32df4ce8a18a92539c6e8a3b200947 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200948;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b200949 .

_:79f295ad32df4ce8a18a92539c6e8a3b200948 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10216 .

_:79f295ad32df4ce8a18a92539c6e8a3b200949 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200950;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b200950 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10791 .

_:79f295ad32df4ce8a18a92539c6e8a3b200952 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10558-1 a owl:Class;
  rdfs:label "CARBAMAZEPINE <-> PAROXETINE"@fr;
  dct:identifier "IAM_10558";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b200954;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de carbamazépine avec signes de surdosage."@fr;
  r:conduiteATenir "Surveillance clinique, contrôle des concentrations plasmatiques de carbamazépine et réduction éventuelle de la posologie de la carbamazépine pendant le traitement par l'antidépresseur sérotoninergique et après son arrêt."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b200960, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b200954 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b200955 .

_:79f295ad32df4ce8a18a92539c6e8a3b200955 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200956;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b200957 .

_:79f295ad32df4ce8a18a92539c6e8a3b200956 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10158 .

_:79f295ad32df4ce8a18a92539c6e8a3b200957 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200958;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b200958 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10694 .

_:79f295ad32df4ce8a18a92539c6e8a3b200960 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10547-1 a owl:Class;
  rdfs:label "CARBAMAZEPINE <-> FLUCONAZOLE"@fr;
  dct:identifier "IAM_10547";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b200962;
  r:natureDuRisque "Pour des doses de fluconazole >= 200 mg par jour : augmentation possible des effets indésirables de la carbamazépine."@fr;
  r:conduiteATenir "Adapter la posologie de carbamazépine, pendant et après l’arrêt du traitement antifongique."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b200968, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b200962 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b200963 .

_:79f295ad32df4ce8a18a92539c6e8a3b200963 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200964;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b200965 .

_:79f295ad32df4ce8a18a92539c6e8a3b200964 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10158 .

_:79f295ad32df4ce8a18a92539c6e8a3b200965 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200966;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b200966 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10381 .

_:79f295ad32df4ce8a18a92539c6e8a3b200968 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10548-1 a owl:Class;
  rdfs:label "CARBAMAZEPINE <-> FLUOXETINE"@fr;
  dct:identifier "IAM_10548";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b200970;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de carbamazépine avec signes de surdosage."@fr;
  r:conduiteATenir "Surveillance clinique, contrôle des concentrations plasmatiques de carbamazépine et réduction éventuelle de la posologie de la carbamazépine pendant le traitement par l'antidépresseur sérotoninergique et après son arrêt."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b200976, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b200970 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b200971 .

_:79f295ad32df4ce8a18a92539c6e8a3b200971 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200972;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b200973 .

_:79f295ad32df4ce8a18a92539c6e8a3b200972 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10158 .

_:79f295ad32df4ce8a18a92539c6e8a3b200973 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200974;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b200974 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10390 .

_:79f295ad32df4ce8a18a92539c6e8a3b200976 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10549-1 a owl:Class;
  rdfs:label "CARBAMAZEPINE <-> FLUVOXAMINE"@fr;
  dct:identifier "IAM_10549";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b200978;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de carbamazépine avec signes de surdosage."@fr;
  r:conduiteATenir "Surveillance clinique, contrôle des concentrations plasmatiques de carbamazépine et réduction éventuelle de la posologie de la carbamazépine pendant le traitement par l'antidépresseur sérotoninergique et après son arrêt."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b200984, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b200978 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b200979 .

_:79f295ad32df4ce8a18a92539c6e8a3b200979 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200980;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b200981 .

_:79f295ad32df4ce8a18a92539c6e8a3b200980 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10158 .

_:79f295ad32df4ce8a18a92539c6e8a3b200981 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200982;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b200982 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10398 .

_:79f295ad32df4ce8a18a92539c6e8a3b200984 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10550-1 a owl:Class;
  rdfs:label "CARBAMAZEPINE <-> ISONIAZIDE"@fr;
  dct:identifier "IAM_10550";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b200986;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de carbamazépine avec signes de surdosage par inhibition de son métabolisme hépatique."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b200992, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b200986 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b200987 .

_:79f295ad32df4ce8a18a92539c6e8a3b200987 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200988;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b200989 .

_:79f295ad32df4ce8a18a92539c6e8a3b200988 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10158 .

_:79f295ad32df4ce8a18a92539c6e8a3b200989 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200990;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b200990 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10490 .

_:79f295ad32df4ce8a18a92539c6e8a3b200992 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10551-1 a owl:Class;
  rdfs:label "CARBAMAZEPINE <-> JOSAMYCINE"@fr;
  dct:identifier "IAM_10551";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b200994;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de carbamazépine avec signes de surdosage, par diminution de son métabolisme hépatique."@fr;
  r:conduiteATenir "Surveillance clinique et, si besoin, dosage plasmatique et réduction éventuelle de la posologie de la carbamazépine."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b201000, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b200994 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b200995 .

_:79f295ad32df4ce8a18a92539c6e8a3b200995 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200996;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b200997 .

_:79f295ad32df4ce8a18a92539c6e8a3b200996 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10158 .

_:79f295ad32df4ce8a18a92539c6e8a3b200997 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b200998;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b200998 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10499 .

_:79f295ad32df4ce8a18a92539c6e8a3b201000 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10552-1 a owl:Class;
  rdfs:label "CARBAMAZEPINE <-> LAMOTRIGINE"@fr;
  dct:identifier "IAM_10552";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b201002;
  r:natureDuRisque "Risque d'augmentation des effets neurologiques (vertiges, ataxie, diplopie) de la carbamazépine lors de l'introduction de la lamotrigine."@fr;
  r:conduiteATenir "Surveillance clinique et réduction éventuelle de la posologie de la carbamazépine."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b201008, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b201002 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b201003 .

_:79f295ad32df4ce8a18a92539c6e8a3b201003 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201004;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b201005 .

_:79f295ad32df4ce8a18a92539c6e8a3b201004 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10158 .

_:79f295ad32df4ce8a18a92539c6e8a3b201005 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201006;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b201006 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10507 .

_:79f295ad32df4ce8a18a92539c6e8a3b201008 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10553-1 a owl:Class;
  rdfs:label "CARBAMAZEPINE <-> LITHIUM"@fr;
  dct:identifier "IAM_10553";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b201010;
  r:natureDuRisque "Risque de neurotoxicité se manifestant par des troubles cérébelleux, confusion, somnolence, ataxie. Ces troubles sont réversibles à l'arrêt du traitement par le lithium."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b201016, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b201010 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b201011 .

_:79f295ad32df4ce8a18a92539c6e8a3b201011 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201012;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b201013 .

_:79f295ad32df4ce8a18a92539c6e8a3b201012 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10158 .

_:79f295ad32df4ce8a18a92539c6e8a3b201013 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201014;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b201014 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10530 .

_:79f295ad32df4ce8a18a92539c6e8a3b201016 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10554-1 a owl:Class;
  rdfs:label "CARBAMAZEPINE <-> MILLEPERTUIS"@fr;
  dct:identifier "IAM_10554";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b201018;
  r:natureDuRisque "Risque de diminution des concentrations plasmatiques et de l'efficacité de la carbamazepine."@fr;
  rdfs:comment "Bien qu'une étude d'interaction rigoureuse, menée sur des volontaires sains, n'ait pas mis en évidence de modification des paramètres pharmacocinétiques de la carbamazépine lorsque celle-ci était administrée conjointement au millepertuis, une association"@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b201024, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b201018 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b201019 .

_:79f295ad32df4ce8a18a92539c6e8a3b201019 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201020;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b201021 .

_:79f295ad32df4ce8a18a92539c6e8a3b201020 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10158 .

_:79f295ad32df4ce8a18a92539c6e8a3b201021 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201022;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b201022 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10588 .

_:79f295ad32df4ce8a18a92539c6e8a3b201024 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10555-1 a owl:Class;
  rdfs:label "CARBAMAZEPINE <-> NINTÉDANIB"@fr;
  dct:identifier "IAM_10555";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b201026;
  r:natureDuRisque "Diminution des concentrations plasmatiques du nintédanib par diminution de son absorption par la carbamazépine."@fr;
  r:conduiteATenir "Surveillance clinique pendant l’association."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b201032, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b201026 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b201027 .

_:79f295ad32df4ce8a18a92539c6e8a3b201027 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201028;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b201029 .

_:79f295ad32df4ce8a18a92539c6e8a3b201028 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10158 .

_:79f295ad32df4ce8a18a92539c6e8a3b201029 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201030;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b201030 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10637 .

_:79f295ad32df4ce8a18a92539c6e8a3b201032 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10608-1 a owl:Class;
  rdfs:label "CICLOSPORINE <-> TERBINAFINE"@fr;
  dct:identifier "IAM_10608";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b201034;
  r:natureDuRisque "Diminution des concentrations sanguines de ciclosporine."@fr;
  r:conduiteATenir "Contrôle des concentrations sanguines de ciclosporine et adaptation éventuelle de sa posologie pendant le traitement par terbinafine et après son arrêt."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b201040, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b201034 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b201035 .

_:79f295ad32df4ce8a18a92539c6e8a3b201035 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201036;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b201037 .

_:79f295ad32df4ce8a18a92539c6e8a3b201036 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10193 .

_:79f295ad32df4ce8a18a92539c6e8a3b201037 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201038;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b201038 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10900 .

_:79f295ad32df4ce8a18a92539c6e8a3b201040 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10557-1 a owl:Class;
  rdfs:label "CARBAMAZEPINE <-> PAMPLEMOUSSE (JUS ET FRUIT)"@fr;
  dct:identifier "IAM_10557";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b201042;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de carbamazépine, avec risque de surdosage, par inhibition de son métabolisme par le pamplemousse."@fr;
  rdfs:comment "Outre l’existence de 3 trois cas cliniques suggérant un risque de surdosage en carbamazépine lors de l’ingestion de jus de pamplemousse, une étude pharmacocinétique chez 10 patients a confirmé une augmentation des concentrations de carbamazépine après ing"@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b201048, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b201042 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b201043 .

_:79f295ad32df4ce8a18a92539c6e8a3b201043 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201044;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b201045 .

_:79f295ad32df4ce8a18a92539c6e8a3b201044 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10130 .

_:79f295ad32df4ce8a18a92539c6e8a3b201045 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201046;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b201046 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10158 .

_:79f295ad32df4ce8a18a92539c6e8a3b201048 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10544-1 a owl:Class;
  rdfs:label "CARBAMAZEPINE <-> ERYTHROMYCINE"@fr;
  dct:identifier "IAM_10544";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b201050;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de carbamazépine, avec signes de surdosage, par inhibition de son métabolisme hépatique."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b201056, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b201050 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b201051 .

_:79f295ad32df4ce8a18a92539c6e8a3b201051 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201052;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b201053 .

_:79f295ad32df4ce8a18a92539c6e8a3b201052 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10158 .

_:79f295ad32df4ce8a18a92539c6e8a3b201053 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201054;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b201054 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10338 .

_:79f295ad32df4ce8a18a92539c6e8a3b201056 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10559-1 a owl:Class;
  rdfs:label "CARBAMAZEPINE <-> PHÉNOBARBITAL (ET, PAR EXTRAPOLATION, PRIMIDONE)"@fr;
  dct:identifier "IAM_10559";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b201058;
  r:natureDuRisque "Diminution progressive des concentrations plasmatiques de carbamazépine et de son métabolite actif sans modification apparente de l'efficacité anticomitiale."@fr;
  r:conduiteATenir "Prudence quant à l'interprétation des concentrations plasmatiques."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b201064, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b201058 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b201059 .

_:79f295ad32df4ce8a18a92539c6e8a3b201059 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201060;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b201061 .

_:79f295ad32df4ce8a18a92539c6e8a3b201060 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10131 .

_:79f295ad32df4ce8a18a92539c6e8a3b201061 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201062;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b201062 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10158 .

_:79f295ad32df4ce8a18a92539c6e8a3b201064 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10560-1 a owl:Class;
  rdfs:label "CARBAMAZEPINE <-> PHÉNYTOÏNE (ET, PAR EXTRAPOLATION, FOSPHÉNYTOÏNE)"@fr;
  dct:identifier "IAM_10560";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b201066;
  r:natureDuRisque "Réduction réciproque des concentrations plasmatiques (augmentation du métabolisme sans modification apparente de l'efficacité anticomitiale)."@fr;
  r:conduiteATenir "Prudence dans l'interprétation des concentrations plasmatiques."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b201072, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b201066 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b201067 .

_:79f295ad32df4ce8a18a92539c6e8a3b201067 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201068;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b201069 .

_:79f295ad32df4ce8a18a92539c6e8a3b201068 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10132 .

_:79f295ad32df4ce8a18a92539c6e8a3b201069 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201070;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b201070 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10158 .

_:79f295ad32df4ce8a18a92539c6e8a3b201072 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10561-1 a owl:Class;
  rdfs:label "CARBAMAZEPINE <-> RIFAMPICINE"@fr;
  dct:identifier "IAM_10561";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b201074;
  r:natureDuRisque "Diminution des concentrations plasmatiques et de l'efficacité de la carbamazépine par augmentation de son métabolisme hépatique par la rifampicine."@fr;
  r:conduiteATenir "Surveillance clinique, contrôle des concentrations plasmatiques et adaptation de la posologie de la carbamazépine pendant le traitement par la rifampicine et après son arrêt."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b201080, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b201074 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b201075 .

_:79f295ad32df4ce8a18a92539c6e8a3b201075 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201076;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b201077 .

_:79f295ad32df4ce8a18a92539c6e8a3b201076 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10158 .

_:79f295ad32df4ce8a18a92539c6e8a3b201077 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201078;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b201078 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:79f295ad32df4ce8a18a92539c6e8a3b201080 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10562-1 a owl:Class;
  rdfs:label "CARBAMAZEPINE <-> RISPERIDONE"@fr;
  dct:identifier "IAM_10562";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b201082;
  r:natureDuRisque "Risque de diminution de la fraction active de la rispéridone et de son efficacité thérapeutique par augmentation de son métabolisme hépatique par la carbamazépine."@fr;
  r:conduiteATenir "Surveillance clinique, et si besoin, adaptation posologique de la rispéridone."@fr;
  rdfs:comment """La rispéridone est majoritairement métabolisée par le CYP2D6 en 9-OH-rispéridone, métabolite actif. La fraction pharmacologiquement active de la rispéridone est ainsi constituée par la molécule mère et son métabolite hydroxylé.
Dans un cas isolé non publi"""@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b201088, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b201082 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b201083 .

_:79f295ad32df4ce8a18a92539c6e8a3b201083 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201084;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b201085 .

_:79f295ad32df4ce8a18a92539c6e8a3b201084 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10158 .

_:79f295ad32df4ce8a18a92539c6e8a3b201085 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201086;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b201086 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10805 .

_:79f295ad32df4ce8a18a92539c6e8a3b201088 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10563-1 a owl:Class;
  rdfs:label "CARBAMAZEPINE <-> SIMVASTATINE"@fr;
  dct:identifier "IAM_10563";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b201090;
  r:natureDuRisque "Diminution importante des concentrations plasmatiques de simvastatine, par augmentation de son métabolisme hépatique."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b201096, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b201090 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b201091 .

_:79f295ad32df4ce8a18a92539c6e8a3b201091 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201092;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b201093 .

_:79f295ad32df4ce8a18a92539c6e8a3b201092 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10158 .

_:79f295ad32df4ce8a18a92539c6e8a3b201093 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201094;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b201094 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10838 .

_:79f295ad32df4ce8a18a92539c6e8a3b201096 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10564-1 a owl:Class;
  rdfs:label "CARBAMAZEPINE <-> TOPIRAMATE"@fr;
  dct:identifier "IAM_10564";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b201098;
  r:natureDuRisque "Diminution des concentrations du topiramate avec risque de moindre efficacité, par augmentation de son métabolisme hépatique par la carbamazépine."@fr;
  r:conduiteATenir "Surveillance clinique, et si besoin, adaptation posologique du topiramate pendant le traitement par la carbamazépine et après son arrêt."@fr;
  rdfs:comment "Les concentrations du topiramate ont diminué de moitié environ en association avec la carbamazépine, tant chez des patients que des volontaires sains. En revanche, le profil pharmacocinétique de la carbamazépine n’est pas modifié par le topiramate."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b201104, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b201098 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b201099 .

_:79f295ad32df4ce8a18a92539c6e8a3b201099 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201100;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b201101 .

_:79f295ad32df4ce8a18a92539c6e8a3b201100 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10158 .

_:79f295ad32df4ce8a18a92539c6e8a3b201101 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201102;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b201102 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10941 .

_:79f295ad32df4ce8a18a92539c6e8a3b201104 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10565-1 a owl:Class;
  rdfs:label "CARBAMAZEPINE <-> VALPROÏQUE (ACIDE) ET, PAR EXTRAPOLATION, VALPROMIDE"@fr;
  dct:identifier "IAM_10565";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b201106;
  r:natureDuRisque "Augmentation des concentrations plasmatiques du métabolite actif de la carbamazépine avec signes de surdosage. De plus, diminution des concentrations plasmatiques d'acide valproïque par augmentation de son métabolisme hépatique par la carbamazépine."@fr;
  r:conduiteATenir "Surveillance clinique, dosages plasmatiques et adaptation de la posologie des deux anticonvulsivants."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b201112, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b201106 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b201107 .

_:79f295ad32df4ce8a18a92539c6e8a3b201107 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201108;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b201109 .

_:79f295ad32df4ce8a18a92539c6e8a3b201108 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10160 .

_:79f295ad32df4ce8a18a92539c6e8a3b201109 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201110;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b201110 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10158 .

_:79f295ad32df4ce8a18a92539c6e8a3b201112 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10566-1 a owl:Class;
  rdfs:label "CARMUSTINE <-> CIMETIDINE"@fr;
  dct:identifier "IAM_10566";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b201114;
  r:natureDuRisque "Avec la cimétidine utilisée à des doses supérieures ou égales à 800 mg/j : toxicité médullaire accrue (inhibition du métabolisme de la carmustine)."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b201120, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b201114 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b201115 .

_:79f295ad32df4ce8a18a92539c6e8a3b201115 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201116;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b201117 .

_:79f295ad32df4ce8a18a92539c6e8a3b201116 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10160 .

_:79f295ad32df4ce8a18a92539c6e8a3b201117 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201118;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b201118 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10196 .

_:79f295ad32df4ce8a18a92539c6e8a3b201120 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10567-1 a owl:Class;
  rdfs:label "CARVEDILOL <-> CIMETIDINE"@fr;
  dct:identifier "IAM_10567";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b201122;
  r:natureDuRisque "Avec la cimétidine utilisée à des doses supérieures ou égales à 800 mg/j : augmentation des concentrations du carvédilol, pouvant être préjudiciables dans le cas du traitement de l'insuffisance cardiaque, par diminution de son métabolisme hépatique par la"@fr;
  r:conduiteATenir "Utiliser un autre antisécrétoire gastrique."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b201128, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b201122 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b201123 .

_:79f295ad32df4ce8a18a92539c6e8a3b201123 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201124;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b201125 .

_:79f295ad32df4ce8a18a92539c6e8a3b201124 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10163 .

_:79f295ad32df4ce8a18a92539c6e8a3b201125 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201126;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b201126 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10196 .

_:79f295ad32df4ce8a18a92539c6e8a3b201128 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10556-1 a owl:Class;
  rdfs:label "CARBAMAZEPINE <-> OLANZAPINE"@fr;
  dct:identifier "IAM_10556";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b201130;
  r:natureDuRisque "Risque de diminution des concentrations plasmatiques de l'olanzapine et de son efficacité thérapeutique, par augmentation de son métabolisme hépatique par la carbamazépine."@fr;
  r:conduiteATenir "Surveillance clinique, et si besoin, adaptation posologique de l'olanzapine."@fr;
  rdfs:comment """Plusieurs publications chez des volontaires sains ou des patients montrent que les concentrations plasmatiques de l’olanzapine sont diminuées de plus de la moitié lors de son association avec la carbamazépine, inducteur puissant des CYP3A4 et CYP1A2. 
L’o"""@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b201136, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b201130 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b201131 .

_:79f295ad32df4ce8a18a92539c6e8a3b201131 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201132;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b201133 .

_:79f295ad32df4ce8a18a92539c6e8a3b201132 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10158 .

_:79f295ad32df4ce8a18a92539c6e8a3b201133 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201134;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b201134 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10658 .

_:79f295ad32df4ce8a18a92539c6e8a3b201136 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10534-1 a owl:Class;
  rdfs:label "CALCIUM <-> HORMONES THYROÏDIENNES"@fr;
  dct:identifier "IAM_10534";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b201138;
  r:natureDuRisque "Diminution de l’absorption des hormones thyroïdiennes."@fr;
  r:conduiteATenir "Prendre les sels de calcium à distance des hormones thyroïdiennes (plus de 2 heures, si possible)."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b201144, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b201138 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b201139 .

_:79f295ad32df4ce8a18a92539c6e8a3b201139 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201140;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b201141 .

_:79f295ad32df4ce8a18a92539c6e8a3b201140 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10082 .

_:79f295ad32df4ce8a18a92539c6e8a3b201141 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201142;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b201142 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10150 .

_:79f295ad32df4ce8a18a92539c6e8a3b201144 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10523-1 a owl:Class;
  rdfs:label "CAFEINE <-> ENOXACINE"@fr;
  dct:identifier "IAM_10523";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b201146;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de caféine, pouvant entraîner excitations et hallucinations, par diminution de son métabolisme hépatique."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b201152, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b201146 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b201147 .

_:79f295ad32df4ce8a18a92539c6e8a3b201147 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201148;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b201149 .

_:79f295ad32df4ce8a18a92539c6e8a3b201148 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10147 .

_:79f295ad32df4ce8a18a92539c6e8a3b201149 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201150;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b201150 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10323 .

_:79f295ad32df4ce8a18a92539c6e8a3b201152 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10524-1 a owl:Class;
  rdfs:label "CAFEINE <-> LITHIUM"@fr;
  dct:identifier "IAM_10524";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b201154;
  r:natureDuRisque "En cas d’arrêt brutal de la consommation de café ou de médicaments contenant de la caféine, risque d’augmentation de la lithémie."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b201160, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b201154 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b201155 .

_:79f295ad32df4ce8a18a92539c6e8a3b201155 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201156;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b201157 .

_:79f295ad32df4ce8a18a92539c6e8a3b201156 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10147 .

_:79f295ad32df4ce8a18a92539c6e8a3b201157 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201158;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b201158 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10530 .

_:79f295ad32df4ce8a18a92539c6e8a3b201160 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10525-1 a owl:Class;
  rdfs:label "CAFEINE <-> MEXILETINE"@fr;
  dct:identifier "IAM_10525";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b201162;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de caféine, par inhibition de son métabolisme hépatique par la méxilétine."@fr;
  rdfs:comment "La caféine est métabolisée par le CYP1A2 et des cas d’intoxication par inhibition de son métabolisme ont été antérieurement décrits avec l’idrocilamide ou la ciprofloxacine. Pour cette dernière, déjà retenue au niveau \"à prendre en compte\", la diminution"@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b201168, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b201162 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b201163 .

_:79f295ad32df4ce8a18a92539c6e8a3b201163 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201164;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b201165 .

_:79f295ad32df4ce8a18a92539c6e8a3b201164 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10147 .

_:79f295ad32df4ce8a18a92539c6e8a3b201165 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201166;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b201166 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10582 .

_:79f295ad32df4ce8a18a92539c6e8a3b201168 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10526-1 a owl:Class;
  rdfs:label "CAFEINE <-> NORFLOXACINE"@fr;
  dct:identifier "IAM_10526";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b201170;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de caféine, par diminution du métabolisme hépatique de la caféine."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b201176, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b201170 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b201171 .

_:79f295ad32df4ce8a18a92539c6e8a3b201171 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201172;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b201173 .

_:79f295ad32df4ce8a18a92539c6e8a3b201172 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10147 .

_:79f295ad32df4ce8a18a92539c6e8a3b201173 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201174;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b201174 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10650 .

_:79f295ad32df4ce8a18a92539c6e8a3b201176 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10527-1 a owl:Class;
  rdfs:label "CAFEINE <-> STIRIPENTOL"@fr;
  dct:identifier "IAM_10527";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b201178;
  r:natureDuRisque "Augmentation possible des concentrations plasmatiques de la caféine, avec risque de surdosage, par inhibition de son métabolisme hépatique."@fr;
  r:conduiteATenir "Surveillance clinique et adaptation éventuelle de la posologie de caféine."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b201184, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b201178 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b201179 .

_:79f295ad32df4ce8a18a92539c6e8a3b201179 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201180;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b201181 .

_:79f295ad32df4ce8a18a92539c6e8a3b201180 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10147 .

_:79f295ad32df4ce8a18a92539c6e8a3b201181 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201182;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b201182 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10859 .

_:79f295ad32df4ce8a18a92539c6e8a3b201184 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10528-1 a owl:Class;
  rdfs:label "CALCITONINE <-> LITHIUM"@fr;
  dct:identifier "IAM_10528";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b201186;
  r:natureDuRisque "Risque de baisse de l’efficacité du lithium par augmentation de son élimination rénale par la calcitonine."@fr;
  r:conduiteATenir "Surveillance clinique et biologique régulière, notamment en début d’association."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b201192, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b201186 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b201187 .

_:79f295ad32df4ce8a18a92539c6e8a3b201187 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201188;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b201189 .

_:79f295ad32df4ce8a18a92539c6e8a3b201188 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10148 .

_:79f295ad32df4ce8a18a92539c6e8a3b201189 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201190;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b201190 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10530 .

_:79f295ad32df4ce8a18a92539c6e8a3b201192 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10529-1 a owl:Class;
  rdfs:label "CALCIUM <-> CYCLINES"@fr;
  dct:identifier "IAM_10529";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b201194;
  r:natureDuRisque "Diminution de l'absorption digestive des cyclines."@fr;
  r:conduiteATenir "Prendre les sels de calcium à distance des cyclines (plus de deux heures, si possible)."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b201200, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b201194 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b201195 .

_:79f295ad32df4ce8a18a92539c6e8a3b201195 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201196;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b201197 .

_:79f295ad32df4ce8a18a92539c6e8a3b201196 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10059 .

_:79f295ad32df4ce8a18a92539c6e8a3b201197 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201198;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b201198 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10150 .

_:79f295ad32df4ce8a18a92539c6e8a3b201200 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10530-1 a owl:Class;
  rdfs:label "CALCIUM <-> DIGOXINE"@fr;
  dct:identifier "IAM_10530";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b201202;
  r:natureDuRisque "Risque de troubles du rythme graves, voire mortels avec les sels de calcium administrés par voie IV."@fr;
  r:conduiteATenir """Contre-indication :
- avec les sels de calcium IV, hormis supplémentation parentérale.

Précaution d'emploi :
- avec les sels de calcium par voie orale.
Surveillance clinique et, s'il y a lieu, contrôle de l'ECG et de la calcémie."""@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b201208, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b201202 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b201203 .

_:79f295ad32df4ce8a18a92539c6e8a3b201203 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201204;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b201205 .

_:79f295ad32df4ce8a18a92539c6e8a3b201204 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10150 .

_:79f295ad32df4ce8a18a92539c6e8a3b201205 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201206;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b201206 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10286 .

_:79f295ad32df4ce8a18a92539c6e8a3b201208 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10531-1 a owl:Class;
  rdfs:label "CALCIUM <-> DIURÉTIQUES THIAZIDIQUES ET APPARENTÉS"@fr;
  dct:identifier "IAM_10531";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b201210;
  r:natureDuRisque "Risque d'hypercalcémie par diminution de l'élimination urinaire du calcium."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b201216, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b201210 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b201211 .

_:79f295ad32df4ce8a18a92539c6e8a3b201211 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201212;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b201213 .

_:79f295ad32df4ce8a18a92539c6e8a3b201212 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10066 .

_:79f295ad32df4ce8a18a92539c6e8a3b201213 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201214;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b201214 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10150 .

_:79f295ad32df4ce8a18a92539c6e8a3b201216 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10546-1 a owl:Class;
  rdfs:label "CARBAMAZEPINE <-> FELBAMATE"@fr;
  dct:identifier "IAM_10546";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b201218;
  r:natureDuRisque "Augmentation des concentrations plasmatiques du métabolite actif de la carbamazépine. De plus, diminution des concentrations plasmatiques de felbamate par augmentation de son métabolisme hépatique par la carbamazépine."@fr;
  r:conduiteATenir "Surveillance clinique, dosages plasmatiques et adaptation éventuelle des posologies des deux anticonvulsivants."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b201224, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b201218 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b201219 .

_:79f295ad32df4ce8a18a92539c6e8a3b201219 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201220;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b201221 .

_:79f295ad32df4ce8a18a92539c6e8a3b201220 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10158 .

_:79f295ad32df4ce8a18a92539c6e8a3b201221 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201222;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b201222 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10369 .

_:79f295ad32df4ce8a18a92539c6e8a3b201224 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10533-1 a owl:Class;
  rdfs:label "CALCIUM <-> FER"@fr;
  dct:identifier "IAM_10533";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b201226;
  r:natureDuRisque "Avec les sels de fer par voie orale : diminution de l'absorption digestive des sels de fer."@fr;
  r:conduiteATenir "Prendre les sels de fer à distance des repas et en l'absence de calcium."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b201232, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b201226 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b201227 .

_:79f295ad32df4ce8a18a92539c6e8a3b201227 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201228;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b201229 .

_:79f295ad32df4ce8a18a92539c6e8a3b201228 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10150 .

_:79f295ad32df4ce8a18a92539c6e8a3b201229 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201230;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b201230 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10375 .

_:79f295ad32df4ce8a18a92539c6e8a3b201232 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10545-1 a owl:Class;
  rdfs:label "CARBAMAZEPINE <-> ETHOSUXIMIDE"@fr;
  dct:identifier "IAM_10545";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b201234;
  r:natureDuRisque "Diminution des concentrations plasmatiques d'éthosuximide."@fr;
  r:conduiteATenir "Surveillance clinique, dosage plasmatique de l'éthosuximide et augmentation éventuelle de sa posologie."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b201240, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b201234 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b201235 .

_:79f295ad32df4ce8a18a92539c6e8a3b201235 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201236;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b201237 .

_:79f295ad32df4ce8a18a92539c6e8a3b201236 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10158 .

_:79f295ad32df4ce8a18a92539c6e8a3b201237 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201238;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b201238 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10352 .

_:79f295ad32df4ce8a18a92539c6e8a3b201240 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10535-1 a owl:Class;
  rdfs:label "CALCIUM <-> STRONTIUM"@fr;
  dct:identifier "IAM_10535";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b201242;
  r:natureDuRisque "Avec les sels de calcium administrés par voie orale : diminution de l'absorption digestive du strontium."@fr;
  r:conduiteATenir "Prendre le strontium à distance des sels de calcium (plus de deux heures, si possible)."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b201248, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b201242 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b201243 .

_:79f295ad32df4ce8a18a92539c6e8a3b201243 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201244;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b201245 .

_:79f295ad32df4ce8a18a92539c6e8a3b201244 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10150 .

_:79f295ad32df4ce8a18a92539c6e8a3b201245 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201246;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b201246 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10863 .

_:79f295ad32df4ce8a18a92539c6e8a3b201248 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10536-1 a owl:Class;
  rdfs:label "CALCIUM <-> ZINC"@fr;
  dct:identifier "IAM_10536";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b201250;
  r:natureDuRisque "Diminution de l’absorption digestive du zinc par le calcium."@fr;
  r:conduiteATenir "Prendre les sels de calcium à distance du zinc (plus de 2 heures si possible)."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b201256, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b201250 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b201251 .

_:79f295ad32df4ce8a18a92539c6e8a3b201251 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201252;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b201253 .

_:79f295ad32df4ce8a18a92539c6e8a3b201252 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10150 .

_:79f295ad32df4ce8a18a92539c6e8a3b201253 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201254;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b201254 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_11005 .

_:79f295ad32df4ce8a18a92539c6e8a3b201256 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10537-1 a owl:Class;
  rdfs:label "CARBAMAZEPINE <-> CIMETIDINE"@fr;
  dct:identifier "IAM_10537";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b201258;
  r:natureDuRisque "Avec la cimétidine utilisée à des doses supérieures ou égales à 800 mg/j : en début de traitement, augmentation des concentrations plasmatiques de carbamazépine par inhibition de son métabolisme hépatique par la cimétidine."@fr;
  r:conduiteATenir "Surveillance clinique et réduction éventuelle de la posologie de la carbamazépine, spécialement pendant les premiers jours de traitement par la cimétidine."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b201264, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b201258 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b201259 .

_:79f295ad32df4ce8a18a92539c6e8a3b201259 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201260;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b201261 .

_:79f295ad32df4ce8a18a92539c6e8a3b201260 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10158 .

_:79f295ad32df4ce8a18a92539c6e8a3b201261 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201262;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b201262 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10196 .

_:79f295ad32df4ce8a18a92539c6e8a3b201264 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10538-1 a owl:Class;
  rdfs:label "CARBAMAZEPINE <-> CLARITHROMYCINE"@fr;
  dct:identifier "IAM_10538";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b201266;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de carbamazépine avec signes de surdosage, par inhibition de son métabolisme hépatique."@fr;
  r:conduiteATenir "Surveillance clinique et réduction éventuelle de la posologie de la carbamazépine."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b201272, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b201266 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b201267 .

_:79f295ad32df4ce8a18a92539c6e8a3b201267 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201268;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b201269 .

_:79f295ad32df4ce8a18a92539c6e8a3b201268 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10158 .

_:79f295ad32df4ce8a18a92539c6e8a3b201269 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201270;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b201270 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10206 .

_:79f295ad32df4ce8a18a92539c6e8a3b201272 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10539-1 a owl:Class;
  rdfs:label "CARBAMAZEPINE <-> CLONAZEPAM"@fr;
  dct:identifier "IAM_10539";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b201274;
  r:natureDuRisque "Augmentation des concentrations plasmatiques du métabolite actif de la carbamazépine. De plus, diminution des concentrations plasmatiques du clonazépam par augmentation de son métabolisme hépatique par la carbamazépine."@fr;
  r:conduiteATenir "Surveillance clinique, dosages plasmatiques et adaptation éventuelle des posologies des deux anticonvulsivants."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b201280, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b201274 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b201275 .

_:79f295ad32df4ce8a18a92539c6e8a3b201275 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201276;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b201277 .

_:79f295ad32df4ce8a18a92539c6e8a3b201276 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10158 .

_:79f295ad32df4ce8a18a92539c6e8a3b201277 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201278;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b201278 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10213 .

_:79f295ad32df4ce8a18a92539c6e8a3b201280 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10540-1 a owl:Class;
  rdfs:label "CARBAMAZEPINE <-> CLOZAPINE"@fr;
  dct:identifier "IAM_10540";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b201282;
  r:natureDuRisque "Risque de majoration des effets hématologiques graves."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b201288, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b201282 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b201283 .

_:79f295ad32df4ce8a18a92539c6e8a3b201283 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201284;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b201285 .

_:79f295ad32df4ce8a18a92539c6e8a3b201284 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10158 .

_:79f295ad32df4ce8a18a92539c6e8a3b201285 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201286;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b201286 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10220 .

_:79f295ad32df4ce8a18a92539c6e8a3b201288 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10541-1 a owl:Class;
  rdfs:label "CARBAMAZEPINE <-> DANAZOL"@fr;
  dct:identifier "IAM_10541";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b201290;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de carbamazépine, avec signes de surdosage."@fr;
  r:conduiteATenir "Surveillance clinique et réduction éventuelle de la posologie de la carbamazépine."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b201296, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b201290 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b201291 .

_:79f295ad32df4ce8a18a92539c6e8a3b201291 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201292;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b201293 .

_:79f295ad32df4ce8a18a92539c6e8a3b201292 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10158 .

_:79f295ad32df4ce8a18a92539c6e8a3b201293 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201294;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b201294 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10248 .

_:79f295ad32df4ce8a18a92539c6e8a3b201296 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10542-1 a owl:Class;
  rdfs:label "CARBAMAZEPINE <-> DIGOXINE"@fr;
  dct:identifier "IAM_10542";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b201298;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de carbamazépine et diminution de la digoxinémie."@fr;
  r:conduiteATenir "Prudence dans l'interprétation des concentrations plasmatiques."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b201304, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b201298 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b201299 .

_:79f295ad32df4ce8a18a92539c6e8a3b201299 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201300;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b201301 .

_:79f295ad32df4ce8a18a92539c6e8a3b201300 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10158 .

_:79f295ad32df4ce8a18a92539c6e8a3b201301 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201302;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b201302 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10286 .

_:79f295ad32df4ce8a18a92539c6e8a3b201304 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10543-1 a owl:Class;
  rdfs:label "CARBAMAZEPINE <-> DIURÉTIQUES HYPOKALIÉMIANTS"@fr;
  dct:identifier "IAM_10543";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b201306;
  r:natureDuRisque "Risque d'hyponatrémie symptomatique."@fr;
  r:conduiteATenir "Surveillance clinique et biologique. Si possible, utiliser une autre classe de diurétiques."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b201312, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b201306 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b201307 .

_:79f295ad32df4ce8a18a92539c6e8a3b201307 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201308;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b201309 .

_:79f295ad32df4ce8a18a92539c6e8a3b201308 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10065 .

_:79f295ad32df4ce8a18a92539c6e8a3b201309 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201310;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b201310 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10158 .

_:79f295ad32df4ce8a18a92539c6e8a3b201312 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10570-1 a owl:Class;
  rdfs:label "CATIORESINE SULFO SODIQUE <-> SORBITOL"@fr;
  dct:identifier "IAM_10570";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b201314;
  r:natureDuRisque "Avec la résine administrée par voie orale et rectale : risque de nécrose colique, éventuellement fatale."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b201320, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b201314 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b201315 .

_:79f295ad32df4ce8a18a92539c6e8a3b201315 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201316;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b201317 .

_:79f295ad32df4ce8a18a92539c6e8a3b201316 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10167 .

_:79f295ad32df4ce8a18a92539c6e8a3b201317 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201318;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b201318 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10853 .

_:79f295ad32df4ce8a18a92539c6e8a3b201320 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10532-1 a owl:Class;
  rdfs:label "CALCIUM <-> ESTRAMUSTINE"@fr;
  dct:identifier "IAM_10532";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b201322;
  r:natureDuRisque "Diminution de l'absorption digestive de l'estramustine."@fr;
  r:conduiteATenir "Prendre les sels de calcium à distance de l'estramustine (plus de 2 heures, si possible)."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b201328, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b201322 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b201323 .

_:79f295ad32df4ce8a18a92539c6e8a3b201323 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201324;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b201325 .

_:79f295ad32df4ce8a18a92539c6e8a3b201324 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10150 .

_:79f295ad32df4ce8a18a92539c6e8a3b201325 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201326;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b201326 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10345 .

_:79f295ad32df4ce8a18a92539c6e8a3b201328 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10595-1 a owl:Class;
  rdfs:label "CICLOSPORINE <-> NIFEDIPINE"@fr;
  dct:identifier "IAM_10595";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b201330;
  r:natureDuRisque "Risque d'addition d'effets indésirables à type de gingivopathies."@fr;
  r:conduiteATenir "Utiliser une autre dihydropyridine."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b201336, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b201330 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b201331 .

_:79f295ad32df4ce8a18a92539c6e8a3b201331 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201332;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b201333 .

_:79f295ad32df4ce8a18a92539c6e8a3b201332 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10193 .

_:79f295ad32df4ce8a18a92539c6e8a3b201333 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201334;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b201334 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10633 .

_:79f295ad32df4ce8a18a92539c6e8a3b201336 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10568-1 a owl:Class;
  rdfs:label "CARVEDILOL <-> RIFAMPICINE"@fr;
  dct:identifier "IAM_10568";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b201338;
  r:natureDuRisque "Diminution importante des concentrations plasmatiques du carvédilol, par augmentation de son métabolisme hépatique par la rifampicine."@fr;
  r:conduiteATenir "Surveillance clinique régulière et adaptation de la posologie du carvédilol pendant le traitement par la rifampicine. A l'arrêt de la rifampicine, risque de remontée importante des concentrations plasmatiques de carvédilol imposant une réduction posologiq"@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b201344, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b201338 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b201339 .

_:79f295ad32df4ce8a18a92539c6e8a3b201339 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201340;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b201341 .

_:79f295ad32df4ce8a18a92539c6e8a3b201340 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10163 .

_:79f295ad32df4ce8a18a92539c6e8a3b201341 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201342;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b201342 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:79f295ad32df4ce8a18a92539c6e8a3b201344 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11038-1 a owl:Class;
  rdfs:label "IMAO IRRÉVERSIBLES <-> INHIBITEURS DE LA CATÉCHOL-O-MÉTHYLTRANSFÉRASE (COMT)"@fr;
  dct:identifier "IAM_11038";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b201346;
  r:natureDuRisque "Potentialisation des effets pharmacologiques, et notamment vasopresseurs, des catécholamines par inhibition conjuguée de leur métabolisme."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b201352, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b201346 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b201347 .

_:79f295ad32df4ce8a18a92539c6e8a3b201347 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201348;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b201349 .

_:79f295ad32df4ce8a18a92539c6e8a3b201348 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10002 .

_:79f295ad32df4ce8a18a92539c6e8a3b201349 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201350;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b201350 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10097 .

_:79f295ad32df4ce8a18a92539c6e8a3b201352 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11039-1 a owl:Class;
  rdfs:label "IMAO IRRÉVERSIBLES <-> INHIBITEURS SÉLECTIFS DE LA RECAPTURE DE LA SÉROTONINE"@fr;
  dct:identifier "IAM_11039";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b201354;
  r:natureDuRisque "Risque d'apparition d'un syndrome sérotoninergique : diarrhée, tachycardie, sueurs, tremblements, confusion voire coma."@fr;
  r:conduiteATenir "Respecter un délai de deux semaines entre l'arrêt de l'IMAO et le début du traitement par l'antidépresseur sérotoninergique, et d'au moins une semaine entre l'arrêt de l'antidépresseur sérotoninergique (sauf pour la fluoxétine : cinq semaines) et le début"@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b201360, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b201354 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b201355 .

_:79f295ad32df4ce8a18a92539c6e8a3b201355 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201356;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b201357 .

_:79f295ad32df4ce8a18a92539c6e8a3b201356 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10002 .

_:79f295ad32df4ce8a18a92539c6e8a3b201357 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201358;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b201358 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10104 .

_:79f295ad32df4ce8a18a92539c6e8a3b201360 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11040-1 a owl:Class;
  rdfs:label "IMAO IRRÉVERSIBLES <-> MÉDICAMENTS MIXTES ADRÉNERGIQUES-SÉROTONINERGIQUES"@fr;
  dct:identifier "IAM_11040";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b201362;
  r:natureDuRisque "Risque d'apparition d'un syndrome sérotoninergique : diarrhée, tachycardie, sueurs, tremblements, confusion voire coma."@fr;
  r:conduiteATenir "Respecter un délai de deux semaines entre l'arrêt de l'IMAO et le début de l'autre traitement, et d'au moins une semaine entre l'arrêt de l'autre traitement et le début de l'IMAO."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b201368, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b201362 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b201363 .

_:79f295ad32df4ce8a18a92539c6e8a3b201363 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201364;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b201365 .

_:79f295ad32df4ce8a18a92539c6e8a3b201364 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10002 .

_:79f295ad32df4ce8a18a92539c6e8a3b201365 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201366;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b201366 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10116 .

_:79f295ad32df4ce8a18a92539c6e8a3b201368 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11041-1 a owl:Class;
  rdfs:label "IMAO IRRÉVERSIBLES <-> MIDODRINE"@fr;
  dct:identifier "IAM_11041";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b201370;
  r:natureDuRisque "Crises hypertensives (inhibition du métabolisme des amines pressives). Du fait de la durée d'action des IMAO, cette interaction est encore possible 15 jours après l'arrêt de l'IMAO."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b201376, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b201370 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b201371 .

_:79f295ad32df4ce8a18a92539c6e8a3b201371 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201372;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b201373 .

_:79f295ad32df4ce8a18a92539c6e8a3b201372 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10002 .

_:79f295ad32df4ce8a18a92539c6e8a3b201373 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201374;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b201374 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10587 .

_:79f295ad32df4ce8a18a92539c6e8a3b201376 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10589-1 a owl:Class;
  rdfs:label "CICLOSPORINE <-> JOSAMYCINE"@fr;
  dct:identifier "IAM_10589";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b201378;
  r:natureDuRisque "Risque d'augmentation des concentrations sanguines de ciclosporine et de la créatininémie."@fr;
  r:conduiteATenir "Dosage des concentrations sanguines de la ciclosporine, contrôle de la fonction rénale et adaptation de la posologie pendant l'association et après l'arrêt du macrolide."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b201384, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b201378 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b201379 .

_:79f295ad32df4ce8a18a92539c6e8a3b201379 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201380;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b201381 .

_:79f295ad32df4ce8a18a92539c6e8a3b201380 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10193 .

_:79f295ad32df4ce8a18a92539c6e8a3b201381 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201382;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b201382 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10499 .

_:79f295ad32df4ce8a18a92539c6e8a3b201384 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10590-1 a owl:Class;
  rdfs:label "CICLOSPORINE <-> LERCANIDIPINE"@fr;
  dct:identifier "IAM_10590";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b201386;
  r:natureDuRisque "Augmentation modérée des concentrations sanguines de l'immunosuppresseur et augmentation plus notable des concentrations de lercanidipine."@fr;
  r:conduiteATenir "Décaler les prises des deux médicaments. Dosage des concentrations sanguines de l'immunosuppresseur, et adaptation si nécessaire de sa posologie pendant l'association et après son arrêt."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b201392, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b201386 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b201387 .

_:79f295ad32df4ce8a18a92539c6e8a3b201387 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201388;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b201389 .

_:79f295ad32df4ce8a18a92539c6e8a3b201388 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10193 .

_:79f295ad32df4ce8a18a92539c6e8a3b201389 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201390;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b201390 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10514 .

_:79f295ad32df4ce8a18a92539c6e8a3b201392 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10591-1 a owl:Class;
  rdfs:label "CICLOSPORINE <-> METHOTREXATE"@fr;
  dct:identifier "IAM_10591";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b201394;
  r:natureDuRisque "Augmentation de la toxicité du méthotrexate et de la ciclosporine avec augmentation de la créatininémie : diminution réciproque des clairances des deux médicaments."@fr;
  r:conduiteATenir "Dosage des concentrations sanguines de ciclosporine et de méthotrexate. Adaptation posologique si nécessaire pendant l'association et après son arrêt."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b201400, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b201394 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b201395 .

_:79f295ad32df4ce8a18a92539c6e8a3b201395 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201396;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b201397 .

_:79f295ad32df4ce8a18a92539c6e8a3b201396 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10193 .

_:79f295ad32df4ce8a18a92539c6e8a3b201397 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201398;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b201398 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10569 .

_:79f295ad32df4ce8a18a92539c6e8a3b201400 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10592-1 a owl:Class;
  rdfs:label "CICLOSPORINE <-> METHYLPREDNISOLONE"@fr;
  dct:identifier "IAM_10592";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b201402;
  r:natureDuRisque "Avec la méthylprednisolone administrée par voie IV : augmentation possible des concentrations sanguines de ciclosporine et de la créatininémie. Mécanisme invoqué : diminution de l'élimination hépatique de la ciclosporine."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b201408, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b201402 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b201403 .

_:79f295ad32df4ce8a18a92539c6e8a3b201403 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201404;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b201405 .

_:79f295ad32df4ce8a18a92539c6e8a3b201404 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10193 .

_:79f295ad32df4ce8a18a92539c6e8a3b201405 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201406;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b201406 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10576 .

_:79f295ad32df4ce8a18a92539c6e8a3b201408 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11037-1 a owl:Class;
  rdfs:label "IFOSFAMIDE <-> VÉMURAFÉNIB"@fr;
  dct:identifier "IAM_11037";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b201410;
  r:natureDuRisque "Risque de diminution des concentrations de l'ifosfamide, avec augmentation de son métabolite actif et toxicité majorée."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b201416, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b201410 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b201411 .

_:79f295ad32df4ce8a18a92539c6e8a3b201411 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201412;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b201413 .

_:79f295ad32df4ce8a18a92539c6e8a3b201412 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10445 .

_:79f295ad32df4ce8a18a92539c6e8a3b201413 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201414;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b201414 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10978 .

_:79f295ad32df4ce8a18a92539c6e8a3b201416 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10594-1 a owl:Class;
  rdfs:label "CICLOSPORINE <-> MODAFINIL"@fr;
  dct:identifier "IAM_10594";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b201418;
  r:natureDuRisque "Risque de diminution des concentrations sanguines et de l'efficacité de l'immunosuppresseur."@fr;
  rdfs:comment "L’existence d’un seul cas de baisse des concentrations plasmatiques de ciclosporine, lors de l’association à du modafinil, s’explique vraisemblablement par l'indication restreinte du modafinil et son usage limité. Dans la mesure où toute suspicion d’induc"@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b201424, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b201418 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b201419 .

_:79f295ad32df4ce8a18a92539c6e8a3b201419 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201420;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b201421 .

_:79f295ad32df4ce8a18a92539c6e8a3b201420 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10193 .

_:79f295ad32df4ce8a18a92539c6e8a3b201421 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201422;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b201422 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10599 .

_:79f295ad32df4ce8a18a92539c6e8a3b201424 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11036-1 a owl:Class;
  rdfs:label "IFOSFAMIDE <-> PHÉNOBARBITAL (ET, PAR EXTRAPOLATION, PRIMIDONE)"@fr;
  dct:identifier "IAM_11036";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b201426;
  r:natureDuRisque "Risque de majoration de la neurotoxicité de l'ifosfamide par augmentation de son métabolisme hépatique par le phénobarbital."@fr;
  rdfs:comment """L'association entre les cytotoxiques et la phénytoïne, qui faisait l'objet d'un double niveau de contrainte, a été harmonisée en une seule association déconseillée. 
Cette modification s'applique de la même façon à l'interaction entre le phénobarbital et"""@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b201432, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b201426 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b201427 .

_:79f295ad32df4ce8a18a92539c6e8a3b201427 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201428;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b201429 .

_:79f295ad32df4ce8a18a92539c6e8a3b201428 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10131 .

_:79f295ad32df4ce8a18a92539c6e8a3b201429 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201430;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b201430 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10445 .

_:79f295ad32df4ce8a18a92539c6e8a3b201432 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10596-1 a owl:Class;
  rdfs:label "CICLOSPORINE <-> NINTÉDANIB"@fr;
  dct:identifier "IAM_10596";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b201434;
  r:natureDuRisque "Augmentation des concentrations plasmatiques du nintédanib par augmentation de son absorption par la ciclosporine."@fr;
  r:conduiteATenir "Surveillance clinique pendant l’association."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b201440, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b201434 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b201435 .

_:79f295ad32df4ce8a18a92539c6e8a3b201435 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201436;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b201437 .

_:79f295ad32df4ce8a18a92539c6e8a3b201436 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10193 .

_:79f295ad32df4ce8a18a92539c6e8a3b201437 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201438;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b201438 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10637 .

_:79f295ad32df4ce8a18a92539c6e8a3b201440 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10597-1 a owl:Class;
  rdfs:label "CICLOSPORINE <-> ORLISTAT"@fr;
  dct:identifier "IAM_10597";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b201442;
  r:natureDuRisque "Diminution des concentrations sanguines de ciclosporine par diminution de son absorption intestinale, avec risque de perte de l'activité immunosuppressive."@fr;
  r:conduiteATenir "Prendre l'orlistat à distance de la ciclosporine (au moins 3 heures). Contrôle renforcé des dosages sanguins de ciclosporine, notamment en début d’association, et lors d’augmentation éventuelle de la posologie de l’orlistat."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b201448, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b201442 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b201443 .

_:79f295ad32df4ce8a18a92539c6e8a3b201443 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201444;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b201445 .

_:79f295ad32df4ce8a18a92539c6e8a3b201444 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10193 .

_:79f295ad32df4ce8a18a92539c6e8a3b201445 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201446;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b201446 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10667 .

_:79f295ad32df4ce8a18a92539c6e8a3b201448 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10598-1 a owl:Class;
  rdfs:label "CICLOSPORINE <-> PITAVASTATINE"@fr;
  dct:identifier "IAM_10598";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b201450;
  r:natureDuRisque "Risque majoré d'effets indésirables (concentration-dépendants) à type de rhabdomyolyse, ou de néphrotoxicité, par diminution du métabolisme de la pitavastatine."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b201456, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b201450 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b201451 .

_:79f295ad32df4ce8a18a92539c6e8a3b201451 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201452;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b201453 .

_:79f295ad32df4ce8a18a92539c6e8a3b201452 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10193 .

_:79f295ad32df4ce8a18a92539c6e8a3b201453 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201454;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b201454 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10735 .

_:79f295ad32df4ce8a18a92539c6e8a3b201456 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10599-1 a owl:Class;
  rdfs:label "CICLOSPORINE <-> POTASSIUM"@fr;
  dct:identifier "IAM_10599";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b201458;
  r:natureDuRisque "Hyperkaliémie essentiellement létale, surtout lors d'une insuffisance rénale (addition des effets hyperkaliémiants)."@fr;
  r:conduiteATenir "Eviter cette association sauf s'il existe une hypokaliémie préalable."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b201464, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b201458 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b201459 .

_:79f295ad32df4ce8a18a92539c6e8a3b201459 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201460;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b201461 .

_:79f295ad32df4ce8a18a92539c6e8a3b201460 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10193 .

_:79f295ad32df4ce8a18a92539c6e8a3b201461 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201462;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b201462 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10742 .

_:79f295ad32df4ce8a18a92539c6e8a3b201464 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10600-1 a owl:Class;
  rdfs:label "CICLOSPORINE <-> PREDNISOLONE"@fr;
  dct:identifier "IAM_10600";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b201466;
  r:natureDuRisque "Augmentation des effets de la prednisolone : aspect cushingoïde, réduction de la tolérance aux glucides (diminution de la clairance de la prednisolone)."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b201472, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b201466 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b201467 .

_:79f295ad32df4ce8a18a92539c6e8a3b201467 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201468;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b201469 .

_:79f295ad32df4ce8a18a92539c6e8a3b201468 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10193 .

_:79f295ad32df4ce8a18a92539c6e8a3b201469 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201470;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b201470 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10752 .

_:79f295ad32df4ce8a18a92539c6e8a3b201472 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10601-1 a owl:Class;
  rdfs:label "CICLOSPORINE <-> REPAGLINIDE"@fr;
  dct:identifier "IAM_10601";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b201474;
  r:natureDuRisque "Augmentation de plus du double des concentrations du répaglinide par augmentation de son absorption."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b201480, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b201474 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b201475 .

_:79f295ad32df4ce8a18a92539c6e8a3b201475 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201476;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b201477 .

_:79f295ad32df4ce8a18a92539c6e8a3b201476 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10193 .

_:79f295ad32df4ce8a18a92539c6e8a3b201477 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201478;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b201478 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10791 .

_:79f295ad32df4ce8a18a92539c6e8a3b201480 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10602-1 a owl:Class;
  rdfs:label "CICLOSPORINE <-> ROSUVASTATINE"@fr;
  dct:identifier "IAM_10602";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b201482;
  r:natureDuRisque "Risque majoré d'effets indésirables (concentration-dépendants) à type de rhabdomyolyse, ou de néphrotoxicité, par diminution du métabolisme de la rosuvastatine."@fr;
  rdfs:comment "La ciclosporine entraîne un doublement des concentrations de l'hypolipémiant. La rosuvastatine ayant une marge thérapeutique étroite et exposant à un risque musculaire et rénal imprévisible, cette association est contre-indiquée."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b201488, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b201482 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b201483 .

_:79f295ad32df4ce8a18a92539c6e8a3b201483 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201484;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b201485 .

_:79f295ad32df4ce8a18a92539c6e8a3b201484 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10193 .

_:79f295ad32df4ce8a18a92539c6e8a3b201485 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201486;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b201486 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10814 .

_:79f295ad32df4ce8a18a92539c6e8a3b201488 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10603-1 a owl:Class;
  rdfs:label "CICLOSPORINE <-> ROXITHROMYCINE"@fr;
  dct:identifier "IAM_10603";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b201490;
  r:natureDuRisque "Risque d'augmentation des concentrations sanguines de ciclosporine et de la créatininémie."@fr;
  r:conduiteATenir "Dosage des concentrations sanguines de la ciclosporine, contrôle de la fonction rénale et adaptation de la posologie pendant l'association et après l'arrêt du macrolide."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b201496, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b201490 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b201491 .

_:79f295ad32df4ce8a18a92539c6e8a3b201491 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201492;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b201493 .

_:79f295ad32df4ce8a18a92539c6e8a3b201492 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10193 .

_:79f295ad32df4ce8a18a92539c6e8a3b201493 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201494;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b201494 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10817 .

_:79f295ad32df4ce8a18a92539c6e8a3b201496 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10604-1 a owl:Class;
  rdfs:label "CICLOSPORINE <-> SIMVASTATINE"@fr;
  dct:identifier "IAM_10604";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b201498;
  r:natureDuRisque "Risque majoré d'effets indésirables (concentration-dépendants) à type de rhabdomyolyse par diminution du métabolisme de la simvastatine."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b201504, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b201498 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b201499 .

_:79f295ad32df4ce8a18a92539c6e8a3b201499 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201500;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b201501 .

_:79f295ad32df4ce8a18a92539c6e8a3b201500 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10193 .

_:79f295ad32df4ce8a18a92539c6e8a3b201501 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201502;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b201502 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10838 .

_:79f295ad32df4ce8a18a92539c6e8a3b201504 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10605-1 a owl:Class;
  rdfs:label "CICLOSPORINE <-> SIROLIMUS"@fr;
  dct:identifier "IAM_10605";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b201506;
  r:natureDuRisque "Augmentation des concentrations sanguines de sirolimus par la ciclosporine. La néphrotoxicité de la ciclosporine est également augmentée lors de l’association."@fr;
  r:conduiteATenir "Il est recommandé d’administrer le sirolimus 4 heures après la ciclosporine. Contrôle de la fonction rénale, pendant l’association et après son arrêt."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b201512, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b201506 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b201507 .

_:79f295ad32df4ce8a18a92539c6e8a3b201507 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201508;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b201509 .

_:79f295ad32df4ce8a18a92539c6e8a3b201508 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10193 .

_:79f295ad32df4ce8a18a92539c6e8a3b201509 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201510;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b201510 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10839 .

_:79f295ad32df4ce8a18a92539c6e8a3b201512 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10593-1 a owl:Class;
  rdfs:label "CICLOSPORINE <-> MIDECAMYCINE"@fr;
  dct:identifier "IAM_10593";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b201514;
  r:natureDuRisque "Risque d'augmentation des concentrations sanguines de ciclosporine et de la créatininémie."@fr;
  r:conduiteATenir "Dosage des concentrations sanguines de la ciclosporine, contrôle de la fonction rénale et adaptation de la posologie pendant l'association et après l'arrêt du macrolide."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b201520, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b201514 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b201515 .

_:79f295ad32df4ce8a18a92539c6e8a3b201515 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201516;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b201517 .

_:79f295ad32df4ce8a18a92539c6e8a3b201516 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10193 .

_:79f295ad32df4ce8a18a92539c6e8a3b201517 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201518;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b201518 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10586 .

_:79f295ad32df4ce8a18a92539c6e8a3b201520 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11289-1 a owl:Class;
  rdfs:label "MILLEPERTUIS <-> ÉRIBULINE"@fr;
  dct:identifier "IAM_11289";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b201522;
  r:natureDuRisque "Risque de diminution des concentrations plasmatiques d’éribuline par le millepertuis."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b201528, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b201522 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b201523 .

_:79f295ad32df4ce8a18a92539c6e8a3b201523 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201524;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b201525 .

_:79f295ad32df4ce8a18a92539c6e8a3b201524 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10335 .

_:79f295ad32df4ce8a18a92539c6e8a3b201525 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201526;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b201526 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10588 .

_:79f295ad32df4ce8a18a92539c6e8a3b201528 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10302-1 a owl:Class;
  rdfs:label "ANTISÉCRÉTOIRES INHIBITEURS DE LA POMPE À PROTONS <-> LÉDIPASVIR"@fr;
  dct:identifier "IAM_10302";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b201530;
  r:natureDuRisque "Diminution des concentrations du lédipasvir en cas d’administration de l’inhibiteur de la pompe à protons avant le lédipasvir."@fr;
  r:conduiteATenir "Il est recommandé de prendre l'’inhibiteur de la pompe à protons et le lédipasvir simultanément."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b201536, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b201530 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b201531 .

_:79f295ad32df4ce8a18a92539c6e8a3b201531 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201532;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b201533 .

_:79f295ad32df4ce8a18a92539c6e8a3b201532 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10043 .

_:79f295ad32df4ce8a18a92539c6e8a3b201533 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201534;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b201534 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10512 .

_:79f295ad32df4ce8a18a92539c6e8a3b201536 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10571-1 a owl:Class;
  rdfs:label "CHLORDIAZEPOXIDE <-> CIMETIDINE"@fr;
  dct:identifier "IAM_10571";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b201538;
  r:natureDuRisque "Avec la cimétidine utilisée à des doses supérieures ou égales à 800 mg/j : risque accru de somnolence."@fr;
  r:conduiteATenir "Avertir les patients de l'augmentation du risque en cas de conduite automobile ou d'utilisation de machines."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b201544, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b201538 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b201539 .

_:79f295ad32df4ce8a18a92539c6e8a3b201539 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201540;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b201541 .

_:79f295ad32df4ce8a18a92539c6e8a3b201540 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10182 .

_:79f295ad32df4ce8a18a92539c6e8a3b201541 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201542;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b201542 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10196 .

_:79f295ad32df4ce8a18a92539c6e8a3b201544 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10572-1 a owl:Class;
  rdfs:label "CHLOROQUINE <-> CICLOSPORINE"@fr;
  dct:identifier "IAM_10572";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b201546;
  r:natureDuRisque "Risque d'augmentation des concentrations sanguines de ciclosporine et de la créatininémie."@fr;
  r:conduiteATenir "Dosage des concentrations sanguines de ciclosporine, contrôle de la fonction rénale et adaptation de la posologie pendant l'association et après l'arrêt de la chloroquine."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b201552, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b201546 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b201547 .

_:79f295ad32df4ce8a18a92539c6e8a3b201547 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201548;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b201549 .

_:79f295ad32df4ce8a18a92539c6e8a3b201548 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10184 .

_:79f295ad32df4ce8a18a92539c6e8a3b201549 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201550;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b201550 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10193 .

_:79f295ad32df4ce8a18a92539c6e8a3b201552 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10573-1 a owl:Class;
  rdfs:label "CHLOROQUINE <-> CIMETIDINE"@fr;
  dct:identifier "IAM_10573";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b201554;
  r:natureDuRisque "Ralentissement de l’élimination de la chloroquine et risque de surdosage."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b201560, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b201554 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b201555 .

_:79f295ad32df4ce8a18a92539c6e8a3b201555 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201556;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b201557 .

_:79f295ad32df4ce8a18a92539c6e8a3b201556 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10184 .

_:79f295ad32df4ce8a18a92539c6e8a3b201557 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201558;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b201558 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10196 .

_:79f295ad32df4ce8a18a92539c6e8a3b201560 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10574-1 a owl:Class;
  rdfs:label "CHLOROQUINE <-> HORMONES THYROÏDIENNES"@fr;
  dct:identifier "IAM_10574";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b201562;
  r:natureDuRisque "Risque d’hypothyroïdie clinique chez les patients substitués par hormones thyroïdiennes."@fr;
  r:conduiteATenir "Surveillance des concentrations sériques de T3 et de T4 et adaptation, si besoin, de la posologie de l'hormone thyroïdienne pendant le traitement par l’antipaludique et après son arrêt."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b201568, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b201562 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b201563 .

_:79f295ad32df4ce8a18a92539c6e8a3b201563 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201564;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b201565 .

_:79f295ad32df4ce8a18a92539c6e8a3b201564 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10082 .

_:79f295ad32df4ce8a18a92539c6e8a3b201565 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201566;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b201566 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10184 .

_:79f295ad32df4ce8a18a92539c6e8a3b201568 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10575-1 a owl:Class;
  rdfs:label "CHLORPROMAZINE <-> INSULINE"@fr;
  dct:identifier "IAM_10575";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b201570;
  r:natureDuRisque "A fortes posologies (100 mg par jour de chlorpromazine) : élévation de la glycémie (diminution de la libération de l'insuline)."@fr;
  r:conduiteATenir "Prévenir le patient et renforcer l'autosurveillance glycémique. Adapter éventuellement la posologie de l'insuline pendant le traitement par le neuroleptique et après son arrêt."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b201576, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b201570 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b201571 .

_:79f295ad32df4ce8a18a92539c6e8a3b201571 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201572;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b201573 .

_:79f295ad32df4ce8a18a92539c6e8a3b201572 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10186 .

_:79f295ad32df4ce8a18a92539c6e8a3b201573 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201574;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b201574 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10458 .

_:79f295ad32df4ce8a18a92539c6e8a3b201576 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10576-1 a owl:Class;
  rdfs:label "CHLORPROMAZINE <-> SULFAMIDES HYPOGLYCÉMIANTS"@fr;
  dct:identifier "IAM_10576";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b201578;
  r:natureDuRisque "A fortes posologies (100 mg par jour de chlorpromazine) : élévation de la glycémie (diminution de la libération de l'insuline)."@fr;
  r:conduiteATenir "Prévenir le patient et renforcer l'autosurveillance glycémique. Adapter éventuellement la posologie du neuroleptique pendant le traitement et après son arrêt."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b201584, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b201578 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b201579 .

_:79f295ad32df4ce8a18a92539c6e8a3b201579 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201580;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b201581 .

_:79f295ad32df4ce8a18a92539c6e8a3b201580 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10147 .

_:79f295ad32df4ce8a18a92539c6e8a3b201581 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201582;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b201582 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10186 .

_:79f295ad32df4ce8a18a92539c6e8a3b201584 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10888-1 a owl:Class;
  rdfs:label "ERGOTAMINE <-> TRICLABENDAZOLE"@fr;
  dct:identifier "IAM_10888";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b201586;
  r:natureDuRisque "Ergotisme avec possibilité de nécrose des extrémités (inhibition du métabolisme hépatique de l’alcaloïde de l’ergot de seigle)."@fr;
  r:conduiteATenir "Respecter un délai de 24 heures entre l’arrêt du triclabendazole et l’ergotamine, et inversement."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b201592, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b201586 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b201587 .

_:79f295ad32df4ce8a18a92539c6e8a3b201587 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201588;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b201589 .

_:79f295ad32df4ce8a18a92539c6e8a3b201588 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10334 .

_:79f295ad32df4ce8a18a92539c6e8a3b201589 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201590;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b201590 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10953 .

_:79f295ad32df4ce8a18a92539c6e8a3b201592 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11461-1 a owl:Class;
  rdfs:label "VERAPAMIL <-> ÉRIBULINE"@fr;
  dct:identifier "IAM_11461";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b201594;
  r:natureDuRisque "Augmentation des concentrations plasmatiques d’éribuline par le vérapamil."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b201600, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b201594 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b201595 .

_:79f295ad32df4ce8a18a92539c6e8a3b201595 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201596;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b201597 .

_:79f295ad32df4ce8a18a92539c6e8a3b201596 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10335 .

_:79f295ad32df4ce8a18a92539c6e8a3b201597 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201598;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b201598 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10980 .

_:79f295ad32df4ce8a18a92539c6e8a3b201600 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10077-1 a owl:Class;
  rdfs:label "ALCOOL (BOISSON OU EXCIPIENT) <-> IMAO IRRÉVERSIBLES"@fr;
  dct:identifier "IAM_10077";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b201602;
  r:natureDuRisque "Majoration des effets hypertenseurs et/ou hyperthermiques de la tyramine présente dans certaines boissons alcoolisées (chianti, certaines bières, etc)."@fr;
  r:conduiteATenir "Eviter la prise de boissons alcoolisées et de médicaments contenant de l'alcool."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b201608, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b201602 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b201603 .

_:79f295ad32df4ce8a18a92539c6e8a3b201603 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201604;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b201605 .

_:79f295ad32df4ce8a18a92539c6e8a3b201604 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10002 .

_:79f295ad32df4ce8a18a92539c6e8a3b201605 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201606;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b201606 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_11013 .

_:79f295ad32df4ce8a18a92539c6e8a3b201608 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11124-1 a owl:Class;
  rdfs:label "INHIBITEURS DE PROTÉASES BOOSTÉS PAR RITONAVIR <-> ÉRIBULINE"@fr;
  dct:identifier "IAM_11124";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b201610;
  r:natureDuRisque "Augmentation des concentrations plasmatiques d’éribuline par le ritonavir."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b201616, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b201610 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b201611 .

_:79f295ad32df4ce8a18a92539c6e8a3b201611 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201612;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b201613 .

_:79f295ad32df4ce8a18a92539c6e8a3b201612 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10100 .

_:79f295ad32df4ce8a18a92539c6e8a3b201613 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201614;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b201614 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10335 .

_:79f295ad32df4ce8a18a92539c6e8a3b201616 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10569-1 a owl:Class;
  rdfs:label "CATIORESINE SULFO CALCIQUE <-> SORBITOL"@fr;
  dct:identifier "IAM_10569";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b201618;
  r:natureDuRisque "Avec la résine administrée par voie orale et rectale : risque de nécrose colique, éventuellement fatale."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b201624, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b201618 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b201619 .

_:79f295ad32df4ce8a18a92539c6e8a3b201619 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201620;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b201621 .

_:79f295ad32df4ce8a18a92539c6e8a3b201620 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10166 .

_:79f295ad32df4ce8a18a92539c6e8a3b201621 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201622;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b201622 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10853 .

_:79f295ad32df4ce8a18a92539c6e8a3b201624 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10893-1 a owl:Class;
  rdfs:label "ERYTHROMYCINE <-> LUMEFANTRINE"@fr;
  dct:identifier "IAM_10893";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b201626;
  r:natureDuRisque "Risque majoré de troubles du rythme ventriculaire, notamment de torsades de pointes."@fr;
  r:conduiteATenir "Si cela est possible, interrompre le torsadogène associé. Si l'association ne peut être évitée, contrôle préalable du QT et surveillance ECG monitorée."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b201632, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b201626 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b201627 .

_:79f295ad32df4ce8a18a92539c6e8a3b201627 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201628;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b201629 .

_:79f295ad32df4ce8a18a92539c6e8a3b201628 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10338 .

_:79f295ad32df4ce8a18a92539c6e8a3b201629 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201630;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b201630 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10541 .

_:79f295ad32df4ce8a18a92539c6e8a3b201632 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10901-1 a owl:Class;
  rdfs:label "ERYTHROMYCINE <-> VINCA-ALCALOÏDES CYTOTOXIQUES"@fr;
  dct:identifier "IAM_10901";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b201634;
  r:natureDuRisque "Risque de majoration de la toxicité de l'antimitotique par diminution de son métabolisme hépatique par l' érythromycine."@fr;
  r:conduiteATenir "Surveillance clinique et biologique étroite. Eventuellement, utiliser un autre antibiotique."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b201640, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b201634 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b201635 .

_:79f295ad32df4ce8a18a92539c6e8a3b201635 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201636;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b201637 .

_:79f295ad32df4ce8a18a92539c6e8a3b201636 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10161 .

_:79f295ad32df4ce8a18a92539c6e8a3b201637 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201638;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b201638 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10338 .

_:79f295ad32df4ce8a18a92539c6e8a3b201640 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10889-1 a owl:Class;
  rdfs:label "ERYTHROMYCINE <-> FIDAXOMICINE"@fr;
  dct:identifier "IAM_10889";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b201642;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de la fidaxomicine."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b201648, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b201642 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b201643 .

_:79f295ad32df4ce8a18a92539c6e8a3b201643 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201644;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b201645 .

_:79f295ad32df4ce8a18a92539c6e8a3b201644 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10338 .

_:79f295ad32df4ce8a18a92539c6e8a3b201645 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201646;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b201646 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10378 .

_:79f295ad32df4ce8a18a92539c6e8a3b201648 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10890-1 a owl:Class;
  rdfs:label "ERYTHROMYCINE <-> GLIBENCLAMIDE"@fr;
  dct:identifier "IAM_10890";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b201650;
  r:natureDuRisque "Risque d'hypoglycémie par augmentation de l’absorption et des concentrations plasmatiques de l’antidiabétique."@fr;
  r:conduiteATenir "Prévenir le patient, renforcer l'autosurveillance glycémique et adapter éventuellement la posologie du sulfamide hypoglycémiant pendant le traitement par l’érythromycine."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b201656, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b201650 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b201651 .

_:79f295ad32df4ce8a18a92539c6e8a3b201651 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201652;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b201653 .

_:79f295ad32df4ce8a18a92539c6e8a3b201652 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10338 .

_:79f295ad32df4ce8a18a92539c6e8a3b201653 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201654;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b201654 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10414 .

_:79f295ad32df4ce8a18a92539c6e8a3b201656 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10421-1 a owl:Class;
  rdfs:label "AUTRES MÉDICAMENTS MÉDICAMENTS HYPONATRÉMIANTS <-> HYPONATRÉMIANTS"@fr;
  dct:identifier "IAM_10421";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b201658;
  r:natureDuRisque "Majoration du risque d’hyponatrémie."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b201660, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b201658 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10087 .

_:79f295ad32df4ce8a18a92539c6e8a3b201660 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11031-1 a owl:Class;
  rdfs:label "IBRUTINIB <-> VERAPAMIL"@fr;
  dct:identifier "IAM_11031";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b201662;
  r:natureDuRisque "Augmentation des concentrations plasmatiques d’ibrutinib par diminution de son métabolisme hépatique par le vérapamil."@fr;
  r:conduiteATenir "Surveiller clinique étroite et réduction de la dose d’ibrutinib à 140 mg par jour pendant la durée de l'association."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b201668, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b201662 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b201663 .

_:79f295ad32df4ce8a18a92539c6e8a3b201663 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201664;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b201665 .

_:79f295ad32df4ce8a18a92539c6e8a3b201664 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10441 .

_:79f295ad32df4ce8a18a92539c6e8a3b201665 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201666;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b201666 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10980 .

_:79f295ad32df4ce8a18a92539c6e8a3b201668 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11032-1 a owl:Class;
  rdfs:label "IDÉLALISIB <-> INHIBITEURS PUISSANTS DU CYP3A4"@fr;
  dct:identifier "IAM_11032";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b201670;
  r:natureDuRisque "Augmentation des concentrations plasmatiques d’idélalisib par diminution de son métabolisme hépatique par l’inhibiteur."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b201676, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b201670 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b201671 .

_:79f295ad32df4ce8a18a92539c6e8a3b201671 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201672;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b201673 .

_:79f295ad32df4ce8a18a92539c6e8a3b201672 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10103 .

_:79f295ad32df4ce8a18a92539c6e8a3b201673 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201674;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b201674 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10444 .

_:79f295ad32df4ce8a18a92539c6e8a3b201676 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11033-1 a owl:Class;
  rdfs:label "IDÉLALISIB <-> MILLEPERTUIS"@fr;
  dct:identifier "IAM_11033";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b201678;
  r:natureDuRisque "Risque de diminution importante des concentrations plasmatiques d’idélalisib par augmentation de son métabolisme hépatique par le millepertuis."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b201684, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b201678 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b201679 .

_:79f295ad32df4ce8a18a92539c6e8a3b201679 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201680;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b201681 .

_:79f295ad32df4ce8a18a92539c6e8a3b201680 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10444 .

_:79f295ad32df4ce8a18a92539c6e8a3b201681 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201682;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b201682 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10588 .

_:79f295ad32df4ce8a18a92539c6e8a3b201684 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11034-1 a owl:Class;
  rdfs:label "IDÉLALISIB <-> RIFAMPICINE"@fr;
  dct:identifier "IAM_11034";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b201686;
  r:natureDuRisque "Diminution des concentrations plasmatiques d’idélalisib par augmentation de son métabolisme hépatique par l’inducteur."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b201692, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b201686 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b201687 .

_:79f295ad32df4ce8a18a92539c6e8a3b201687 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201688;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b201689 .

_:79f295ad32df4ce8a18a92539c6e8a3b201688 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10444 .

_:79f295ad32df4ce8a18a92539c6e8a3b201689 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201690;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b201690 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:79f295ad32df4ce8a18a92539c6e8a3b201692 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11035-1 a owl:Class;
  rdfs:label "IDÉLALISIB <-> SUBSTRATS À RISQUE DU CYP3A4"@fr;
  dct:identifier "IAM_11035";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b201694;
  r:natureDuRisque "Augmentation des concentrations plasmatiques du substrat par diminution de son métabolisme hépatique par l’idelalisib."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b201700, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b201694 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b201695 .

_:79f295ad32df4ce8a18a92539c6e8a3b201695 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201696;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b201697 .

_:79f295ad32df4ce8a18a92539c6e8a3b201696 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10145 .

_:79f295ad32df4ce8a18a92539c6e8a3b201697 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201698;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b201698 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10444 .

_:79f295ad32df4ce8a18a92539c6e8a3b201700 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11087-1 a owl:Class;
  rdfs:label "INDUCTEURS ENZYMATIQUES <-> ÉRIBULINE"@fr;
  dct:identifier "IAM_11087";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b201702;
  r:natureDuRisque "Risque de diminution des concentrations plasmatiques d’éribuline par l’inducteur."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b201708, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b201702 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b201703 .

_:79f295ad32df4ce8a18a92539c6e8a3b201703 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201704;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b201705 .

_:79f295ad32df4ce8a18a92539c6e8a3b201704 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10094 .

_:79f295ad32df4ce8a18a92539c6e8a3b201705 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201706;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b201706 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10335 .

_:79f295ad32df4ce8a18a92539c6e8a3b201708 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10138-1 a owl:Class;
  rdfs:label "AMIODARONE <-> OLAPARIB"@fr;
  dct:identifier "IAM_10138";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b201710;
  r:natureDuRisque "Augmentation des concentrations plasmatiques d’olaparib par l' amiodarone"@fr;
  r:conduiteATenir "Si l’association ne peut être évitée, limiter la dose d’olaparib à 200 mg 2 fois par jour avec l’amiodarone."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b201716, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b201710 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b201711 .

_:79f295ad32df4ce8a18a92539c6e8a3b201711 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201712;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b201713 .

_:79f295ad32df4ce8a18a92539c6e8a3b201712 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10066 .

_:79f295ad32df4ce8a18a92539c6e8a3b201713 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201714;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b201714 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10659 .

_:79f295ad32df4ce8a18a92539c6e8a3b201716 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10127-1 a owl:Class;
  rdfs:label "AMIODARONE <-> DABIGATRAN"@fr;
  dct:identifier "IAM_10127";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b201718;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de dabigatran, avec majoration du risque de saignement."@fr;
  r:conduiteATenir "Dans l'indication post-chirurgicale : surveillance clinique et adaptation de la posologie du dabigatran si nécessaire, sans excéder 150 mg/j."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b201724, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b201718 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b201719 .

_:79f295ad32df4ce8a18a92539c6e8a3b201719 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201720;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b201721 .

_:79f295ad32df4ce8a18a92539c6e8a3b201720 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10066 .

_:79f295ad32df4ce8a18a92539c6e8a3b201721 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201722;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b201722 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10240 .

_:79f295ad32df4ce8a18a92539c6e8a3b201724 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10128-1 a owl:Class;
  rdfs:label "AMIODARONE <-> DACLATASVIR"@fr;
  dct:identifier "IAM_10128";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b201726;
  r:natureDuRisque """Uniquement lors de la bithérapie daclatasvir/sofosbuvir :
Survenue de bradycardie éventuellement brutale, pouvant avoir des conséquences fatales."""@fr;
  r:conduiteATenir "Si l’association ne peut être évitée, surveillance clinique et ECG étroite, en particulier pendant les premières semaines de traitement par la bithérapie."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b201732, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b201726 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b201727 .

_:79f295ad32df4ce8a18a92539c6e8a3b201727 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201728;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b201729 .

_:79f295ad32df4ce8a18a92539c6e8a3b201728 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10066 .

_:79f295ad32df4ce8a18a92539c6e8a3b201729 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201730;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b201730 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10243 .

_:79f295ad32df4ce8a18a92539c6e8a3b201732 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10129-1 a owl:Class;
  rdfs:label "AMIODARONE <-> DIGOXINE"@fr;
  dct:identifier "IAM_10129";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b201734;
  r:natureDuRisque "Dépression de l'automatisme (bradycardie excessive) et troubles de la conduction auriculo-ventriculaire. De plus, augmentation de la digoxinémie par diminution de la clairance de la digoxine."@fr;
  r:conduiteATenir "Surveillance clinique, ECG et, s'il y a lieu, contrôle de la digoxinémie et adaptation de la posologie de la digoxine."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b201740, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b201734 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b201735 .

_:79f295ad32df4ce8a18a92539c6e8a3b201735 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201736;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b201737 .

_:79f295ad32df4ce8a18a92539c6e8a3b201736 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10066 .

_:79f295ad32df4ce8a18a92539c6e8a3b201737 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201738;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b201738 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10286 .

_:79f295ad32df4ce8a18a92539c6e8a3b201740 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10130-1 a owl:Class;
  rdfs:label "AMIODARONE <-> DILTIAZEM"@fr;
  dct:identifier "IAM_10130";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b201742;
  r:natureDuRisque """Pour diltiazem voie injectable : risque de bradycardie et de bloc auriculo-ventriculaire

Pour diltiazem per os : risque de bradycardie ou de bloc auriculo-ventriculaire, notamment chez les personnes âgées."""@fr;
  r:conduiteATenir """Précaution d'emploi avec :
- le diltiazem per os
Surveillance clinique et ECG."""@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b201748, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b201742 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b201743 .

_:79f295ad32df4ce8a18a92539c6e8a3b201743 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201744;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b201745 .

_:79f295ad32df4ce8a18a92539c6e8a3b201744 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10066 .

_:79f295ad32df4ce8a18a92539c6e8a3b201745 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201746;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b201746 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10290 .

_:79f295ad32df4ce8a18a92539c6e8a3b201748 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10131-1 a owl:Class;
  rdfs:label "AMIODARONE <-> ESMOLOL"@fr;
  dct:identifier "IAM_10131";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b201750;
  r:natureDuRisque "Troubles de la contractilité, de l'automatisme et de la conduction (suppression des mécanismes sympathiques compensateurs)."@fr;
  r:conduiteATenir "Surveillance clinique et ECG."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b201756, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b201750 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b201751 .

_:79f295ad32df4ce8a18a92539c6e8a3b201751 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201752;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b201753 .

_:79f295ad32df4ce8a18a92539c6e8a3b201752 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10066 .

_:79f295ad32df4ce8a18a92539c6e8a3b201753 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201754;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b201754 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10341 .

_:79f295ad32df4ce8a18a92539c6e8a3b201756 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10132-1 a owl:Class;
  rdfs:label "AMIODARONE <-> FIDAXOMICINE"@fr;
  dct:identifier "IAM_10132";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b201758;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de la fidaxomicine."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b201764, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b201758 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b201759 .

_:79f295ad32df4ce8a18a92539c6e8a3b201759 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201760;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b201761 .

_:79f295ad32df4ce8a18a92539c6e8a3b201760 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10066 .

_:79f295ad32df4ce8a18a92539c6e8a3b201761 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201762;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b201762 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10378 .

_:79f295ad32df4ce8a18a92539c6e8a3b201764 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10133-1 a owl:Class;
  rdfs:label "AMIODARONE <-> FLUCONAZOLE"@fr;
  dct:identifier "IAM_10133";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b201766;
  r:natureDuRisque "Risque d’allongement de l’intervalle QT."@fr;
  r:conduiteATenir "Surveillance clinique, particulièrement aux fortes doses de fluconazole (800 mg/j)."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b201772, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b201766 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b201767 .

_:79f295ad32df4ce8a18a92539c6e8a3b201767 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201768;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b201769 .

_:79f295ad32df4ce8a18a92539c6e8a3b201768 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10066 .

_:79f295ad32df4ce8a18a92539c6e8a3b201769 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201770;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b201770 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10381 .

_:79f295ad32df4ce8a18a92539c6e8a3b201772 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10134-1 a owl:Class;
  rdfs:label "AMIODARONE <-> IBRUTINIB"@fr;
  dct:identifier "IAM_10134";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b201774;
  r:natureDuRisque "Risque d'augmentation des concentrations plasmatiques d’ibrutinib par diminution de son métabolisme hépatique par l’amiodarone."@fr;
  r:conduiteATenir "Si l’association ne peut être évitée, surveillance clinique étroite et réduction de la dose d’ibrutinib à 140 mg par jour pendant la durée de l’association."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b201780, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b201774 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b201775 .

_:79f295ad32df4ce8a18a92539c6e8a3b201775 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201776;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b201777 .

_:79f295ad32df4ce8a18a92539c6e8a3b201776 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10066 .

_:79f295ad32df4ce8a18a92539c6e8a3b201777 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201778;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b201778 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10441 .

_:79f295ad32df4ce8a18a92539c6e8a3b201780 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10135-1 a owl:Class;
  rdfs:label "AMIODARONE <-> LÉDIPASVIR"@fr;
  dct:identifier "IAM_10135";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b201782;
  r:natureDuRisque "Uniquement lors de la bithérapie lédipasvir/sofosbuvir, survenue de bradycardie, éventuellement brutale, pouvant avoir des conséquences fatales."@fr;
  r:conduiteATenir "Si l’association ne peut être évitée, il est recommandé de surveiller étroitement les patients, en particulier pendant les premières semaines de traitement par la bithérapie (surveillance clinique et ECG)."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b201788, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b201782 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b201783 .

_:79f295ad32df4ce8a18a92539c6e8a3b201783 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201784;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b201785 .

_:79f295ad32df4ce8a18a92539c6e8a3b201784 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10066 .

_:79f295ad32df4ce8a18a92539c6e8a3b201785 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201786;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b201786 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10512 .

_:79f295ad32df4ce8a18a92539c6e8a3b201788 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10059-1 a owl:Class;
  rdfs:label "ALBENDAZOLE <-> ANTICONVULSIVANTS INDUCTEURS ENZYMATIQUES"@fr;
  dct:identifier "IAM_10059";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b201790;
  r:natureDuRisque "Diminution importante des concentrations plasmatiques de l’albendazole et de son métabolite actif par l’inducteur, avec risque de baisse de son efficacité."@fr;
  r:conduiteATenir "Surveillance clinique de la réponse thérapeutique et adaptation éventuelle de la posologie de l’albendazole pendant le traitement avec l’inducteur enzymatique et après son arrêt."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b201796, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b201790 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b201791 .

_:79f295ad32df4ce8a18a92539c6e8a3b201791 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201792;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b201793 .

_:79f295ad32df4ce8a18a92539c6e8a3b201792 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10029 .

_:79f295ad32df4ce8a18a92539c6e8a3b201793 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201794;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b201794 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10042 .

_:79f295ad32df4ce8a18a92539c6e8a3b201796 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10137-1 a owl:Class;
  rdfs:label "AMIODARONE <-> NINTÉDANIB"@fr;
  dct:identifier "IAM_10137";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b201798;
  r:natureDuRisque "Augmentation des concentrations plasmatiques du nintédanib par augmentation de son absorption par l'amiodarone."@fr;
  r:conduiteATenir "Surveillance clinique pendant l’association."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b201804, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b201798 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b201799 .

_:79f295ad32df4ce8a18a92539c6e8a3b201799 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201800;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b201801 .

_:79f295ad32df4ce8a18a92539c6e8a3b201800 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10066 .

_:79f295ad32df4ce8a18a92539c6e8a3b201801 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201802;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b201802 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10637 .

_:79f295ad32df4ce8a18a92539c6e8a3b201804 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10124-1 a owl:Class;
  rdfs:label "AMIODARONE <-> BÊTA-BLOQUANTS DANS L'INSUFFISANCE CARDIAQUE"@fr;
  dct:identifier "IAM_10124";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b201806;
  r:chapeau """A l’heure actuelle, 4 bêta-bloquants ont l'indication \"insuffisance cardiaque\" : le carvédilol, le bisoprolol, le métoprolol et le névibolol.
Les interactions médicamenteuses des bêta-bloquants, lorsqu’ils sont prescrits dans l’insuffisance cardiaque, pe"""@fr;
  r:natureDuRisque "Troubles de l'automatisme et de la conduction cardiaque avec risque de bradycardie excessive."@fr;
  r:conduiteATenir "Surveillance clinique et ECG régulière."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b201812, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b201806 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b201807 .

_:79f295ad32df4ce8a18a92539c6e8a3b201807 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201808;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b201809 .

_:79f295ad32df4ce8a18a92539c6e8a3b201808 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10055 .

_:79f295ad32df4ce8a18a92539c6e8a3b201809 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201810;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b201810 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10066 .

_:79f295ad32df4ce8a18a92539c6e8a3b201812 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10139-1 a owl:Class;
  rdfs:label "AMIODARONE <-> OMBITASVIR + PARITAPRÉVIR"@fr;
  dct:identifier "IAM_10139";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b201814;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de l'amiodarone par diminution de son métabolisme hépatique par la bithérapie."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b201820, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b201814 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b201815 .

_:79f295ad32df4ce8a18a92539c6e8a3b201815 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201816;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b201817 .

_:79f295ad32df4ce8a18a92539c6e8a3b201816 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10128 .

_:79f295ad32df4ce8a18a92539c6e8a3b201817 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201818;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b201818 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10066 .

_:79f295ad32df4ce8a18a92539c6e8a3b201820 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10140-1 a owl:Class;
  rdfs:label "AMIODARONE <-> ORLISTAT"@fr;
  dct:identifier "IAM_10140";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b201822;
  r:natureDuRisque "Risque de diminution des concentrations plasmatiques de l'amiodarone et de son métabolite actif."@fr;
  r:conduiteATenir "Surveillance clinique et, si besoin, ECG."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b201828, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b201822 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b201823 .

_:79f295ad32df4ce8a18a92539c6e8a3b201823 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201824;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b201825 .

_:79f295ad32df4ce8a18a92539c6e8a3b201824 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10066 .

_:79f295ad32df4ce8a18a92539c6e8a3b201825 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201826;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b201826 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10667 .

_:79f295ad32df4ce8a18a92539c6e8a3b201828 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10141-1 a owl:Class;
  rdfs:label "AMIODARONE <-> PHÉNYTOÏNE (ET, PAR EXTRAPOLATION, FOSPHÉNYTOÏNE)"@fr;
  dct:identifier "IAM_10141";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b201830;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de la phénytoïne avec signes de surdosage, en particulier neurologiques (diminution du métabolisme hépatique de la phénytoïne)."@fr;
  r:conduiteATenir "Surveillance clinique, contrôle des concentrations plasmatiques de phénytoïne et adaptation éventuelle de sa posologie."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b201836, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b201830 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b201831 .

_:79f295ad32df4ce8a18a92539c6e8a3b201831 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201832;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b201833 .

_:79f295ad32df4ce8a18a92539c6e8a3b201832 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10132 .

_:79f295ad32df4ce8a18a92539c6e8a3b201833 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201834;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b201834 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10066 .

_:79f295ad32df4ce8a18a92539c6e8a3b201836 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10142-1 a owl:Class;
  rdfs:label "AMIODARONE <-> SIMVASTATINE"@fr;
  dct:identifier "IAM_10142";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b201838;
  r:natureDuRisque "Risque majoré d'effets indésirables (concentration-dépendants) à type de rhabdomyolyse (diminution du métabolisme hépatique de la simvastatine)."@fr;
  r:conduiteATenir "Ne pas dépasser la posologie de 20 mg/j de simvastatine ou utiliser une autre statine non concernée par ce type d’interaction."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b201844, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b201838 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b201839 .

_:79f295ad32df4ce8a18a92539c6e8a3b201839 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201840;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b201841 .

_:79f295ad32df4ce8a18a92539c6e8a3b201840 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10066 .

_:79f295ad32df4ce8a18a92539c6e8a3b201841 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201842;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b201842 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10838 .

_:79f295ad32df4ce8a18a92539c6e8a3b201844 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10143-1 a owl:Class;
  rdfs:label "AMIODARONE <-> SOFOSBUVIR"@fr;
  dct:identifier "IAM_10143";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b201846;
  r:natureDuRisque """Uniquement lors de la bithérapie daclatasvir/sofosbuvir ou lédipasvir/sofosbuvir :
Survenue de bradycardie éventuellement brutale, pouvant avoir des conséquences fatales."""@fr;
  r:conduiteATenir "Si l’association ne peut être évitée, surveillance clinique et ECG étroite, en particulier pendant les premières semaines de traitement par la bithérapie."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b201852, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b201846 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b201847 .

_:79f295ad32df4ce8a18a92539c6e8a3b201847 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201848;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b201849 .

_:79f295ad32df4ce8a18a92539c6e8a3b201848 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10066 .

_:79f295ad32df4ce8a18a92539c6e8a3b201849 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201850;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b201850 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10850 .

_:79f295ad32df4ce8a18a92539c6e8a3b201852 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10144-1 a owl:Class;
  rdfs:label "AMIODARONE <-> TACROLIMUS"@fr;
  dct:identifier "IAM_10144";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b201854;
  r:natureDuRisque "Augmentation des concentrations sanguines de tacrolimus par inhibition de son métabolisme par l’amiodarone."@fr;
  r:conduiteATenir "Dosage des concentrations sanguines de tacrolimus, contrôle de la fonction rénale et adaptation de la posologie de tacrolimus pendant l’association et à l’arrêt de l’amiodarone."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b201860, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b201854 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b201855 .

_:79f295ad32df4ce8a18a92539c6e8a3b201855 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201856;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b201857 .

_:79f295ad32df4ce8a18a92539c6e8a3b201856 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10066 .

_:79f295ad32df4ce8a18a92539c6e8a3b201857 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201858;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b201858 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10880 .

_:79f295ad32df4ce8a18a92539c6e8a3b201860 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10145-1 a owl:Class;
  rdfs:label "AMIODARONE <-> TAMSULOSINE"@fr;
  dct:identifier "IAM_10145";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b201862;
  r:natureDuRisque "Risque de majoration des effets indésirables de la tamsulosine, par inhibition de son métabolisme hépatique."@fr;
  r:conduiteATenir "Surveillance clinique et adaptation de la posologie de la tamsulosine pendant le traitement par l’inhibiteur enzymatique et après son arrêt, le cas échéant."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b201868, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b201862 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b201863 .

_:79f295ad32df4ce8a18a92539c6e8a3b201863 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201864;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b201865 .

_:79f295ad32df4ce8a18a92539c6e8a3b201864 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10066 .

_:79f295ad32df4ce8a18a92539c6e8a3b201865 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201866;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b201866 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10883 .

_:79f295ad32df4ce8a18a92539c6e8a3b201868 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10147-1 a owl:Class;
  rdfs:label "AMIODARONE <-> VERAPAMIL"@fr;
  dct:identifier "IAM_10147";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b201870;
  r:natureDuRisque """Pour vérapamil voie injectable :
-risque de bradycardie ou de bloc auriculo-ventriculaire.

Pour vérapamil per os :
-risque de bradycardie ou de bloc auriculo-ventriculaire, notamment chez les personnes âgées."""@fr;
  r:conduiteATenir """Association déconseillée avec :
- le vérapamil IV
Si l'association ne peut être évitée, surveillance clinique et ECG continu.

Précaution d'emploi avec :
- le vérapamil per os
Surveillance clinique et ECG."""@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b201876, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b201870 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b201871 .

_:79f295ad32df4ce8a18a92539c6e8a3b201871 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201872;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b201873 .

_:79f295ad32df4ce8a18a92539c6e8a3b201872 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10066 .

_:79f295ad32df4ce8a18a92539c6e8a3b201873 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201874;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b201874 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10980 .

_:79f295ad32df4ce8a18a92539c6e8a3b201876 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10148-1 a owl:Class;
  rdfs:label "AMIODARONE <-> VORICONAZOLE"@fr;
  dct:identifier "IAM_10148";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b201878;
  r:natureDuRisque "Risque majoré de troubles du rythme ventriculaire, notamment de torsades de pointes, par possible diminution du métabolisme de l’amiodarone."@fr;
  r:conduiteATenir "Surveillance clinique et ECG, et adaptation éventuelle de la posologie de l’amiodarone."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b201884, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b201878 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b201879 .

_:79f295ad32df4ce8a18a92539c6e8a3b201879 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201880;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b201881 .

_:79f295ad32df4ce8a18a92539c6e8a3b201880 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10066 .

_:79f295ad32df4ce8a18a92539c6e8a3b201881 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201882;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b201882 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10998 .

_:79f295ad32df4ce8a18a92539c6e8a3b201884 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10136-1 a owl:Class;
  rdfs:label "AMIODARONE <-> LIDOCAINE"@fr;
  dct:identifier "IAM_10136";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b201886;
  r:natureDuRisque "Risque d’augmentation des concentrations plasmatiques de lidocaïne, avec possibilité d’effets indésirables neurologiques et cardiaques, par diminution de son métabolisme hépatique par l’amiodarone."@fr;
  r:conduiteATenir "Surveillance clinique, ECG et éventuellement contrôle des concentrations plasmatiques de lidocaïne. Si besoin, adaptation de la posologie de la lidocaïne pendant le traitement par amiodarone et après son arrêt."@fr;
  rdfs:comment "La littérature rapporte des cas d’augmentation des effets indésirables de la lidocaïne lorsqu'elle est associée à l’amiodarone. Il s’agit d’une interaction métabolique avec augmentation des concentrations plasmatiques de lidocaïne, l’amiodarone étant un i"@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b201892, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b201886 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b201887 .

_:79f295ad32df4ce8a18a92539c6e8a3b201887 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201888;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b201889 .

_:79f295ad32df4ce8a18a92539c6e8a3b201888 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10066 .

_:79f295ad32df4ce8a18a92539c6e8a3b201889 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201890;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b201890 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10523 .

_:79f295ad32df4ce8a18a92539c6e8a3b201892 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10115-1 a owl:Class;
  rdfs:label "AMINOSIDES <-> CEFALOTINE"@fr;
  dct:identifier "IAM_10115";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b201894;
  r:natureDuRisque "L'augmentation de la néphrotoxicité des aminosides par la céfalotine est discutée."@fr;
  r:conduiteATenir "Surveillance de la fonction rénale."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b201900, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b201894 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b201895 .

_:79f295ad32df4ce8a18a92539c6e8a3b201895 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201896;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b201897 .

_:79f295ad32df4ce8a18a92539c6e8a3b201896 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10011 .

_:79f295ad32df4ce8a18a92539c6e8a3b201897 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201898;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b201898 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10168 .

_:79f295ad32df4ce8a18a92539c6e8a3b201900 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11079-1 a owl:Class;
  rdfs:label "IMMUNOSUPPRESSEURS <-> RANOLAZINE"@fr;
  dct:identifier "IAM_11079";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b201902;
  r:natureDuRisque "Augmentation des concentrations sanguines de l'immunosuppresseur par inhibition de son métabolisme par la ranolazine."@fr;
  r:conduiteATenir "Surveillance clinique et biologique, et adaptation éventuelle de la posologie de l’immunosuppresseur."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b201908, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b201902 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b201903 .

_:79f295ad32df4ce8a18a92539c6e8a3b201903 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201904;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b201905 .

_:79f295ad32df4ce8a18a92539c6e8a3b201904 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10093 .

_:79f295ad32df4ce8a18a92539c6e8a3b201905 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201906;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b201906 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10786 .

_:79f295ad32df4ce8a18a92539c6e8a3b201908 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10061-1 a owl:Class;
  rdfs:label "ALBENDAZOLE <-> RIFAMPICINE"@fr;
  dct:identifier "IAM_10061";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b201910;
  r:natureDuRisque "Diminution importante des concentrations plasmatiques de l’albendazole et de son métabolite actif par l’inducteur, avec risque de baisse de son efficacité."@fr;
  r:conduiteATenir "Surveillance clinique de la réponse thérapeutique et adaptation éventuelle de la posologie de l’albendazole pendant le traitement avec l’inducteur enzymatique et après son arrêt."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b201916, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b201910 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b201911 .

_:79f295ad32df4ce8a18a92539c6e8a3b201911 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201912;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b201913 .

_:79f295ad32df4ce8a18a92539c6e8a3b201912 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10042 .

_:79f295ad32df4ce8a18a92539c6e8a3b201913 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201914;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b201914 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:79f295ad32df4ce8a18a92539c6e8a3b201916 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10062-1 a owl:Class;
  rdfs:label "ALCALINISANTS URINAIRES <-> HYDROQUINIDINE"@fr;
  dct:identifier "IAM_10062";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b201918;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de l'hydroquinidine et risque de surdosage (diminution de l'excrétion rénale de l'hydroquinidine par alcalinisation des urines)."@fr;
  r:conduiteATenir "Surveillance clinique, ECG et éventuellement contrôle des concentrations de l'hydroquinidine ; si besoin, adaptation de la posologie pendant le traitement alcalinisant et après son arrêt."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b201924, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b201918 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b201919 .

_:79f295ad32df4ce8a18a92539c6e8a3b201919 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201920;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b201921 .

_:79f295ad32df4ce8a18a92539c6e8a3b201920 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10006 .

_:79f295ad32df4ce8a18a92539c6e8a3b201921 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201922;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b201922 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10434 .

_:79f295ad32df4ce8a18a92539c6e8a3b201924 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10063-1 a owl:Class;
  rdfs:label "ALCALINISANTS URINAIRES <-> QUINIDINE"@fr;
  dct:identifier "IAM_10063";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b201926;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de la quinidine et risque de surdosage (diminution de l'excrétion rénale de la quinidine par alcalinisation des urines)."@fr;
  r:conduiteATenir "Surveillance clinique, ECG et éventuellement contrôle de la quinidinémie ; si besoin, adaptation de la posologie pendant le traitement alcalinisant et après son arrêt."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b201932, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b201926 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b201927 .

_:79f295ad32df4ce8a18a92539c6e8a3b201927 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201928;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b201929 .

_:79f295ad32df4ce8a18a92539c6e8a3b201928 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10006 .

_:79f295ad32df4ce8a18a92539c6e8a3b201929 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201930;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b201930 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10776 .

_:79f295ad32df4ce8a18a92539c6e8a3b201932 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10064-1 a owl:Class;
  rdfs:label "ALCALOÏDES DE L'ERGOT DE SEIGLE DOPAMINERGIQUES <-> ALCALOÏDES DE L'ERGOT DE SEIGLE VASOCONSTRICTEURS"@fr;
  dct:identifier "IAM_10064";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b201934;
  r:natureDuRisque "Risque de vasoconstriction et/ou de poussées hypertensives."@fr;
  rdfs:comment "Les propriétés pharmacologiques des dérivés de l'ergot exposent à un risque de vasoconstriction, qui peut être grave selon les antécédents du patient. Les risques vasculaires sont en effet communs à tous les dérivés de l'ergot et pourraient s'additionner"@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b201940, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b201934 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b201935 .

_:79f295ad32df4ce8a18a92539c6e8a3b201935 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201936;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b201937 .

_:79f295ad32df4ce8a18a92539c6e8a3b201936 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10007 .

_:79f295ad32df4ce8a18a92539c6e8a3b201937 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201938;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b201938 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10008 .

_:79f295ad32df4ce8a18a92539c6e8a3b201940 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10065-1 a owl:Class;
  rdfs:label "ALCALOÏDES DE L'ERGOT DE SEIGLE DOPAMINERGIQUES <-> ANTIPARKINSONIENS ANTICHOLINERGIQUES"@fr;
  dct:identifier "IAM_10065";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b201942;
  r:natureDuRisque "Risque de majoration des troubles neuropsychiques."@fr;
  r:conduiteATenir "Surveillance clinique et biologique régulière, notamment en début d'association."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b201948, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b201942 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b201943 .

_:79f295ad32df4ce8a18a92539c6e8a3b201943 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201944;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b201945 .

_:79f295ad32df4ce8a18a92539c6e8a3b201944 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10007 .

_:79f295ad32df4ce8a18a92539c6e8a3b201945 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201946;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b201946 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10037 .

_:79f295ad32df4ce8a18a92539c6e8a3b201948 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10066-1 a owl:Class;
  rdfs:label "ALCALOÏDES DE L'ERGOT DE SEIGLE DOPAMINERGIQUES <-> MACROLIDES (SAUF SPIRAMYCINE)"@fr;
  dct:identifier "IAM_10066";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b201950;
  r:natureDuRisque "Augmentation des concentrations plasmatiques du dopaminergique avec accroissement possible de son activité ou apparition de signes de surdosage."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b201956, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b201950 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b201951 .

_:79f295ad32df4ce8a18a92539c6e8a3b201951 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201952;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b201953 .

_:79f295ad32df4ce8a18a92539c6e8a3b201952 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10007 .

_:79f295ad32df4ce8a18a92539c6e8a3b201953 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201954;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b201954 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10107 .

_:79f295ad32df4ce8a18a92539c6e8a3b201956 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10067-1 a owl:Class;
  rdfs:label "ALCALOÏDES DE L'ERGOT DE SEIGLE DOPAMINERGIQUES <-> SYMPATHOMIMÉTIQUES ALPHA (VOIES ORALE ET/OU NASALE)"@fr;
  dct:identifier "IAM_10067";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b201958;
  r:natureDuRisque "Risque de vasoconstriction et/ou de poussées hypertensives."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b201964, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b201958 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b201959 .

_:79f295ad32df4ce8a18a92539c6e8a3b201959 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201960;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b201961 .

_:79f295ad32df4ce8a18a92539c6e8a3b201960 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10007 .

_:79f295ad32df4ce8a18a92539c6e8a3b201961 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201962;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b201962 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10148 .

_:79f295ad32df4ce8a18a92539c6e8a3b201964 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10068-1 a owl:Class;
  rdfs:label "ALCALOÏDES DE L'ERGOT DE SEIGLE DOPAMINERGIQUES <-> SYMPATHOMIMÉTIQUES INDIRECTS"@fr;
  dct:identifier "IAM_10068";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b201966;
  r:natureDuRisque "Risque de vasoconstriction et/ou de poussées hypertensives."@fr;
  rdfs:comment """Les décisions suivantes, émanant de trois instances de l'Afssaps, ont été prises en compte : 
- la Commission Nationale de Pharmacovigilance a pris acte d'une toxicité de la phénylpropanolamine supérieure à celle des autres sympathomimétiques indirects ("""@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b201972, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b201966 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b201967 .

_:79f295ad32df4ce8a18a92539c6e8a3b201967 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201968;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b201969 .

_:79f295ad32df4ce8a18a92539c6e8a3b201968 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10007 .

_:79f295ad32df4ce8a18a92539c6e8a3b201969 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201970;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b201970 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10150 .

_:79f295ad32df4ce8a18a92539c6e8a3b201972 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10126-1 a owl:Class;
  rdfs:label "AMIODARONE <-> COBICISTAT"@fr;
  dct:identifier "IAM_10126";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b201974;
  r:natureDuRisque "Risque de majoration des effets indésirables de l'amiodarone par diminution de son métabolisme par le cobicistat."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b201980, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b201974 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b201975 .

_:79f295ad32df4ce8a18a92539c6e8a3b201975 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201976;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b201977 .

_:79f295ad32df4ce8a18a92539c6e8a3b201976 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10066 .

_:79f295ad32df4ce8a18a92539c6e8a3b201977 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201978;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b201978 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10221 .

_:79f295ad32df4ce8a18a92539c6e8a3b201980 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10070-1 a owl:Class;
  rdfs:label "ALCALOÏDES DE L'ERGOT DE SEIGLE VASOCONSTRICTEURS <-> INHIBITEURS PUISSANTS DU CYP3A4"@fr;
  dct:identifier "IAM_10070";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b201982;
  r:chapeau "Certains médicaments possèdent la capacité d’inhiber fortement le CYP3A4, une enzyme qui intervient dans le métabolisme de nombreux médicaments. Lorsque l’activité de cette enzyme est inhibée, elle n’est plus en mesure de métaboliser le médicament qui va"@fr;
  r:natureDuRisque "Risque de vasoconstriction coronaire ou des extrémités (ergotisme), ou de poussées hypertensives."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b201988, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b201982 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b201983 .

_:79f295ad32df4ce8a18a92539c6e8a3b201983 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201984;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b201985 .

_:79f295ad32df4ce8a18a92539c6e8a3b201984 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10008 .

_:79f295ad32df4ce8a18a92539c6e8a3b201985 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201986;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b201986 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10103 .

_:79f295ad32df4ce8a18a92539c6e8a3b201988 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10125-1 a owl:Class;
  rdfs:label "AMIODARONE <-> CICLOSPORINE"@fr;
  dct:identifier "IAM_10125";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b201990;
  r:natureDuRisque "Augmentation des concentrations sanguines de ciclosporine, par diminution de son métabolisme hépatique, avec risque d'effets néphrotoxiques."@fr;
  r:conduiteATenir "Dosage des concentrations sanguines de ciclosporine, contrôle de la fonction rénale et adaptation de la posologie de la ciclosporine pendant le traitement par l'amiodarone."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b201996, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b201990 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b201991 .

_:79f295ad32df4ce8a18a92539c6e8a3b201991 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201992;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b201993 .

_:79f295ad32df4ce8a18a92539c6e8a3b201992 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10066 .

_:79f295ad32df4ce8a18a92539c6e8a3b201993 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b201994;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b201994 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10193 .

_:79f295ad32df4ce8a18a92539c6e8a3b201996 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10116-1 a owl:Class;
  rdfs:label "AMINOSIDES <-> CICLOSPORINE"@fr;
  dct:identifier "IAM_10116";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b201998;
  r:natureDuRisque "Augmentation de la créatininémie plus importante que sous ciclosporine seule, avec majoration du risque néphrotoxique."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b202004, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b201998 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b201999 .

_:79f295ad32df4ce8a18a92539c6e8a3b201999 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202000;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b202001 .

_:79f295ad32df4ce8a18a92539c6e8a3b202000 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10011 .

_:79f295ad32df4ce8a18a92539c6e8a3b202001 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202002;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b202002 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10193 .

_:79f295ad32df4ce8a18a92539c6e8a3b202004 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10117-1 a owl:Class;
  rdfs:label "AMINOSIDES <-> CURARES"@fr;
  dct:identifier "IAM_10117";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b202006;
  r:chapeau """Certaines substances peuvent modifier l'intensité et/ou la durée de l'effet des curares non dépolarisants. 
Les médicaments susceptibles de potentialiser l'action des curares non dépolarisants sont :
- les anesthésiques volatils tels que isoflurane, enflu"""@fr;
  r:natureDuRisque "Potentialisation des curares lorque l'antibiotique est administré par voie parentérale et/ou péritonéale avant, pendant ou après l'agent curarisant."@fr;
  r:conduiteATenir "Surveiller le degré de curarisation en fin d'anesthésie."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b202012, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b202006 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b202007 .

_:79f295ad32df4ce8a18a92539c6e8a3b202007 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202008;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b202009 .

_:79f295ad32df4ce8a18a92539c6e8a3b202008 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10011 .

_:79f295ad32df4ce8a18a92539c6e8a3b202009 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202010;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b202010 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10057 .

_:79f295ad32df4ce8a18a92539c6e8a3b202012 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10118-1 a owl:Class;
  rdfs:label "AMINOSIDES <-> DIURÉTIQUES DE L'ANSE"@fr;
  dct:identifier "IAM_10118";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b202014;
  r:natureDuRisque "Augmentation des risques néphrotoxiques et ototoxiques de l'aminoside (insuffisance rénale fonctionnelle liée à la déshydratation entraînée par le diurétique)."@fr;
  r:conduiteATenir "Association possible sous contrôle de l'état d'hydratation, des fonctions rénale et cochléovestibulaire, et éventuellement, des concentrations plasmatiques de l'aminoside."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b202020, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b202014 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b202015 .

_:79f295ad32df4ce8a18a92539c6e8a3b202015 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202016;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b202017 .

_:79f295ad32df4ce8a18a92539c6e8a3b202016 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10011 .

_:79f295ad32df4ce8a18a92539c6e8a3b202017 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202018;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b202018 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10064 .

_:79f295ad32df4ce8a18a92539c6e8a3b202020 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10119-1 a owl:Class;
  rdfs:label "AMINOSIDES <-> ORGANOPLATINES"@fr;
  dct:identifier "IAM_10119";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b202022;
  r:natureDuRisque "Addition des effets néphrotoxiques et/ou ototoxiques, notamment en cas d'insuffisance rénale préalable."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b202028, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b202022 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b202023 .

_:79f295ad32df4ce8a18a92539c6e8a3b202023 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202024;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b202025 .

_:79f295ad32df4ce8a18a92539c6e8a3b202024 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10011 .

_:79f295ad32df4ce8a18a92539c6e8a3b202025 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202026;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b202026 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10129 .

_:79f295ad32df4ce8a18a92539c6e8a3b202028 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10120-1 a owl:Class;
  rdfs:label "AMINOSIDES <-> POLYMYXINE B"@fr;
  dct:identifier "IAM_10120";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b202030;
  r:natureDuRisque "Addition des effets néphrotoxiques."@fr;
  r:conduiteATenir "Si l'association ne peut être évitée, surveillance stricte avec une justification bactériologique indiscutable."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b202036, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b202030 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b202031 .

_:79f295ad32df4ce8a18a92539c6e8a3b202031 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202032;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b202033 .

_:79f295ad32df4ce8a18a92539c6e8a3b202032 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10011 .

_:79f295ad32df4ce8a18a92539c6e8a3b202033 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202034;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b202034 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10739 .

_:79f295ad32df4ce8a18a92539c6e8a3b202036 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10121-1 a owl:Class;
  rdfs:label "AMINOSIDES <-> TACROLIMUS"@fr;
  dct:identifier "IAM_10121";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b202038;
  r:natureDuRisque "Augmentation de la créatininémie plus importante que sous tacrolimus seul (synergie des effets néphrotoxiques des deux substances)."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b202044, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b202038 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b202039 .

_:79f295ad32df4ce8a18a92539c6e8a3b202039 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202040;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b202041 .

_:79f295ad32df4ce8a18a92539c6e8a3b202040 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10011 .

_:79f295ad32df4ce8a18a92539c6e8a3b202041 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202042;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b202042 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10880 .

_:79f295ad32df4ce8a18a92539c6e8a3b202044 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10146-1 a owl:Class;
  rdfs:label "AMIODARONE <-> TELAPREVIR"@fr;
  dct:identifier "IAM_10146";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b202046;
  r:natureDuRisque "Troubles de l'automatisme et de la conduction cardiaque avec risque de bradycardie excessive."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b202052, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b202046 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b202047 .

_:79f295ad32df4ce8a18a92539c6e8a3b202047 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202048;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b202049 .

_:79f295ad32df4ce8a18a92539c6e8a3b202048 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10066 .

_:79f295ad32df4ce8a18a92539c6e8a3b202049 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202050;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b202050 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10887 .

_:79f295ad32df4ce8a18a92539c6e8a3b202052 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10122-1 a owl:Class;
  rdfs:label "AMIODARONE <-> ANTIVITAMINES K"@fr;
  dct:identifier "IAM_10122";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b202054;
  r:natureDuRisque "Augmentation de l'effet de l'antivitamine K et du risque hémorragique."@fr;
  r:conduiteATenir "Contrôle plus fréquent de l'INR. Adaptation éventuelle de la posologie de l'antivitamine K pendant le traitement par l'amiodarone et 8 jours après son arrêt."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b202060, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b202054 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b202055 .

_:79f295ad32df4ce8a18a92539c6e8a3b202055 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202056;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b202057 .

_:79f295ad32df4ce8a18a92539c6e8a3b202056 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10046 .

_:79f295ad32df4ce8a18a92539c6e8a3b202057 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202058;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b202058 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10066 .

_:79f295ad32df4ce8a18a92539c6e8a3b202060 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10123-1 a owl:Class;
  rdfs:label "AMIODARONE <-> BÊTA-BLOQUANTS (SAUF ESMOLOL ET SOTALOL)"@fr;
  dct:identifier "IAM_10123";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b202062;
  r:natureDuRisque "Troubles de l'automatisme et de la conduction (suppression des mécanismes sympathiques compensateurs)."@fr;
  r:conduiteATenir "Surveillance clinique et ECG."@fr;
  rdfs:comment """L'amiodarone a longtemps été déconseillée avec les bêta-bloquants, en raison d’une majoration possible du risque de bradycardie et de torsades de pointes.
Cependant, considérant que :
- le risque de torsades de pointes est exceptionnel avec l’amiodarone,"""@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b202068, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b202062 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b202063 .

_:79f295ad32df4ce8a18a92539c6e8a3b202063 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202064;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b202065 .

_:79f295ad32df4ce8a18a92539c6e8a3b202064 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10053 .

_:79f295ad32df4ce8a18a92539c6e8a3b202065 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202066;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b202066 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10066 .

_:79f295ad32df4ce8a18a92539c6e8a3b202068 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10151-1 a owl:Class;
  rdfs:label "AMPHOTERICINE B <-> TACROLIMUS"@fr;
  dct:identifier "IAM_10151";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b202070;
  r:natureDuRisque "Avec l'amphotéricine B administrée par voie IV : augmentation de la créatininémie plus importante que sous tacrolimus seul (synergie des effets néphrotoxiques des deux substances)."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b202076, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b202070 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b202071 .

_:79f295ad32df4ce8a18a92539c6e8a3b202071 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202072;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b202073 .

_:79f295ad32df4ce8a18a92539c6e8a3b202072 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10072 .

_:79f295ad32df4ce8a18a92539c6e8a3b202073 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202074;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b202074 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10880 .

_:79f295ad32df4ce8a18a92539c6e8a3b202076 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10069-1 a owl:Class;
  rdfs:label "ALCALOÏDES DE L'ERGOT DE SEIGLE VASOCONSTRICTEURS <-> INHIBITEURS DE PROTÉASES BOOSTÉS PAR RITONAVIR"@fr;
  dct:identifier "IAM_10069";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b202078;
  r:chapeau "Le ritonavir est désormais utilisé à la dose de 100 mg 2 fois par jour en association à un autre inhibiteur de protéase, dans le but d'augmenter de façon très significative la biodisponibilité de l'inhibiteur de protéase associé (ou boosté), ce qui permet"@fr;
  r:natureDuRisque "Risque de vasoconstriction coronaire ou des extrémités (ergotisme), ou de poussées hypertensives."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b202084, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b202078 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b202079 .

_:79f295ad32df4ce8a18a92539c6e8a3b202079 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202080;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b202081 .

_:79f295ad32df4ce8a18a92539c6e8a3b202080 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10008 .

_:79f295ad32df4ce8a18a92539c6e8a3b202081 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202082;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b202082 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10100 .

_:79f295ad32df4ce8a18a92539c6e8a3b202084 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10185-1 a owl:Class;
  rdfs:label "ANTAGONISTES DES RÉCEPTEURS DE L'ANGIOTENSINE II <-> INHIBITEURS DE L'ENZYME DE CONVERSION"@fr;
  dct:identifier "IAM_10185";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b202086;
  r:natureDuRisque "Dans les indications où cette association est possible, risque accru de dégradation de la fonction rénale, voire insuffisance rénale aiguë, et majoration de l'hyperkaliémie, ainsi que de l'hypotension et des syncopes."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b202092, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b202086 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b202087 .

_:79f295ad32df4ce8a18a92539c6e8a3b202087 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202088;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b202089 .

_:79f295ad32df4ce8a18a92539c6e8a3b202088 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10020 .

_:79f295ad32df4ce8a18a92539c6e8a3b202089 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202090;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b202090 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10096 .

_:79f295ad32df4ce8a18a92539c6e8a3b202092 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10149-1 a owl:Class;
  rdfs:label "AMLODIPINE <-> SIMVASTATINE"@fr;
  dct:identifier "IAM_10149";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b202094;
  r:natureDuRisque "Risque majoré d’effets indésirables (dose-dépendants) à type de rhabdomyolyse (diminution du métabolisme hépatique de l’hypocholestérolémiant)."@fr;
  r:conduiteATenir "Ne pas dépasser la posologie de 20 mg/j de simvastatine ou utiliser une autre statine non concernée par ce type d’interaction."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b202100, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b202094 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b202095 .

_:79f295ad32df4ce8a18a92539c6e8a3b202095 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202096;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b202097 .

_:79f295ad32df4ce8a18a92539c6e8a3b202096 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10069 .

_:79f295ad32df4ce8a18a92539c6e8a3b202097 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202098;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b202098 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10838 .

_:79f295ad32df4ce8a18a92539c6e8a3b202100 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10176-1 a owl:Class;
  rdfs:label "ANESTHÉSIQUES VOLATILS HALOGÉNÉS <-> SYMPATHOMIMÉTIQUES INDIRECTS"@fr;
  dct:identifier "IAM_10176";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b202102;
  r:natureDuRisque "Poussée hypertensive peropératoire."@fr;
  r:conduiteATenir "En cas d'intervention programmée, il est préférable d'interrompre le traitement quelques jours avant l'intervention."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b202108, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b202102 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b202103 .

_:79f295ad32df4ce8a18a92539c6e8a3b202103 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202104;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b202105 .

_:79f295ad32df4ce8a18a92539c6e8a3b202104 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10017 .

_:79f295ad32df4ce8a18a92539c6e8a3b202105 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202106;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b202106 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10150 .

_:79f295ad32df4ce8a18a92539c6e8a3b202108 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10075-1 a owl:Class;
  rdfs:label "ALCOOL (BOISSON OU EXCIPIENT) <-> ANTABUSE (RÉACTION)"@fr;
  dct:identifier "IAM_10075";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b202110;
  r:natureDuRisque "Effet antabuse (chaleur, rougeurs, vomissements, tachycardie)."@fr;
  r:conduiteATenir "Eviter la prise de boissons alcoolisées et de médicaments contenant de l'alcool. Tenir compte de l’élimination complète des médicaments en se référant à leur demi-vie avant la reprise de boissons alcoolisées ou du médicament contenant de l’alcool."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b202116, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b202110 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b202111 .

_:79f295ad32df4ce8a18a92539c6e8a3b202111 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202112;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b202113 .

_:79f295ad32df4ce8a18a92539c6e8a3b202112 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10018 .

_:79f295ad32df4ce8a18a92539c6e8a3b202113 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202114;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b202114 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_11013 .

_:79f295ad32df4ce8a18a92539c6e8a3b202116 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10177-1 a owl:Class;
  rdfs:label "ANTAGONISTES DES CANAUX CALCIQUES <-> ANTICONVULSIVANTS INDUCTEURS ENZYMATIQUES"@fr;
  dct:identifier "IAM_10177";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b202118;
  r:natureDuRisque "Diminution des concentrations plasmatiques de l'antagoniste du calcium par augmentation de son métabolisme hépatique."@fr;
  r:conduiteATenir """Précaution d'emploi :
Surveillance clinique et adaptation éventuelle de la posologie de l'antagoniste du calcium pendant le traitement par l'anticonvulsivant et après son arrêt."""@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b202124, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b202118 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b202119 .

_:79f295ad32df4ce8a18a92539c6e8a3b202119 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202120;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b202121 .

_:79f295ad32df4ce8a18a92539c6e8a3b202120 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10019 .

_:79f295ad32df4ce8a18a92539c6e8a3b202121 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202122;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b202122 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10029 .

_:79f295ad32df4ce8a18a92539c6e8a3b202124 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10178-1 a owl:Class;
  rdfs:label "ANTAGONISTES DES CANAUX CALCIQUES <-> IDÉLALISIB"@fr;
  dct:identifier "IAM_10178";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b202126;
  r:natureDuRisque "Majoration des effets indésirables de l’antagoniste des canaux calciques, à type d’hypotension orthostatique, notamment chez le sujet âgé."@fr;
  r:conduiteATenir "Surveillance clinique et adaptation de la posologie de l’antagoniste calcique pendant le traitement par l’idélalisib et après son arrêt."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b202132, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b202126 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b202127 .

_:79f295ad32df4ce8a18a92539c6e8a3b202127 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202128;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b202129 .

_:79f295ad32df4ce8a18a92539c6e8a3b202128 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10019 .

_:79f295ad32df4ce8a18a92539c6e8a3b202129 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202130;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b202130 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10444 .

_:79f295ad32df4ce8a18a92539c6e8a3b202132 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10179-1 a owl:Class;
  rdfs:label "ANTAGONISTES DES CANAUX CALCIQUES <-> INHIBITEURS PUISSANTS DU CYP3A4"@fr;
  dct:identifier "IAM_10179";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b202134;
  r:natureDuRisque "Majoration des effets indésirables de l’antagoniste des canaux calciques, le plus souvent à type d'hypotension notamment chez le sujet âgé."@fr;
  r:conduiteATenir "Surveillance clinique et adaptation posologique pendant le traitement par l’inhibiteur enzymatique et après son arrêt."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b202140, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b202134 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b202135 .

_:79f295ad32df4ce8a18a92539c6e8a3b202135 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202136;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b202137 .

_:79f295ad32df4ce8a18a92539c6e8a3b202136 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10019 .

_:79f295ad32df4ce8a18a92539c6e8a3b202137 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202138;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b202138 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10103 .

_:79f295ad32df4ce8a18a92539c6e8a3b202140 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10180-1 a owl:Class;
  rdfs:label "ANTAGONISTES DES CANAUX CALCIQUES <-> RIFAMPICINE"@fr;
  dct:identifier "IAM_10180";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b202142;
  r:natureDuRisque "Diminution des concentrations plasmatiques de l'antagoniste du calcium par augmentation de son métabolisme hépatique."@fr;
  r:conduiteATenir """Précaution d'emploi :
Surveillance clinique et adaptation éventuelle de la posologie de l'antagoniste du calcium pendant le traitement par la rifampicine et après son arrêt."""@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b202148, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b202142 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b202143 .

_:79f295ad32df4ce8a18a92539c6e8a3b202143 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202144;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b202145 .

_:79f295ad32df4ce8a18a92539c6e8a3b202144 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10019 .

_:79f295ad32df4ce8a18a92539c6e8a3b202145 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202146;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b202146 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:79f295ad32df4ce8a18a92539c6e8a3b202148 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10181-1 a owl:Class;
  rdfs:label "ANTAGONISTES DES RÉCEPTEURS DE L'ANGIOTENSINE II <-> ANTI-INFLAMMATOIRES NON STÉROÏDIENS"@fr;
  dct:identifier "IAM_10181";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b202150;
  r:natureDuRisque "Insuffisance rénale aiguë chez le patient à risque (sujet âgé, déshydratation, traitement associé avec diurétiques, altération de la fonction rénale), par diminution de la filtration glomérulaire (inhibition des prostaglandines vasodilatatrices due aux an"@fr;
  r:conduiteATenir "Hydrater le malade et surveiller la fonction rénale en début de traitement et régulièrement pendant l’association."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b202156, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b202150 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b202151 .

_:79f295ad32df4ce8a18a92539c6e8a3b202151 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202152;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b202153 .

_:79f295ad32df4ce8a18a92539c6e8a3b202152 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10020 .

_:79f295ad32df4ce8a18a92539c6e8a3b202153 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202154;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b202154 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10022 .

_:79f295ad32df4ce8a18a92539c6e8a3b202156 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10182-1 a owl:Class;
  rdfs:label "ANTAGONISTES DES RÉCEPTEURS DE L'ANGIOTENSINE II <-> DIURÉTIQUES ÉPARGNEURS DE POTASSIUM (SEULS OU ASSOCIÉS)"@fr;
  dct:identifier "IAM_10182";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b202158;
  r:natureDuRisque "Risque d'hyperkaliémie (potentiellement létale) surtout en cas d'insuffisance rénale (addition des effets hyperkaliémiants)."@fr;
  r:conduiteATenir """Précaution d'emploi :
- pour la spironolactone à des doses comprises entre 12,5 mg et 50 mg/jour, et pour l’éplérénone utilisées dans le traitement de l'insuffisance cardiaque, ainsi qu'en cas d'hypokaliémie : contrôle strict de la kaliémie et de la fonct"""@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b202164, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b202158 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b202159 .

_:79f295ad32df4ce8a18a92539c6e8a3b202159 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202160;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b202161 .

_:79f295ad32df4ce8a18a92539c6e8a3b202160 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10020 .

_:79f295ad32df4ce8a18a92539c6e8a3b202161 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202162;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b202162 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10067 .

_:79f295ad32df4ce8a18a92539c6e8a3b202164 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10174-1 a owl:Class;
  rdfs:label "ANESTHÉSIQUES VOLATILS HALOGÉNÉS <-> ISOPRENALINE"@fr;
  dct:identifier "IAM_10174";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b202166;
  r:natureDuRisque "Troubles du rythme ventriculaire graves par augmentation de l'excitabilité cardiaque."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b202172, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b202166 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b202167 .

_:79f295ad32df4ce8a18a92539c6e8a3b202167 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202168;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b202169 .

_:79f295ad32df4ce8a18a92539c6e8a3b202168 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10017 .

_:79f295ad32df4ce8a18a92539c6e8a3b202169 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202170;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b202170 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10491 .

_:79f295ad32df4ce8a18a92539c6e8a3b202172 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10184-1 a owl:Class;
  rdfs:label "ANTAGONISTES DES RÉCEPTEURS DE L'ANGIOTENSINE II <-> EPLERENONE"@fr;
  dct:identifier "IAM_10184";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b202174;
  r:natureDuRisque "Majoration du risque d’hyperkaliémie, notamment chez le sujet âgé."@fr;
  r:conduiteATenir "Contrôle strict de la kaliémie et de la fonction rénale pendant l’association."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b202180, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b202174 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b202175 .

_:79f295ad32df4ce8a18a92539c6e8a3b202175 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202176;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b202177 .

_:79f295ad32df4ce8a18a92539c6e8a3b202176 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10020 .

_:79f295ad32df4ce8a18a92539c6e8a3b202177 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202178;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b202178 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10329 .

_:79f295ad32df4ce8a18a92539c6e8a3b202180 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10173-1 a owl:Class;
  rdfs:label "ANESTHÉSIQUES VOLATILS HALOGÉNÉS <-> ISONIAZIDE"@fr;
  dct:identifier "IAM_10173";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b202182;
  r:natureDuRisque "Potentialisation de l'effet hépatotoxique de l'isonazide, avec formation accrue de métabolites toxiques de l'isoniazide."@fr;
  r:conduiteATenir "En cas d'intervention programmée, arrêter, par prudence, le traitement par l'isoniazide une semaine avant l'intervention et ne le reprendre que 15 jours après."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b202188, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b202182 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b202183 .

_:79f295ad32df4ce8a18a92539c6e8a3b202183 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202184;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b202185 .

_:79f295ad32df4ce8a18a92539c6e8a3b202184 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10017 .

_:79f295ad32df4ce8a18a92539c6e8a3b202185 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202186;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b202186 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10490 .

_:79f295ad32df4ce8a18a92539c6e8a3b202188 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10186-1 a owl:Class;
  rdfs:label "ANTAGONISTES DES RÉCEPTEURS DE L'ANGIOTENSINE II <-> LITHIUM"@fr;
  dct:identifier "IAM_10186";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b202190;
  r:natureDuRisque "Augmentation de la lithémie pouvant atteindre des valeurs toxiques (diminution de l'excrétion rénale du lithium)."@fr;
  r:conduiteATenir "Si l'usage d'un antagoniste de l'angiotensine II est indispensable, surveillance stricte de la lithémie et adaptation de la posologie."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b202196, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b202190 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b202191 .

_:79f295ad32df4ce8a18a92539c6e8a3b202191 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202192;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b202193 .

_:79f295ad32df4ce8a18a92539c6e8a3b202192 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10020 .

_:79f295ad32df4ce8a18a92539c6e8a3b202193 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202194;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b202194 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10530 .

_:79f295ad32df4ce8a18a92539c6e8a3b202196 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10187-1 a owl:Class;
  rdfs:label "ANTAGONISTES DES RÉCEPTEURS DE L'ANGIOTENSINE II <-> POTASSIUM"@fr;
  dct:identifier "IAM_10187";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b202198;
  r:natureDuRisque "Hyperkaliémie (potentiellement létale) surtout lors d'une insuffisance rénale (addition des effets hyperkaliémiants)."@fr;
  r:conduiteATenir "Eviter cette association sauf s'il existe une hypokaliémie préalable."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b202204, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b202198 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b202199 .

_:79f295ad32df4ce8a18a92539c6e8a3b202199 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202200;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b202201 .

_:79f295ad32df4ce8a18a92539c6e8a3b202200 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10020 .

_:79f295ad32df4ce8a18a92539c6e8a3b202201 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202202;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b202202 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10742 .

_:79f295ad32df4ce8a18a92539c6e8a3b202204 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10188-1 a owl:Class;
  rdfs:label "ANTIAGRÉGANTS PLAQUETTAIRES <-> ANTICOAGULANTS ORAUX"@fr;
  dct:identifier "IAM_10188";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b202206;
  r:natureDuRisque "Augmentation du risque hémorragique."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b202212, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b202206 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b202207 .

_:79f295ad32df4ce8a18a92539c6e8a3b202207 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202208;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b202209 .

_:79f295ad32df4ce8a18a92539c6e8a3b202208 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10023 .

_:79f295ad32df4ce8a18a92539c6e8a3b202209 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202210;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b202210 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10028 .

_:79f295ad32df4ce8a18a92539c6e8a3b202212 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10189-1 a owl:Class;
  rdfs:label "ANTIAGRÉGANTS PLAQUETTAIRES <-> DÉFIBROTIDE"@fr;
  dct:identifier "IAM_10189";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b202214;
  r:natureDuRisque "Risque hémorragique accru."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b202220, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b202214 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b202215 .

_:79f295ad32df4ce8a18a92539c6e8a3b202215 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202216;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b202217 .

_:79f295ad32df4ce8a18a92539c6e8a3b202216 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10023 .

_:79f295ad32df4ce8a18a92539c6e8a3b202217 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202218;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b202218 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10262 .

_:79f295ad32df4ce8a18a92539c6e8a3b202220 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10190-1 a owl:Class;
  rdfs:label "ANTIAGRÉGANTS PLAQUETTAIRES <-> HÉPARINES"@fr;
  dct:identifier "IAM_10190";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b202222;
  r:natureDuRisque "Augmentation du risque hémorragique."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b202228, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b202222 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b202223 .

_:79f295ad32df4ce8a18a92539c6e8a3b202223 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202224;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b202225 .

_:79f295ad32df4ce8a18a92539c6e8a3b202224 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10023 .

_:79f295ad32df4ce8a18a92539c6e8a3b202225 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202226;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b202226 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10088 .

_:79f295ad32df4ce8a18a92539c6e8a3b202228 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10191-1 a owl:Class;
  rdfs:label "ANTIAGRÉGANTS PLAQUETTAIRES <-> THROMBOLYTIQUES"@fr;
  dct:identifier "IAM_10191";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b202230;
  r:chapeau """Plusieurs substances sont impliquées dans des interactions, du fait de leurs propriétés antiagrégantes plaquettaires. 
L’utilisation de plusieurs antiagrégants plaquettaires majore le risque de saignement, de même que leur association à l’héparine et aux"""@fr;
  r:natureDuRisque "Augmentation du risque hémorragique."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b202236, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b202230 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b202231 .

_:79f295ad32df4ce8a18a92539c6e8a3b202231 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202232;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b202233 .

_:79f295ad32df4ce8a18a92539c6e8a3b202232 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10023 .

_:79f295ad32df4ce8a18a92539c6e8a3b202233 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202234;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b202234 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10151 .

_:79f295ad32df4ce8a18a92539c6e8a3b202236 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10192-1 a owl:Class;
  rdfs:label "ANTIARYTHMIQUES <-> AUTRES ANTIARYTHMIQUES"@fr;
  dct:identifier "IAM_10192";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b202238;
  r:natureDuRisque "L'association de deux antiarythmiques est très délicate. Elle est dans la majorité des cas, contre-indiquée ou déconseillée."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b202240, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b202238 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10024 .

_:79f295ad32df4ce8a18a92539c6e8a3b202240 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10193-1 a owl:Class;
  rdfs:label "ANTIARYTHMIQUES CLASSE I (SAUF LIDOCAÏNE) <-> BÊTA-BLOQUANTS (SAUF ESMOLOL ET SOTALOL)"@fr;
  dct:identifier "IAM_10193";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b202242;
  r:natureDuRisque "Troubles de la contractilité, de l'automatisme et de la conduction (suppression des mécanismes sympathiques compensateurs)."@fr;
  r:conduiteATenir "Surveillance clinique et ECG."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b202248, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b202242 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b202243 .

_:79f295ad32df4ce8a18a92539c6e8a3b202243 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202244;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b202245 .

_:79f295ad32df4ce8a18a92539c6e8a3b202244 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10025 .

_:79f295ad32df4ce8a18a92539c6e8a3b202245 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202246;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b202246 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10053 .

_:79f295ad32df4ce8a18a92539c6e8a3b202248 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10194-1 a owl:Class;
  rdfs:label "ANTIARYTHMIQUES CLASSE I (SAUF LIDOCAÏNE) <-> BÊTA-BLOQUANTS DANS L'INSUFFISANCE CARDIAQUE"@fr;
  dct:identifier "IAM_10194";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b202250;
  r:chapeau """A l’heure actuelle, 4 bêta-bloquants ont l'indication \"insuffisance cardiaque\" : le carvédilol, le bisoprolol, le métoprolol et le névibolol.
Les interactions médicamenteuses des bêta-bloquants, lorsqu’ils sont prescrits dans l’insuffisance cardiaque, pe"""@fr;
  r:natureDuRisque "Effet inotrope négatif avec risque de décompensation cardiaque."@fr;
  rdfs:comment """Les études effectuées avec des antiarythmiques de classe I prescrits à des insuffisants cardiaques ont montré une surmortalité dans le groupe traité.
Ces études ont été faites avant l'utilisation des bêta-bloquants dans cette indication, mais qu'il s'agis"""@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b202256, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b202250 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b202251 .

_:79f295ad32df4ce8a18a92539c6e8a3b202251 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202252;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b202253 .

_:79f295ad32df4ce8a18a92539c6e8a3b202252 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10025 .

_:79f295ad32df4ce8a18a92539c6e8a3b202253 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202254;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b202254 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10055 .

_:79f295ad32df4ce8a18a92539c6e8a3b202256 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10195-1 a owl:Class;
  rdfs:label "ANTIARYTHMIQUES CLASSE IA <-> ANTICONVULSIVANTS INDUCTEURS ENZYMATIQUES"@fr;
  dct:identifier "IAM_10195";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b202258;
  r:natureDuRisque "Diminution des concentrations plasmatiques et de l'efficacité de l'antiarythmique, par augmentation de son métabolisme hépatique par l'inducteur."@fr;
  r:conduiteATenir "Surveillance clinique, ECG et contrôle des concentrations plasmatiques ; si besoin, adaptation de la posologie de l'antiarythmique pendant le traitement par l'inducteur et après son arrêt."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b202264, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b202258 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b202259 .

_:79f295ad32df4ce8a18a92539c6e8a3b202259 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202260;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b202261 .

_:79f295ad32df4ce8a18a92539c6e8a3b202260 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10026 .

_:79f295ad32df4ce8a18a92539c6e8a3b202261 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202262;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b202262 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10029 .

_:79f295ad32df4ce8a18a92539c6e8a3b202264 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10183-1 a owl:Class;
  rdfs:label "ANTAGONISTES DES RÉCEPTEURS DE L'ANGIOTENSINE II <-> DIURÉTIQUES HYPOKALIÉMIANTS"@fr;
  dct:identifier "IAM_10183";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b202266;
  r:natureDuRisque "Risque d'hypotension artérielle brutale et/ou d'insuffisance rénale aiguë lors de l'instauration ou de l'augmentation de la posologie d'un traitement par un antagoniste de l'angiotensine II en cas de déplétion hydrosodée préexistante."@fr;
  r:conduiteATenir """Dans l'hypertension artérielle, lorsqu'un traitement diurétique préalable a pu entraîner une déplétion hydrosodée, il faut : 
- soit arrêter le diurétique avant de débuter le traitement par l'antagoniste de l'angiotensine II, et réintroduire un diurétique"""@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b202272, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b202266 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b202267 .

_:79f295ad32df4ce8a18a92539c6e8a3b202267 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202268;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b202269 .

_:79f295ad32df4ce8a18a92539c6e8a3b202268 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10020 .

_:79f295ad32df4ce8a18a92539c6e8a3b202269 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202270;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b202270 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10065 .

_:79f295ad32df4ce8a18a92539c6e8a3b202272 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10162-1 a owl:Class;
  rdfs:label "ANALGÉSIQUES MORPHINIQUES DE PALIER III <-> MORPHINIQUES AGONISTES-ANTAGONISTES"@fr;
  dct:identifier "IAM_10162";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b202274;
  r:natureDuRisque "Diminution de l'effet antalgique par blocage compétitif des récepteurs, avec risque d'apparition d'un syndrome de sevrage."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b202280, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b202274 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b202275 .

_:79f295ad32df4ce8a18a92539c6e8a3b202275 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202276;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b202277 .

_:79f295ad32df4ce8a18a92539c6e8a3b202276 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10014 .

_:79f295ad32df4ce8a18a92539c6e8a3b202277 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202278;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b202278 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10110 .

_:79f295ad32df4ce8a18a92539c6e8a3b202280 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10058-1 a owl:Class;
  rdfs:label "AGOMELATINE <-> FLUVOXAMINE"@fr;
  dct:identifier "IAM_10058";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b202282;
  r:natureDuRisque "Augmentation des concentrations d'agomélatine, avec risque de majoration des effets indésirables."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b202288, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b202282 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b202283 .

_:79f295ad32df4ce8a18a92539c6e8a3b202283 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202284;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b202285 .

_:79f295ad32df4ce8a18a92539c6e8a3b202284 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10041 .

_:79f295ad32df4ce8a18a92539c6e8a3b202285 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202286;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b202286 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10398 .

_:79f295ad32df4ce8a18a92539c6e8a3b202288 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10152-1 a owl:Class;
  rdfs:label "AMPHOTERICINE B <-> ZIDOVUDINE"@fr;
  dct:identifier "IAM_10152";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b202290;
  r:natureDuRisque "Avec l'amphotéricine B administrée par voie IV : augmentation de la toxicité hématologique (addition d'effets de toxicité médullaire)."@fr;
  r:conduiteATenir "Contrôle plus fréquent de l'hémogramme."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b202296, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b202290 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b202291 .

_:79f295ad32df4ce8a18a92539c6e8a3b202291 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202292;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b202293 .

_:79f295ad32df4ce8a18a92539c6e8a3b202292 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10072 .

_:79f295ad32df4ce8a18a92539c6e8a3b202293 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202294;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b202294 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_11004 .

_:79f295ad32df4ce8a18a92539c6e8a3b202296 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10153-1 a owl:Class;
  rdfs:label "ANAGRELIDE <-> ANTIAGRÉGANTS PLAQUETTAIRES"@fr;
  dct:identifier "IAM_10153";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b202298;
  r:natureDuRisque "Majoration des événements hémorragiques."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b202304, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b202298 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b202299 .

_:79f295ad32df4ce8a18a92539c6e8a3b202299 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202300;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b202301 .

_:79f295ad32df4ce8a18a92539c6e8a3b202300 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10023 .

_:79f295ad32df4ce8a18a92539c6e8a3b202301 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202302;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b202302 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10075 .

_:79f295ad32df4ce8a18a92539c6e8a3b202304 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10154-1 a owl:Class;
  rdfs:label "ANAGRELIDE <-> SUBSTANCES SUSCEPTIBLES DE DONNER DES TORSADES DE POINTES"@fr;
  dct:identifier "IAM_10154";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b202306;
  r:natureDuRisque "Risque majoré de troubles du rythme ventriculaire, notamment de torsades de pointes."@fr;
  r:conduiteATenir """Surveillance clinique et électrocardiographique pendant
l'association."""@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b202312, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b202306 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b202307 .

_:79f295ad32df4ce8a18a92539c6e8a3b202307 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202308;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b202309 .

_:79f295ad32df4ce8a18a92539c6e8a3b202308 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10143 .

_:79f295ad32df4ce8a18a92539c6e8a3b202309 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202310;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b202310 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10075 .

_:79f295ad32df4ce8a18a92539c6e8a3b202312 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10155-1 a owl:Class;
  rdfs:label "ANAKINRA <-> ANTI-TNF ALPHA"@fr;
  dct:identifier "IAM_10155";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b202314;
  r:natureDuRisque "Risque accru d'infections graves et de neutropénies."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b202320, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b202314 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b202315 .

_:79f295ad32df4ce8a18a92539c6e8a3b202315 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202316;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b202317 .

_:79f295ad32df4ce8a18a92539c6e8a3b202316 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10021 .

_:79f295ad32df4ce8a18a92539c6e8a3b202317 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202318;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b202318 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10076 .

_:79f295ad32df4ce8a18a92539c6e8a3b202320 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10156-1 a owl:Class;
  rdfs:label "ANAKINRA <-> ETANERCEPT"@fr;
  dct:identifier "IAM_10156";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b202322;
  r:natureDuRisque "Risque accru d'infections graves et de neutropénies."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b202328, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b202322 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b202323 .

_:79f295ad32df4ce8a18a92539c6e8a3b202323 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202324;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b202325 .

_:79f295ad32df4ce8a18a92539c6e8a3b202324 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10076 .

_:79f295ad32df4ce8a18a92539c6e8a3b202325 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202326;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b202326 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10349 .

_:79f295ad32df4ce8a18a92539c6e8a3b202328 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10159-1 a owl:Class;
  rdfs:label "ANALGÉSIQUES MORPHINIQUES AGONISTES <-> AUTRES ANALGÉSIQUES MORPHINIQUES AGONISTES"@fr;
  dct:identifier "IAM_10159";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b202330;
  r:natureDuRisque "Risque majoré de dépression respiratoire, pouvant être fatale en cas de surdosage."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b202332, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b202330 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10012 .

_:79f295ad32df4ce8a18a92539c6e8a3b202332 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10157-1 a owl:Class;
  rdfs:label "ANALGÉSIQUES MORPHINIQUES AGONISTES <-> ANTITUSSIFS MORPHINE-LIKE"@fr;
  dct:identifier "IAM_10157";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b202334;
  r:natureDuRisque "Risque majoré de dépression respiratoire, pouvant être fatale en cas de surdosage."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b202340, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b202334 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b202335 .

_:79f295ad32df4ce8a18a92539c6e8a3b202335 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202336;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b202337 .

_:79f295ad32df4ce8a18a92539c6e8a3b202336 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10012 .

_:79f295ad32df4ce8a18a92539c6e8a3b202337 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202338;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b202338 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10044 .

_:79f295ad32df4ce8a18a92539c6e8a3b202340 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10158-1 a owl:Class;
  rdfs:label "ANALGÉSIQUES MORPHINIQUES AGONISTES <-> ANTITUSSIFS MORPHINIQUES VRAIS"@fr;
  dct:identifier "IAM_10158";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b202342;
  r:natureDuRisque "Risque majoré de dépression respiratoire, pouvant être fatale en cas de surdosage."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b202348, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b202342 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b202343 .

_:79f295ad32df4ce8a18a92539c6e8a3b202343 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202344;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b202345 .

_:79f295ad32df4ce8a18a92539c6e8a3b202344 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10012 .

_:79f295ad32df4ce8a18a92539c6e8a3b202345 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202346;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b202346 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10045 .

_:79f295ad32df4ce8a18a92539c6e8a3b202348 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10175-1 a owl:Class;
  rdfs:label "ANESTHÉSIQUES VOLATILS HALOGÉNÉS <-> SYMPATHOMIMÉTIQUES ALPHA ET BÊTA (VOIE IM ET IV)"@fr;
  dct:identifier "IAM_10175";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b202350;
  r:natureDuRisque "Troubles du rythme ventriculaire graves par augmentation de l'excitabilité cardiaque."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b202356, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b202350 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b202351 .

_:79f295ad32df4ce8a18a92539c6e8a3b202351 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202352;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b202353 .

_:79f295ad32df4ce8a18a92539c6e8a3b202352 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10017 .

_:79f295ad32df4ce8a18a92539c6e8a3b202353 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202354;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b202354 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10149 .

_:79f295ad32df4ce8a18a92539c6e8a3b202356 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10161-1 a owl:Class;
  rdfs:label "ANALGÉSIQUES MORPHINIQUES DE PALIER II <-> MORPHINIQUES ANTAGONISTES PARTIELS"@fr;
  dct:identifier "IAM_10161";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b202358;
  r:natureDuRisque "Risque de diminution de l’effet antalgique."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b202364, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b202358 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b202359 .

_:79f295ad32df4ce8a18a92539c6e8a3b202359 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202360;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b202361 .

_:79f295ad32df4ce8a18a92539c6e8a3b202360 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10013 .

_:79f295ad32df4ce8a18a92539c6e8a3b202361 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202362;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b202362 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10111 .

_:79f295ad32df4ce8a18a92539c6e8a3b202364 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10150-1 a owl:Class;
  rdfs:label "AMPHOTERICINE B <-> CICLOSPORINE"@fr;
  dct:identifier "IAM_10150";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b202366;
  r:natureDuRisque "Avec l'amphotéricine B administrée par voie IV : augmentation de la créatininémie plus importante que sous ciclosporine seule (synergie des effets néphrotoxiques des deux substances)."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b202372, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b202366 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b202367 .

_:79f295ad32df4ce8a18a92539c6e8a3b202367 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202368;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b202369 .

_:79f295ad32df4ce8a18a92539c6e8a3b202368 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10072 .

_:79f295ad32df4ce8a18a92539c6e8a3b202369 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202370;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b202370 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10193 .

_:79f295ad32df4ce8a18a92539c6e8a3b202372 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10163-1 a owl:Class;
  rdfs:label "ANALGÉSIQUES MORPHINIQUES DE PALIER III <-> MORPHINIQUES ANTAGONISTES PARTIELS"@fr;
  dct:identifier "IAM_10163";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b202374;
  r:natureDuRisque "Risque de diminution de l’effet antalgique."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b202380, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b202374 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b202375 .

_:79f295ad32df4ce8a18a92539c6e8a3b202375 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202376;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b202377 .

_:79f295ad32df4ce8a18a92539c6e8a3b202376 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10014 .

_:79f295ad32df4ce8a18a92539c6e8a3b202377 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202378;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b202378 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10111 .

_:79f295ad32df4ce8a18a92539c6e8a3b202380 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10164-1 a owl:Class;
  rdfs:label "ANALOGUES DE LA SOMATOSTATINE <-> CICLOSPORINE"@fr;
  dct:identifier "IAM_10164";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b202382;
  r:natureDuRisque "Avec la ciclosporine administrée par voie orale : baisse des concentrations sanguines de ciclosporine (diminution de son absorption intestinale)."@fr;
  r:conduiteATenir "Augmentation des doses de ciclosporine sous contrôle des concentrations plasmatiques et réduction de la posologie après l'arrêt du traitement par l'analogue de la somatostatine."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b202388, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b202382 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b202383 .

_:79f295ad32df4ce8a18a92539c6e8a3b202383 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202384;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b202385 .

_:79f295ad32df4ce8a18a92539c6e8a3b202384 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10015 .

_:79f295ad32df4ce8a18a92539c6e8a3b202385 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202386;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b202386 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10193 .

_:79f295ad32df4ce8a18a92539c6e8a3b202388 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10165-1 a owl:Class;
  rdfs:label "ANALOGUES DE LA SOMATOSTATINE <-> INSULINE"@fr;
  dct:identifier "IAM_10165";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b202390;
  r:natureDuRisque "Risque d'hypoglycémie ou d'hyperglycémie : diminution ou augmentation des besoins en insuline, par diminution ou augmentation de la sécrétion de glucagon endogène."@fr;
  r:conduiteATenir "Prévenir le patient du risque d'hypoglycémie ou d'hyperglycémie, renforcer l'autosurveillance glycémique et adapter si besoin la posologie de l'insuline pendant le traitement par l'analogue de la somatostatine."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b202396, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b202390 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b202391 .

_:79f295ad32df4ce8a18a92539c6e8a3b202391 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202392;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b202393 .

_:79f295ad32df4ce8a18a92539c6e8a3b202392 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10015 .

_:79f295ad32df4ce8a18a92539c6e8a3b202393 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202394;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b202394 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10458 .

_:79f295ad32df4ce8a18a92539c6e8a3b202396 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10166-1 a owl:Class;
  rdfs:label "ANALOGUES DE LA SOMATOSTATINE <-> PIOGLITAZONE"@fr;
  dct:identifier "IAM_10166";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b202398;
  r:natureDuRisque """Risque d’hypoglycémie ou d’hyperglycémie : diminution ou
augmentation des besoins en glitazone, par diminution ou
augmentation de la sécrétion de glucagon endogène."""@fr;
  r:conduiteATenir """Renforcer l’autosurveillance glycémique et adapter si besoin la
posologie de la glitazone pendant le traitement par l'analogue de la
somatostatine."""@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b202404, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b202398 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b202399 .

_:79f295ad32df4ce8a18a92539c6e8a3b202399 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202400;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b202401 .

_:79f295ad32df4ce8a18a92539c6e8a3b202400 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10015 .

_:79f295ad32df4ce8a18a92539c6e8a3b202401 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202402;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b202402 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10723 .

_:79f295ad32df4ce8a18a92539c6e8a3b202404 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10167-1 a owl:Class;
  rdfs:label "ANALOGUES DE LA SOMATOSTATINE <-> REPAGLINIDE"@fr;
  dct:identifier "IAM_10167";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b202406;
  r:natureDuRisque "Risque d'hypoglycémie ou d'hyperglycémie : diminution ou augmentation des besoins en repaglidine, par diminution ou augmentation de la sécrétion de glucagon endogène."@fr;
  r:conduiteATenir "Renforcer l'autosurveillance glycémique et adapter si besoin la posologie de la repaglidine pendant le traitement par l'analogue de la somatostatine."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b202412, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b202406 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b202407 .

_:79f295ad32df4ce8a18a92539c6e8a3b202407 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202408;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b202409 .

_:79f295ad32df4ce8a18a92539c6e8a3b202408 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10015 .

_:79f295ad32df4ce8a18a92539c6e8a3b202409 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202410;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b202410 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10791 .

_:79f295ad32df4ce8a18a92539c6e8a3b202412 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10168-1 a owl:Class;
  rdfs:label "ANALOGUES DE LA SOMATOSTATINE <-> SULFAMIDES HYPOGLYCÉMIANTS"@fr;
  dct:identifier "IAM_10168";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b202414;
  r:natureDuRisque "Risque d'hypoglycémie ou d'hyperglycémie : diminution ou augmentation des besoins en sulfamide hypoglycemiant, par diminution ou augmentation de la sécrétion de glucagon endogène."@fr;
  r:conduiteATenir "Renforcer l'autosurveillance glycémique et adapter si besoin la posologie du sulfamide hypoglycemiant pendant le traitement par l'analogue de la somatostatine."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b202420, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b202414 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b202415 .

_:79f295ad32df4ce8a18a92539c6e8a3b202415 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202416;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b202417 .

_:79f295ad32df4ce8a18a92539c6e8a3b202416 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10015 .

_:79f295ad32df4ce8a18a92539c6e8a3b202417 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202418;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b202418 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10147 .

_:79f295ad32df4ce8a18a92539c6e8a3b202420 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10169-1 a owl:Class;
  rdfs:label "ANDROGÈNES <-> ANTIVITAMINES K"@fr;
  dct:identifier "IAM_10169";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b202422;
  r:natureDuRisque "Augmentation du risque hémorragique par effet direct sur la coagulation et/ou les systèmes fibrinolytiques."@fr;
  r:conduiteATenir "Contrôle plus fréquent de l’INR. Adaptation de la posologie de l’antivitamine K pendant le traitement par l'androgène et après son arrêt."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b202428, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b202422 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b202423 .

_:79f295ad32df4ce8a18a92539c6e8a3b202423 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202424;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b202425 .

_:79f295ad32df4ce8a18a92539c6e8a3b202424 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10016 .

_:79f295ad32df4ce8a18a92539c6e8a3b202425 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202426;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b202426 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10046 .

_:79f295ad32df4ce8a18a92539c6e8a3b202428 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10170-1 a owl:Class;
  rdfs:label "ANDROGÈNES <-> INDUCTEURS ENZYMATIQUES"@fr;
  dct:identifier "IAM_10170";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b202430;
  r:chapeau "Certains médicaments ont la propriété d'activer considérablement certaines voies métaboliques hépatiques par induction enzymatique. Associés à des médicaments fortement métabolisés au niveau du foie, ils sont, de ce fait, en mesure d'en modifier les conce"@fr;
  r:natureDuRisque "Risque de diminution des concentrations plasmatiques de l'androgène et par conséquent de son efficacité, par augmentation de son métabolisme hépatique par l’inducteur."@fr;
  r:conduiteATenir "Surveillance clinique et biologique pendant l’association et 1 à 2 semaines après l’arrêt de l’inducteur."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b202436, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b202430 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b202431 .

_:79f295ad32df4ce8a18a92539c6e8a3b202431 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202432;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b202433 .

_:79f295ad32df4ce8a18a92539c6e8a3b202432 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10016 .

_:79f295ad32df4ce8a18a92539c6e8a3b202433 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202434;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b202434 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10094 .

_:79f295ad32df4ce8a18a92539c6e8a3b202436 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10171-1 a owl:Class;
  rdfs:label "ANESTHÉSIQUES VOLATILS HALOGÉNÉS <-> BÊTA-BLOQUANTS (SAUF ESMOLOL)"@fr;
  dct:identifier "IAM_10171";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b202438;
  r:natureDuRisque "Réduction des réactions cardiovasculaires de compensation par les bêta-bloquants. L'inhibition bêta-adrénergique peut être levée durant l'intervention par les bêta-mimétiques."@fr;
  r:conduiteATenir "En règle générale, ne pas arrêter le traitement bêta-bloquant et, de toute façon, éviter l'arrêt brutal. Informer l'anesthésiste de ce traitement."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b202444, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b202438 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b202439 .

_:79f295ad32df4ce8a18a92539c6e8a3b202439 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202440;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b202441 .

_:79f295ad32df4ce8a18a92539c6e8a3b202440 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10017 .

_:79f295ad32df4ce8a18a92539c6e8a3b202441 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202442;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b202442 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10054 .

_:79f295ad32df4ce8a18a92539c6e8a3b202444 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10172-1 a owl:Class;
  rdfs:label "ANESTHÉSIQUES VOLATILS HALOGÉNÉS <-> BÊTA-BLOQUANTS DANS L'INSUFFISANCE CARDIAQUE"@fr;
  dct:identifier "IAM_10172";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b202446;
  r:natureDuRisque "Réduction des réactions cardiovasculaires de compensation par les bêta-bloquants. L'inhibition bêta-adrénergique peut être levée durant l'intervention par les bêta-stimulants."@fr;
  r:conduiteATenir "En règle générale, ne pas arrêter le traitement bêta-bloquant et, de toute façon, éviter l'arrêt brutal. Informer l'anesthésiste de ce traitement."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b202452, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b202446 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b202447 .

_:79f295ad32df4ce8a18a92539c6e8a3b202447 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202448;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b202449 .

_:79f295ad32df4ce8a18a92539c6e8a3b202448 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10017 .

_:79f295ad32df4ce8a18a92539c6e8a3b202449 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202450;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b202450 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10055 .

_:79f295ad32df4ce8a18a92539c6e8a3b202452 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10160-1 a owl:Class;
  rdfs:label "ANALGÉSIQUES MORPHINIQUES DE PALIER II <-> MORPHINIQUES AGONISTES-ANTAGONISTES"@fr;
  dct:identifier "IAM_10160";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b202454;
  r:natureDuRisque "Diminution de l'effet antalgique par blocage compétitif des récepteurs, avec risque d'apparition d'un syndrome de sevrage."@fr;
  rdfs:comment "L’association d’agonistes-antagonistes morphiniques (buprénorphine, nalbuphine, pentazocine) avec des analgésiques morphiniques agonistes a été contre-indiquée jusqu'à présent, et ce, quel que soit leur niveau (palier II ou III de la classification de l'O"@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b202460, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b202454 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b202455 .

_:79f295ad32df4ce8a18a92539c6e8a3b202455 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202456;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b202457 .

_:79f295ad32df4ce8a18a92539c6e8a3b202456 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10013 .

_:79f295ad32df4ce8a18a92539c6e8a3b202457 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202458;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b202458 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10110 .

_:79f295ad32df4ce8a18a92539c6e8a3b202460 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10101-1 a owl:Class;
  rdfs:label "ALLOPURINOL <-> VIDARABINE"@fr;
  dct:identifier "IAM_10101";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b202462;
  r:natureDuRisque "Risque accru de troubles neurologiques (tremblements, confusion) par inhibition partielle du métabolisme de l'antiviral."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b202468, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b202462 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b202463 .

_:79f295ad32df4ce8a18a92539c6e8a3b202463 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202464;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b202465 .

_:79f295ad32df4ce8a18a92539c6e8a3b202464 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10051 .

_:79f295ad32df4ce8a18a92539c6e8a3b202465 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202466;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b202466 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10981 .

_:79f295ad32df4ce8a18a92539c6e8a3b202468 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10090-1 a owl:Class;
  rdfs:label "ALISKIREN <-> ANTAGONISTES DES RÉCEPTEURS DE L'ANGIOTENSINE II"@fr;
  dct:identifier "IAM_10090";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b202470;
  r:natureDuRisque "Risque d’hyperkaliémie, d’insuffisance rénale, d’augmentation de la morbi-mortalité cardio-vasculaire."@fr;
  r:conduiteATenir """Contre-indication :
- chez le patient diabétique ou insuffisant rénal

Association déconseillée :
- dans les autres cas"""@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b202476, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b202470 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b202471 .

_:79f295ad32df4ce8a18a92539c6e8a3b202471 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202472;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b202473 .

_:79f295ad32df4ce8a18a92539c6e8a3b202472 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10020 .

_:79f295ad32df4ce8a18a92539c6e8a3b202473 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202474;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b202474 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10048 .

_:79f295ad32df4ce8a18a92539c6e8a3b202476 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10091-1 a owl:Class;
  rdfs:label "ALISKIREN <-> CICLOSPORINE"@fr;
  dct:identifier "IAM_10091";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b202478;
  r:natureDuRisque "Augmentation de près de 5 fois des concentrations plasmatiques d’aliskiren et majoration du risque de ses effets indésirables."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b202484, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b202478 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b202479 .

_:79f295ad32df4ce8a18a92539c6e8a3b202479 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202480;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b202481 .

_:79f295ad32df4ce8a18a92539c6e8a3b202480 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10048 .

_:79f295ad32df4ce8a18a92539c6e8a3b202481 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202482;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b202482 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10193 .

_:79f295ad32df4ce8a18a92539c6e8a3b202484 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10092-1 a owl:Class;
  rdfs:label "ALISKIREN <-> INHIBITEURS DE L'ENZYME DE CONVERSION"@fr;
  dct:identifier "IAM_10092";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b202486;
  r:natureDuRisque "Risque d’hyperkaliémie, d’insuffisance rénale, d’augmentation de la morbi-mortalité cardio-vasculaire."@fr;
  r:conduiteATenir """Contre-indication :
- chez le patient diabétique ou insuffisant rénal

Association déconseillée :
- dans les autres cas"""@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b202492, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b202486 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b202487 .

_:79f295ad32df4ce8a18a92539c6e8a3b202487 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202488;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b202489 .

_:79f295ad32df4ce8a18a92539c6e8a3b202488 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10096 .

_:79f295ad32df4ce8a18a92539c6e8a3b202489 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202490;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b202490 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10048 .

_:79f295ad32df4ce8a18a92539c6e8a3b202492 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10093-1 a owl:Class;
  rdfs:label "ALISKIREN <-> ITRACONAZOLE"@fr;
  dct:identifier "IAM_10093";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b202494;
  r:natureDuRisque "Augmentation de près de 6 fois des concentrations plasmatiques d’aliskiren et majoration du risque de ses effets indésirables."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b202500, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b202494 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b202495 .

_:79f295ad32df4ce8a18a92539c6e8a3b202495 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202496;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b202497 .

_:79f295ad32df4ce8a18a92539c6e8a3b202496 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10048 .

_:79f295ad32df4ce8a18a92539c6e8a3b202497 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202498;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b202498 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10496 .

_:79f295ad32df4ce8a18a92539c6e8a3b202500 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10094-1 a owl:Class;
  rdfs:label "ALISKIREN <-> PAMPLEMOUSSE (JUS ET FRUIT)"@fr;
  dct:identifier "IAM_10094";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b202502;
  r:natureDuRisque "Risque de diminution de l’efficacité de l’aliskiren en cas de consommation de pamplemousse."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b202508, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b202502 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b202503 .

_:79f295ad32df4ce8a18a92539c6e8a3b202503 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202504;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b202505 .

_:79f295ad32df4ce8a18a92539c6e8a3b202504 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10130 .

_:79f295ad32df4ce8a18a92539c6e8a3b202505 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202506;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b202506 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10048 .

_:79f295ad32df4ce8a18a92539c6e8a3b202508 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10095-1 a owl:Class;
  rdfs:label "ALISKIREN <-> QUINIDINE"@fr;
  dct:identifier "IAM_10095";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b202510;
  r:natureDuRisque "Augmentation des concentrations plasmatiques d’aliskiren et majoration du risque de ses effets indésirables."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b202516, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b202510 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b202511 .

_:79f295ad32df4ce8a18a92539c6e8a3b202511 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202512;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b202513 .

_:79f295ad32df4ce8a18a92539c6e8a3b202512 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10048 .

_:79f295ad32df4ce8a18a92539c6e8a3b202513 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202514;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b202514 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10776 .

_:79f295ad32df4ce8a18a92539c6e8a3b202516 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10096-1 a owl:Class;
  rdfs:label "ALISKIREN <-> SACUBITRIL"@fr;
  dct:identifier "IAM_10096";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b202518;
  r:natureDuRisque "Chez les patients diabétiques ou insuffisants rénaux, augmentation des effets indésirables tels que hypotension, hyperkaliémie."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b202524, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b202518 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b202519 .

_:79f295ad32df4ce8a18a92539c6e8a3b202519 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202520;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b202521 .

_:79f295ad32df4ce8a18a92539c6e8a3b202520 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10048 .

_:79f295ad32df4ce8a18a92539c6e8a3b202521 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202522;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b202522 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10821 .

_:79f295ad32df4ce8a18a92539c6e8a3b202524 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10097-1 a owl:Class;
  rdfs:label "ALISKIREN <-> VERAPAMIL"@fr;
  dct:identifier "IAM_10097";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b202526;
  r:natureDuRisque "Augmentation des concentrations plasmatiques d’aliskiren et majoration du risque de ses effets indésirables."@fr;
  r:conduiteATenir "Surveillance clinique."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b202532, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b202526 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b202527 .

_:79f295ad32df4ce8a18a92539c6e8a3b202527 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202528;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b202529 .

_:79f295ad32df4ce8a18a92539c6e8a3b202528 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10048 .

_:79f295ad32df4ce8a18a92539c6e8a3b202529 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202530;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b202530 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10980 .

_:79f295ad32df4ce8a18a92539c6e8a3b202532 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10098-1 a owl:Class;
  rdfs:label "ALLOPURINOL <-> ANTIVITAMINES K"@fr;
  dct:identifier "IAM_10098";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b202534;
  r:natureDuRisque "Augmentation de l'effet de l'antivitamine K et du risque hémorragique (diminution de son métabolisme hépatique)."@fr;
  r:conduiteATenir "Contrôle plus fréquent de l'INR. Adaptation éventuelle de la posologie de l'antivitamine K pendant le traitement par l'allopurinol et 8 jours après son arrêt."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b202540, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b202534 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b202535 .

_:79f295ad32df4ce8a18a92539c6e8a3b202535 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202536;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b202537 .

_:79f295ad32df4ce8a18a92539c6e8a3b202536 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10046 .

_:79f295ad32df4ce8a18a92539c6e8a3b202537 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202538;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b202538 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10051 .

_:79f295ad32df4ce8a18a92539c6e8a3b202540 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10060-1 a owl:Class;
  rdfs:label "ALBENDAZOLE <-> INHIBITEURS DE PROTÉASES BOOSTÉS PAR RITONAVIR"@fr;
  dct:identifier "IAM_10060";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b202542;
  r:natureDuRisque "Diminution importante des concentrations plasmatiques de l’albendazole et de son métabolite actif par le ritonavir, avec risque de baisse de son efficacité."@fr;
  r:conduiteATenir "Surveillance clinique de la réponse thérapeutique et adaptation éventuelle de la posologie de l’albendazole pendant le traitement avec l’inducteur enzymatique et après son arrêt."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b202548, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b202542 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b202543 .

_:79f295ad32df4ce8a18a92539c6e8a3b202543 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202544;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b202545 .

_:79f295ad32df4ce8a18a92539c6e8a3b202544 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10100 .

_:79f295ad32df4ce8a18a92539c6e8a3b202545 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202546;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b202546 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10042 .

_:79f295ad32df4ce8a18a92539c6e8a3b202548 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10100-1 a owl:Class;
  rdfs:label "ALLOPURINOL <-> PÉNICILLINES A"@fr;
  dct:identifier "IAM_10100";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b202550;
  r:natureDuRisque "Risque accru de réactions cutanées."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b202556, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b202550 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b202551 .

_:79f295ad32df4ce8a18a92539c6e8a3b202551 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202552;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b202553 .

_:79f295ad32df4ce8a18a92539c6e8a3b202552 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10139 .

_:79f295ad32df4ce8a18a92539c6e8a3b202553 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202554;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b202554 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10051 .

_:79f295ad32df4ce8a18a92539c6e8a3b202556 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10087-1 a owl:Class;
  rdfs:label "ALFENTANIL <-> INHIBITEURS PUISSANTS DU CYP3A4"@fr;
  dct:identifier "IAM_10087";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b202558;
  r:natureDuRisque "Augmentation de l'effet dépresseur respiratoire de l'analgésique opiacé par diminution de son métabolisme hépatique."@fr;
  r:conduiteATenir "Surveillance clinique et adaptation de la posologie de l’analgésique opiacé en cas de traitement par un inhibiteur puissant du CYP3A4."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b202564, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b202558 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b202559 .

_:79f295ad32df4ce8a18a92539c6e8a3b202559 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202560;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b202561 .

_:79f295ad32df4ce8a18a92539c6e8a3b202560 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10103 .

_:79f295ad32df4ce8a18a92539c6e8a3b202561 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202562;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b202562 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10045 .

_:79f295ad32df4ce8a18a92539c6e8a3b202564 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10103-1 a owl:Class;
  rdfs:label "ALPHABLOQUANTS À VISÉE UROLOGIQUE <-> ANTIHYPERTENSEURS SAUF ALPHA-BLOQUANTS"@fr;
  dct:identifier "IAM_10103";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b202566;
  r:natureDuRisque "Majoration de l'effet hypotenseur. Risque d'hypotension orthostatique majoré."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b202572, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b202566 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b202567 .

_:79f295ad32df4ce8a18a92539c6e8a3b202567 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202568;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b202569 .

_:79f295ad32df4ce8a18a92539c6e8a3b202568 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10009 .

_:79f295ad32df4ce8a18a92539c6e8a3b202569 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202570;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b202570 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10035 .

_:79f295ad32df4ce8a18a92539c6e8a3b202572 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10102-1 a owl:Class;
  rdfs:label "ALPHABLOQUANTS À VISÉE UROLOGIQUE <-> ANTIHYPERTENSEURS ALPHA-BLOQUANTS"@fr;
  dct:identifier "IAM_10102";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b202574;
  r:natureDuRisque "Majoration de l'effet hypotenseur. Risque d'hypotension orthostatique sévère."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b202580, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b202574 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b202575 .

_:79f295ad32df4ce8a18a92539c6e8a3b202575 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202576;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b202577 .

_:79f295ad32df4ce8a18a92539c6e8a3b202576 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10009 .

_:79f295ad32df4ce8a18a92539c6e8a3b202577 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202578;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b202578 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10033 .

_:79f295ad32df4ce8a18a92539c6e8a3b202580 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10104-1 a owl:Class;
  rdfs:label "ALPHABLOQUANTS À VISÉE UROLOGIQUE <-> INHIBITEURS DE LA PHOSPHODIESTERASE DE TYPE 5"@fr;
  dct:identifier "IAM_10104";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b202582;
  r:natureDuRisque "Risque d’hypotension orthostatique, notamment chez le sujet âgé."@fr;
  r:conduiteATenir """Association déconseillée :
- avec la doxazosine

Précaution d'emploi :
- avec les autres alpha-bloquants
Débuter le traitement aux posologies minimales recommandées et adapter progressivement les doses si besoin."""@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b202588, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b202582 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b202583 .

_:79f295ad32df4ce8a18a92539c6e8a3b202583 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202584;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b202585 .

_:79f295ad32df4ce8a18a92539c6e8a3b202584 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10009 .

_:79f295ad32df4ce8a18a92539c6e8a3b202585 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202586;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b202586 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10098 .

_:79f295ad32df4ce8a18a92539c6e8a3b202588 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10105-1 a owl:Class;
  rdfs:label "ALPHA-TOCOPHEROL <-> ANTIVITAMINES K"@fr;
  dct:identifier "IAM_10105";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b202590;
  r:natureDuRisque "Avec la vitamine E utilisée à des doses supérieures ou égales à 500 mg/j : augmentation de l'effet de l'antivitamine K et du risque hémorragique."@fr;
  r:conduiteATenir "Contrôle plus fréquent de l'INR. Adaptation éventuelle de la posologie de l'antivitamine K pendant le traitement par vitamine E et après son arrêt."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b202596, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b202590 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b202591 .

_:79f295ad32df4ce8a18a92539c6e8a3b202591 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202592;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b202593 .

_:79f295ad32df4ce8a18a92539c6e8a3b202592 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10046 .

_:79f295ad32df4ce8a18a92539c6e8a3b202593 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202594;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b202594 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10054 .

_:79f295ad32df4ce8a18a92539c6e8a3b202596 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10106-1 a owl:Class;
  rdfs:label "ALPRAZOLAM <-> INHIBITEURS PUISSANTS DU CYP3A4"@fr;
  dct:identifier "IAM_10106";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b202598;
  r:natureDuRisque "Possible augmentation de l'effet sédatif de l'alprazolam."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b202604, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b202598 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b202599 .

_:79f295ad32df4ce8a18a92539c6e8a3b202599 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202600;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b202601 .

_:79f295ad32df4ce8a18a92539c6e8a3b202600 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10103 .

_:79f295ad32df4ce8a18a92539c6e8a3b202601 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202602;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b202602 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10055 .

_:79f295ad32df4ce8a18a92539c6e8a3b202604 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10107-1 a owl:Class;
  rdfs:label "ALUMINIUM (SELS) <-> CITRATES"@fr;
  dct:identifier "IAM_10107";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b202606;
  r:natureDuRisque "Risque de facilitation du passage systémique de l’aluminium, notamment en cas de fonction rénale altérée."@fr;
  r:conduiteATenir "Prendre les topiques gastro-intestinaux à base d'aluminium à distance des citrates (plus de 2 heures si possible), y compris les citrates naturels (jus d'agrumes)."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b202612, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b202606 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b202607 .

_:79f295ad32df4ce8a18a92539c6e8a3b202607 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202608;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b202609 .

_:79f295ad32df4ce8a18a92539c6e8a3b202608 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10010 .

_:79f295ad32df4ce8a18a92539c6e8a3b202609 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202610;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b202610 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10056 .

_:79f295ad32df4ce8a18a92539c6e8a3b202612 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10108-1 a owl:Class;
  rdfs:label "AMBRISENTAN <-> CICLOSPORINE"@fr;
  dct:identifier "IAM_10108";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b202614;
  r:natureDuRisque "Doublement des concentrations d’ambrisentan, avec majoration de l’effet vasodilatateur (céphalées)."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b202620, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b202614 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b202615 .

_:79f295ad32df4ce8a18a92539c6e8a3b202615 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202616;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b202617 .

_:79f295ad32df4ce8a18a92539c6e8a3b202616 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10061 .

_:79f295ad32df4ce8a18a92539c6e8a3b202617 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202618;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b202618 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10193 .

_:79f295ad32df4ce8a18a92539c6e8a3b202620 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10109-1 a owl:Class;
  rdfs:label "AMINOGLUTETHIMIDE <-> ANTIVITAMINES K"@fr;
  dct:identifier "IAM_10109";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b202622;
  r:natureDuRisque "Décrit pour warfarine et acénocoumarol. Diminution de l'effet de l'antivitamine K, par augmentation de son métabolisme hépatique par l'aminogluthétimide."@fr;
  r:conduiteATenir "Contrôle plus fréquent de l'INR. Adaptation éventuelle de la posologie de l'antivitamine K pendant le traitement par aminogluthétimide et deux semaines après son arrêt."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b202628, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b202622 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b202623 .

_:79f295ad32df4ce8a18a92539c6e8a3b202623 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202624;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b202625 .

_:79f295ad32df4ce8a18a92539c6e8a3b202624 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10046 .

_:79f295ad32df4ce8a18a92539c6e8a3b202625 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202626;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b202626 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10064 .

_:79f295ad32df4ce8a18a92539c6e8a3b202628 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10110-1 a owl:Class;
  rdfs:label "AMINOGLUTETHIMIDE <-> DEXAMETHASONE"@fr;
  dct:identifier "IAM_10110";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b202630;
  r:natureDuRisque "Diminution de l'efficacité de la dexaméthasone, par augmentation de son métabolisme hépatique."@fr;
  r:conduiteATenir "Adaptation de la posologie de la dexaméthasone."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b202636, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b202630 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b202631 .

_:79f295ad32df4ce8a18a92539c6e8a3b202631 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202632;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b202633 .

_:79f295ad32df4ce8a18a92539c6e8a3b202632 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10064 .

_:79f295ad32df4ce8a18a92539c6e8a3b202633 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202634;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b202634 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10272 .

_:79f295ad32df4ce8a18a92539c6e8a3b202636 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10099-1 a owl:Class;
  rdfs:label "ALLOPURINOL <-> DIDANOSINE"@fr;
  dct:identifier "IAM_10099";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b202638;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de didanosine et de ses effets indésirables."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b202644, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b202638 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b202639 .

_:79f295ad32df4ce8a18a92539c6e8a3b202639 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202640;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b202641 .

_:79f295ad32df4ce8a18a92539c6e8a3b202640 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10051 .

_:79f295ad32df4ce8a18a92539c6e8a3b202641 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202642;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b202642 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10283 .

_:79f295ad32df4ce8a18a92539c6e8a3b202644 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10013-1 a owl:Class;
  rdfs:label "ACIDE ACETYLSALICYLIQUE <-> ANAGRELIDE"@fr;
  dct:identifier "IAM_10013";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b202646;
  r:natureDuRisque "Majoration des événements hémorragiques."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b202652, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b202646 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b202647 .

_:79f295ad32df4ce8a18a92539c6e8a3b202647 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202648;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b202649 .

_:79f295ad32df4ce8a18a92539c6e8a3b202648 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10012 .

_:79f295ad32df4ce8a18a92539c6e8a3b202649 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202650;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b202650 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10075 .

_:79f295ad32df4ce8a18a92539c6e8a3b202652 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10002-1 a owl:Class;
  rdfs:label "ABATACEPT <-> VACCINS VIVANTS ATTÉNUÉS"@fr;
  dct:identifier "IAM_10002";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b202654;
  r:natureDuRisque "Risque de maladie vaccinale généralisée, éventuellement mortelle."@fr;
  r:conduiteATenir "ainsi que pendant les 3 mois suivant l'arrêt du traitement."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b202660, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b202654 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b202655 .

_:79f295ad32df4ce8a18a92539c6e8a3b202655 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202656;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b202657 .

_:79f295ad32df4ce8a18a92539c6e8a3b202656 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10159 .

_:79f295ad32df4ce8a18a92539c6e8a3b202657 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202658;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b202658 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10002 .

_:79f295ad32df4ce8a18a92539c6e8a3b202660 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10003-1 a owl:Class;
  rdfs:label "ABIRATERONE <-> ANTICONVULSIVANTS INDUCTEURS ENZYMATIQUES"@fr;
  dct:identifier "IAM_10003";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b202662;
  r:natureDuRisque "Diminution notable des concentrations plasmatiques de l’abiratérone, avec risque de moindre efficacité."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b202668, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b202662 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b202663 .

_:79f295ad32df4ce8a18a92539c6e8a3b202663 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202664;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b202665 .

_:79f295ad32df4ce8a18a92539c6e8a3b202664 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10029 .

_:79f295ad32df4ce8a18a92539c6e8a3b202665 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202666;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b202666 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10004 .

_:79f295ad32df4ce8a18a92539c6e8a3b202668 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10004-1 a owl:Class;
  rdfs:label "ABIRATERONE <-> FLECAINIDE"@fr;
  dct:identifier "IAM_10004";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b202670;
  r:natureDuRisque "Risque d'augmentation des effets indésirables du flecaïnide, par diminution de son métabolisme hépatique par l'abiratérone."@fr;
  r:conduiteATenir "Surveillance clinique. Si besoin, adaptation de la posologie du flécaïnide pendant le traitement par l'abiratérone."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b202676, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b202670 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b202671 .

_:79f295ad32df4ce8a18a92539c6e8a3b202671 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202672;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b202673 .

_:79f295ad32df4ce8a18a92539c6e8a3b202672 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10004 .

_:79f295ad32df4ce8a18a92539c6e8a3b202673 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202674;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b202674 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10380 .

_:79f295ad32df4ce8a18a92539c6e8a3b202676 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10005-1 a owl:Class;
  rdfs:label "ABIRATERONE <-> METOPROLOL"@fr;
  dct:identifier "IAM_10005";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b202678;
  r:natureDuRisque "Chez l'insuffisant cardiaque, risque d'augmentation des effets indésirables du métoprolol, par diminution de son métabolisme hépatique par l'abiratérone."@fr;
  r:conduiteATenir "Surveillance clinique. Si besoin, adaptation de la posologie du métoprolol pendant le traitement par l'abiratérone."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b202684, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b202678 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b202679 .

_:79f295ad32df4ce8a18a92539c6e8a3b202679 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202680;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b202681 .

_:79f295ad32df4ce8a18a92539c6e8a3b202680 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10004 .

_:79f295ad32df4ce8a18a92539c6e8a3b202681 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202682;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b202682 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10579 .

_:79f295ad32df4ce8a18a92539c6e8a3b202684 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10006-1 a owl:Class;
  rdfs:label "ABIRATERONE <-> PROPAFENONE"@fr;
  dct:identifier "IAM_10006";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b202686;
  r:natureDuRisque "Risque d'augmentation des effets indésirables de la propafénone, par diminution de son métabolisme hépatique par l'abiratérone."@fr;
  r:conduiteATenir "Surveillance clinique. Si besoin, adaptation de la posologie de la propafénone pendant le traitement par l'abiratérone."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b202692, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b202686 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b202687 .

_:79f295ad32df4ce8a18a92539c6e8a3b202687 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202688;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b202689 .

_:79f295ad32df4ce8a18a92539c6e8a3b202688 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10004 .

_:79f295ad32df4ce8a18a92539c6e8a3b202689 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202690;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b202690 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10765 .

_:79f295ad32df4ce8a18a92539c6e8a3b202692 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10007-1 a owl:Class;
  rdfs:label "ABIRATERONE <-> RIFAMPICINE"@fr;
  dct:identifier "IAM_10007";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b202694;
  r:natureDuRisque "Diminution notable des concentrations plasmatiques de l’abiratérone, avec risque de moindre efficacité."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b202700, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b202694 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b202695 .

_:79f295ad32df4ce8a18a92539c6e8a3b202695 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202696;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b202697 .

_:79f295ad32df4ce8a18a92539c6e8a3b202696 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10004 .

_:79f295ad32df4ce8a18a92539c6e8a3b202697 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202698;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b202698 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:79f295ad32df4ce8a18a92539c6e8a3b202700 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10008-1 a owl:Class;
  rdfs:label "ACETAZOLAMIDE <-> ACIDE ACETYLSALICYLIQUE"@fr;
  dct:identifier "IAM_10008";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b202702;
  r:natureDuRisque "Majoration des effets indésirables, et notamment de l'acidose métabolique, de l'acide acétylsalicylique à doses élevées et de l'acétazolamide, par diminution de l'élimination de l'acide acétylsalicylique par l'acétazolamide."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b202708, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b202702 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b202703 .

_:79f295ad32df4ce8a18a92539c6e8a3b202703 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202704;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b202705 .

_:79f295ad32df4ce8a18a92539c6e8a3b202704 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10008 .

_:79f295ad32df4ce8a18a92539c6e8a3b202705 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202706;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b202706 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10012 .

_:79f295ad32df4ce8a18a92539c6e8a3b202708 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10009-1 a owl:Class;
  rdfs:label "ACETAZOLAMIDE <-> CARBAMAZEPINE"@fr;
  dct:identifier "IAM_10009";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b202710;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de carbamazépine avec signes de surdosage."@fr;
  r:conduiteATenir "Surveillance clinique et, si besoin, contrôle des concentrations plasmatiques de carbamazépine et réduction éventuelle de sa posologie."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b202716, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b202710 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b202711 .

_:79f295ad32df4ce8a18a92539c6e8a3b202711 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202712;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b202713 .

_:79f295ad32df4ce8a18a92539c6e8a3b202712 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10008 .

_:79f295ad32df4ce8a18a92539c6e8a3b202713 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202714;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b202714 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10158 .

_:79f295ad32df4ce8a18a92539c6e8a3b202716 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10010-1 a owl:Class;
  rdfs:label "ACETAZOLAMIDE <-> LITHIUM"@fr;
  dct:identifier "IAM_10010";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b202718;
  r:natureDuRisque "Diminution de la lithémie avec risque de baisse de l’efficacité thérapeutique."@fr;
  r:conduiteATenir "Surveillance stricte de la lithémie et adaptation éventuelle de la posologie du lithium."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b202724, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b202718 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b202719 .

_:79f295ad32df4ce8a18a92539c6e8a3b202719 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202720;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b202721 .

_:79f295ad32df4ce8a18a92539c6e8a3b202720 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10008 .

_:79f295ad32df4ce8a18a92539c6e8a3b202721 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202722;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b202722 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10530 .

_:79f295ad32df4ce8a18a92539c6e8a3b202724 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10089-1 a owl:Class;
  rdfs:label "ALFUZOSINE <-> OMBITASVIR + PARITAPRÉVIR"@fr;
  dct:identifier "IAM_10089";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b202726;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de l'afuzosine par diminution de son métabolisme hépatique par la bithérapie."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b202732, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b202726 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b202727 .

_:79f295ad32df4ce8a18a92539c6e8a3b202727 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202728;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b202729 .

_:79f295ad32df4ce8a18a92539c6e8a3b202728 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10128 .

_:79f295ad32df4ce8a18a92539c6e8a3b202729 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202730;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b202730 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10046 .

_:79f295ad32df4ce8a18a92539c6e8a3b202732 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10012-1 a owl:Class;
  rdfs:label "ACIDE ACETOHYDROXAMIQUE <-> FER"@fr;
  dct:identifier "IAM_10012";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b202734;
  r:natureDuRisque "Diminution de l'absorption digestive de ces deux médicaments par chélation du fer."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b202740, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b202734 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b202735 .

_:79f295ad32df4ce8a18a92539c6e8a3b202735 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202736;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b202737 .

_:79f295ad32df4ce8a18a92539c6e8a3b202736 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10011 .

_:79f295ad32df4ce8a18a92539c6e8a3b202737 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202738;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b202738 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10375 .

_:79f295ad32df4ce8a18a92539c6e8a3b202740 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10088-1 a owl:Class;
  rdfs:label "ALFUZOSINE <-> INHIBITEURS PUISSANTS DU CYP3A4"@fr;
  dct:identifier "IAM_10088";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b202742;
  r:natureDuRisque "Risque d’augmentation des concentrations plasmatiques de l’alfuzosine et de ses effets indésirables."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b202748, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b202742 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b202743 .

_:79f295ad32df4ce8a18a92539c6e8a3b202743 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202744;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b202745 .

_:79f295ad32df4ce8a18a92539c6e8a3b202744 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10103 .

_:79f295ad32df4ce8a18a92539c6e8a3b202745 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202746;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b202746 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10046 .

_:79f295ad32df4ce8a18a92539c6e8a3b202748 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10071-1 a owl:Class;
  rdfs:label "ALCALOÏDES DE L'ERGOT DE SEIGLE VASOCONSTRICTEURS <-> OMBITASVIR + PARITAPRÉVIR"@fr;
  dct:identifier "IAM_10071";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b202750;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de l'alcaloïde de l'ergot de seigle vasoconstricteur par diminution de son métabolisme hépatique par la bithérapie."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b202756, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b202750 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b202751 .

_:79f295ad32df4ce8a18a92539c6e8a3b202751 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202752;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b202753 .

_:79f295ad32df4ce8a18a92539c6e8a3b202752 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10008 .

_:79f295ad32df4ce8a18a92539c6e8a3b202753 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202754;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b202754 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10128 .

_:79f295ad32df4ce8a18a92539c6e8a3b202756 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10072-1 a owl:Class;
  rdfs:label "ALCALOÏDES DE L'ERGOT DE SEIGLE VASOCONSTRICTEURS <-> SYMPATHOMIMÉTIQUES ALPHA (VOIES ORALE ET/OU NASALE)"@fr;
  dct:identifier "IAM_10072";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b202758;
  r:natureDuRisque "Risque de vasoconstriction et/ou de poussées hypertensives."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b202764, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b202758 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b202759 .

_:79f295ad32df4ce8a18a92539c6e8a3b202759 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202760;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b202761 .

_:79f295ad32df4ce8a18a92539c6e8a3b202760 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10008 .

_:79f295ad32df4ce8a18a92539c6e8a3b202761 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202762;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b202762 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10148 .

_:79f295ad32df4ce8a18a92539c6e8a3b202764 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10073-1 a owl:Class;
  rdfs:label "ALCALOÏDES DE L'ERGOT DE SEIGLE VASOCONSTRICTEURS <-> SYMPATHOMIMÉTIQUES INDIRECTS"@fr;
  dct:identifier "IAM_10073";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b202766;
  r:natureDuRisque "Risque de vasoconstriction et/ou de poussées hypertensives."@fr;
  rdfs:comment """Les décisions suivantes, émanant de trois instances de l'Afssaps, ont été prises en compte : 
- la Commission Nationale de Pharmacovigilance a pris acte d'une toxicité de la phénylpropanolamine supérieure à celle des autres sympathomimétiques indirects ("""@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b202772, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b202766 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b202767 .

_:79f295ad32df4ce8a18a92539c6e8a3b202767 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202768;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b202769 .

_:79f295ad32df4ce8a18a92539c6e8a3b202768 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10008 .

_:79f295ad32df4ce8a18a92539c6e8a3b202769 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202770;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b202770 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10150 .

_:79f295ad32df4ce8a18a92539c6e8a3b202772 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10074-1 a owl:Class;
  rdfs:label "ALCALOÏDES DE L'ERGOT DE SEIGLE VASOCONSTRICTEURS <-> TRIPTANS"@fr;
  dct:identifier "IAM_10074";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b202774;
  r:natureDuRisque "Risque d'hypertension artérielle, de vasoconstriction artérielle coronaire."@fr;
  r:conduiteATenir "Respecter un délai de 6 à 24 heures, selon le triptan, entre la prise de celui-ci et celle de l'alcaloïde ergoté"@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b202780, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b202774 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b202775 .

_:79f295ad32df4ce8a18a92539c6e8a3b202775 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202776;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b202777 .

_:79f295ad32df4ce8a18a92539c6e8a3b202776 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10008 .

_:79f295ad32df4ce8a18a92539c6e8a3b202777 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202778;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b202778 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10156 .

_:79f295ad32df4ce8a18a92539c6e8a3b202780 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10082-1 a owl:Class;
  rdfs:label "ALDESLEUKINE <-> PRODUITS DE CONTRASTE IODÉS"@fr;
  dct:identifier "IAM_10082";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b202782;
  r:natureDuRisque "Majoration du risque de réaction aux produits de contraste en cas de traitement antérieur par interleukine 2 : éruption cutanée ou plus rarement hypotension, oligurie voire insuffisance rénale."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b202788, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b202782 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b202783 .

_:79f295ad32df4ce8a18a92539c6e8a3b202783 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202784;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b202785 .

_:79f295ad32df4ce8a18a92539c6e8a3b202784 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10133 .

_:79f295ad32df4ce8a18a92539c6e8a3b202785 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202786;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b202786 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10043 .

_:79f295ad32df4ce8a18a92539c6e8a3b202788 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10083-1 a owl:Class;
  rdfs:label "ALFENTANIL <-> CIMETIDINE"@fr;
  dct:identifier "IAM_10083";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b202790;
  r:natureDuRisque "Avec la cimétidine utilisée à des doses supérieures ou égales à 800 mg/j : augmentation de l'effet dépresseur respiratoire de l'analgésique opiacé par diminution de son métabolisme hépatique."@fr;
  r:conduiteATenir "Adapter la posologie de l'alfentanil en cas de traitement par la cimétidine."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b202796, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b202790 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b202791 .

_:79f295ad32df4ce8a18a92539c6e8a3b202791 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202792;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b202793 .

_:79f295ad32df4ce8a18a92539c6e8a3b202792 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10045 .

_:79f295ad32df4ce8a18a92539c6e8a3b202793 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202794;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b202794 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10196 .

_:79f295ad32df4ce8a18a92539c6e8a3b202796 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10084-1 a owl:Class;
  rdfs:label "ALFENTANIL <-> DILTIAZEM"@fr;
  dct:identifier "IAM_10084";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b202798;
  r:natureDuRisque "Augmentation de l'effet dépresseur respiratoire de l'analgésique opiacé par diminution de son métabolisme hépatique."@fr;
  r:conduiteATenir "Adapter la posologie de l'alfentanil en cas de traitement par le diltiazem."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b202804, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b202798 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b202799 .

_:79f295ad32df4ce8a18a92539c6e8a3b202799 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202800;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b202801 .

_:79f295ad32df4ce8a18a92539c6e8a3b202800 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10045 .

_:79f295ad32df4ce8a18a92539c6e8a3b202801 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202802;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b202802 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10290 .

_:79f295ad32df4ce8a18a92539c6e8a3b202804 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10085-1 a owl:Class;
  rdfs:label "ALFENTANIL <-> ERYTHROMYCINE"@fr;
  dct:identifier "IAM_10085";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b202806;
  r:natureDuRisque "Augmentation de l'effet dépresseur respiratoire de l'analgésique opiacé par diminution de son métabolisme hépatique."@fr;
  r:conduiteATenir "Adapter la posologie de l'alfentanil en cas de traitement par l'érythromycine."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b202812, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b202806 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b202807 .

_:79f295ad32df4ce8a18a92539c6e8a3b202807 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202808;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b202809 .

_:79f295ad32df4ce8a18a92539c6e8a3b202808 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10045 .

_:79f295ad32df4ce8a18a92539c6e8a3b202809 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202810;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b202810 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10338 .

_:79f295ad32df4ce8a18a92539c6e8a3b202812 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10086-1 a owl:Class;
  rdfs:label "ALFENTANIL <-> FLUCONAZOLE"@fr;
  dct:identifier "IAM_10086";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b202814;
  r:natureDuRisque "Augmentation de l'effet dépresseur respiratoire de l'analgésique opiacé par diminution de son métabolisme hépatique."@fr;
  r:conduiteATenir "Adapter la posologie de l'alfentanil en cas de traitement par le fluconazole."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b202820, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b202814 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b202815 .

_:79f295ad32df4ce8a18a92539c6e8a3b202815 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202816;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b202817 .

_:79f295ad32df4ce8a18a92539c6e8a3b202816 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10045 .

_:79f295ad32df4ce8a18a92539c6e8a3b202817 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202818;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b202818 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10381 .

_:79f295ad32df4ce8a18a92539c6e8a3b202820 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10112-1 a owl:Class;
  rdfs:label "AMINOSIDES <-> ATALUREN"@fr;
  dct:identifier "IAM_10112";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b202822;
  r:natureDuRisque "Risque de potentialisation de la toxicité rénale de l’aminoside."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b202828, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b202822 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b202823 .

_:79f295ad32df4ce8a18a92539c6e8a3b202823 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202824;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b202825 .

_:79f295ad32df4ce8a18a92539c6e8a3b202824 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10011 .

_:79f295ad32df4ce8a18a92539c6e8a3b202825 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202826;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b202826 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10086 .

_:79f295ad32df4ce8a18a92539c6e8a3b202828 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10011-1 a owl:Class;
  rdfs:label "ACETAZOLAMIDE <-> VALPROÏQUE (ACIDE) ET, PAR EXTRAPOLATION, VALPROMIDE"@fr;
  dct:identifier "IAM_10011";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b202830;
  r:natureDuRisque "Augmentation de l'hyperammoniémie, avec risque accru d'encéphalopathie."@fr;
  r:conduiteATenir "Surveillance clinique et biologique régulière."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b202836, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b202830 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b202831 .

_:79f295ad32df4ce8a18a92539c6e8a3b202831 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202832;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b202833 .

_:79f295ad32df4ce8a18a92539c6e8a3b202832 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10160 .

_:79f295ad32df4ce8a18a92539c6e8a3b202833 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202834;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b202834 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10008 .

_:79f295ad32df4ce8a18a92539c6e8a3b202836 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10047-1 a owl:Class;
  rdfs:label "AFATINIB <-> AMIODARONE"@fr;
  dct:identifier "IAM_10047";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b202838;
  r:natureDuRisque "Augmentation des concentrations plasmatiques d’afatinib par augmentation de son absorption par l'amiodarone."@fr;
  r:conduiteATenir """Il est recommandé d’administrer l'amiodarone le plus à distance possible de l’afatinib, en respectant de préférence un intervalle
de 6 heures ou de 12 heures par rapport à la prise d’afatinib."""@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b202844, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b202838 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b202839 .

_:79f295ad32df4ce8a18a92539c6e8a3b202839 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202840;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b202841 .

_:79f295ad32df4ce8a18a92539c6e8a3b202840 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10040 .

_:79f295ad32df4ce8a18a92539c6e8a3b202841 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202842;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b202842 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10066 .

_:79f295ad32df4ce8a18a92539c6e8a3b202844 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10113-1 a owl:Class;
  rdfs:label "AMINOSIDES <-> AUTRES AMINOSIDES"@fr;
  dct:identifier "IAM_10113";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b202846;
  r:natureDuRisque "Risque accru de néphrotoxicité et d'ototoxicité (l'ototoxicité est cumulative en cas d'administrations successives)."@fr;
  r:conduiteATenir """A prendre en compte :
- en cas d'administrations successives"""@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b202848, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b202846 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10011 .

_:79f295ad32df4ce8a18a92539c6e8a3b202848 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10037-1 a owl:Class;
  rdfs:label "ACIDE FUSIDIQUE <-> INHIBITEURS DE L'HMG-COA RÉDUCTASE (STATINES)"@fr;
  dct:identifier "IAM_10037";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b202850;
  r:natureDuRisque """Risque majoré d'effets indésirables (concentration-dépendants) à
type de rhabdomyolyse."""@fr;
  r:conduiteATenir """Arrêter le traitement par l'inhibiteur de l'HMG Co-A
réductase avant d'initier un traitement par acide fusidique ou utiliser un autre antibiotique."""@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b202856, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b202850 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b202851 .

_:79f295ad32df4ce8a18a92539c6e8a3b202851 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202852;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b202853 .

_:79f295ad32df4ce8a18a92539c6e8a3b202852 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10095 .

_:79f295ad32df4ce8a18a92539c6e8a3b202853 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202854;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b202854 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10021 .

_:79f295ad32df4ce8a18a92539c6e8a3b202856 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10038-1 a owl:Class;
  rdfs:label "ACIDE FUSIDIQUE <-> OMBITASVIR + PARITAPRÉVIR"@fr;
  dct:identifier "IAM_10038";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b202858;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de l'acide fusidique par diminution de son métabolisme hépatique par la bithérapie."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b202864, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b202858 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b202859 .

_:79f295ad32df4ce8a18a92539c6e8a3b202859 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202860;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b202861 .

_:79f295ad32df4ce8a18a92539c6e8a3b202860 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10128 .

_:79f295ad32df4ce8a18a92539c6e8a3b202861 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202862;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b202862 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10021 .

_:79f295ad32df4ce8a18a92539c6e8a3b202864 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10039-1 a owl:Class;
  rdfs:label "ACIDE NICOTINIQUE <-> ALCOOL (BOISSON OU EXCIPIENT)"@fr;
  dct:identifier "IAM_10039";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b202866;
  r:natureDuRisque "Risque de prurit, de rougeur et de chaleur, lié à une potentialisation de l'effet vasodilatateur."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b202872, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b202866 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b202867 .

_:79f295ad32df4ce8a18a92539c6e8a3b202867 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202868;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b202869 .

_:79f295ad32df4ce8a18a92539c6e8a3b202868 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10026 .

_:79f295ad32df4ce8a18a92539c6e8a3b202869 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202870;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b202870 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_11013 .

_:79f295ad32df4ce8a18a92539c6e8a3b202872 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10040-1 a owl:Class;
  rdfs:label "ACIDE URSODESOXYCHOLIQUE <-> CICLOSPORINE"@fr;
  dct:identifier "IAM_10040";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b202874;
  r:natureDuRisque "Risque de variation des concentrations sanguines de ciclosporine."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b202880, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b202874 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b202875 .

_:79f295ad32df4ce8a18a92539c6e8a3b202875 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202876;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b202877 .

_:79f295ad32df4ce8a18a92539c6e8a3b202876 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10033 .

_:79f295ad32df4ce8a18a92539c6e8a3b202877 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202878;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b202878 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10193 .

_:79f295ad32df4ce8a18a92539c6e8a3b202880 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10041-1 a owl:Class;
  rdfs:label "ACITRETINE <-> ALCOOL (BOISSON OU EXCIPIENT)"@fr;
  dct:identifier "IAM_10041";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b202882;
  r:natureDuRisque "Chez la femme en âge de procréer, risque de transformation de l’acitrétine en étrétinate, puissant tératogène dont la demi-vie très prolongée (120 jours) expose à un risque tératogène majeur en cas de grossesse, pendant le traitement et les 2 mois suivan"@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b202888, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b202882 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b202883 .

_:79f295ad32df4ce8a18a92539c6e8a3b202883 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202884;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b202885 .

_:79f295ad32df4ce8a18a92539c6e8a3b202884 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10036 .

_:79f295ad32df4ce8a18a92539c6e8a3b202885 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202886;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b202886 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_11013 .

_:79f295ad32df4ce8a18a92539c6e8a3b202888 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10042-1 a owl:Class;
  rdfs:label "ACITRETINE <-> METHOTREXATE"@fr;
  dct:identifier "IAM_10042";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b202890;
  r:natureDuRisque "Risque de majoration de l’hépatotoxicité du méthotrexate."@fr;
  r:conduiteATenir "Si l’association est jugée nécessaire, renforcer la surveillance du bilan hépatique."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b202896, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b202890 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b202891 .

_:79f295ad32df4ce8a18a92539c6e8a3b202891 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202892;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b202893 .

_:79f295ad32df4ce8a18a92539c6e8a3b202892 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10036 .

_:79f295ad32df4ce8a18a92539c6e8a3b202893 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202894;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b202894 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10569 .

_:79f295ad32df4ce8a18a92539c6e8a3b202896 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10045-1 a owl:Class;
  rdfs:label "ADRÉNALINE (VOIE BUCCO-DENTAIRE OU SOUS-CUTANÉE) <-> IMAO IRRÉVERSIBLES"@fr;
  dct:identifier "IAM_10045";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b202898;
  r:natureDuRisque "Troubles du rythme ventriculaire graves par augmentation de l'excitabilité cardiaque."@fr;
  r:conduiteATenir "Limiter l'apport, par exemple : moins de 0,1 mg d'adrénaline en 10 minutes ou 0,3 mg en 1 heure chez l'adulte."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b202904, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b202898 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b202899 .

_:79f295ad32df4ce8a18a92539c6e8a3b202899 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202900;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b202901 .

_:79f295ad32df4ce8a18a92539c6e8a3b202900 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10002 .

_:79f295ad32df4ce8a18a92539c6e8a3b202901 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202902;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b202902 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10005 .

_:79f295ad32df4ce8a18a92539c6e8a3b202904 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10043-1 a owl:Class;
  rdfs:label "ADRÉNALINE (VOIE BUCCO-DENTAIRE OU SOUS-CUTANÉE) <-> ANESTHÉSIQUES VOLATILS HALOGÉNÉS"@fr;
  dct:identifier "IAM_10043";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b202906;
  r:natureDuRisque "Troubles du rythme ventriculaire graves par augmentation de l'excitabilité cardiaque."@fr;
  r:conduiteATenir "Limiter l'apport, par exemple : moins de 0,1 mg d'adrénaline en 10 minutes ou 0,3 mg en 1 heure chez l'adulte."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b202912, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b202906 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b202907 .

_:79f295ad32df4ce8a18a92539c6e8a3b202907 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202908;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b202909 .

_:79f295ad32df4ce8a18a92539c6e8a3b202908 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10005 .

_:79f295ad32df4ce8a18a92539c6e8a3b202909 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202910;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b202910 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10017 .

_:79f295ad32df4ce8a18a92539c6e8a3b202912 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10035-1 a owl:Class;
  rdfs:label "ACIDE CLODRONIQUE <-> ESTRAMUSTINE"@fr;
  dct:identifier "IAM_10035";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b202914;
  r:natureDuRisque "Risque d’augmentation des concentrations plasmatiques d’estramustine par le clodronate."@fr;
  r:conduiteATenir "Surveillance clinique au cours de l’association."@fr;
  rdfs:comment "Une étude effectuée chez 12 patients ne montre pas de modification significative des paramètres pharmacocinétiques (Cmax, AUC) ou de l’excrétion diurne du clodronate, lorsqu’il est associé à l’estramustine. En revanche, une augmentation de 77% de la Cmax"@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b202920, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b202914 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b202915 .

_:79f295ad32df4ce8a18a92539c6e8a3b202915 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202916;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b202917 .

_:79f295ad32df4ce8a18a92539c6e8a3b202916 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10017 .

_:79f295ad32df4ce8a18a92539c6e8a3b202917 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202918;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b202918 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10345 .

_:79f295ad32df4ce8a18a92539c6e8a3b202920 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10046-1 a owl:Class;
  rdfs:label "ADRÉNALINE (VOIE BUCCO-DENTAIRE OU SOUS-CUTANÉE) <-> MÉDICAMENTS MIXTES ADRÉNERGIQUES-SÉROTONINERGIQUES"@fr;
  dct:identifier "IAM_10046";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b202922;
  r:natureDuRisque "Troubles du rythme ventriculaire graves par augmentation de l'excitabilité cardiaque."@fr;
  r:conduiteATenir "Limiter l'apport, par exemple : moins de 0,1 mg d'adrénaline en 10 minutes ou 0,3 mg en 1 heure chez l'adulte."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b202928, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b202922 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b202923 .

_:79f295ad32df4ce8a18a92539c6e8a3b202923 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202924;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b202925 .

_:79f295ad32df4ce8a18a92539c6e8a3b202924 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10005 .

_:79f295ad32df4ce8a18a92539c6e8a3b202925 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202926;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b202926 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10116 .

_:79f295ad32df4ce8a18a92539c6e8a3b202928 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10034-1 a owl:Class;
  rdfs:label "ACIDE CHOLIQUE <-> PHÉNOBARBITAL (ET, PAR EXTRAPOLATION, PRIMIDONE)"@fr;
  dct:identifier "IAM_10034";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b202930;
  r:natureDuRisque "Effet antagoniste du barbiturique."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b202936, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b202930 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b202931 .

_:79f295ad32df4ce8a18a92539c6e8a3b202931 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202932;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b202933 .

_:79f295ad32df4ce8a18a92539c6e8a3b202932 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10131 .

_:79f295ad32df4ce8a18a92539c6e8a3b202933 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202934;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b202934 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10016 .

_:79f295ad32df4ce8a18a92539c6e8a3b202936 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10048-1 a owl:Class;
  rdfs:label "AFATINIB <-> ANTICONVULSIVANTS INDUCTEURS ENZYMATIQUES"@fr;
  dct:identifier "IAM_10048";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b202938;
  r:natureDuRisque "Diminution des concentrations plasmatiques de l’afatinib par augmentation de son métabolisme par ces substances."@fr;
  r:conduiteATenir "Surveillance clinique pendant l’association et 1 à 2 semaines après leur arrêt."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b202944, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b202938 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b202939 .

_:79f295ad32df4ce8a18a92539c6e8a3b202939 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202940;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b202941 .

_:79f295ad32df4ce8a18a92539c6e8a3b202940 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10029 .

_:79f295ad32df4ce8a18a92539c6e8a3b202941 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202942;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b202942 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10040 .

_:79f295ad32df4ce8a18a92539c6e8a3b202944 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10049-1 a owl:Class;
  rdfs:label "AFATINIB <-> CICLOSPORINE"@fr;
  dct:identifier "IAM_10049";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b202946;
  r:natureDuRisque "Augmentation des concentrations plasmatique d’afatinib par augmentation de son absorption par la ciclosporine."@fr;
  r:conduiteATenir """Il est recommandé d’administrer la ciclosporine le plus à distance possible de l’afatinib, en respectant de préférence un intervalle
 de 6 heures ou de 12 heures par rapport à la prise d’afatinib."""@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b202952, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b202946 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b202947 .

_:79f295ad32df4ce8a18a92539c6e8a3b202947 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202948;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b202949 .

_:79f295ad32df4ce8a18a92539c6e8a3b202948 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10040 .

_:79f295ad32df4ce8a18a92539c6e8a3b202949 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202950;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b202950 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10193 .

_:79f295ad32df4ce8a18a92539c6e8a3b202952 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10050-1 a owl:Class;
  rdfs:label "AFATINIB <-> ERYTHROMYCINE"@fr;
  dct:identifier "IAM_10050";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b202954;
  r:natureDuRisque "Augmentation des concentrations plasmatique d’afatinib par augmentation de son absorption par l'érythromycine."@fr;
  r:conduiteATenir """Il est recommandé d’administrer l'érythromycine le plus à distance possible de l’afatinib, en respectant de préférence un intervalle
 de 6 heures ou de 12 heures par rapport à la prise d’afatinib."""@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b202960, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b202954 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b202955 .

_:79f295ad32df4ce8a18a92539c6e8a3b202955 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202956;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b202957 .

_:79f295ad32df4ce8a18a92539c6e8a3b202956 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10040 .

_:79f295ad32df4ce8a18a92539c6e8a3b202957 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202958;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b202958 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10338 .

_:79f295ad32df4ce8a18a92539c6e8a3b202960 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10051-1 a owl:Class;
  rdfs:label "AFATINIB <-> INHIBITEURS DE PROTÉASES BOOSTÉS PAR RITONAVIR"@fr;
  dct:identifier "IAM_10051";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b202962;
  r:natureDuRisque "Augmentation des concentrations plasmatique d’afatinib par augmentation de son absorption par l'inhibiteur de protéases."@fr;
  r:conduiteATenir "Il est recommandé d’administrer l'inhibiteur de protéases le plus à distance possible de l’afatinib, en respectant de préférence un intervalle de 6 heures ou de 12 heures par rapport à la prise d’afatinib."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b202968, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b202962 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b202963 .

_:79f295ad32df4ce8a18a92539c6e8a3b202963 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202964;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b202965 .

_:79f295ad32df4ce8a18a92539c6e8a3b202964 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10100 .

_:79f295ad32df4ce8a18a92539c6e8a3b202965 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202966;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b202966 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10040 .

_:79f295ad32df4ce8a18a92539c6e8a3b202968 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10052-1 a owl:Class;
  rdfs:label "AFATINIB <-> ITRACONAZOLE"@fr;
  dct:identifier "IAM_10052";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b202970;
  r:natureDuRisque "Augmentation des concentrations plasmatique d’afatinib par augmentation de son absorption par l'itraconazole."@fr;
  r:conduiteATenir """Il est recommandé d’administrer l'itraconazole le plus à distance possible de l’afatinib, en respectant de préférence un intervalle
de 6 heures ou de 12 heures par rapport à la prise d’afatinib."""@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b202976, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b202970 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b202971 .

_:79f295ad32df4ce8a18a92539c6e8a3b202971 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202972;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b202973 .

_:79f295ad32df4ce8a18a92539c6e8a3b202972 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10040 .

_:79f295ad32df4ce8a18a92539c6e8a3b202973 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202974;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b202974 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10496 .

_:79f295ad32df4ce8a18a92539c6e8a3b202976 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10053-1 a owl:Class;
  rdfs:label "AFATINIB <-> KETOCONAZOLE"@fr;
  dct:identifier "IAM_10053";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b202978;
  r:natureDuRisque "Augmentation des concentrations plasmatique d’afatinib par augmentation de son absorption par le kétoconazole."@fr;
  r:conduiteATenir """Il est recommandé d’administrer le kétoconazole le plus à distance possible de l’afatinib, en respectant de préférence un intervalle 
de 6 heures ou de 12 heures par rapport à la prise d’afatinib."""@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b202984, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b202978 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b202979 .

_:79f295ad32df4ce8a18a92539c6e8a3b202979 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202980;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b202981 .

_:79f295ad32df4ce8a18a92539c6e8a3b202980 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10040 .

_:79f295ad32df4ce8a18a92539c6e8a3b202981 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202982;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b202982 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10501 .

_:79f295ad32df4ce8a18a92539c6e8a3b202984 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10054-1 a owl:Class;
  rdfs:label "AFATINIB <-> PRIMIDONE"@fr;
  dct:identifier "IAM_10054";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b202986;
  r:natureDuRisque "Diminution des concentrations plasmatiques de l’afatinib par augmentation de son métabolisme par la primidone."@fr;
  r:conduiteATenir "Surveillance clinique pendant l’association et 1 à 2 semaines après leur arrêt."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b202992, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b202986 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b202987 .

_:79f295ad32df4ce8a18a92539c6e8a3b202987 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202988;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b202989 .

_:79f295ad32df4ce8a18a92539c6e8a3b202988 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10040 .

_:79f295ad32df4ce8a18a92539c6e8a3b202989 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202990;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b202990 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10756 .

_:79f295ad32df4ce8a18a92539c6e8a3b202992 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10055-1 a owl:Class;
  rdfs:label "AFATINIB <-> RIFAMPICINE"@fr;
  dct:identifier "IAM_10055";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b202994;
  r:natureDuRisque "Diminution des concentrations plasmatiques de l’afatinib par augmentation de son métabolisme par la rifampicine."@fr;
  r:conduiteATenir "Surveillance clinique pendant l’association et 1 à 2 semaines après leur arrêt."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b203000, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b202994 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b202995 .

_:79f295ad32df4ce8a18a92539c6e8a3b202995 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202996;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b202997 .

_:79f295ad32df4ce8a18a92539c6e8a3b202996 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10040 .

_:79f295ad32df4ce8a18a92539c6e8a3b202997 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b202998;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b202998 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:79f295ad32df4ce8a18a92539c6e8a3b203000 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10056-1 a owl:Class;
  rdfs:label "AFATINIB <-> VERAPAMIL"@fr;
  dct:identifier "IAM_10056";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b203002;
  r:natureDuRisque "Augmentation des concentrations plasmatique d’afatinib par augmentation de son absorption par le vérapamil."@fr;
  r:conduiteATenir """Il est recommandé d’administrer le vérapamil le plus à distance possible de l’afatinib, en respectant de préférence un intervalle
de 6 heures ou de 12 heures par rapport à la prise d’afatinib."""@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b203008, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b203002 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b203003 .

_:79f295ad32df4ce8a18a92539c6e8a3b203003 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203004;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b203005 .

_:79f295ad32df4ce8a18a92539c6e8a3b203004 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10040 .

_:79f295ad32df4ce8a18a92539c6e8a3b203005 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203006;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b203006 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10980 .

_:79f295ad32df4ce8a18a92539c6e8a3b203008 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10057-1 a owl:Class;
  rdfs:label "AGOMELATINE <-> CIPROFLOXACINE"@fr;
  dct:identifier "IAM_10057";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b203010;
  r:natureDuRisque """Augmentation des concentrations d'agomélatine, avec risque de 
majoration des effets indésirables."""@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b203016, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b203010 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b203011 .

_:79f295ad32df4ce8a18a92539c6e8a3b203011 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203012;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b203013 .

_:79f295ad32df4ce8a18a92539c6e8a3b203012 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10041 .

_:79f295ad32df4ce8a18a92539c6e8a3b203013 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203014;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b203014 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10200 .

_:79f295ad32df4ce8a18a92539c6e8a3b203016 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10044-1 a owl:Class;
  rdfs:label "ADRÉNALINE (VOIE BUCCO-DENTAIRE OU SOUS-CUTANÉE) <-> ANTIDÉPRESSEURS IMIPRAMINIQUES"@fr;
  dct:identifier "IAM_10044";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b203018;
  r:natureDuRisque "Troubles du rythme ventriculaire graves par augmentation de l'excitabilité cardiaque."@fr;
  r:conduiteATenir "Limiter l'apport, par exemple : moins de 0,1 mg d'adrénaline en 10 minutes ou 0,3 mg en 1 heure chez l'adulte."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b203024, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b203018 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b203019 .

_:79f295ad32df4ce8a18a92539c6e8a3b203019 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203020;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b203021 .

_:79f295ad32df4ce8a18a92539c6e8a3b203020 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10005 .

_:79f295ad32df4ce8a18a92539c6e8a3b203021 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203022;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b203022 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10032 .

_:79f295ad32df4ce8a18a92539c6e8a3b203024 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10023-1 a owl:Class;
  rdfs:label "ACIDE ACETYLSALICYLIQUE <-> HÉPARINES NON FRACTIONNÉES (DOSES CURATIVES ET/OU SUJET ÂGÉ)"@fr;
  dct:identifier "IAM_10023";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b203026;
  r:natureDuRisque "Augmentation du risque hémorragique (inhibition de la fonction plaquettaire et agression de la muqueuse gastroduodénale par l’acide acétylsalicylique)."@fr;
  r:conduiteATenir """A prendre en compte avec :
- des doses antiagrégantes (de 50 mg à 375 mg par jour)."""@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b203032, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b203026 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b203027 .

_:79f295ad32df4ce8a18a92539c6e8a3b203027 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203028;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b203029 .

_:79f295ad32df4ce8a18a92539c6e8a3b203028 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10091 .

_:79f295ad32df4ce8a18a92539c6e8a3b203029 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203030;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b203030 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10012 .

_:79f295ad32df4ce8a18a92539c6e8a3b203032 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10205-1 a owl:Class;
  rdfs:label "ANTICOAGULANTS ORAUX <-> INHIBITEURS SÉLECTIFS DE LA RECAPTURE DE LA SÉROTONINE"@fr;
  dct:identifier "IAM_10205";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b203034;
  r:natureDuRisque "Augmentation du risque hémorragique."@fr;
  r:conduiteATenir "Surveillance clinique et, le cas échéant, contrôle plus fréquent de l'INR. Adaptation éventuelle de la posologie de l'anticoagulant oral pendant la durée de l'association et à son arrêt."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b203040, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b203034 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b203035 .

_:79f295ad32df4ce8a18a92539c6e8a3b203035 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203036;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b203037 .

_:79f295ad32df4ce8a18a92539c6e8a3b203036 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10028 .

_:79f295ad32df4ce8a18a92539c6e8a3b203037 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203038;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b203038 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10104 .

_:79f295ad32df4ce8a18a92539c6e8a3b203040 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10114-1 a owl:Class;
  rdfs:label "AMINOSIDES <-> BOTULIQUE (TOXINE)"@fr;
  dct:identifier "IAM_10114";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b203042;
  r:natureDuRisque "Risque d'augmentation des effets de la toxine botulique avec les aminosides (par extrapolation à partir des effets observés au cours du botulisme)."@fr;
  r:conduiteATenir "Utiliser un autre antibiotique."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b203048, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b203042 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b203043 .

_:79f295ad32df4ce8a18a92539c6e8a3b203043 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203044;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b203045 .

_:79f295ad32df4ce8a18a92539c6e8a3b203044 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10011 .

_:79f295ad32df4ce8a18a92539c6e8a3b203045 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203046;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b203046 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10131 .

_:79f295ad32df4ce8a18a92539c6e8a3b203048 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10014-1 a owl:Class;
  rdfs:label "ACIDE ACETYLSALICYLIQUE <-> ANTAGONISTES DES RÉCEPTEURS DE L'ANGIOTENSINE II"@fr;
  dct:identifier "IAM_10014";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b203050;
  r:natureDuRisque """Pour des doses anti-inflammatoires d'acide acétylsalicylique (>= 1g par prise et/ou >= 3g par jour) ou pour des doses antalgiques ou antipyrétiques (>= 500 mg par prise et/ou < 3g par jour) : 

Insuffisance rénale aiguë chez le malade déshydraté, par dimi"""@fr;
  r:conduiteATenir "Hydrater le malade et surveiller la fonction rénale en début de traitement."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b203056, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b203050 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b203051 .

_:79f295ad32df4ce8a18a92539c6e8a3b203051 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203052;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b203053 .

_:79f295ad32df4ce8a18a92539c6e8a3b203052 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10020 .

_:79f295ad32df4ce8a18a92539c6e8a3b203053 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203054;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b203054 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10012 .

_:79f295ad32df4ce8a18a92539c6e8a3b203056 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10015-1 a owl:Class;
  rdfs:label "ACIDE ACETYLSALICYLIQUE <-> ANTICOAGULANTS ORAUX"@fr;
  dct:identifier "IAM_10015";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b203058;
  r:natureDuRisque "Majoration du risque hémorragique, notamment en cas d’antécédent d’ulcère gastro-duodénal."@fr;
  r:conduiteATenir """A prendre en compte avec :
- des doses antiagrégantes (de 50 mg à 375 mg par jour)"""@fr;
  rdfs:comment "Jusqu'à présent, cette interaction se présentait selon deux niveaux distincts : une contre-indication avec l'acide acétylsalicylique administré à doses anti-inflammatoires et une association déconseillée avec l'aspirine donnée à doses antalgiques ou anti"@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b203064, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b203058 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b203059 .

_:79f295ad32df4ce8a18a92539c6e8a3b203059 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203060;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b203061 .

_:79f295ad32df4ce8a18a92539c6e8a3b203060 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10028 .

_:79f295ad32df4ce8a18a92539c6e8a3b203061 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203062;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b203062 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10012 .

_:79f295ad32df4ce8a18a92539c6e8a3b203064 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10016-1 a owl:Class;
  rdfs:label "ACIDE ACETYLSALICYLIQUE <-> ANTI-INFLAMMATOIRES NON STÉROÏDIENS"@fr;
  dct:identifier "IAM_10016";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b203066;
  r:natureDuRisque "Majoration du risque ulcérogène et hémorragique digestif."@fr;
  r:conduiteATenir """A prendre en compte avec :
- des doses antiagrégantes (de 50 mg à 375 mg par jour en 1 ou plusieurs prises)"""@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b203072, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b203066 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b203067 .

_:79f295ad32df4ce8a18a92539c6e8a3b203067 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203068;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b203069 .

_:79f295ad32df4ce8a18a92539c6e8a3b203068 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10022 .

_:79f295ad32df4ce8a18a92539c6e8a3b203069 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203070;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b203070 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10012 .

_:79f295ad32df4ce8a18a92539c6e8a3b203072 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10017-1 a owl:Class;
  rdfs:label "ACIDE ACETYLSALICYLIQUE <-> CLOPIDOGREL"@fr;
  dct:identifier "IAM_10017";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b203074;
  r:natureDuRisque "Majoration du risque hémorragique par addition des activités antiagrégantes plaquettaires."@fr;
  r:conduiteATenir """Association déconseillée :
- en dehors des indications validées pour cette association dans les syndromes coronariens aigus.

Précaution d'emploi :
- dans les indications validées pour cette association dans les syndromes coronariens aigus. Surveillance c"""@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b203080, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b203074 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b203075 .

_:79f295ad32df4ce8a18a92539c6e8a3b203075 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203076;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b203077 .

_:79f295ad32df4ce8a18a92539c6e8a3b203076 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10012 .

_:79f295ad32df4ce8a18a92539c6e8a3b203077 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203078;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b203078 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10216 .

_:79f295ad32df4ce8a18a92539c6e8a3b203080 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10018-1 a owl:Class;
  rdfs:label "ACIDE ACETYLSALICYLIQUE <-> DEFERASIROX"@fr;
  dct:identifier "IAM_10018";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b203082;
  r:natureDuRisque "Majoration du risque ulcérogène et hémorragique digestif."@fr;
  r:conduiteATenir """A prendre en compte :
- Pour des doses anti-inflammatoires d'acide acétylsalicylique (1g par prise et/ou 3g par jour)
- Pour des doses antalgiques ou antipyrétiques d'acide acétylsalicylique (500 mg par prise et/ou <3g par jour) et (500 mg par prise e"""@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b203088, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b203082 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b203083 .

_:79f295ad32df4ce8a18a92539c6e8a3b203083 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203084;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b203085 .

_:79f295ad32df4ce8a18a92539c6e8a3b203084 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10012 .

_:79f295ad32df4ce8a18a92539c6e8a3b203085 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203086;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b203086 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10259 .

_:79f295ad32df4ce8a18a92539c6e8a3b203088 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10019-1 a owl:Class;
  rdfs:label "ACIDE ACETYLSALICYLIQUE <-> DIURÉTIQUES"@fr;
  dct:identifier "IAM_10019";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b203090;
  r:natureDuRisque """Pour des doses anti-inflammatoires d'acide acétylsalicylique (>= 1g par prise et/ou >= 3g par jour) ou pour des doses antalgiques ou antipyrétiques (>= 500 mg par prise et/ou < 3g par jour) : 

Insuffisance rénale aiguë chez le malade déshydraté, par dimi"""@fr;
  r:conduiteATenir "Hydrater le malade et surveiller la fonction rénale en début de traitement."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b203096, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b203090 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b203091 .

_:79f295ad32df4ce8a18a92539c6e8a3b203091 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203092;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b203093 .

_:79f295ad32df4ce8a18a92539c6e8a3b203092 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10063 .

_:79f295ad32df4ce8a18a92539c6e8a3b203093 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203094;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b203094 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10012 .

_:79f295ad32df4ce8a18a92539c6e8a3b203096 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10020-1 a owl:Class;
  rdfs:label "ACIDE ACETYLSALICYLIQUE <-> GLUCOCORTICOÏDES (SAUF HYDROCORTISONE)"@fr;
  dct:identifier "IAM_10020";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b203098;
  r:natureDuRisque "Majoration du risque hémorragique."@fr;
  r:conduiteATenir """Association déconseillée avec :
- des doses anti-inflammatoires d'acide acétylsalicylique (>=1g par prise et/ou >=3g par jour)

A prendre en compte avec :
- des doses antalgiques ou antipyrétiques (>=500 mg par prise et/ou <3g par jour)."""@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b203104, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b203098 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b203099 .

_:79f295ad32df4ce8a18a92539c6e8a3b203099 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203100;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b203101 .

_:79f295ad32df4ce8a18a92539c6e8a3b203100 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10081 .

_:79f295ad32df4ce8a18a92539c6e8a3b203101 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203102;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b203102 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10012 .

_:79f295ad32df4ce8a18a92539c6e8a3b203104 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10036-1 a owl:Class;
  rdfs:label "ACIDE FOLINIQUE <-> FLUOROURACILE (ET, PAR EXTRAPOLATION, AUTRES FLUOROPYRIMIDINES)"@fr;
  dct:identifier "IAM_10036";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b203106;
  r:natureDuRisque "Potentialisation des effets, à la fois cytostatiques et indésirables, du fluoro-uracile."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b203112, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b203106 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b203107 .

_:79f295ad32df4ce8a18a92539c6e8a3b203107 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203108;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b203109 .

_:79f295ad32df4ce8a18a92539c6e8a3b203108 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10076 .

_:79f295ad32df4ce8a18a92539c6e8a3b203109 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203110;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b203110 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10019 .

_:79f295ad32df4ce8a18a92539c6e8a3b203112 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10022-1 a owl:Class;
  rdfs:label "ACIDE ACETYLSALICYLIQUE <-> HÉPARINES DE BAS POIDS MOLÉCULAIRE ET APPARENTÉS (DOSES PRÉVENTIVES)"@fr;
  dct:identifier "IAM_10022";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b203114;
  r:natureDuRisque "L’utilisation conjointe de médicaments agissant à divers niveaux de l’hémostase majore le risque de saignement. Ainsi, chez le sujet de moins de 65 ans, l’association de l'héparine à doses préventives, ou de substances apparentées, à l’acide acétylsalicyl"@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b203120, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b203114 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b203115 .

_:79f295ad32df4ce8a18a92539c6e8a3b203115 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203116;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b203117 .

_:79f295ad32df4ce8a18a92539c6e8a3b203116 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10090 .

_:79f295ad32df4ce8a18a92539c6e8a3b203117 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203118;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b203118 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10012 .

_:79f295ad32df4ce8a18a92539c6e8a3b203120 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10111-1 a owl:Class;
  rdfs:label "AMINOSIDES <-> AMPHOTERICINE B"@fr;
  dct:identifier "IAM_10111";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b203122;
  r:natureDuRisque "Avec l'amphotéricine B administrée par voie IV : risque accru de néphrotoxicité."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b203128, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b203122 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b203123 .

_:79f295ad32df4ce8a18a92539c6e8a3b203123 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203124;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b203125 .

_:79f295ad32df4ce8a18a92539c6e8a3b203124 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10011 .

_:79f295ad32df4ce8a18a92539c6e8a3b203125 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203126;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b203126 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10072 .

_:79f295ad32df4ce8a18a92539c6e8a3b203128 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10024-1 a owl:Class;
  rdfs:label "ACIDE ACETYLSALICYLIQUE <-> HÉPARINES NON FRACTIONNÉES (DOSES PRÉVENTIVES)"@fr;
  dct:identifier "IAM_10024";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b203130;
  r:natureDuRisque "L’utilisation conjointe de médicaments agissant à divers niveaux de l’hémostase majore le risque de saignement. Ainsi, chez le sujet de moins de 65 ans, l’association des héparines à doses préventives à l’acide acétylsalicylique, quelle que soit la dose,"@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b203136, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b203130 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b203131 .

_:79f295ad32df4ce8a18a92539c6e8a3b203131 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203132;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b203133 .

_:79f295ad32df4ce8a18a92539c6e8a3b203132 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10092 .

_:79f295ad32df4ce8a18a92539c6e8a3b203133 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203134;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b203134 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10012 .

_:79f295ad32df4ce8a18a92539c6e8a3b203136 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10025-1 a owl:Class;
  rdfs:label "ACIDE ACETYLSALICYLIQUE <-> INHIBITEURS DE L'ENZYME DE CONVERSION"@fr;
  dct:identifier "IAM_10025";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b203138;
  r:natureDuRisque """Pour des doses anti-inflammatoires d'acide acétylsalicylique (>= 1g par prise et/ou >= 3g par jour) ou pour des doses antalgiques ou antipyrétiques (>= 500 mg par prise et/ou < 3g par jour) : 

Insuffisance rénale aiguë chez le malade déshydraté, par dim"""@fr;
  r:conduiteATenir "Hydrater le malade et surveiller la fonction rénale en début de traitement."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b203144, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b203138 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b203139 .

_:79f295ad32df4ce8a18a92539c6e8a3b203139 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203140;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b203141 .

_:79f295ad32df4ce8a18a92539c6e8a3b203140 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10096 .

_:79f295ad32df4ce8a18a92539c6e8a3b203141 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203142;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b203142 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10012 .

_:79f295ad32df4ce8a18a92539c6e8a3b203144 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10026-1 a owl:Class;
  rdfs:label "ACIDE ACETYLSALICYLIQUE <-> INHIBITEURS SÉLECTIFS DE LA RECAPTURE DE LA SÉROTONINE"@fr;
  dct:identifier "IAM_10026";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b203146;
  r:natureDuRisque "Majoration du risque hémorragique."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b203152, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b203146 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b203147 .

_:79f295ad32df4ce8a18a92539c6e8a3b203147 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203148;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b203149 .

_:79f295ad32df4ce8a18a92539c6e8a3b203148 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10104 .

_:79f295ad32df4ce8a18a92539c6e8a3b203149 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203150;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b203150 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10012 .

_:79f295ad32df4ce8a18a92539c6e8a3b203152 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10027-1 a owl:Class;
  rdfs:label "ACIDE ACETYLSALICYLIQUE <-> METHOTREXATE"@fr;
  dct:identifier "IAM_10027";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b203154;
  r:natureDuRisque "Majoration de la toxicité, notamment hématologique, du méthotrexate (diminution de sa clairance rénale par l'acide acétylsalicylique)."@fr;
  r:conduiteATenir """Avec le méthotrexate utilisé à des doses > 20 mg/semaine : 
- contre-indication avec l'acide acétylsalicylique utilisé à doses antalgiques, antipyrétiques ou anti-inflammatoires
- précaution d'emploi avec des doses antiagrégantes plaquettaires d'acide acé"""@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b203160, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b203154 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b203155 .

_:79f295ad32df4ce8a18a92539c6e8a3b203155 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203156;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b203157 .

_:79f295ad32df4ce8a18a92539c6e8a3b203156 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10012 .

_:79f295ad32df4ce8a18a92539c6e8a3b203157 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203158;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b203158 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10569 .

_:79f295ad32df4ce8a18a92539c6e8a3b203160 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10028-1 a owl:Class;
  rdfs:label "ACIDE ACETYLSALICYLIQUE <-> PEMETREXED"@fr;
  dct:identifier "IAM_10028";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b203162;
  r:natureDuRisque "Risque de majoration de la toxicité du pemetrexed (diminution de sa clairance rénale par l’acide acétylsalicylique à doses anti-inflammatoires)."@fr;
  r:conduiteATenir """Association déconseillée : 
- en cas de fonction rénale faible à modérée .

Précaution d'emploi :
- en cas de fonction rénale normale. Surveillance biologique de la fonction rénale."""@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b203168, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b203162 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b203163 .

_:79f295ad32df4ce8a18a92539c6e8a3b203163 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203164;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b203165 .

_:79f295ad32df4ce8a18a92539c6e8a3b203164 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10012 .

_:79f295ad32df4ce8a18a92539c6e8a3b203165 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203166;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b203166 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10700 .

_:79f295ad32df4ce8a18a92539c6e8a3b203168 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10029-1 a owl:Class;
  rdfs:label "ACIDE ACETYLSALICYLIQUE <-> PROBENECIDE"@fr;
  dct:identifier "IAM_10029";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b203170;
  r:natureDuRisque "Diminution de l’effet uricosurique par compétition de l’élimination de l’acide urique au niveau des tubules rénaux."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b203176, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b203170 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b203171 .

_:79f295ad32df4ce8a18a92539c6e8a3b203171 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203172;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b203173 .

_:79f295ad32df4ce8a18a92539c6e8a3b203172 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10012 .

_:79f295ad32df4ce8a18a92539c6e8a3b203173 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203174;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b203174 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10758 .

_:79f295ad32df4ce8a18a92539c6e8a3b203176 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10030-1 a owl:Class;
  rdfs:label "ACIDE ACETYLSALICYLIQUE <-> THROMBOLYTIQUES"@fr;
  dct:identifier "IAM_10030";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b203178;
  r:natureDuRisque "Augmentation du risque hémorragique."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b203184, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b203178 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b203179 .

_:79f295ad32df4ce8a18a92539c6e8a3b203179 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203180;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b203181 .

_:79f295ad32df4ce8a18a92539c6e8a3b203180 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10151 .

_:79f295ad32df4ce8a18a92539c6e8a3b203181 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203182;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b203182 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10012 .

_:79f295ad32df4ce8a18a92539c6e8a3b203184 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10031-1 a owl:Class;
  rdfs:label "ACIDE ACETYLSALICYLIQUE <-> TICAGRELOR"@fr;
  dct:identifier "IAM_10031";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b203186;
  r:natureDuRisque """Majoration du risque hémorragique par addition des activités
antiagrégantes plaquettaires."""@fr;
  r:conduiteATenir """Association déconseillée :
- en dehors des indications validées pour cette association dans les syndromes coronariens aigus.

Précaution d'emploi :
- dans les indications validées pour cette association dans les syndromes coronariens aigus. Surveillance c"""@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b203192, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b203186 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b203187 .

_:79f295ad32df4ce8a18a92539c6e8a3b203187 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203188;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b203189 .

_:79f295ad32df4ce8a18a92539c6e8a3b203188 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10012 .

_:79f295ad32df4ce8a18a92539c6e8a3b203189 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203190;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b203190 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10926 .

_:79f295ad32df4ce8a18a92539c6e8a3b203192 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10032-1 a owl:Class;
  rdfs:label "ACIDE ACETYLSALICYLIQUE <-> TICLOPIDINE"@fr;
  dct:identifier "IAM_10032";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b203194;
  r:natureDuRisque "Majoration du risque hémorragique par addition des activités antiagrégantes plaquettaires."@fr;
  r:conduiteATenir "Si l’association ne peut être évitée, surveillance clinique étroite."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b203200, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b203194 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b203195 .

_:79f295ad32df4ce8a18a92539c6e8a3b203195 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203196;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b203197 .

_:79f295ad32df4ce8a18a92539c6e8a3b203196 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10012 .

_:79f295ad32df4ce8a18a92539c6e8a3b203197 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203198;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b203198 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10928 .

_:79f295ad32df4ce8a18a92539c6e8a3b203200 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10033-1 a owl:Class;
  rdfs:label "ACIDE ASCORBIQUE <-> DÉFÉROXAMINE"@fr;
  dct:identifier "IAM_10033";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b203202;
  r:natureDuRisque "Avec l'acide ascorbique à fortes doses et par voie IV : anomalies de la fonction cardiaque, voire insuffisance cardiaque aiguë (en général réversible à l'arrêt de la vitamine C)."@fr;
  r:conduiteATenir "En cas d'hémochromatose, ne donner de la vitamine C qu'après avoir commencé le traitement par la déféroxamine. Surveiller la fonction cardiaque en cas d'association."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b203208, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b203202 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b203203 .

_:79f295ad32df4ce8a18a92539c6e8a3b203203 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203204;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b203205 .

_:79f295ad32df4ce8a18a92539c6e8a3b203204 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10015 .

_:79f295ad32df4ce8a18a92539c6e8a3b203205 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203206;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b203206 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10261 .

_:79f295ad32df4ce8a18a92539c6e8a3b203208 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10021-1 a owl:Class;
  rdfs:label "ACIDE ACETYLSALICYLIQUE <-> HÉPARINES DE BAS POIDS MOLÉCULAIRE ET APPARENTÉS (DOSES CURATIVES ET/OU SUJET ÂGÉ)"@fr;
  dct:identifier "IAM_10021";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b203210;
  r:natureDuRisque "Augmentation du risque hémorragique (inhibition de la fonction plaquettaire et agression de la muqueuse gastroduodénale par l’acide acétylsalicylique."@fr;
  r:conduiteATenir """A prendre en compte avec :
- des doses antiagrégantes (de 50 mg à 375 mg par jour)."""@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b203216, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b203210 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b203211 .

_:79f295ad32df4ce8a18a92539c6e8a3b203211 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203212;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b203213 .

_:79f295ad32df4ce8a18a92539c6e8a3b203212 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10089 .

_:79f295ad32df4ce8a18a92539c6e8a3b203213 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203214;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b203214 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10012 .

_:79f295ad32df4ce8a18a92539c6e8a3b203216 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10245-1 a owl:Class;
  rdfs:label "ANTICONVULSIVANTS INDUCTEURS ENZYMATIQUES <-> TELITHROMYCINE"@fr;
  dct:identifier "IAM_10245";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b203218;
  r:natureDuRisque "Diminution des concentrations plasmatiques de la télithromycine, avec risque d'échec du traitement anti-infectieux, par augmentation de son métabolisme hépatique par l'inducteur."@fr;
  rdfs:comment "Compte tenu de la baisse très importante (80%) des concentrations de télithromycine en présence de rifampicine, l'interaction a été extrapolée aux autres inducteurs enzymatiques puissants, le phénobarbital, la primidone, la phénytoïne et la carbamazépine,"@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b203224, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b203218 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b203219 .

_:79f295ad32df4ce8a18a92539c6e8a3b203219 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203220;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b203221 .

_:79f295ad32df4ce8a18a92539c6e8a3b203220 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10029 .

_:79f295ad32df4ce8a18a92539c6e8a3b203221 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203222;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b203222 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10889 .

_:79f295ad32df4ce8a18a92539c6e8a3b203224 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10232-1 a owl:Class;
  rdfs:label "ANTICONVULSIVANTS INDUCTEURS ENZYMATIQUES <-> MONTELUKAST"@fr;
  dct:identifier "IAM_10232";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b203226;
  r:natureDuRisque "Risque de baisse de l'efficacité du montélukast par augmentation de son métabolisme hépatique par l'inducteur."@fr;
  r:conduiteATenir "Surveillance clinique et adaptation éventuelle de la posologie de l'anti-asthmatique pendant le traitement par l'inducteur et après son arrêt."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b203232, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b203226 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b203227 .

_:79f295ad32df4ce8a18a92539c6e8a3b203227 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203228;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b203229 .

_:79f295ad32df4ce8a18a92539c6e8a3b203228 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10029 .

_:79f295ad32df4ce8a18a92539c6e8a3b203229 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203230;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b203230 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10604 .

_:79f295ad32df4ce8a18a92539c6e8a3b203232 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10233-1 a owl:Class;
  rdfs:label "ANTICONVULSIVANTS INDUCTEURS ENZYMATIQUES <-> NIMODIPINE"@fr;
  dct:identifier "IAM_10233";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b203234;
  r:natureDuRisque "Diminution des concentrations plasmatiques de l'antagoniste du calcium par augmentation de son métabolisme hépatique par l'inducteur."@fr;
  r:conduiteATenir "Surveillance clinique et adaptation éventuelle de la posologie de l'antagoniste du calcium pendant le traitement par l'inducteur et après son arrêt."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b203240, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b203234 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b203235 .

_:79f295ad32df4ce8a18a92539c6e8a3b203235 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203236;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b203237 .

_:79f295ad32df4ce8a18a92539c6e8a3b203236 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10029 .

_:79f295ad32df4ce8a18a92539c6e8a3b203237 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203238;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b203238 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10636 .

_:79f295ad32df4ce8a18a92539c6e8a3b203240 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10234-1 a owl:Class;
  rdfs:label "ANTICONVULSIVANTS INDUCTEURS ENZYMATIQUES <-> PÉRAMPANEL"@fr;
  dct:identifier "IAM_10234";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b203242;
  r:natureDuRisque "Diminution importante (jusqu’aux deux-tiers) des concentrations de pérampanel."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b203248, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b203242 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b203243 .

_:79f295ad32df4ce8a18a92539c6e8a3b203243 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203244;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b203245 .

_:79f295ad32df4ce8a18a92539c6e8a3b203244 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10029 .

_:79f295ad32df4ce8a18a92539c6e8a3b203245 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203246;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b203246 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10706 .

_:79f295ad32df4ce8a18a92539c6e8a3b203248 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10235-1 a owl:Class;
  rdfs:label "ANTICONVULSIVANTS INDUCTEURS ENZYMATIQUES <-> POSACONAZOLE"@fr;
  dct:identifier "IAM_10235";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b203250;
  r:natureDuRisque "Diminution des concentrations plasmatiques et de l'efficacité du posaconazole."@fr;
  r:conduiteATenir "Surveillance clinique. Si possible, dosages plasmatiques du posaconazole et adaptation éventuelle de sa posologie."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b203256, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b203250 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b203251 .

_:79f295ad32df4ce8a18a92539c6e8a3b203251 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203252;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b203253 .

_:79f295ad32df4ce8a18a92539c6e8a3b203252 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10029 .

_:79f295ad32df4ce8a18a92539c6e8a3b203253 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203254;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b203254 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10741 .

_:79f295ad32df4ce8a18a92539c6e8a3b203256 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10236-1 a owl:Class;
  rdfs:label "ANTICONVULSIVANTS INDUCTEURS ENZYMATIQUES <-> PRAZIQUANTEL"@fr;
  dct:identifier "IAM_10236";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b203258;
  r:natureDuRisque "Diminution très importante des concentrations plasmatiques du praziquantel, avec risque d'échec du traitement, par augmentation de son métabolisme hépatique par l'inducteur."@fr;
  rdfs:comment "La mesure des concentrations du praziquantel chez des patients traités par anticonvulsivants inducteurs enzymatiques, suggère que l'effet inducteur du phénobarbital, de la phénytoine ou de la carbamazépine retentit de façon importante sur le métabolisme d"@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b203264, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b203258 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b203259 .

_:79f295ad32df4ce8a18a92539c6e8a3b203259 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203260;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b203261 .

_:79f295ad32df4ce8a18a92539c6e8a3b203260 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10029 .

_:79f295ad32df4ce8a18a92539c6e8a3b203261 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203262;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b203262 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10750 .

_:79f295ad32df4ce8a18a92539c6e8a3b203264 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10238-1 a owl:Class;
  rdfs:label "ANTICONVULSIVANTS INDUCTEURS ENZYMATIQUES <-> PROPAFENONE"@fr;
  dct:identifier "IAM_10238";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b203266;
  r:natureDuRisque "Diminution des concentrations plasmatiques de la propafénone par augmentation de son métabolisme hépatique par l'inducteur."@fr;
  r:conduiteATenir "Surveillance clinique et ECG. S'il y a lieu, adaptation de la posologie de la propafénone pendant l'association et après l'arrêt de l'inducteur."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b203272, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b203266 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b203267 .

_:79f295ad32df4ce8a18a92539c6e8a3b203267 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203268;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b203269 .

_:79f295ad32df4ce8a18a92539c6e8a3b203268 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10029 .

_:79f295ad32df4ce8a18a92539c6e8a3b203269 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203270;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b203270 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10765 .

_:79f295ad32df4ce8a18a92539c6e8a3b203272 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10239-1 a owl:Class;
  rdfs:label "ANTICONVULSIVANTS INDUCTEURS ENZYMATIQUES <-> QUETIAPINE"@fr;
  dct:identifier "IAM_10239";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b203274;
  r:natureDuRisque "Diminution très importante des concentrations plasmatiques de quétiapine par augmentation de son métabolisme hépatique par l'inducteur, avec risque d’inefficacité."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b203280, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b203274 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b203275 .

_:79f295ad32df4ce8a18a92539c6e8a3b203275 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203276;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b203277 .

_:79f295ad32df4ce8a18a92539c6e8a3b203276 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10029 .

_:79f295ad32df4ce8a18a92539c6e8a3b203277 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203278;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b203278 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10773 .

_:79f295ad32df4ce8a18a92539c6e8a3b203280 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10240-1 a owl:Class;
  rdfs:label "ANTICONVULSIVANTS INDUCTEURS ENZYMATIQUES <-> QUININE"@fr;
  dct:identifier "IAM_10240";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b203282;
  r:natureDuRisque "Risque de perte de l’efficacité de la quinine par augmentation de son métabolisme hépatique par l’inducteur."@fr;
  r:conduiteATenir "Surveillance clinique et adaptation de la posologie de la quinine pendant le traitement par l’inducteur et après son arrêt."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b203288, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b203282 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b203283 .

_:79f295ad32df4ce8a18a92539c6e8a3b203283 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203284;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b203285 .

_:79f295ad32df4ce8a18a92539c6e8a3b203284 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10029 .

_:79f295ad32df4ce8a18a92539c6e8a3b203285 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203286;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b203286 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10777 .

_:79f295ad32df4ce8a18a92539c6e8a3b203288 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10241-1 a owl:Class;
  rdfs:label "ANTICONVULSIVANTS INDUCTEURS ENZYMATIQUES <-> RANOLAZINE"@fr;
  dct:identifier "IAM_10241";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b203290;
  r:natureDuRisque "Risque de diminution importante des concentrations de ranolazine."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b203296, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b203290 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b203291 .

_:79f295ad32df4ce8a18a92539c6e8a3b203291 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203292;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b203293 .

_:79f295ad32df4ce8a18a92539c6e8a3b203292 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10029 .

_:79f295ad32df4ce8a18a92539c6e8a3b203293 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203294;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b203294 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10786 .

_:79f295ad32df4ce8a18a92539c6e8a3b203296 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10196-1 a owl:Class;
  rdfs:label "ANTIARYTHMIQUES CLASSE IA <-> ESMOLOL"@fr;
  dct:identifier "IAM_10196";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b203298;
  r:natureDuRisque "Troubles de la contractilité, de l'automatisme et de la conduction (suppression des mécanismes sympathiques compensateurs)."@fr;
  r:conduiteATenir "Surveillance clinique et ECG."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b203304, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b203298 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b203299 .

_:79f295ad32df4ce8a18a92539c6e8a3b203299 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203300;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b203301 .

_:79f295ad32df4ce8a18a92539c6e8a3b203300 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10026 .

_:79f295ad32df4ce8a18a92539c6e8a3b203301 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203302;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b203302 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10341 .

_:79f295ad32df4ce8a18a92539c6e8a3b203304 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10243-1 a owl:Class;
  rdfs:label "ANTICONVULSIVANTS INDUCTEURS ENZYMATIQUES <-> STIRIPENTOL"@fr;
  dct:identifier "IAM_10243";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b203306;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de l'anticonvulsivant, avec risque de surdosage, par inhibition de son métabolisme hépatique par le stiripentol."@fr;
  r:conduiteATenir "Surveillance clinique et dosage plasmatique, lorsque cela est possible, de l'anticonvulsivant associé au stiripentol et adaptation éventuelle de sa posologie."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b203312, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b203306 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b203307 .

_:79f295ad32df4ce8a18a92539c6e8a3b203307 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203308;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b203309 .

_:79f295ad32df4ce8a18a92539c6e8a3b203308 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10029 .

_:79f295ad32df4ce8a18a92539c6e8a3b203309 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203310;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b203310 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10859 .

_:79f295ad32df4ce8a18a92539c6e8a3b203312 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11010-1 a owl:Class;
  rdfs:label "HALOPERIDOL <-> RIFAMPICINE"@fr;
  dct:identifier "IAM_11010";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b203314;
  r:natureDuRisque "Risque de diminution des concentrations plasmatiques de l'halopéridol et de son efficacité thérapeutique, par augmentation de son métabolisme hépatique par la rifampicine."@fr;
  r:conduiteATenir "Surveillance clinique et, si besoin, adaptation posologique pendant le traitement par la rifampicine et après son arrêt."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b203320, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b203314 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b203315 .

_:79f295ad32df4ce8a18a92539c6e8a3b203315 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203316;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b203317 .

_:79f295ad32df4ce8a18a92539c6e8a3b203316 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10426 .

_:79f295ad32df4ce8a18a92539c6e8a3b203317 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203318;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b203318 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:79f295ad32df4ce8a18a92539c6e8a3b203320 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10246-1 a owl:Class;
  rdfs:label "ANTICONVULSIVANTS INDUCTEURS ENZYMATIQUES <-> THÉOPHYLLINE (ET, PAR EXTRAPOLATION, AMINOPHYLLINE)"@fr;
  dct:identifier "IAM_10246";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b203322;
  r:natureDuRisque "Diminution des concentrations plasmatiques et de l'efficacité de la théophylline par augmentation de son métabolisme hépatique par l'inducteur."@fr;
  r:conduiteATenir "Surveillance clinique et, si besoin, de la théophyllinémie. Adaptation éventuelle de la posologie de la théophylline pendant le traitement par l'inducteur et après son arrêt."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b203328, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b203322 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b203323 .

_:79f295ad32df4ce8a18a92539c6e8a3b203323 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203324;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b203325 .

_:79f295ad32df4ce8a18a92539c6e8a3b203324 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10029 .

_:79f295ad32df4ce8a18a92539c6e8a3b203325 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203326;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b203326 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10152 .

_:79f295ad32df4ce8a18a92539c6e8a3b203328 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10247-1 a owl:Class;
  rdfs:label "ANTICONVULSIVANTS INDUCTEURS ENZYMATIQUES <-> TIAGABINE"@fr;
  dct:identifier "IAM_10247";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b203330;
  r:natureDuRisque "Diminution des concentrations plasmatiques de la tiagabine par augmentation de son métabolisme hépatique par l'inducteur."@fr;
  r:conduiteATenir "Une augmentation de la posologie de tiagabine peut s'avérer nécessaire en cas d'association à un anticonvulsivant inducteur enzymatique."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b203336, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b203330 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b203331 .

_:79f295ad32df4ce8a18a92539c6e8a3b203331 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203332;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b203333 .

_:79f295ad32df4ce8a18a92539c6e8a3b203332 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10029 .

_:79f295ad32df4ce8a18a92539c6e8a3b203333 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203334;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b203334 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10922 .

_:79f295ad32df4ce8a18a92539c6e8a3b203336 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10248-1 a owl:Class;
  rdfs:label "ANTICONVULSIVANTS INDUCTEURS ENZYMATIQUES <-> TICAGRELOR"@fr;
  dct:identifier "IAM_10248";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b203338;
  r:natureDuRisque "Diminution importante des concentrations plasmatiques de ticagrelor par augmentation de son métabolisme hépatique par l'anticonvulsivant inducteur enzymatique, avec risque de diminution de l’effet thérapeutique."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b203344, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b203338 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b203339 .

_:79f295ad32df4ce8a18a92539c6e8a3b203339 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203340;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b203341 .

_:79f295ad32df4ce8a18a92539c6e8a3b203340 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10029 .

_:79f295ad32df4ce8a18a92539c6e8a3b203341 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203342;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b203342 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10926 .

_:79f295ad32df4ce8a18a92539c6e8a3b203344 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10249-1 a owl:Class;
  rdfs:label "ANTICONVULSIVANTS INDUCTEURS ENZYMATIQUES <-> ULIPRISTAL"@fr;
  dct:identifier "IAM_10249";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b203346;
  r:natureDuRisque "Risque de diminution de l’effet de l’ulipristal, par augmentation de son métabolisme hépatique par l’inducteur."@fr;
  r:conduiteATenir "Préférer une alternative thérapeutique peu ou pas métabolisée."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b203352, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b203346 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b203347 .

_:79f295ad32df4ce8a18a92539c6e8a3b203347 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203348;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b203349 .

_:79f295ad32df4ce8a18a92539c6e8a3b203348 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10029 .

_:79f295ad32df4ce8a18a92539c6e8a3b203349 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203350;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b203350 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10964 .

_:79f295ad32df4ce8a18a92539c6e8a3b203352 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10250-1 a owl:Class;
  rdfs:label "ANTICONVULSIVANTS INDUCTEURS ENZYMATIQUES <-> VITAMINE D"@fr;
  dct:identifier "IAM_10250";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b203354;
  r:natureDuRisque "Diminution des concentrations de vitamine D plus marquée qu’en l’absence d'inducteur."@fr;
  r:conduiteATenir "Dosage des concentrations de vitamine D et supplémentation si nécessaire."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b203360, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b203354 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b203355 .

_:79f295ad32df4ce8a18a92539c6e8a3b203355 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203356;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b203357 .

_:79f295ad32df4ce8a18a92539c6e8a3b203356 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10029 .

_:79f295ad32df4ce8a18a92539c6e8a3b203357 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203358;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b203358 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10162 .

_:79f295ad32df4ce8a18a92539c6e8a3b203360 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10251-1 a owl:Class;
  rdfs:label "ANTICONVULSIVANTS INDUCTEURS ENZYMATIQUES <-> VORICONAZOLE"@fr;
  dct:identifier "IAM_10251";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b203362;
  r:natureDuRisque """- pour carbamazépine, phénobarbital, primidone : Risque de baisse de l'efficacité du voriconazole par augmentation de son métabolisme hépatique par l'inducteur.

- pour phénytoïne, fosphénytoïne : 
Diminution importante des concentrations plasmatiques du"""@fr;
  r:conduiteATenir """Contre-indication :
- pour carbamazépine, phénobarbital, primidone

Association déconseillée :
- pour phénytoïne, fosphénytoïne
Si l'association ne peut être évitée, surveillance clinique étroite, dosage des concentrations plasmatiques de phénytoïne et ad"""@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b203368, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b203362 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b203363 .

_:79f295ad32df4ce8a18a92539c6e8a3b203363 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203364;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b203365 .

_:79f295ad32df4ce8a18a92539c6e8a3b203364 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10029 .

_:79f295ad32df4ce8a18a92539c6e8a3b203365 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203366;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b203366 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10998 .

_:79f295ad32df4ce8a18a92539c6e8a3b203368 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10237-1 a owl:Class;
  rdfs:label "ANTICONVULSIVANTS INDUCTEURS ENZYMATIQUES <-> PROCARBAZINE"@fr;
  dct:identifier "IAM_10237";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b203370;
  r:natureDuRisque "Augmentation des réactions d'hypersensibilité (hyperéosinophilie, rash), par augmentation du métabolisme de la procarbazine par l'inducteur."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b203376, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b203370 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b203371 .

_:79f295ad32df4ce8a18a92539c6e8a3b203371 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203372;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b203373 .

_:79f295ad32df4ce8a18a92539c6e8a3b203372 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10029 .

_:79f295ad32df4ce8a18a92539c6e8a3b203373 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203374;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b203374 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10759 .

_:79f295ad32df4ce8a18a92539c6e8a3b203376 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10252-1 a owl:Class;
  rdfs:label "ANTICONVULSIVANTS MÉTABOLISÉS <-> MILLEPERTUIS"@fr;
  dct:identifier "IAM_10252";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b203378;
  r:natureDuRisque "Risque de diminution des concentrations plasmatiques et de l'efficacité de l'anticonvulsivant."@fr;
  rdfs:comment "Une contre-indication a été retenue entre la quasi totalité des médicaments anticonvulsivants et le millepertuis. Cette plante médicinale est un inducteur enzymatique puissant qui expose à une baisse des concentrations plasmatiques de nombreux médicaments"@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b203384, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b203378 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b203379 .

_:79f295ad32df4ce8a18a92539c6e8a3b203379 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203380;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b203381 .

_:79f295ad32df4ce8a18a92539c6e8a3b203380 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10030 .

_:79f295ad32df4ce8a18a92539c6e8a3b203381 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203382;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b203382 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10588 .

_:79f295ad32df4ce8a18a92539c6e8a3b203384 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10253-1 a owl:Class;
  rdfs:label "ANTICORPS MONOCLONAUX (HORS ANTI-TNF ALPHA) <-> VACCINS VIVANTS ATTÉNUÉS"@fr;
  dct:identifier "IAM_10253";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b203386;
  r:natureDuRisque "Risque de maladie vaccinale généralisée, éventuellement mortelle."@fr;
  r:conduiteATenir """Association déconseillée avec :
- bélimumab, blinatumomab, canakinumab, obinutuzumab, ofatumumab, rituximab, tocilizumab, ustékinumab 

A prendre en compte avec :
- alemtuzumab, bevacizumab, brentuximab, cetuximab, daratumumab, dénosumab, ibritumomab, ipi"""@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b203392, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b203386 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b203387 .

_:79f295ad32df4ce8a18a92539c6e8a3b203387 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203388;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b203389 .

_:79f295ad32df4ce8a18a92539c6e8a3b203388 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10031 .

_:79f295ad32df4ce8a18a92539c6e8a3b203389 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203390;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b203390 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10159 .

_:79f295ad32df4ce8a18a92539c6e8a3b203392 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10242-1 a owl:Class;
  rdfs:label "ANTICONVULSIVANTS INDUCTEURS ENZYMATIQUES <-> RIVAROXABAN"@fr;
  dct:identifier "IAM_10242";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b203394;
  r:natureDuRisque "Diminution des concentrations plasmatiques de rivaroxaban, avec risque de diminution de l'effet thérapeutique."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b203400, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b203394 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b203395 .

_:79f295ad32df4ce8a18a92539c6e8a3b203395 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203396;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b203397 .

_:79f295ad32df4ce8a18a92539c6e8a3b203396 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10029 .

_:79f295ad32df4ce8a18a92539c6e8a3b203397 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203398;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b203398 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10808 .

_:79f295ad32df4ce8a18a92539c6e8a3b203400 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11000-1 a owl:Class;
  rdfs:label "GLUCOCORTICOÏDES (SAUF HYDROCORTISONE) <-> ISONIAZIDE"@fr;
  dct:identifier "IAM_11000";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b203402;
  r:natureDuRisque "Décrit pour la prednisolone. Diminution des concentrations plasmatiques de l'isoniazide. Mécanisme invoqué : augmentation du métabolisme hépatique de l'isoniazide et diminution de celui des glucocorticoïdes."@fr;
  r:conduiteATenir "Surveillance clinique et biologique."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b203408, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b203402 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b203403 .

_:79f295ad32df4ce8a18a92539c6e8a3b203403 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203404;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b203405 .

_:79f295ad32df4ce8a18a92539c6e8a3b203404 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10081 .

_:79f295ad32df4ce8a18a92539c6e8a3b203405 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203406;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b203406 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10490 .

_:79f295ad32df4ce8a18a92539c6e8a3b203408 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10343-1 a owl:Class;
  rdfs:label "ANTIVITAMINES K <-> ITRACONAZOLE"@fr;
  dct:identifier "IAM_10343";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b203410;
  r:natureDuRisque "Augmentation de l'effet de l'antivitamine K et du risque hémorragique."@fr;
  r:conduiteATenir "Contrôle plus fréquent de l'INR. Adaptation éventuelle de la posologie de l'antivitamine K pendant le traitement par l'itraconazole et 8 jours après son arrêt."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b203416, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b203410 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b203411 .

_:79f295ad32df4ce8a18a92539c6e8a3b203411 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203412;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b203413 .

_:79f295ad32df4ce8a18a92539c6e8a3b203412 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10046 .

_:79f295ad32df4ce8a18a92539c6e8a3b203413 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203414;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b203414 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10496 .

_:79f295ad32df4ce8a18a92539c6e8a3b203416 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10344-1 a owl:Class;
  rdfs:label "ANTIVITAMINES K <-> LEVOCARNITINE"@fr;
  dct:identifier "IAM_10344";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b203418;
  r:natureDuRisque "Augmentation de l'effet de l'antivitamine K et du risque hémorragique"@fr;
  r:conduiteATenir "Contrôle plus fréquent de l'INR. Adaptation éventuelle de la posologie de l'antivitamine K pendant le traitement par la lévocarnitine et 8 jours après son arrêt."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b203424, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b203418 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b203419 .

_:79f295ad32df4ce8a18a92539c6e8a3b203419 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203420;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b203421 .

_:79f295ad32df4ce8a18a92539c6e8a3b203420 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10046 .

_:79f295ad32df4ce8a18a92539c6e8a3b203421 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203422;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b203422 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10516 .

_:79f295ad32df4ce8a18a92539c6e8a3b203424 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10345-1 a owl:Class;
  rdfs:label "ANTIVITAMINES K <-> MACROLIDES (SAUF SPIRAMYCINE)"@fr;
  dct:identifier "IAM_10345";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b203426;
  r:chapeau """ANTI-INFECTIEUX ET INR
De nombreux cas d’augmentation de l’activité des antivitamines K ont été rapportés chez des patients recevant des antibiotiques. Le contexte infectieux ou inflammatoire marqué, l’âge et l’état général du patient apparaissent comme d"""@fr;
  r:natureDuRisque "Augmentation de l'effet de l'antivitamine K et du risque hémorragique."@fr;
  r:conduiteATenir "Contrôle plus fréquent de l'INR. Adaptation éventuelle de la posologie de l'antivitamine K pendant le traitement par le macrolide et après son arrêt."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b203432, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b203426 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b203427 .

_:79f295ad32df4ce8a18a92539c6e8a3b203427 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203428;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b203429 .

_:79f295ad32df4ce8a18a92539c6e8a3b203428 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10046 .

_:79f295ad32df4ce8a18a92539c6e8a3b203429 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203430;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b203430 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10107 .

_:79f295ad32df4ce8a18a92539c6e8a3b203432 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10346-1 a owl:Class;
  rdfs:label "ANTIVITAMINES K <-> METHYLPREDNISOLONE"@fr;
  dct:identifier "IAM_10346";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b203434;
  r:chapeau """ANTI-INFECTIEUX ET INR
De nombreux cas d’augmentation de l’activité des antivitamines K ont été rapportés chez des patients recevant des antibiotiques. Le contexte infectieux ou inflammatoire marqué, l’âge et l’état général du patient apparaissent comme d"""@fr;
  r:natureDuRisque "Pour des doses de 0,5 à 1g de méthylprednisolone administrées en bolus : augmentation de l'effet de l'antivitamine K et du risque hémorragique."@fr;
  r:conduiteATenir "Contrôle de l'INR 2 à 4 jours après le bolus de méthylprednisolone ou en présence de tous signes hémorragiques."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b203440, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b203434 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b203435 .

_:79f295ad32df4ce8a18a92539c6e8a3b203435 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203436;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b203437 .

_:79f295ad32df4ce8a18a92539c6e8a3b203436 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10046 .

_:79f295ad32df4ce8a18a92539c6e8a3b203437 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203438;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b203438 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10576 .

_:79f295ad32df4ce8a18a92539c6e8a3b203440 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10347-1 a owl:Class;
  rdfs:label "ANTIVITAMINES K <-> MICONAZOLE"@fr;
  dct:identifier "IAM_10347";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b203442;
  r:natureDuRisque "Hémorragies imprévisibles, éventuellement graves."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b203448, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b203442 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b203443 .

_:79f295ad32df4ce8a18a92539c6e8a3b203443 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203444;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b203445 .

_:79f295ad32df4ce8a18a92539c6e8a3b203444 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10046 .

_:79f295ad32df4ce8a18a92539c6e8a3b203445 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203446;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b203446 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10584 .

_:79f295ad32df4ce8a18a92539c6e8a3b203448 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10348-1 a owl:Class;
  rdfs:label "ANTIVITAMINES K <-> MILLEPERTUIS"@fr;
  dct:identifier "IAM_10348";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b203450;
  r:natureDuRisque "Diminution des concentrations plasmatiques de l'antivitamine K, en raison de son effet inducteur enzymatique, avec risque de baisse d'efficacité voire d'annulation de l'effet dont les conséquences peuvent être éventuellement graves (évènement thrombotique"@fr;
  r:conduiteATenir "En cas d'association fortuite, ne pas interrompre brutalement la prise de millepertuis mais contrôler l'INR avant puis après l'arrêt du millepertuis."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b203456, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b203450 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b203451 .

_:79f295ad32df4ce8a18a92539c6e8a3b203451 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203452;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b203453 .

_:79f295ad32df4ce8a18a92539c6e8a3b203452 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10046 .

_:79f295ad32df4ce8a18a92539c6e8a3b203453 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203454;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b203454 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10588 .

_:79f295ad32df4ce8a18a92539c6e8a3b203456 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10349-1 a owl:Class;
  rdfs:label "ANTIVITAMINES K <-> NEVIRAPINE"@fr;
  dct:identifier "IAM_10349";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b203458;
  r:natureDuRisque "Diminution de l'effet de l'antivitamine K par augmentation de son métabolisme hépatique."@fr;
  r:conduiteATenir "Contrôle plus fréquent de l'INR. Adaptation éventuelle de la posologie de l'antivitamine K."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b203464, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b203458 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b203459 .

_:79f295ad32df4ce8a18a92539c6e8a3b203459 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203460;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b203461 .

_:79f295ad32df4ce8a18a92539c6e8a3b203460 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10046 .

_:79f295ad32df4ce8a18a92539c6e8a3b203461 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203462;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b203462 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10628 .

_:79f295ad32df4ce8a18a92539c6e8a3b203464 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10350-1 a owl:Class;
  rdfs:label "ANTIVITAMINES K <-> NOSCAPINE"@fr;
  dct:identifier "IAM_10350";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b203466;
  r:natureDuRisque "Augmentation de l’effet de l’antivitamine K et du risque hémorragique."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b203472, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b203466 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b203467 .

_:79f295ad32df4ce8a18a92539c6e8a3b203467 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203468;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b203469 .

_:79f295ad32df4ce8a18a92539c6e8a3b203468 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10046 .

_:79f295ad32df4ce8a18a92539c6e8a3b203469 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203470;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b203470 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10653 .

_:79f295ad32df4ce8a18a92539c6e8a3b203472 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10351-1 a owl:Class;
  rdfs:label "ANTIVITAMINES K <-> ORLISTAT"@fr;
  dct:identifier "IAM_10351";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b203474;
  r:chapeau """ANTI-INFECTIEUX ET INR
De nombreux cas d’augmentation de l’activité des antivitamines K ont été rapportés chez des patients recevant des antibiotiques. Le contexte infectieux ou inflammatoire marqué, l’âge et l’état général du patient apparaissent comme d"""@fr;
  r:natureDuRisque "Augmentation de l'effet de l'antivitamine K et du risque hémorragique."@fr;
  r:conduiteATenir "Contrôle plus fréquent de l'INR. Adaptation éventuelle de la posologie de l'antivitamine K pendant le traitement par l'orlistat et après son arrêt."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b203480, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b203474 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b203475 .

_:79f295ad32df4ce8a18a92539c6e8a3b203475 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203476;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b203477 .

_:79f295ad32df4ce8a18a92539c6e8a3b203476 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10046 .

_:79f295ad32df4ce8a18a92539c6e8a3b203477 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203478;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b203478 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10667 .

_:79f295ad32df4ce8a18a92539c6e8a3b203480 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10231-1 a owl:Class;
  rdfs:label "ANTICONVULSIVANTS INDUCTEURS ENZYMATIQUES <-> MINÉRALOCORTICOÏDES"@fr;
  dct:identifier "IAM_10231";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b203482;
  r:natureDuRisque "Diminution des concentrations plasmatiques et de l'efficacité des corticoïdes par augmentation de leur métabolisme hépatique par l'inducteur : les conséquences sont particulièrement importantes chez les addisoniens traités par l'hydrocortisone et en cas d"@fr;
  r:conduiteATenir "Surveillance clinique et biologique ; adaptation de la posologie des corticoïdes pendant le traitement par l'inducteur et après son arrêt."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b203488, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b203482 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b203483 .

_:79f295ad32df4ce8a18a92539c6e8a3b203483 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203484;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b203485 .

_:79f295ad32df4ce8a18a92539c6e8a3b203484 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10029 .

_:79f295ad32df4ce8a18a92539c6e8a3b203485 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203486;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b203486 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10108 .

_:79f295ad32df4ce8a18a92539c6e8a3b203488 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10999-1 a owl:Class;
  rdfs:label "GLOBULINES ANTILYMPHOCYTAIRES <-> VACCINS VIVANTS ATTÉNUÉS"@fr;
  dct:identifier "IAM_10999";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b203490;
  r:natureDuRisque "Risque de maladie généralisée éventuellement mortelle. Ce risque est majoré chez les sujets âgés déjà immunodéprimés par la maladie sous-jacente."@fr;
  r:conduiteATenir "En particulier, utiliser un vaccin inactivé lorsqu'il existe (poliomyélite)."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b203496, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b203490 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b203491 .

_:79f295ad32df4ce8a18a92539c6e8a3b203491 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203492;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b203493 .

_:79f295ad32df4ce8a18a92539c6e8a3b203492 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10080 .

_:79f295ad32df4ce8a18a92539c6e8a3b203493 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203494;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b203494 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10159 .

_:79f295ad32df4ce8a18a92539c6e8a3b203496 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10230-1 a owl:Class;
  rdfs:label "ANTICONVULSIVANTS INDUCTEURS ENZYMATIQUES <-> MIDAZOLAM"@fr;
  dct:identifier "IAM_10230";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b203498;
  r:natureDuRisque "Risque de diminution des concentrations plasmatiques du midazolam par l'anticonvulsivant."@fr;
  rdfs:comment """L’administration de carbamazépine ou de phénytoïne diminue significativement les concentrations plasmatiques et la demi-vie d’une dose orale de 15 mg de midazolam.
Le midazolam administré par voie orale subit un effet de premier passage hépatique importan"""@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b203504, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b203498 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b203499 .

_:79f295ad32df4ce8a18a92539c6e8a3b203499 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203500;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b203501 .

_:79f295ad32df4ce8a18a92539c6e8a3b203500 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10029 .

_:79f295ad32df4ce8a18a92539c6e8a3b203501 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203502;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b203502 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10585 .

_:79f295ad32df4ce8a18a92539c6e8a3b203504 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11001-1 a owl:Class;
  rdfs:label "GLUCOCORTICOÏDES (SAUF HYDROCORTISONE) <-> RIFAMPICINE"@fr;
  dct:identifier "IAM_11001";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b203506;
  r:natureDuRisque "Diminution des concentrations plasmatiques et de l'efficacité des corticoïdes par augmentation de leur métabolisme hépatique par la rifampicine ; les conséquences sont particulièrement importantes chez les addisoniens traités par l'hydrocortisone et en ca"@fr;
  r:conduiteATenir "Surveillance clinique et biologique ; adaptation de la posologie des corticoïdes pendant le traitement par la rifampicine et après son arrêt."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b203512, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b203506 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b203507 .

_:79f295ad32df4ce8a18a92539c6e8a3b203507 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203508;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b203509 .

_:79f295ad32df4ce8a18a92539c6e8a3b203508 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10081 .

_:79f295ad32df4ce8a18a92539c6e8a3b203509 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203510;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b203510 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:79f295ad32df4ce8a18a92539c6e8a3b203512 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11002-1 a owl:Class;
  rdfs:label "GLUCOCORTICOÏDES (SAUF HYDROCORTISONE) <-> VACCINS VIVANTS ATTÉNUÉS"@fr;
  dct:identifier "IAM_11002";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b203514;
  r:natureDuRisque "A l'exception des voies inhalées et locales, et pour des posologies supérieures à 10 mg/j d’équivalent-prednisone (ou > 2 mg/kg/j chez l’enfant ou > 20 mg/j chez l’enfant de plus de 10 kg) pendant plus de deux semaines et pour les « bolus » de corticoïdes"@fr;
  r:conduiteATenir "Et pendant les 3 mois suivant l'arrêt de la corticothérapie."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b203520, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b203514 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b203515 .

_:79f295ad32df4ce8a18a92539c6e8a3b203515 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203516;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b203517 .

_:79f295ad32df4ce8a18a92539c6e8a3b203516 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10081 .

_:79f295ad32df4ce8a18a92539c6e8a3b203517 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203518;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b203518 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10159 .

_:79f295ad32df4ce8a18a92539c6e8a3b203520 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11003-1 a owl:Class;
  rdfs:label "GLYCEROL <-> LITHIUM"@fr;
  dct:identifier "IAM_11003";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b203522;
  r:natureDuRisque "Diminution de la lithémie avec risque de baisse de l’efficacité thérapeutique."@fr;
  r:conduiteATenir "Surveillance stricte de la lithémie et adaptation éventuelle de la posologie du lithium."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b203528, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b203522 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b203523 .

_:79f295ad32df4ce8a18a92539c6e8a3b203523 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203524;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b203525 .

_:79f295ad32df4ce8a18a92539c6e8a3b203524 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10419 .

_:79f295ad32df4ce8a18a92539c6e8a3b203525 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203526;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b203526 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10530 .

_:79f295ad32df4ce8a18a92539c6e8a3b203528 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11004-1 a owl:Class;
  rdfs:label "GRISEOFULVINE <-> PROGESTATIFS CONTRACEPTIFS"@fr;
  dct:identifier "IAM_11004";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b203530;
  r:natureDuRisque "Risque de diminution de l'efficacité du contraceptif hormonal par augmentation de son métabolisme hépatique."@fr;
  r:conduiteATenir "Utiliser une méthode contraceptive fiable, additionnelle ou alternative, pendant la durée de l'association et un cycle suivant."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b203536, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b203530 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b203531 .

_:79f295ad32df4ce8a18a92539c6e8a3b203531 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203532;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b203533 .

_:79f295ad32df4ce8a18a92539c6e8a3b203532 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10134 .

_:79f295ad32df4ce8a18a92539c6e8a3b203533 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203534;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b203534 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10422 .

_:79f295ad32df4ce8a18a92539c6e8a3b203536 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11005-1 a owl:Class;
  rdfs:label "GUANETHIDINE <-> IMAO IRRÉVERSIBLES"@fr;
  dct:identifier "IAM_11005";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b203538;
  r:natureDuRisque "Avec la guanéthidine utilisée par voie IV : risque de réactions vasculaires imprévisibles, notamment d'hypotension."@fr;
  r:conduiteATenir "Interrompre le traitement par IMAO 15 jours avant le traitement par guanéthidine."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b203544, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b203538 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b203539 .

_:79f295ad32df4ce8a18a92539c6e8a3b203539 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203540;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b203541 .

_:79f295ad32df4ce8a18a92539c6e8a3b203540 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10002 .

_:79f295ad32df4ce8a18a92539c6e8a3b203541 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203542;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b203542 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10423 .

_:79f295ad32df4ce8a18a92539c6e8a3b203544 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11006-1 a owl:Class;
  rdfs:label "HALOFANTRINE <-> INHIBITEURS PUISSANTS DU CYP3A4"@fr;
  dct:identifier "IAM_11006";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b203546;
  r:natureDuRisque "Risque majoré de troubles du rythme ventriculaires, notamment de torsades de pointes."@fr;
  r:conduiteATenir "Si cela est possible, interrompre l'inhibiteur. Si l'association ne peut être évitée, contrôle préalable du QT et surveillance ECG monitorée."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b203552, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b203546 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b203547 .

_:79f295ad32df4ce8a18a92539c6e8a3b203547 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203548;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b203549 .

_:79f295ad32df4ce8a18a92539c6e8a3b203548 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10103 .

_:79f295ad32df4ce8a18a92539c6e8a3b203549 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203550;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b203550 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10425 .

_:79f295ad32df4ce8a18a92539c6e8a3b203552 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11007-1 a owl:Class;
  rdfs:label "HALOFANTRINE <-> JOSAMYCINE"@fr;
  dct:identifier "IAM_11007";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b203554;
  r:natureDuRisque "Risque majoré de troubles du rythme ventriculaire, notamment de torsades de pointes."@fr;
  r:conduiteATenir "Si cela est possible, interrompre le macrolide. Si l’association ne peut être évitée, contrôle préalable du QT et surveillance ECG monitorée."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b203560, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b203554 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b203555 .

_:79f295ad32df4ce8a18a92539c6e8a3b203555 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203556;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b203557 .

_:79f295ad32df4ce8a18a92539c6e8a3b203556 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10425 .

_:79f295ad32df4ce8a18a92539c6e8a3b203557 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203558;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b203558 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10499 .

_:79f295ad32df4ce8a18a92539c6e8a3b203560 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11008-1 a owl:Class;
  rdfs:label "HALOFANTRINE <-> PAMPLEMOUSSE (JUS ET FRUIT)"@fr;
  dct:identifier "IAM_11008";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b203562;
  r:natureDuRisque "Risque majoré de troubles du rythme ventriculaire, notamment de torsades de pointes."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b203568, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b203562 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b203563 .

_:79f295ad32df4ce8a18a92539c6e8a3b203563 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203564;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b203565 .

_:79f295ad32df4ce8a18a92539c6e8a3b203564 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10130 .

_:79f295ad32df4ce8a18a92539c6e8a3b203565 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203566;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b203566 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10425 .

_:79f295ad32df4ce8a18a92539c6e8a3b203568 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11009-1 a owl:Class;
  rdfs:label "HALOFANTRINE <-> STIRIPENTOL"@fr;
  dct:identifier "IAM_11009";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b203570;
  r:natureDuRisque "Risque majoré de troubles du rythme ventriculaire, notamment de torsades de pointes."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b203576, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b203570 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b203571 .

_:79f295ad32df4ce8a18a92539c6e8a3b203571 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203572;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b203573 .

_:79f295ad32df4ce8a18a92539c6e8a3b203572 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10425 .

_:79f295ad32df4ce8a18a92539c6e8a3b203573 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203574;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b203574 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10859 .

_:79f295ad32df4ce8a18a92539c6e8a3b203576 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10256-1 a owl:Class;
  rdfs:label "ANTIDÉPRESSEURS IMIPRAMINIQUES <-> CLONIDINE"@fr;
  dct:identifier "IAM_10256";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b203578;
  r:natureDuRisque "Décrit pour désipramine, imipramine : inhibition de l'effet antihypertenseur de la clonidine (antagonisme au niveau des récepteurs adrénergiques)."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b203584, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b203578 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b203579 .

_:79f295ad32df4ce8a18a92539c6e8a3b203579 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203580;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b203581 .

_:79f295ad32df4ce8a18a92539c6e8a3b203580 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10032 .

_:79f295ad32df4ce8a18a92539c6e8a3b203581 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203582;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b203582 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10214 .

_:79f295ad32df4ce8a18a92539c6e8a3b203584 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10352-1 a owl:Class;
  rdfs:label "ANTIVITAMINES K <-> PARACETAMOL"@fr;
  dct:identifier "IAM_10352";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b203586;
  r:natureDuRisque "Risque d’augmentation de l’effet de l’antivitamine K et du risque hémorragique en cas de prise de paracétamol aux doses maximales (4 g/j) pendant au moins 4 jours."@fr;
  r:conduiteATenir "Contrôle plus fréquent de l’INR. Adaptation éventuelle de la posologie de l’antivitamine K pendant le traitement par le paracétamol et après son arrêt."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b203592, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b203586 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b203587 .

_:79f295ad32df4ce8a18a92539c6e8a3b203587 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203588;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b203589 .

_:79f295ad32df4ce8a18a92539c6e8a3b203588 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10046 .

_:79f295ad32df4ce8a18a92539c6e8a3b203589 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203590;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b203590 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10690 .

_:79f295ad32df4ce8a18a92539c6e8a3b203592 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10292-1 a owl:Class;
  rdfs:label "ANTISÉCRÉTOIRES ANTIHISTAMINIQUES H2 <-> ITRACONAZOLE"@fr;
  dct:identifier "IAM_10292";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b203594;
  r:natureDuRisque "Diminution de l'absorption de l'azolé antifongique, par augmentation du pH intragastrique par l'antisécrétoire."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b203600, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b203594 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b203595 .

_:79f295ad32df4ce8a18a92539c6e8a3b203595 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203596;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b203597 .

_:79f295ad32df4ce8a18a92539c6e8a3b203596 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10042 .

_:79f295ad32df4ce8a18a92539c6e8a3b203597 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203598;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b203598 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10496 .

_:79f295ad32df4ce8a18a92539c6e8a3b203600 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10254-1 a owl:Class;
  rdfs:label "ANTIDÉPRESSEURS IMIPRAMINIQUES <-> BACLOFENE"@fr;
  dct:identifier "IAM_10254";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b203602;
  r:natureDuRisque "Risque d'augmentation de l'hypotonie musculaire."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b203608, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b203602 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b203603 .

_:79f295ad32df4ce8a18a92539c6e8a3b203603 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203604;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b203605 .

_:79f295ad32df4ce8a18a92539c6e8a3b203604 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10032 .

_:79f295ad32df4ce8a18a92539c6e8a3b203605 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203606;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b203606 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10102 .

_:79f295ad32df4ce8a18a92539c6e8a3b203608 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10282-1 a owl:Class;
  rdfs:label "ANTI-INFLAMMATOIRES NON STÉROÏDIENS <-> TENOFOVIR DISOPROXIL"@fr;
  dct:identifier "IAM_10282";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b203610;
  r:natureDuRisque "Risque de majoration de la néphrotoxicité du ténofovir, notamment avec des doses élevées de l'anti-inflammatoire ou en présence de facteurs de risque d'insuffisance rénale."@fr;
  r:conduiteATenir "En cas d’association, surveiller la fonction rénale."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b203616, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b203610 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b203611 .

_:79f295ad32df4ce8a18a92539c6e8a3b203611 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203612;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b203613 .

_:79f295ad32df4ce8a18a92539c6e8a3b203612 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10022 .

_:79f295ad32df4ce8a18a92539c6e8a3b203613 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203614;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b203614 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10896 .

_:79f295ad32df4ce8a18a92539c6e8a3b203616 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10283-1 a owl:Class;
  rdfs:label "ANTIPARASITAIRES SUSCEPTIBLES DE DONNER DES TORSADES DE POINTES <-> SUBSTANCES SUSCEPTIBLES DE DONNER DES TORSADES DE POINTES"@fr;
  dct:identifier "IAM_10283";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b203618;
  r:chapeau "Ce trouble du rythme cardiaque grave peut être provoqué par un certain nombre de médicaments, antiarythmiques ou non. L'hypokaliémie (cf. médicaments hypokaliémiants) est un facteur favorisant, de même que la bradycardie (cf. médicaments bradycardisants)"@fr;
  r:natureDuRisque "Risque majoré de troubles du rythme ventriculaire, notamment de torsades de pointes."@fr;
  r:conduiteATenir """Contre-indication:
- avec le citalopram, la dompéridone, l'escitalopram, l'hydroxyzine
et la pipéraquine.

Association déconseillée:
- avec les autres médicaments susceptibles de donner des torsades de pointes.
Si cela est possible, interrompre l'un des d"""@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b203624, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b203618 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b203619 .

_:79f295ad32df4ce8a18a92539c6e8a3b203619 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203620;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b203621 .

_:79f295ad32df4ce8a18a92539c6e8a3b203620 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10036 .

_:79f295ad32df4ce8a18a92539c6e8a3b203621 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203622;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b203622 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10143 .

_:79f295ad32df4ce8a18a92539c6e8a3b203624 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10284-1 a owl:Class;
  rdfs:label "ANTIPARKINSONIENS DOPAMINERGIQUES <-> NEUROLEPTIQUES ANTIPSYCHOTIQUES (SAUF CLOZAPINE)"@fr;
  dct:identifier "IAM_10284";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b203626;
  r:natureDuRisque "Antagonisme réciproque du dopaminergique et des neuroleptiques. Le dopaminergique peut provoquer ou aggraver les troubles psychotiques. En cas de nécessité d'un traitement par neuroleptiques chez le patient parkinsonien traité par dopaminergique, ces dern"@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b203632, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b203626 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b203627 .

_:79f295ad32df4ce8a18a92539c6e8a3b203627 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203628;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b203629 .

_:79f295ad32df4ce8a18a92539c6e8a3b203628 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10038 .

_:79f295ad32df4ce8a18a92539c6e8a3b203629 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203630;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b203630 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10125 .

_:79f295ad32df4ce8a18a92539c6e8a3b203632 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10285-1 a owl:Class;
  rdfs:label "ANTIPURINES <-> ANTIVITAMINES K"@fr;
  dct:identifier "IAM_10285";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b203634;
  r:chapeau """ANTI-INFECTIEUX ET INR
De nombreux cas d’augmentation de l’activité des antivitamines K ont été rapportés chez des patients recevant des antibiotiques. Le contexte infectieux ou inflammatoire marqué, l’âge et l’état général du patient apparaissent comme d"""@fr;
  r:natureDuRisque "Diminution de l'effet de l'antivitamine K par augmentation de son métabolisme hépatique."@fr;
  r:conduiteATenir "Contrôle plus fréquent de l'INR. Adaptation éventuelle de la posologie de l'antivitamine K à la mise en route du traitement par l'immunomodulateur et après son arrêt."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b203640, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b203634 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b203635 .

_:79f295ad32df4ce8a18a92539c6e8a3b203635 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203636;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b203637 .

_:79f295ad32df4ce8a18a92539c6e8a3b203636 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10039 .

_:79f295ad32df4ce8a18a92539c6e8a3b203637 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203638;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b203638 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10046 .

_:79f295ad32df4ce8a18a92539c6e8a3b203640 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10286-1 a owl:Class;
  rdfs:label "ANTIPURINES <-> DÉRIVÉS DE L'ACIDE AMINOSALICYLIQUE (ASA)"@fr;
  dct:identifier "IAM_10286";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b203642;
  r:natureDuRisque "Risque de majoration de l'effet myélosuppresseur de l'immunomodulateur par inhibition de son métabolisme hépatique par le dérivé de l'ASA, notamment chez les sujets présentant un déficit partiel en thiopurine méthyltransférase (TPMT)."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b203648, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b203642 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b203643 .

_:79f295ad32df4ce8a18a92539c6e8a3b203643 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203644;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b203645 .

_:79f295ad32df4ce8a18a92539c6e8a3b203644 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10039 .

_:79f295ad32df4ce8a18a92539c6e8a3b203645 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203646;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b203646 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10070 .

_:79f295ad32df4ce8a18a92539c6e8a3b203648 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10287-1 a owl:Class;
  rdfs:label "ANTIPURINES <-> INHIBITEURS DE LA XANTHINE OXYDASE"@fr;
  dct:identifier "IAM_10287";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b203650;
  r:natureDuRisque "Insuffisance médullaire éventuellement grave."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b203656, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b203650 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b203651 .

_:79f295ad32df4ce8a18a92539c6e8a3b203651 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203652;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b203653 .

_:79f295ad32df4ce8a18a92539c6e8a3b203652 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10039 .

_:79f295ad32df4ce8a18a92539c6e8a3b203653 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203654;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b203654 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10099 .

_:79f295ad32df4ce8a18a92539c6e8a3b203656 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10288-1 a owl:Class;
  rdfs:label "ANTIPURINES <-> RIBAVIRINE"@fr;
  dct:identifier "IAM_10288";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b203658;
  r:natureDuRisque "Risque majoré d'effets indésirables graves, par inhibition du métabolisme de l'immunomodulateur par la ribavirine."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b203664, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b203658 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b203659 .

_:79f295ad32df4ce8a18a92539c6e8a3b203659 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203660;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b203661 .

_:79f295ad32df4ce8a18a92539c6e8a3b203660 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10039 .

_:79f295ad32df4ce8a18a92539c6e8a3b203661 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203662;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b203662 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10797 .

_:79f295ad32df4ce8a18a92539c6e8a3b203664 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10289-1 a owl:Class;
  rdfs:label "ANTISÉCRÉTOIRES ANTIHISTAMINIQUES H2 <-> ATAZANAVIR"@fr;
  dct:identifier "IAM_10289";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b203666;
  r:natureDuRisque "Risque de diminution des concentrations plasmatiques de l'atazanavir."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b203672, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b203666 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b203667 .

_:79f295ad32df4ce8a18a92539c6e8a3b203667 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203668;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b203669 .

_:79f295ad32df4ce8a18a92539c6e8a3b203668 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10042 .

_:79f295ad32df4ce8a18a92539c6e8a3b203669 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203670;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b203670 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10087 .

_:79f295ad32df4ce8a18a92539c6e8a3b203672 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10280-1 a owl:Class;
  rdfs:label "ANTI-INFLAMMATOIRES NON STÉROÏDIENS <-> PENTOXIFYLLINE"@fr;
  dct:identifier "IAM_10280";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b203674;
  r:natureDuRisque "Majoration du risque hémorragique."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b203680, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b203674 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b203675 .

_:79f295ad32df4ce8a18a92539c6e8a3b203675 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203676;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b203677 .

_:79f295ad32df4ce8a18a92539c6e8a3b203676 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10022 .

_:79f295ad32df4ce8a18a92539c6e8a3b203677 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203678;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b203678 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10705 .

_:79f295ad32df4ce8a18a92539c6e8a3b203680 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10291-1 a owl:Class;
  rdfs:label "ANTISÉCRÉTOIRES ANTIHISTAMINIQUES H2 <-> INHIBITEURS DES TYROSINE KINASES MÉTABOLISÉS"@fr;
  dct:identifier "IAM_10291";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b203682;
  r:natureDuRisque "Risque de diminution de la biodisponibilité de l’inhibiteur de tyrosine kinases, en raison de son absorption pH-dépendante."@fr;
  r:conduiteATenir "- sauf avec le vandétanib."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b203688, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b203682 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b203683 .

_:79f295ad32df4ce8a18a92539c6e8a3b203683 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203684;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b203685 .

_:79f295ad32df4ce8a18a92539c6e8a3b203684 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10042 .

_:79f295ad32df4ce8a18a92539c6e8a3b203685 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203686;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b203686 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10101 .

_:79f295ad32df4ce8a18a92539c6e8a3b203688 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10279-1 a owl:Class;
  rdfs:label "ANTI-INFLAMMATOIRES NON STÉROÏDIENS <-> PEMETREXED"@fr;
  dct:identifier "IAM_10279";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b203690;
  r:natureDuRisque "Risque de majoration de la toxicité du pemetrexed (diminution de sa clairance rénale par les AINS)."@fr;
  r:conduiteATenir """Association déconseillée : 
- en cas de fonction rénale faible à modérée.

Précaution d'emploi :
- en cas de fonction rénale normale. Surveillance biologique de la fonction rénale."""@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b203696, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b203690 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b203691 .

_:79f295ad32df4ce8a18a92539c6e8a3b203691 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203692;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b203693 .

_:79f295ad32df4ce8a18a92539c6e8a3b203692 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10022 .

_:79f295ad32df4ce8a18a92539c6e8a3b203693 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203694;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b203694 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10700 .

_:79f295ad32df4ce8a18a92539c6e8a3b203696 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10293-1 a owl:Class;
  rdfs:label "ANTISÉCRÉTOIRES ANTIHISTAMINIQUES H2 <-> KETOCONAZOLE"@fr;
  dct:identifier "IAM_10293";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b203698;
  r:natureDuRisque "Diminution de l'absorption de l'azolé antifongique, par augmentation du pH intragastrique par l'antisécrétoire."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b203704, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b203698 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b203699 .

_:79f295ad32df4ce8a18a92539c6e8a3b203699 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203700;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b203701 .

_:79f295ad32df4ce8a18a92539c6e8a3b203700 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10042 .

_:79f295ad32df4ce8a18a92539c6e8a3b203701 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203702;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b203702 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10501 .

_:79f295ad32df4ce8a18a92539c6e8a3b203704 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10294-1 a owl:Class;
  rdfs:label "ANTISÉCRÉTOIRES ANTIHISTAMINIQUES H2 <-> POSACONAZOLE"@fr;
  dct:identifier "IAM_10294";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b203706;
  r:natureDuRisque "Diminution de l'absorption de l'azolé antifongique, par augmentation du pH intragastrique par l'antisécrétoire."@fr;
  r:conduiteATenir """Association déconseillée:
- uniquement avec la forme suspension buvable de posaconazole."""@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b203712, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b203706 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b203707 .

_:79f295ad32df4ce8a18a92539c6e8a3b203707 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203708;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b203709 .

_:79f295ad32df4ce8a18a92539c6e8a3b203708 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10042 .

_:79f295ad32df4ce8a18a92539c6e8a3b203709 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203710;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b203710 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10741 .

_:79f295ad32df4ce8a18a92539c6e8a3b203712 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10295-1 a owl:Class;
  rdfs:label "ANTISÉCRÉTOIRES ANTIHISTAMINIQUES H2 <-> RILPIVIRINE"@fr;
  dct:identifier "IAM_10295";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b203714;
  r:natureDuRisque "Risque de diminution des concentrations plasmatiques de la rilpivirine."@fr;
  r:conduiteATenir "Si nécessaire, utiliser un antihistaminique H2 actif en une prise par jour, à prendre au moins 12 heures avant, ou au moins 4 heures après."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b203720, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b203714 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b203715 .

_:79f295ad32df4ce8a18a92539c6e8a3b203715 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203716;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b203717 .

_:79f295ad32df4ce8a18a92539c6e8a3b203716 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10042 .

_:79f295ad32df4ce8a18a92539c6e8a3b203717 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203718;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b203718 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10803 .

_:79f295ad32df4ce8a18a92539c6e8a3b203720 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10296-1 a owl:Class;
  rdfs:label "ANTISÉCRÉTOIRES ANTIHISTAMINIQUES H2 <-> ULIPRISTAL"@fr;
  dct:identifier "IAM_10296";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b203722;
  r:natureDuRisque "Risque de diminution de l’effet de l’ulipristal, par diminution de son absorption."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b203728, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b203722 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b203723 .

_:79f295ad32df4ce8a18a92539c6e8a3b203723 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203724;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b203725 .

_:79f295ad32df4ce8a18a92539c6e8a3b203724 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10042 .

_:79f295ad32df4ce8a18a92539c6e8a3b203725 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203726;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b203726 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10964 .

_:79f295ad32df4ce8a18a92539c6e8a3b203728 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10297-1 a owl:Class;
  rdfs:label "ANTISÉCRÉTOIRES INHIBITEURS DE LA POMPE À PROTONS <-> ATAZANAVIR"@fr;
  dct:identifier "IAM_10297";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b203730;
  r:natureDuRisque "Diminution très importante des concentrations plasmatiques de l'atazanavir, avec risque d'échec thérapeutique."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b203736, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b203730 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b203731 .

_:79f295ad32df4ce8a18a92539c6e8a3b203731 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203732;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b203733 .

_:79f295ad32df4ce8a18a92539c6e8a3b203732 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10043 .

_:79f295ad32df4ce8a18a92539c6e8a3b203733 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203734;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b203734 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10087 .

_:79f295ad32df4ce8a18a92539c6e8a3b203736 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10298-1 a owl:Class;
  rdfs:label "ANTISÉCRÉTOIRES INHIBITEURS DE LA POMPE À PROTONS <-> CYANOCOBALAMINE"@fr;
  dct:identifier "IAM_10298";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b203738;
  r:natureDuRisque "Risque de carence en cyanocobalamine après traitement prolongé (quelques années), la réduction de l’acidité gastrique par ces médicaments pouvant diminuer l’absorption digestive de la vitamine B12."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b203744, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b203738 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b203739 .

_:79f295ad32df4ce8a18a92539c6e8a3b203739 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203740;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b203741 .

_:79f295ad32df4ce8a18a92539c6e8a3b203740 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10043 .

_:79f295ad32df4ce8a18a92539c6e8a3b203741 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203742;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b203742 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10233 .

_:79f295ad32df4ce8a18a92539c6e8a3b203744 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10299-1 a owl:Class;
  rdfs:label "ANTISÉCRÉTOIRES INHIBITEURS DE LA POMPE À PROTONS <-> INHIBITEURS DES TYROSINE KINASES MÉTABOLISÉS"@fr;
  dct:identifier "IAM_10299";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b203746;
  r:natureDuRisque "Risque de diminution de la biodisponibilité de l’inhibiteur de tyrosine kinases, en raison de son absorption pH-dépendante."@fr;
  r:conduiteATenir "- sauf avec l'imatinib et le vandétanib"@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b203752, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b203746 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b203747 .

_:79f295ad32df4ce8a18a92539c6e8a3b203747 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203748;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b203749 .

_:79f295ad32df4ce8a18a92539c6e8a3b203748 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10043 .

_:79f295ad32df4ce8a18a92539c6e8a3b203749 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203750;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b203750 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10101 .

_:79f295ad32df4ce8a18a92539c6e8a3b203752 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10300-1 a owl:Class;
  rdfs:label "ANTISÉCRÉTOIRES INHIBITEURS DE LA POMPE À PROTONS <-> ITRACONAZOLE"@fr;
  dct:identifier "IAM_10300";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b203754;
  r:natureDuRisque "Diminution de l'absorption de l'azolé antifongique, par augmentation du pH intragastrique par l'antisécrétoire."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b203760, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b203754 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b203755 .

_:79f295ad32df4ce8a18a92539c6e8a3b203755 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203756;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b203757 .

_:79f295ad32df4ce8a18a92539c6e8a3b203756 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10043 .

_:79f295ad32df4ce8a18a92539c6e8a3b203757 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203758;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b203758 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10496 .

_:79f295ad32df4ce8a18a92539c6e8a3b203760 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10301-1 a owl:Class;
  rdfs:label "ANTISÉCRÉTOIRES INHIBITEURS DE LA POMPE À PROTONS <-> KETOCONAZOLE"@fr;
  dct:identifier "IAM_10301";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b203762;
  r:natureDuRisque "Diminution de l'absorption de l'azolé antifongique, par augmentation du pH intragastrique par l'antisécrétoire."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b203768, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b203762 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b203763 .

_:79f295ad32df4ce8a18a92539c6e8a3b203763 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203764;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b203765 .

_:79f295ad32df4ce8a18a92539c6e8a3b203764 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10043 .

_:79f295ad32df4ce8a18a92539c6e8a3b203765 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203766;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b203766 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10501 .

_:79f295ad32df4ce8a18a92539c6e8a3b203768 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10715-1 a owl:Class;
  rdfs:label "DACLATASVIR <-> INDUCTEURS ENZYMATIQUES"@fr;
  dct:identifier "IAM_10715";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b203770;
  r:natureDuRisque "Diminution des concentrations plasmatiques de daclatasvir par augmentation de son métabolisme hépatique par l'inducteur."@fr;
  r:conduiteATenir """Contre-indication:
- avec la rifampicine
- avec les anticonvulsivants inducteurs enzymatiques
- avec l'oxcarbazépine

Précaution d'emploi:
- avec les autres inducteurs, la dose recommandée est de 90 mg/jour de daclatasvir"""@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b203776, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b203770 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b203771 .

_:79f295ad32df4ce8a18a92539c6e8a3b203771 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203772;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b203773 .

_:79f295ad32df4ce8a18a92539c6e8a3b203772 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10094 .

_:79f295ad32df4ce8a18a92539c6e8a3b203773 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203774;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b203774 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10243 .

_:79f295ad32df4ce8a18a92539c6e8a3b203776 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10290-1 a owl:Class;
  rdfs:label "ANTISÉCRÉTOIRES ANTIHISTAMINIQUES H2 <-> CYANOCOBALAMINE"@fr;
  dct:identifier "IAM_10290";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b203778;
  r:natureDuRisque "Risque de carence en cyanocobalamine après traitement prolongé (quelques années), la réduction de l’acidité gastrique par ces médicaments pouvant diminuer l’absorption digestive de la vitamine B12."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b203784, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b203778 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b203779 .

_:79f295ad32df4ce8a18a92539c6e8a3b203779 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203780;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b203781 .

_:79f295ad32df4ce8a18a92539c6e8a3b203780 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10042 .

_:79f295ad32df4ce8a18a92539c6e8a3b203781 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203782;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b203782 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10233 .

_:79f295ad32df4ce8a18a92539c6e8a3b203784 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10268-1 a owl:Class;
  rdfs:label "ANTI-INFLAMMATOIRES NON STÉROÏDIENS <-> DEFERASIROX"@fr;
  dct:identifier "IAM_10268";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b203786;
  r:natureDuRisque "Majoration du risque ulcérogène et hémorragique digestif."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b203792, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b203786 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b203787 .

_:79f295ad32df4ce8a18a92539c6e8a3b203787 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203788;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b203789 .

_:79f295ad32df4ce8a18a92539c6e8a3b203788 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10022 .

_:79f295ad32df4ce8a18a92539c6e8a3b203789 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203790;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b203790 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10259 .

_:79f295ad32df4ce8a18a92539c6e8a3b203792 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10227-1 a owl:Class;
  rdfs:label "ANTICONVULSIVANTS INDUCTEURS ENZYMATIQUES <-> IVABRADINE"@fr;
  dct:identifier "IAM_10227";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b203794;
  r:natureDuRisque "Risque de diminution de l'efficacité de l’ivabradine, par augmentation de son métabolisme par l’inducteur."@fr;
  r:conduiteATenir "Surveillance clinique et adaptation de la posologie de l’ivabradine pendant l’association et après l’arrêt de l’inducteur."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b203800, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b203794 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b203795 .

_:79f295ad32df4ce8a18a92539c6e8a3b203795 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203796;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b203797 .

_:79f295ad32df4ce8a18a92539c6e8a3b203796 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10029 .

_:79f295ad32df4ce8a18a92539c6e8a3b203797 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203798;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b203798 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10497 .

_:79f295ad32df4ce8a18a92539c6e8a3b203800 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10257-1 a owl:Class;
  rdfs:label "ANTIDÉPRESSEURS IMIPRAMINIQUES <-> INHIBITEURS SÉLECTIFS DE LA RECAPTURE DE LA SÉROTONINE"@fr;
  dct:identifier "IAM_10257";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b203802;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de l'antidépresseur imipraminique avec risque de convulsions et augmentation des effets indésirables."@fr;
  r:conduiteATenir "Surveillance clinique accrue et, si nécessaire, adaptation posologique."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b203808, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b203802 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b203803 .

_:79f295ad32df4ce8a18a92539c6e8a3b203803 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203804;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b203805 .

_:79f295ad32df4ce8a18a92539c6e8a3b203804 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10032 .

_:79f295ad32df4ce8a18a92539c6e8a3b203805 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203806;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b203806 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10104 .

_:79f295ad32df4ce8a18a92539c6e8a3b203808 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10258-1 a owl:Class;
  rdfs:label "ANTIDÉPRESSEURS IMIPRAMINIQUES <-> ORLISTAT"@fr;
  dct:identifier "IAM_10258";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b203810;
  r:natureDuRisque "Risque d'échec thérapeutique en cas de traitement concomitant par orlistat."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b203816, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b203810 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b203811 .

_:79f295ad32df4ce8a18a92539c6e8a3b203811 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203812;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b203813 .

_:79f295ad32df4ce8a18a92539c6e8a3b203812 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10032 .

_:79f295ad32df4ce8a18a92539c6e8a3b203813 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203814;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b203814 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10667 .

_:79f295ad32df4ce8a18a92539c6e8a3b203816 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10259-1 a owl:Class;
  rdfs:label "ANTIDÉPRESSEURS IMIPRAMINIQUES <-> SYMPATHOMIMÉTIQUES ALPHA ET BÊTA (VOIE IM ET IV)"@fr;
  dct:identifier "IAM_10259";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b203818;
  r:natureDuRisque "Hypertension paroxystique avec possibilité de troubles du rythme (inhibition de l'entrée du sympathomimétique dans la fibre sympathique)."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b203824, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b203818 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b203819 .

_:79f295ad32df4ce8a18a92539c6e8a3b203819 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203820;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b203821 .

_:79f295ad32df4ce8a18a92539c6e8a3b203820 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10032 .

_:79f295ad32df4ce8a18a92539c6e8a3b203821 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203822;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b203822 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10149 .

_:79f295ad32df4ce8a18a92539c6e8a3b203824 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10260-1 a owl:Class;
  rdfs:label "ANTIHYPERTENSEURS ALPHA-BLOQUANTS <-> ANTIHYPERTENSEURS SAUF ALPHA-BLOQUANTS"@fr;
  dct:identifier "IAM_10260";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b203826;
  r:natureDuRisque "Majoration de l'effet hypotenseur. Risque majoré d'hypotension orthostatique."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b203832, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b203826 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b203827 .

_:79f295ad32df4ce8a18a92539c6e8a3b203827 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203828;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b203829 .

_:79f295ad32df4ce8a18a92539c6e8a3b203828 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10033 .

_:79f295ad32df4ce8a18a92539c6e8a3b203829 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203830;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b203830 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10035 .

_:79f295ad32df4ce8a18a92539c6e8a3b203832 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10261-1 a owl:Class;
  rdfs:label "ANTIHYPERTENSEURS ALPHA-BLOQUANTS <-> INHIBITEURS DE LA PHOSPHODIESTERASE DE TYPE 5"@fr;
  dct:identifier "IAM_10261";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b203834;
  r:natureDuRisque "Risque d’hypotension orthostatique, notamment chez le sujet âgé."@fr;
  r:conduiteATenir """Association déconseillée :
- avec la doxazosine 

Précaution d'emploi :
- avec les autres alpha-bloquants
Débuter le traitement aux posologies minimales recommandées et adapter progressivement les doses si besoin."""@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b203840, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b203834 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b203835 .

_:79f295ad32df4ce8a18a92539c6e8a3b203835 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203836;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b203837 .

_:79f295ad32df4ce8a18a92539c6e8a3b203836 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10033 .

_:79f295ad32df4ce8a18a92539c6e8a3b203837 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203838;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b203838 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10098 .

_:79f295ad32df4ce8a18a92539c6e8a3b203840 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10262-1 a owl:Class;
  rdfs:label "ANTIHYPERTENSEURS CENTRAUX <-> BÊTA-BLOQUANTS (SAUF ESMOLOL)"@fr;
  dct:identifier "IAM_10262";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b203842;
  r:natureDuRisque "Augmentation importante de la pression artérielle en cas d'arrêt brutal du traitement par l'antihypertenseur central."@fr;
  r:conduiteATenir "Eviter l'arrêt brutal du traitement par l'antihypertenseur central. Surveillance clinique."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b203848, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b203842 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b203843 .

_:79f295ad32df4ce8a18a92539c6e8a3b203843 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203844;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b203845 .

_:79f295ad32df4ce8a18a92539c6e8a3b203844 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10034 .

_:79f295ad32df4ce8a18a92539c6e8a3b203845 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203846;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b203846 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10054 .

_:79f295ad32df4ce8a18a92539c6e8a3b203848 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10263-1 a owl:Class;
  rdfs:label "ANTIHYPERTENSEURS CENTRAUX <-> BÊTA-BLOQUANTS DANS L'INSUFFISANCE CARDIAQUE"@fr;
  dct:identifier "IAM_10263";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b203850;
  r:natureDuRisque "Diminution centrale du tonus sympathique et effet vasodilatateur des antihypertenseurs centraux, préjudiciables en cas d'insuffisance cardiaque traitée par bêta-bloquant et vasodilatateur."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b203856, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b203850 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b203851 .

_:79f295ad32df4ce8a18a92539c6e8a3b203851 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203852;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b203853 .

_:79f295ad32df4ce8a18a92539c6e8a3b203852 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10034 .

_:79f295ad32df4ce8a18a92539c6e8a3b203853 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203854;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b203854 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10055 .

_:79f295ad32df4ce8a18a92539c6e8a3b203856 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10265-1 a owl:Class;
  rdfs:label "ANTI-INFLAMMATOIRES NON STÉROÏDIENS <-> AUTRES ANTI-INFLAMMATOIRES NON STÉROÏDIENS"@fr;
  dct:identifier "IAM_10265";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b203858;
  r:natureDuRisque "Avec les autres anti-inflammatoires non stéroïdiens : majoration du risque ulcérogène et hémorragique digestif."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b203860, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b203858 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10022 .

_:79f295ad32df4ce8a18a92539c6e8a3b203860 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10281-1 a owl:Class;
  rdfs:label "ANTI-INFLAMMATOIRES NON STÉROÏDIENS <-> TACROLIMUS"@fr;
  dct:identifier "IAM_10281";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b203862;
  r:natureDuRisque "Risque d’addition des effets néphrotoxiques, notamment chez le sujet âgé."@fr;
  r:conduiteATenir "Surveiller la fonction rénale en début de traitement par l’AINS."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b203868, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b203862 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b203863 .

_:79f295ad32df4ce8a18a92539c6e8a3b203863 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203864;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b203865 .

_:79f295ad32df4ce8a18a92539c6e8a3b203864 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10022 .

_:79f295ad32df4ce8a18a92539c6e8a3b203865 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203866;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b203866 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10880 .

_:79f295ad32df4ce8a18a92539c6e8a3b203868 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10267-1 a owl:Class;
  rdfs:label "ANTI-INFLAMMATOIRES NON STÉROÏDIENS <-> CICLOSPORINE"@fr;
  dct:identifier "IAM_10267";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b203870;
  r:natureDuRisque "Risque d’addition des effets néphrotoxiques, notamment chez le sujet âgé."@fr;
  r:conduiteATenir "Surveiller la fonction rénale en début de traitement par l’AINS."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b203876, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b203870 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b203871 .

_:79f295ad32df4ce8a18a92539c6e8a3b203871 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203872;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b203873 .

_:79f295ad32df4ce8a18a92539c6e8a3b203872 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10022 .

_:79f295ad32df4ce8a18a92539c6e8a3b203873 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203874;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b203874 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10193 .

_:79f295ad32df4ce8a18a92539c6e8a3b203876 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10255-1 a owl:Class;
  rdfs:label "ANTIDÉPRESSEURS IMIPRAMINIQUES <-> BÊTA-BLOQUANTS DANS L'INSUFFISANCE CARDIAQUE"@fr;
  dct:identifier "IAM_10255";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b203878;
  r:natureDuRisque "Effet vasodilatateur et risque d'hypotension, notamment orthostatique (effet additif)."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b203884, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b203878 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b203879 .

_:79f295ad32df4ce8a18a92539c6e8a3b203879 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203880;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b203881 .

_:79f295ad32df4ce8a18a92539c6e8a3b203880 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10032 .

_:79f295ad32df4ce8a18a92539c6e8a3b203881 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203882;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b203882 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10055 .

_:79f295ad32df4ce8a18a92539c6e8a3b203884 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10269-1 a owl:Class;
  rdfs:label "ANTI-INFLAMMATOIRES NON STÉROÏDIENS <-> DIURÉTIQUES"@fr;
  dct:identifier "IAM_10269";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b203886;
  r:natureDuRisque "Insuffisance rénale aiguë chez le malade à risque (sujet âgé et/ou déshydraté) par diminution de la filtration glomérulaire (inhibition des prostaglandines vasodilatatrices due aux anti-inflammatoires non stéroïdiens). Par ailleurs, réduction de l'effet a"@fr;
  r:conduiteATenir "Hydrater le malade et surveiller la fonction rénale en début de traitement."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b203892, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b203886 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b203887 .

_:79f295ad32df4ce8a18a92539c6e8a3b203887 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203888;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b203889 .

_:79f295ad32df4ce8a18a92539c6e8a3b203888 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10022 .

_:79f295ad32df4ce8a18a92539c6e8a3b203889 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203890;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b203890 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10063 .

_:79f295ad32df4ce8a18a92539c6e8a3b203892 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10270-1 a owl:Class;
  rdfs:label "ANTI-INFLAMMATOIRES NON STÉROÏDIENS <-> GLUCOCORTICOÏDES (SAUF HYDROCORTISONE)"@fr;
  dct:identifier "IAM_10270";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b203894;
  r:natureDuRisque "Augmentation du risque d’ulcération et d’hémorragie gastro-intestinale."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b203900, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b203894 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b203895 .

_:79f295ad32df4ce8a18a92539c6e8a3b203895 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203896;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b203897 .

_:79f295ad32df4ce8a18a92539c6e8a3b203896 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10022 .

_:79f295ad32df4ce8a18a92539c6e8a3b203897 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203898;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b203898 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10081 .

_:79f295ad32df4ce8a18a92539c6e8a3b203900 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10271-1 a owl:Class;
  rdfs:label "ANTI-INFLAMMATOIRES NON STÉROÏDIENS <-> HÉPARINES DE BAS POIDS MOLÉCULAIRE ET APPARENTÉS (DOSES CURATIVES ET/OU SUJET ÂGÉ)"@fr;
  dct:identifier "IAM_10271";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b203902;
  r:natureDuRisque "Augmentation du risque hémorragique (agression de la muqueuse gastroduodénale par les anti-inflammatoires non stéroïdiens)."@fr;
  r:conduiteATenir "Si l'association ne peut être évitée, surveillance clinique étroite."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b203908, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b203902 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b203903 .

_:79f295ad32df4ce8a18a92539c6e8a3b203903 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203904;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b203905 .

_:79f295ad32df4ce8a18a92539c6e8a3b203904 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10022 .

_:79f295ad32df4ce8a18a92539c6e8a3b203905 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203906;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b203906 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10089 .

_:79f295ad32df4ce8a18a92539c6e8a3b203908 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10272-1 a owl:Class;
  rdfs:label "ANTI-INFLAMMATOIRES NON STÉROÏDIENS <-> HÉPARINES DE BAS POIDS MOLÉCULAIRE ET APPARENTÉS (DOSES PRÉVENTIVES)"@fr;
  dct:identifier "IAM_10272";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b203910;
  r:chapeau """Dans le cas de leur utilisation à doses prophylactiques (en dehors du sujet âgé), l'utilisation de médicaments agissant à divers niveaux de l'hémostase majore le risque de saignement. 
Ainsi, chez le sujet non âgé, l'association de l'héparine ou de molécu"""@fr;
  r:natureDuRisque "Augmentation du risque hémorragique."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b203916, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b203910 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b203911 .

_:79f295ad32df4ce8a18a92539c6e8a3b203911 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203912;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b203913 .

_:79f295ad32df4ce8a18a92539c6e8a3b203912 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10022 .

_:79f295ad32df4ce8a18a92539c6e8a3b203913 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203914;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b203914 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10090 .

_:79f295ad32df4ce8a18a92539c6e8a3b203916 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10274-1 a owl:Class;
  rdfs:label "ANTI-INFLAMMATOIRES NON STÉROÏDIENS <-> HÉPARINES NON FRACTIONNÉES (DOSES PRÉVENTIVES)"@fr;
  dct:identifier "IAM_10274";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b203918;
  r:chapeau """Dans le cas de leur utilisation à doses prophylactiques (en dehors du sujet âgé), l'utilisation de médicaments agissant à divers niveaux de l'hémostase majore le risque de saignement. 
Ainsi, chez le sujet non âgé, l'association de l'héparine ou de molécu"""@fr;
  r:natureDuRisque "Augmentation du risque hémorragique."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b203924, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b203918 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b203919 .

_:79f295ad32df4ce8a18a92539c6e8a3b203919 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203920;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b203921 .

_:79f295ad32df4ce8a18a92539c6e8a3b203920 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10022 .

_:79f295ad32df4ce8a18a92539c6e8a3b203921 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203922;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b203922 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10092 .

_:79f295ad32df4ce8a18a92539c6e8a3b203924 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10273-1 a owl:Class;
  rdfs:label "ANTI-INFLAMMATOIRES NON STÉROÏDIENS <-> HÉPARINES NON FRACTIONNÉES (DOSES CURATIVES ET/OU SUJET ÂGÉ)"@fr;
  dct:identifier "IAM_10273";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b203926;
  r:natureDuRisque "Augmentation du risque hémorragique (agression de la muqueuse gastroduodénale par les anti-inflammatoires non stéroïdiens)."@fr;
  r:conduiteATenir "Si l'association ne peut être évitée, surveillance clinique étroite."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b203932, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b203926 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b203927 .

_:79f295ad32df4ce8a18a92539c6e8a3b203927 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203928;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b203929 .

_:79f295ad32df4ce8a18a92539c6e8a3b203928 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10022 .

_:79f295ad32df4ce8a18a92539c6e8a3b203929 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203930;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b203930 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10091 .

_:79f295ad32df4ce8a18a92539c6e8a3b203932 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10275-1 a owl:Class;
  rdfs:label "ANTI-INFLAMMATOIRES NON STÉROÏDIENS <-> INHIBITEURS DE L'ENZYME DE CONVERSION"@fr;
  dct:identifier "IAM_10275";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b203934;
  r:natureDuRisque "Insuffisance rénale aiguë chez le patient à risque (âgé, déshydraté, sous diurétiques, avec une fonction rénale altérée), par diminution de la filtration glomérulaire (inhibition des prostaglandines vasodilatatrices due aux anti-inflammatoires non stéroïd"@fr;
  r:conduiteATenir "Hydrater le malade et surveiller la fonction rénale en début de traitement et régulièrement pendant l’association."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b203940, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b203934 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b203935 .

_:79f295ad32df4ce8a18a92539c6e8a3b203935 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203936;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b203937 .

_:79f295ad32df4ce8a18a92539c6e8a3b203936 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10022 .

_:79f295ad32df4ce8a18a92539c6e8a3b203937 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203938;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b203938 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10096 .

_:79f295ad32df4ce8a18a92539c6e8a3b203940 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10276-1 a owl:Class;
  rdfs:label "ANTI-INFLAMMATOIRES NON STÉROÏDIENS <-> INHIBITEURS SÉLECTIFS DE LA RECAPTURE DE LA SÉROTONINE"@fr;
  dct:identifier "IAM_10276";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b203942;
  r:natureDuRisque "Majoration du risque hémorragique."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b203948, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b203942 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b203943 .

_:79f295ad32df4ce8a18a92539c6e8a3b203943 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203944;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b203945 .

_:79f295ad32df4ce8a18a92539c6e8a3b203944 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10022 .

_:79f295ad32df4ce8a18a92539c6e8a3b203945 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203946;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b203946 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10104 .

_:79f295ad32df4ce8a18a92539c6e8a3b203948 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10277-1 a owl:Class;
  rdfs:label "ANTI-INFLAMMATOIRES NON STÉROÏDIENS <-> LITHIUM"@fr;
  dct:identifier "IAM_10277";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b203950;
  r:natureDuRisque "Augmentation de la lithémie pouvant atteindre des valeurs toxiques (diminution de l'excrétion rénale du lithium)."@fr;
  r:conduiteATenir "Si l'association ne peut être évitée, surveiller étroitement la lithémie et adapter la posologie du lithium pendant l'association et après l'arrêt de l'anti-inflammatoire non stéroïdien."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b203956, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b203950 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b203951 .

_:79f295ad32df4ce8a18a92539c6e8a3b203951 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203952;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b203953 .

_:79f295ad32df4ce8a18a92539c6e8a3b203952 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10022 .

_:79f295ad32df4ce8a18a92539c6e8a3b203953 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203954;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b203954 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10530 .

_:79f295ad32df4ce8a18a92539c6e8a3b203956 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10278-1 a owl:Class;
  rdfs:label "ANTI-INFLAMMATOIRES NON STÉROÏDIENS <-> METHOTREXATE"@fr;
  dct:identifier "IAM_10278";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b203958;
  r:natureDuRisque "Augmentation de la toxicité hématologique du méthotrexate (diminution de la clairance rénale du méthotrexate par les anti-inflammatoires)."@fr;
  r:conduiteATenir """Association déconseillée:
- pour des doses de méthotrexate supérieures à 20 mg par semaine.
- avec le kétoprofène et le méthotrexate à des doses supérieures à 20 mg par semaines, respecter un intervalle d'au moins 12 heures entre l'arrêt ou le début d'un"""@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b203964, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b203958 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b203959 .

_:79f295ad32df4ce8a18a92539c6e8a3b203959 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203960;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b203961 .

_:79f295ad32df4ce8a18a92539c6e8a3b203960 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10022 .

_:79f295ad32df4ce8a18a92539c6e8a3b203961 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203962;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b203962 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10569 .

_:79f295ad32df4ce8a18a92539c6e8a3b203964 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10266-1 a owl:Class;
  rdfs:label "ANTI-INFLAMMATOIRES NON STÉROÏDIENS <-> BÊTA-BLOQUANTS (SAUF ESMOLOL)"@fr;
  dct:identifier "IAM_10266";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b203966;
  r:natureDuRisque "Réduction de l'effet antihypertenseur (inhibition des prostaglandines vasodilatatrices par les anti-inflammatoires non stéroïdiens)."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b203972, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b203966 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b203967 .

_:79f295ad32df4ce8a18a92539c6e8a3b203967 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203968;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b203969 .

_:79f295ad32df4ce8a18a92539c6e8a3b203968 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10022 .

_:79f295ad32df4ce8a18a92539c6e8a3b203969 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203970;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b203970 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10054 .

_:79f295ad32df4ce8a18a92539c6e8a3b203972 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10677-1 a owl:Class;
  rdfs:label "COLCHICINE <-> FIBRATES"@fr;
  dct:identifier "IAM_10677";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b203974;
  r:natureDuRisque "Risque de majoration des effets indésirables musculaires de ces substances, et notamment de rhabdomyolyse."@fr;
  r:conduiteATenir "Surveillance clinique et biologique, particulièrement au début de l’association."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b203980, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b203974 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b203975 .

_:79f295ad32df4ce8a18a92539c6e8a3b203975 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203976;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b203977 .

_:79f295ad32df4ce8a18a92539c6e8a3b203976 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10074 .

_:79f295ad32df4ce8a18a92539c6e8a3b203977 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203978;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b203978 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10225 .

_:79f295ad32df4ce8a18a92539c6e8a3b203980 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11229-1 a owl:Class;
  rdfs:label "LÉDIPASVIR <-> RIFAMPICINE"@fr;
  dct:identifier "IAM_11229";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b203982;
  r:natureDuRisque "Diminution importante des concentrations plasmatiques du lédipasvir par augmentation de son métabolisme hépatique par la rifampicine."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b203988, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b203982 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b203983 .

_:79f295ad32df4ce8a18a92539c6e8a3b203983 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203984;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b203985 .

_:79f295ad32df4ce8a18a92539c6e8a3b203984 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10512 .

_:79f295ad32df4ce8a18a92539c6e8a3b203985 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203986;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b203986 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:79f295ad32df4ce8a18a92539c6e8a3b203988 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10264-1 a owl:Class;
  rdfs:label "ANTI-INFLAMMATOIRES NON STÉROÏDIENS <-> ANTICOAGULANTS ORAUX"@fr;
  dct:identifier "IAM_10264";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b203990;
  r:natureDuRisque "Augmentation du risque hémorragique de l'anticoagulant oral (agression de la muqueuse gastroduodénale par les anti-inflammatoires non stéroïdiens)."@fr;
  r:conduiteATenir "Si l'association ne peut être évitée, surveillance clinique étroite, voire biologique ."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b203996, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b203990 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b203991 .

_:79f295ad32df4ce8a18a92539c6e8a3b203991 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203992;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b203993 .

_:79f295ad32df4ce8a18a92539c6e8a3b203992 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10022 .

_:79f295ad32df4ce8a18a92539c6e8a3b203993 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b203994;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b203994 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10028 .

_:79f295ad32df4ce8a18a92539c6e8a3b203996 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10202-1 a owl:Class;
  rdfs:label "ANTICOAGULANTS ORAUX <-> DÉFIBROTIDE"@fr;
  dct:identifier "IAM_10202";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b203998;
  r:natureDuRisque "Risque hémorragique accru."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b204004, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b203998 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b203999 .

_:79f295ad32df4ce8a18a92539c6e8a3b203999 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204000;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b204001 .

_:79f295ad32df4ce8a18a92539c6e8a3b204000 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10028 .

_:79f295ad32df4ce8a18a92539c6e8a3b204001 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204002;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b204002 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10262 .

_:79f295ad32df4ce8a18a92539c6e8a3b204004 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10203-1 a owl:Class;
  rdfs:label "ANTICOAGULANTS ORAUX <-> GLUCOCORTICOÏDES (SAUF HYDROCORTISONE)"@fr;
  dct:identifier "IAM_10203";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b204006;
  r:natureDuRisque "Glucocorticoïdes (voies générale et rectale) : impact éventuel de la corticothérapie sur le métabolisme de l'antivitamine K et sur celui des facteurs de la coagulation. Risque hémorragique propre à la corticothérapie (muqueuse digestive, fragilité vascula"@fr;
  r:conduiteATenir "Lorsque l'association est justifiée, renforcer la surveillance : le cas échéant, avec les antivitamines K, contrôle biologique au 8e jour, puis tous les 15 jours pendant la corticothérapie et après son arrêt."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b204012, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b204006 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b204007 .

_:79f295ad32df4ce8a18a92539c6e8a3b204007 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204008;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b204009 .

_:79f295ad32df4ce8a18a92539c6e8a3b204008 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10028 .

_:79f295ad32df4ce8a18a92539c6e8a3b204009 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204010;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b204010 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10081 .

_:79f295ad32df4ce8a18a92539c6e8a3b204012 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10353-1 a owl:Class;
  rdfs:label "ANTIVITAMINES K <-> PENTOXIFYLLINE"@fr;
  dct:identifier "IAM_10353";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b204014;
  r:natureDuRisque "Augmentation du risque hémorragique."@fr;
  r:conduiteATenir "Contrôle plus fréquent de l'INR. Adaptation éventuelle de la posologie de l'antivitamine K pendant le traitement par la pentoxifylline et 8 jours après son arrêt."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b204020, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b204014 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b204015 .

_:79f295ad32df4ce8a18a92539c6e8a3b204015 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204016;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b204017 .

_:79f295ad32df4ce8a18a92539c6e8a3b204016 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10046 .

_:79f295ad32df4ce8a18a92539c6e8a3b204017 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204018;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b204018 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10705 .

_:79f295ad32df4ce8a18a92539c6e8a3b204020 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10354-1 a owl:Class;
  rdfs:label "ANTIVITAMINES K <-> PRISTINAMYCINE"@fr;
  dct:identifier "IAM_10354";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b204022;
  r:natureDuRisque "Augmentation de l'effet de l'antivitamine K et du risque hémorragique."@fr;
  r:conduiteATenir "Contrôle plus fréquent de l'INR. Adaptation éventuelle de la posologie de l'antivitamine K pendant le traitement par la pristinamycine et après son arrêt."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b204028, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b204022 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b204023 .

_:79f295ad32df4ce8a18a92539c6e8a3b204023 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204024;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b204025 .

_:79f295ad32df4ce8a18a92539c6e8a3b204024 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10046 .

_:79f295ad32df4ce8a18a92539c6e8a3b204025 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204026;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b204026 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10757 .

_:79f295ad32df4ce8a18a92539c6e8a3b204028 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10355-1 a owl:Class;
  rdfs:label "ANTIVITAMINES K <-> PROGUANIL"@fr;
  dct:identifier "IAM_10355";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b204030;
  r:natureDuRisque "Risque d’augmentation de l’effet de l’antivitamine K et du risque hémorragique."@fr;
  r:conduiteATenir "Contrôle plus fréquent de l’INR. Adaptation éventuelle de la posologie de l’antivitamine K pendant le traitement par le proguanil et après son arrêt."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b204036, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b204030 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b204031 .

_:79f295ad32df4ce8a18a92539c6e8a3b204031 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204032;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b204033 .

_:79f295ad32df4ce8a18a92539c6e8a3b204032 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10046 .

_:79f295ad32df4ce8a18a92539c6e8a3b204033 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204034;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b204034 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10761 .

_:79f295ad32df4ce8a18a92539c6e8a3b204036 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10356-1 a owl:Class;
  rdfs:label "ANTIVITAMINES K <-> PROPAFENONE"@fr;
  dct:identifier "IAM_10356";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b204038;
  r:natureDuRisque "Augmentation de l'effet anticoagulant et du risque hémorragique. Mécanisme invoqué : inhibition du métabolisme de l'antivitamine K."@fr;
  r:conduiteATenir "Contrôle plus fréquent de l'INR. Adaptation éventuelle de la posologie de l'antivitamine K pendant le traitement par la propafénone et après son arrêt."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b204044, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b204038 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b204039 .

_:79f295ad32df4ce8a18a92539c6e8a3b204039 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204040;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b204041 .

_:79f295ad32df4ce8a18a92539c6e8a3b204040 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10046 .

_:79f295ad32df4ce8a18a92539c6e8a3b204041 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204042;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b204042 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10765 .

_:79f295ad32df4ce8a18a92539c6e8a3b204044 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10673-1 a owl:Class;
  rdfs:label "COBICISTAT <-> RIFAMPICINE"@fr;
  dct:identifier "IAM_10673";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b204046;
  r:natureDuRisque "Risque de diminution de l’efficacité du cobicistat par augmentation de son métabolisme par l’inducteur."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b204052, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b204046 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b204047 .

_:79f295ad32df4ce8a18a92539c6e8a3b204047 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204048;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b204049 .

_:79f295ad32df4ce8a18a92539c6e8a3b204048 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10221 .

_:79f295ad32df4ce8a18a92539c6e8a3b204049 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204050;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b204050 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:79f295ad32df4ce8a18a92539c6e8a3b204052 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10200-1 a owl:Class;
  rdfs:label "ANTICHOLINESTÉRASIQUES <-> SUXAMETHONIUM"@fr;
  dct:identifier "IAM_10200";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b204054;
  r:chapeau """(voir aussi \"bradycardisants\")

+ MEDICAMENTS ATROPINIQUES
Il convient de prendre en compte le risque lié à l'association d'un médicament à action atropinique (imipraminiques, neuroleptiques phénothiaziniques, antispasmodiques, certains antihistaminiques"""@fr;
  r:natureDuRisque "Risque d'allongement du bloc moteur, majoré en cas de déficit partiel en pseudocholinestérase."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b204060, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b204054 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b204055 .

_:79f295ad32df4ce8a18a92539c6e8a3b204055 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204056;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b204057 .

_:79f295ad32df4ce8a18a92539c6e8a3b204056 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10027 .

_:79f295ad32df4ce8a18a92539c6e8a3b204057 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204058;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b204058 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10878 .

_:79f295ad32df4ce8a18a92539c6e8a3b204060 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10676-1 a owl:Class;
  rdfs:label "COCAINE <-> DISULFIRAME"@fr;
  dct:identifier "IAM_10676";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b204062;
  r:natureDuRisque "Augmentation des concentrations de cocaïne par diminution de son métabolisme par le disulfirame, avec risque majoré de survenue de torsades de pointes."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b204068, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b204062 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b204063 .

_:79f295ad32df4ce8a18a92539c6e8a3b204063 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204064;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b204065 .

_:79f295ad32df4ce8a18a92539c6e8a3b204064 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10223 .

_:79f295ad32df4ce8a18a92539c6e8a3b204065 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204066;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b204066 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10299 .

_:79f295ad32df4ce8a18a92539c6e8a3b204068 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10199-1 a owl:Class;
  rdfs:label "ANTICHOLINESTÉRASIQUES <-> PILOCARPINE"@fr;
  dct:identifier "IAM_10199";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b204070;
  r:natureDuRisque "Risque d'addition des effets indésirables cholinergiques, notamment digestifs."@fr;
  rdfs:comment "La pilocarpine est un parasympathomimétique direct utilisé dans le traitement du glaucome sous forme de collyre. Il existe aussi une AMM par voie orale dont l’indication est l’hyposialie et la xérostomie après radiothérapie chez l’adulte, ainsi que les sé"@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b204076, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b204070 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b204071 .

_:79f295ad32df4ce8a18a92539c6e8a3b204071 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204072;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b204073 .

_:79f295ad32df4ce8a18a92539c6e8a3b204072 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10027 .

_:79f295ad32df4ce8a18a92539c6e8a3b204073 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204074;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b204074 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10719 .

_:79f295ad32df4ce8a18a92539c6e8a3b204076 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10678-1 a owl:Class;
  rdfs:label "COLCHICINE <-> FLUCONAZOLE"@fr;
  dct:identifier "IAM_10678";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b204078;
  r:natureDuRisque "Augmentation des effets indésirables de la colchicine, aux conséquences potentiellement fatales."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b204084, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b204078 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b204079 .

_:79f295ad32df4ce8a18a92539c6e8a3b204079 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204080;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b204081 .

_:79f295ad32df4ce8a18a92539c6e8a3b204080 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10225 .

_:79f295ad32df4ce8a18a92539c6e8a3b204081 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204082;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b204082 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10381 .

_:79f295ad32df4ce8a18a92539c6e8a3b204084 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10679-1 a owl:Class;
  rdfs:label "COLCHICINE <-> INHIBITEURS DE L'HMG-COA RÉDUCTASE (STATINES)"@fr;
  dct:identifier "IAM_10679";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b204086;
  r:natureDuRisque "Risque de majoration des effets indésirables musculaires de ces substances, et notamment de rhabdomyolyse."@fr;
  r:conduiteATenir "Surveillance clinique et biologique, notamment au début de l'association."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b204092, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b204086 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b204087 .

_:79f295ad32df4ce8a18a92539c6e8a3b204087 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204088;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b204089 .

_:79f295ad32df4ce8a18a92539c6e8a3b204088 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10095 .

_:79f295ad32df4ce8a18a92539c6e8a3b204089 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204090;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b204090 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10225 .

_:79f295ad32df4ce8a18a92539c6e8a3b204092 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10680-1 a owl:Class;
  rdfs:label "COLCHICINE <-> INHIBITEURS PUISSANTS DU CYP3A4"@fr;
  dct:identifier "IAM_10680";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b204094;
  r:natureDuRisque "Augmentation des effets indésirables de la colchicine, aux conséquences potentiellement fatales."@fr;
  r:conduiteATenir """Contre-indication :
- avec les macrolides

Association déconseillée :
- avec les antifongiques azolés, les inhibiteurs de protéases boostés par ritonavir et le cobicistat"""@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b204100, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b204094 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b204095 .

_:79f295ad32df4ce8a18a92539c6e8a3b204095 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204096;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b204097 .

_:79f295ad32df4ce8a18a92539c6e8a3b204096 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10103 .

_:79f295ad32df4ce8a18a92539c6e8a3b204097 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204098;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b204098 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10225 .

_:79f295ad32df4ce8a18a92539c6e8a3b204100 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10681-1 a owl:Class;
  rdfs:label "COLCHICINE <-> MACROLIDES (SAUF SPIRAMYCINE)"@fr;
  dct:identifier "IAM_10681";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b204102;
  r:natureDuRisque "Augmentation des effets indésirables de la colchicine, aux conséquences potentiellement fatales."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b204108, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b204102 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b204103 .

_:79f295ad32df4ce8a18a92539c6e8a3b204103 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204104;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b204105 .

_:79f295ad32df4ce8a18a92539c6e8a3b204104 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10107 .

_:79f295ad32df4ce8a18a92539c6e8a3b204105 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204106;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b204106 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10225 .

_:79f295ad32df4ce8a18a92539c6e8a3b204108 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10682-1 a owl:Class;
  rdfs:label "COLCHICINE <-> OMBITASVIR + PARITAPRÉVIR"@fr;
  dct:identifier "IAM_10682";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b204110;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de la colchicine par diminution de son métabolisme hépatique par la bithérapie."@fr;
  r:conduiteATenir """Contre-indication:
- chez les patients insuffisants rénaux et/ou hépatiques."""@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b204116, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b204110 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b204111 .

_:79f295ad32df4ce8a18a92539c6e8a3b204111 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204112;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b204113 .

_:79f295ad32df4ce8a18a92539c6e8a3b204112 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10128 .

_:79f295ad32df4ce8a18a92539c6e8a3b204113 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204114;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b204114 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10225 .

_:79f295ad32df4ce8a18a92539c6e8a3b204116 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10683-1 a owl:Class;
  rdfs:label "COLCHICINE <-> PRISTINAMYCINE"@fr;
  dct:identifier "IAM_10683";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b204118;
  r:natureDuRisque "Augmentation des effets indésirables de la colchicine aux conséquences potentiellement fatales."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b204124, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b204118 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b204119 .

_:79f295ad32df4ce8a18a92539c6e8a3b204119 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204120;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b204121 .

_:79f295ad32df4ce8a18a92539c6e8a3b204120 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10225 .

_:79f295ad32df4ce8a18a92539c6e8a3b204121 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204122;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b204122 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10757 .

_:79f295ad32df4ce8a18a92539c6e8a3b204124 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10684-1 a owl:Class;
  rdfs:label "COLCHICINE <-> VERAPAMIL"@fr;
  dct:identifier "IAM_10684";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b204126;
  r:natureDuRisque "Risque de majoration des effets indésirables de la colchicine, par augmentation de ses concentrations plasmatiques par le vérapamil."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b204132, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b204126 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b204127 .

_:79f295ad32df4ce8a18a92539c6e8a3b204127 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204128;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b204129 .

_:79f295ad32df4ce8a18a92539c6e8a3b204128 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10225 .

_:79f295ad32df4ce8a18a92539c6e8a3b204129 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204130;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b204130 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10980 .

_:79f295ad32df4ce8a18a92539c6e8a3b204132 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10685-1 a owl:Class;
  rdfs:label "COLISTINE <-> CURARES"@fr;
  dct:identifier "IAM_10685";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b204134;
  r:natureDuRisque "Potentialisation des curares lorque l'antibiotique est administré par voie parentérale et/ou péritonéale avant, pendant ou après l'agent curarisant."@fr;
  r:conduiteATenir "Surveiller le degré de curarisation en fin d'anesthésie."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b204140, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b204134 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b204135 .

_:79f295ad32df4ce8a18a92539c6e8a3b204135 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204136;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b204137 .

_:79f295ad32df4ce8a18a92539c6e8a3b204136 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10057 .

_:79f295ad32df4ce8a18a92539c6e8a3b204137 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204138;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b204138 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10228 .

_:79f295ad32df4ce8a18a92539c6e8a3b204140 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10686-1 a owl:Class;
  rdfs:label "CRIZOTINIB <-> SUBSTRATS À RISQUE DU CYP3A4"@fr;
  dct:identifier "IAM_10686";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b204142;
  r:natureDuRisque "Risque de majoration de la toxicité de ces molécules par diminution de leur métabolisme et/ou augmentation de leur biodisponibilité par le crizotinib."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b204148, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b204142 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b204143 .

_:79f295ad32df4ce8a18a92539c6e8a3b204143 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204144;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b204145 .

_:79f295ad32df4ce8a18a92539c6e8a3b204144 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10145 .

_:79f295ad32df4ce8a18a92539c6e8a3b204145 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204146;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b204146 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10231 .

_:79f295ad32df4ce8a18a92539c6e8a3b204148 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10229-1 a owl:Class;
  rdfs:label "ANTICONVULSIVANTS INDUCTEURS ENZYMATIQUES <-> METRONIDAZOLE"@fr;
  dct:identifier "IAM_10229";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b204150;
  r:natureDuRisque "Diminution des concentrations plasmatiques du métronidazole par augmentation de son métabolisme hépatique par l’inducteur."@fr;
  r:conduiteATenir "Surveillance clinique et adaptation éventuelle de la posologie de métronidazole pendant le traitement par l’inducteur et après son arrêt."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b204156, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b204150 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b204151 .

_:79f295ad32df4ce8a18a92539c6e8a3b204151 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204152;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b204153 .

_:79f295ad32df4ce8a18a92539c6e8a3b204152 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10029 .

_:79f295ad32df4ce8a18a92539c6e8a3b204153 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204154;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b204154 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10580 .

_:79f295ad32df4ce8a18a92539c6e8a3b204156 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10674-1 a owl:Class;
  rdfs:label "COBICISTAT <-> TÉNOFOVIR ALAFÉNAMIDE"@fr;
  dct:identifier "IAM_10674";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b204158;
  r:natureDuRisque "Avec l'atazanavir, le darunavir ou le lopinavir boostés par cobicistat, augmentation des concentrations plasmatiques du ténofovir alafénamide par augmentation de son absorption."@fr;
  r:conduiteATenir "En cas de co-administration, la dose de ténofovir alafénamide doit être limitée à 10 mg par jour. L’association avec les autres inhibiteurs de protéases du VIH n’a pas été étudiée."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b204164, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b204158 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b204159 .

_:79f295ad32df4ce8a18a92539c6e8a3b204159 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204160;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b204161 .

_:79f295ad32df4ce8a18a92539c6e8a3b204160 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10221 .

_:79f295ad32df4ce8a18a92539c6e8a3b204161 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204162;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b204162 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10895 .

_:79f295ad32df4ce8a18a92539c6e8a3b204164 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10215-1 a owl:Class;
  rdfs:label "ANTICONVULSIVANTS INDUCTEURS ENZYMATIQUES <-> DEFERASIROX"@fr;
  dct:identifier "IAM_10215";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b204166;
  r:natureDuRisque "Risque de diminution des concentrations plasmatiques de déférasirox."@fr;
  r:conduiteATenir "Surveiller la ferritinémie pendant et après le traitement par l’inducteur enzymatique. Si besoin, adaptation de la posologie de déférasirox."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b204172, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b204166 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b204167 .

_:79f295ad32df4ce8a18a92539c6e8a3b204167 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204168;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b204169 .

_:79f295ad32df4ce8a18a92539c6e8a3b204168 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10029 .

_:79f295ad32df4ce8a18a92539c6e8a3b204169 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204170;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b204170 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10259 .

_:79f295ad32df4ce8a18a92539c6e8a3b204172 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11078-1 a owl:Class;
  rdfs:label "IMMUNOSUPPRESSEURS <-> QUINUPRISTINE"@fr;
  dct:identifier "IAM_11078";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b204174;
  r:natureDuRisque "Augmentation des concentrations sanguines de l'immunosuppresseur par inhibition de son métabolisme hépatique."@fr;
  r:conduiteATenir "Dosage des concentrations sanguines de l'immunosuppresseur, contrôle de la fonction rénale et adaptation de la posologie pendant l'association et après son arrêt."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b204180, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b204174 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b204175 .

_:79f295ad32df4ce8a18a92539c6e8a3b204175 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204176;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b204177 .

_:79f295ad32df4ce8a18a92539c6e8a3b204176 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10093 .

_:79f295ad32df4ce8a18a92539c6e8a3b204177 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204178;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b204178 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10778 .

_:79f295ad32df4ce8a18a92539c6e8a3b204180 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10206-1 a owl:Class;
  rdfs:label "ANTICOAGULANTS ORAUX <-> IPILIMUMAB"@fr;
  dct:identifier "IAM_10206";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b204182;
  r:natureDuRisque "Augmentation du risque d'hémorragies digestives."@fr;
  r:conduiteATenir "Surveillance clinique étroite."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b204188, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b204182 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b204183 .

_:79f295ad32df4ce8a18a92539c6e8a3b204183 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204184;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b204185 .

_:79f295ad32df4ce8a18a92539c6e8a3b204184 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10028 .

_:79f295ad32df4ce8a18a92539c6e8a3b204185 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204186;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b204186 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10482 .

_:79f295ad32df4ce8a18a92539c6e8a3b204188 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10207-1 a owl:Class;
  rdfs:label "ANTICOAGULANTS ORAUX <-> MÉDICAMENTS MIXTES ADRÉNERGIQUES-SÉROTONINERGIQUES"@fr;
  dct:identifier "IAM_10207";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b204190;
  r:natureDuRisque "Augmentation du risque hémorragique."@fr;
  r:conduiteATenir "Surveillance clinique et, le cas échéant, contrôle plus fréquent de l'INR. Adaptation éventuelle de la posologie de l'anticoagulant oral pendant la durée de l'association et à son arrêt."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b204196, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b204190 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b204191 .

_:79f295ad32df4ce8a18a92539c6e8a3b204191 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204192;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b204193 .

_:79f295ad32df4ce8a18a92539c6e8a3b204192 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10028 .

_:79f295ad32df4ce8a18a92539c6e8a3b204193 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204194;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b204194 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10116 .

_:79f295ad32df4ce8a18a92539c6e8a3b204196 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10244-1 a owl:Class;
  rdfs:label "ANTICONVULSIVANTS INDUCTEURS ENZYMATIQUES <-> TELAPREVIR"@fr;
  dct:identifier "IAM_10244";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b204198;
  r:natureDuRisque "Risque de diminution très importante des concentrations de télaprévir."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b204204, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b204198 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b204199 .

_:79f295ad32df4ce8a18a92539c6e8a3b204199 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204200;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b204201 .

_:79f295ad32df4ce8a18a92539c6e8a3b204200 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10029 .

_:79f295ad32df4ce8a18a92539c6e8a3b204201 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204202;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b204202 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10887 .

_:79f295ad32df4ce8a18a92539c6e8a3b204204 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10208-1 a owl:Class;
  rdfs:label "ANTICONVULSIVANTS INDUCTEURS ENZYMATIQUES <-> ANTIVITAMINES K"@fr;
  dct:identifier "IAM_10208";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b204206;
  r:chapeau """ANTI-INFECTIEUX ET INR
De nombreux cas d’augmentation de l’activité des antivitamines K ont été rapportés chez des patients recevant des antibiotiques. Le contexte infectieux ou inflammatoire marqué, l’âge et l’état général du patient apparaissent comme d"""@fr;
  r:natureDuRisque "Diminution (ou, rarement, augmentation avec la phénytoïne) de l'effet de l'antivitamine K par augmentation de son métabolisme hépatique par l'anticonvulsivant inducteur."@fr;
  r:conduiteATenir "Contrôle plus fréquent de l'INR. Adaptation éventuelle de la posologie de l'antivitamine K pendant le traitement par l'anticonvulsivant inducteur et 8 jours après son arrêt."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b204212, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b204206 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b204207 .

_:79f295ad32df4ce8a18a92539c6e8a3b204207 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204208;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b204209 .

_:79f295ad32df4ce8a18a92539c6e8a3b204208 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10029 .

_:79f295ad32df4ce8a18a92539c6e8a3b204209 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204210;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b204210 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10046 .

_:79f295ad32df4ce8a18a92539c6e8a3b204212 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10209-1 a owl:Class;
  rdfs:label "ANTICONVULSIVANTS INDUCTEURS ENZYMATIQUES <-> APIXABAN"@fr;
  dct:identifier "IAM_10209";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b204214;
  r:natureDuRisque "Diminution des concentrations plasmatiques de l’apixaban par l' anticonvulsivant inducteur enzymatique, avec risque de diminution de l’effet thérapeutique."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b204220, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b204214 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b204215 .

_:79f295ad32df4ce8a18a92539c6e8a3b204215 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204216;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b204217 .

_:79f295ad32df4ce8a18a92539c6e8a3b204216 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10029 .

_:79f295ad32df4ce8a18a92539c6e8a3b204217 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204218;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b204218 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10078 .

_:79f295ad32df4ce8a18a92539c6e8a3b204220 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10210-1 a owl:Class;
  rdfs:label "ANTICONVULSIVANTS INDUCTEURS ENZYMATIQUES <-> APREPITANT"@fr;
  dct:identifier "IAM_10210";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b204222;
  r:natureDuRisque "Risque de diminution très importante des concentrations d'aprépitant."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b204228, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b204222 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b204223 .

_:79f295ad32df4ce8a18a92539c6e8a3b204223 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204224;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b204225 .

_:79f295ad32df4ce8a18a92539c6e8a3b204224 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10029 .

_:79f295ad32df4ce8a18a92539c6e8a3b204225 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204226;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b204226 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10080 .

_:79f295ad32df4ce8a18a92539c6e8a3b204228 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10211-1 a owl:Class;
  rdfs:label "ANTICONVULSIVANTS INDUCTEURS ENZYMATIQUES <-> BOCEPREVIR"@fr;
  dct:identifier "IAM_10211";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b204230;
  r:natureDuRisque "Risque de diminution des concentrations plasmatiques de bocéprévir."@fr;
  r:conduiteATenir "Si l’association ne peut être évitée, surveillance clinique et biologique régulière, notamment en début d'association."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b204236, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b204230 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b204231 .

_:79f295ad32df4ce8a18a92539c6e8a3b204231 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204232;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b204233 .

_:79f295ad32df4ce8a18a92539c6e8a3b204232 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10029 .

_:79f295ad32df4ce8a18a92539c6e8a3b204233 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204234;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b204234 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10126 .

_:79f295ad32df4ce8a18a92539c6e8a3b204236 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10212-1 a owl:Class;
  rdfs:label "ANTICONVULSIVANTS INDUCTEURS ENZYMATIQUES <-> BOSENTAN"@fr;
  dct:identifier "IAM_10212";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b204238;
  r:natureDuRisque "Risque de diminution des concentrations plasmatiques de bosentan."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b204244, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b204238 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b204239 .

_:79f295ad32df4ce8a18a92539c6e8a3b204239 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204240;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b204241 .

_:79f295ad32df4ce8a18a92539c6e8a3b204240 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10029 .

_:79f295ad32df4ce8a18a92539c6e8a3b204241 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204242;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b204242 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10129 .

_:79f295ad32df4ce8a18a92539c6e8a3b204244 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10201-1 a owl:Class;
  rdfs:label "ANTICOAGULANTS ORAUX <-> AUTRES ANTICOAGULANTS ORAUX"@fr;
  dct:identifier "IAM_10201";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b204246;
  r:natureDuRisque "Risque de majoration des événements hémorragiques lors du relais d'un anticoagulant oral par un autre."@fr;
  r:conduiteATenir "Tenir compte de la demi-vie de l'anticoagulant oral et observer, le cas échéant, un délai de carence avant le début du traitement par l'autre. Penser à informer le patient."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b204248, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b204246 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10028 .

_:79f295ad32df4ce8a18a92539c6e8a3b204248 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10214-1 a owl:Class;
  rdfs:label "ANTICONVULSIVANTS INDUCTEURS ENZYMATIQUES <-> DABIGATRAN"@fr;
  dct:identifier "IAM_10214";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b204250;
  r:natureDuRisque "Diminution des concentrations plasmatiques de dabigatran, avec risque de diminution de l'effet thérapeutique."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b204256, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b204250 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b204251 .

_:79f295ad32df4ce8a18a92539c6e8a3b204251 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204252;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b204253 .

_:79f295ad32df4ce8a18a92539c6e8a3b204252 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10029 .

_:79f295ad32df4ce8a18a92539c6e8a3b204253 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204254;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b204254 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10240 .

_:79f295ad32df4ce8a18a92539c6e8a3b204256 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11230-1 a owl:Class;
  rdfs:label "LÉDIPASVIR <-> TENOFOVIR DISOPROXIL"@fr;
  dct:identifier "IAM_11230";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b204258;
  r:natureDuRisque "Lors de sa co-administration avec un inhibiteur de protéase, augmentation des concentrations plasmatiques du ténofovir par le lédipasvir."@fr;
  r:conduiteATenir "Surveillance clinique et biologique, notamment de la fonction rénale."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b204264, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b204258 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b204259 .

_:79f295ad32df4ce8a18a92539c6e8a3b204259 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204260;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b204261 .

_:79f295ad32df4ce8a18a92539c6e8a3b204260 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10512 .

_:79f295ad32df4ce8a18a92539c6e8a3b204261 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204262;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b204262 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10896 .

_:79f295ad32df4ce8a18a92539c6e8a3b204264 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10216-1 a owl:Class;
  rdfs:label "ANTICONVULSIVANTS INDUCTEURS ENZYMATIQUES <-> DÉLAMANID"@fr;
  dct:identifier "IAM_10216";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b204266;
  r:natureDuRisque "Diminution des concentrations plasmatiques de delamanid par augmentation de son métabolisme hépatique par l’inducteur."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b204272, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b204266 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b204267 .

_:79f295ad32df4ce8a18a92539c6e8a3b204267 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204268;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b204269 .

_:79f295ad32df4ce8a18a92539c6e8a3b204268 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10029 .

_:79f295ad32df4ce8a18a92539c6e8a3b204269 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204270;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b204270 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10263 .

_:79f295ad32df4ce8a18a92539c6e8a3b204272 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10217-1 a owl:Class;
  rdfs:label "ANTICONVULSIVANTS INDUCTEURS ENZYMATIQUES <-> DOXYCYCLINE"@fr;
  dct:identifier "IAM_10217";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b204274;
  r:natureDuRisque "Diminution des concentrations plasmatiques de la doxycycline par augmentation de son métabolisme hépatique par l'inducteur."@fr;
  r:conduiteATenir "Surveillance clinique et adaptation éventuelle de la posologie de la doxycycline."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b204280, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b204274 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b204275 .

_:79f295ad32df4ce8a18a92539c6e8a3b204275 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204276;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b204277 .

_:79f295ad32df4ce8a18a92539c6e8a3b204276 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10029 .

_:79f295ad32df4ce8a18a92539c6e8a3b204277 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204278;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b204278 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10309 .

_:79f295ad32df4ce8a18a92539c6e8a3b204280 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10218-1 a owl:Class;
  rdfs:label "ANTICONVULSIVANTS INDUCTEURS ENZYMATIQUES <-> DRONEDARONE"@fr;
  dct:identifier "IAM_10218";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b204282;
  r:natureDuRisque "Diminution importante des concentrations de dronédarone par augmentation de son métabolisme, sans modification notable du métabolite actif."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b204288, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b204282 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b204283 .

_:79f295ad32df4ce8a18a92539c6e8a3b204283 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204284;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b204285 .

_:79f295ad32df4ce8a18a92539c6e8a3b204284 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10029 .

_:79f295ad32df4ce8a18a92539c6e8a3b204285 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204286;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b204286 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10311 .

_:79f295ad32df4ce8a18a92539c6e8a3b204288 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10219-1 a owl:Class;
  rdfs:label "ANTICONVULSIVANTS INDUCTEURS ENZYMATIQUES <-> ESTROGÈNES NON CONTRACEPTIFS"@fr;
  dct:identifier "IAM_10219";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b204290;
  r:natureDuRisque "Diminution de l'efficacité de l'estrogène."@fr;
  r:conduiteATenir "Surveillance clinique et adaptation éventuelle de la posologie du traitement hormonal pendant l'administration de l'anticonvulsivant inducteur et après son arrêt."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b204296, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b204290 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b204291 .

_:79f295ad32df4ce8a18a92539c6e8a3b204291 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204292;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b204293 .

_:79f295ad32df4ce8a18a92539c6e8a3b204292 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10029 .

_:79f295ad32df4ce8a18a92539c6e8a3b204293 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204294;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b204294 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10072 .

_:79f295ad32df4ce8a18a92539c6e8a3b204296 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10220-1 a owl:Class;
  rdfs:label "ANTICONVULSIVANTS INDUCTEURS ENZYMATIQUES <-> FENTANYL"@fr;
  dct:identifier "IAM_10220";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b204298;
  r:natureDuRisque "Diminution des concentrations plasmatiques de fentanyl par augmentation de son métabolisme hépatique par l'anticonvulsivant."@fr;
  r:conduiteATenir "Préférer un autre morphinique."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b204304, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b204298 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b204299 .

_:79f295ad32df4ce8a18a92539c6e8a3b204299 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204300;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b204301 .

_:79f295ad32df4ce8a18a92539c6e8a3b204300 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10029 .

_:79f295ad32df4ce8a18a92539c6e8a3b204301 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204302;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b204302 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10374 .

_:79f295ad32df4ce8a18a92539c6e8a3b204304 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10221-1 a owl:Class;
  rdfs:label "ANTICONVULSIVANTS INDUCTEURS ENZYMATIQUES <-> GLUCOCORTICOÏDES (SAUF HYDROCORTISONE)"@fr;
  dct:identifier "IAM_10221";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b204306;
  r:natureDuRisque "Diminution des concentrations plasmatiques et de l'efficacité des corticoïdes par augmentation de leur métabolisme hépatique par l'inducteur : les conséquences sont particulièrement importantes chez les addisoniens traités par l'hydrocortisone et en cas d"@fr;
  r:conduiteATenir "Surveillance clinique et biologique ; adaptation de la posologie des corticoïdes pendant le traitement par l'inducteur et après son arrêt."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b204312, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b204306 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b204307 .

_:79f295ad32df4ce8a18a92539c6e8a3b204307 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204308;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b204309 .

_:79f295ad32df4ce8a18a92539c6e8a3b204308 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10029 .

_:79f295ad32df4ce8a18a92539c6e8a3b204309 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204310;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b204310 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10081 .

_:79f295ad32df4ce8a18a92539c6e8a3b204312 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10222-1 a owl:Class;
  rdfs:label "ANTICONVULSIVANTS INDUCTEURS ENZYMATIQUES <-> HALOPERIDOL"@fr;
  dct:identifier "IAM_10222";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b204314;
  r:natureDuRisque "Surveillance clinique et, si besoin, adaptation posologique pendant le traitement par la carbamazépine et après son arrêt."@fr;
  r:conduiteATenir "Surveillance clinique et, si besoin, adaptation posologique pendant le traitement par la carbamazépine et après son arrêt."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b204320, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b204314 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b204315 .

_:79f295ad32df4ce8a18a92539c6e8a3b204315 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204316;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b204317 .

_:79f295ad32df4ce8a18a92539c6e8a3b204316 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10029 .

_:79f295ad32df4ce8a18a92539c6e8a3b204317 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204318;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b204318 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10426 .

_:79f295ad32df4ce8a18a92539c6e8a3b204320 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10223-1 a owl:Class;
  rdfs:label "ANTICONVULSIVANTS INDUCTEURS ENZYMATIQUES <-> HORMONES THYROÏDIENNES"@fr;
  dct:identifier "IAM_10223";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b204322;
  r:natureDuRisque "Risque d'hypothyroïdie clinique chez les patients hypothyroïdiens, par augmentation du métabolisme de la T3 et de la T4."@fr;
  r:conduiteATenir "Surveillance des concentrations sériques de T3 et de T4 et adaptation, si besoin, de la posologie des hormones thyroïdiennes pendant le traitement par l'inducteur et après son arrêt."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b204328, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b204322 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b204323 .

_:79f295ad32df4ce8a18a92539c6e8a3b204323 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204324;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b204325 .

_:79f295ad32df4ce8a18a92539c6e8a3b204324 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10029 .

_:79f295ad32df4ce8a18a92539c6e8a3b204325 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204326;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b204326 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10082 .

_:79f295ad32df4ce8a18a92539c6e8a3b204328 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10197-1 a owl:Class;
  rdfs:label "ANTIARYTHMIQUES CLASSE IA <-> RIFAMPICINE"@fr;
  dct:identifier "IAM_10197";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b204330;
  r:natureDuRisque "Diminution des concentrations plasmatiques et de l'efficacité de l'antiarythmique (augmentation de son métabolisme hépatique)."@fr;
  r:conduiteATenir "Surveillance clinique, ECG et éventuellement de la concentration plasmatique de l'antiarythmique. Si besoin, adaptation de la posologie de l'antiarythmique pendant le traitement par la rifampicine et après son arrêt (risque de surdosage en antiarythmique)"@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b204336, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b204330 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b204331 .

_:79f295ad32df4ce8a18a92539c6e8a3b204331 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204332;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b204333 .

_:79f295ad32df4ce8a18a92539c6e8a3b204332 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10026 .

_:79f295ad32df4ce8a18a92539c6e8a3b204333 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204334;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b204334 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:79f295ad32df4ce8a18a92539c6e8a3b204336 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10198-1 a owl:Class;
  rdfs:label "ANTICHOLINESTÉRASIQUES <-> BÊTA-BLOQUANTS DANS L'INSUFFISANCE CARDIAQUE"@fr;
  dct:identifier "IAM_10198";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b204338;
  r:chapeau """(voir aussi \"bradycardisants\")

+ MEDICAMENTS ATROPINIQUES
Il convient de prendre en compte le risque lié à l'association d'un médicament à action atropinique (imipraminiques, neuroleptiques phénothiaziniques, antispasmodiques, certains antihistaminiques"""@fr;
  r:natureDuRisque "Risque de bradycardie excessive (addition des effets bradycardisants)."@fr;
  r:conduiteATenir "Surveillance clinique régulière, notamment en début d'association."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b204344, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b204338 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b204339 .

_:79f295ad32df4ce8a18a92539c6e8a3b204339 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204340;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b204341 .

_:79f295ad32df4ce8a18a92539c6e8a3b204340 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10027 .

_:79f295ad32df4ce8a18a92539c6e8a3b204341 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204342;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b204342 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10055 .

_:79f295ad32df4ce8a18a92539c6e8a3b204344 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10213-1 a owl:Class;
  rdfs:label "ANTICONVULSIVANTS INDUCTEURS ENZYMATIQUES <-> COBICISTAT"@fr;
  dct:identifier "IAM_10213";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b204346;
  r:natureDuRisque "Risque de diminution de l’efficacité du cobicistat par augmentation de son métabolisme par l’inducteur."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b204352, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b204346 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b204347 .

_:79f295ad32df4ce8a18a92539c6e8a3b204347 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204348;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b204349 .

_:79f295ad32df4ce8a18a92539c6e8a3b204348 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10029 .

_:79f295ad32df4ce8a18a92539c6e8a3b204349 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204350;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b204350 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10221 .

_:79f295ad32df4ce8a18a92539c6e8a3b204352 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10588-1 a owl:Class;
  rdfs:label "CICLOSPORINE <-> FIDAXOMICINE"@fr;
  dct:identifier "IAM_10588";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b204354;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de la fidaxomicine."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b204360, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b204354 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b204355 .

_:79f295ad32df4ce8a18a92539c6e8a3b204355 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204356;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b204357 .

_:79f295ad32df4ce8a18a92539c6e8a3b204356 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10193 .

_:79f295ad32df4ce8a18a92539c6e8a3b204357 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204358;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b204358 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10378 .

_:79f295ad32df4ce8a18a92539c6e8a3b204360 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10998-1 a owl:Class;
  rdfs:label "GLOBULINES ANTILYMPHOCYTAIRES <-> IMMUNOSUPPRESSEURS"@fr;
  dct:identifier "IAM_10998";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b204362;
  r:natureDuRisque "Immunodépression excessive avec risque de lymphoprolifération."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b204368, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b204362 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b204363 .

_:79f295ad32df4ce8a18a92539c6e8a3b204363 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204364;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b204365 .

_:79f295ad32df4ce8a18a92539c6e8a3b204364 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10080 .

_:79f295ad32df4ce8a18a92539c6e8a3b204365 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204366;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b204366 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10093 .

_:79f295ad32df4ce8a18a92539c6e8a3b204368 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10578-1 a owl:Class;
  rdfs:label "CICLOSPORINE <-> CLINDAMYCINE"@fr;
  dct:identifier "IAM_10578";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b204370;
  r:natureDuRisque "Diminution des concentrations sanguines de l'immunosuppresseur avec risque de perte de l'activité immunosuppressive."@fr;
  r:conduiteATenir "Contrôle renforcé des dosages sanguins de ciclosporine et augmentation éventuelle de sa posologie."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b204376, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b204370 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b204371 .

_:79f295ad32df4ce8a18a92539c6e8a3b204371 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204372;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b204373 .

_:79f295ad32df4ce8a18a92539c6e8a3b204372 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10193 .

_:79f295ad32df4ce8a18a92539c6e8a3b204373 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204374;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b204374 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10209 .

_:79f295ad32df4ce8a18a92539c6e8a3b204376 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10579-1 a owl:Class;
  rdfs:label "CICLOSPORINE <-> COLCHICINE"@fr;
  dct:identifier "IAM_10579";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b204378;
  r:natureDuRisque "Risque d’addition des effets indésirables neuromusculaires et augmentation de la toxicité de la colchicine avec risque de surdosage par inhibition de son élimination par la ciclosporine, notamment en cas d’insuffisance rénale préexistante."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b204384, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b204378 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b204379 .

_:79f295ad32df4ce8a18a92539c6e8a3b204379 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204380;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b204381 .

_:79f295ad32df4ce8a18a92539c6e8a3b204380 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10193 .

_:79f295ad32df4ce8a18a92539c6e8a3b204381 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204382;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b204382 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10225 .

_:79f295ad32df4ce8a18a92539c6e8a3b204384 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10580-1 a owl:Class;
  rdfs:label "CICLOSPORINE <-> DABIGATRAN"@fr;
  dct:identifier "IAM_10580";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b204386;
  r:natureDuRisque "Augmentation de plus du double des concentrations plasmatiques de dabigatran, avec majoration du risque de saignement."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b204392, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b204386 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b204387 .

_:79f295ad32df4ce8a18a92539c6e8a3b204387 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204388;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b204389 .

_:79f295ad32df4ce8a18a92539c6e8a3b204388 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10193 .

_:79f295ad32df4ce8a18a92539c6e8a3b204389 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204390;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b204390 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10240 .

_:79f295ad32df4ce8a18a92539c6e8a3b204392 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10581-1 a owl:Class;
  rdfs:label "CICLOSPORINE <-> DANAZOL"@fr;
  dct:identifier "IAM_10581";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b204394;
  r:natureDuRisque "Augmentation des concentrations sanguines de ciclosporine par inhibition de son métabolisme hépatique."@fr;
  r:conduiteATenir "Dosage des concentrations sanguines de ciclosporine, contrôle de la fonction rénale et adaptation de la posologie pendant l’association et après son arrêt."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b204400, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b204394 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b204395 .

_:79f295ad32df4ce8a18a92539c6e8a3b204395 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204396;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b204397 .

_:79f295ad32df4ce8a18a92539c6e8a3b204396 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10193 .

_:79f295ad32df4ce8a18a92539c6e8a3b204397 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204398;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b204398 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10248 .

_:79f295ad32df4ce8a18a92539c6e8a3b204400 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10582-1 a owl:Class;
  rdfs:label "CICLOSPORINE <-> DIURÉTIQUES ÉPARGNEURS DE POTASSIUM (SEULS OU ASSOCIÉS)"@fr;
  dct:identifier "IAM_10582";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b204402;
  r:natureDuRisque "Hyperkaliémie potentiellement létale, surtout lors d'une insuffisance rénale (addition des effets hyperkaliémiants)."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b204408, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b204402 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b204403 .

_:79f295ad32df4ce8a18a92539c6e8a3b204403 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204404;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b204405 .

_:79f295ad32df4ce8a18a92539c6e8a3b204404 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10067 .

_:79f295ad32df4ce8a18a92539c6e8a3b204405 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204406;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b204406 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10193 .

_:79f295ad32df4ce8a18a92539c6e8a3b204408 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10583-1 a owl:Class;
  rdfs:label "CICLOSPORINE <-> DIURÉTIQUES HYPOKALIÉMIANTS"@fr;
  dct:identifier "IAM_10583";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b204410;
  r:natureDuRisque "Risque d'augmentation de la créatininémie sans modification des concentrations sanguines de ciclosporine, même en l'absence de déplétion hydrosodée. Egalement, risque d'hyperuricémie et de complications comme la goutte."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b204416, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b204410 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b204411 .

_:79f295ad32df4ce8a18a92539c6e8a3b204411 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204412;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b204413 .

_:79f295ad32df4ce8a18a92539c6e8a3b204412 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10065 .

_:79f295ad32df4ce8a18a92539c6e8a3b204413 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204414;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b204414 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10193 .

_:79f295ad32df4ce8a18a92539c6e8a3b204416 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10584-1 a owl:Class;
  rdfs:label "CICLOSPORINE <-> ÉRIBULINE"@fr;
  dct:identifier "IAM_10584";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b204418;
  r:natureDuRisque "Augmentation des concentrations plasmatiques d’éribuline par la ciclosporine."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b204424, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b204418 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b204419 .

_:79f295ad32df4ce8a18a92539c6e8a3b204419 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204420;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b204421 .

_:79f295ad32df4ce8a18a92539c6e8a3b204420 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10193 .

_:79f295ad32df4ce8a18a92539c6e8a3b204421 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204422;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b204422 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10335 .

_:79f295ad32df4ce8a18a92539c6e8a3b204424 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10585-1 a owl:Class;
  rdfs:label "CICLOSPORINE <-> EVEROLIMUS"@fr;
  dct:identifier "IAM_10585";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b204426;
  r:natureDuRisque "Augmentation des concentrations sanguines de l’évérolimus par la ciclosporine. La néphrotoxicité de la ciclosporine est également augmentée lors de l’association."@fr;
  r:conduiteATenir "Dosage des concentrations sanguines d’évérolimus, éventuellement adaptation de la posologie et contrôle de la fonction rénale, pendant l’association et après son arrêt."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b204432, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b204426 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b204427 .

_:79f295ad32df4ce8a18a92539c6e8a3b204427 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204428;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b204429 .

_:79f295ad32df4ce8a18a92539c6e8a3b204428 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10193 .

_:79f295ad32df4ce8a18a92539c6e8a3b204429 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204430;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b204430 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10363 .

_:79f295ad32df4ce8a18a92539c6e8a3b204432 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10510-1 a owl:Class;
  rdfs:label "BUSPIRONE <-> DILTIAZEM"@fr;
  dct:identifier "IAM_10510";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b204434;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de la buspirone par diminution de son métabolisme hépatique par le diltiazem, avec augmentation de ses effets indésirables."@fr;
  r:conduiteATenir "Surveillance clinique et adaptation de la posologie de la buspirone si nécessaire."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b204440, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b204434 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b204435 .

_:79f295ad32df4ce8a18a92539c6e8a3b204435 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204436;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b204437 .

_:79f295ad32df4ce8a18a92539c6e8a3b204436 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10141 .

_:79f295ad32df4ce8a18a92539c6e8a3b204437 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204438;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b204438 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10290 .

_:79f295ad32df4ce8a18a92539c6e8a3b204440 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10587-1 a owl:Class;
  rdfs:label "CICLOSPORINE <-> FENOFIBRATE"@fr;
  dct:identifier "IAM_10587";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b204442;
  r:natureDuRisque "Risque d'augmentation de la néphrotoxicité de la ciclosporine."@fr;
  r:conduiteATenir "Surveillance clinique et biologique de la fonction rénale, pendant et après l'association."@fr;
  rdfs:comment "Des augmentations réversibles de la créatininémie ont été rapportées parmi les évènements indésirables rares du fénofibrate. De plus, diverses données bibliographiques indiquent une potentialisation du risque de néphrotoxicité chez des patients transplant"@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b204448, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b204442 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b204443 .

_:79f295ad32df4ce8a18a92539c6e8a3b204443 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204444;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b204445 .

_:79f295ad32df4ce8a18a92539c6e8a3b204444 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10193 .

_:79f295ad32df4ce8a18a92539c6e8a3b204445 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204446;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b204446 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10371 .

_:79f295ad32df4ce8a18a92539c6e8a3b204448 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10509-1 a owl:Class;
  rdfs:label "BUSPIRONE <-> DIAZEPAM"@fr;
  dct:identifier "IAM_10509";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b204450;
  r:natureDuRisque "Risque de majoration des effets indésirables de la buspirone."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b204456, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b204450 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b204451 .

_:79f295ad32df4ce8a18a92539c6e8a3b204451 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204452;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b204453 .

_:79f295ad32df4ce8a18a92539c6e8a3b204452 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10141 .

_:79f295ad32df4ce8a18a92539c6e8a3b204453 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204454;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b204454 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10280 .

_:79f295ad32df4ce8a18a92539c6e8a3b204456 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10882-1 a owl:Class;
  rdfs:label "EPLERENONE <-> INHIBITEURS PUISSANTS DU CYP3A4"@fr;
  dct:identifier "IAM_10882";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b204458;
  r:natureDuRisque "Risque d’augmentation des concentrations plasmatiques de l’éplérénone par l'inhibiteur et de ses effets indésirables, notamment l’hyperkaliémie."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b204464, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b204458 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b204459 .

_:79f295ad32df4ce8a18a92539c6e8a3b204459 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204460;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b204461 .

_:79f295ad32df4ce8a18a92539c6e8a3b204460 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10103 .

_:79f295ad32df4ce8a18a92539c6e8a3b204461 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204462;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b204462 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10329 .

_:79f295ad32df4ce8a18a92539c6e8a3b204464 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10883-1 a owl:Class;
  rdfs:label "ERGOTAMINE <-> MACROLIDES (SAUF SPIRAMYCINE)"@fr;
  dct:identifier "IAM_10883";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b204466;
  r:natureDuRisque "Ergotisme avec possibilité de nécrose des extrémités (diminution de l'élimination hépatique de l'ergotamine)."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b204472, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b204466 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b204467 .

_:79f295ad32df4ce8a18a92539c6e8a3b204467 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204468;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b204469 .

_:79f295ad32df4ce8a18a92539c6e8a3b204468 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10107 .

_:79f295ad32df4ce8a18a92539c6e8a3b204469 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204470;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b204470 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10334 .

_:79f295ad32df4ce8a18a92539c6e8a3b204472 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10884-1 a owl:Class;
  rdfs:label "ERGOTAMINE <-> OXPRENOLOL"@fr;
  dct:identifier "IAM_10884";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b204474;
  r:natureDuRisque "Ergotisme : quelques cas de spasme artériel avec ischémie des extrémités ont été observés (addition d'effets vasculaires)."@fr;
  r:conduiteATenir "Surveillance clinique renforcée, en particulier pendant les premières semaines de l'association."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b204480, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b204474 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b204475 .

_:79f295ad32df4ce8a18a92539c6e8a3b204475 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204476;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b204477 .

_:79f295ad32df4ce8a18a92539c6e8a3b204476 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10334 .

_:79f295ad32df4ce8a18a92539c6e8a3b204477 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204478;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b204478 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10678 .

_:79f295ad32df4ce8a18a92539c6e8a3b204480 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10885-1 a owl:Class;
  rdfs:label "ERGOTAMINE <-> PROPRANOLOL"@fr;
  dct:identifier "IAM_10885";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b204482;
  r:natureDuRisque "Ergotisme : quelques cas de spasme artériel avec ischémie des extrémités ont été observés (addition d'effets vasculaires)."@fr;
  r:conduiteATenir "Surveillance clinique renforcée, en particulier pendant les premières semaines de l'association."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b204488, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b204482 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b204483 .

_:79f295ad32df4ce8a18a92539c6e8a3b204483 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204484;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b204485 .

_:79f295ad32df4ce8a18a92539c6e8a3b204484 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10334 .

_:79f295ad32df4ce8a18a92539c6e8a3b204485 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204486;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b204486 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10767 .

_:79f295ad32df4ce8a18a92539c6e8a3b204488 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10886-1 a owl:Class;
  rdfs:label "ERGOTAMINE <-> QUINUPRISTINE"@fr;
  dct:identifier "IAM_10886";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b204490;
  r:natureDuRisque "Ergotisme avec possibilité de nécrose des extrémités (inhibition du métabolisme hépatique de l'alcaloïde de l'ergot de seigle)."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b204496, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b204490 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b204491 .

_:79f295ad32df4ce8a18a92539c6e8a3b204491 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204492;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b204493 .

_:79f295ad32df4ce8a18a92539c6e8a3b204492 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10334 .

_:79f295ad32df4ce8a18a92539c6e8a3b204493 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204494;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b204494 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10778 .

_:79f295ad32df4ce8a18a92539c6e8a3b204496 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10887-1 a owl:Class;
  rdfs:label "ERGOTAMINE <-> STIRIPENTOL"@fr;
  dct:identifier "IAM_10887";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b204498;
  r:natureDuRisque "Ergotisme avec possibilité de nécrose des extrémités (inhibition de l’élimination hépatique de l'alcaloïde de l’ergot de seigle)."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b204504, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b204498 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b204499 .

_:79f295ad32df4ce8a18a92539c6e8a3b204499 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204500;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b204501 .

_:79f295ad32df4ce8a18a92539c6e8a3b204500 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10334 .

_:79f295ad32df4ce8a18a92539c6e8a3b204501 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204502;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b204502 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10859 .

_:79f295ad32df4ce8a18a92539c6e8a3b204504 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10224-1 a owl:Class;
  rdfs:label "ANTICONVULSIVANTS INDUCTEURS ENZYMATIQUES <-> IDÉLALISIB"@fr;
  dct:identifier "IAM_10224";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b204506;
  r:natureDuRisque "Diminution des concentrations plasmatiques d’idélalisib par augmentation de son métabolisme hépatique par l'anticonvulsivant inducteur enzymatique."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b204512, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b204506 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b204507 .

_:79f295ad32df4ce8a18a92539c6e8a3b204507 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204508;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b204509 .

_:79f295ad32df4ce8a18a92539c6e8a3b204508 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10029 .

_:79f295ad32df4ce8a18a92539c6e8a3b204509 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204510;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b204510 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10444 .

_:79f295ad32df4ce8a18a92539c6e8a3b204512 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10225-1 a owl:Class;
  rdfs:label "ANTICONVULSIVANTS INDUCTEURS ENZYMATIQUES <-> INHIBITEURS DE PROTÉASES BOOSTÉS PAR RITONAVIR"@fr;
  dct:identifier "IAM_10225";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b204514;
  r:chapeau "Le ritonavir est désormais utilisé à la dose de 100 mg 2 fois par jour en association à un autre inhibiteur de protéase, dans le but d'augmenter de façon très significative la biodisponibilité de l'inhibiteur de protéase associé (ou boosté), ce qui permet"@fr;
  r:natureDuRisque "Risque de baisse de l'efficacité de l'inhibiteur de protéases par augmentation de son métabolisme hépatique par l'inducteur."@fr;
  r:conduiteATenir "Surveillance clinique et biologique régulière, notamment en début d'association."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b204520, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b204514 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b204515 .

_:79f295ad32df4ce8a18a92539c6e8a3b204515 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204516;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b204517 .

_:79f295ad32df4ce8a18a92539c6e8a3b204516 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10029 .

_:79f295ad32df4ce8a18a92539c6e8a3b204517 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204518;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b204518 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10100 .

_:79f295ad32df4ce8a18a92539c6e8a3b204520 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10226-1 a owl:Class;
  rdfs:label "ANTICONVULSIVANTS INDUCTEURS ENZYMATIQUES <-> INHIBITEURS DES TYROSINE KINASES MÉTABOLISÉS"@fr;
  dct:identifier "IAM_10226";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b204522;
  r:natureDuRisque "Diminution des concentrations plasmatiques et de l’efficacité de l’inhibiteur de tyrosine kinase, par augmentation de son métabolisme par l’inducteur."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b204528, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b204522 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b204523 .

_:79f295ad32df4ce8a18a92539c6e8a3b204523 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204524;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b204525 .

_:79f295ad32df4ce8a18a92539c6e8a3b204524 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10029 .

_:79f295ad32df4ce8a18a92539c6e8a3b204525 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204526;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b204526 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10101 .

_:79f295ad32df4ce8a18a92539c6e8a3b204528 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10204-1 a owl:Class;
  rdfs:label "ANTICOAGULANTS ORAUX <-> HÉPARINES DE BAS POIDS MOLÉCULAIRE ET APPARENTÉS (DOSES CURATIVES ET/OU SUJET ÂGÉ)"@fr;
  dct:identifier "IAM_10204";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b204530;
  r:natureDuRisque "Augmentation du risque hémorragique."@fr;
  r:conduiteATenir "Si l'association ne peut être évitée, renforcer la surveillance clinique et, le cas échéant, biologique."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b204536, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b204530 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b204531 .

_:79f295ad32df4ce8a18a92539c6e8a3b204531 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204532;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b204533 .

_:79f295ad32df4ce8a18a92539c6e8a3b204532 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10028 .

_:79f295ad32df4ce8a18a92539c6e8a3b204533 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204534;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b204534 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10089 .

_:79f295ad32df4ce8a18a92539c6e8a3b204536 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10586-1 a owl:Class;
  rdfs:label "CICLOSPORINE <-> EZETIMIBE"@fr;
  dct:identifier "IAM_10586";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b204538;
  r:natureDuRisque "D’une part, risque majoré d'effets indésirables (concentration-dépendants) à type de rhabdomyolyse, par augmentation des concentrations d’ézétimibe ; d’autre part, possible augmentation des concentrations de ciclosporine."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b204544, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b204538 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b204539 .

_:79f295ad32df4ce8a18a92539c6e8a3b204539 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204540;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b204541 .

_:79f295ad32df4ce8a18a92539c6e8a3b204540 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10193 .

_:79f295ad32df4ce8a18a92539c6e8a3b204541 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204542;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b204542 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10365 .

_:79f295ad32df4ce8a18a92539c6e8a3b204544 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10409-1 a owl:Class;
  rdfs:label "AUTRES CORTICOÏDES, NOTAMMENT INHALÉS <-> INHIBITEURS DE PROTÉASES BOOSTÉS PAR RITONAVIR"@fr;
  dct:identifier "IAM_10409";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b204546;
  r:natureDuRisque "En cas d’utilisation prolongée par voie orale ou inhalée : augmentation des concentrations plasmatiques du corticoïde par diminution de son métabolisme hépatique par l’inhibiteur de protéases, avec risque d’apparition d’un syndrome cushingoïde voire d’une"@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b204552, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b204546 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b204547 .

_:79f295ad32df4ce8a18a92539c6e8a3b204547 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204548;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b204549 .

_:79f295ad32df4ce8a18a92539c6e8a3b204548 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10047 .

_:79f295ad32df4ce8a18a92539c6e8a3b204549 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204550;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b204550 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10100 .

_:79f295ad32df4ce8a18a92539c6e8a3b204552 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11231-1 a owl:Class;
  rdfs:label "LERCANIDIPINE <-> PAMPLEMOUSSE (JUS ET FRUIT)"@fr;
  dct:identifier "IAM_11231";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b204554;
  r:natureDuRisque "Risque majoré d'effets indésirables, notamment d'oedèmes, par diminution du métabolisme intestinal de la dihydropyridine."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b204560, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b204554 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b204555 .

_:79f295ad32df4ce8a18a92539c6e8a3b204555 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204556;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b204557 .

_:79f295ad32df4ce8a18a92539c6e8a3b204556 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10130 .

_:79f295ad32df4ce8a18a92539c6e8a3b204557 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204558;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b204558 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10514 .

_:79f295ad32df4ce8a18a92539c6e8a3b204560 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11232-1 a owl:Class;
  rdfs:label "LEVODOPA <-> METHYLDOPA"@fr;
  dct:identifier "IAM_11232";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b204562;
  r:natureDuRisque "Augmentation des effets de la lévodopa mais également de ses effets indésirables. Majoration de l'effet antihypertenseur de la méthyldopa."@fr;
  r:conduiteATenir "Surveillance clinique et éventuellement diminution des doses de lévodopa."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b204568, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b204562 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b204563 .

_:79f295ad32df4ce8a18a92539c6e8a3b204563 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204564;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b204565 .

_:79f295ad32df4ce8a18a92539c6e8a3b204564 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10517 .

_:79f295ad32df4ce8a18a92539c6e8a3b204565 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204566;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b204566 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10572 .

_:79f295ad32df4ce8a18a92539c6e8a3b204568 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11233-1 a owl:Class;
  rdfs:label "LEVODOPA <-> NEUROLEPTIQUES ANTIÉMÉTIQUES"@fr;
  dct:identifier "IAM_11233";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b204570;
  r:natureDuRisque "Antagonisme réciproque entre la lévodopa et le neuroleptique."@fr;
  r:conduiteATenir "Utiliser un antiémétique dénué d'effets extrapyramidaux."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b204576, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b204570 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b204571 .

_:79f295ad32df4ce8a18a92539c6e8a3b204571 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204572;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b204573 .

_:79f295ad32df4ce8a18a92539c6e8a3b204572 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10126 .

_:79f295ad32df4ce8a18a92539c6e8a3b204573 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204574;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b204574 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10517 .

_:79f295ad32df4ce8a18a92539c6e8a3b204576 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11234-1 a owl:Class;
  rdfs:label "LEVODOPA <-> NEUROLEPTIQUES ANTIPSYCHOTIQUES (SAUF CLOZAPINE)"@fr;
  dct:identifier "IAM_11234";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b204578;
  r:natureDuRisque "Antagonisme réciproque de la lévodopa et des neuroleptiques."@fr;
  r:conduiteATenir "Chez le patient parkinsonien, utiliser les doses minimales efficaces de chacun des deux médicaments."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b204584, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b204578 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b204579 .

_:79f295ad32df4ce8a18a92539c6e8a3b204579 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204580;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b204581 .

_:79f295ad32df4ce8a18a92539c6e8a3b204580 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10125 .

_:79f295ad32df4ce8a18a92539c6e8a3b204581 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204582;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b204582 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10517 .

_:79f295ad32df4ce8a18a92539c6e8a3b204584 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11235-1 a owl:Class;
  rdfs:label "LEVODOPA <-> RESERPINE"@fr;
  dct:identifier "IAM_11235";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b204586;
  r:natureDuRisque "Inhibition des effets de la lévodopa."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b204592, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b204586 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b204587 .

_:79f295ad32df4ce8a18a92539c6e8a3b204587 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204588;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b204589 .

_:79f295ad32df4ce8a18a92539c6e8a3b204588 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10517 .

_:79f295ad32df4ce8a18a92539c6e8a3b204589 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204590;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b204590 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10792 .

_:79f295ad32df4ce8a18a92539c6e8a3b204592 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10303-1 a owl:Class;
  rdfs:label "ANTISÉCRÉTOIRES INHIBITEURS DE LA POMPE À PROTONS <-> METHOTREXATE"@fr;
  dct:identifier "IAM_10303";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b204594;
  r:natureDuRisque "Risque d’augmentation de la toxicité du méthotrexate par diminution de son élimination."@fr;
  r:conduiteATenir """Association déconseillée :
- avec le méthotrexate aux doses > 20 mg / semaine

A prendre en compte :
- pour des doses inférieures"""@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b204600, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b204594 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b204595 .

_:79f295ad32df4ce8a18a92539c6e8a3b204595 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204596;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b204597 .

_:79f295ad32df4ce8a18a92539c6e8a3b204596 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10043 .

_:79f295ad32df4ce8a18a92539c6e8a3b204597 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204598;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b204598 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10569 .

_:79f295ad32df4ce8a18a92539c6e8a3b204600 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10403-1 a owl:Class;
  rdfs:label "ATORVASTATINE <-> VERAPAMIL"@fr;
  dct:identifier "IAM_10403";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b204602;
  r:natureDuRisque "Risque majoré d'effets indésirables (concentration-dépendants) à type de rhabdomyolyse, par diminution du métabolisme hépatique de l'hypocholestérolémiant."@fr;
  r:conduiteATenir "Utiliser des doses plus faibles d'hypocholestérolémiant. Si l'objectif thérapeutique n'est pas atteint, utiliser une autre statine non concernée par ce type d'interaction."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b204608, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b204602 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b204603 .

_:79f295ad32df4ce8a18a92539c6e8a3b204603 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204604;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b204605 .

_:79f295ad32df4ce8a18a92539c6e8a3b204604 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10089 .

_:79f295ad32df4ce8a18a92539c6e8a3b204605 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204606;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b204606 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10980 .

_:79f295ad32df4ce8a18a92539c6e8a3b204608 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10404-1 a owl:Class;
  rdfs:label "ATOVAQUONE <-> EFAVIRENZ"@fr;
  dct:identifier "IAM_10404";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b204610;
  r:natureDuRisque "Diminution des concentrations plasmatiques d'atovaquone par l'inducteur enzymatique."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b204616, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b204610 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b204611 .

_:79f295ad32df4ce8a18a92539c6e8a3b204611 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204612;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b204613 .

_:79f295ad32df4ce8a18a92539c6e8a3b204612 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10090 .

_:79f295ad32df4ce8a18a92539c6e8a3b204613 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204614;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b204614 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10318 .

_:79f295ad32df4ce8a18a92539c6e8a3b204616 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10405-1 a owl:Class;
  rdfs:label "ATOVAQUONE <-> INHIBITEURS DE PROTÉASES BOOSTÉS PAR RITONAVIR"@fr;
  dct:identifier "IAM_10405";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b204618;
  r:natureDuRisque "Diminution, éventuellement très importante, des concentrations plasmatiques de l’atovaquone par augmentation de son métabolisme."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b204624, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b204618 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b204619 .

_:79f295ad32df4ce8a18a92539c6e8a3b204619 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204620;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b204621 .

_:79f295ad32df4ce8a18a92539c6e8a3b204620 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10100 .

_:79f295ad32df4ce8a18a92539c6e8a3b204621 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204622;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b204622 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10090 .

_:79f295ad32df4ce8a18a92539c6e8a3b204624 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10577-1 a owl:Class;
  rdfs:label "CICLOSPORINE <-> CIMETIDINE"@fr;
  dct:identifier "IAM_10577";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b204626;
  r:natureDuRisque "Avec la cimétidine utilisée à des doses supérieures ou égales à 800 mg/j : augmentation des concentrations sanguines de ciclosporine."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b204632, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b204626 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b204627 .

_:79f295ad32df4ce8a18a92539c6e8a3b204627 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204628;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b204629 .

_:79f295ad32df4ce8a18a92539c6e8a3b204628 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10193 .

_:79f295ad32df4ce8a18a92539c6e8a3b204629 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204630;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b204630 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10196 .

_:79f295ad32df4ce8a18a92539c6e8a3b204632 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10407-1 a owl:Class;
  rdfs:label "ATOVAQUONE <-> RIFAMPICINE"@fr;
  dct:identifier "IAM_10407";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b204634;
  r:natureDuRisque "Diminution des concentrations plasmatiques d'atovaquone par l'inducteur enzymatique."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b204640, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b204634 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b204635 .

_:79f295ad32df4ce8a18a92539c6e8a3b204635 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204636;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b204637 .

_:79f295ad32df4ce8a18a92539c6e8a3b204636 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10090 .

_:79f295ad32df4ce8a18a92539c6e8a3b204637 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204638;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b204638 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:79f295ad32df4ce8a18a92539c6e8a3b204640 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10228-1 a owl:Class;
  rdfs:label "ANTICONVULSIVANTS INDUCTEURS ENZYMATIQUES <-> LÉDIPASVIR"@fr;
  dct:identifier "IAM_10228";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b204642;
  r:natureDuRisque "Diminution importante des concentrations plasmatiques du lédipasvir par augmentation de son métabolisme hépatique par l'anticonvulsivant inducteur enzymatique."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b204648, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b204642 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b204643 .

_:79f295ad32df4ce8a18a92539c6e8a3b204643 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204644;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b204645 .

_:79f295ad32df4ce8a18a92539c6e8a3b204644 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10029 .

_:79f295ad32df4ce8a18a92539c6e8a3b204645 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204646;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b204646 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10512 .

_:79f295ad32df4ce8a18a92539c6e8a3b204648 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10410-1 a owl:Class;
  rdfs:label "AUTRES CORTICOÏDES, NOTAMMENT INHALÉS <-> ITRACONAZOLE"@fr;
  dct:identifier "IAM_10410";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b204650;
  r:natureDuRisque "En cas d’utilisation prolongée par voie orale ou inhalée : augmentation des concentrations plasmatiques du corticoïde par diminution de son métabolisme hépatique par l’itraconazole, avec risque d’apparition d’un syndrome cushingoïde voire d’une insuffisan"@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b204656, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b204650 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b204651 .

_:79f295ad32df4ce8a18a92539c6e8a3b204651 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204652;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b204653 .

_:79f295ad32df4ce8a18a92539c6e8a3b204652 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10047 .

_:79f295ad32df4ce8a18a92539c6e8a3b204653 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204654;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b204654 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10496 .

_:79f295ad32df4ce8a18a92539c6e8a3b204656 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10411-1 a owl:Class;
  rdfs:label "AUTRES CORTICOÏDES, NOTAMMENT INHALÉS <-> KETOCONAZOLE"@fr;
  dct:identifier "IAM_10411";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b204658;
  r:natureDuRisque "En cas d’utilisation prolongée par voie orale ou inhalée : augmentation des concentrations plasmatiques du corticoïde par diminution de son métabolisme hépatique par le kétoconazole, avec risque d’apparition d’un syndrome cushingoïde voire d’une insuffisa"@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b204664, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b204658 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b204659 .

_:79f295ad32df4ce8a18a92539c6e8a3b204659 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204660;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b204661 .

_:79f295ad32df4ce8a18a92539c6e8a3b204660 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10047 .

_:79f295ad32df4ce8a18a92539c6e8a3b204661 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204662;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b204662 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10501 .

_:79f295ad32df4ce8a18a92539c6e8a3b204664 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10500-1 a owl:Class;
  rdfs:label "BUPROPION <-> FLECAINIDE"@fr;
  dct:identifier "IAM_10500";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b204666;
  r:natureDuRisque "Risque d'augmentation des effets indésirables du flécaïnide par diminution de son métabolisme hépatique par le bupropion."@fr;
  r:conduiteATenir "Surveillance clinique. Si besoin, adaptation de la posologie du flécaïnide pendant le traitement par le bupropion."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b204672, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b204666 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b204667 .

_:79f295ad32df4ce8a18a92539c6e8a3b204667 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204668;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b204669 .

_:79f295ad32df4ce8a18a92539c6e8a3b204668 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10140 .

_:79f295ad32df4ce8a18a92539c6e8a3b204669 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204670;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b204670 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10380 .

_:79f295ad32df4ce8a18a92539c6e8a3b204672 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10503-1 a owl:Class;
  rdfs:label "BUPROPION <-> METOPROLOL"@fr;
  dct:identifier "IAM_10503";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b204674;
  r:natureDuRisque "Avec le métoprolol utilisé dans l'insuffisance cardiaque : risque d'augmentation des effets indésirables du métoprolol par diminution de son métabolisme hépatique par le bupropion."@fr;
  r:conduiteATenir "Surveillance clinique. Si besoin, adaptation de la posologie du métoprolol pendant le traitement par le bupropion."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b204680, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b204674 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b204675 .

_:79f295ad32df4ce8a18a92539c6e8a3b204675 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204676;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b204677 .

_:79f295ad32df4ce8a18a92539c6e8a3b204676 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10140 .

_:79f295ad32df4ce8a18a92539c6e8a3b204677 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204678;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b204678 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10579 .

_:79f295ad32df4ce8a18a92539c6e8a3b204680 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10504-1 a owl:Class;
  rdfs:label "BUPROPION <-> NORTRIPTYLINE"@fr;
  dct:identifier "IAM_10504";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b204682;
  r:natureDuRisque "Risque d'augmentation des effets indésirables de la nortriptyline par diminution de son métabolisme hépatique par le bupropion."@fr;
  r:conduiteATenir "Surveillance clinique. Si besoin, adaptation de la posologie de la nortriptyline pendant le traitement par le bupropion."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b204688, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b204682 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b204683 .

_:79f295ad32df4ce8a18a92539c6e8a3b204683 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204684;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b204685 .

_:79f295ad32df4ce8a18a92539c6e8a3b204684 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10140 .

_:79f295ad32df4ce8a18a92539c6e8a3b204685 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204686;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b204686 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10652 .

_:79f295ad32df4ce8a18a92539c6e8a3b204688 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10502-1 a owl:Class;
  rdfs:label "BUPROPION <-> MEQUITAZINE"@fr;
  dct:identifier "IAM_10502";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b204690;
  r:natureDuRisque "Risque de majoration des effets indésirables de la méquitazine, par inhibition de son métabolisme par l’inhibiteur enzymatique."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b204696, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b204690 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b204691 .

_:79f295ad32df4ce8a18a92539c6e8a3b204691 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204692;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b204693 .

_:79f295ad32df4ce8a18a92539c6e8a3b204692 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10140 .

_:79f295ad32df4ce8a18a92539c6e8a3b204693 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204694;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b204694 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10561 .

_:79f295ad32df4ce8a18a92539c6e8a3b204696 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10505-1 a owl:Class;
  rdfs:label "BUPROPION <-> PROPAFENONE"@fr;
  dct:identifier "IAM_10505";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b204698;
  r:natureDuRisque "Risque d'augmentation des effets indésirables de la propafénone par diminution de son métabolisme hépatique par le bupropion."@fr;
  r:conduiteATenir "Surveillance clinique. Si besoin, adaptation de la posologie de la propafénone pendant le traitement par le bupropion."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b204704, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b204698 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b204699 .

_:79f295ad32df4ce8a18a92539c6e8a3b204699 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204700;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b204701 .

_:79f295ad32df4ce8a18a92539c6e8a3b204700 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10140 .

_:79f295ad32df4ce8a18a92539c6e8a3b204701 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204702;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b204702 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10765 .

_:79f295ad32df4ce8a18a92539c6e8a3b204704 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10506-1 a owl:Class;
  rdfs:label "BUPROPION <-> TAMOXIFENE"@fr;
  dct:identifier "IAM_10506";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b204706;
  r:natureDuRisque "Risque de baisse de l'efficacité du tamoxifène, par inhibition de la formation de son métabolite actif par la terbinafine."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b204712, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b204706 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b204707 .

_:79f295ad32df4ce8a18a92539c6e8a3b204707 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204708;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b204709 .

_:79f295ad32df4ce8a18a92539c6e8a3b204708 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10140 .

_:79f295ad32df4ce8a18a92539c6e8a3b204709 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204710;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b204710 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10882 .

_:79f295ad32df4ce8a18a92539c6e8a3b204712 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10507-1 a owl:Class;
  rdfs:label "BUPROPION <-> TRAMADOL"@fr;
  dct:identifier "IAM_10507";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b204714;
  r:natureDuRisque "Augmentation des concentrations plasmatiques du tramadol par diminution de son métabolisme hépatique par le bupropion. De plus, risque de convulsions par addition des effets des deux médicaments."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b204720, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b204714 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b204715 .

_:79f295ad32df4ce8a18a92539c6e8a3b204715 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204716;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b204717 .

_:79f295ad32df4ce8a18a92539c6e8a3b204716 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10140 .

_:79f295ad32df4ce8a18a92539c6e8a3b204717 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204718;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b204718 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10945 .

_:79f295ad32df4ce8a18a92539c6e8a3b204720 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10508-1 a owl:Class;
  rdfs:label "BUPROPION <-> VÉMURAFÉNIB"@fr;
  dct:identifier "IAM_10508";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b204722;
  r:natureDuRisque "Risque de diminution des concentrations du bupropion, avec augmentation de son métabolite actif et toxicité majorée."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b204728, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b204722 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b204723 .

_:79f295ad32df4ce8a18a92539c6e8a3b204723 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204724;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b204725 .

_:79f295ad32df4ce8a18a92539c6e8a3b204724 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10140 .

_:79f295ad32df4ce8a18a92539c6e8a3b204725 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204726;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b204726 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10978 .

_:79f295ad32df4ce8a18a92539c6e8a3b204728 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10406-1 a owl:Class;
  rdfs:label "ATOVAQUONE <-> RIFABUTINE"@fr;
  dct:identifier "IAM_10406";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b204730;
  r:natureDuRisque "Diminution modérée des concentrations plasmatiques d'atovaquone par l'inducteur enzymatique."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b204736, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b204730 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b204731 .

_:79f295ad32df4ce8a18a92539c6e8a3b204731 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204732;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b204733 .

_:79f295ad32df4ce8a18a92539c6e8a3b204732 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10090 .

_:79f295ad32df4ce8a18a92539c6e8a3b204733 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204734;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b204734 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10800 .

_:79f295ad32df4ce8a18a92539c6e8a3b204736 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11263-1 a owl:Class;
  rdfs:label "MEQUITAZINE <-> TERBINAFINE"@fr;
  dct:identifier "IAM_11263";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b204738;
  r:natureDuRisque "Risque de majoration des effets indésirables de la méquitazine, par inhibition de son métabolisme par l’inhibiteur enzymatique."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b204744, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b204738 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b204739 .

_:79f295ad32df4ce8a18a92539c6e8a3b204739 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204740;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b204741 .

_:79f295ad32df4ce8a18a92539c6e8a3b204740 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10561 .

_:79f295ad32df4ce8a18a92539c6e8a3b204741 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204742;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b204742 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10900 .

_:79f295ad32df4ce8a18a92539c6e8a3b204744 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10418-1 a owl:Class;
  rdfs:label "AUTRES MÉDICAMENTS ABAISSANT LE SEUIL ÉPILEPTOGÈNE <-> MÉDICAMENTS ABAISSANT LE SEUIL ÉPILEPTOGÈNE"@fr;
  dct:identifier "IAM_10418";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b204746;
  r:chapeau "L'utilisation conjointe de médicaments proconvulsivants, ou abaissant le seuil épileptogène, devra être soigneusement pesée, en raison de la sévérité du risque encouru. Ces médicaments sont représentés notamment par la plupart des antidépresseurs (imipram"@fr;
  r:natureDuRisque "Risque accru de convulsions."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b204748, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b204746 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10114 .

_:79f295ad32df4ce8a18a92539c6e8a3b204748 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10420-1 a owl:Class;
  rdfs:label "AUTRES MÉDICAMENTS ATROPINIQUES <-> MÉDICAMENTS ATROPINIQUES"@fr;
  dct:identifier "IAM_10420";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b204750;
  r:natureDuRisque "Addition des effets indésirables atropiniques à type de rétention urinaire, constipation, sécheresse de la bouche…."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b204752, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b204750 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10115 .

_:79f295ad32df4ce8a18a92539c6e8a3b204752 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10422-1 a owl:Class;
  rdfs:label "AUTRES MÉDICAMENTS MÉTHÉMOGLOBINISANTS <-> MÉDICAMENTS MÉTHÉMOGLOBINISANTS"@fr;
  dct:identifier "IAM_10422";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b204754;
  r:natureDuRisque "Risque d'addition des effets méthémoglobinisants."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b204756, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b204754 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10117 .

_:79f295ad32df4ce8a18a92539c6e8a3b204756 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11258-1 a owl:Class;
  rdfs:label "MÉDICAMENTS MIXTES ADRÉNERGIQUES-SÉROTONINERGIQUES <-> ORLISTAT"@fr;
  dct:identifier "IAM_11258";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b204758;
  r:natureDuRisque "Risque d'échec thérapeutique en cas de traitement concomitant par orlistat."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b204764, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b204758 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b204759 .

_:79f295ad32df4ce8a18a92539c6e8a3b204759 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204760;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b204761 .

_:79f295ad32df4ce8a18a92539c6e8a3b204760 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10116 .

_:79f295ad32df4ce8a18a92539c6e8a3b204761 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204762;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b204762 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10667 .

_:79f295ad32df4ce8a18a92539c6e8a3b204764 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11259-1 a owl:Class;
  rdfs:label "MÉDICAMENTS MIXTES ADRÉNERGIQUES-SÉROTONINERGIQUES <-> SYMPATHOMIMÉTIQUES ALPHA ET BÊTA (VOIE IM ET IV)"@fr;
  dct:identifier "IAM_11259";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b204766;
  r:natureDuRisque "Hypertension paroxystique avec possibilité de troubles du rythme (inhibition de l'entrée du sympathomimétique dans la fibre sympathique)."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b204772, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b204766 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b204767 .

_:79f295ad32df4ce8a18a92539c6e8a3b204767 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204768;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b204769 .

_:79f295ad32df4ce8a18a92539c6e8a3b204768 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10116 .

_:79f295ad32df4ce8a18a92539c6e8a3b204769 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204770;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b204770 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10149 .

_:79f295ad32df4ce8a18a92539c6e8a3b204772 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10423-1 a owl:Class;
  rdfs:label "AUTRES MÉDICAMENTS NÉPHROTOXIQUES <-> MÉDICAMENTS NÉPHROTOXIQUES"@fr;
  dct:identifier "IAM_10423";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b204774;
  r:chapeau """L'utilisation conjointe de médicaments ayant une toxicité rénale propre augmente le risque de néphrotoxicité. Si une telle association est nécessaire, il faut renforcer la surveillance biologique rénale.
Les médicaments concernés sont représentés notammen"""@fr;
  r:natureDuRisque "Risque de majoration de la néphrotoxicité."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b204776, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b204774 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10118 .

_:79f295ad32df4ce8a18a92539c6e8a3b204776 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10424-1 a owl:Class;
  rdfs:label "AUTRES MÉDICAMENTS OTOTOXIQUES <-> MÉDICAMENTS OTOTOXIQUES"@fr;
  dct:identifier "IAM_10424";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b204778;
  r:natureDuRisque "Majoration de l'ototoxicité."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b204780, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b204778 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10119 .

_:79f295ad32df4ce8a18a92539c6e8a3b204780 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10079-1 a owl:Class;
  rdfs:label "ALCOOL (BOISSON OU EXCIPIENT) <-> MÉDICAMENTS SÉDATIFS"@fr;
  dct:identifier "IAM_10079";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b204782;
  r:natureDuRisque "Majoration par l'alcool de l'effet sédatif de ces substances. L'altération de la vigilance peut rendre dangereuses la conduite de véhicules et l'utilisation de machines."@fr;
  r:conduiteATenir "Eviter la prise de boissons alcoolisées et de médicaments contenant de l'alcool."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b204788, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b204782 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b204783 .

_:79f295ad32df4ce8a18a92539c6e8a3b204783 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204784;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b204785 .

_:79f295ad32df4ce8a18a92539c6e8a3b204784 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10120 .

_:79f295ad32df4ce8a18a92539c6e8a3b204785 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204786;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b204786 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_11013 .

_:79f295ad32df4ce8a18a92539c6e8a3b204788 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10425-1 a owl:Class;
  rdfs:label "AUTRES MÉDICAMENTS SÉDATIFS <-> MÉDICAMENTS SÉDATIFS"@fr;
  dct:identifier "IAM_10425";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b204790;
  r:natureDuRisque """Majoration de la dépression centrale.
L'altération de la vigilance peut rendre dangereuses la conduite de véhicules et l'utilisation de machines."""@fr;
  r:conduiteATenir """Association déconseillée:
- avec l'oxybate de sodium.

A prendre en compte:
- avec les autres médicaments sédatifs."""@fr;
  rdfs:comment "A"@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b204792, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b204790 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10120 .

_:79f295ad32df4ce8a18a92539c6e8a3b204792 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11218-1 a owl:Class;
  rdfs:label "KETOCONAZOLE <-> RIFAMPICINE"@fr;
  dct:identifier "IAM_11218";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b204794;
  r:natureDuRisque "Diminution des concentrations plasmatiques et de l'efficacité des deux anti-infectieux (induction enzymatique par la rifampicine et diminution de l'absorption intestinale par l’azolé antifongique)."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b204800, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b204794 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b204795 .

_:79f295ad32df4ce8a18a92539c6e8a3b204795 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204796;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b204797 .

_:79f295ad32df4ce8a18a92539c6e8a3b204796 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10501 .

_:79f295ad32df4ce8a18a92539c6e8a3b204797 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204798;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b204798 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:79f295ad32df4ce8a18a92539c6e8a3b204800 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11262-1 a owl:Class;
  rdfs:label "MEQUITAZINE <-> PAROXETINE"@fr;
  dct:identifier "IAM_11262";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b204802;
  r:natureDuRisque "Risque de majoration des effets indésirables de la méquitazine, par inhibition de son métabolisme par l’inhibiteur enzymatique."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b204808, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b204802 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b204803 .

_:79f295ad32df4ce8a18a92539c6e8a3b204803 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204804;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b204805 .

_:79f295ad32df4ce8a18a92539c6e8a3b204804 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10561 .

_:79f295ad32df4ce8a18a92539c6e8a3b204805 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204806;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b204806 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10694 .

_:79f295ad32df4ce8a18a92539c6e8a3b204808 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10417-1 a owl:Class;
  rdfs:label "AUTRES MÉDICAMENTS À L'ORIGINE D'UN SYNDROME SÉROTONINERGIQUE <-> MÉDICAMENTS À L'ORIGINE D'UN SYNDROME SÉROTONINERGIQUE"@fr;
  dct:identifier "IAM_10417";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b204810;
  r:natureDuRisque "Risque d'apparition ou de majoration d'un syndrome sérotoninergique en cas d'association de ces médicaments."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b204812, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b204810 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10121 .

_:79f295ad32df4ce8a18a92539c6e8a3b204812 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10080-1 a owl:Class;
  rdfs:label "ALCOOL (BOISSON OU EXCIPIENT) <-> METFORMINE"@fr;
  dct:identifier "IAM_10080";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b204814;
  r:natureDuRisque "Risque majoré d'acidose lactique lors d'intoxication alcoolique aiguë, particulièrement en cas de jeûne ou dénutrition, ou bien d'insuffisance hépatocellulaire."@fr;
  r:conduiteATenir "Eviter la prise de boissons alcoolisées et de médicaments contenant de l'alcool."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b204820, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b204814 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b204815 .

_:79f295ad32df4ce8a18a92539c6e8a3b204815 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204816;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b204817 .

_:79f295ad32df4ce8a18a92539c6e8a3b204816 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10566 .

_:79f295ad32df4ce8a18a92539c6e8a3b204817 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204818;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b204818 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_11013 .

_:79f295ad32df4ce8a18a92539c6e8a3b204820 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11264-1 a owl:Class;
  rdfs:label "METFORMINE <-> PRODUITS DE CONTRASTE IODÉS"@fr;
  dct:identifier "IAM_11264";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b204822;
  r:natureDuRisque "Acidose lactique liée aux concentrations élevées de metformine en rapport avec l'insuffisance rénale fonctionnelle induite par l'examen radiologique."@fr;
  r:conduiteATenir "Le traitement par la metformine doit être suspendu au moment de l'examen radiologique pour n'être repris que 2 jours après."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b204828, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b204822 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b204823 .

_:79f295ad32df4ce8a18a92539c6e8a3b204823 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204824;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b204825 .

_:79f295ad32df4ce8a18a92539c6e8a3b204824 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10133 .

_:79f295ad32df4ce8a18a92539c6e8a3b204825 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204826;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b204826 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10566 .

_:79f295ad32df4ce8a18a92539c6e8a3b204828 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11265-1 a owl:Class;
  rdfs:label "METHADONE <-> MORPHINIQUES AGONISTES-ANTAGONISTES"@fr;
  dct:identifier "IAM_11265";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b204830;
  r:natureDuRisque "Diminution de l'effet de la méthadone par blocage compétitif des récepteurs."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b204836, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b204830 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b204831 .

_:79f295ad32df4ce8a18a92539c6e8a3b204831 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204832;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b204833 .

_:79f295ad32df4ce8a18a92539c6e8a3b204832 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10110 .

_:79f295ad32df4ce8a18a92539c6e8a3b204833 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204834;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b204834 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10567 .

_:79f295ad32df4ce8a18a92539c6e8a3b204836 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11266-1 a owl:Class;
  rdfs:label "METHADONE <-> SUBSTANCES SUSCEPTIBLES DE DONNER DES TORSADES DE POINTES"@fr;
  dct:identifier "IAM_11266";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b204838;
  r:natureDuRisque "Risque majoré de troubles du rythme ventriculaire, notamment de torsades de pointes."@fr;
  r:conduiteATenir """Contre-indication :
- avec le citalopram, la dompéridone, l'escitalopram, l'hydroxyzine
et la pipéraquine.

Association déconseillée:
- avec les autres médicaments susceptibles de donner des torsades de pointes."""@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b204844, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b204838 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b204839 .

_:79f295ad32df4ce8a18a92539c6e8a3b204839 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204840;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b204841 .

_:79f295ad32df4ce8a18a92539c6e8a3b204840 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10143 .

_:79f295ad32df4ce8a18a92539c6e8a3b204841 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204842;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b204842 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10567 .

_:79f295ad32df4ce8a18a92539c6e8a3b204844 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11267-1 a owl:Class;
  rdfs:label "METHENAMINE <-> SULFAMETHIZOL"@fr;
  dct:identifier "IAM_11267";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b204846;
  r:natureDuRisque "Précipitation cristalline dans les voies urinaires (favorisée par l'acidification des urines)."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b204852, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b204846 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b204847 .

_:79f295ad32df4ce8a18a92539c6e8a3b204847 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204848;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b204849 .

_:79f295ad32df4ce8a18a92539c6e8a3b204848 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10568 .

_:79f295ad32df4ce8a18a92539c6e8a3b204849 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204850;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b204850 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10870 .

_:79f295ad32df4ce8a18a92539c6e8a3b204852 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11268-1 a owl:Class;
  rdfs:label "METHOTREXATE <-> PÉNICILLINES"@fr;
  dct:identifier "IAM_11268";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b204854;
  r:natureDuRisque "Augmentation des effets et de la toxicité hématologique du méthotrexate : inhibition de la sécrétion tubulaire rénale du méthotrexate par les pénicillines."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b204860, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b204854 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b204855 .

_:79f295ad32df4ce8a18a92539c6e8a3b204855 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204856;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b204857 .

_:79f295ad32df4ce8a18a92539c6e8a3b204856 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10138 .

_:79f295ad32df4ce8a18a92539c6e8a3b204857 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204858;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b204858 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10569 .

_:79f295ad32df4ce8a18a92539c6e8a3b204860 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11269-1 a owl:Class;
  rdfs:label "METHOTREXATE <-> PROBENECIDE"@fr;
  dct:identifier "IAM_11269";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b204862;
  r:natureDuRisque "Augmentation de la toxicité du méthotrexate : inhibition de la sécrétion tubulaire rénale du méthotrexate par le probénécide."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b204868, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b204862 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b204863 .

_:79f295ad32df4ce8a18a92539c6e8a3b204863 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204864;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b204865 .

_:79f295ad32df4ce8a18a92539c6e8a3b204864 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10569 .

_:79f295ad32df4ce8a18a92539c6e8a3b204865 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204866;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b204866 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10758 .

_:79f295ad32df4ce8a18a92539c6e8a3b204868 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11270-1 a owl:Class;
  rdfs:label "METHOTREXATE <-> SULFAMIDES ANTIBACTÉRIENS"@fr;
  dct:identifier "IAM_11270";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b204870;
  r:natureDuRisque "Augmentation de la toxicité hématologique du méthotrexate."@fr;
  r:conduiteATenir "Dosage des concentrations de méthotrexate. Adapatation posologique si nécessaire pendant l'association et après son arrêt."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b204876, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b204870 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b204871 .

_:79f295ad32df4ce8a18a92539c6e8a3b204871 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204872;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b204873 .

_:79f295ad32df4ce8a18a92539c6e8a3b204872 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10146 .

_:79f295ad32df4ce8a18a92539c6e8a3b204873 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204874;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b204874 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10569 .

_:79f295ad32df4ce8a18a92539c6e8a3b204876 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11271-1 a owl:Class;
  rdfs:label "METHOTREXATE <-> TRIMETHOPRIME"@fr;
  dct:identifier "IAM_11271";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b204878;
  r:natureDuRisque "Augmentation de la toxicité hématologique du méthotrexate (diminution de son excrétion rénale ainsi qu'inhibition de la dihydrofolate réductase)."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b204884, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b204878 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b204879 .

_:79f295ad32df4ce8a18a92539c6e8a3b204879 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204880;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b204881 .

_:79f295ad32df4ce8a18a92539c6e8a3b204880 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10569 .

_:79f295ad32df4ce8a18a92539c6e8a3b204881 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204882;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b204882 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10955 .

_:79f295ad32df4ce8a18a92539c6e8a3b204884 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11261-1 a owl:Class;
  rdfs:label "MEFLOQUINE <-> QUININE"@fr;
  dct:identifier "IAM_11261";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b204886;
  r:natureDuRisque "Pour la quinine administrée par voie IV : risque majoré de survenue de crises épileptiques par addition des effets proconvulsivants."@fr;
  r:conduiteATenir "Respecter un délai minimum de 12 heures entre la fin de l'administration IV de quinine et le début de l'administration de méfloquine."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b204892, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b204886 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b204887 .

_:79f295ad32df4ce8a18a92539c6e8a3b204887 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204888;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b204889 .

_:79f295ad32df4ce8a18a92539c6e8a3b204888 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10555 .

_:79f295ad32df4ce8a18a92539c6e8a3b204889 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204890;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b204890 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10777 .

_:79f295ad32df4ce8a18a92539c6e8a3b204892 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11244-1 a owl:Class;
  rdfs:label "LITHIUM <-> ORLISTAT"@fr;
  dct:identifier "IAM_11244";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b204894;
  r:natureDuRisque "Risque d'échec thérapeutique en cas de traitement concomitant par orlistat."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b204900, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b204894 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b204895 .

_:79f295ad32df4ce8a18a92539c6e8a3b204895 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204896;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b204897 .

_:79f295ad32df4ce8a18a92539c6e8a3b204896 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10530 .

_:79f295ad32df4ce8a18a92539c6e8a3b204897 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204898;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b204898 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10667 .

_:79f295ad32df4ce8a18a92539c6e8a3b204900 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11321-1 a owl:Class;
  rdfs:label "MYCOPHENOLATE SODIQUE <-> VACCINS VIVANTS ATTÉNUÉS"@fr;
  dct:identifier "IAM_11321";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b204902;
  r:natureDuRisque "Risque de maladie vaccinale généralisée éventuellement mortelle."@fr;
  r:conduiteATenir "Et pendant les 3 mois suivant l'arrêt du traitement."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b204908, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b204902 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b204903 .

_:79f295ad32df4ce8a18a92539c6e8a3b204903 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204904;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b204905 .

_:79f295ad32df4ce8a18a92539c6e8a3b204904 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10159 .

_:79f295ad32df4ce8a18a92539c6e8a3b204905 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204906;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b204906 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10610 .

_:79f295ad32df4ce8a18a92539c6e8a3b204908 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11220-1 a owl:Class;
  rdfs:label "KETOCONAZOLE <-> SIMVASTATINE"@fr;
  dct:identifier "IAM_11220";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b204910;
  r:natureDuRisque "Risque majoré d'effets indésirables (concentration-dépendants) à type de rhabdomyolyse (diminution du métabolisme hépatique de l'hypocholestérolémiant)."@fr;
  r:conduiteATenir "Utiliser une statine non concernée par ce type d'interaction."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b204916, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b204910 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b204911 .

_:79f295ad32df4ce8a18a92539c6e8a3b204911 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204912;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b204913 .

_:79f295ad32df4ce8a18a92539c6e8a3b204912 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10501 .

_:79f295ad32df4ce8a18a92539c6e8a3b204913 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204914;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b204914 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10838 .

_:79f295ad32df4ce8a18a92539c6e8a3b204916 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11221-1 a owl:Class;
  rdfs:label "KETOCONAZOLE <-> TÉNOFOVIR ALAFÉNAMIDE"@fr;
  dct:identifier "IAM_11221";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b204918;
  r:natureDuRisque "Augmentation des concentrations plasmatiques du ténofovir alafénamide par augmentation de son absorption."@fr;
  r:conduiteATenir "En cas de co-administration avec le kétoconazole, la dose de ténofovir alafénamide doit être limitée à 10 mg par jour."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b204924, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b204918 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b204919 .

_:79f295ad32df4ce8a18a92539c6e8a3b204919 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204920;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b204921 .

_:79f295ad32df4ce8a18a92539c6e8a3b204920 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10501 .

_:79f295ad32df4ce8a18a92539c6e8a3b204921 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204922;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b204922 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10895 .

_:79f295ad32df4ce8a18a92539c6e8a3b204924 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11236-1 a owl:Class;
  rdfs:label "LEVODOPA <-> SPIRAMYCINE"@fr;
  dct:identifier "IAM_11236";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b204926;
  r:natureDuRisque "En cas d'association avec la carbidopa : inhibition de l'absorption de la carbidopa avec diminution des concentrations plasmatiques de la lévodopa."@fr;
  r:conduiteATenir "Surveillance clinique et adaptation éventuelle de la posologie de la lévodopa."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b204932, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b204926 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b204927 .

_:79f295ad32df4ce8a18a92539c6e8a3b204927 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204928;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b204929 .

_:79f295ad32df4ce8a18a92539c6e8a3b204928 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10517 .

_:79f295ad32df4ce8a18a92539c6e8a3b204929 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204930;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b204930 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10856 .

_:79f295ad32df4ce8a18a92539c6e8a3b204932 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11237-1 a owl:Class;
  rdfs:label "LEVODOPA <-> TETRABENAZINE"@fr;
  dct:identifier "IAM_11237";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b204934;
  r:natureDuRisque "Antagonisme réciproque entre la lévodopa et la tétrabénazine."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b204940, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b204934 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b204935 .

_:79f295ad32df4ce8a18a92539c6e8a3b204935 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204936;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b204937 .

_:79f295ad32df4ce8a18a92539c6e8a3b204936 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10517 .

_:79f295ad32df4ce8a18a92539c6e8a3b204937 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204938;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b204938 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10908 .

_:79f295ad32df4ce8a18a92539c6e8a3b204940 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11238-1 a owl:Class;
  rdfs:label "LEVOFLOXACINE <-> SUBSTANCES SUSCEPTIBLES DE DONNER DES TORSADES DE POINTES"@fr;
  dct:identifier "IAM_11238";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b204942;
  r:natureDuRisque "Risque majoré de troubles du rythme ventriculaire, notamment de torsades de pointes."@fr;
  r:conduiteATenir """Surveillance clinique et électrocardiographique pendant
l'association."""@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b204948, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b204942 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b204943 .

_:79f295ad32df4ce8a18a92539c6e8a3b204943 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204944;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b204945 .

_:79f295ad32df4ce8a18a92539c6e8a3b204944 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10143 .

_:79f295ad32df4ce8a18a92539c6e8a3b204945 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204946;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b204946 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10518 .

_:79f295ad32df4ce8a18a92539c6e8a3b204948 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11239-1 a owl:Class;
  rdfs:label "LINEZOLIDE <-> RIFAMPICINE"@fr;
  dct:identifier "IAM_11239";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b204950;
  r:natureDuRisque "Risque de diminution de l'efficacité du linézolide par augmentation de son métabolisme hépatique par la rifampicine."@fr;
  r:conduiteATenir "Surveillance clinique et augmentation éventuelle de la posologie du linézolide pendant le traitement par la rifampicine."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b204956, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b204950 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b204951 .

_:79f295ad32df4ce8a18a92539c6e8a3b204951 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204952;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b204953 .

_:79f295ad32df4ce8a18a92539c6e8a3b204952 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10526 .

_:79f295ad32df4ce8a18a92539c6e8a3b204953 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204954;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b204954 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:79f295ad32df4ce8a18a92539c6e8a3b204956 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11240-1 a owl:Class;
  rdfs:label "LITHIUM <-> MANNITOL"@fr;
  dct:identifier "IAM_11240";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b204958;
  r:natureDuRisque "Diminution de la lithémie avec risque de baisse de l’efficacité thérapeutique."@fr;
  r:conduiteATenir "Surveillance stricte de la lithémie et adaptation éventuelle de la posologie du lithium."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b204964, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b204958 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b204959 .

_:79f295ad32df4ce8a18a92539c6e8a3b204959 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204960;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b204961 .

_:79f295ad32df4ce8a18a92539c6e8a3b204960 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10530 .

_:79f295ad32df4ce8a18a92539c6e8a3b204961 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204962;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b204962 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10549 .

_:79f295ad32df4ce8a18a92539c6e8a3b204964 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11241-1 a owl:Class;
  rdfs:label "LITHIUM <-> METHYLDOPA"@fr;
  dct:identifier "IAM_11241";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b204966;
  r:natureDuRisque "Augmentation de la lithémie pouvant atteindre des valeurs toxiques, avec signes de surdosage en lithium."@fr;
  r:conduiteATenir "Surveillance clinique et adaptation de la posologie de lithium."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b204972, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b204966 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b204967 .

_:79f295ad32df4ce8a18a92539c6e8a3b204967 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204968;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b204969 .

_:79f295ad32df4ce8a18a92539c6e8a3b204968 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10530 .

_:79f295ad32df4ce8a18a92539c6e8a3b204969 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204970;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b204970 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10572 .

_:79f295ad32df4ce8a18a92539c6e8a3b204972 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11254-1 a owl:Class;
  rdfs:label "MÉDICAMENTS À RISQUE LORS DU SEVRAGE TABAGIQUE <-> TRAITEMENTS DE SUBSTITUTION NICOTINIQUE"@fr;
  dct:identifier "IAM_11254";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b204974;
  r:natureDuRisque "Risque de surdosage lors du remplacement du tabac par le traitement substitutif."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b204980, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b204974 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b204975 .

_:79f295ad32df4ce8a18a92539c6e8a3b204975 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204976;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b204977 .

_:79f295ad32df4ce8a18a92539c6e8a3b204976 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10123 .

_:79f295ad32df4ce8a18a92539c6e8a3b204977 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204978;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b204978 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10155 .

_:79f295ad32df4ce8a18a92539c6e8a3b204980 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11243-1 a owl:Class;
  rdfs:label "LITHIUM <-> NEUROLEPTIQUES"@fr;
  dct:identifier "IAM_11243";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b204982;
  r:natureDuRisque "Risque d’apparition de signes neuropsychiques évocateurs d’un syndrome malin des neuroleptiques ou d’une intoxication au lithium."@fr;
  r:conduiteATenir "Surveillance clinique et biologique régulière, notamment en début d'association."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b204988, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b204982 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b204983 .

_:79f295ad32df4ce8a18a92539c6e8a3b204983 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204984;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b204985 .

_:79f295ad32df4ce8a18a92539c6e8a3b204984 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10124 .

_:79f295ad32df4ce8a18a92539c6e8a3b204985 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204986;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b204986 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10530 .

_:79f295ad32df4ce8a18a92539c6e8a3b204988 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11255-1 a owl:Class;
  rdfs:label "MÉDICAMENTS ABAISSANT LA PRESSION ARTÉRIELLE <-> MÉDICAMENTS À L'ORIGINE D'UNE HYPOTENSION ORTHOSTATIQUE"@fr;
  dct:identifier "IAM_11255";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b204990;
  r:natureDuRisque "Risque de majoration d’une hypotension, notamment orthostatique."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b204996, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b204990 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b204991 .

_:79f295ad32df4ce8a18a92539c6e8a3b204991 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204992;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b204993 .

_:79f295ad32df4ce8a18a92539c6e8a3b204992 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10113 .

_:79f295ad32df4ce8a18a92539c6e8a3b204993 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b204994;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b204994 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10122 .

_:79f295ad32df4ce8a18a92539c6e8a3b204996 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11245-1 a owl:Class;
  rdfs:label "LITHIUM <-> SODIUM (BICARBONATE DE)"@fr;
  dct:identifier "IAM_11245";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b204998;
  r:natureDuRisque "Risque de baisse de l’efficacité du lithium par augmentation de son élimination rénale par les sels de sodium."@fr;
  r:conduiteATenir "Eviter les surcharges sodées et tenir compte de la présence de sodium dans certains médicaments comme les antiacides."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b205004, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b204998 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b204999 .

_:79f295ad32df4ce8a18a92539c6e8a3b204999 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205000;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b205001 .

_:79f295ad32df4ce8a18a92539c6e8a3b205000 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10530 .

_:79f295ad32df4ce8a18a92539c6e8a3b205001 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205002;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b205002 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10841 .

_:79f295ad32df4ce8a18a92539c6e8a3b205004 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11246-1 a owl:Class;
  rdfs:label "LITHIUM <-> SODIUM (CHLORURE DE)"@fr;
  dct:identifier "IAM_11246";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b205006;
  r:natureDuRisque "Risque de baisse de l’efficacité du lithium par augmentation de son élimination rénale par les sels de sodium."@fr;
  r:conduiteATenir "Eviter les surcharges sodées et tenir compte de la présence de sodium dans certains médicaments comme les antiacides."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b205012, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b205006 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b205007 .

_:79f295ad32df4ce8a18a92539c6e8a3b205007 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205008;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b205009 .

_:79f295ad32df4ce8a18a92539c6e8a3b205008 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10530 .

_:79f295ad32df4ce8a18a92539c6e8a3b205009 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205010;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b205010 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10842 .

_:79f295ad32df4ce8a18a92539c6e8a3b205012 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11247-1 a owl:Class;
  rdfs:label "LITHIUM <-> THEOPHYLLINE"@fr;
  dct:identifier "IAM_11247";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b205014;
  r:natureDuRisque "Diminution de la lithémie avec risque de baisse de l’efficacité thérapeutique."@fr;
  r:conduiteATenir "Surveillance stricte de la lithémie et adaptation éventuelle de la posologie du lithium."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b205020, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b205014 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b205015 .

_:79f295ad32df4ce8a18a92539c6e8a3b205015 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205016;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b205017 .

_:79f295ad32df4ce8a18a92539c6e8a3b205016 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10530 .

_:79f295ad32df4ce8a18a92539c6e8a3b205017 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205018;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b205018 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10915 .

_:79f295ad32df4ce8a18a92539c6e8a3b205020 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11248-1 a owl:Class;
  rdfs:label "LITHIUM <-> TOPIRAMATE"@fr;
  dct:identifier "IAM_11248";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b205022;
  r:natureDuRisque "Pour des doses de topiramate >= 200 mg par jour : augmentation de la lithémie pouvant atteindre des valeurs toxiques, avec signes de surdosage en lithium."@fr;
  r:conduiteATenir "Surveillance clinique et biologique. Adaptation de la posologie du lithium."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b205028, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b205022 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b205023 .

_:79f295ad32df4ce8a18a92539c6e8a3b205023 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205024;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b205025 .

_:79f295ad32df4ce8a18a92539c6e8a3b205024 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10530 .

_:79f295ad32df4ce8a18a92539c6e8a3b205025 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205026;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b205026 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10941 .

_:79f295ad32df4ce8a18a92539c6e8a3b205028 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11249-1 a owl:Class;
  rdfs:label "LOMITAPIDE <-> MILLEPERTUIS"@fr;
  dct:identifier "IAM_11249";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b205030;
  r:natureDuRisque "Risque de diminution des concentrations plasmatiques du lomitapide."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b205036, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b205030 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b205031 .

_:79f295ad32df4ce8a18a92539c6e8a3b205031 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205032;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b205033 .

_:79f295ad32df4ce8a18a92539c6e8a3b205032 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10533 .

_:79f295ad32df4ce8a18a92539c6e8a3b205033 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205034;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b205034 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10588 .

_:79f295ad32df4ce8a18a92539c6e8a3b205036 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11250-1 a owl:Class;
  rdfs:label "LURASIDONE <-> MILLEPERTUIS"@fr;
  dct:identifier "IAM_11250";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b205038;
  r:natureDuRisque "Diminution des concentrations plasmatiques de la lurasidone par augmentation de son métabolisme hépatique par le millepertuis."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b205044, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b205038 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b205039 .

_:79f295ad32df4ce8a18a92539c6e8a3b205039 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205040;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b205041 .

_:79f295ad32df4ce8a18a92539c6e8a3b205040 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10542 .

_:79f295ad32df4ce8a18a92539c6e8a3b205041 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205042;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b205042 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10588 .

_:79f295ad32df4ce8a18a92539c6e8a3b205044 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11251-1 a owl:Class;
  rdfs:label "LURASIDONE <-> PAMPLEMOUSSE (JUS ET FRUIT)"@fr;
  dct:identifier "IAM_11251";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b205046;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de la lurasidone par diminution de son métabolisme par le pamplemousse."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b205052, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b205046 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b205047 .

_:79f295ad32df4ce8a18a92539c6e8a3b205047 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205048;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b205049 .

_:79f295ad32df4ce8a18a92539c6e8a3b205048 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10130 .

_:79f295ad32df4ce8a18a92539c6e8a3b205049 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205050;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b205050 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10542 .

_:79f295ad32df4ce8a18a92539c6e8a3b205052 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11252-1 a owl:Class;
  rdfs:label "MACITENTAN <-> MILLEPERTUIS"@fr;
  dct:identifier "IAM_11252";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b205054;
  r:natureDuRisque "Risque de diminution des concentrations plasmatiques de macitentan par augmentation de son métabolisme par le millepertuis."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b205060, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b205054 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b205055 .

_:79f295ad32df4ce8a18a92539c6e8a3b205055 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205056;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b205057 .

_:79f295ad32df4ce8a18a92539c6e8a3b205056 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10544 .

_:79f295ad32df4ce8a18a92539c6e8a3b205057 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205058;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b205058 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10588 .

_:79f295ad32df4ce8a18a92539c6e8a3b205060 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11253-1 a owl:Class;
  rdfs:label "MARAVIROC <-> MILLEPERTUIS"@fr;
  dct:identifier "IAM_11253";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b205062;
  r:natureDuRisque "Risque de diminution des concentrations plasmatiques de maraviroc pouvant conduire à une perte de la réponse virologique."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b205068, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b205062 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b205063 .

_:79f295ad32df4ce8a18a92539c6e8a3b205063 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205064;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b205065 .

_:79f295ad32df4ce8a18a92539c6e8a3b205064 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10551 .

_:79f295ad32df4ce8a18a92539c6e8a3b205065 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205066;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b205066 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10588 .

_:79f295ad32df4ce8a18a92539c6e8a3b205068 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11274-1 a owl:Class;
  rdfs:label "METOPROLOL <-> PHÉNOBARBITAL (ET, PAR EXTRAPOLATION, PRIMIDONE)"@fr;
  dct:identifier "IAM_11274";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b205070;
  r:natureDuRisque "Diminution des concentrations plasmatiques du métoprolol avec réduction de ses effets cliniques (augmentation de son métabolisme hépatique)."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b205076, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b205070 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b205071 .

_:79f295ad32df4ce8a18a92539c6e8a3b205071 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205072;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b205073 .

_:79f295ad32df4ce8a18a92539c6e8a3b205072 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10131 .

_:79f295ad32df4ce8a18a92539c6e8a3b205073 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205074;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b205074 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10579 .

_:79f295ad32df4ce8a18a92539c6e8a3b205076 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11242-1 a owl:Class;
  rdfs:label "LITHIUM <-> METRONIDAZOLE"@fr;
  dct:identifier "IAM_11242";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b205078;
  r:natureDuRisque "Augmentation de la lithémie pouvant atteindre des valeurs toxiques, avec signes de surdosage en lithium."@fr;
  r:conduiteATenir "Surveillance stricte de la lithémie et adaptation éventuelle de la posologie du lithium."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b205084, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b205078 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b205079 .

_:79f295ad32df4ce8a18a92539c6e8a3b205079 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205080;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b205081 .

_:79f295ad32df4ce8a18a92539c6e8a3b205080 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10530 .

_:79f295ad32df4ce8a18a92539c6e8a3b205081 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205082;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b205082 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10580 .

_:79f295ad32df4ce8a18a92539c6e8a3b205084 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11310-1 a owl:Class;
  rdfs:label "MIRABÉGRON <-> PROPAFENONE"@fr;
  dct:identifier "IAM_11310";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b205086;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de la propafénone par diminution de son métabolisme par le mirabégron."@fr;
  r:conduiteATenir "Surveillance clinique et réduction éventuelle de la posologie de la propafénone pendant l'association."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b205092, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b205086 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b205087 .

_:79f295ad32df4ce8a18a92539c6e8a3b205087 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205088;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b205089 .

_:79f295ad32df4ce8a18a92539c6e8a3b205088 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10591 .

_:79f295ad32df4ce8a18a92539c6e8a3b205089 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205090;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b205090 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10765 .

_:79f295ad32df4ce8a18a92539c6e8a3b205092 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11272-1 a owl:Class;
  rdfs:label "METOPROLOL <-> MIRABÉGRON"@fr;
  dct:identifier "IAM_11272";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b205094;
  r:natureDuRisque "Avec le métoprolol utilisé dans l'insuffisance cardiaque, augmentation des concentrations plasmatiques du métoprolol par diminution de son métabolisme par le mirabégron."@fr;
  r:conduiteATenir "Surveillance clinique et réduction éventuelle de la posologie du métoprolol pendant l'association."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b205100, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b205094 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b205095 .

_:79f295ad32df4ce8a18a92539c6e8a3b205095 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205096;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b205097 .

_:79f295ad32df4ce8a18a92539c6e8a3b205096 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10579 .

_:79f295ad32df4ce8a18a92539c6e8a3b205097 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205098;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b205098 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10591 .

_:79f295ad32df4ce8a18a92539c6e8a3b205100 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11300-1 a owl:Class;
  rdfs:label "MILLEPERTUIS <-> SOFOSBUVIR"@fr;
  dct:identifier "IAM_11300";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b205102;
  r:natureDuRisque """Risque de diminution des concentrations plasmatiques de 
sofosbuvir par diminution de son absorption intestinale par
le millepertuis."""@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b205108, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b205102 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b205103 .

_:79f295ad32df4ce8a18a92539c6e8a3b205103 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205104;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b205105 .

_:79f295ad32df4ce8a18a92539c6e8a3b205104 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10588 .

_:79f295ad32df4ce8a18a92539c6e8a3b205105 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205106;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b205106 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10850 .

_:79f295ad32df4ce8a18a92539c6e8a3b205108 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11301-1 a owl:Class;
  rdfs:label "MILLEPERTUIS <-> TELAPREVIR"@fr;
  dct:identifier "IAM_11301";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b205110;
  r:natureDuRisque "Risque de diminution très importante des concentrations de télaprévir."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b205116, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b205110 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b205111 .

_:79f295ad32df4ce8a18a92539c6e8a3b205111 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205112;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b205113 .

_:79f295ad32df4ce8a18a92539c6e8a3b205112 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10588 .

_:79f295ad32df4ce8a18a92539c6e8a3b205113 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205114;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b205114 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10887 .

_:79f295ad32df4ce8a18a92539c6e8a3b205116 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11302-1 a owl:Class;
  rdfs:label "MILLEPERTUIS <-> TELITHROMYCINE"@fr;
  dct:identifier "IAM_11302";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b205118;
  r:natureDuRisque "Diminution des concentrations plasmatiques de la télithromycine, avec risque d'échec du traitement anti-infectieux, par augmentation du métabolisme hépatique de la télithromycine par le millepertuis."@fr;
  rdfs:comment "Le millepertuis a des propriétés d'induction enzymatique importantes. En raison du risque d'échec de l'antibiothérapie, une contre-indication a été retenue entre la télithromycine et le millepertuis."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b205124, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b205118 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b205119 .

_:79f295ad32df4ce8a18a92539c6e8a3b205119 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205120;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b205121 .

_:79f295ad32df4ce8a18a92539c6e8a3b205120 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10588 .

_:79f295ad32df4ce8a18a92539c6e8a3b205121 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205122;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b205122 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10889 .

_:79f295ad32df4ce8a18a92539c6e8a3b205124 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11303-1 a owl:Class;
  rdfs:label "MILLEPERTUIS <-> THÉOPHYLLINE (ET, PAR EXTRAPOLATION, AMINOPHYLLINE)"@fr;
  dct:identifier "IAM_11303";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b205126;
  r:natureDuRisque "Diminution des concentrations plasmatiques de la théophylline, en raison de l'effet inducteur enzymatique du millepertuis, avec risque de baisse d'efficacité voire d'annulation de l'effet dont les conséquences peuvent être éventuellement graves (survenue"@fr;
  r:conduiteATenir "En cas d'association fortuite, ne pas interrompre brutalement la prise de millepertuis mais contrôler les concentrations plasmatiques (ou l'efficacité) du médicament associé avant puis après l'arrêt du millepertuis."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b205132, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b205126 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b205127 .

_:79f295ad32df4ce8a18a92539c6e8a3b205127 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205128;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b205129 .

_:79f295ad32df4ce8a18a92539c6e8a3b205128 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10152 .

_:79f295ad32df4ce8a18a92539c6e8a3b205129 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205130;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b205130 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10588 .

_:79f295ad32df4ce8a18a92539c6e8a3b205132 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11304-1 a owl:Class;
  rdfs:label "MILLEPERTUIS <-> TICAGRELOR"@fr;
  dct:identifier "IAM_11304";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b205134;
  r:natureDuRisque "Risque de diminution importante des concentrations plasmatiques de ticagrelor par augmentation de son métabolisme hépatique par le millepertuis, avec diminution de son effet thérapeutique."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b205140, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b205134 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b205135 .

_:79f295ad32df4ce8a18a92539c6e8a3b205135 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205136;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b205137 .

_:79f295ad32df4ce8a18a92539c6e8a3b205136 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10588 .

_:79f295ad32df4ce8a18a92539c6e8a3b205137 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205138;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b205138 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10926 .

_:79f295ad32df4ce8a18a92539c6e8a3b205140 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11305-1 a owl:Class;
  rdfs:label "MILLEPERTUIS <-> ULIPRISTAL"@fr;
  dct:identifier "IAM_11305";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b205142;
  r:natureDuRisque "Risque de diminution de l’effet de l’ulipristal, par augmentation de son métabolisme hépatique par l’inducteur."@fr;
  r:conduiteATenir "Préférer une alternative thérapeutique peu ou pas métabolisée."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b205148, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b205142 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b205143 .

_:79f295ad32df4ce8a18a92539c6e8a3b205143 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205144;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b205145 .

_:79f295ad32df4ce8a18a92539c6e8a3b205144 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10588 .

_:79f295ad32df4ce8a18a92539c6e8a3b205145 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205146;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b205146 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10964 .

_:79f295ad32df4ce8a18a92539c6e8a3b205148 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11306-1 a owl:Class;
  rdfs:label "MILLEPERTUIS <-> VERAPAMIL"@fr;
  dct:identifier "IAM_11306";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b205150;
  r:natureDuRisque "Réduction importante des concentrations de vérapamil, avec risque de perte de son effet thérapeutique."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b205156, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b205150 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b205151 .

_:79f295ad32df4ce8a18a92539c6e8a3b205151 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205152;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b205153 .

_:79f295ad32df4ce8a18a92539c6e8a3b205152 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10588 .

_:79f295ad32df4ce8a18a92539c6e8a3b205153 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205154;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b205154 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10980 .

_:79f295ad32df4ce8a18a92539c6e8a3b205156 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11307-1 a owl:Class;
  rdfs:label "MILLEPERTUIS <-> VISMODÉGIB"@fr;
  dct:identifier "IAM_11307";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b205158;
  r:natureDuRisque "Risque de diminution des concentrations plasmatiques de vismodégib."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b205164, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b205158 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b205159 .

_:79f295ad32df4ce8a18a92539c6e8a3b205159 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205160;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b205161 .

_:79f295ad32df4ce8a18a92539c6e8a3b205160 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10588 .

_:79f295ad32df4ce8a18a92539c6e8a3b205161 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205162;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b205162 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10996 .

_:79f295ad32df4ce8a18a92539c6e8a3b205164 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11298-1 a owl:Class;
  rdfs:label "MILLEPERTUIS <-> SIMÉPRÉVIR"@fr;
  dct:identifier "IAM_11298";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b205166;
  r:natureDuRisque "Risque de diminution des concentrations plasmatiques de simeprévir par augmentation de son métabolisme hépatique par le millepertuis."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b205172, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b205166 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b205167 .

_:79f295ad32df4ce8a18a92539c6e8a3b205167 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205168;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b205169 .

_:79f295ad32df4ce8a18a92539c6e8a3b205168 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10588 .

_:79f295ad32df4ce8a18a92539c6e8a3b205169 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205170;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b205170 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10837 .

_:79f295ad32df4ce8a18a92539c6e8a3b205172 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11309-1 a owl:Class;
  rdfs:label "MINÉRALOCORTICOÏDES <-> RIFAMPICINE"@fr;
  dct:identifier "IAM_11309";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b205174;
  r:natureDuRisque "Diminution des concentrations plasmatiques et de l'efficacité des corticoïdes par augmentation de leur métabolisme hépatique par la rifampicine ; les conséquences sont particulièrement importantes chez les addisoniens traités par l'hydrocortisone et en ca"@fr;
  r:conduiteATenir "Surveillance clinique et biologique ; adaptation de la posologie des corticoïdes pendant le traitement par la rifampicine et après son arrêt."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b205180, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b205174 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b205175 .

_:79f295ad32df4ce8a18a92539c6e8a3b205175 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205176;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b205177 .

_:79f295ad32df4ce8a18a92539c6e8a3b205176 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10108 .

_:79f295ad32df4ce8a18a92539c6e8a3b205177 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205178;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b205178 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:79f295ad32df4ce8a18a92539c6e8a3b205180 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11297-1 a owl:Class;
  rdfs:label "MILLEPERTUIS <-> RILPIVIRINE"@fr;
  dct:identifier "IAM_11297";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b205182;
  r:natureDuRisque "Risque de diminution des concentrations plasmatiques de rilpivirine par augmentation de son métabolisme hépatique par le millepertuis."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b205188, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b205182 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b205183 .

_:79f295ad32df4ce8a18a92539c6e8a3b205183 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205184;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b205185 .

_:79f295ad32df4ce8a18a92539c6e8a3b205184 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10588 .

_:79f295ad32df4ce8a18a92539c6e8a3b205185 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205186;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b205186 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10803 .

_:79f295ad32df4ce8a18a92539c6e8a3b205188 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11311-1 a owl:Class;
  rdfs:label "MITOMYCINE C <-> VINCA-ALCALOÏDES CYTOTOXIQUES"@fr;
  dct:identifier "IAM_11311";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b205190;
  r:natureDuRisque "Risque de majoration de la toxicité pulmonaire de la mitomycine et des vinca-alcaloïdes."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b205196, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b205190 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b205191 .

_:79f295ad32df4ce8a18a92539c6e8a3b205191 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205192;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b205193 .

_:79f295ad32df4ce8a18a92539c6e8a3b205192 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10161 .

_:79f295ad32df4ce8a18a92539c6e8a3b205193 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205194;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b205194 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10593 .

_:79f295ad32df4ce8a18a92539c6e8a3b205196 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11312-1 a owl:Class;
  rdfs:label "MITOTANE <-> SPIRONOLACTONE"@fr;
  dct:identifier "IAM_11312";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b205198;
  r:natureDuRisque "Risque de blocage de l’action du mitotane par la spironolactone."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b205204, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b205198 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b205199 .

_:79f295ad32df4ce8a18a92539c6e8a3b205199 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205200;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b205201 .

_:79f295ad32df4ce8a18a92539c6e8a3b205200 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10594 .

_:79f295ad32df4ce8a18a92539c6e8a3b205201 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205202;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b205202 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10857 .

_:79f295ad32df4ce8a18a92539c6e8a3b205204 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11313-1 a owl:Class;
  rdfs:label "MIZOLASTINE <-> TELITHROMYCINE"@fr;
  dct:identifier "IAM_11313";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b205206;
  r:natureDuRisque "Risque majoré de troubles du rythme ventriculaire, notamment de torsades de pointes."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b205212, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b205206 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b205207 .

_:79f295ad32df4ce8a18a92539c6e8a3b205207 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205208;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b205209 .

_:79f295ad32df4ce8a18a92539c6e8a3b205208 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10597 .

_:79f295ad32df4ce8a18a92539c6e8a3b205209 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205210;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b205210 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10889 .

_:79f295ad32df4ce8a18a92539c6e8a3b205212 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11314-1 a owl:Class;
  rdfs:label "MODAFINIL <-> SOFOSBUVIR"@fr;
  dct:identifier "IAM_11314";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b205214;
  r:natureDuRisque "Risque de diminution des concentrations plasmatiques de sofosbuvir par diminution de son absorption intestinale par le modafinil."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b205220, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b205214 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b205215 .

_:79f295ad32df4ce8a18a92539c6e8a3b205215 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205216;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b205217 .

_:79f295ad32df4ce8a18a92539c6e8a3b205216 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10599 .

_:79f295ad32df4ce8a18a92539c6e8a3b205217 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205218;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b205218 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10850 .

_:79f295ad32df4ce8a18a92539c6e8a3b205220 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11315-1 a owl:Class;
  rdfs:label "MONTELUKAST <-> RIFAMPICINE"@fr;
  dct:identifier "IAM_11315";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b205222;
  r:natureDuRisque "Risque de baisse de l'efficacité du montélukast par augmentation de son métabolisme hépatique par la rifampicine."@fr;
  r:conduiteATenir "Surveillance clinique et adaptation éventuelle de la posologie de l'antiasthmatique pendant le traitement par la rifampicine et après son arrêt."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b205228, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b205222 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b205223 .

_:79f295ad32df4ce8a18a92539c6e8a3b205223 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205224;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b205225 .

_:79f295ad32df4ce8a18a92539c6e8a3b205224 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10604 .

_:79f295ad32df4ce8a18a92539c6e8a3b205225 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205226;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b205226 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:79f295ad32df4ce8a18a92539c6e8a3b205228 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11316-1 a owl:Class;
  rdfs:label "MORPHINE <-> RIFAMPICINE"@fr;
  dct:identifier "IAM_11316";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b205230;
  r:natureDuRisque "Diminution des concentrations plasmatiques et de l'efficacité de la morphine et de son métabolite actif."@fr;
  r:conduiteATenir "Surveillance clinique et adaptation éventuelle de la posologie de la morphine pendant le traitement par la rifampicine et après son arrêt."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b205236, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b205230 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b205231 .

_:79f295ad32df4ce8a18a92539c6e8a3b205231 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205232;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b205233 .

_:79f295ad32df4ce8a18a92539c6e8a3b205232 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10606 .

_:79f295ad32df4ce8a18a92539c6e8a3b205233 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205234;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b205234 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:79f295ad32df4ce8a18a92539c6e8a3b205236 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11317-1 a owl:Class;
  rdfs:label "MORPHINIQUES AGONISTES-ANTAGONISTES <-> MORPHINIQUES ANTAGONISTES PARTIELS"@fr;
  dct:identifier "IAM_11317";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b205238;
  r:natureDuRisque "Risque de diminution de l’effet antalgique et/ou d’apparition d’un syndrome de sevrage."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b205244, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b205238 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b205239 .

_:79f295ad32df4ce8a18a92539c6e8a3b205239 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205240;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b205241 .

_:79f295ad32df4ce8a18a92539c6e8a3b205240 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10110 .

_:79f295ad32df4ce8a18a92539c6e8a3b205241 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205242;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b205242 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10111 .

_:79f295ad32df4ce8a18a92539c6e8a3b205244 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11318-1 a owl:Class;
  rdfs:label "MORPHINIQUES ANTAGONISTES PARTIELS <-> MORPHINIQUES EN TRAITEMENT DE SUBSTITUTION"@fr;
  dct:identifier "IAM_11318";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b205246;
  r:natureDuRisque "Risque d’apparition d’un syndrome de sevrage."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b205252, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b205246 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b205247 .

_:79f295ad32df4ce8a18a92539c6e8a3b205247 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205248;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b205249 .

_:79f295ad32df4ce8a18a92539c6e8a3b205248 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10111 .

_:79f295ad32df4ce8a18a92539c6e8a3b205249 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205250;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b205250 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10112 .

_:79f295ad32df4ce8a18a92539c6e8a3b205252 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11319-1 a owl:Class;
  rdfs:label "MYCOPHENOLATE MOFETIL <-> PÉNICILLINES A"@fr;
  dct:identifier "IAM_11319";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b205254;
  r:natureDuRisque "Diminution des concentrations de l’acide mycophénolique d’environ un tiers, avec risque potentiel de baisse d’efficacité."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b205260, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b205254 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b205255 .

_:79f295ad32df4ce8a18a92539c6e8a3b205255 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205256;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b205257 .

_:79f295ad32df4ce8a18a92539c6e8a3b205256 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10139 .

_:79f295ad32df4ce8a18a92539c6e8a3b205257 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205258;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b205258 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10609 .

_:79f295ad32df4ce8a18a92539c6e8a3b205260 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10713-1 a owl:Class;
  rdfs:label "DACARBAZINE <-> FOTEMUSTINE"@fr;
  dct:identifier "IAM_10713";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b205262;
  r:natureDuRisque "Avec la dacarbazine à doses élevées : risque de toxicité pulmonaire (syndrome de détresse respiratoire aiguë de l'adulte)."@fr;
  r:conduiteATenir "Ne pas utiliser simultanément mais respecter un délai d'une semaine entre la dernière administration de fotémustine et le premier jour de la cure de dacarbazine."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b205268, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b205262 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b205263 .

_:79f295ad32df4ce8a18a92539c6e8a3b205263 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205264;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b205265 .

_:79f295ad32df4ce8a18a92539c6e8a3b205264 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10242 .

_:79f295ad32df4ce8a18a92539c6e8a3b205265 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205266;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b205266 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10404 .

_:79f295ad32df4ce8a18a92539c6e8a3b205268 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11308-1 a owl:Class;
  rdfs:label "MILLEPERTUIS <-> VORICONAZOLE"@fr;
  dct:identifier "IAM_11308";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b205270;
  r:natureDuRisque "Réduction importante des concentrations de voriconazole, avec risque de perte de son effet thérapeutique."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b205276, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b205270 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b205271 .

_:79f295ad32df4ce8a18a92539c6e8a3b205271 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205272;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b205273 .

_:79f295ad32df4ce8a18a92539c6e8a3b205272 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10588 .

_:79f295ad32df4ce8a18a92539c6e8a3b205273 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205274;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b205274 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10998 .

_:79f295ad32df4ce8a18a92539c6e8a3b205276 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11285-1 a owl:Class;
  rdfs:label "MIDAZOLAM <-> RIFAMPICINE"@fr;
  dct:identifier "IAM_11285";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b205278;
  r:natureDuRisque "Risque d'absence d'effet du midazolam, avec diminution très importante de ses concentrations plasmatiques, par augmentation de son métabolisme hépatique."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b205284, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b205278 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b205279 .

_:79f295ad32df4ce8a18a92539c6e8a3b205279 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205280;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b205281 .

_:79f295ad32df4ce8a18a92539c6e8a3b205280 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10585 .

_:79f295ad32df4ce8a18a92539c6e8a3b205281 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205282;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b205282 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:79f295ad32df4ce8a18a92539c6e8a3b205284 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11217-1 a owl:Class;
  rdfs:label "KETOCONAZOLE <-> NINTÉDANIB"@fr;
  dct:identifier "IAM_11217";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b205286;
  r:natureDuRisque "Augmentation des concentrations plasmatiques du nintédanib par augmentation de son absorption par le kétoconazole."@fr;
  r:conduiteATenir "Surveillance clinique pendant l’association."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b205292, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b205286 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b205287 .

_:79f295ad32df4ce8a18a92539c6e8a3b205287 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205288;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b205289 .

_:79f295ad32df4ce8a18a92539c6e8a3b205288 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10501 .

_:79f295ad32df4ce8a18a92539c6e8a3b205289 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205290;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b205290 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10637 .

_:79f295ad32df4ce8a18a92539c6e8a3b205292 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11275-1 a owl:Class;
  rdfs:label "METOPROLOL <-> RIFAMPICINE"@fr;
  dct:identifier "IAM_11275";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b205294;
  r:natureDuRisque "Diminution des concentrations plasmatiques et de l'efficacité du bêta-bloquant (augmentation de son métabolisme hépatique)."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b205300, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b205294 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b205295 .

_:79f295ad32df4ce8a18a92539c6e8a3b205295 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205296;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b205297 .

_:79f295ad32df4ce8a18a92539c6e8a3b205296 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10579 .

_:79f295ad32df4ce8a18a92539c6e8a3b205297 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205298;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b205298 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:79f295ad32df4ce8a18a92539c6e8a3b205300 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11276-1 a owl:Class;
  rdfs:label "METOPROLOL <-> TERBINAFINE"@fr;
  dct:identifier "IAM_11276";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b205302;
  r:natureDuRisque "Chez l'insuffisant cardiaque, risque d'augmentation des effets indésirables du métoprolol, par diminution de son métabolisme hépatique par la terbinafine."@fr;
  r:conduiteATenir "Surveillance clinique. Si besoin, adaptation de la posologie du métoprolol pendant le traitement par la terbinafine."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b205308, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b205302 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b205303 .

_:79f295ad32df4ce8a18a92539c6e8a3b205303 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205304;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b205305 .

_:79f295ad32df4ce8a18a92539c6e8a3b205304 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10579 .

_:79f295ad32df4ce8a18a92539c6e8a3b205305 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205306;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b205306 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10900 .

_:79f295ad32df4ce8a18a92539c6e8a3b205308 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11277-1 a owl:Class;
  rdfs:label "METRONIDAZOLE <-> RIFAMPICINE"@fr;
  dct:identifier "IAM_11277";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b205310;
  r:natureDuRisque "Diminution des concentrations plasmatiques du métronidazole par augmentation de son métabolisme hépatique par la rifampicine."@fr;
  r:conduiteATenir "Surveillance clinique et adaptation éventuelle de la posologie de métronidazole pendant le traitement par la rifampicine et après son arrêt."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b205316, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b205310 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b205311 .

_:79f295ad32df4ce8a18a92539c6e8a3b205311 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205312;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b205313 .

_:79f295ad32df4ce8a18a92539c6e8a3b205312 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10580 .

_:79f295ad32df4ce8a18a92539c6e8a3b205313 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205314;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b205314 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:79f295ad32df4ce8a18a92539c6e8a3b205316 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11278-1 a owl:Class;
  rdfs:label "METYRAPONE <-> PHÉNYTOÏNE (ET, PAR EXTRAPOLATION, FOSPHÉNYTOÏNE)"@fr;
  dct:identifier "IAM_11278";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b205318;
  r:natureDuRisque "Risque de faux négatif du test à la métyrapone, dû à une diminution de ses concentrations plasmatiques, par augmentation de son métabolisme hépatique par la phénytoïne."@fr;
  r:conduiteATenir "Doubler la posologie de métyrapone."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b205324, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b205318 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b205319 .

_:79f295ad32df4ce8a18a92539c6e8a3b205319 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205320;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b205321 .

_:79f295ad32df4ce8a18a92539c6e8a3b205320 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10132 .

_:79f295ad32df4ce8a18a92539c6e8a3b205321 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205322;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b205322 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10581 .

_:79f295ad32df4ce8a18a92539c6e8a3b205324 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11279-1 a owl:Class;
  rdfs:label "MEXILETINE <-> PHÉNYTOÏNE (ET, PAR EXTRAPOLATION, FOSPHÉNYTOÏNE)"@fr;
  dct:identifier "IAM_11279";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b205326;
  r:natureDuRisque "Diminution de l'activité antiarythmique, des concentrations plasmatiques et de la demi-vie de la méxilétine (augmentation de son métabolisme hépatique)."@fr;
  r:conduiteATenir "Surveillance clinique, ECG et éventuellement des concentrations plasmatiques de la mexilétine ; s'il y a lieu, adaptation de la posologie de la mexilétine pendant le traitement par la phénytoïne et après son arrêt."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b205332, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b205326 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b205327 .

_:79f295ad32df4ce8a18a92539c6e8a3b205327 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205328;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b205329 .

_:79f295ad32df4ce8a18a92539c6e8a3b205328 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10132 .

_:79f295ad32df4ce8a18a92539c6e8a3b205329 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205330;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b205330 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10582 .

_:79f295ad32df4ce8a18a92539c6e8a3b205332 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11280-1 a owl:Class;
  rdfs:label "MEXILETINE <-> THÉOPHYLLINE (ET, PAR EXTRAPOLATION, AMINOPHYLLINE)"@fr;
  dct:identifier "IAM_11280";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b205334;
  r:natureDuRisque "Augmentation de la théophyllinémie avec risque de surdosage (diminution du métabolisme hépatique de la théophylline)."@fr;
  r:conduiteATenir "Surveillance clinique et éventuellement de la théophyllinémie ; s'il y a lieu, adaptation de la posologie de la théophylline pendant le traitement par la mexilétine et après son arrêt."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b205340, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b205334 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b205335 .

_:79f295ad32df4ce8a18a92539c6e8a3b205335 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205336;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b205337 .

_:79f295ad32df4ce8a18a92539c6e8a3b205336 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10152 .

_:79f295ad32df4ce8a18a92539c6e8a3b205337 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205338;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b205338 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10582 .

_:79f295ad32df4ce8a18a92539c6e8a3b205340 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11281-1 a owl:Class;
  rdfs:label "MICONAZOLE <-> PHÉNYTOÏNE (ET, PAR EXTRAPOLATION, FOSPHÉNYTOÏNE)"@fr;
  dct:identifier "IAM_11281";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b205342;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de phénytoïne pouvant atteindre des valeurs toxiques. Mécanisme invoqué : inhibition du métabolisme hépatique de la phénytoïne."@fr;
  r:conduiteATenir "Surveillance clinique étroite."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b205348, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b205342 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b205343 .

_:79f295ad32df4ce8a18a92539c6e8a3b205343 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205344;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b205345 .

_:79f295ad32df4ce8a18a92539c6e8a3b205344 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10132 .

_:79f295ad32df4ce8a18a92539c6e8a3b205345 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205346;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b205346 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10584 .

_:79f295ad32df4ce8a18a92539c6e8a3b205348 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11282-1 a owl:Class;
  rdfs:label "MICONAZOLE <-> SULFAMIDES HYPOGLYCÉMIANTS"@fr;
  dct:identifier "IAM_11282";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b205350;
  r:natureDuRisque "Avec le miconazole par voie générale et gel buccal : augmentation de l'effet hypoglycémiant avec survenue possible de manifestations hypoglycémiques, voire de coma."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b205356, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b205350 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b205351 .

_:79f295ad32df4ce8a18a92539c6e8a3b205351 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205352;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b205353 .

_:79f295ad32df4ce8a18a92539c6e8a3b205352 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10147 .

_:79f295ad32df4ce8a18a92539c6e8a3b205353 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205354;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b205354 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10584 .

_:79f295ad32df4ce8a18a92539c6e8a3b205356 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11299-1 a owl:Class;
  rdfs:label "MILLEPERTUIS <-> SIMVASTATINE"@fr;
  dct:identifier "IAM_11299";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b205358;
  r:natureDuRisque "Diminution de l’efficacité de l’hypocholestérolémiant par augmentation de son métabolisme hépatique par le millepertuis."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b205364, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b205358 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b205359 .

_:79f295ad32df4ce8a18a92539c6e8a3b205359 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205360;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b205361 .

_:79f295ad32df4ce8a18a92539c6e8a3b205360 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10588 .

_:79f295ad32df4ce8a18a92539c6e8a3b205361 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205362;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b205362 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10838 .

_:79f295ad32df4ce8a18a92539c6e8a3b205364 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11284-1 a owl:Class;
  rdfs:label "MIDAZOLAM <-> OMBITASVIR + PARITAPRÉVIR"@fr;
  dct:identifier "IAM_11284";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b205366;
  r:natureDuRisque "Augmentation des concentrations plasmatiques du midazolam par diminution de son métabolisme hépatique par la bithérapie."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b205372, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b205366 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b205367 .

_:79f295ad32df4ce8a18a92539c6e8a3b205367 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205368;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b205369 .

_:79f295ad32df4ce8a18a92539c6e8a3b205368 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10128 .

_:79f295ad32df4ce8a18a92539c6e8a3b205369 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205370;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b205370 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10585 .

_:79f295ad32df4ce8a18a92539c6e8a3b205372 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11273-1 a owl:Class;
  rdfs:label "METOPROLOL <-> PAROXETINE"@fr;
  dct:identifier "IAM_11273";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b205374;
  r:natureDuRisque "Risque de majoration des effets indésirables du métoprolol, avec notamment bradycardie excessive, par inhibition de son métabolisme par la paroxétine."@fr;
  r:conduiteATenir "Surveillance clinique accrue ; si besoin, adaptation de la posologie du métoprolol pendant la durée du traitement par la paroxétine et après son arrêt."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b205380, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b205374 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b205375 .

_:79f295ad32df4ce8a18a92539c6e8a3b205375 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205376;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b205377 .

_:79f295ad32df4ce8a18a92539c6e8a3b205376 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10579 .

_:79f295ad32df4ce8a18a92539c6e8a3b205377 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205378;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b205378 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10694 .

_:79f295ad32df4ce8a18a92539c6e8a3b205380 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11286-1 a owl:Class;
  rdfs:label "MIDAZOLAM <-> ROXITHROMYCINE"@fr;
  dct:identifier "IAM_11286";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b205382;
  r:natureDuRisque "Majoration légère de la sédation."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b205388, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b205382 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b205383 .

_:79f295ad32df4ce8a18a92539c6e8a3b205383 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205384;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b205385 .

_:79f295ad32df4ce8a18a92539c6e8a3b205384 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10585 .

_:79f295ad32df4ce8a18a92539c6e8a3b205385 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205386;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b205386 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10817 .

_:79f295ad32df4ce8a18a92539c6e8a3b205388 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11287-1 a owl:Class;
  rdfs:label "MIDAZOLAM <-> STIRIPENTOL"@fr;
  dct:identifier "IAM_11287";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b205390;
  r:natureDuRisque "Augmentation des concentrations plasmatiques du midazolam par diminution de son métabolisme hépatique avec majoration de la sédation."@fr;
  r:conduiteATenir "Surveillance clinique et réduction de la posologie pendant le traitement par le stiripentol."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b205396, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b205390 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b205391 .

_:79f295ad32df4ce8a18a92539c6e8a3b205391 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205392;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b205393 .

_:79f295ad32df4ce8a18a92539c6e8a3b205392 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10585 .

_:79f295ad32df4ce8a18a92539c6e8a3b205393 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205394;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b205394 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10859 .

_:79f295ad32df4ce8a18a92539c6e8a3b205396 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11288-1 a owl:Class;
  rdfs:label "MIDAZOLAM <-> VERAPAMIL"@fr;
  dct:identifier "IAM_11288";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b205398;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de midazolam (diminution de son métabolisme hépatique avec majoration de la sédation)."@fr;
  r:conduiteATenir "Surveillance clinique et réduction de la posologie de midazolam pendant le traitement par le vérapamil."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b205404, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b205398 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b205399 .

_:79f295ad32df4ce8a18a92539c6e8a3b205399 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205400;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b205401 .

_:79f295ad32df4ce8a18a92539c6e8a3b205400 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10585 .

_:79f295ad32df4ce8a18a92539c6e8a3b205401 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205402;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b205402 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10980 .

_:79f295ad32df4ce8a18a92539c6e8a3b205404 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11290-1 a owl:Class;
  rdfs:label "MILLEPERTUIS <-> NEVIRAPINE"@fr;
  dct:identifier "IAM_11290";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b205406;
  r:natureDuRisque "Risque de diminution significative des concentrations plasmatiques de la névirapine par augmentation de son métabolisme hépatique par le millepertuis."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b205412, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b205406 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b205407 .

_:79f295ad32df4ce8a18a92539c6e8a3b205407 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205408;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b205409 .

_:79f295ad32df4ce8a18a92539c6e8a3b205408 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10588 .

_:79f295ad32df4ce8a18a92539c6e8a3b205409 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205410;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b205410 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10628 .

_:79f295ad32df4ce8a18a92539c6e8a3b205412 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11291-1 a owl:Class;
  rdfs:label "MILLEPERTUIS <-> NINTÉDANIB"@fr;
  dct:identifier "IAM_11291";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b205414;
  r:natureDuRisque "Diminution des concentrations plasmatiques du nintédanib par diminution de son absorption par le millepertuis."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b205420, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b205414 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b205415 .

_:79f295ad32df4ce8a18a92539c6e8a3b205415 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205416;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b205417 .

_:79f295ad32df4ce8a18a92539c6e8a3b205416 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10588 .

_:79f295ad32df4ce8a18a92539c6e8a3b205417 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205418;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b205418 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10637 .

_:79f295ad32df4ce8a18a92539c6e8a3b205420 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11292-1 a owl:Class;
  rdfs:label "MILLEPERTUIS <-> OXYCODONE"@fr;
  dct:identifier "IAM_11292";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b205422;
  r:natureDuRisque "Diminution des concentrations plasmatiques de l’oxycodone par augmentation de son métabolisme par le millepertuis."@fr;
  r:conduiteATenir "Adaptation éventuelle de la posologie de l’oxycodone ."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b205428, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b205422 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b205423 .

_:79f295ad32df4ce8a18a92539c6e8a3b205423 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205424;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b205425 .

_:79f295ad32df4ce8a18a92539c6e8a3b205424 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10588 .

_:79f295ad32df4ce8a18a92539c6e8a3b205425 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205426;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b205426 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10681 .

_:79f295ad32df4ce8a18a92539c6e8a3b205428 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11293-1 a owl:Class;
  rdfs:label "MILLEPERTUIS <-> PROGESTATIFS CONTRACEPTIFS"@fr;
  dct:identifier "IAM_11293";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b205430;
  r:natureDuRisque "Diminution des concentrations plasmatiques du contraceptif hormonal, en raison de l'effet inducteur enzymatique du millepertuis, avec risque de baisse d'efficacité voire d'annulation de l'effet dont les conséquences peuvent être éventuellement graves (sur"@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b205436, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b205430 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b205431 .

_:79f295ad32df4ce8a18a92539c6e8a3b205431 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205432;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b205433 .

_:79f295ad32df4ce8a18a92539c6e8a3b205432 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10134 .

_:79f295ad32df4ce8a18a92539c6e8a3b205433 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205434;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b205434 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10588 .

_:79f295ad32df4ce8a18a92539c6e8a3b205436 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11294-1 a owl:Class;
  rdfs:label "MILLEPERTUIS <-> PROPAFENONE"@fr;
  dct:identifier "IAM_11294";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b205438;
  r:natureDuRisque "Diminution des concentrations plasmatiques de la propafénone par augmentation de son métabolisme hépatique par le millepertuis."@fr;
  r:conduiteATenir "Surveillance clinique et ECG. S'il y a lieu, adaptation de la posologie de la propafénone pendant l'association et après l'arrêt du millepertuis."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b205444, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b205438 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b205439 .

_:79f295ad32df4ce8a18a92539c6e8a3b205439 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205440;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b205441 .

_:79f295ad32df4ce8a18a92539c6e8a3b205440 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10588 .

_:79f295ad32df4ce8a18a92539c6e8a3b205441 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205442;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b205442 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10765 .

_:79f295ad32df4ce8a18a92539c6e8a3b205444 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11295-1 a owl:Class;
  rdfs:label "MILLEPERTUIS <-> QUETIAPINE"@fr;
  dct:identifier "IAM_11295";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b205446;
  r:natureDuRisque "Diminution très importante des concentrations plasmatiques de quétiapine par augmentation de son métabolisme hépatique par l'inducteur, avec risque d’inefficacité."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b205452, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b205446 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b205447 .

_:79f295ad32df4ce8a18a92539c6e8a3b205447 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205448;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b205449 .

_:79f295ad32df4ce8a18a92539c6e8a3b205448 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10588 .

_:79f295ad32df4ce8a18a92539c6e8a3b205449 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205450;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b205450 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10773 .

_:79f295ad32df4ce8a18a92539c6e8a3b205452 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11296-1 a owl:Class;
  rdfs:label "MILLEPERTUIS <-> RÉGORAFÉNIB"@fr;
  dct:identifier "IAM_11296";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b205454;
  r:natureDuRisque "Diminution des concentrations plasmatiques de régorafenib par augmentation de son métabolisme par le millepertuis"@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b205460, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b205454 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b205455 .

_:79f295ad32df4ce8a18a92539c6e8a3b205455 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205456;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b205457 .

_:79f295ad32df4ce8a18a92539c6e8a3b205456 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10588 .

_:79f295ad32df4ce8a18a92539c6e8a3b205457 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205458;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b205458 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10789 .

_:79f295ad32df4ce8a18a92539c6e8a3b205460 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11283-1 a owl:Class;
  rdfs:label "MIDAZOLAM <-> MILLEPERTUIS"@fr;
  dct:identifier "IAM_11283";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b205462;
  r:natureDuRisque "Risque de diminution des concentrations plasmatiques de midazolam par le millepertuis."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b205468, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b205462 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b205463 .

_:79f295ad32df4ce8a18a92539c6e8a3b205463 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205464;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b205465 .

_:79f295ad32df4ce8a18a92539c6e8a3b205464 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10585 .

_:79f295ad32df4ce8a18a92539c6e8a3b205465 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205466;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b205466 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10588 .

_:79f295ad32df4ce8a18a92539c6e8a3b205468 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11147-1 a owl:Class;
  rdfs:label "INHIBITEURS DES TYROSINE KINASES MÉTABOLISÉS <-> MILLEPERTUIS"@fr;
  dct:identifier "IAM_11147";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b205470;
  r:natureDuRisque "Diminution des concentrations plasmatiques et de l’efficacité de l’inhibiteur de tyrosine kinase, par augmentation de son métabolisme par le millepertuis."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b205476, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b205470 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b205471 .

_:79f295ad32df4ce8a18a92539c6e8a3b205471 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205472;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b205473 .

_:79f295ad32df4ce8a18a92539c6e8a3b205472 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10101 .

_:79f295ad32df4ce8a18a92539c6e8a3b205473 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205474;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b205474 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10588 .

_:79f295ad32df4ce8a18a92539c6e8a3b205476 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11135-1 a owl:Class;
  rdfs:label "INHIBITEURS DE PROTÉASES BOOSTÉS PAR RITONAVIR <-> RIFABUTINE"@fr;
  dct:identifier "IAM_11135";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b205478;
  r:chapeau "Le ritonavir est désormais utilisé à la dose de 100 mg 2 fois par jour en association à un autre inhibiteur de protéase, dans le but d'augmenter de façon très significative la biodisponibilité de l'inhibiteur de protéase associé (ou boosté), ce qui permet"@fr;
  r:natureDuRisque "Risque de baisse de l'efficacité de l'inhibiteur de protéases (ce d'autant que la posologie de la rifabutine est importante) d'une part, et risque d'augmentation des effets indésirables (uvéites) de la rifabutine, d'autre part."@fr;
  r:conduiteATenir "Surveillance clinique et biologique régulière, notamment en début d'association."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b205484, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b205478 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b205479 .

_:79f295ad32df4ce8a18a92539c6e8a3b205479 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205480;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b205481 .

_:79f295ad32df4ce8a18a92539c6e8a3b205480 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10100 .

_:79f295ad32df4ce8a18a92539c6e8a3b205481 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205482;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b205482 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10800 .

_:79f295ad32df4ce8a18a92539c6e8a3b205484 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11136-1 a owl:Class;
  rdfs:label "INHIBITEURS DE PROTÉASES BOOSTÉS PAR RITONAVIR <-> RIFAMPICINE"@fr;
  dct:identifier "IAM_11136";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b205486;
  r:natureDuRisque """Diminution très importante des concentrations plasmatiques de l'inhibiteur de protéases, par augmentation de son métabolisme hépatique par la rifampicine.

Pour l'association (saquinavir + ritonavir) :
risque de toxicité hépatocellulaire sévère."""@fr;
  r:conduiteATenir "Dans l'attente de données complémentaires avec les inhibiteurs de protéases \"boostés\"."@fr;
  rdfs:comment "La rifampicine est un inducteur enzymatique puissant des CYP450 et diminue fortement la concentration des inhibiteurs de protéases avec un risque de perte d’efficacité du traitement antirétroviral. Une contre-indication entre la majorité des inhibiteurs d"@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b205492, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b205486 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b205487 .

_:79f295ad32df4ce8a18a92539c6e8a3b205487 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205488;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b205489 .

_:79f295ad32df4ce8a18a92539c6e8a3b205488 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10100 .

_:79f295ad32df4ce8a18a92539c6e8a3b205489 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205490;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b205490 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:79f295ad32df4ce8a18a92539c6e8a3b205492 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11137-1 a owl:Class;
  rdfs:label "INHIBITEURS DE PROTÉASES BOOSTÉS PAR RITONAVIR <-> ROSUVASTATINE"@fr;
  dct:identifier "IAM_11137";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b205494;
  r:chapeau "Le ritonavir est désormais utilisé à la dose de 100 mg 2 fois par jour en association à un autre inhibiteur de protéase, dans le but d'augmenter de façon très significative la biodisponibilité de l'inhibiteur de protéase associé (ou boosté), ce qui permet"@fr;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de la rosuvastatine par augmentation de son absorption."@fr;
  r:conduiteATenir "Surveillance clinique et biologique."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b205500, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b205494 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b205495 .

_:79f295ad32df4ce8a18a92539c6e8a3b205495 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205496;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b205497 .

_:79f295ad32df4ce8a18a92539c6e8a3b205496 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10100 .

_:79f295ad32df4ce8a18a92539c6e8a3b205497 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205498;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b205498 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10814 .

_:79f295ad32df4ce8a18a92539c6e8a3b205500 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11138-1 a owl:Class;
  rdfs:label "INHIBITEURS DE PROTÉASES BOOSTÉS PAR RITONAVIR <-> SIMVASTATINE"@fr;
  dct:identifier "IAM_11138";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b205502;
  r:natureDuRisque "Risque majoré d'effets indésirables (concentration-dépendants) à type de rhabdomyolyse (diminution du métabolisme hépatique de la simvastatine)."@fr;
  rdfs:comment "Le groupe de travail européen de pharmacovigilance a émis des recommandations s'appliquant à tous les inhibiteurs de protéases (IPs), inhibiteurs puissants du CYP3A4. Celles-ci modulent les niveaux de contrainte existants entre les IPs et les statines mét"@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b205508, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b205502 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b205503 .

_:79f295ad32df4ce8a18a92539c6e8a3b205503 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205504;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b205505 .

_:79f295ad32df4ce8a18a92539c6e8a3b205504 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10100 .

_:79f295ad32df4ce8a18a92539c6e8a3b205505 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205506;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b205506 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10838 .

_:79f295ad32df4ce8a18a92539c6e8a3b205508 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11140-1 a owl:Class;
  rdfs:label "INHIBITEURS DE PROTÉASES BOOSTÉS PAR RITONAVIR <-> TÉNOFOVIR ALAFÉNAMIDE"@fr;
  dct:identifier "IAM_11140";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b205510;
  r:natureDuRisque "Avec l'atazanavir, le darunavir ou le lopinavir, augmentation des concentrations plasmatiques du ténofovir alafénamide par augmentation de son absorption."@fr;
  r:conduiteATenir "En cas de co-administration, la dose de ténofovir alafénamide doit être limitée à 10 mg par jour. L’association avec les autres inhibiteurs de protéases du VIH n’a pas été étudiée."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b205516, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b205510 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b205511 .

_:79f295ad32df4ce8a18a92539c6e8a3b205511 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205512;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b205513 .

_:79f295ad32df4ce8a18a92539c6e8a3b205512 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10100 .

_:79f295ad32df4ce8a18a92539c6e8a3b205513 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205514;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b205514 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10895 .

_:79f295ad32df4ce8a18a92539c6e8a3b205516 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11141-1 a owl:Class;
  rdfs:label "INHIBITEURS DE PROTÉASES BOOSTÉS PAR RITONAVIR <-> THÉOPHYLLINE (ET, PAR EXTRAPOLATION, AMINOPHYLLINE)"@fr;
  dct:identifier "IAM_11141";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b205518;
  r:chapeau "Le ritonavir est désormais utilisé à la dose de 100 mg 2 fois par jour en association à un autre inhibiteur de protéase, dans le but d'augmenter de façon très significative la biodisponibilité de l'inhibiteur de protéase associé (ou boosté), ce qui permet"@fr;
  r:natureDuRisque "Diminution des concentrations plasmatiques de la théophylline, par augmentation de son métabolisme hépatique."@fr;
  r:conduiteATenir "Surveillance clinique et éventuellement de la théophyllinémie ; s'il y a lieu, adaptation de la posologie de la théophylline pendant le traitement par l'inhibiteur de protéases et après son arrêt."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b205524, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b205518 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b205519 .

_:79f295ad32df4ce8a18a92539c6e8a3b205519 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205520;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b205521 .

_:79f295ad32df4ce8a18a92539c6e8a3b205520 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10100 .

_:79f295ad32df4ce8a18a92539c6e8a3b205521 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205522;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b205522 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10152 .

_:79f295ad32df4ce8a18a92539c6e8a3b205524 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11142-1 a owl:Class;
  rdfs:label "INHIBITEURS DE PROTÉASES BOOSTÉS PAR RITONAVIR <-> ULIPRISTAL"@fr;
  dct:identifier "IAM_11142";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b205526;
  r:natureDuRisque "Risque de diminution de l’effet de l’ulipristal, par augmentation de son métabolisme hépatique par le ritonavir."@fr;
  r:conduiteATenir "Préférer une alternative thérapeutique peu ou pas métabolisée."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b205532, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b205526 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b205527 .

_:79f295ad32df4ce8a18a92539c6e8a3b205527 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205528;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b205529 .

_:79f295ad32df4ce8a18a92539c6e8a3b205528 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10100 .

_:79f295ad32df4ce8a18a92539c6e8a3b205529 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205530;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b205530 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10964 .

_:79f295ad32df4ce8a18a92539c6e8a3b205532 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11143-1 a owl:Class;
  rdfs:label "INHIBITEURS DE PROTÉASES BOOSTÉS PAR RITONAVIR <-> VENLAFAXINE"@fr;
  dct:identifier "IAM_11143";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b205534;
  r:natureDuRisque "Augmentation des concentrations de venlafaxine avec risque de surdosage."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b205540, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b205534 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b205535 .

_:79f295ad32df4ce8a18a92539c6e8a3b205535 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205536;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b205537 .

_:79f295ad32df4ce8a18a92539c6e8a3b205536 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10100 .

_:79f295ad32df4ce8a18a92539c6e8a3b205537 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205538;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b205538 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10979 .

_:79f295ad32df4ce8a18a92539c6e8a3b205540 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11145-1 a owl:Class;
  rdfs:label "INHIBITEURS DE PROTÉASES BOOSTÉS PAR RITONAVIR <-> VORICONAZOLE"@fr;
  dct:identifier "IAM_11145";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b205542;
  r:chapeau "Le ritonavir est désormais utilisé à la dose de 100 mg 2 fois par jour en association à un autre inhibiteur de protéase, dans le but d'augmenter de façon très significative la biodisponibilité de l'inhibiteur de protéase associé (ou boosté), ce qui permet"@fr;
  r:natureDuRisque "Baisse très importante des concentrations de l’antifongique par augmentation de son métabolisme par le ritonavir, avec risque d’échec du traitement."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b205548, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b205542 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b205543 .

_:79f295ad32df4ce8a18a92539c6e8a3b205543 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205544;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b205545 .

_:79f295ad32df4ce8a18a92539c6e8a3b205544 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10100 .

_:79f295ad32df4ce8a18a92539c6e8a3b205545 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205546;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b205546 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10998 .

_:79f295ad32df4ce8a18a92539c6e8a3b205548 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11219-1 a owl:Class;
  rdfs:label "KETOCONAZOLE <-> SALMETEROL"@fr;
  dct:identifier "IAM_11219";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b205550;
  r:natureDuRisque "Augmentation importante des concentrations de salmétérol par diminution de son métabolisme hépatique par le kétoconazole."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b205556, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b205550 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b205551 .

_:79f295ad32df4ce8a18a92539c6e8a3b205551 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205552;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b205553 .

_:79f295ad32df4ce8a18a92539c6e8a3b205552 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10501 .

_:79f295ad32df4ce8a18a92539c6e8a3b205553 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205554;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b205554 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10823 .

_:79f295ad32df4ce8a18a92539c6e8a3b205556 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11149-1 a owl:Class;
  rdfs:label "INHIBITEURS PUISSANTS DU CYP3A4 <-> IRINOTECAN"@fr;
  dct:identifier "IAM_11149";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b205558;
  r:natureDuRisque "Risque de majoration des effets indésirables de l’irinotécan par augmentation des concentrations plasmatiques de son métabolite actif."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b205564, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b205558 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b205559 .

_:79f295ad32df4ce8a18a92539c6e8a3b205559 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205560;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b205561 .

_:79f295ad32df4ce8a18a92539c6e8a3b205560 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10103 .

_:79f295ad32df4ce8a18a92539c6e8a3b205561 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205562;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b205562 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10486 .

_:79f295ad32df4ce8a18a92539c6e8a3b205564 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11119-1 a owl:Class;
  rdfs:label "INHIBITEURS DE L'ENZYME DE CONVERSION <-> SACUBITRIL"@fr;
  dct:identifier "IAM_11119";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b205566;
  r:natureDuRisque "Augmentation du risque d'angioedème."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b205572, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b205566 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b205567 .

_:79f295ad32df4ce8a18a92539c6e8a3b205567 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205568;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b205569 .

_:79f295ad32df4ce8a18a92539c6e8a3b205568 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10096 .

_:79f295ad32df4ce8a18a92539c6e8a3b205569 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205570;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b205570 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10821 .

_:79f295ad32df4ce8a18a92539c6e8a3b205572 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11148-1 a owl:Class;
  rdfs:label "INHIBITEURS DES TYROSINE KINASES MÉTABOLISÉS <-> RIFAMPICINE"@fr;
  dct:identifier "IAM_11148";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b205574;
  r:natureDuRisque "Diminution des concentrations plasmatiques et de l’efficacité de l’inhibiteur de tyrosine kinase, par augmentation de son métabolisme par l’inducteur."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b205580, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b205574 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b205575 .

_:79f295ad32df4ce8a18a92539c6e8a3b205575 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205576;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b205577 .

_:79f295ad32df4ce8a18a92539c6e8a3b205576 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10101 .

_:79f295ad32df4ce8a18a92539c6e8a3b205577 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205578;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b205578 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:79f295ad32df4ce8a18a92539c6e8a3b205580 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10419-1 a owl:Class;
  rdfs:label "AUTRES MÉDICAMENTS AGISSANT SUR L'HÉMOSTASE <-> INHIBITEURS DIRECTS DE LA THROMBINE À INDICATION SPÉCIFIQUE"@fr;
  dct:identifier "IAM_10419";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b205582;
  r:natureDuRisque "Majoration du risque hémorragique."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b205588, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b205582 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b205583 .

_:79f295ad32df4ce8a18a92539c6e8a3b205583 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205584;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b205585 .

_:79f295ad32df4ce8a18a92539c6e8a3b205584 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10102 .

_:79f295ad32df4ce8a18a92539c6e8a3b205585 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205586;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b205586 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10163 .

_:79f295ad32df4ce8a18a92539c6e8a3b205588 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11150-1 a owl:Class;
  rdfs:label "INHIBITEURS PUISSANTS DU CYP3A4 <-> ISAVUCONAZOLE"@fr;
  dct:identifier "IAM_11150";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b205590;
  r:natureDuRisque "Augmentation des concentrations plasmatiques d’isavuconazole par diminution de son métabolisme hépatique par l’inhibiteur."@fr;
  r:conduiteATenir """Contre-indication:
- avec le kétoconazole


Précaution d'emploi:
- avec les autres inhibiteurs puissants du CYP3A4"""@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b205596, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b205590 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b205591 .

_:79f295ad32df4ce8a18a92539c6e8a3b205591 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205592;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b205593 .

_:79f295ad32df4ce8a18a92539c6e8a3b205592 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10103 .

_:79f295ad32df4ce8a18a92539c6e8a3b205593 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205594;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b205594 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10487 .

_:79f295ad32df4ce8a18a92539c6e8a3b205596 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11151-1 a owl:Class;
  rdfs:label "INHIBITEURS PUISSANTS DU CYP3A4 <-> IVABRADINE"@fr;
  dct:identifier "IAM_11151";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b205598;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de l’ivabradine et par conséquent de ses effets indésirables (inhibition de son métabolisme hépatique par l’inhibiteur)."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b205604, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b205598 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b205599 .

_:79f295ad32df4ce8a18a92539c6e8a3b205599 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205600;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b205601 .

_:79f295ad32df4ce8a18a92539c6e8a3b205600 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10103 .

_:79f295ad32df4ce8a18a92539c6e8a3b205601 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205602;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b205602 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10497 .

_:79f295ad32df4ce8a18a92539c6e8a3b205604 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11152-1 a owl:Class;
  rdfs:label "INHIBITEURS PUISSANTS DU CYP3A4 <-> IVACAFTOR"@fr;
  dct:identifier "IAM_11152";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b205606;
  r:natureDuRisque "Augmentation importante des concentrations d’ivacaftor, avec risques de majoration des effets indésirables."@fr;
  r:conduiteATenir "Réduire la dose du quart, soit 150 mg 1 jour sur 2."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b205612, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b205606 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b205607 .

_:79f295ad32df4ce8a18a92539c6e8a3b205607 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205608;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b205609 .

_:79f295ad32df4ce8a18a92539c6e8a3b205608 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10103 .

_:79f295ad32df4ce8a18a92539c6e8a3b205609 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205610;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b205610 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10498 .

_:79f295ad32df4ce8a18a92539c6e8a3b205612 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11153-1 a owl:Class;
  rdfs:label "INHIBITEURS PUISSANTS DU CYP3A4 <-> LOMITAPIDE"@fr;
  dct:identifier "IAM_11153";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b205614;
  r:natureDuRisque "Augmentation des concentrations plasmatiques du lomitapide par diminution de son métabolisme hépatique par l’inhibiteur."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b205620, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b205614 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b205615 .

_:79f295ad32df4ce8a18a92539c6e8a3b205615 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205616;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b205617 .

_:79f295ad32df4ce8a18a92539c6e8a3b205616 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10103 .

_:79f295ad32df4ce8a18a92539c6e8a3b205617 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205618;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b205618 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10533 .

_:79f295ad32df4ce8a18a92539c6e8a3b205620 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11154-1 a owl:Class;
  rdfs:label "INHIBITEURS PUISSANTS DU CYP3A4 <-> LURASIDONE"@fr;
  dct:identifier "IAM_11154";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b205622;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de la lurasidone par diminution de son métabolisme hépatique par l’inhibiteur."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b205628, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b205622 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b205623 .

_:79f295ad32df4ce8a18a92539c6e8a3b205623 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205624;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b205625 .

_:79f295ad32df4ce8a18a92539c6e8a3b205624 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10103 .

_:79f295ad32df4ce8a18a92539c6e8a3b205625 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205626;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b205626 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10542 .

_:79f295ad32df4ce8a18a92539c6e8a3b205628 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11155-1 a owl:Class;
  rdfs:label "INHIBITEURS PUISSANTS DU CYP3A4 <-> MARAVIROC"@fr;
  dct:identifier "IAM_11155";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b205630;
  r:natureDuRisque "Augmentation des concentrations de maraviroc par l’inhibiteur."@fr;
  r:conduiteATenir """La dose de maraviroc doit être diminuée à 150 mg deux fois par jour en cas de co-administration avec cet inhibiteur.
A l'exception du tipranavir boosté par ritonavir où la dose de maraviroc doit être de 300 mg deux fois par jour."""@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b205636, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b205630 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b205631 .

_:79f295ad32df4ce8a18a92539c6e8a3b205631 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205632;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b205633 .

_:79f295ad32df4ce8a18a92539c6e8a3b205632 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10103 .

_:79f295ad32df4ce8a18a92539c6e8a3b205633 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205634;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b205634 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10551 .

_:79f295ad32df4ce8a18a92539c6e8a3b205636 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11156-1 a owl:Class;
  rdfs:label "INHIBITEURS PUISSANTS DU CYP3A4 <-> METHYLPREDNISOLONE"@fr;
  dct:identifier "IAM_11156";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b205638;
  r:natureDuRisque "En cas d’utilisation prolongée, augmentation des concentrations plasmatiques du corticoïde par diminution de son métabolisme hépatique par l’inhibiteur, avec risque d'apparition d'un syndrome cushingoïde."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b205644, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b205638 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b205639 .

_:79f295ad32df4ce8a18a92539c6e8a3b205639 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205640;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b205641 .

_:79f295ad32df4ce8a18a92539c6e8a3b205640 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10103 .

_:79f295ad32df4ce8a18a92539c6e8a3b205641 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205642;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b205642 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10576 .

_:79f295ad32df4ce8a18a92539c6e8a3b205644 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11146-1 a owl:Class;
  rdfs:label "INHIBITEURS DES TYROSINE KINASES MÉTABOLISÉS <-> INHIBITEURS PUISSANTS DU CYP3A4"@fr;
  dct:identifier "IAM_11146";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b205646;
  r:chapeau "Certains médicaments possèdent la capacité d’inhiber fortement le CYP3A4, une enzyme qui intervient dans le métabolisme de nombreux médicaments. Lorsque l’activité de cette enzyme est inhibée, elle n’est plus en mesure de métaboliser le médicament qui va"@fr;
  r:natureDuRisque """Risque de majoration des effets indésirables de l’inhibiteur de
tyrosine kinase par diminution de son métabolisme."""@fr;
  r:conduiteATenir """Association déconseillée :
- avec l'axitinib, le bosutinib, le céritinib, le cobimétinib, le dabrafenib, le dasatinib, le nilotinib, le sunitinib
- avec l'ibrutinib, si l’association ne peut être évitée ,surveillance clinique étroite et réduction de la do"""@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b205652, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b205646 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b205647 .

_:79f295ad32df4ce8a18a92539c6e8a3b205647 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205648;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b205649 .

_:79f295ad32df4ce8a18a92539c6e8a3b205648 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10101 .

_:79f295ad32df4ce8a18a92539c6e8a3b205649 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205650;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b205650 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10103 .

_:79f295ad32df4ce8a18a92539c6e8a3b205652 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11109-1 a owl:Class;
  rdfs:label "INDUCTEURS ENZYMATIQUES <-> VISMODÉGIB"@fr;
  dct:identifier "IAM_11109";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b205654;
  r:natureDuRisque "Risque de diminution des concentrations plasmatiques de vismodegib par augmentation de son métabolisme hépatique par l’inducteur."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b205660, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b205654 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b205655 .

_:79f295ad32df4ce8a18a92539c6e8a3b205655 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205656;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b205657 .

_:79f295ad32df4ce8a18a92539c6e8a3b205656 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10094 .

_:79f295ad32df4ce8a18a92539c6e8a3b205657 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205658;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b205658 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10996 .

_:79f295ad32df4ce8a18a92539c6e8a3b205660 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11098-1 a owl:Class;
  rdfs:label "INDUCTEURS ENZYMATIQUES <-> OMBITASVIR + PARITAPRÉVIR"@fr;
  dct:identifier "IAM_11098";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b205662;
  r:chapeau "Certains médicaments ont la propriété d'activer considérablement certaines voies métaboliques hépatiques par induction enzymatique. Associés à des médicaments fortement métabolisés au niveau du foie, ils sont, de ce fait, en mesure d'en modifier les conce"@fr;
  r:natureDuRisque "Diminution des concentrations plasmatiques de la bithérapie par augmentation de son métabolisme hépatique par l’inducteur."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b205668, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b205662 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b205663 .

_:79f295ad32df4ce8a18a92539c6e8a3b205663 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205664;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b205665 .

_:79f295ad32df4ce8a18a92539c6e8a3b205664 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10094 .

_:79f295ad32df4ce8a18a92539c6e8a3b205665 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205666;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b205666 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10128 .

_:79f295ad32df4ce8a18a92539c6e8a3b205668 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11099-1 a owl:Class;
  rdfs:label "INDUCTEURS ENZYMATIQUES <-> OXYCODONE"@fr;
  dct:identifier "IAM_11099";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b205670;
  r:natureDuRisque "Diminution des concentrations plasmatiques de l’oxycodone par augmentation de son métabolisme par l’inducteur."@fr;
  r:conduiteATenir "Adaptation éventuelle de la posologie d’oxycodone ."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b205676, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b205670 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b205671 .

_:79f295ad32df4ce8a18a92539c6e8a3b205671 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205672;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b205673 .

_:79f295ad32df4ce8a18a92539c6e8a3b205672 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10094 .

_:79f295ad32df4ce8a18a92539c6e8a3b205673 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205674;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b205674 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10681 .

_:79f295ad32df4ce8a18a92539c6e8a3b205676 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11100-1 a owl:Class;
  rdfs:label "INDUCTEURS ENZYMATIQUES <-> PROGESTATIFS CONTRACEPTIFS"@fr;
  dct:identifier "IAM_11100";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b205678;
  r:natureDuRisque "Diminution de l'efficacité contraceptive du contraceptif hormonal, par augmentation de son métabolisme hépatique par l'inducteur."@fr;
  r:conduiteATenir "Utiliser de préférence une autre méthode contraceptive, en particulier de type mécanique, pendant la durée de l'association et un cycle suivant."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b205684, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b205678 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b205679 .

_:79f295ad32df4ce8a18a92539c6e8a3b205679 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205680;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b205681 .

_:79f295ad32df4ce8a18a92539c6e8a3b205680 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10094 .

_:79f295ad32df4ce8a18a92539c6e8a3b205681 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205682;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b205682 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10134 .

_:79f295ad32df4ce8a18a92539c6e8a3b205684 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11101-1 a owl:Class;
  rdfs:label "INDUCTEURS ENZYMATIQUES <-> PROGESTATIFS NON CONTRACEPTIFS, ASSOCIÉS OU NON À UN ESTROGÈNE"@fr;
  dct:identifier "IAM_11101";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b205686;
  r:chapeau "Certains médicaments ont la propriété d'activer considérablement certaines voies métaboliques hépatiques par induction enzymatique. Associés à des médicaments fortement métabolisés au niveau du foie, ils sont, de ce fait, en mesure d'en modifier les conce"@fr;
  r:natureDuRisque "Diminution de l'efficacité du progestatif."@fr;
  r:conduiteATenir "Surveillance clinique et adaptation éventuelle de la posologie du traitement hormonal pendant l'administration de l'inducteur et après son arrêt."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b205692, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b205686 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b205687 .

_:79f295ad32df4ce8a18a92539c6e8a3b205687 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205688;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b205689 .

_:79f295ad32df4ce8a18a92539c6e8a3b205688 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10094 .

_:79f295ad32df4ce8a18a92539c6e8a3b205689 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205690;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b205690 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10135 .

_:79f295ad32df4ce8a18a92539c6e8a3b205692 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11102-1 a owl:Class;
  rdfs:label "INDUCTEURS ENZYMATIQUES <-> RÉGORAFÉNIB"@fr;
  dct:identifier "IAM_11102";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b205694;
  r:natureDuRisque "Diminution des concentrations plasmatiques de régorafenib par augmentation de son métabolisme par l’inducteur."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b205700, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b205694 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b205695 .

_:79f295ad32df4ce8a18a92539c6e8a3b205695 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205696;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b205697 .

_:79f295ad32df4ce8a18a92539c6e8a3b205696 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10094 .

_:79f295ad32df4ce8a18a92539c6e8a3b205697 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205698;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b205698 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10789 .

_:79f295ad32df4ce8a18a92539c6e8a3b205700 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11103-1 a owl:Class;
  rdfs:label "INDUCTEURS ENZYMATIQUES <-> RILPIVIRINE"@fr;
  dct:identifier "IAM_11103";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b205702;
  r:natureDuRisque "Diminution significative des concentrations plasmatiques de rilpivirine par augmentation de son métabolisme hépatique par l’inducteur."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b205708, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b205702 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b205703 .

_:79f295ad32df4ce8a18a92539c6e8a3b205703 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205704;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b205705 .

_:79f295ad32df4ce8a18a92539c6e8a3b205704 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10094 .

_:79f295ad32df4ce8a18a92539c6e8a3b205705 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205706;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b205706 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10803 .

_:79f295ad32df4ce8a18a92539c6e8a3b205708 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11104-1 a owl:Class;
  rdfs:label "INDUCTEURS ENZYMATIQUES <-> SERTRALINE"@fr;
  dct:identifier "IAM_11104";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b205710;
  r:natureDuRisque "Risque d’inefficacité du traitement antidépresseur."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b205716, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b205710 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b205711 .

_:79f295ad32df4ce8a18a92539c6e8a3b205711 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205712;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b205713 .

_:79f295ad32df4ce8a18a92539c6e8a3b205712 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10094 .

_:79f295ad32df4ce8a18a92539c6e8a3b205713 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205714;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b205714 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10831 .

_:79f295ad32df4ce8a18a92539c6e8a3b205716 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11105-1 a owl:Class;
  rdfs:label "INDUCTEURS ENZYMATIQUES <-> SIMÉPRÉVIR"@fr;
  dct:identifier "IAM_11105";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b205718;
  r:natureDuRisque "Diminution des concentrations plasmatiques de simeprévir par augmentation de son métabolisme hépatique par l’inducteur"@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b205724, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b205718 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b205719 .

_:79f295ad32df4ce8a18a92539c6e8a3b205719 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205720;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b205721 .

_:79f295ad32df4ce8a18a92539c6e8a3b205720 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10094 .

_:79f295ad32df4ce8a18a92539c6e8a3b205721 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205722;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b205722 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10837 .

_:79f295ad32df4ce8a18a92539c6e8a3b205724 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11106-1 a owl:Class;
  rdfs:label "INDUCTEURS ENZYMATIQUES <-> SOFOSBUVIR"@fr;
  dct:identifier "IAM_11106";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b205726;
  r:natureDuRisque """Risque de diminution des concentrations plasmatiques de 
sofosbuvir par diminution de son absorption intestinale par
l’inducteur."""@fr;
  r:conduiteATenir """Contre-indication :
- avec la rifampicine
- avec les anticonvulsivants inducteurs enzymatiques

Association déconseillée:
- avec les autres inducteurs."""@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b205732, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b205726 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b205727 .

_:79f295ad32df4ce8a18a92539c6e8a3b205727 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205728;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b205729 .

_:79f295ad32df4ce8a18a92539c6e8a3b205728 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10094 .

_:79f295ad32df4ce8a18a92539c6e8a3b205729 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205730;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b205730 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10850 .

_:79f295ad32df4ce8a18a92539c6e8a3b205732 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11134-1 a owl:Class;
  rdfs:label "INHIBITEURS DE PROTÉASES BOOSTÉS PAR RITONAVIR <-> QUINIDINE"@fr;
  dct:identifier "IAM_11134";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b205734;
  r:natureDuRisque "Risque majoré de troubles du rythme ventriculaire, notamment de torsades de pointes."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b205740, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b205734 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b205735 .

_:79f295ad32df4ce8a18a92539c6e8a3b205735 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205736;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b205737 .

_:79f295ad32df4ce8a18a92539c6e8a3b205736 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10100 .

_:79f295ad32df4ce8a18a92539c6e8a3b205737 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205738;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b205738 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10776 .

_:79f295ad32df4ce8a18a92539c6e8a3b205740 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11108-1 a owl:Class;
  rdfs:label "INDUCTEURS ENZYMATIQUES <-> VÉMURAFÉNIB"@fr;
  dct:identifier "IAM_11108";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b205742;
  r:natureDuRisque "Risque de diminution des concentrations du vémurafénib, avec moindre efficacité."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b205748, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b205742 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b205743 .

_:79f295ad32df4ce8a18a92539c6e8a3b205743 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205744;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b205745 .

_:79f295ad32df4ce8a18a92539c6e8a3b205744 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10094 .

_:79f295ad32df4ce8a18a92539c6e8a3b205745 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205746;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b205746 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10978 .

_:79f295ad32df4ce8a18a92539c6e8a3b205748 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11133-1 a owl:Class;
  rdfs:label "INHIBITEURS DE PROTÉASES BOOSTÉS PAR RITONAVIR <-> PROGESTATIFS CONTRACEPTIFS"@fr;
  dct:identifier "IAM_11133";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b205750;
  r:chapeau "Le ritonavir est désormais utilisé à la dose de 100 mg 2 fois par jour en association à un autre inhibiteur de protéase, dans le but d'augmenter de façon très significative la biodisponibilité de l'inhibiteur de protéase associé (ou boosté), ce qui permet"@fr;
  r:natureDuRisque "Risque de diminution de l'efficacité contraceptive par diminution des concentrations en contraceptif hormonal, dûe à l'augmentation de son métabolisme hépatique par le ritonavir."@fr;
  r:conduiteATenir "Utiliser de préférence une autre méthode contraceptive, en particulier de type mécanique (préservatif ou stérilet), pendant la durée de l'association et un cycle suivant."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b205756, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b205750 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b205751 .

_:79f295ad32df4ce8a18a92539c6e8a3b205751 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205752;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b205753 .

_:79f295ad32df4ce8a18a92539c6e8a3b205752 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10100 .

_:79f295ad32df4ce8a18a92539c6e8a3b205753 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205754;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b205754 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10134 .

_:79f295ad32df4ce8a18a92539c6e8a3b205756 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11110-1 a owl:Class;
  rdfs:label "INDUCTEURS ENZYMATIQUES <-> VORTIOXÉTINE"@fr;
  dct:identifier "IAM_11110";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b205758;
  r:natureDuRisque "Diminution des concentrations plasmatiques de la vortioxétine."@fr;
  r:conduiteATenir "Surveillance clinique et adaptation éventuelle de la posologie de la vortioxétine pendant l'association et 1 à 2 semaines après l’arrêt de l’inducteur."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b205764, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b205758 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b205759 .

_:79f295ad32df4ce8a18a92539c6e8a3b205759 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205760;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b205761 .

_:79f295ad32df4ce8a18a92539c6e8a3b205760 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10094 .

_:79f295ad32df4ce8a18a92539c6e8a3b205761 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205762;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b205762 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10999 .

_:79f295ad32df4ce8a18a92539c6e8a3b205764 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11111-1 a owl:Class;
  rdfs:label "INHIBITEURS DE LA PHOSPHODIESTERASE DE TYPE 5 <-> INHIBITEURS PUISSANTS DU CYP3A4"@fr;
  dct:identifier "IAM_11111";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b205766;
  r:chapeau "Certains médicaments possèdent la capacité d’inhiber fortement le CYP3A4, une enzyme qui intervient dans le métabolisme de nombreux médicaments. Lorsque l’activité de cette enzyme est inhibée, elle n’est plus en mesure de métaboliser le médicament qui va"@fr;
  r:natureDuRisque "Augmentation (très importante pour l'avanafil et le vardénafil) des concentrations plasmatiques de l'IPDE5, avec risque d'hypotension (sévère avec le vardénafil)."@fr;
  r:conduiteATenir "Pour connaître les risques et les niveaux de contrainte de chaque IPDE5 avec les inhibiteurs puissants du CYP3A4, il convient de se reporter aux AMM specifiques à chacun d'eux."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b205772, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b205766 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b205767 .

_:79f295ad32df4ce8a18a92539c6e8a3b205767 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205768;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b205769 .

_:79f295ad32df4ce8a18a92539c6e8a3b205768 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10098 .

_:79f295ad32df4ce8a18a92539c6e8a3b205769 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205770;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b205770 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10103 .

_:79f295ad32df4ce8a18a92539c6e8a3b205772 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11112-1 a owl:Class;
  rdfs:label "INHIBITEURS DE LA PHOSPHODIESTERASE DE TYPE 5 <-> RIOCIGUAT"@fr;
  dct:identifier "IAM_11112";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b205774;
  r:natureDuRisque "Risque d'hypotension importante (effet synergique)."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b205780, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b205774 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b205775 .

_:79f295ad32df4ce8a18a92539c6e8a3b205775 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205776;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b205777 .

_:79f295ad32df4ce8a18a92539c6e8a3b205776 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10098 .

_:79f295ad32df4ce8a18a92539c6e8a3b205777 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205778;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b205778 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10804 .

_:79f295ad32df4ce8a18a92539c6e8a3b205780 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11113-1 a owl:Class;
  rdfs:label "INHIBITEURS DE LA XANTHINE OXYDASE <-> THÉOPHYLLINE (ET, PAR EXTRAPOLATION, AMINOPHYLLINE)"@fr;
  dct:identifier "IAM_11113";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b205782;
  r:natureDuRisque "En cas de posologies élevées de l'inhibiteur, augmentation des concentrations plasmatiques de théophylline par inhibition de son métabolisme."@fr;
  r:conduiteATenir "Surveillance clinique et contrôle de la théophyllinémie jusqu'à deux à trois semaines après la mise en route du traitement par l'inhibiteur ; s'il y a lieu, adaptation de la posologie pendant le traitement par l'association."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b205788, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b205782 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b205783 .

_:79f295ad32df4ce8a18a92539c6e8a3b205783 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205784;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b205785 .

_:79f295ad32df4ce8a18a92539c6e8a3b205784 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10099 .

_:79f295ad32df4ce8a18a92539c6e8a3b205785 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205786;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b205786 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10152 .

_:79f295ad32df4ce8a18a92539c6e8a3b205788 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11114-1 a owl:Class;
  rdfs:label "INHIBITEURS DE L'ENZYME DE CONVERSION <-> INSULINE"@fr;
  dct:identifier "IAM_11114";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b205790;
  r:natureDuRisque "L'utilisation des IEC peut entraîner une majoration de l'effet hypoglycémiant chez le diabétique traité par insuline. La survenue de malaises hypoglycémiques semble exceptionnelle (amélioration de la tolérance au glucose qui aurait pour conséquence une ré"@fr;
  r:conduiteATenir "Renforcer l'autosurveillance glycémique."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b205796, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b205790 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b205791 .

_:79f295ad32df4ce8a18a92539c6e8a3b205791 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205792;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b205793 .

_:79f295ad32df4ce8a18a92539c6e8a3b205792 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10096 .

_:79f295ad32df4ce8a18a92539c6e8a3b205793 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205794;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b205794 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10458 .

_:79f295ad32df4ce8a18a92539c6e8a3b205796 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11115-1 a owl:Class;
  rdfs:label "INHIBITEURS DE L'ENZYME DE CONVERSION <-> LITHIUM"@fr;
  dct:identifier "IAM_11115";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b205798;
  r:natureDuRisque "Augmentation de la lithémie pouvant atteindre des valeurs toxiques (diminution de l'excrétion rénale du lithium)."@fr;
  r:conduiteATenir "Si l'usage d'un IEC est indispensable, surveillance stricte de la lithémie et adaptation de la posologie du lithium."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b205804, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b205798 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b205799 .

_:79f295ad32df4ce8a18a92539c6e8a3b205799 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205800;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b205801 .

_:79f295ad32df4ce8a18a92539c6e8a3b205800 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10096 .

_:79f295ad32df4ce8a18a92539c6e8a3b205801 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205802;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b205802 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10530 .

_:79f295ad32df4ce8a18a92539c6e8a3b205804 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11116-1 a owl:Class;
  rdfs:label "INHIBITEURS DE L'ENZYME DE CONVERSION <-> OR"@fr;
  dct:identifier "IAM_11116";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b205806;
  r:natureDuRisque "Avec les sels d'or administrés par voie IV : risque de réaction «nitritoïde» à l’introduction de l’IEC (nausées, vomissements, effets vasomoteurs à type de flush, hypotension, éventuellement collapsus)."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b205812, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b205806 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b205807 .

_:79f295ad32df4ce8a18a92539c6e8a3b205807 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205808;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b205809 .

_:79f295ad32df4ce8a18a92539c6e8a3b205808 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10096 .

_:79f295ad32df4ce8a18a92539c6e8a3b205809 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205810;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b205810 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10666 .

_:79f295ad32df4ce8a18a92539c6e8a3b205812 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11117-1 a owl:Class;
  rdfs:label "INHIBITEURS DE L'ENZYME DE CONVERSION <-> POTASSIUM"@fr;
  dct:identifier "IAM_11117";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b205814;
  r:natureDuRisque "Hyperkaliémie (potentiellement létale) surtout lors d'une insuffisance rénale (addition des effets hyperkaliémiants)."@fr;
  r:conduiteATenir "Sauf s'il existe une hypokaliémie."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b205820, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b205814 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b205815 .

_:79f295ad32df4ce8a18a92539c6e8a3b205815 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205816;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b205817 .

_:79f295ad32df4ce8a18a92539c6e8a3b205816 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10096 .

_:79f295ad32df4ce8a18a92539c6e8a3b205817 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205818;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b205818 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10742 .

_:79f295ad32df4ce8a18a92539c6e8a3b205820 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11118-1 a owl:Class;
  rdfs:label "INHIBITEURS DE L'ENZYME DE CONVERSION <-> RACECADOTRIL"@fr;
  dct:identifier "IAM_11118";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b205822;
  r:natureDuRisque "Risque de majoration des effets indésirables à type d'œdème angio-neurotique (angio-œdème)."@fr;
  r:conduiteATenir """Contre-indication:
- en cas d'antécédents d'angio-oedème sous IEC.

Association déconseillée:
- en l'absence d’antécédents d'angio-oedème sous IEC."""@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b205828, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b205822 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b205823 .

_:79f295ad32df4ce8a18a92539c6e8a3b205823 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205824;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b205825 .

_:79f295ad32df4ce8a18a92539c6e8a3b205824 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10096 .

_:79f295ad32df4ce8a18a92539c6e8a3b205825 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205826;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b205826 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10780 .

_:79f295ad32df4ce8a18a92539c6e8a3b205828 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11159-1 a owl:Class;
  rdfs:label "INHIBITEURS PUISSANTS DU CYP3A4 <-> OMBITASVIR + PARITAPRÉVIR"@fr;
  dct:identifier "IAM_11159";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b205830;
  r:chapeau "Certains médicaments possèdent la capacité d’inhiber fortement le CYP3A4, une enzyme qui intervient dans le métabolisme de nombreux médicaments. Lorsque l’activité de cette enzyme est inhibée, elle n’est plus en mesure de métaboliser le médicament qui va"@fr;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de la bithérapie par diminution de son métabolisme hépatique par l’inhibiteur."@fr;
  r:conduiteATenir """Contre-indication: 
- sauf avec le ritonavir."""@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b205836, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b205830 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b205831 .

_:79f295ad32df4ce8a18a92539c6e8a3b205831 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205832;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b205833 .

_:79f295ad32df4ce8a18a92539c6e8a3b205832 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10103 .

_:79f295ad32df4ce8a18a92539c6e8a3b205833 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205834;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b205834 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10128 .

_:79f295ad32df4ce8a18a92539c6e8a3b205836 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11107-1 a owl:Class;
  rdfs:label "INDUCTEURS ENZYMATIQUES <-> TÉNOFOVIR ALAFÉNAMIDE"@fr;
  dct:identifier "IAM_11107";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b205838;
  r:natureDuRisque "Diminution des concentrations plasmatiques du ténofovir alafénamide par diminution de son absorption par l’inducteur."@fr;
  r:conduiteATenir "Si l'association ne peut être évitée, surveillance clinique pendant l’association et 1 à 2 semaines après l’arrêt de l’inducteur."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b205844, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b205838 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b205839 .

_:79f295ad32df4ce8a18a92539c6e8a3b205839 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205840;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b205841 .

_:79f295ad32df4ce8a18a92539c6e8a3b205840 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10094 .

_:79f295ad32df4ce8a18a92539c6e8a3b205841 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205842;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b205842 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10895 .

_:79f295ad32df4ce8a18a92539c6e8a3b205844 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11203-1 a owl:Class;
  rdfs:label "ITRACONAZOLE <-> VINCA-ALCALOÏDES CYTOTOXIQUES"@fr;
  dct:identifier "IAM_11203";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b205846;
  r:natureDuRisque "Majoration de la neurotoxicité de l'antimitotique, par diminution de son métabolisme hépatique par l'itraconazole."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b205852, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b205846 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b205847 .

_:79f295ad32df4ce8a18a92539c6e8a3b205847 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205848;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b205849 .

_:79f295ad32df4ce8a18a92539c6e8a3b205848 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10161 .

_:79f295ad32df4ce8a18a92539c6e8a3b205849 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205850;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b205850 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10496 .

_:79f295ad32df4ce8a18a92539c6e8a3b205852 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11157-1 a owl:Class;
  rdfs:label "INHIBITEURS PUISSANTS DU CYP3A4 <-> MIDAZOLAM"@fr;
  dct:identifier "IAM_11157";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b205854;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de midazolam par diminution de son métabolisme hépatique, avec majoration de la sédation."@fr;
  r:conduiteATenir """Association déconseillée:
- avec le midazolam per os

Précaution d'emploi avec :
- avec le midazolam IV et sublingual
Surveillance clinique et réduction de la posologie de midazolam en cas de traitement par l'inhibiteur."""@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b205860, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b205854 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b205855 .

_:79f295ad32df4ce8a18a92539c6e8a3b205855 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205856;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b205857 .

_:79f295ad32df4ce8a18a92539c6e8a3b205856 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10103 .

_:79f295ad32df4ce8a18a92539c6e8a3b205857 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205858;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b205858 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10585 .

_:79f295ad32df4ce8a18a92539c6e8a3b205860 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10078-1 a owl:Class;
  rdfs:label "ALCOOL (BOISSON OU EXCIPIENT) <-> INSULINE"@fr;
  dct:identifier "IAM_10078";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b205862;
  r:natureDuRisque "Augmentation de la réaction hypoglycémique (inhibition des réactions de compensation pouvant faciliter la survenue de coma hypoglycémique)."@fr;
  r:conduiteATenir "Eviter la prise de boissons alcoolisées et de médicaments contenant de l'alcool."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b205868, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b205862 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b205863 .

_:79f295ad32df4ce8a18a92539c6e8a3b205863 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205864;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b205865 .

_:79f295ad32df4ce8a18a92539c6e8a3b205864 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10458 .

_:79f295ad32df4ce8a18a92539c6e8a3b205865 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205866;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b205866 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_11013 .

_:79f295ad32df4ce8a18a92539c6e8a3b205868 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11184-1 a owl:Class;
  rdfs:label "IRINOTECAN <-> MILLEPERTUIS"@fr;
  dct:identifier "IAM_11184";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b205870;
  r:natureDuRisque "Diminution des concentrations plasmatiques du métabolite actif de l'irinotécan, avec risque d'échec du traitement cytotoxique."@fr;
  rdfs:comment "Une étude randomisée, chez 5 patients traités par irinotécan, a mis en évidence une diminution de 42 % des concentrations de son métabolite actif, le SN-38, qui est un substrat de l'isoenzyme CYP3A4. En cas d'association de l'irinotécan avec le millepertu"@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b205876, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b205870 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b205871 .

_:79f295ad32df4ce8a18a92539c6e8a3b205871 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205872;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b205873 .

_:79f295ad32df4ce8a18a92539c6e8a3b205872 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10486 .

_:79f295ad32df4ce8a18a92539c6e8a3b205873 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205874;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b205874 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10588 .

_:79f295ad32df4ce8a18a92539c6e8a3b205876 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11185-1 a owl:Class;
  rdfs:label "ISAVUCONAZOLE <-> MILLEPERTUIS"@fr;
  dct:identifier "IAM_11185";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b205878;
  r:natureDuRisque "Diminution des concentrations plasmatiques d’isavuconazole par augmentation de son métabolisme hépatique par le millepertuis."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b205884, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b205878 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b205879 .

_:79f295ad32df4ce8a18a92539c6e8a3b205879 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205880;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b205881 .

_:79f295ad32df4ce8a18a92539c6e8a3b205880 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10487 .

_:79f295ad32df4ce8a18a92539c6e8a3b205881 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205882;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b205882 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10588 .

_:79f295ad32df4ce8a18a92539c6e8a3b205884 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11186-1 a owl:Class;
  rdfs:label "ISONIAZIDE <-> KETOCONAZOLE"@fr;
  dct:identifier "IAM_11186";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b205886;
  r:natureDuRisque "Diminution des concentrations plasmatiques de kétoconazole."@fr;
  r:conduiteATenir "Espacer les prises des deux anti-infectieux d'au moins 12 heures. Surveiller les concentrations plasmatiques du kétoconazole et adapter éventuellement sa posologie."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b205892, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b205886 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b205887 .

_:79f295ad32df4ce8a18a92539c6e8a3b205887 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205888;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b205889 .

_:79f295ad32df4ce8a18a92539c6e8a3b205888 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10490 .

_:79f295ad32df4ce8a18a92539c6e8a3b205889 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205890;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b205890 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10501 .

_:79f295ad32df4ce8a18a92539c6e8a3b205892 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11187-1 a owl:Class;
  rdfs:label "ISONIAZIDE <-> PHÉNYTOÏNE (ET, PAR EXTRAPOLATION, FOSPHÉNYTOÏNE)"@fr;
  dct:identifier "IAM_11187";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b205894;
  r:natureDuRisque "Surdosage en phénytoïne (diminution de son métabolisme)."@fr;
  r:conduiteATenir "Surveillance clinique étroite, dosage des concentrations plasmatiques de phénytoïne et adaptation éventuelle de sa posologie pendant le traitement par l'isoniazide et après son arrêt."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b205900, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b205894 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b205895 .

_:79f295ad32df4ce8a18a92539c6e8a3b205895 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205896;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b205897 .

_:79f295ad32df4ce8a18a92539c6e8a3b205896 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10132 .

_:79f295ad32df4ce8a18a92539c6e8a3b205897 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205898;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b205898 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10490 .

_:79f295ad32df4ce8a18a92539c6e8a3b205900 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11188-1 a owl:Class;
  rdfs:label "ISONIAZIDE <-> PYRAZINAMIDE"@fr;
  dct:identifier "IAM_11188";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b205902;
  r:natureDuRisque "Addition des effets hépatotoxiques."@fr;
  r:conduiteATenir "Surveillance clinique et biologique."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b205908, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b205902 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b205903 .

_:79f295ad32df4ce8a18a92539c6e8a3b205903 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205904;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b205905 .

_:79f295ad32df4ce8a18a92539c6e8a3b205904 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10490 .

_:79f295ad32df4ce8a18a92539c6e8a3b205905 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205906;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b205906 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10770 .

_:79f295ad32df4ce8a18a92539c6e8a3b205908 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11189-1 a owl:Class;
  rdfs:label "ISONIAZIDE <-> RIFAMPICINE"@fr;
  dct:identifier "IAM_11189";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b205910;
  r:natureDuRisque "Augmentation de l'hépatotoxicité de l'isoniazide (augmentation de la formation de métabolites toxiques de l'isoniazide)."@fr;
  r:conduiteATenir "Surveillance clinique et biologique de cette association classique. En cas d'hépatite, arrêter l'isoniazide."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b205916, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b205910 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b205911 .

_:79f295ad32df4ce8a18a92539c6e8a3b205911 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205912;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b205913 .

_:79f295ad32df4ce8a18a92539c6e8a3b205912 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10490 .

_:79f295ad32df4ce8a18a92539c6e8a3b205913 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205914;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b205914 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:79f295ad32df4ce8a18a92539c6e8a3b205916 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11190-1 a owl:Class;
  rdfs:label "ISONIAZIDE <-> STAVUDINE"@fr;
  dct:identifier "IAM_11190";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b205918;
  r:natureDuRisque "Risque majoré de survenue de neuropathies périphériques par addition d'effets indésirables."@fr;
  r:conduiteATenir "Surveillance clinique et biologique régulière, notamment en début d'association."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b205924, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b205918 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b205919 .

_:79f295ad32df4ce8a18a92539c6e8a3b205919 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205920;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b205921 .

_:79f295ad32df4ce8a18a92539c6e8a3b205920 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10490 .

_:79f295ad32df4ce8a18a92539c6e8a3b205921 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205922;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b205922 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10858 .

_:79f295ad32df4ce8a18a92539c6e8a3b205924 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11182-1 a owl:Class;
  rdfs:label "INHIBITEURS SÉLECTIFS DE LA RECAPTURE DE LA SÉROTONINE <-> TRAMADOL"@fr;
  dct:identifier "IAM_11182";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b205926;
  r:natureDuRisque "Risque d'apparition de convulsions et/ou d'un syndrome sérotoninergique."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b205932, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b205926 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b205927 .

_:79f295ad32df4ce8a18a92539c6e8a3b205927 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205928;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b205929 .

_:79f295ad32df4ce8a18a92539c6e8a3b205928 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10104 .

_:79f295ad32df4ce8a18a92539c6e8a3b205929 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205930;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b205930 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10945 .

_:79f295ad32df4ce8a18a92539c6e8a3b205932 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11192-1 a owl:Class;
  rdfs:label "ITRACONAZOLE <-> LUMEFANTRINE"@fr;
  dct:identifier "IAM_11192";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b205934;
  r:natureDuRisque "Risque majoré de troubles du rythme ventriculaire, notamment de torsades de pointes."@fr;
  r:conduiteATenir "Si cela est possible, interrompre le torsadogène associé. Si l'association ne peut être évitée, contrôle préalable du QT et surveillance ECG monitorée."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b205940, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b205934 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b205935 .

_:79f295ad32df4ce8a18a92539c6e8a3b205935 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205936;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b205937 .

_:79f295ad32df4ce8a18a92539c6e8a3b205936 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10496 .

_:79f295ad32df4ce8a18a92539c6e8a3b205937 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205938;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b205938 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10541 .

_:79f295ad32df4ce8a18a92539c6e8a3b205940 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11181-1 a owl:Class;
  rdfs:label "INHIBITEURS SÉLECTIFS DE LA RECAPTURE DE LA SÉROTONINE <-> ORLISTAT"@fr;
  dct:identifier "IAM_11181";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b205942;
  r:natureDuRisque "Risque d'échec thérapeutique en cas de traitement concomitant par orlistat."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b205948, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b205942 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b205943 .

_:79f295ad32df4ce8a18a92539c6e8a3b205943 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205944;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b205945 .

_:79f295ad32df4ce8a18a92539c6e8a3b205944 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10104 .

_:79f295ad32df4ce8a18a92539c6e8a3b205945 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205946;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b205946 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10667 .

_:79f295ad32df4ce8a18a92539c6e8a3b205948 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11191-1 a owl:Class;
  rdfs:label "ITRACONAZOLE <-> LERCANIDIPINE"@fr;
  dct:identifier "IAM_11191";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b205950;
  r:natureDuRisque "Risque majoré d'effets indesirables, notamment d'oedèmes, par diminution du métabolisme hépatique de la dihydropyridine."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b205956, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b205950 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b205951 .

_:79f295ad32df4ce8a18a92539c6e8a3b205951 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205952;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b205953 .

_:79f295ad32df4ce8a18a92539c6e8a3b205952 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10496 .

_:79f295ad32df4ce8a18a92539c6e8a3b205953 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205954;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b205954 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10514 .

_:79f295ad32df4ce8a18a92539c6e8a3b205956 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11193-1 a owl:Class;
  rdfs:label "ITRACONAZOLE <-> MILLEPERTUIS"@fr;
  dct:identifier "IAM_11193";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b205958;
  r:natureDuRisque "Risque de diminution importante des concentrations plasmatiques d’itraconazole, avec risque de perte d’efficacité, par augmentation de son métabolisme hépatique par le millepertuis."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b205964, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b205958 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b205959 .

_:79f295ad32df4ce8a18a92539c6e8a3b205959 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205960;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b205961 .

_:79f295ad32df4ce8a18a92539c6e8a3b205960 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10496 .

_:79f295ad32df4ce8a18a92539c6e8a3b205961 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205962;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b205962 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10588 .

_:79f295ad32df4ce8a18a92539c6e8a3b205964 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11210-1 a owl:Class;
  rdfs:label "JOSAMYCINE <-> SILDENAFIL"@fr;
  dct:identifier "IAM_11210";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b205966;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de sildénafil, avec risque d'hypotension."@fr;
  r:conduiteATenir "Débuter le traitement par sildénafil à la dose minimale en cas d'association avec la josamycine."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b205972, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b205966 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b205967 .

_:79f295ad32df4ce8a18a92539c6e8a3b205967 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205968;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b205969 .

_:79f295ad32df4ce8a18a92539c6e8a3b205968 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10499 .

_:79f295ad32df4ce8a18a92539c6e8a3b205969 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205970;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b205970 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10834 .

_:79f295ad32df4ce8a18a92539c6e8a3b205972 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11211-1 a owl:Class;
  rdfs:label "JOSAMYCINE <-> TACROLIMUS"@fr;
  dct:identifier "IAM_11211";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b205974;
  r:natureDuRisque "Augmentation des concentrations sanguines de tacrolimus et de la créatininémie, par inhibition du métabolisme hépatique du tacrolimus par la josamycine."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b205980, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b205974 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b205975 .

_:79f295ad32df4ce8a18a92539c6e8a3b205975 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205976;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b205977 .

_:79f295ad32df4ce8a18a92539c6e8a3b205976 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10499 .

_:79f295ad32df4ce8a18a92539c6e8a3b205977 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205978;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b205978 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10880 .

_:79f295ad32df4ce8a18a92539c6e8a3b205980 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11212-1 a owl:Class;
  rdfs:label "JOSAMYCINE <-> THÉOPHYLLINE (ET, PAR EXTRAPOLATION, AMINOPHYLLINE)"@fr;
  dct:identifier "IAM_11212";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b205982;
  r:natureDuRisque "Risque d'augmentation de la théophyllinémie, particulièrement chez l'enfant."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b205988, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b205982 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b205983 .

_:79f295ad32df4ce8a18a92539c6e8a3b205983 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205984;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b205985 .

_:79f295ad32df4ce8a18a92539c6e8a3b205984 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10152 .

_:79f295ad32df4ce8a18a92539c6e8a3b205985 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205986;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b205986 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10499 .

_:79f295ad32df4ce8a18a92539c6e8a3b205988 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11223-1 a owl:Class;
  rdfs:label "KETOCONAZOLE <-> VINCA-ALCALOÏDES CYTOTOXIQUES"@fr;
  dct:identifier "IAM_11223";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b205990;
  r:natureDuRisque "Majoration de la neurotoxicité de l'antimitotique, par diminution de son métabolisme hépatique par le kétoconazole."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b205996, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b205990 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b205991 .

_:79f295ad32df4ce8a18a92539c6e8a3b205991 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205992;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b205993 .

_:79f295ad32df4ce8a18a92539c6e8a3b205992 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10161 .

_:79f295ad32df4ce8a18a92539c6e8a3b205993 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b205994;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b205994 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10501 .

_:79f295ad32df4ce8a18a92539c6e8a3b205996 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11214-1 a owl:Class;
  rdfs:label "KETOCONAZOLE <-> LUMEFANTRINE"@fr;
  dct:identifier "IAM_11214";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b205998;
  r:natureDuRisque "Risque majoré de troubles du rythme ventriculaire, notamment de torsades de pointes."@fr;
  r:conduiteATenir "Si cela est possible, interrompre le torsadogène associé. Si l'association ne peut être évitée, contrôle préalable du QT et surveillance ECG monitorée."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b206004, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b205998 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b205999 .

_:79f295ad32df4ce8a18a92539c6e8a3b205999 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206000;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b206001 .

_:79f295ad32df4ce8a18a92539c6e8a3b206000 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10501 .

_:79f295ad32df4ce8a18a92539c6e8a3b206001 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206002;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b206002 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10541 .

_:79f295ad32df4ce8a18a92539c6e8a3b206004 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11213-1 a owl:Class;
  rdfs:label "KETOCONAZOLE <-> LERCANIDIPINE"@fr;
  dct:identifier "IAM_11213";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b206006;
  r:natureDuRisque "Risque majoré d'effets indesirables, notamment d'oedèmes, par diminution du métabolisme hépatique de la dihydropyridine."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b206012, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b206006 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b206007 .

_:79f295ad32df4ce8a18a92539c6e8a3b206007 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206008;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b206009 .

_:79f295ad32df4ce8a18a92539c6e8a3b206008 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10501 .

_:79f295ad32df4ce8a18a92539c6e8a3b206009 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206010;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b206010 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10514 .

_:79f295ad32df4ce8a18a92539c6e8a3b206012 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11215-1 a owl:Class;
  rdfs:label "KETOCONAZOLE <-> MIZOLASTINE"@fr;
  dct:identifier "IAM_11215";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b206014;
  r:natureDuRisque "Risque de troubles du rythme ventriculaire, notamment de torsades de pointes."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b206020, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b206014 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b206015 .

_:79f295ad32df4ce8a18a92539c6e8a3b206015 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206016;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b206017 .

_:79f295ad32df4ce8a18a92539c6e8a3b206016 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10501 .

_:79f295ad32df4ce8a18a92539c6e8a3b206017 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206018;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b206018 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10597 .

_:79f295ad32df4ce8a18a92539c6e8a3b206020 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11216-1 a owl:Class;
  rdfs:label "KETOCONAZOLE <-> NEVIRAPINE"@fr;
  dct:identifier "IAM_11216";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b206022;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de névirapine par diminution de son métabolisme hépatique par le kétoconazole, d'une part, et diminution des concentrations plasmatiques du kétoconazole par augmentation de son métabolisme hépatique par la névi"@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b206028, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b206022 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b206023 .

_:79f295ad32df4ce8a18a92539c6e8a3b206023 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206024;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b206025 .

_:79f295ad32df4ce8a18a92539c6e8a3b206024 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10501 .

_:79f295ad32df4ce8a18a92539c6e8a3b206025 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206026;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b206026 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10628 .

_:79f295ad32df4ce8a18a92539c6e8a3b206028 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11199-1 a owl:Class;
  rdfs:label "ITRACONAZOLE <-> TELAPREVIR"@fr;
  dct:identifier "IAM_11199";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b206030;
  r:natureDuRisque "Risque d’augmentation des concentrations plasmatiques de télaprévir et de l’itraconazole."@fr;
  r:conduiteATenir "Surveillance clinique. Eviter des doses élevées d’itraconazole (> 200 mg par jour)."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b206036, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b206030 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b206031 .

_:79f295ad32df4ce8a18a92539c6e8a3b206031 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206032;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b206033 .

_:79f295ad32df4ce8a18a92539c6e8a3b206032 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10496 .

_:79f295ad32df4ce8a18a92539c6e8a3b206033 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206034;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b206034 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10887 .

_:79f295ad32df4ce8a18a92539c6e8a3b206036 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11170-1 a owl:Class;
  rdfs:label "INHIBITEURS PUISSANTS DU CYP3A4 <-> SUBSTRATS À RISQUE DU CYP3A4"@fr;
  dct:identifier "IAM_11170";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b206038;
  r:chapeau "Pour connaître les risques et les niveaux de contrainte de chacun de ces substrats avec les inhibiteurs puissants du CYP3A4, il convient de se reporter aux interactions spécifiques de chaque substrat."@fr;
  r:natureDuRisque "Majoration des effets indésirables propres à chaque substrat, avec conséquences souvent sévères."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b206044, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b206038 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b206039 .

_:79f295ad32df4ce8a18a92539c6e8a3b206039 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206040;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b206041 .

_:79f295ad32df4ce8a18a92539c6e8a3b206040 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10103 .

_:79f295ad32df4ce8a18a92539c6e8a3b206041 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206042;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b206042 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10145 .

_:79f295ad32df4ce8a18a92539c6e8a3b206044 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11322-1 a owl:Class;
  rdfs:label "NEBIVOLOL <-> PAROXETINE"@fr;
  dct:identifier "IAM_11322";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b206046;
  r:natureDuRisque "Risque de majoration des effets indésirables du nébivolol avec notamment bradycardie excessive, par inhibition de son métabolisme par l’antidépresseur."@fr;
  r:conduiteATenir "Surveillance clinique accrue ; si besoin, adaptation de la posologie du nébivolol pendant la durée du traitement par l’antidépresseur et après son arrêt."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b206052, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b206046 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b206047 .

_:79f295ad32df4ce8a18a92539c6e8a3b206047 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206048;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b206049 .

_:79f295ad32df4ce8a18a92539c6e8a3b206048 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10623 .

_:79f295ad32df4ce8a18a92539c6e8a3b206049 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206050;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b206050 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10694 .

_:79f295ad32df4ce8a18a92539c6e8a3b206052 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11160-1 a owl:Class;
  rdfs:label "INHIBITEURS PUISSANTS DU CYP3A4 <-> OXYCODONE"@fr;
  dct:identifier "IAM_11160";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b206054;
  r:natureDuRisque "Majoration des effets indésirables, notamment respiratoires, de l’oxycodone par diminution de son métabolisme par l'inhibiteur."@fr;
  r:conduiteATenir "Surveillance clinique et adaptation éventuelle de la posologie de l’oxycodone pendant le traitement par l'inhibiteur et après son arrêt."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b206060, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b206054 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b206055 .

_:79f295ad32df4ce8a18a92539c6e8a3b206055 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206056;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b206057 .

_:79f295ad32df4ce8a18a92539c6e8a3b206056 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10103 .

_:79f295ad32df4ce8a18a92539c6e8a3b206057 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206058;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b206058 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10681 .

_:79f295ad32df4ce8a18a92539c6e8a3b206060 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11161-1 a owl:Class;
  rdfs:label "INHIBITEURS PUISSANTS DU CYP3A4 <-> PANOBINOSTAT"@fr;
  dct:identifier "IAM_11161";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b206062;
  r:natureDuRisque "Risque de majoration des effets indésirables, notamment cardiaques, du panobinostat par diminution de son métabolisme par l’inhibiteur."@fr;
  r:conduiteATenir "Surveillance clinique et ECG. Débuter le traitement à dose réduite de moitié (10 mg)."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b206068, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b206062 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b206063 .

_:79f295ad32df4ce8a18a92539c6e8a3b206063 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206064;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b206065 .

_:79f295ad32df4ce8a18a92539c6e8a3b206064 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10103 .

_:79f295ad32df4ce8a18a92539c6e8a3b206065 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206066;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b206066 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10688 .

_:79f295ad32df4ce8a18a92539c6e8a3b206068 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11162-1 a owl:Class;
  rdfs:label "INHIBITEURS PUISSANTS DU CYP3A4 <-> PIMOZIDE"@fr;
  dct:identifier "IAM_11162";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b206070;
  r:natureDuRisque "Risque majoré de troubles du rythme ventriculaire, notamment de torsades de pointes."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b206076, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b206070 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b206071 .

_:79f295ad32df4ce8a18a92539c6e8a3b206071 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206072;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b206073 .

_:79f295ad32df4ce8a18a92539c6e8a3b206072 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10103 .

_:79f295ad32df4ce8a18a92539c6e8a3b206073 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206074;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b206074 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10721 .

_:79f295ad32df4ce8a18a92539c6e8a3b206076 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11163-1 a owl:Class;
  rdfs:label "INHIBITEURS PUISSANTS DU CYP3A4 <-> QUETIAPINE"@fr;
  dct:identifier "IAM_11163";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b206078;
  r:natureDuRisque "Augmentation importante des concentrations de quétiapine, avec risque de surdosage."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b206084, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b206078 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b206079 .

_:79f295ad32df4ce8a18a92539c6e8a3b206079 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206080;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b206081 .

_:79f295ad32df4ce8a18a92539c6e8a3b206080 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10103 .

_:79f295ad32df4ce8a18a92539c6e8a3b206081 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206082;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b206082 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10773 .

_:79f295ad32df4ce8a18a92539c6e8a3b206084 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11164-1 a owl:Class;
  rdfs:label "INHIBITEURS PUISSANTS DU CYP3A4 <-> QUININE"@fr;
  dct:identifier "IAM_11164";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b206086;
  r:natureDuRisque "Risque de majoration des effets indésirables de la quinine, notamment troubles du rythme ventriculaire et troubles neurosensoriels (cinchonisme)."@fr;
  r:conduiteATenir """Association déconseillée : 
- avec les inhibiteurs de protéases

Précaution d’emploi : 
- avec les azolés antifongiques et certains macrolides.
Surveillance clinique et ECG. Adaptation éventuelle de la posologie de la quinine pendant le traitement par l’i"""@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b206092, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b206086 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b206087 .

_:79f295ad32df4ce8a18a92539c6e8a3b206087 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206088;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b206089 .

_:79f295ad32df4ce8a18a92539c6e8a3b206088 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10103 .

_:79f295ad32df4ce8a18a92539c6e8a3b206089 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206090;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b206090 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10777 .

_:79f295ad32df4ce8a18a92539c6e8a3b206092 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11165-1 a owl:Class;
  rdfs:label "INHIBITEURS PUISSANTS DU CYP3A4 <-> RANOLAZINE"@fr;
  dct:identifier "IAM_11165";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b206094;
  r:natureDuRisque "Augmentation des concentrations de ranolazine par diminution de son métabolisme par l'inhibiteur."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b206100, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b206094 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b206095 .

_:79f295ad32df4ce8a18a92539c6e8a3b206095 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206096;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b206097 .

_:79f295ad32df4ce8a18a92539c6e8a3b206096 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10103 .

_:79f295ad32df4ce8a18a92539c6e8a3b206097 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206098;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b206098 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10786 .

_:79f295ad32df4ce8a18a92539c6e8a3b206100 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11166-1 a owl:Class;
  rdfs:label "INHIBITEURS PUISSANTS DU CYP3A4 <-> RÉGORAFÉNIB"@fr;
  dct:identifier "IAM_11166";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b206102;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de régorafenib par diminution de son métabolisme hépatique par l’inhibiteur."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b206108, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b206102 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b206103 .

_:79f295ad32df4ce8a18a92539c6e8a3b206103 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206104;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b206105 .

_:79f295ad32df4ce8a18a92539c6e8a3b206104 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10103 .

_:79f295ad32df4ce8a18a92539c6e8a3b206105 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206106;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b206106 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10789 .

_:79f295ad32df4ce8a18a92539c6e8a3b206108 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11167-1 a owl:Class;
  rdfs:label "INHIBITEURS PUISSANTS DU CYP3A4 <-> RIOCIGUAT"@fr;
  dct:identifier "IAM_11167";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b206110;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de riociguat par diminution de son métabolisme hépatique par l’inhibiteur."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b206116, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b206110 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b206111 .

_:79f295ad32df4ce8a18a92539c6e8a3b206111 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206112;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b206113 .

_:79f295ad32df4ce8a18a92539c6e8a3b206112 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10103 .

_:79f295ad32df4ce8a18a92539c6e8a3b206113 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206114;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b206114 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10804 .

_:79f295ad32df4ce8a18a92539c6e8a3b206116 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11183-1 a owl:Class;
  rdfs:label "INHIBITEURS SÉLECTIFS DE LA RECAPTURE DE LA SÉROTONINE <-> TRIPTANS"@fr;
  dct:identifier "IAM_11183";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b206118;
  r:natureDuRisque "Risque d'apparition d'un syndrome sérotoninergique."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b206124, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b206118 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b206119 .

_:79f295ad32df4ce8a18a92539c6e8a3b206119 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206120;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b206121 .

_:79f295ad32df4ce8a18a92539c6e8a3b206120 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10104 .

_:79f295ad32df4ce8a18a92539c6e8a3b206121 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206122;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b206122 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10156 .

_:79f295ad32df4ce8a18a92539c6e8a3b206124 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11169-1 a owl:Class;
  rdfs:label "INHIBITEURS PUISSANTS DU CYP3A4 <-> SIMÉPRÉVIR"@fr;
  dct:identifier "IAM_11169";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b206126;
  r:natureDuRisque "Risque d’augmentation des concentrations plasmatiques de siméprévir par diminution de son métabolisme hépatique par l’inhibiteur."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b206132, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b206126 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b206127 .

_:79f295ad32df4ce8a18a92539c6e8a3b206127 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206128;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b206129 .

_:79f295ad32df4ce8a18a92539c6e8a3b206128 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10103 .

_:79f295ad32df4ce8a18a92539c6e8a3b206129 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206130;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b206130 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10837 .

_:79f295ad32df4ce8a18a92539c6e8a3b206132 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11158-1 a owl:Class;
  rdfs:label "INHIBITEURS PUISSANTS DU CYP3A4 <-> OLAPARIB"@fr;
  dct:identifier "IAM_11158";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b206134;
  r:natureDuRisque "Augmentation des concentrations plasmatiques d’olaparib par l’inhibiteur."@fr;
  r:conduiteATenir "Si l’association ne peut être évitée, limiter la dose d’olaparib à 150 mg deux fois par jour."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b206140, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b206134 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b206135 .

_:79f295ad32df4ce8a18a92539c6e8a3b206135 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206136;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b206137 .

_:79f295ad32df4ce8a18a92539c6e8a3b206136 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10103 .

_:79f295ad32df4ce8a18a92539c6e8a3b206137 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206138;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b206138 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10659 .

_:79f295ad32df4ce8a18a92539c6e8a3b206140 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11171-1 a owl:Class;
  rdfs:label "INHIBITEURS PUISSANTS DU CYP3A4 <-> SUFENTANIL"@fr;
  dct:identifier "IAM_11171";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b206142;
  r:natureDuRisque "Augmentation de l’effet dépresseur respiratoire de l’analgésique opiacé par diminution de son métabolisme hépatique."@fr;
  r:conduiteATenir "Surveillance clinique et adaptation de la posologie de l’analgésique opiacé en cas de traitement par un inhibiteur puissant du CYP3A4."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b206148, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b206142 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b206143 .

_:79f295ad32df4ce8a18a92539c6e8a3b206143 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206144;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b206145 .

_:79f295ad32df4ce8a18a92539c6e8a3b206144 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10103 .

_:79f295ad32df4ce8a18a92539c6e8a3b206145 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206146;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b206146 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10865 .

_:79f295ad32df4ce8a18a92539c6e8a3b206148 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11172-1 a owl:Class;
  rdfs:label "INHIBITEURS PUISSANTS DU CYP3A4 <-> TAMSULOSINE"@fr;
  dct:identifier "IAM_11172";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b206150;
  r:natureDuRisque "Risque de majoration des effets indésirables de la tamsulosine, par inhibition de son métabolisme hépatique."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b206156, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b206150 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b206151 .

_:79f295ad32df4ce8a18a92539c6e8a3b206151 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206152;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b206153 .

_:79f295ad32df4ce8a18a92539c6e8a3b206152 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10103 .

_:79f295ad32df4ce8a18a92539c6e8a3b206153 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206154;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b206154 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10883 .

_:79f295ad32df4ce8a18a92539c6e8a3b206156 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11173-1 a owl:Class;
  rdfs:label "INHIBITEURS PUISSANTS DU CYP3A4 <-> TELITHROMYCINE"@fr;
  dct:identifier "IAM_11173";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b206158;
  r:natureDuRisque "Risque de majoration des effets indésirables, notamment à type de troubles du rythme cardiaque."@fr;
  r:conduiteATenir "chez le patient insuffisant rénal ou hépatique sévère."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b206164, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b206158 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b206159 .

_:79f295ad32df4ce8a18a92539c6e8a3b206159 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206160;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b206161 .

_:79f295ad32df4ce8a18a92539c6e8a3b206160 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10103 .

_:79f295ad32df4ce8a18a92539c6e8a3b206161 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206162;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b206162 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10889 .

_:79f295ad32df4ce8a18a92539c6e8a3b206164 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11174-1 a owl:Class;
  rdfs:label "INHIBITEURS PUISSANTS DU CYP3A4 <-> TICAGRELOR"@fr;
  dct:identifier "IAM_11174";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b206166;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de ticagrelor par diminution de son métabolisme hépatique par l’inhibiteur."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b206172, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b206166 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b206167 .

_:79f295ad32df4ce8a18a92539c6e8a3b206167 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206168;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b206169 .

_:79f295ad32df4ce8a18a92539c6e8a3b206168 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10103 .

_:79f295ad32df4ce8a18a92539c6e8a3b206169 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206170;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b206170 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10926 .

_:79f295ad32df4ce8a18a92539c6e8a3b206172 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11175-1 a owl:Class;
  rdfs:label "INHIBITEURS PUISSANTS DU CYP3A4 <-> TRASTUZUMAB EMTANSINE"@fr;
  dct:identifier "IAM_11175";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b206174;
  r:natureDuRisque "Augmentation des concentrations plasmatiques du DM1, un composant du trastuzumab emtansine, par inhibition de son métabolisme par l’inhibiteur."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b206180, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b206174 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b206175 .

_:79f295ad32df4ce8a18a92539c6e8a3b206175 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206176;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b206177 .

_:79f295ad32df4ce8a18a92539c6e8a3b206176 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10103 .

_:79f295ad32df4ce8a18a92539c6e8a3b206177 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206178;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b206178 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10948 .

_:79f295ad32df4ce8a18a92539c6e8a3b206180 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11176-1 a owl:Class;
  rdfs:label "INHIBITEURS PUISSANTS DU CYP3A4 <-> VERAPAMIL"@fr;
  dct:identifier "IAM_11176";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b206182;
  r:natureDuRisque "Bradycardie et/ou troubles de la conduction auriculo-ventriculaire, par diminution du métabolisme hépatique du vérapamil par l’inhibiteur."@fr;
  r:conduiteATenir "Surveillance clinique et ECG. S’il y a lieu, adaptation de la posologie du vérapamil pendant le traitement par l’inhibiteur, et après son arrêt, le cas échéant."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b206188, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b206182 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b206183 .

_:79f295ad32df4ce8a18a92539c6e8a3b206183 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206184;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b206185 .

_:79f295ad32df4ce8a18a92539c6e8a3b206184 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10103 .

_:79f295ad32df4ce8a18a92539c6e8a3b206185 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206186;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b206186 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10980 .

_:79f295ad32df4ce8a18a92539c6e8a3b206188 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11177-1 a owl:Class;
  rdfs:label "INHIBITEURS PUISSANTS DU CYP3A4 <-> ZOLPIDEM"@fr;
  dct:identifier "IAM_11177";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b206190;
  r:natureDuRisque "Légère augmentation de l'effet sédatif du zolpidem."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b206196, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b206190 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b206191 .

_:79f295ad32df4ce8a18a92539c6e8a3b206191 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206192;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b206193 .

_:79f295ad32df4ce8a18a92539c6e8a3b206192 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10103 .

_:79f295ad32df4ce8a18a92539c6e8a3b206193 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206194;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b206194 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_11008 .

_:79f295ad32df4ce8a18a92539c6e8a3b206196 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11178-1 a owl:Class;
  rdfs:label "INHIBITEURS PUISSANTS DU CYP3A4 <-> ZOPICLONE"@fr;
  dct:identifier "IAM_11178";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b206198;
  r:natureDuRisque "Légère augmentation de l'effet sédatif de la zopiclone."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b206204, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b206198 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b206199 .

_:79f295ad32df4ce8a18a92539c6e8a3b206199 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206200;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b206201 .

_:79f295ad32df4ce8a18a92539c6e8a3b206200 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10103 .

_:79f295ad32df4ce8a18a92539c6e8a3b206201 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206202;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b206202 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_11010 .

_:79f295ad32df4ce8a18a92539c6e8a3b206204 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11179-1 a owl:Class;
  rdfs:label "INHIBITEURS SÉLECTIFS DE LA RECAPTURE DE LA SÉROTONINE <-> LITHIUM"@fr;
  dct:identifier "IAM_11179";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b206206;
  r:natureDuRisque "Risque d'apparition d'un syndrome sérotoninergique."@fr;
  r:conduiteATenir "Surveillance clinique et biologique régulière, notamment en début d'association."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b206212, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b206206 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b206207 .

_:79f295ad32df4ce8a18a92539c6e8a3b206207 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206208;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b206209 .

_:79f295ad32df4ce8a18a92539c6e8a3b206208 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10104 .

_:79f295ad32df4ce8a18a92539c6e8a3b206209 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206210;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b206210 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10530 .

_:79f295ad32df4ce8a18a92539c6e8a3b206212 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11180-1 a owl:Class;
  rdfs:label "INHIBITEURS SÉLECTIFS DE LA RECAPTURE DE LA SÉROTONINE <-> MILLEPERTUIS"@fr;
  dct:identifier "IAM_11180";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b206214;
  r:natureDuRisque "Risque d'apparition d'un syndrome sérotoninergique."@fr;
  r:conduiteATenir "Surveillance clinique et biologique régulière, notamment en début d'association."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b206220, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b206214 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b206215 .

_:79f295ad32df4ce8a18a92539c6e8a3b206215 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206216;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b206217 .

_:79f295ad32df4ce8a18a92539c6e8a3b206216 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10104 .

_:79f295ad32df4ce8a18a92539c6e8a3b206217 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206218;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b206218 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10588 .

_:79f295ad32df4ce8a18a92539c6e8a3b206220 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11168-1 a owl:Class;
  rdfs:label "INHIBITEURS PUISSANTS DU CYP3A4 <-> RIVAROXABAN"@fr;
  dct:identifier "IAM_11168";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b206222;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de rivaroxaban, avec majoration du risque de saignement."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b206228, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b206222 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b206223 .

_:79f295ad32df4ce8a18a92539c6e8a3b206223 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206224;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b206225 .

_:79f295ad32df4ce8a18a92539c6e8a3b206224 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10103 .

_:79f295ad32df4ce8a18a92539c6e8a3b206225 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206226;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b206226 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10808 .

_:79f295ad32df4ce8a18a92539c6e8a3b206228 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11448-1 a owl:Class;
  rdfs:label "TÉNOFOVIR ALAFÉNAMIDE <-> VERAPAMIL"@fr;
  dct:identifier "IAM_11448";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b206230;
  r:natureDuRisque "Augmentation des concentrations plasmatiques du ténofovir alafénamide par augmentation de son absorption."@fr;
  r:conduiteATenir "En cas de co-administration avec le vérapamil, la dose de ténofovir alafénamide doit être limitée à 10 mg par jour."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b206236, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b206230 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b206231 .

_:79f295ad32df4ce8a18a92539c6e8a3b206231 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206232;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b206233 .

_:79f295ad32df4ce8a18a92539c6e8a3b206232 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10895 .

_:79f295ad32df4ce8a18a92539c6e8a3b206233 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206234;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b206234 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10980 .

_:79f295ad32df4ce8a18a92539c6e8a3b206236 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11439-1 a owl:Class;
  rdfs:label "SUBSTANCES SUSCEPTIBLES DE DONNER DES TORSADES DE POINTES <-> TORSADOGÈNES (SAUF ANTIPARASITAIRES, NEUROLEPTIQUES, MÉTHADONE)"@fr;
  dct:identifier "IAM_11439";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b206238;
  r:chapeau "Ce trouble du rythme cardiaque grave peut être provoqué par un certain nombre de médicaments, antiarythmiques ou non. L'hypokaliémie (cf. médicaments hypokaliémiants) est un facteur favorisant, de même que la bradycardie (cf. médicaments bradycardisants)"@fr;
  r:natureDuRisque "Risque majoré de troubles du rythme ventriculaire, notamment de torsades de pointes."@fr;
  r:conduiteATenir """Contre-indication:
- Pour l'érythromycine et la vincamine, seules les formes administrées par voie intraveineuse sont concernées par cette interaction.
- Pour la spiramycine, la voie IV et la voie orale sont concernées.

Association déconseillée:
- avec l"""@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b206244, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b206238 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b206239 .

_:79f295ad32df4ce8a18a92539c6e8a3b206239 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206240;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b206241 .

_:79f295ad32df4ce8a18a92539c6e8a3b206240 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10143 .

_:79f295ad32df4ce8a18a92539c6e8a3b206241 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206242;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b206242 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10154 .

_:79f295ad32df4ce8a18a92539c6e8a3b206244 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11440-1 a owl:Class;
  rdfs:label "SUCRALFATE <-> SULPIRIDE"@fr;
  dct:identifier "IAM_11440";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b206246;
  r:natureDuRisque "Diminution de l'absorption digestive du sulpiride."@fr;
  r:conduiteATenir "Prendre le sucralfate à distance du sulpiride (plus de 2 heures, si possible)."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b206252, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b206246 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b206247 .

_:79f295ad32df4ce8a18a92539c6e8a3b206247 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206248;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b206249 .

_:79f295ad32df4ce8a18a92539c6e8a3b206248 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10864 .

_:79f295ad32df4ce8a18a92539c6e8a3b206249 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206250;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b206250 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10875 .

_:79f295ad32df4ce8a18a92539c6e8a3b206252 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10081-1 a owl:Class;
  rdfs:label "ALCOOL (BOISSON OU EXCIPIENT) <-> SULFAMIDES HYPOGLYCÉMIANTS"@fr;
  dct:identifier "IAM_10081";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b206254;
  r:natureDuRisque "Effet antabuse, notamment pour glibenclamide, glipizide, tolbutamide. Augmentation de la réaction hypoglycémique (inhibition des réactions de compensation) pouvant faciliter la survenue de coma hypoglycémique."@fr;
  r:conduiteATenir "Eviter la prise de boissons alcoolisées et de médicaments contenant de l'alcool."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b206260, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b206254 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b206255 .

_:79f295ad32df4ce8a18a92539c6e8a3b206255 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206256;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b206257 .

_:79f295ad32df4ce8a18a92539c6e8a3b206256 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10147 .

_:79f295ad32df4ce8a18a92539c6e8a3b206257 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206258;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b206258 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_11013 .

_:79f295ad32df4ce8a18a92539c6e8a3b206260 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11441-1 a owl:Class;
  rdfs:label "SYMPATHOMIMÉTIQUES ALPHA (VOIES ORALE ET/OU NASALE) <-> SYMPATHOMIMÉTIQUES INDIRECTS"@fr;
  dct:identifier "IAM_11441";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b206262;
  r:natureDuRisque "Risque de vasoconstriction et/ou de poussées hypertensives."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b206268, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b206262 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b206263 .

_:79f295ad32df4ce8a18a92539c6e8a3b206263 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206264;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b206265 .

_:79f295ad32df4ce8a18a92539c6e8a3b206264 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10148 .

_:79f295ad32df4ce8a18a92539c6e8a3b206265 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206266;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b206266 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10150 .

_:79f295ad32df4ce8a18a92539c6e8a3b206268 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10427-1 a owl:Class;
  rdfs:label "AUTRES SYMPATHOMIMETIQUES INDIRECTS <-> SYMPATHOMIMÉTIQUES INDIRECTS"@fr;
  dct:identifier "IAM_10427";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b206270;
  r:natureDuRisque "Risque de vasoconstriction et/ou de crises hypertensives."@fr;
  rdfs:comment """Les décisions suivantes, émanant de trois instances de l'Afssaps, ont été prises en compte : 
- la Commission Nationale de Pharmacovigilance a pris acte d'une toxicité de la phénylpropanolamine supérieure à celle des autres sympathomimétiques indirects ("""@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b206272, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b206270 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10150 .

_:79f295ad32df4ce8a18a92539c6e8a3b206272 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11442-1 a owl:Class;
  rdfs:label "TACROLIMUS <-> VERAPAMIL"@fr;
  dct:identifier "IAM_11442";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b206274;
  r:natureDuRisque "Augmentation des concentrations sanguines du tacrolimus (diminution de son métabolisme hépatique par le verapamil)."@fr;
  r:conduiteATenir "Dosage des concentrations sanguines de l’immunosuppresseur, contrôle de la fonction rénale et adaptation de la posologie pendant l’association et après son arrêt."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b206280, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b206274 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b206275 .

_:79f295ad32df4ce8a18a92539c6e8a3b206275 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206276;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b206277 .

_:79f295ad32df4ce8a18a92539c6e8a3b206276 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10880 .

_:79f295ad32df4ce8a18a92539c6e8a3b206277 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206278;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b206278 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10980 .

_:79f295ad32df4ce8a18a92539c6e8a3b206280 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11443-1 a owl:Class;
  rdfs:label "TAMOXIFENE <-> TERBINAFINE"@fr;
  dct:identifier "IAM_11443";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b206282;
  r:natureDuRisque "Risque de baisse de l'efficacité du tamoxifène, par inhibition de la formation de son métabolite actif par la terbinafine."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b206288, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b206282 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b206283 .

_:79f295ad32df4ce8a18a92539c6e8a3b206283 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206284;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b206285 .

_:79f295ad32df4ce8a18a92539c6e8a3b206284 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10882 .

_:79f295ad32df4ce8a18a92539c6e8a3b206285 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206286;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b206286 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10900 .

_:79f295ad32df4ce8a18a92539c6e8a3b206288 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11444-1 a owl:Class;
  rdfs:label "TAMSULOSINE <-> VERAPAMIL"@fr;
  dct:identifier "IAM_11444";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b206290;
  r:natureDuRisque "Risque de majoration des effets indésirables de la tamsulosine, par inhibition de son métabolisme hépatique."@fr;
  r:conduiteATenir "Surveillance clinique et adaptation de la posologie de la tamsulosine pensant le traitement par l’inhibiteur enzymatique et après son arrêt, le cas échéant."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b206296, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b206290 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b206291 .

_:79f295ad32df4ce8a18a92539c6e8a3b206291 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206292;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b206293 .

_:79f295ad32df4ce8a18a92539c6e8a3b206292 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10883 .

_:79f295ad32df4ce8a18a92539c6e8a3b206293 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206294;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b206294 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10980 .

_:79f295ad32df4ce8a18a92539c6e8a3b206296 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11445-1 a owl:Class;
  rdfs:label "TELAPREVIR <-> TÉNOFOVIR ALAFÉNAMIDE"@fr;
  dct:identifier "IAM_11445";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b206298;
  r:natureDuRisque "Risque de diminution de l'efficacité du ténofovir alafénamide par diminution de son activité intracellulaire par le télaprévir."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b206304, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b206298 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b206299 .

_:79f295ad32df4ce8a18a92539c6e8a3b206299 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206300;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b206301 .

_:79f295ad32df4ce8a18a92539c6e8a3b206300 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10887 .

_:79f295ad32df4ce8a18a92539c6e8a3b206301 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206302;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b206302 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10895 .

_:79f295ad32df4ce8a18a92539c6e8a3b206304 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11415-1 a owl:Class;
  rdfs:label "RIFAMPICINE <-> TIAGABINE"@fr;
  dct:identifier "IAM_11415";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b206306;
  r:natureDuRisque "Diminution des concentrations plasmatiques de la tiagabine par augmentation de son métabolisme hépatique."@fr;
  r:conduiteATenir "Une augmentation de la posologie de la tiagabine peut s’avérer nécessaire en cas d’association à la rifampicine."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b206312, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b206306 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b206307 .

_:79f295ad32df4ce8a18a92539c6e8a3b206307 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206308;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b206309 .

_:79f295ad32df4ce8a18a92539c6e8a3b206308 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:79f295ad32df4ce8a18a92539c6e8a3b206309 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206310;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b206310 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10922 .

_:79f295ad32df4ce8a18a92539c6e8a3b206312 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11446-1 a owl:Class;
  rdfs:label "TELITHROMYCINE <-> VENLAFAXINE"@fr;
  dct:identifier "IAM_11446";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b206314;
  r:natureDuRisque "Augmentation des concentrations de venlafaxine avec risque de surdosage."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b206320, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b206314 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b206315 .

_:79f295ad32df4ce8a18a92539c6e8a3b206315 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206316;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b206317 .

_:79f295ad32df4ce8a18a92539c6e8a3b206316 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10889 .

_:79f295ad32df4ce8a18a92539c6e8a3b206317 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206318;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b206318 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10979 .

_:79f295ad32df4ce8a18a92539c6e8a3b206320 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11436-1 a owl:Class;
  rdfs:label "STIRIPENTOL <-> THÉOPHYLLINE (ET, PAR EXTRAPOLATION, AMINOPHYLLINE)"@fr;
  dct:identifier "IAM_11436";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b206322;
  r:natureDuRisque "Augmentation possible de la théophyllinémie, avec risque de surdosage, par inhibition de son métabolisme hépatique."@fr;
  r:conduiteATenir "Surveillance clinique, dosage plasmatique et adaptation éventuelle de la posologie de théophylline."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b206328, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b206322 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b206323 .

_:79f295ad32df4ce8a18a92539c6e8a3b206323 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206324;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b206325 .

_:79f295ad32df4ce8a18a92539c6e8a3b206324 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10152 .

_:79f295ad32df4ce8a18a92539c6e8a3b206325 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206326;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b206326 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10859 .

_:79f295ad32df4ce8a18a92539c6e8a3b206328 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11449-1 a owl:Class;
  rdfs:label "TERBINAFINE <-> VORTIOXÉTINE"@fr;
  dct:identifier "IAM_11449";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b206330;
  r:natureDuRisque "Risque d’augmentation des effets indésirables de la vortioxétine par diminution importante de son métabolisme hépatique."@fr;
  r:conduiteATenir "Surveillance clinique et adaptation éventuelle de la posologie de la vortioxétine pendant le traitement par la terbinafine et après son arrêt."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b206336, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b206330 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b206331 .

_:79f295ad32df4ce8a18a92539c6e8a3b206331 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206332;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b206333 .

_:79f295ad32df4ce8a18a92539c6e8a3b206332 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10900 .

_:79f295ad32df4ce8a18a92539c6e8a3b206333 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206334;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b206334 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10999 .

_:79f295ad32df4ce8a18a92539c6e8a3b206336 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11450-1 a owl:Class;
  rdfs:label "TÉRIFLUNOMIDE <-> VACCINS VIVANTS ATTÉNUÉS"@fr;
  dct:identifier "IAM_11450";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b206338;
  r:natureDuRisque "Risque de maladie vaccinale généralisée, éventuellement mortelle."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b206344, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b206338 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b206339 .

_:79f295ad32df4ce8a18a92539c6e8a3b206339 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206340;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b206341 .

_:79f295ad32df4ce8a18a92539c6e8a3b206340 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10159 .

_:79f295ad32df4ce8a18a92539c6e8a3b206341 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206342;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b206342 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10902 .

_:79f295ad32df4ce8a18a92539c6e8a3b206344 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11451-1 a owl:Class;
  rdfs:label "THALIDOMIDE <-> ZALCITABINE"@fr;
  dct:identifier "IAM_11451";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b206346;
  r:natureDuRisque "Risque majoré de survenue de neuropathies périphériques par addition d'effets indésirables."@fr;
  r:conduiteATenir "Surveillance clinique et biologique régulière, notamment en début d'association."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b206352, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b206346 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b206347 .

_:79f295ad32df4ce8a18a92539c6e8a3b206347 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206348;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b206349 .

_:79f295ad32df4ce8a18a92539c6e8a3b206348 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10913 .

_:79f295ad32df4ce8a18a92539c6e8a3b206349 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206350;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b206350 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_11002 .

_:79f295ad32df4ce8a18a92539c6e8a3b206352 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11454-1 a owl:Class;
  rdfs:label "THEOPHYLLINE <-> VÉMURAFÉNIB"@fr;
  dct:identifier "IAM_11454";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b206354;
  r:natureDuRisque "Augmentation importante des concentrations de théophylline, avec risques de majoration de ses effets indésirables."@fr;
  r:conduiteATenir "Surveillance clinique et adaptation de la posologie de la théophylline pendant le traitement par vémurafénib et après son arrêt."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b206360, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b206354 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b206355 .

_:79f295ad32df4ce8a18a92539c6e8a3b206355 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206356;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b206357 .

_:79f295ad32df4ce8a18a92539c6e8a3b206356 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10915 .

_:79f295ad32df4ce8a18a92539c6e8a3b206357 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206358;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b206358 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10978 .

_:79f295ad32df4ce8a18a92539c6e8a3b206360 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11452-1 a owl:Class;
  rdfs:label "THÉOPHYLLINE (ET, PAR EXTRAPOLATION, AMINOPHYLLINE) <-> TIABENDAZOLE"@fr;
  dct:identifier "IAM_11452";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b206362;
  r:natureDuRisque "Augmentation de la théophyllinémie avec risque de surdosage, par diminution du métabolisme hépatique de la théophylline."@fr;
  r:conduiteATenir "Surveillance clinique et éventuellement de la théophyllinémie ; s'il y a lieu, adaptation de la posologie de la théophylline pendant le traitement (et après son arrêt, dans le cas où l'anthelminthique est prescrit pour une durée excédant 48 heures)."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b206368, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b206362 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b206363 .

_:79f295ad32df4ce8a18a92539c6e8a3b206363 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206364;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b206365 .

_:79f295ad32df4ce8a18a92539c6e8a3b206364 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10152 .

_:79f295ad32df4ce8a18a92539c6e8a3b206365 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206366;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b206366 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10921 .

_:79f295ad32df4ce8a18a92539c6e8a3b206368 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11453-1 a owl:Class;
  rdfs:label "THÉOPHYLLINE (ET, PAR EXTRAPOLATION, AMINOPHYLLINE) <-> TICLOPIDINE"@fr;
  dct:identifier "IAM_11453";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b206370;
  r:natureDuRisque "Augmentation de la théophyllinémie avec risque de surdosage (diminution de la clairance plasmatique de la théophylline)."@fr;
  r:conduiteATenir "Surveillance clinique et éventuellement de la théophyllinémie ; s'il y a lieu, adaptation de la posologie de la théophylline pendant le traitement par la ticlopidine et après son arrêt."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b206376, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b206370 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b206371 .

_:79f295ad32df4ce8a18a92539c6e8a3b206371 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206372;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b206373 .

_:79f295ad32df4ce8a18a92539c6e8a3b206372 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10152 .

_:79f295ad32df4ce8a18a92539c6e8a3b206373 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206374;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b206374 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10928 .

_:79f295ad32df4ce8a18a92539c6e8a3b206376 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11455-1 a owl:Class;
  rdfs:label "TICAGRELOR <-> VERAPAMIL"@fr;
  dct:identifier "IAM_11455";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b206378;
  r:natureDuRisque "Risque d’augmentation des concentrations plasmatiques de ticagrelor par diminution de son métabolisme hépatique."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b206384, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b206378 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b206379 .

_:79f295ad32df4ce8a18a92539c6e8a3b206379 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206380;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b206381 .

_:79f295ad32df4ce8a18a92539c6e8a3b206380 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10926 .

_:79f295ad32df4ce8a18a92539c6e8a3b206381 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206382;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b206382 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10980 .

_:79f295ad32df4ce8a18a92539c6e8a3b206384 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11257-1 a owl:Class;
  rdfs:label "MÉDICAMENTS ADMINISTRÉS PAR VOIE ORALE <-> TOPIQUES GASTRO-INTESTINAUX, ANTIACIDES ET ADSORBANTS"@fr;
  dct:identifier "IAM_11257";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b206386;
  r:natureDuRisque "Diminution de l'absorption de certains autres médicaments ingérés simultanément."@fr;
  r:conduiteATenir "Par mesure de précaution, il convient de prendre ces topiques ou antiacides à distance de tout autre médicament (plus de 2 heures, si possible)."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b206392, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b206386 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b206387 .

_:79f295ad32df4ce8a18a92539c6e8a3b206387 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206388;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b206389 .

_:79f295ad32df4ce8a18a92539c6e8a3b206388 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10153 .

_:79f295ad32df4ce8a18a92539c6e8a3b206389 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206390;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b206390 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10166 .

_:79f295ad32df4ce8a18a92539c6e8a3b206392 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11456-1 a owl:Class;
  rdfs:label "TOPIRAMATE <-> VALPROÏQUE (ACIDE) ET, PAR EXTRAPOLATION, VALPROMIDE"@fr;
  dct:identifier "IAM_11456";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b206394;
  r:natureDuRisque "Augmentation de l'hyperammoniémie, avec risque accru d'encéphalopathie."@fr;
  r:conduiteATenir "Surveillance clinique et biologique régulière."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b206400, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b206394 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b206395 .

_:79f295ad32df4ce8a18a92539c6e8a3b206395 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206396;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b206397 .

_:79f295ad32df4ce8a18a92539c6e8a3b206396 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10160 .

_:79f295ad32df4ce8a18a92539c6e8a3b206397 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206398;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b206398 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10941 .

_:79f295ad32df4ce8a18a92539c6e8a3b206400 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11447-1 a owl:Class;
  rdfs:label "TELITHROMYCINE <-> VINCA-ALCALOÏDES CYTOTOXIQUES"@fr;
  dct:identifier "IAM_11447";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b206402;
  r:natureDuRisque "Risque de majoration de la toxicité de l'antimitotique par diminution de son métabolisme hépatique par la télithromycine."@fr;
  r:conduiteATenir "Surveillance clinique et biologique étroite. Eventuellement, utiliser un autre antibiotique."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b206408, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b206402 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b206403 .

_:79f295ad32df4ce8a18a92539c6e8a3b206403 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206404;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b206405 .

_:79f295ad32df4ce8a18a92539c6e8a3b206404 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10161 .

_:79f295ad32df4ce8a18a92539c6e8a3b206405 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206406;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b206406 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10889 .

_:79f295ad32df4ce8a18a92539c6e8a3b206408 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11427-1 a owl:Class;
  rdfs:label "SIMVASTATINE <-> STIRIPENTOL"@fr;
  dct:identifier "IAM_11427";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b206410;
  r:natureDuRisque "Risque majoré d’effets indésirables (dose-dépendants) à type de rhabdomyolyse (diminution du métabolisme hépatique de l’hypocholestérolémiant)."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b206416, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b206410 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b206411 .

_:79f295ad32df4ce8a18a92539c6e8a3b206411 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206412;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b206413 .

_:79f295ad32df4ce8a18a92539c6e8a3b206412 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10838 .

_:79f295ad32df4ce8a18a92539c6e8a3b206413 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206414;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b206414 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10859 .

_:79f295ad32df4ce8a18a92539c6e8a3b206416 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11320-1 a owl:Class;
  rdfs:label "MYCOPHENOLATE MOFETIL <-> VACCINS VIVANTS ATTÉNUÉS"@fr;
  dct:identifier "IAM_11320";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b206418;
  r:natureDuRisque "Risque de maladie vaccinale généralisée éventuellement mortelle."@fr;
  r:conduiteATenir "Et pendant les 3 mois suivant l'arrêt du traitement."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b206424, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b206418 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b206419 .

_:79f295ad32df4ce8a18a92539c6e8a3b206419 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206420;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b206421 .

_:79f295ad32df4ce8a18a92539c6e8a3b206420 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10159 .

_:79f295ad32df4ce8a18a92539c6e8a3b206421 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206422;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b206422 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10609 .

_:79f295ad32df4ce8a18a92539c6e8a3b206424 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11417-1 a owl:Class;
  rdfs:label "RIFAMPICINE <-> ULIPRISTAL"@fr;
  dct:identifier "IAM_11417";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b206426;
  r:natureDuRisque "Risque de diminution de l’effet de l’ulipristal, par augmentation de son métabolisme hépatique par l’inducteur."@fr;
  r:conduiteATenir "Préférer une alternative thérapeutique peu ou pas métabolisée."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b206432, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b206426 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b206427 .

_:79f295ad32df4ce8a18a92539c6e8a3b206427 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206428;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b206429 .

_:79f295ad32df4ce8a18a92539c6e8a3b206428 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:79f295ad32df4ce8a18a92539c6e8a3b206429 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206430;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b206430 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10964 .

_:79f295ad32df4ce8a18a92539c6e8a3b206432 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11418-1 a owl:Class;
  rdfs:label "RIFAMPICINE <-> VALPROÏQUE (ACIDE) ET, PAR EXTRAPOLATION, VALPROMIDE"@fr;
  dct:identifier "IAM_11418";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b206434;
  r:natureDuRisque "Risque de survenue de crises convulsives, par augmentation du métabolisme hépatique du valproate par la rifampicine."@fr;
  r:conduiteATenir "Surveillance clinique et biologique, et adaptation éventuelle de la posologie de l'anticonvulsivant pendant le traitement par la rifampicine et après son arrêt."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b206440, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b206434 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b206435 .

_:79f295ad32df4ce8a18a92539c6e8a3b206435 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206436;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b206437 .

_:79f295ad32df4ce8a18a92539c6e8a3b206436 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10160 .

_:79f295ad32df4ce8a18a92539c6e8a3b206437 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206438;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b206438 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:79f295ad32df4ce8a18a92539c6e8a3b206440 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11419-1 a owl:Class;
  rdfs:label "RIFAMPICINE <-> VITAMINE D"@fr;
  dct:identifier "IAM_11419";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b206442;
  r:natureDuRisque "Diminution des concentrations de vitamine D plus marquée qu’en l’absence de traitement par la rifampicine"@fr;
  r:conduiteATenir "Dosage des concentrations de vitamine D et supplémentation si nécessaire."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b206448, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b206442 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b206443 .

_:79f295ad32df4ce8a18a92539c6e8a3b206443 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206444;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b206445 .

_:79f295ad32df4ce8a18a92539c6e8a3b206444 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10162 .

_:79f295ad32df4ce8a18a92539c6e8a3b206445 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206446;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b206446 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:79f295ad32df4ce8a18a92539c6e8a3b206448 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11420-1 a owl:Class;
  rdfs:label "RIFAMPICINE <-> VORICONAZOLE"@fr;
  dct:identifier "IAM_11420";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b206450;
  r:natureDuRisque "Diminution importante des concentrations plasmatiques du voriconazole avec risque de perte d'efficacité, par augmentation de son métabolisme hépatique par la rifampicine."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b206456, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b206450 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b206451 .

_:79f295ad32df4ce8a18a92539c6e8a3b206451 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206452;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b206453 .

_:79f295ad32df4ce8a18a92539c6e8a3b206452 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:79f295ad32df4ce8a18a92539c6e8a3b206453 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206454;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b206454 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10998 .

_:79f295ad32df4ce8a18a92539c6e8a3b206456 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11421-1 a owl:Class;
  rdfs:label "RIFAMPICINE <-> ZOLPIDEM"@fr;
  dct:identifier "IAM_11421";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b206458;
  r:natureDuRisque "Diminution des concentrations plasmatiques et de l'efficacité du zolpidem par augmentation de son métabolisme hépatique par la rifampicine."@fr;
  r:conduiteATenir "Surveillance clinique. Utiliser éventuellement un autre hypnotique."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b206464, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b206458 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b206459 .

_:79f295ad32df4ce8a18a92539c6e8a3b206459 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206460;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b206461 .

_:79f295ad32df4ce8a18a92539c6e8a3b206460 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:79f295ad32df4ce8a18a92539c6e8a3b206461 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206462;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b206462 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_11008 .

_:79f295ad32df4ce8a18a92539c6e8a3b206464 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11422-1 a owl:Class;
  rdfs:label "RIFAMPICINE <-> ZOPICLONE"@fr;
  dct:identifier "IAM_11422";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b206466;
  r:natureDuRisque "Diminution des concentrations plasmatiques et de l'efficacité de la zopiclone par augmentation de son métabolisme hépatique par la rifampicine."@fr;
  r:conduiteATenir "Surveillance clinique. Utiliser éventuellement un autre hypnotique."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b206472, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b206466 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b206467 .

_:79f295ad32df4ce8a18a92539c6e8a3b206467 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206468;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b206469 .

_:79f295ad32df4ce8a18a92539c6e8a3b206468 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:79f295ad32df4ce8a18a92539c6e8a3b206469 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206470;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b206470 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_11010 .

_:79f295ad32df4ce8a18a92539c6e8a3b206472 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11423-1 a owl:Class;
  rdfs:label "ROXITHROMYCINE <-> SIMVASTATINE"@fr;
  dct:identifier "IAM_11423";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b206474;
  r:natureDuRisque "Risque majoré d'effets indésirables (concentration-dépendants) à type de rhabdomyolyse."@fr;
  r:conduiteATenir "Utiliser des doses plus faibles d’hypocholestérolémiant."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b206480, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b206474 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b206475 .

_:79f295ad32df4ce8a18a92539c6e8a3b206475 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206476;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b206477 .

_:79f295ad32df4ce8a18a92539c6e8a3b206476 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10817 .

_:79f295ad32df4ce8a18a92539c6e8a3b206477 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206478;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b206478 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10838 .

_:79f295ad32df4ce8a18a92539c6e8a3b206480 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11424-1 a owl:Class;
  rdfs:label "ROXITHROMYCINE <-> SUBSTANCES SUSCEPTIBLES DE DONNER DES TORSADES DE POINTES"@fr;
  dct:identifier "IAM_11424";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b206482;
  r:natureDuRisque """Risque majoré de troubles du rythme ventriculaire, notamment de
torsades de pointes."""@fr;
  r:conduiteATenir "Surveillance clinique et électrocardiographique pendant l'association."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b206488, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b206482 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b206483 .

_:79f295ad32df4ce8a18a92539c6e8a3b206483 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206484;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b206485 .

_:79f295ad32df4ce8a18a92539c6e8a3b206484 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10143 .

_:79f295ad32df4ce8a18a92539c6e8a3b206485 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206486;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b206486 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10817 .

_:79f295ad32df4ce8a18a92539c6e8a3b206488 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11438-1 a owl:Class;
  rdfs:label "SUBSTANCES À ABSORPTION RÉDUITE PAR LES TOPIQUES GASTRO-INTESTINAUX, ANTIACIDES ET ADSORBANTS <-> TOPIQUES GASTRO-INTESTINAUX, ANTIACIDES ET ADSORBANTS"@fr;
  dct:identifier "IAM_11438";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b206490;
  r:natureDuRisque "Diminution de l'absorption de ces substances."@fr;
  r:conduiteATenir "Prendre les topiques ou antiacides, adsorbants à distance de ces substances (plus de 2 heures, si possible)."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b206496, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b206490 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b206491 .

_:79f295ad32df4ce8a18a92539c6e8a3b206491 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206492;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b206493 .

_:79f295ad32df4ce8a18a92539c6e8a3b206492 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10144 .

_:79f295ad32df4ce8a18a92539c6e8a3b206493 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206494;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b206494 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10153 .

_:79f295ad32df4ce8a18a92539c6e8a3b206496 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11426-1 a owl:Class;
  rdfs:label "RUFINAMIDE <-> VALPROÏQUE (ACIDE) ET, PAR EXTRAPOLATION, VALPROMIDE"@fr;
  dct:identifier "IAM_11426";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b206498;
  r:natureDuRisque "Possible augmentation des concentrations de rufinamide, notamment chez l’enfant de moins de 30 kg."@fr;
  r:conduiteATenir """Chez l’enfant de moins de 30 kg :
ne pas dépasser la dose totale de 600 mg/j après la période de titration."""@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b206504, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b206498 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b206499 .

_:79f295ad32df4ce8a18a92539c6e8a3b206499 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206500;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b206501 .

_:79f295ad32df4ce8a18a92539c6e8a3b206500 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10160 .

_:79f295ad32df4ce8a18a92539c6e8a3b206501 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206502;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b206502 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10818 .

_:79f295ad32df4ce8a18a92539c6e8a3b206504 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11437-1 a owl:Class;
  rdfs:label "STRONTIUM <-> ZINC"@fr;
  dct:identifier "IAM_11437";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b206506;
  r:natureDuRisque "Diminution de l'absorption digestive du strontium."@fr;
  r:conduiteATenir "Prendre le strontium à distance des sels de zinc (plus de deux heures, si possible)."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b206512, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b206506 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b206507 .

_:79f295ad32df4ce8a18a92539c6e8a3b206507 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206508;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b206509 .

_:79f295ad32df4ce8a18a92539c6e8a3b206508 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10863 .

_:79f295ad32df4ce8a18a92539c6e8a3b206509 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206510;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b206510 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_11005 .

_:79f295ad32df4ce8a18a92539c6e8a3b206512 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11428-1 a owl:Class;
  rdfs:label "SIMVASTATINE <-> TELAPREVIR"@fr;
  dct:identifier "IAM_11428";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b206514;
  r:natureDuRisque "Risque majoré d'effets indésirables (concentration-dépendants) à type de rhabdomyolyse (diminution du métabolisme hépatique de la simvastatine)."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b206520, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b206514 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b206515 .

_:79f295ad32df4ce8a18a92539c6e8a3b206515 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206516;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b206517 .

_:79f295ad32df4ce8a18a92539c6e8a3b206516 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10838 .

_:79f295ad32df4ce8a18a92539c6e8a3b206517 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206518;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b206518 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10887 .

_:79f295ad32df4ce8a18a92539c6e8a3b206520 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11429-1 a owl:Class;
  rdfs:label "SIMVASTATINE <-> TELITHROMYCINE"@fr;
  dct:identifier "IAM_11429";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b206522;
  r:natureDuRisque "Risque majoré d’effets indésirables (dose-dépendants) à type de rhabdomyolyse (diminution du métabolisme hépatique de l’hypocholestérolémiant)."@fr;
  rdfs:comment """La télithromycine est un inhibiteur du CYP3A4. Par conséquent, son administration peut inhiber le métabolisme des médicaments qui sont métabolisés par ce cytochrome, dont la simvastatine. 
L’association de la télithromycine avec la simvastatine augmente d"""@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b206528, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b206522 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b206523 .

_:79f295ad32df4ce8a18a92539c6e8a3b206523 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206524;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b206525 .

_:79f295ad32df4ce8a18a92539c6e8a3b206524 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10838 .

_:79f295ad32df4ce8a18a92539c6e8a3b206525 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206526;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b206526 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10889 .

_:79f295ad32df4ce8a18a92539c6e8a3b206528 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11430-1 a owl:Class;
  rdfs:label "SIMVASTATINE <-> VERAPAMIL"@fr;
  dct:identifier "IAM_11430";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b206530;
  r:natureDuRisque "Risque majoré d’effets indésirables (dose-dépendants) à type de rhabdomyolyse (diminution du métabolisme hépatique de l’hypocholestérolémiant)."@fr;
  r:conduiteATenir "Ne pas dépasser la posologie de 20 mg/j de simvastatine ou utiliser une autre statine non concernée par ce type d’interaction."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b206536, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b206530 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b206531 .

_:79f295ad32df4ce8a18a92539c6e8a3b206531 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206532;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b206533 .

_:79f295ad32df4ce8a18a92539c6e8a3b206532 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10838 .

_:79f295ad32df4ce8a18a92539c6e8a3b206533 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206534;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b206534 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10980 .

_:79f295ad32df4ce8a18a92539c6e8a3b206536 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11431-1 a owl:Class;
  rdfs:label "SIMVASTATINE <-> VORICONAZOLE"@fr;
  dct:identifier "IAM_11431";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b206538;
  r:natureDuRisque "Risque majoré d'effets indésirables (concentration-dépendants) à type de rhabdomyolyse par diminution du métabolisme hépatique de la simvastatine."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b206544, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b206538 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b206539 .

_:79f295ad32df4ce8a18a92539c6e8a3b206539 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206540;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b206541 .

_:79f295ad32df4ce8a18a92539c6e8a3b206540 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10838 .

_:79f295ad32df4ce8a18a92539c6e8a3b206541 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206542;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b206542 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10998 .

_:79f295ad32df4ce8a18a92539c6e8a3b206544 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11432-1 a owl:Class;
  rdfs:label "SIROLIMUS <-> VERAPAMIL"@fr;
  dct:identifier "IAM_11432";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b206546;
  r:natureDuRisque "Augmentation des concentrations sanguines du sirolimus (diminution de son métabolisme hépatique par le vérapamil)."@fr;
  r:conduiteATenir "Dosage des concentrations sanguines de l’immunosuppresseur, contrôle de la fonction rénale et adaptation de la posologie pendant l’association et après son arrêt."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b206552, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b206546 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b206547 .

_:79f295ad32df4ce8a18a92539c6e8a3b206547 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206548;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b206549 .

_:79f295ad32df4ce8a18a92539c6e8a3b206548 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10839 .

_:79f295ad32df4ce8a18a92539c6e8a3b206549 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206550;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b206550 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10980 .

_:79f295ad32df4ce8a18a92539c6e8a3b206552 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11260-1 a owl:Class;
  rdfs:label "MÉDICAMENTS UTILISÉS PAR VOIE VAGINALE <-> SPERMICIDES"@fr;
  dct:identifier "IAM_11260";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b206554;
  r:natureDuRisque "Tout traitement local vaginal est susceptible d'inactiver une contraception locale spermicide."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b206560, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b206554 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b206555 .

_:79f295ad32df4ce8a18a92539c6e8a3b206555 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206556;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b206557 .

_:79f295ad32df4ce8a18a92539c6e8a3b206556 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10142 .

_:79f295ad32df4ce8a18a92539c6e8a3b206557 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206558;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b206558 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10165 .

_:79f295ad32df4ce8a18a92539c6e8a3b206560 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11434-1 a owl:Class;
  rdfs:label "STAVUDINE <-> ZALCITABINE"@fr;
  dct:identifier "IAM_11434";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b206562;
  r:natureDuRisque "Risque de diminution de l'efficacité de chaque antiviral, par antagonisme compétitif de la réaction de phosphorylation à l'origine des métabolites actifs."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b206568, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b206562 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b206563 .

_:79f295ad32df4ce8a18a92539c6e8a3b206563 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206564;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b206565 .

_:79f295ad32df4ce8a18a92539c6e8a3b206564 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10858 .

_:79f295ad32df4ce8a18a92539c6e8a3b206565 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206566;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b206566 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_11002 .

_:79f295ad32df4ce8a18a92539c6e8a3b206568 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11433-1 a owl:Class;
  rdfs:label "STAVUDINE <-> THALIDOMIDE"@fr;
  dct:identifier "IAM_11433";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b206570;
  r:natureDuRisque "Risque majoré de survenue de neuropathies périphériques par addition d'effets indésirables."@fr;
  r:conduiteATenir "Surveillance clinique et biologique régulière, notamment en début d'association."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b206576, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b206570 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b206571 .

_:79f295ad32df4ce8a18a92539c6e8a3b206571 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206572;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b206573 .

_:79f295ad32df4ce8a18a92539c6e8a3b206572 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10858 .

_:79f295ad32df4ce8a18a92539c6e8a3b206573 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206574;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b206574 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10913 .

_:79f295ad32df4ce8a18a92539c6e8a3b206576 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11435-1 a owl:Class;
  rdfs:label "STAVUDINE <-> ZIDOVUDINE"@fr;
  dct:identifier "IAM_11435";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b206578;
  r:natureDuRisque "Risque de diminution de l'efficacité de chaque antiviral par antagoniste compétitif de la réaction de phosphorylation à l'origine des métabolites actifs."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b206584, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b206578 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b206579 .

_:79f295ad32df4ce8a18a92539c6e8a3b206579 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206580;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b206581 .

_:79f295ad32df4ce8a18a92539c6e8a3b206580 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10858 .

_:79f295ad32df4ce8a18a92539c6e8a3b206581 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206582;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b206582 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_11004 .

_:79f295ad32df4ce8a18a92539c6e8a3b206584 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11459-1 a owl:Class;
  rdfs:label "VALPROÏQUE (ACIDE) ET, PAR EXTRAPOLATION, VALPROMIDE <-> ZONISAMIDE"@fr;
  dct:identifier "IAM_11459";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b206586;
  r:natureDuRisque "Augmentation de l'hyperammoniémie, avec risque accru d'encéphalopathie."@fr;
  r:conduiteATenir "Surveillance clinique et biologique régulière."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b206592, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b206586 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b206587 .

_:79f295ad32df4ce8a18a92539c6e8a3b206587 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206588;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b206589 .

_:79f295ad32df4ce8a18a92539c6e8a3b206588 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10160 .

_:79f295ad32df4ce8a18a92539c6e8a3b206589 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206590;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b206590 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_11009 .

_:79f295ad32df4ce8a18a92539c6e8a3b206592 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11425-1 a owl:Class;
  rdfs:label "ROXITHROMYCINE <-> THÉOPHYLLINE (ET, PAR EXTRAPOLATION, AMINOPHYLLINE)"@fr;
  dct:identifier "IAM_11425";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b206594;
  r:natureDuRisque "Risque d'augmentation de la théophyllinémie, particulièrement chez l'enfant."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b206600, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b206594 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b206595 .

_:79f295ad32df4ce8a18a92539c6e8a3b206595 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206596;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b206597 .

_:79f295ad32df4ce8a18a92539c6e8a3b206596 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10152 .

_:79f295ad32df4ce8a18a92539c6e8a3b206597 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206598;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b206598 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10817 .

_:79f295ad32df4ce8a18a92539c6e8a3b206600 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10104-2 a owl:Class;
  rdfs:label "ALPHABLOQUANTS À VISÉE UROLOGIQUE <-> INHIBITEURS DE LA PHOSPHODIESTERASE DE TYPE 5"@fr;
  dct:identifier "IAM_10104";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b206602;
  r:natureDuRisque "Risque d’hypotension orthostatique, notamment chez le sujet âgé."@fr;
  r:conduiteATenir """Association déconseillée :
- avec la doxazosine

Précaution d'emploi :
- avec les autres alpha-bloquants
Débuter le traitement aux posologies minimales recommandées et adapter progressivement les doses si besoin."""@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b206608, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b206602 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b206603 .

_:79f295ad32df4ce8a18a92539c6e8a3b206603 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206604;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b206605 .

_:79f295ad32df4ce8a18a92539c6e8a3b206604 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10009 .

_:79f295ad32df4ce8a18a92539c6e8a3b206605 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206606;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b206606 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10098 .

_:79f295ad32df4ce8a18a92539c6e8a3b206608 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11457-1 a owl:Class;
  rdfs:label "TRAMADOL <-> VENLAFAXINE"@fr;
  dct:identifier "IAM_11457";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b206610;
  r:natureDuRisque "Risque d'apparition de convulsions et/ou d'un syndrome sérotoninergique."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b206616, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b206610 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b206611 .

_:79f295ad32df4ce8a18a92539c6e8a3b206611 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206612;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b206613 .

_:79f295ad32df4ce8a18a92539c6e8a3b206612 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10945 .

_:79f295ad32df4ce8a18a92539c6e8a3b206613 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206614;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b206614 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10979 .

_:79f295ad32df4ce8a18a92539c6e8a3b206616 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10092-2 a owl:Class;
  rdfs:label "ALISKIREN <-> INHIBITEURS DE L'ENZYME DE CONVERSION"@fr;
  dct:identifier "IAM_10092";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b206618;
  r:natureDuRisque "Risque d’hyperkaliémie, d’insuffisance rénale, d’augmentation de la morbi-mortalité cardio-vasculaire."@fr;
  r:conduiteATenir """Contre-indication :
- chez le patient diabétique ou insuffisant rénal

Association déconseillée :
- dans les autres cas"""@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b206624, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b206618 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b206619 .

_:79f295ad32df4ce8a18a92539c6e8a3b206619 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206620;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b206621 .

_:79f295ad32df4ce8a18a92539c6e8a3b206620 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10096 .

_:79f295ad32df4ce8a18a92539c6e8a3b206621 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206622;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b206622 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10048 .

_:79f295ad32df4ce8a18a92539c6e8a3b206624 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10680-2 a owl:Class;
  rdfs:label "COLCHICINE <-> INHIBITEURS PUISSANTS DU CYP3A4"@fr;
  dct:identifier "IAM_10680";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b206626;
  r:natureDuRisque "Augmentation des effets indésirables de la colchicine, aux conséquences potentiellement fatales."@fr;
  r:conduiteATenir """Contre-indication :
- avec les macrolides

Association déconseillée :
- avec les antifongiques azolés, les inhibiteurs de protéases boostés par ritonavir et le cobicistat"""@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b206632, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b206626 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b206627 .

_:79f295ad32df4ce8a18a92539c6e8a3b206627 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206628;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b206629 .

_:79f295ad32df4ce8a18a92539c6e8a3b206628 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10103 .

_:79f295ad32df4ce8a18a92539c6e8a3b206629 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206630;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b206630 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10225 .

_:79f295ad32df4ce8a18a92539c6e8a3b206632 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11324-2 a owl:Class;
  rdfs:label "NEUROLEPTIQUES SUSCEPTIBLES DE DONNER DES TORSADES DE POINTES <-> SUBSTANCES SUSCEPTIBLES DE DONNER DES TORSADES DE POINTES"@fr;
  dct:identifier "IAM_11324";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b206634;
  r:chapeau "Ce trouble du rythme cardiaque grave peut être provoqué par un certain nombre de médicaments, antiarythmiques ou non. L'hypokaliémie (cf. médicaments hypokaliémiants) est un facteur favorisant, de même que la bradycardie (cf. médicaments bradycardisants)"@fr;
  r:natureDuRisque "Risque majoré de troubles du rythme ventriculaire, notamment de torsades de pointes."@fr;
  r:conduiteATenir """Contre-indication :
- avec le citalopram, la dompéridone, l'escitalopram, l'hydroxyzine et la pipéraquine.

Association déconseillée:
- avec les autres médicaments susceptibles de donner des torsades de pointes."""@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b206640, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b206634 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b206635 .

_:79f295ad32df4ce8a18a92539c6e8a3b206635 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206636;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b206637 .

_:79f295ad32df4ce8a18a92539c6e8a3b206636 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10127 .

_:79f295ad32df4ce8a18a92539c6e8a3b206637 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206638;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b206638 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10143 .

_:79f295ad32df4ce8a18a92539c6e8a3b206640 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10283-2 a owl:Class;
  rdfs:label "ANTIPARASITAIRES SUSCEPTIBLES DE DONNER DES TORSADES DE POINTES <-> SUBSTANCES SUSCEPTIBLES DE DONNER DES TORSADES DE POINTES"@fr;
  dct:identifier "IAM_10283";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b206642;
  r:chapeau "Ce trouble du rythme cardiaque grave peut être provoqué par un certain nombre de médicaments, antiarythmiques ou non. L'hypokaliémie (cf. médicaments hypokaliémiants) est un facteur favorisant, de même que la bradycardie (cf. médicaments bradycardisants)"@fr;
  r:natureDuRisque "Risque majoré de troubles du rythme ventriculaire, notamment de torsades de pointes."@fr;
  r:conduiteATenir """Contre-indication:
- avec le citalopram, la dompéridone, l'escitalopram, l'hydroxyzine
et la pipéraquine.

Association déconseillée:
- avec les autres médicaments susceptibles de donner des torsades de pointes.
Si cela est possible, interrompre l'un des d"""@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b206648, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b206642 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b206643 .

_:79f295ad32df4ce8a18a92539c6e8a3b206643 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206644;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b206645 .

_:79f295ad32df4ce8a18a92539c6e8a3b206644 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10036 .

_:79f295ad32df4ce8a18a92539c6e8a3b206645 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206646;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b206646 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10143 .

_:79f295ad32df4ce8a18a92539c6e8a3b206648 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10113-2 a owl:Class;
  rdfs:label "AMINOSIDES <-> AUTRES AMINOSIDES"@fr;
  dct:identifier "IAM_10113";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b206650;
  r:natureDuRisque "Risque accru de néphrotoxicité et d'ototoxicité (l'ototoxicité est cumulative en cas d'administrations successives)."@fr;
  r:conduiteATenir """Contre-indication :
- en cas d'administration simultanée"""@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b206652, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b206650 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10011 .

_:79f295ad32df4ce8a18a92539c6e8a3b206652 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10182-2 a owl:Class;
  rdfs:label "ANTAGONISTES DES RÉCEPTEURS DE L'ANGIOTENSINE II <-> DIURÉTIQUES ÉPARGNEURS DE POTASSIUM (SEULS OU ASSOCIÉS)"@fr;
  dct:identifier "IAM_10182";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b206654;
  r:natureDuRisque "Risque d'hyperkaliémie (potentiellement létale) surtout en cas d'insuffisance rénale (addition des effets hyperkaliémiants)."@fr;
  r:conduiteATenir """Association déconseillée :
- si l'association est justifiée, contrôle strict de la kaliémie et de la fonctioénale"""@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b206660, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b206654 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b206655 .

_:79f295ad32df4ce8a18a92539c6e8a3b206655 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206656;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b206657 .

_:79f295ad32df4ce8a18a92539c6e8a3b206656 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10020 .

_:79f295ad32df4ce8a18a92539c6e8a3b206657 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206658;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b206658 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10067 .

_:79f295ad32df4ce8a18a92539c6e8a3b206660 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11085-2 a owl:Class;
  rdfs:label "IMMUNOSUPPRESSEURS <-> VORICONAZOLE"@fr;
  dct:identifier "IAM_11085";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b206662;
  r:natureDuRisque "Augmentation des concentrations sanguines de l'immunosuppresseur par inhibition de son métabolisme hépatique par le voriconazole."@fr;
  r:conduiteATenir """Association déconseillée
- avec l'évérolimus, le sirolimus, et le temsirolimus.

Précaution d'emploi
- avec la ciclosporine et le tacrolimus :
dosage des concentrations sanguines de l'immunosuppresseur, contrôle de la fonction rénale et adaptation de la p"""@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b206668, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b206662 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b206663 .

_:79f295ad32df4ce8a18a92539c6e8a3b206663 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206664;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b206665 .

_:79f295ad32df4ce8a18a92539c6e8a3b206664 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10093 .

_:79f295ad32df4ce8a18a92539c6e8a3b206665 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206666;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b206666 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10998 .

_:79f295ad32df4ce8a18a92539c6e8a3b206668 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10826-2 a owl:Class;
  rdfs:label "DIURÉTIQUES ÉPARGNEURS DE POTASSIUM (SEULS OU ASSOCIÉS) <-> INHIBITEURS DE L'ENZYME DE CONVERSION"@fr;
  dct:identifier "IAM_10826";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b206670;
  r:natureDuRisque "Risque d'hyperkaliémie (potentiellement létale) surtout en cas d'insuffisance rénale (addition des effets hyperkaliémiants)."@fr;
  r:conduiteATenir """Association déconseillée :
- si l'association est justifiée, contrôle strict de la kaliémie et de la fonction rénale"""@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b206676, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b206670 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b206671 .

_:79f295ad32df4ce8a18a92539c6e8a3b206671 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206672;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b206673 .

_:79f295ad32df4ce8a18a92539c6e8a3b206672 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10067 .

_:79f295ad32df4ce8a18a92539c6e8a3b206673 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206674;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b206674 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10096 .

_:79f295ad32df4ce8a18a92539c6e8a3b206676 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11106-2 a owl:Class;
  rdfs:label "INDUCTEURS ENZYMATIQUES <-> SOFOSBUVIR"@fr;
  dct:identifier "IAM_11106";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b206678;
  r:natureDuRisque """Risque de diminution des concentrations plasmatiques de 
sofosbuvir par diminution de son absorption intestinale par
l’inducteur."""@fr;
  r:conduiteATenir """Contre-indication :
- avec la rifampicine
- avec les anticonvulsivants inducteurs enzymatiques

Association déconseillée:
- avec les autres inducteurs."""@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b206684, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b206678 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b206679 .

_:79f295ad32df4ce8a18a92539c6e8a3b206679 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206680;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b206681 .

_:79f295ad32df4ce8a18a92539c6e8a3b206680 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10094 .

_:79f295ad32df4ce8a18a92539c6e8a3b206681 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206682;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b206682 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10850 .

_:79f295ad32df4ce8a18a92539c6e8a3b206684 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10278-2 a owl:Class;
  rdfs:label "ANTI-INFLAMMATOIRES NON STÉROÏDIENS <-> METHOTREXATE"@fr;
  dct:identifier "IAM_10278";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b206686;
  r:natureDuRisque "Augmentation de la toxicité hématologique du méthotrexate (diminution de la clairance rénale du méthotrexate par les anti-inflammatoires)."@fr;
  r:conduiteATenir """Association déconseillée:
- pour des doses de méthotrexate supérieures à 20 mg par semaine.
- avec le kétoprofène et le méthotrexate à des doses supérieures à 20 mg par semaines, respecter un intervalle d'au moins 12 heures entre l'arrêt ou le début d'un"""@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b206692, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b206686 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b206687 .

_:79f295ad32df4ce8a18a92539c6e8a3b206687 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206688;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b206689 .

_:79f295ad32df4ce8a18a92539c6e8a3b206688 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10022 .

_:79f295ad32df4ce8a18a92539c6e8a3b206689 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206690;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b206690 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10569 .

_:79f295ad32df4ce8a18a92539c6e8a3b206692 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10251-2 a owl:Class;
  rdfs:label "ANTICONVULSIVANTS INDUCTEURS ENZYMATIQUES <-> VORICONAZOLE"@fr;
  dct:identifier "IAM_10251";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b206694;
  r:natureDuRisque """- pour carbamazépine, phénobarbital, primidone : Risque de baisse de l'efficacité du voriconazole par augmentation de son métabolisme hépatique par l'inducteur.

- pour phénytoïne, fosphénytoïne : 
Diminution importante des concentrations plasmatiques du"""@fr;
  r:conduiteATenir """Contre-indication :
- pour carbamazépine, phénobarbital, primidone

Association déconseillée :
- pour phénytoïne, fosphénytoïne
Si l'association ne peut être évitée, surveillance clinique étroite, dosage des concentrations plasmatiques de phénytoïne et ad"""@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b206700, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b206694 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b206695 .

_:79f295ad32df4ce8a18a92539c6e8a3b206695 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206696;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b206697 .

_:79f295ad32df4ce8a18a92539c6e8a3b206696 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10029 .

_:79f295ad32df4ce8a18a92539c6e8a3b206697 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206698;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b206698 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10998 .

_:79f295ad32df4ce8a18a92539c6e8a3b206700 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11127-2 a owl:Class;
  rdfs:label "INHIBITEURS DE PROTÉASES BOOSTÉS PAR RITONAVIR <-> LAMOTRIGINE"@fr;
  dct:identifier "IAM_11127";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b206702;
  r:chapeau "Le ritonavir est désormais utilisé à la dose de 100 mg 2 fois par jour en association à un autre inhibiteur de protéase, dans le but d'augmenter de façon très significative la biodisponibilité de l'inhibiteur de protéase associé (ou boosté), ce qui permet"@fr;
  r:natureDuRisque "Risque de diminution des concentrations et de l’efficacité de la lamotrigine par augmentation de son métabolisme hépatique par le ritonavir."@fr;
  r:conduiteATenir """Association déconseillée 
- Eviter de mettre en route le traitement par ritonavir pendant la période d’ajustement posologique de la lamotrigine.

Précaution d'emploi
- Surveillance clinique et adaptation de la posologie de la lamotrigine lors de la mise e"""@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b206708, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b206702 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b206703 .

_:79f295ad32df4ce8a18a92539c6e8a3b206703 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206704;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b206705 .

_:79f295ad32df4ce8a18a92539c6e8a3b206704 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10100 .

_:79f295ad32df4ce8a18a92539c6e8a3b206705 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206706;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b206706 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10507 .

_:79f295ad32df4ce8a18a92539c6e8a3b206708 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11146-2 a owl:Class;
  rdfs:label "INHIBITEURS DES TYROSINE KINASES MÉTABOLISÉS <-> INHIBITEURS PUISSANTS DU CYP3A4"@fr;
  dct:identifier "IAM_11146";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b206710;
  r:chapeau "Certains médicaments possèdent la capacité d’inhiber fortement le CYP3A4, une enzyme qui intervient dans le métabolisme de nombreux médicaments. Lorsque l’activité de cette enzyme est inhibée, elle n’est plus en mesure de métaboliser le médicament qui va"@fr;
  r:natureDuRisque """Risque de majoration des effets indésirables de l’inhibiteur de
tyrosine kinase par diminution de son métabolisme."""@fr;
  r:conduiteATenir """Association déconseillée :
- avec l'axitinib, le bosutinib, le céritinib, le cobimétinib, le dabrafenib, le dasatinib, le nilotinib, le sunitinib
- avec l'ibrutinib, si l’association ne peut être évitée ,surveillance clinique étroite et réduction de la do"""@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b206716, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b206710 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b206711 .

_:79f295ad32df4ce8a18a92539c6e8a3b206711 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206712;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b206713 .

_:79f295ad32df4ce8a18a92539c6e8a3b206712 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10101 .

_:79f295ad32df4ce8a18a92539c6e8a3b206713 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206714;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b206714 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10103 .

_:79f295ad32df4ce8a18a92539c6e8a3b206716 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10903-2 a owl:Class;
  rdfs:label "ESMOLOL <-> VERAPAMIL"@fr;
  dct:identifier "IAM_10903";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b206718;
  r:natureDuRisque "Troubles de l'automatisme (bradycardie excessive, arrêt sinusal), troubles de la conduction sino-auriculaire et auriculo-ventriculaire et défaillance cardiaque."@fr;
  r:conduiteATenir """Association déconseillée :
- en cas d'altération de la fonction ventriculaire gauche."""@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b206724, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b206718 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b206719 .

_:79f295ad32df4ce8a18a92539c6e8a3b206719 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206720;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b206721 .

_:79f295ad32df4ce8a18a92539c6e8a3b206720 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10341 .

_:79f295ad32df4ce8a18a92539c6e8a3b206721 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206722;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b206722 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10980 .

_:79f295ad32df4ce8a18a92539c6e8a3b206724 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10180-2 a owl:Class;
  rdfs:label "ANTAGONISTES DES CANAUX CALCIQUES <-> RIFAMPICINE"@fr;
  dct:identifier "IAM_10180";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b206726;
  r:natureDuRisque "Diminution des concentrations plasmatiques de l'antagoniste du calcium par augmentation de son métabolisme hépatique."@fr;
  r:conduiteATenir "Association déconseillée avec la nimodipine"@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b206732, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b206726 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b206727 .

_:79f295ad32df4ce8a18a92539c6e8a3b206727 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206728;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b206729 .

_:79f295ad32df4ce8a18a92539c6e8a3b206728 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10019 .

_:79f295ad32df4ce8a18a92539c6e8a3b206729 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206730;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b206730 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:79f295ad32df4ce8a18a92539c6e8a3b206732 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10697-2 a owl:Class;
  rdfs:label "CYPROTERONE <-> INDUCTEURS ENZYMATIQUES"@fr;
  dct:identifier "IAM_10697";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b206734;
  r:natureDuRisque "Risque de diminution de l'efficacité de la cyprotérone."@fr;
  r:conduiteATenir """Association déconseillée:
- dans son utilisation comme contraceptif hormonal: utiliser de préférence une autre méthode de contraception en particulier de type mécanique, pendant la durée de l'association et un cycle suivant.

Précaution d'emploi
- dans se"""@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b206740, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b206734 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b206735 .

_:79f295ad32df4ce8a18a92539c6e8a3b206735 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206736;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b206737 .

_:79f295ad32df4ce8a18a92539c6e8a3b206736 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10094 .

_:79f295ad32df4ce8a18a92539c6e8a3b206737 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206738;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b206738 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10238 .

_:79f295ad32df4ce8a18a92539c6e8a3b206740 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10261-2 a owl:Class;
  rdfs:label "ANTIHYPERTENSEURS ALPHA-BLOQUANTS <-> INHIBITEURS DE LA PHOSPHODIESTERASE DE TYPE 5"@fr;
  dct:identifier "IAM_10261";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b206742;
  r:natureDuRisque "Risque d’hypotension orthostatique, notamment chez le sujet âgé."@fr;
  r:conduiteATenir """Association déconseillée :
- avec la doxazosine 

Précaution d'emploi :
- avec les autres alpha-bloquants
Débuter le traitement aux posologies minimales recommandées et adapter progressivement les doses si besoin."""@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b206748, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b206742 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b206743 .

_:79f295ad32df4ce8a18a92539c6e8a3b206743 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206744;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b206745 .

_:79f295ad32df4ce8a18a92539c6e8a3b206744 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10033 .

_:79f295ad32df4ce8a18a92539c6e8a3b206745 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206746;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b206746 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10098 .

_:79f295ad32df4ce8a18a92539c6e8a3b206748 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10023-2 a owl:Class;
  rdfs:label "ACIDE ACETYLSALICYLIQUE <-> HÉPARINES NON FRACTIONNÉES (DOSES CURATIVES ET/OU SUJET ÂGÉ)"@fr;
  dct:identifier "IAM_10023";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b206750;
  r:natureDuRisque "Augmentation du risque hémorragique (inhibition de la fonction plaquettaire et agression de la muqueuse gastroduodénale par l’acide acétylsalicylique)."@fr;
  r:conduiteATenir """Association déconseillée avec :
- des doses anti-inflammatoires d'acide acétylsalicylique (>=1g par prise et/ou >=3g par jour) 
- des doses antalgiques ou antipyrétiques (>=500 mg par prise et/ou <3g par jour)
Utiliser un autre anti-inflammatoire ou un au"""@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b206756, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b206750 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b206751 .

_:79f295ad32df4ce8a18a92539c6e8a3b206751 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206752;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b206753 .

_:79f295ad32df4ce8a18a92539c6e8a3b206752 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10091 .

_:79f295ad32df4ce8a18a92539c6e8a3b206753 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206754;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b206754 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10012 .

_:79f295ad32df4ce8a18a92539c6e8a3b206756 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10020-2 a owl:Class;
  rdfs:label "ACIDE ACETYLSALICYLIQUE <-> GLUCOCORTICOÏDES (SAUF HYDROCORTISONE)"@fr;
  dct:identifier "IAM_10020";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b206758;
  r:natureDuRisque "Majoration du risque hémorragique."@fr;
  r:conduiteATenir """Association déconseillée avec :
- des doses anti-inflammatoires d'acide acétylsalicylique (>=1g par prise et/ou >=3g par jour)

A prendre en compte avec :
- des doses antalgiques ou antipyrétiques (>=500 mg par prise et/ou <3g par jour)."""@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b206764, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b206758 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b206759 .

_:79f295ad32df4ce8a18a92539c6e8a3b206759 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206760;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b206761 .

_:79f295ad32df4ce8a18a92539c6e8a3b206760 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10081 .

_:79f295ad32df4ce8a18a92539c6e8a3b206761 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206762;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b206762 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10012 .

_:79f295ad32df4ce8a18a92539c6e8a3b206764 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10021-2 a owl:Class;
  rdfs:label "ACIDE ACETYLSALICYLIQUE <-> HÉPARINES DE BAS POIDS MOLÉCULAIRE ET APPARENTÉS (DOSES CURATIVES ET/OU SUJET ÂGÉ)"@fr;
  dct:identifier "IAM_10021";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b206766;
  r:natureDuRisque "Augmentation du risque hémorragique (inhibition de la fonction plaquettaire et agression de la muqueuse gastroduodénale par l’acide acétylsalicylique."@fr;
  r:conduiteATenir """Association déconseillée avec :
- des doses anti-inflammatoires d'acide acétylsalicylique (>=1g par prise et/ou >=3g par jour) 
- des doses antalgiques ou antipyrétiques (>=500 mg par prise et/ou <3g par jour)
Utiliser un autre anti-inflammatoire ou un au"""@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b206772, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b206766 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b206767 .

_:79f295ad32df4ce8a18a92539c6e8a3b206767 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206768;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b206769 .

_:79f295ad32df4ce8a18a92539c6e8a3b206768 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10089 .

_:79f295ad32df4ce8a18a92539c6e8a3b206769 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206770;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b206770 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10012 .

_:79f295ad32df4ce8a18a92539c6e8a3b206772 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10303-2 a owl:Class;
  rdfs:label "ANTISÉCRÉTOIRES INHIBITEURS DE LA POMPE À PROTONS <-> METHOTREXATE"@fr;
  dct:identifier "IAM_10303";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b206774;
  r:natureDuRisque "Risque d’augmentation de la toxicité du méthotrexate par diminution de son élimination."@fr;
  r:conduiteATenir """Association déconseillée :
- avec le méthotrexate aux doses > 20 mg / semaine

A prendre en compte :
- pour des doses inférieures"""@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b206780, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b206774 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b206775 .

_:79f295ad32df4ce8a18a92539c6e8a3b206775 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206776;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b206777 .

_:79f295ad32df4ce8a18a92539c6e8a3b206776 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10043 .

_:79f295ad32df4ce8a18a92539c6e8a3b206777 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206778;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b206778 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10569 .

_:79f295ad32df4ce8a18a92539c6e8a3b206780 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11157-2 a owl:Class;
  rdfs:label "INHIBITEURS PUISSANTS DU CYP3A4 <-> MIDAZOLAM"@fr;
  dct:identifier "IAM_11157";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b206782;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de midazolam par diminution de son métabolisme hépatique, avec majoration de la sédation."@fr;
  r:conduiteATenir """Association déconseillée:
- avec le midazolam per os

Précaution d'emploi avec :
- avec le midazolam IV et sublingual
Surveillance clinique et réduction de la posologie de midazolam en cas de traitement par l'inhibiteur."""@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b206788, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b206782 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b206783 .

_:79f295ad32df4ce8a18a92539c6e8a3b206783 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206784;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b206785 .

_:79f295ad32df4ce8a18a92539c6e8a3b206784 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10103 .

_:79f295ad32df4ce8a18a92539c6e8a3b206785 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206786;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b206786 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10585 .

_:79f295ad32df4ce8a18a92539c6e8a3b206788 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11150-2 a owl:Class;
  rdfs:label "INHIBITEURS PUISSANTS DU CYP3A4 <-> ISAVUCONAZOLE"@fr;
  dct:identifier "IAM_11150";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b206790;
  r:natureDuRisque "Augmentation des concentrations plasmatiques d’isavuconazole par diminution de son métabolisme hépatique par l’inhibiteur."@fr;
  r:conduiteATenir """Contre-indication:
- avec le kétoconazole


Précaution d'emploi:
- avec les autres inhibiteurs puissants du CYP3A4"""@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b206796, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b206790 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b206791 .

_:79f295ad32df4ce8a18a92539c6e8a3b206791 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206792;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b206793 .

_:79f295ad32df4ce8a18a92539c6e8a3b206792 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10103 .

_:79f295ad32df4ce8a18a92539c6e8a3b206793 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206794;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b206794 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10487 .

_:79f295ad32df4ce8a18a92539c6e8a3b206796 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11414-1 a owl:Class;
  rdfs:label "RIFAMPICINE <-> THÉOPHYLLINE (ET, PAR EXTRAPOLATION, AMINOPHYLLINE)"@fr;
  dct:identifier "IAM_11414";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b206798;
  r:natureDuRisque "Diminution des concentrations plasmatiques et de l'efficacité de la théophylline (augmentation de son métabolisme par induction enzymatique)."@fr;
  r:conduiteATenir "Surveillance clinique et, si besoin, de la théophyllinémie. Adapter, s'il y a lieu, la posologie de la théophylline pendant le traitement par la rifampicine et après son arrêt."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b206804, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b206798 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b206799 .

_:79f295ad32df4ce8a18a92539c6e8a3b206799 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206800;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b206801 .

_:79f295ad32df4ce8a18a92539c6e8a3b206800 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10152 .

_:79f295ad32df4ce8a18a92539c6e8a3b206801 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206802;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b206802 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:79f295ad32df4ce8a18a92539c6e8a3b206804 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11460-1 a owl:Class;
  rdfs:label "VENLAFAXINE <-> VORICONAZOLE"@fr;
  dct:identifier "IAM_11460";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b206806;
  r:natureDuRisque "Augmentation des concentrations de venlafaxine avec risque de surdosage."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b206812, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b206806 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b206807 .

_:79f295ad32df4ce8a18a92539c6e8a3b206807 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206808;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b206809 .

_:79f295ad32df4ce8a18a92539c6e8a3b206808 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10979 .

_:79f295ad32df4ce8a18a92539c6e8a3b206809 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206810;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b206810 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10998 .

_:79f295ad32df4ce8a18a92539c6e8a3b206812 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10310-2 a owl:Class;
  rdfs:label "ANTISPASMODIQUES URINAIRES <-> INHIBITEURS PUISSANTS DU CYP3A4"@fr;
  dct:identifier "IAM_10310";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b206814;
  r:chapeau "Certains médicaments possèdent la capacité d’inhiber fortement le CYP3A4, une enzyme qui intervient dans le métabolisme de nombreux médicaments. Lorsque l’activité de cette enzyme est inhibée, elle n’est plus en mesure de métaboliser le médicament qui va"@fr;
  r:natureDuRisque "Risque de majoration des effets indésirables."@fr;
  r:conduiteATenir """Contre-indication :
- avec la darifénacine
- avec la fésotérodine et la solifénacine, en cas d'insuffisance rénale ou hépatique, modérée à sévère.

Association déconseillée : 
- avec la toltérodine

Précaution d'emploi:
- avec la fésotérodine ou la solifé"""@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b206820, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b206814 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b206815 .

_:79f295ad32df4ce8a18a92539c6e8a3b206815 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206816;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b206817 .

_:79f295ad32df4ce8a18a92539c6e8a3b206816 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10041 .

_:79f295ad32df4ce8a18a92539c6e8a3b206817 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206818;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b206818 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10103 .

_:79f295ad32df4ce8a18a92539c6e8a3b206820 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11111-2 a owl:Class;
  rdfs:label "INHIBITEURS DE LA PHOSPHODIESTERASE DE TYPE 5 <-> INHIBITEURS PUISSANTS DU CYP3A4"@fr;
  dct:identifier "IAM_11111";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b206822;
  r:chapeau "Certains médicaments possèdent la capacité d’inhiber fortement le CYP3A4, une enzyme qui intervient dans le métabolisme de nombreux médicaments. Lorsque l’activité de cette enzyme est inhibée, elle n’est plus en mesure de métaboliser le médicament qui va"@fr;
  r:natureDuRisque "Augmentation (très importante pour l'avanafil et le vardénafil) des concentrations plasmatiques de l'IPDE5, avec risque d'hypotension (sévère avec le vardénafil)."@fr;
  r:conduiteATenir "Pour connaître les risques et les niveaux de contrainte de chaque IPDE5 avec les inhibiteurs puissants du CYP3A4, il convient de se reporter aux AMM specifiques à chacun d'eux."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b206828, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b206822 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b206823 .

_:79f295ad32df4ce8a18a92539c6e8a3b206823 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206824;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b206825 .

_:79f295ad32df4ce8a18a92539c6e8a3b206824 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10098 .

_:79f295ad32df4ce8a18a92539c6e8a3b206825 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206826;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b206826 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10103 .

_:79f295ad32df4ce8a18a92539c6e8a3b206828 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10015-2 a owl:Class;
  rdfs:label "ACIDE ACETYLSALICYLIQUE <-> ANTICOAGULANTS ORAUX"@fr;
  dct:identifier "IAM_10015";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b206830;
  r:natureDuRisque "Majoration du risque hémorragique, notamment en cas d’antécédent d’ulcère gastro-duodénal."@fr;
  r:conduiteATenir """Association déconseillée avec :
- des doses antalgiques ou antipyrétiques (>=500 mg par prise et/ou <3g par jour) en l'absence d’antécédent d’ulcère gastro-duodénal
- des doses antiagrégantes (de 50 mg à 375 mg par jour) et en cas d’antécédent d’ulcère ga"""@fr;
  rdfs:comment "Jusqu'à présent, cette interaction se présentait selon deux niveaux distincts : une contre-indication avec l'acide acétylsalicylique administré à doses anti-inflammatoires et une association déconseillée avec l'aspirine donnée à doses antalgiques ou anti"@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b206836, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b206830 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b206831 .

_:79f295ad32df4ce8a18a92539c6e8a3b206831 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206832;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b206833 .

_:79f295ad32df4ce8a18a92539c6e8a3b206832 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10028 .

_:79f295ad32df4ce8a18a92539c6e8a3b206833 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206834;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b206834 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10012 .

_:79f295ad32df4ce8a18a92539c6e8a3b206836 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10192-2 a owl:Class;
  rdfs:label "ANTIARYTHMIQUES <-> AUTRES ANTIARYTHMIQUES"@fr;
  dct:identifier "IAM_10192";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b206838;
  r:natureDuRisque "L'association de deux antiarythmiques est très délicate. Elle est dans la majorité des cas, contre-indiquée ou déconseillée."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b206840, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b206838 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10024 .

_:79f295ad32df4ce8a18a92539c6e8a3b206840 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10310-3 a owl:Class;
  rdfs:label "ANTISPASMODIQUES URINAIRES <-> INHIBITEURS PUISSANTS DU CYP3A4"@fr;
  dct:identifier "IAM_10310";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b206842;
  r:chapeau "Certains médicaments possèdent la capacité d’inhiber fortement le CYP3A4, une enzyme qui intervient dans le métabolisme de nombreux médicaments. Lorsque l’activité de cette enzyme est inhibée, elle n’est plus en mesure de métaboliser le médicament qui va"@fr;
  r:natureDuRisque "Risque de majoration des effets indésirables."@fr;
  r:conduiteATenir """Contre-indication :
- avec la darifénacine
- avec la fésotérodine et la solifénacine, en cas d'insuffisance rénale ou hépatique, modérée à sévère.

Association déconseillée : 
- avec la toltérodine

Précaution d'emploi:
- avec la fésotérodine ou la solifé"""@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b206848, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b206842 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b206843 .

_:79f295ad32df4ce8a18a92539c6e8a3b206843 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206844;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b206845 .

_:79f295ad32df4ce8a18a92539c6e8a3b206844 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10041 .

_:79f295ad32df4ce8a18a92539c6e8a3b206845 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206846;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b206846 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10103 .

_:79f295ad32df4ce8a18a92539c6e8a3b206848 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11111-3 a owl:Class;
  rdfs:label "INHIBITEURS DE LA PHOSPHODIESTERASE DE TYPE 5 <-> INHIBITEURS PUISSANTS DU CYP3A4"@fr;
  dct:identifier "IAM_11111";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b206850;
  r:chapeau "Certains médicaments possèdent la capacité d’inhiber fortement le CYP3A4, une enzyme qui intervient dans le métabolisme de nombreux médicaments. Lorsque l’activité de cette enzyme est inhibée, elle n’est plus en mesure de métaboliser le médicament qui va"@fr;
  r:natureDuRisque "Augmentation (très importante pour l'avanafil et le vardénafil) des concentrations plasmatiques de l'IPDE5, avec risque d'hypotension (sévère avec le vardénafil)."@fr;
  r:conduiteATenir "Pour connaître les risques et les niveaux de contrainte de chaque IPDE5 avec les inhibiteurs puissants du CYP3A4, il convient de se reporter aux AMM specifiques à chacun d'eux."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b206856, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b206850 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b206851 .

_:79f295ad32df4ce8a18a92539c6e8a3b206851 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206852;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b206853 .

_:79f295ad32df4ce8a18a92539c6e8a3b206852 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10098 .

_:79f295ad32df4ce8a18a92539c6e8a3b206853 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206854;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b206854 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10103 .

_:79f295ad32df4ce8a18a92539c6e8a3b206856 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10015-3 a owl:Class;
  rdfs:label "ACIDE ACETYLSALICYLIQUE <-> ANTICOAGULANTS ORAUX"@fr;
  dct:identifier "IAM_10015";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b206858;
  r:natureDuRisque "Majoration du risque hémorragique, notamment en cas d’antécédent d’ulcère gastro-duodénal."@fr;
  r:conduiteATenir """Contre-indication avec :
- des doses anti-inflammatoires d'acide acétylsalicylique (>=1g par prise et/ou >=3g par jour)
- des doses antalgiques ou antipyrétiques (>=500 mg par prise et/ou <3g par jour) et en cas d’antécédent d’ulcère gastro-duodénal"""@fr;
  rdfs:comment "Jusqu'à présent, cette interaction se présentait selon deux niveaux distincts : une contre-indication avec l'acide acétylsalicylique administré à doses anti-inflammatoires et une association déconseillée avec l'aspirine donnée à doses antalgiques ou anti"@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b206864, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b206858 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b206859 .

_:79f295ad32df4ce8a18a92539c6e8a3b206859 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206860;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b206861 .

_:79f295ad32df4ce8a18a92539c6e8a3b206860 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10028 .

_:79f295ad32df4ce8a18a92539c6e8a3b206861 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206862;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b206862 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10012 .

_:79f295ad32df4ce8a18a92539c6e8a3b206864 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11118-2 a owl:Class;
  rdfs:label "INHIBITEURS DE L'ENZYME DE CONVERSION <-> RACECADOTRIL"@fr;
  dct:identifier "IAM_11118";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b206866;
  r:natureDuRisque "Risque de majoration des effets indésirables à type d'œdème angio-neurotique (angio-œdème)."@fr;
  r:conduiteATenir """Contre-indication:
- en cas d'antécédents d'angio-oedème sous IEC.

Association déconseillée:
- en l'absence d’antécédents d'angio-oedème sous IEC."""@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b206872, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b206866 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b206867 .

_:79f295ad32df4ce8a18a92539c6e8a3b206867 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206868;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b206869 .

_:79f295ad32df4ce8a18a92539c6e8a3b206868 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10096 .

_:79f295ad32df4ce8a18a92539c6e8a3b206869 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206870;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b206870 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10780 .

_:79f295ad32df4ce8a18a92539c6e8a3b206872 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10530-2 a owl:Class;
  rdfs:label "CALCIUM <-> DIGOXINE"@fr;
  dct:identifier "IAM_10530";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b206874;
  r:natureDuRisque "Risque de troubles du rythme graves, voire mortels avec les sels de calcium administrés par voie IV."@fr;
  r:conduiteATenir """Contre-indication :
- avec les sels de calcium IV, hormis supplémentation parentérale.

Précaution d'emploi :
- avec les sels de calcium par voie orale.
Surveillance clinique et, s'il y a lieu, contrôle de l'ECG et de la calcémie."""@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b206880, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b206874 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b206875 .

_:79f295ad32df4ce8a18a92539c6e8a3b206875 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206876;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b206877 .

_:79f295ad32df4ce8a18a92539c6e8a3b206876 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10150 .

_:79f295ad32df4ce8a18a92539c6e8a3b206877 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206878;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b206878 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10286 .

_:79f295ad32df4ce8a18a92539c6e8a3b206880 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11458-1 a owl:Class;
  rdfs:label "VALPROÏQUE (ACIDE) ET, PAR EXTRAPOLATION, VALPROMIDE <-> ZIDOVUDINE"@fr;
  dct:identifier "IAM_11458";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b206882;
  r:natureDuRisque "Risque d’augmentation des effets indésirables, notamment hématologiques, de la zidovudine par diminution de son métabolisme par l’acide valproïque."@fr;
  r:conduiteATenir "Surveillance clinique et biologique régulière. Un hémogramme à la recherche d’une anémie devrait être réalisé au cours des deux premiers mois de l’association."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b206888, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b206882 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b206883 .

_:79f295ad32df4ce8a18a92539c6e8a3b206883 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206884;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b206885 .

_:79f295ad32df4ce8a18a92539c6e8a3b206884 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10160 .

_:79f295ad32df4ce8a18a92539c6e8a3b206885 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206886;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b206886 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_11004 .

_:79f295ad32df4ce8a18a92539c6e8a3b206888 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10715-2 a owl:Class;
  rdfs:label "DACLATASVIR <-> INDUCTEURS ENZYMATIQUES"@fr;
  dct:identifier "IAM_10715";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b206890;
  r:natureDuRisque "Diminution des concentrations plasmatiques de daclatasvir par augmentation de son métabolisme hépatique par l'inducteur."@fr;
  r:conduiteATenir """Contre-indication:
- avec la rifampicine
- avec les anticonvulsivants inducteurs enzymatiques
- avec l'oxcarbazépine

Précaution d'emploi:
- avec les autres inducteurs, la dose recommandée est de 90 mg/jour de daclatasvir"""@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b206896, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b206890 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b206891 .

_:79f295ad32df4ce8a18a92539c6e8a3b206891 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206892;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b206893 .

_:79f295ad32df4ce8a18a92539c6e8a3b206892 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10094 .

_:79f295ad32df4ce8a18a92539c6e8a3b206893 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206894;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b206894 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10243 .

_:79f295ad32df4ce8a18a92539c6e8a3b206896 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10027-2 a owl:Class;
  rdfs:label "ACIDE ACETYLSALICYLIQUE <-> METHOTREXATE"@fr;
  dct:identifier "IAM_10027";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b206898;
  r:natureDuRisque "Majoration de la toxicité, notamment hématologique, du méthotrexate (diminution de sa clairance rénale par l'acide acétylsalicylique)."@fr;
  r:conduiteATenir """Avec le méthotrexate utilisé à des doses > 20 mg/semaine : 
- contre-indication avec l'acide acétylsalicylique utilisé à doses antalgiques, antipyrétiques ou anti-inflammatoires
- précaution d'emploi avec des doses antiagrégantes plaquettaires d'acide acé"""@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b206904, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b206898 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b206899 .

_:79f295ad32df4ce8a18a92539c6e8a3b206899 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206900;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b206901 .

_:79f295ad32df4ce8a18a92539c6e8a3b206900 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10012 .

_:79f295ad32df4ce8a18a92539c6e8a3b206901 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206902;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b206902 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10569 .

_:79f295ad32df4ce8a18a92539c6e8a3b206904 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11122-2 a owl:Class;
  rdfs:label "INHIBITEURS DE L'HMG-COA RÉDUCTASE (STATINES) <-> LÉDIPASVIR"@fr;
  dct:identifier "IAM_11122";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b206906;
  r:natureDuRisque "Risque d’augmentation des concentrations plasmatiques de la statine et de ses effets indésirables à type de rhabdomyolyse."@fr;
  r:conduiteATenir """Contre-indication :
- avec la rosuvastatine.

Précaution d'emploi :
- avec les autres inhibiteurs de l'HMG Co-A réductase.
Surveillance clinique et biologique. Adaptation éventuelle de la posologie de la statine."""@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b206912, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b206906 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b206907 .

_:79f295ad32df4ce8a18a92539c6e8a3b206907 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206908;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b206909 .

_:79f295ad32df4ce8a18a92539c6e8a3b206908 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10095 .

_:79f295ad32df4ce8a18a92539c6e8a3b206909 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206910;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b206910 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10512 .

_:79f295ad32df4ce8a18a92539c6e8a3b206912 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11266-2 a owl:Class;
  rdfs:label "METHADONE <-> SUBSTANCES SUSCEPTIBLES DE DONNER DES TORSADES DE POINTES"@fr;
  dct:identifier "IAM_11266";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b206914;
  r:natureDuRisque "Risque majoré de troubles du rythme ventriculaire, notamment de torsades de pointes."@fr;
  r:conduiteATenir """Contre-indication :
- avec le citalopram, la dompéridone, l'escitalopram, l'hydroxyzine
et la pipéraquine.

Association déconseillée:
- avec les autres médicaments susceptibles de donner des torsades de pointes."""@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b206920, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b206914 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b206915 .

_:79f295ad32df4ce8a18a92539c6e8a3b206915 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206916;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b206917 .

_:79f295ad32df4ce8a18a92539c6e8a3b206916 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10143 .

_:79f295ad32df4ce8a18a92539c6e8a3b206917 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206918;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b206918 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10567 .

_:79f295ad32df4ce8a18a92539c6e8a3b206920 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11059-2 a owl:Class;
  rdfs:label "IMAO-A RÉVERSIBLES, Y COMPRIS LINEZOLIDE ET BLEU DE MÉTHYLÈNE <-> SYMPATHOMIMÉTIQUES INDIRECTS"@fr;
  dct:identifier "IAM_11059";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b206922;
  r:natureDuRisque "Risque de vasoconstriction et/ou de poussées hypertensives."@fr;
  r:conduiteATenir """Contre-indication :
avec le bupropion

Association déconseillée :
avec les autres sympathomimétiques indirects"""@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b206928, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b206922 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b206923 .

_:79f295ad32df4ce8a18a92539c6e8a3b206923 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206924;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b206925 .

_:79f295ad32df4ce8a18a92539c6e8a3b206924 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10003 .

_:79f295ad32df4ce8a18a92539c6e8a3b206925 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206926;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b206926 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10150 .

_:79f295ad32df4ce8a18a92539c6e8a3b206928 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11439-2 a owl:Class;
  rdfs:label "SUBSTANCES SUSCEPTIBLES DE DONNER DES TORSADES DE POINTES <-> TORSADOGÈNES (SAUF ANTIPARASITAIRES, NEUROLEPTIQUES, MÉTHADONE)"@fr;
  dct:identifier "IAM_11439";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b206930;
  r:chapeau "Ce trouble du rythme cardiaque grave peut être provoqué par un certain nombre de médicaments, antiarythmiques ou non. L'hypokaliémie (cf. médicaments hypokaliémiants) est un facteur favorisant, de même que la bradycardie (cf. médicaments bradycardisants)"@fr;
  r:natureDuRisque "Risque majoré de troubles du rythme ventriculaire, notamment de torsades de pointes."@fr;
  r:conduiteATenir """Contre-indication:
- Pour l'érythromycine et la vincamine, seules les formes administrées par voie intraveineuse sont concernées par cette interaction.
- Pour la spiramycine, la voie IV et la voie orale sont concernées.

Association déconseillée:
- avec l"""@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b206936, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b206930 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b206931 .

_:79f295ad32df4ce8a18a92539c6e8a3b206931 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206932;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b206933 .

_:79f295ad32df4ce8a18a92539c6e8a3b206932 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10143 .

_:79f295ad32df4ce8a18a92539c6e8a3b206933 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206934;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b206934 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10154 .

_:79f295ad32df4ce8a18a92539c6e8a3b206936 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10939-2 a owl:Class;
  rdfs:label "FIBRATES <-> INHIBITEURS DE L'HMG-COA RÉDUCTASE (STATINES)"@fr;
  dct:identifier "IAM_10939";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b206938;
  r:natureDuRisque "Risque d'addition d'effets indésirables (dose-dépendants) à type de rhabdomyolyse. En outre, avec le gemfibrozil, diminution du métabolisme de la simvastatine et de la rosuvastatine, ce qui majore le risque musculaire, ainsi que la néphrotoxicité de la ro"@fr;
  r:conduiteATenir """Contre-indication 
- entre le gemfibrozil et la simvastatine
- pour des doses de rosuvastatine de 40 mg

Association déconseillée 
- entre les autres fibrates et les autres statines 
- ne pas dépasser 10 mg de simvastatine (cette restriction de doses ne"""@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b206944, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b206938 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b206939 .

_:79f295ad32df4ce8a18a92539c6e8a3b206939 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206940;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b206941 .

_:79f295ad32df4ce8a18a92539c6e8a3b206940 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10074 .

_:79f295ad32df4ce8a18a92539c6e8a3b206941 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206942;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b206942 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10095 .

_:79f295ad32df4ce8a18a92539c6e8a3b206944 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10828-2 a owl:Class;
  rdfs:label "DIURÉTIQUES ÉPARGNEURS DE POTASSIUM (SEULS OU ASSOCIÉS) <-> POTASSIUM"@fr;
  dct:identifier "IAM_10828";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b206946;
  r:natureDuRisque "Hyperkaliémie potentiellement létale, notamment chez l'insuffisant rénal (addition des effets hyperkaliémiants)."@fr;
  r:conduiteATenir "Contre-indication:-en dehors d'une hypokaliémie ou en cas d'utilisation parentérale des sels de potassium"@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b206952, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b206946 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b206947 .

_:79f295ad32df4ce8a18a92539c6e8a3b206947 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206948;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b206949 .

_:79f295ad32df4ce8a18a92539c6e8a3b206948 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10067 .

_:79f295ad32df4ce8a18a92539c6e8a3b206949 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206950;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b206950 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10742 .

_:79f295ad32df4ce8a18a92539c6e8a3b206952 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10090-2 a owl:Class;
  rdfs:label "ALISKIREN <-> ANTAGONISTES DES RÉCEPTEURS DE L'ANGIOTENSINE II"@fr;
  dct:identifier "IAM_10090";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b206954;
  r:natureDuRisque "Risque d’hyperkaliémie, d’insuffisance rénale, d’augmentation de la morbi-mortalité cardio-vasculaire."@fr;
  r:conduiteATenir """Contre-indication :
- chez le patient diabétique ou insuffisant rénal

Association déconseillée :
- dans les autres cas"""@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b206960, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b206954 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b206955 .

_:79f295ad32df4ce8a18a92539c6e8a3b206955 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206956;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b206957 .

_:79f295ad32df4ce8a18a92539c6e8a3b206956 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10020 .

_:79f295ad32df4ce8a18a92539c6e8a3b206957 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206958;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b206958 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10048 .

_:79f295ad32df4ce8a18a92539c6e8a3b206960 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11029-2 a owl:Class;
  rdfs:label "HYDROXYCHLOROQUINE <-> SUBSTANCES SUSCEPTIBLES DE DONNER DES TORSADES DE POINTES"@fr;
  dct:identifier "IAM_11029";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b206962;
  r:natureDuRisque "Risque majoré de troubles du rythme ventriculaire, notamment de torsades de pointes."@fr;
  r:conduiteATenir """Contre-indication :
- avec le citalopram, la dompéridone, l'escitalopram, l'hydroxyzine et la pipéraquine.

Association déconseillée:
- avec les autres médicaments susceptibles de donner des torsades de pointes."""@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b206968, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b206962 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b206963 .

_:79f295ad32df4ce8a18a92539c6e8a3b206963 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206964;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b206965 .

_:79f295ad32df4ce8a18a92539c6e8a3b206964 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10143 .

_:79f295ad32df4ce8a18a92539c6e8a3b206965 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206966;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b206966 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10437 .

_:79f295ad32df4ce8a18a92539c6e8a3b206968 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10192-3 a owl:Class;
  rdfs:label "ANTIARYTHMIQUES <-> AUTRES ANTIARYTHMIQUES"@fr;
  dct:identifier "IAM_10192";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b206970;
  r:natureDuRisque "L'association de deux antiarythmiques est très délicate. Elle est dans la majorité des cas, contre-indiquée ou déconseillée."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b206972, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b206970 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10024 .

_:79f295ad32df4ce8a18a92539c6e8a3b206972 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11358-1 a owl:Class;
  rdfs:label "PEG-INTERFERON ALFA-2A <-> TELBIVUDINE"@fr;
  dct:identifier "IAM_11358";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b206974;
  r:natureDuRisque "Risque majoré de neuropathies périphériques."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b206980, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b206974 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b206975 .

_:79f295ad32df4ce8a18a92539c6e8a3b206975 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206976;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b206977 .

_:79f295ad32df4ce8a18a92539c6e8a3b206976 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10698 .

_:79f295ad32df4ce8a18a92539c6e8a3b206977 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206978;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b206978 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10888 .

_:79f295ad32df4ce8a18a92539c6e8a3b206980 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11347-1 a owl:Class;
  rdfs:label "PAMPLEMOUSSE (JUS ET FRUIT) <-> RÉGORAFÉNIB"@fr;
  dct:identifier "IAM_11347";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b206982;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de régorafenib par diminution de son métabolisme hépatique par le pamplemousse."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b206988, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b206982 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b206983 .

_:79f295ad32df4ce8a18a92539c6e8a3b206983 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206984;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b206985 .

_:79f295ad32df4ce8a18a92539c6e8a3b206984 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10130 .

_:79f295ad32df4ce8a18a92539c6e8a3b206985 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206986;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b206986 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10789 .

_:79f295ad32df4ce8a18a92539c6e8a3b206988 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11348-1 a owl:Class;
  rdfs:label "PAMPLEMOUSSE (JUS ET FRUIT) <-> SERTRALINE"@fr;
  dct:identifier "IAM_11348";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b206990;
  r:natureDuRisque "Augmentation parfois importante des concentrations de l’antidépresseur chez certains patients par diminution de son métabolisme intestinal."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b206996, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b206990 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b206991 .

_:79f295ad32df4ce8a18a92539c6e8a3b206991 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206992;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b206993 .

_:79f295ad32df4ce8a18a92539c6e8a3b206992 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10130 .

_:79f295ad32df4ce8a18a92539c6e8a3b206993 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b206994;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b206994 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10831 .

_:79f295ad32df4ce8a18a92539c6e8a3b206996 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11349-1 a owl:Class;
  rdfs:label "PAMPLEMOUSSE (JUS ET FRUIT) <-> SIMVASTATINE"@fr;
  dct:identifier "IAM_11349";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b206998;
  r:natureDuRisque "Augmentation considérable des concentrations plasmatiques de l'hypolipémiant, avec risque de survenue d'effets indésirables, notamment musculaires."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b207004, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b206998 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b206999 .

_:79f295ad32df4ce8a18a92539c6e8a3b206999 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207000;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b207001 .

_:79f295ad32df4ce8a18a92539c6e8a3b207000 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10130 .

_:79f295ad32df4ce8a18a92539c6e8a3b207001 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207002;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b207002 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10838 .

_:79f295ad32df4ce8a18a92539c6e8a3b207004 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11350-1 a owl:Class;
  rdfs:label "PAMPLEMOUSSE (JUS ET FRUIT) <-> TICAGRELOR"@fr;
  dct:identifier "IAM_11350";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b207006;
  r:natureDuRisque "Doublement des concentrations plasmatiques de l'antiagrégant, avec risque de majoration des effets indésirables, notamment hémorragiques."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b207012, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b207006 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b207007 .

_:79f295ad32df4ce8a18a92539c6e8a3b207007 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207008;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b207009 .

_:79f295ad32df4ce8a18a92539c6e8a3b207008 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10130 .

_:79f295ad32df4ce8a18a92539c6e8a3b207009 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207010;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b207010 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10926 .

_:79f295ad32df4ce8a18a92539c6e8a3b207012 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11351-1 a owl:Class;
  rdfs:label "PAMPLEMOUSSE (JUS ET FRUIT) <-> VARDENAFIL"@fr;
  dct:identifier "IAM_11351";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b207014;
  r:natureDuRisque "Augmentation des concentrations plasmatiques du vardénafil, avec risque d’hypotension."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b207020, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b207014 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b207015 .

_:79f295ad32df4ce8a18a92539c6e8a3b207015 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207016;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b207017 .

_:79f295ad32df4ce8a18a92539c6e8a3b207016 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10130 .

_:79f295ad32df4ce8a18a92539c6e8a3b207017 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207018;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b207018 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10975 .

_:79f295ad32df4ce8a18a92539c6e8a3b207020 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11352-1 a owl:Class;
  rdfs:label "PAMPLEMOUSSE (JUS ET FRUIT) <-> VERAPAMIL"@fr;
  dct:identifier "IAM_11352";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b207022;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de vérapamil, avec risque de survenue d’effets indésirables."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b207028, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b207022 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b207023 .

_:79f295ad32df4ce8a18a92539c6e8a3b207023 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207024;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b207025 .

_:79f295ad32df4ce8a18a92539c6e8a3b207024 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10130 .

_:79f295ad32df4ce8a18a92539c6e8a3b207025 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207026;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b207026 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10980 .

_:79f295ad32df4ce8a18a92539c6e8a3b207028 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11353-1 a owl:Class;
  rdfs:label "PAROXETINE <-> PIMOZIDE"@fr;
  dct:identifier "IAM_11353";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b207030;
  r:natureDuRisque "Risque majoré de troubles du rythme ventriculaire, notamment de torsades de pointes."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b207036, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b207030 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b207031 .

_:79f295ad32df4ce8a18a92539c6e8a3b207031 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207032;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b207033 .

_:79f295ad32df4ce8a18a92539c6e8a3b207032 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10694 .

_:79f295ad32df4ce8a18a92539c6e8a3b207033 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207034;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b207034 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10721 .

_:79f295ad32df4ce8a18a92539c6e8a3b207036 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11354-1 a owl:Class;
  rdfs:label "PAROXETINE <-> RISPERIDONE"@fr;
  dct:identifier "IAM_11354";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b207038;
  r:natureDuRisque "Augmentation de la fraction active de la rispéridone par diminution de son métabolisme hépatique par la paroxétine, avec risque de majoration des effets indésirables."@fr;
  r:conduiteATenir "Surveillance clinique et, si besoin, adaptation posologique de la rispéridone."@fr;
  rdfs:comment "La rispéridone est majoritairement métabolisée par le CYP2D6 en 9-OH-rispéridone, métabolite actif. La fraction pharmacologiquement active de la rispéridone est ainsi constituée par la molécule mère et son métabolite hydroxylé. La paroxétine est un inhibi"@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b207044, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b207038 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b207039 .

_:79f295ad32df4ce8a18a92539c6e8a3b207039 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207040;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b207041 .

_:79f295ad32df4ce8a18a92539c6e8a3b207040 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10694 .

_:79f295ad32df4ce8a18a92539c6e8a3b207041 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207042;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b207042 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10805 .

_:79f295ad32df4ce8a18a92539c6e8a3b207044 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11355-1 a owl:Class;
  rdfs:label "PAROXETINE <-> TAMOXIFENE"@fr;
  dct:identifier "IAM_11355";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b207046;
  r:natureDuRisque "Baisse de l’efficacité du tamoxifène, par inhibition de la formation de son métabolite actif par la paroxétine."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b207052, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b207046 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b207047 .

_:79f295ad32df4ce8a18a92539c6e8a3b207047 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207048;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b207049 .

_:79f295ad32df4ce8a18a92539c6e8a3b207048 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10694 .

_:79f295ad32df4ce8a18a92539c6e8a3b207049 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207050;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b207050 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10882 .

_:79f295ad32df4ce8a18a92539c6e8a3b207052 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11416-1 a owl:Class;
  rdfs:label "RIFAMPICINE <-> TICAGRELOR"@fr;
  dct:identifier "IAM_11416";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b207054;
  r:natureDuRisque "Diminution importante des concentrations plasmatiques de ticagrelor par augmentation de son métabolisme hépatique par la rifampicine, avec risque de diminution de l’effet thérapeutique."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b207060, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b207054 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b207055 .

_:79f295ad32df4ce8a18a92539c6e8a3b207055 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207056;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b207057 .

_:79f295ad32df4ce8a18a92539c6e8a3b207056 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:79f295ad32df4ce8a18a92539c6e8a3b207057 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207058;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b207058 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10926 .

_:79f295ad32df4ce8a18a92539c6e8a3b207060 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11357-1 a owl:Class;
  rdfs:label "PEFLOXACINE <-> THÉOPHYLLINE (ET, PAR EXTRAPOLATION, AMINOPHYLLINE)"@fr;
  dct:identifier "IAM_11357";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b207062;
  r:natureDuRisque "Augmentation de la théophyllinémie avec risque de surdosage (diminution du métabolisme de la théophylline)."@fr;
  r:conduiteATenir "Surveillance clinique et éventuellement de la théophyllinémie."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b207068, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b207062 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b207063 .

_:79f295ad32df4ce8a18a92539c6e8a3b207063 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207064;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b207065 .

_:79f295ad32df4ce8a18a92539c6e8a3b207064 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10152 .

_:79f295ad32df4ce8a18a92539c6e8a3b207065 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207066;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b207066 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10697 .

_:79f295ad32df4ce8a18a92539c6e8a3b207068 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11344-1 a owl:Class;
  rdfs:label "ORLISTAT <-> VITAMINE D"@fr;
  dct:identifier "IAM_11344";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b207070;
  r:natureDuRisque "Diminution de l'absorption de la vitamine D."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b207076, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b207070 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b207071 .

_:79f295ad32df4ce8a18a92539c6e8a3b207071 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207072;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b207073 .

_:79f295ad32df4ce8a18a92539c6e8a3b207072 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10162 .

_:79f295ad32df4ce8a18a92539c6e8a3b207073 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207074;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b207074 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10667 .

_:79f295ad32df4ce8a18a92539c6e8a3b207076 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11359-1 a owl:Class;
  rdfs:label "PÉNEMS <-> VALPROÏQUE (ACIDE) ET, PAR EXTRAPOLATION, VALPROMIDE"@fr;
  dct:identifier "IAM_11359";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b207078;
  r:natureDuRisque "Risque de survenue de crises convulsives, par diminution rapide des concentrations plasmatiques de l’acide valproïque, pouvant devenir indétectables."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b207084, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b207078 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b207079 .

_:79f295ad32df4ce8a18a92539c6e8a3b207079 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207080;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b207081 .

_:79f295ad32df4ce8a18a92539c6e8a3b207080 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10137 .

_:79f295ad32df4ce8a18a92539c6e8a3b207081 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207082;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b207082 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10160 .

_:79f295ad32df4ce8a18a92539c6e8a3b207084 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11361-1 a owl:Class;
  rdfs:label "PENTAMIDINE <-> ZALCITABINE"@fr;
  dct:identifier "IAM_11361";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b207086;
  r:natureDuRisque "Risque accru de neuropathies périphériques par addition d'effets indésirables."@fr;
  r:conduiteATenir "Surveillance clinique et biologique régulière, notamment en début d'association."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b207092, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b207086 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b207087 .

_:79f295ad32df4ce8a18a92539c6e8a3b207087 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207088;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b207089 .

_:79f295ad32df4ce8a18a92539c6e8a3b207088 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10703 .

_:79f295ad32df4ce8a18a92539c6e8a3b207089 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207090;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b207090 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_11002 .

_:79f295ad32df4ce8a18a92539c6e8a3b207092 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11360-1 a owl:Class;
  rdfs:label "PENTAMIDINE <-> STAVUDINE"@fr;
  dct:identifier "IAM_11360";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b207094;
  r:natureDuRisque "Risque majoré de survenue de neuropathies périphériques par addition d'effets indésirables."@fr;
  r:conduiteATenir "Surveillance clinique et biologique régulière, notamment en début d'association."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b207100, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b207094 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b207095 .

_:79f295ad32df4ce8a18a92539c6e8a3b207095 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207096;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b207097 .

_:79f295ad32df4ce8a18a92539c6e8a3b207096 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10703 .

_:79f295ad32df4ce8a18a92539c6e8a3b207097 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207098;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b207098 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10858 .

_:79f295ad32df4ce8a18a92539c6e8a3b207100 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11362-1 a owl:Class;
  rdfs:label "PENTOXIFYLLINE <-> THÉOPHYLLINE (ET, PAR EXTRAPOLATION, AMINOPHYLLINE)"@fr;
  dct:identifier "IAM_11362";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b207102;
  r:natureDuRisque "Augmentation de la théophyllinémie avec risque de surdosage (compétition au niveau du métabolisme hépatique de la théophylline)."@fr;
  r:conduiteATenir "Surveillance clinique et éventuellement de la théophyllinémie ; s'il y a lieu, adaptation de la posologie de la théophylline pendant le traitement par la pentoxifylline et après son arrêt."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b207108, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b207102 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b207103 .

_:79f295ad32df4ce8a18a92539c6e8a3b207103 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207104;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b207105 .

_:79f295ad32df4ce8a18a92539c6e8a3b207104 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10152 .

_:79f295ad32df4ce8a18a92539c6e8a3b207105 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207106;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b207106 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10705 .

_:79f295ad32df4ce8a18a92539c6e8a3b207108 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11384-1 a owl:Class;
  rdfs:label "PROGESTATIFS CONTRACEPTIFS <-> PÉRAMPANEL"@fr;
  dct:identifier "IAM_11384";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b207110;
  r:natureDuRisque "Pour des doses de pérampanel >= 12 mg/jour : Risque de diminution de l’efficacité contraceptive."@fr;
  r:conduiteATenir "Utiliser de préférence une autre méthode contraceptive, en particulier de type mécanique."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b207116, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b207110 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b207111 .

_:79f295ad32df4ce8a18a92539c6e8a3b207111 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207112;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b207113 .

_:79f295ad32df4ce8a18a92539c6e8a3b207112 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10134 .

_:79f295ad32df4ce8a18a92539c6e8a3b207113 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207114;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b207114 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10706 .

_:79f295ad32df4ce8a18a92539c6e8a3b207116 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11363-1 a owl:Class;
  rdfs:label "PÉRAMPANEL <-> RIFAMPICINE"@fr;
  dct:identifier "IAM_11363";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b207118;
  r:natureDuRisque "Diminution importante (jusqu’aux deux-tiers) des concentrations de pérampanel."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b207124, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b207118 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b207119 .

_:79f295ad32df4ce8a18a92539c6e8a3b207119 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207120;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b207121 .

_:79f295ad32df4ce8a18a92539c6e8a3b207120 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10706 .

_:79f295ad32df4ce8a18a92539c6e8a3b207121 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207122;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b207122 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:79f295ad32df4ce8a18a92539c6e8a3b207124 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11364-1 a owl:Class;
  rdfs:label "PHÉNOBARBITAL (ET, PAR EXTRAPOLATION, PRIMIDONE) <-> PHÉNYTOÏNE (ET, PAR EXTRAPOLATION, FOSPHÉNYTOÏNE)"@fr;
  dct:identifier "IAM_11364";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b207126;
  r:natureDuRisque """En cas de traitement antérieur par le phénobarbital ou la primidone, et adjonction de phénytoïne, augmentation des concentrations plasmatiques de phénobarbital pouvant entraîner des signes toxiques (inhibition du métabolisme par compétition).

En cas de t"""@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b207132, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b207126 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b207127 .

_:79f295ad32df4ce8a18a92539c6e8a3b207127 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207128;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b207129 .

_:79f295ad32df4ce8a18a92539c6e8a3b207128 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10131 .

_:79f295ad32df4ce8a18a92539c6e8a3b207129 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207130;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b207130 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10132 .

_:79f295ad32df4ce8a18a92539c6e8a3b207132 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11365-1 a owl:Class;
  rdfs:label "PHÉNOBARBITAL (ET, PAR EXTRAPOLATION, PRIMIDONE) <-> PROPRANOLOL"@fr;
  dct:identifier "IAM_11365";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b207134;
  r:natureDuRisque "Diminution des concentrations plasmatiques du propranolol avec réduction de ses effets cliniques (augmentation de son métabolisme hépatique)."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b207140, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b207134 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b207135 .

_:79f295ad32df4ce8a18a92539c6e8a3b207135 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207136;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b207137 .

_:79f295ad32df4ce8a18a92539c6e8a3b207136 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10131 .

_:79f295ad32df4ce8a18a92539c6e8a3b207137 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207138;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b207138 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10767 .

_:79f295ad32df4ce8a18a92539c6e8a3b207140 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11366-1 a owl:Class;
  rdfs:label "PHÉNOBARBITAL (ET, PAR EXTRAPOLATION, PRIMIDONE) <-> VALPROÏQUE (ACIDE) ET, PAR EXTRAPOLATION, VALPROMIDE"@fr;
  dct:identifier "IAM_11366";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b207142;
  r:natureDuRisque "Augmentation de l'hyperammoniémie, avec risque accru d'encéphalopathie."@fr;
  r:conduiteATenir "Surveillance clinique et biologique régulière."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b207148, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b207142 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b207143 .

_:79f295ad32df4ce8a18a92539c6e8a3b207143 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207144;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b207145 .

_:79f295ad32df4ce8a18a92539c6e8a3b207144 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10131 .

_:79f295ad32df4ce8a18a92539c6e8a3b207145 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207146;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b207146 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10160 .

_:79f295ad32df4ce8a18a92539c6e8a3b207148 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11356-1 a owl:Class;
  rdfs:label "PAROXETINE <-> VORTIOXÉTINE"@fr;
  dct:identifier "IAM_11356";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b207150;
  r:natureDuRisque "Risque d’augmentation des effets indésirables de la vortioxétine par diminution importante de son métabolisme hépatique."@fr;
  r:conduiteATenir "Surveillance clinique et adaptation éventuelle de la posologie de la vortioxétine pendant le traitement par la paroxétine et après son arrêt."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b207156, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b207150 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b207151 .

_:79f295ad32df4ce8a18a92539c6e8a3b207151 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207152;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b207153 .

_:79f295ad32df4ce8a18a92539c6e8a3b207152 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10694 .

_:79f295ad32df4ce8a18a92539c6e8a3b207153 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207154;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b207154 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10999 .

_:79f295ad32df4ce8a18a92539c6e8a3b207156 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11334-1 a owl:Class;
  rdfs:label "OLAPARIB <-> VERAPAMIL"@fr;
  dct:identifier "IAM_11334";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b207158;
  r:natureDuRisque "Augmentation des concentrations plasmatiques d’olaparib par le vérapamil."@fr;
  r:conduiteATenir "Si l’association ne peut être évitée, limiter la dose d’olaparib à 200 mg deux fois par jour."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b207164, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b207158 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b207159 .

_:79f295ad32df4ce8a18a92539c6e8a3b207159 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207160;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b207161 .

_:79f295ad32df4ce8a18a92539c6e8a3b207160 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10659 .

_:79f295ad32df4ce8a18a92539c6e8a3b207161 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207162;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b207162 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10980 .

_:79f295ad32df4ce8a18a92539c6e8a3b207164 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11323-1 a owl:Class;
  rdfs:label "NEUROLEPTIQUES <-> ORLISTAT"@fr;
  dct:identifier "IAM_11323";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b207166;
  r:natureDuRisque "Risque d'échec thérapeutique en cas de traitement concomitant par orlistat."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b207172, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b207166 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b207167 .

_:79f295ad32df4ce8a18a92539c6e8a3b207167 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207168;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b207169 .

_:79f295ad32df4ce8a18a92539c6e8a3b207168 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10124 .

_:79f295ad32df4ce8a18a92539c6e8a3b207169 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207170;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b207170 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10667 .

_:79f295ad32df4ce8a18a92539c6e8a3b207172 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11324-1 a owl:Class;
  rdfs:label "NEUROLEPTIQUES SUSCEPTIBLES DE DONNER DES TORSADES DE POINTES <-> SUBSTANCES SUSCEPTIBLES DE DONNER DES TORSADES DE POINTES"@fr;
  dct:identifier "IAM_11324";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b207174;
  r:chapeau "Ce trouble du rythme cardiaque grave peut être provoqué par un certain nombre de médicaments, antiarythmiques ou non. L'hypokaliémie (cf. médicaments hypokaliémiants) est un facteur favorisant, de même que la bradycardie (cf. médicaments bradycardisants)"@fr;
  r:natureDuRisque "Risque majoré de troubles du rythme ventriculaire, notamment de torsades de pointes."@fr;
  r:conduiteATenir """Contre-indication :
- avec le citalopram, la dompéridone, l'escitalopram, l'hydroxyzine et la pipéraquine.

Association déconseillée:
- avec les autres médicaments susceptibles de donner des torsades de pointes."""@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b207180, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b207174 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b207175 .

_:79f295ad32df4ce8a18a92539c6e8a3b207175 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207176;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b207177 .

_:79f295ad32df4ce8a18a92539c6e8a3b207176 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10127 .

_:79f295ad32df4ce8a18a92539c6e8a3b207177 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207178;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b207178 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10143 .

_:79f295ad32df4ce8a18a92539c6e8a3b207180 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11325-1 a owl:Class;
  rdfs:label "NEVIRAPINE <-> RIFAMPICINE"@fr;
  dct:identifier "IAM_11325";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b207182;
  r:natureDuRisque "Diminution des concentrations plasmatiques de la névirapine par augmentation de son métabolisme hépatique par la rifampicine."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b207188, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b207182 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b207183 .

_:79f295ad32df4ce8a18a92539c6e8a3b207183 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207184;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b207185 .

_:79f295ad32df4ce8a18a92539c6e8a3b207184 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10628 .

_:79f295ad32df4ce8a18a92539c6e8a3b207185 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207186;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b207186 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:79f295ad32df4ce8a18a92539c6e8a3b207188 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11326-1 a owl:Class;
  rdfs:label "NEVIRAPINE <-> VORICONAZOLE"@fr;
  dct:identifier "IAM_11326";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b207190;
  r:natureDuRisque "Risque de baisse de l'efficacité du voriconazole par augmentation de son métabolisme hépatique par la névirapine."@fr;
  r:conduiteATenir "Si l'association ne peut être évitée, surveillance clinique étroite et adaptation éventuelle de la posologie du voriconazole pendant l'association."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b207196, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b207190 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b207191 .

_:79f295ad32df4ce8a18a92539c6e8a3b207191 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207192;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b207193 .

_:79f295ad32df4ce8a18a92539c6e8a3b207192 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10628 .

_:79f295ad32df4ce8a18a92539c6e8a3b207193 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207194;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b207194 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10998 .

_:79f295ad32df4ce8a18a92539c6e8a3b207196 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11327-1 a owl:Class;
  rdfs:label "NIMODIPINE <-> RIFAMPICINE"@fr;
  dct:identifier "IAM_11327";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b207198;
  r:natureDuRisque "Diminution des concentrations plasmatiques de l'antagoniste du calcium par augmentation de son métabolisme hépatique."@fr;
  r:conduiteATenir "Surveillance clinique et adaptation éventuelle de la posologie de l'antagoniste du calcium pendant le traitement par la rifampicine et après son arrêt."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b207204, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b207198 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b207199 .

_:79f295ad32df4ce8a18a92539c6e8a3b207199 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207200;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b207201 .

_:79f295ad32df4ce8a18a92539c6e8a3b207200 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10636 .

_:79f295ad32df4ce8a18a92539c6e8a3b207201 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207202;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b207202 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:79f295ad32df4ce8a18a92539c6e8a3b207204 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11328-1 a owl:Class;
  rdfs:label "NIMODIPINE <-> VALPROÏQUE (ACIDE) ET, PAR EXTRAPOLATION, VALPROMIDE"@fr;
  dct:identifier "IAM_11328";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b207206;
  r:natureDuRisque "Avec la nimodipine par voie orale, et par extrapolation, par voie injectable : risque de majoration de l'effet hypotenseur de la nimodipine par augmentation de ses concentrations plasmatiques (diminution de son métabolisme par l'acide valproïque)."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b207212, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b207206 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b207207 .

_:79f295ad32df4ce8a18a92539c6e8a3b207207 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207208;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b207209 .

_:79f295ad32df4ce8a18a92539c6e8a3b207208 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10160 .

_:79f295ad32df4ce8a18a92539c6e8a3b207209 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207210;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b207210 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10636 .

_:79f295ad32df4ce8a18a92539c6e8a3b207212 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11329-1 a owl:Class;
  rdfs:label "NINTÉDANIB <-> PHÉNYTOÏNE (ET, PAR EXTRAPOLATION, FOSPHÉNYTOÏNE)"@fr;
  dct:identifier "IAM_11329";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b207214;
  r:natureDuRisque "Diminution des concentrations plasmatiques du nintédanib par diminution de son absorption par la phénytoïne ou la fosphénytoïne."@fr;
  r:conduiteATenir "Surveillance clinique pendant l’association."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b207220, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b207214 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b207215 .

_:79f295ad32df4ce8a18a92539c6e8a3b207215 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207216;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b207217 .

_:79f295ad32df4ce8a18a92539c6e8a3b207216 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10132 .

_:79f295ad32df4ce8a18a92539c6e8a3b207217 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207218;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b207218 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10637 .

_:79f295ad32df4ce8a18a92539c6e8a3b207220 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11330-1 a owl:Class;
  rdfs:label "NINTÉDANIB <-> RIFAMPICINE"@fr;
  dct:identifier "IAM_11330";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b207222;
  r:natureDuRisque "Diminution des concentrations plasmatiques du nintédanib par diminution de son absorption par la rifampicine."@fr;
  r:conduiteATenir "Surveillance clinique pendant l’association."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b207228, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b207222 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b207223 .

_:79f295ad32df4ce8a18a92539c6e8a3b207223 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207224;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b207225 .

_:79f295ad32df4ce8a18a92539c6e8a3b207224 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10637 .

_:79f295ad32df4ce8a18a92539c6e8a3b207225 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207226;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b207226 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:79f295ad32df4ce8a18a92539c6e8a3b207228 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11331-1 a owl:Class;
  rdfs:label "NINTÉDANIB <-> VERAPAMIL"@fr;
  dct:identifier "IAM_11331";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b207230;
  r:natureDuRisque "Augmentation des concentrations plasmatiques du nintédanib par augmentation de son absorption par le vérapamil."@fr;
  r:conduiteATenir "Surveillance clinique pendant l’association."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b207236, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b207230 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b207231 .

_:79f295ad32df4ce8a18a92539c6e8a3b207231 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207232;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b207233 .

_:79f295ad32df4ce8a18a92539c6e8a3b207232 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10637 .

_:79f295ad32df4ce8a18a92539c6e8a3b207233 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207234;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b207234 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10980 .

_:79f295ad32df4ce8a18a92539c6e8a3b207236 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11346-1 a owl:Class;
  rdfs:label "OXCARBAZEPINE <-> TOPIRAMATE"@fr;
  dct:identifier "IAM_11346";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b207238;
  r:natureDuRisque "Risque de diminution des concentrations du topiramate avec risque de moindre efficacité, par augmentation de son métabolisme hépatique par l'oxcarbazépine."@fr;
  r:conduiteATenir "Surveillance clinique, et si besoin, adaptation posologique du topiramate pendant le traitement par l'oxcarbazépine et après son arrêt."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b207244, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b207238 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b207239 .

_:79f295ad32df4ce8a18a92539c6e8a3b207239 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207240;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b207241 .

_:79f295ad32df4ce8a18a92539c6e8a3b207240 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10674 .

_:79f295ad32df4ce8a18a92539c6e8a3b207241 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207242;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b207242 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10941 .

_:79f295ad32df4ce8a18a92539c6e8a3b207244 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11333-1 a owl:Class;
  rdfs:label "NORFLOXACINE <-> THÉOPHYLLINE (ET, PAR EXTRAPOLATION, AMINOPHYLLINE)"@fr;
  dct:identifier "IAM_11333";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b207246;
  r:natureDuRisque "Augmentation de la théophyllinémie avec risque de surdosage (diminution du métabolisme de la théophylline)."@fr;
  r:conduiteATenir "Surveillance clinique et éventuellement de la théophyllinémie."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b207252, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b207246 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b207247 .

_:79f295ad32df4ce8a18a92539c6e8a3b207247 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207248;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b207249 .

_:79f295ad32df4ce8a18a92539c6e8a3b207248 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10152 .

_:79f295ad32df4ce8a18a92539c6e8a3b207249 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207250;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b207250 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10650 .

_:79f295ad32df4ce8a18a92539c6e8a3b207252 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11345-1 a owl:Class;
  rdfs:label "OXCARBAZEPINE <-> PÉRAMPANEL"@fr;
  dct:identifier "IAM_11345";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b207254;
  r:natureDuRisque "Diminution de moitié des concentrations de pérampanel et légère augmentation de celles de l’oxcarbazépine."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b207260, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b207254 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b207255 .

_:79f295ad32df4ce8a18a92539c6e8a3b207255 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207256;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b207257 .

_:79f295ad32df4ce8a18a92539c6e8a3b207256 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10674 .

_:79f295ad32df4ce8a18a92539c6e8a3b207257 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207258;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b207258 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10706 .

_:79f295ad32df4ce8a18a92539c6e8a3b207260 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11335-1 a owl:Class;
  rdfs:label "OMBITASVIR + PARITAPRÉVIR <-> PIMOZIDE"@fr;
  dct:identifier "IAM_11335";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b207262;
  r:natureDuRisque "Augmentation des concentrations plasmatiques du pimozide par diminution de son métabolisme hépatique par la bithérapie."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b207268, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b207262 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b207263 .

_:79f295ad32df4ce8a18a92539c6e8a3b207263 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207264;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b207265 .

_:79f295ad32df4ce8a18a92539c6e8a3b207264 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10128 .

_:79f295ad32df4ce8a18a92539c6e8a3b207265 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207266;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b207266 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10721 .

_:79f295ad32df4ce8a18a92539c6e8a3b207268 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11336-1 a owl:Class;
  rdfs:label "OMBITASVIR + PARITAPRÉVIR <-> QUETIAPINE"@fr;
  dct:identifier "IAM_11336";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b207270;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de la quétiapine par diminution de son métabolisme hépatique par la bithérapie."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b207276, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b207270 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b207271 .

_:79f295ad32df4ce8a18a92539c6e8a3b207271 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207272;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b207273 .

_:79f295ad32df4ce8a18a92539c6e8a3b207272 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10128 .

_:79f295ad32df4ce8a18a92539c6e8a3b207273 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207274;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b207274 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10773 .

_:79f295ad32df4ce8a18a92539c6e8a3b207276 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11337-1 a owl:Class;
  rdfs:label "OMBITASVIR + PARITAPRÉVIR <-> QUINIDINE"@fr;
  dct:identifier "IAM_11337";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b207278;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de la quinidine par diminution de son métabolisme hépatique par la bithérapie."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b207284, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b207278 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b207279 .

_:79f295ad32df4ce8a18a92539c6e8a3b207279 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207280;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b207281 .

_:79f295ad32df4ce8a18a92539c6e8a3b207280 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10128 .

_:79f295ad32df4ce8a18a92539c6e8a3b207281 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207282;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b207282 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10776 .

_:79f295ad32df4ce8a18a92539c6e8a3b207284 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11338-1 a owl:Class;
  rdfs:label "OMBITASVIR + PARITAPRÉVIR <-> SILDENAFIL"@fr;
  dct:identifier "IAM_11338";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b207286;
  r:natureDuRisque "Augmentation des concentrations plasmatiques du sildénafil par diminution de son métabolisme hépatique par la bithérapie."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b207292, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b207286 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b207287 .

_:79f295ad32df4ce8a18a92539c6e8a3b207287 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207288;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b207289 .

_:79f295ad32df4ce8a18a92539c6e8a3b207288 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10128 .

_:79f295ad32df4ce8a18a92539c6e8a3b207289 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207290;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b207290 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10834 .

_:79f295ad32df4ce8a18a92539c6e8a3b207292 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11339-1 a owl:Class;
  rdfs:label "OMBITASVIR + PARITAPRÉVIR <-> SIMVASTATINE"@fr;
  dct:identifier "IAM_11339";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b207294;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de la simvastatine par diminution de son métabolisme hépatique par la bithérapie."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b207300, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b207294 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b207295 .

_:79f295ad32df4ce8a18a92539c6e8a3b207295 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207296;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b207297 .

_:79f295ad32df4ce8a18a92539c6e8a3b207296 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10128 .

_:79f295ad32df4ce8a18a92539c6e8a3b207297 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207298;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b207298 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10838 .

_:79f295ad32df4ce8a18a92539c6e8a3b207300 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11340-1 a owl:Class;
  rdfs:label "OMBITASVIR + PARITAPRÉVIR <-> TICAGRELOR"@fr;
  dct:identifier "IAM_11340";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b207302;
  r:natureDuRisque "Augmentation des concentrations plasmatiques du ticagrélor par diminution de son métabolisme hépatique par la bithérapie."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b207308, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b207302 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b207303 .

_:79f295ad32df4ce8a18a92539c6e8a3b207303 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207304;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b207305 .

_:79f295ad32df4ce8a18a92539c6e8a3b207304 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10128 .

_:79f295ad32df4ce8a18a92539c6e8a3b207305 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207306;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b207306 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10926 .

_:79f295ad32df4ce8a18a92539c6e8a3b207308 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11341-1 a owl:Class;
  rdfs:label "OMEPRAZOLE <-> TACROLIMUS"@fr;
  dct:identifier "IAM_11341";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b207310;
  r:natureDuRisque "Augmentation des concentrations sanguines du tacrolimus."@fr;
  r:conduiteATenir "Dosage des concentrations sanguines du tacrolimus, contrôle de la fonction rénale et adaptation de la posologie pendant l'association et après son arrêt."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b207316, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b207310 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b207311 .

_:79f295ad32df4ce8a18a92539c6e8a3b207311 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207312;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b207313 .

_:79f295ad32df4ce8a18a92539c6e8a3b207312 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10664 .

_:79f295ad32df4ce8a18a92539c6e8a3b207313 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207314;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b207314 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10880 .

_:79f295ad32df4ce8a18a92539c6e8a3b207316 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11342-1 a owl:Class;
  rdfs:label "ONDANSETRON <-> SUBSTANCES SUSCEPTIBLES DE DONNER DES TORSADES DE POINTES"@fr;
  dct:identifier "IAM_11342";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b207318;
  r:natureDuRisque """Risque majoré de troubles du rythme ventriculaire, notamment de
torsades de pointes."""@fr;
  r:conduiteATenir "Surveillance clinique et électrocardiographique pendant l'association."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b207324, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b207318 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b207319 .

_:79f295ad32df4ce8a18a92539c6e8a3b207319 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207320;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b207321 .

_:79f295ad32df4ce8a18a92539c6e8a3b207320 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10143 .

_:79f295ad32df4ce8a18a92539c6e8a3b207321 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207322;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b207322 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10665 .

_:79f295ad32df4ce8a18a92539c6e8a3b207324 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11343-1 a owl:Class;
  rdfs:label "ONDANSETRON <-> TRAMADOL"@fr;
  dct:identifier "IAM_11343";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b207326;
  r:natureDuRisque "Diminution de l’intensité et de la durée de l’effet analgésique du tramadol et risque de diminution de l’effet antiémétique de l’ondansétron."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b207332, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b207326 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b207327 .

_:79f295ad32df4ce8a18a92539c6e8a3b207327 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207328;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b207329 .

_:79f295ad32df4ce8a18a92539c6e8a3b207328 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10665 .

_:79f295ad32df4ce8a18a92539c6e8a3b207329 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207330;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b207330 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10945 .

_:79f295ad32df4ce8a18a92539c6e8a3b207332 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11369-1 a owl:Class;
  rdfs:label "PHÉNYTOÏNE (ET, PAR EXTRAPOLATION, FOSPHÉNYTOÏNE) <-> SULFAMETHIZOL"@fr;
  dct:identifier "IAM_11369";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b207334;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de phénytoïne jusqu'à des valeurs toxiques (inhibition de son métabolisme)."@fr;
  r:conduiteATenir "Utiliser de préférence une autre classe d'anti-infectieux, sinon surveillance clinique étroite, dosage des concentrations de phénytoïne et adaptation éventuelle de sa posologie pendant le traitement par le sulfamide anti-infectieux et après son arrêt."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b207340, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b207334 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b207335 .

_:79f295ad32df4ce8a18a92539c6e8a3b207335 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207336;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b207337 .

_:79f295ad32df4ce8a18a92539c6e8a3b207336 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10132 .

_:79f295ad32df4ce8a18a92539c6e8a3b207337 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207338;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b207338 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10870 .

_:79f295ad32df4ce8a18a92539c6e8a3b207340 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11332-1 a owl:Class;
  rdfs:label "NORFLOXACINE <-> SUBSTANCES SUSCEPTIBLES DE DONNER DES TORSADES DE POINTES"@fr;
  dct:identifier "IAM_11332";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b207342;
  r:natureDuRisque "Risque majoré de troubles du rythme ventriculaire, notamment de torsades de pointes."@fr;
  r:conduiteATenir """Surveillance clinique et électrocardiographique pendant
l'association."""@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b207348, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b207342 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b207343 .

_:79f295ad32df4ce8a18a92539c6e8a3b207343 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207344;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b207345 .

_:79f295ad32df4ce8a18a92539c6e8a3b207344 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10143 .

_:79f295ad32df4ce8a18a92539c6e8a3b207345 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207346;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b207346 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10650 .

_:79f295ad32df4ce8a18a92539c6e8a3b207348 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10426-1 a owl:Class;
  rdfs:label "AUTRES RÉTINOÏDES <-> RÉTINOÏDES"@fr;
  dct:identifier "IAM_10426";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b207350;
  r:natureDuRisque "Risque de symptômes évocateurs d’une hypervitaminose A."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b207352, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b207350 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10141 .

_:79f295ad32df4ce8a18a92539c6e8a3b207352 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11367-1 a owl:Class;
  rdfs:label "PHÉNYTOÏNE (ET, PAR EXTRAPOLATION, FOSPHÉNYTOÏNE) <-> SUCRALFATE"@fr;
  dct:identifier "IAM_11367";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b207354;
  r:natureDuRisque "Diminution de l'absorption digestive de la phénytoïne."@fr;
  r:conduiteATenir "Prendre le sucralfate à distance de la phénytoïne (plus de 2 heures, si possible)."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b207360, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b207354 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b207355 .

_:79f295ad32df4ce8a18a92539c6e8a3b207355 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207356;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b207357 .

_:79f295ad32df4ce8a18a92539c6e8a3b207356 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10132 .

_:79f295ad32df4ce8a18a92539c6e8a3b207357 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207358;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b207358 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10864 .

_:79f295ad32df4ce8a18a92539c6e8a3b207360 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11395-1 a owl:Class;
  rdfs:label "QUINIDINE <-> TRICLABENDAZOLE"@fr;
  dct:identifier "IAM_11395";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b207362;
  r:natureDuRisque "Risque majoré de troubles du rythme ventriculaire, notamment de torsades de pointes (inhibition du métabolisme hépatique du médicament torsadogène)."@fr;
  r:conduiteATenir "Respecter un délai de 24 heures entre l’arrêt du triclabendazole et la prise du médicament torsadogène, et inversement."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b207368, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b207362 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b207363 .

_:79f295ad32df4ce8a18a92539c6e8a3b207363 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207364;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b207365 .

_:79f295ad32df4ce8a18a92539c6e8a3b207364 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10776 .

_:79f295ad32df4ce8a18a92539c6e8a3b207365 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207366;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b207366 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10953 .

_:79f295ad32df4ce8a18a92539c6e8a3b207368 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11396-1 a owl:Class;
  rdfs:label "QUINIDINE <-> VERAPAMIL"@fr;
  dct:identifier "IAM_11396";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b207370;
  r:natureDuRisque "Risque de majoration importante des effets hémodynamiques du vérapamil, avec hypotension et bradycardie sévères."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b207376, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b207370 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b207371 .

_:79f295ad32df4ce8a18a92539c6e8a3b207371 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207372;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b207373 .

_:79f295ad32df4ce8a18a92539c6e8a3b207372 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10776 .

_:79f295ad32df4ce8a18a92539c6e8a3b207373 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207374;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b207374 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10980 .

_:79f295ad32df4ce8a18a92539c6e8a3b207376 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11397-1 a owl:Class;
  rdfs:label "QUINIDINE <-> VORICONAZOLE"@fr;
  dct:identifier "IAM_11397";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b207378;
  r:natureDuRisque "Risque majoré de troubles du rythme ventriculaire, notamment de torsades de pointes."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b207384, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b207378 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b207379 .

_:79f295ad32df4ce8a18a92539c6e8a3b207379 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207380;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b207381 .

_:79f295ad32df4ce8a18a92539c6e8a3b207380 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10776 .

_:79f295ad32df4ce8a18a92539c6e8a3b207381 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207382;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b207382 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10998 .

_:79f295ad32df4ce8a18a92539c6e8a3b207384 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11398-1 a owl:Class;
  rdfs:label "QUINIDINE <-> VORTIOXÉTINE"@fr;
  dct:identifier "IAM_11398";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b207386;
  r:natureDuRisque "Risque d’augmentation des effets indésirables de la vortioxétine par diminution importante de son métabolisme hépatique."@fr;
  r:conduiteATenir "Surveillance clinique et adaptation éventuelle de la posologie de la vortioxétine pendant le traitement par la quinidine et après son arrêt."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b207392, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b207386 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b207387 .

_:79f295ad32df4ce8a18a92539c6e8a3b207387 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207388;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b207389 .

_:79f295ad32df4ce8a18a92539c6e8a3b207388 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10776 .

_:79f295ad32df4ce8a18a92539c6e8a3b207389 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207390;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b207390 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10999 .

_:79f295ad32df4ce8a18a92539c6e8a3b207392 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11399-1 a owl:Class;
  rdfs:label "QUININE <-> RIFAMPICINE"@fr;
  dct:identifier "IAM_11399";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b207394;
  r:natureDuRisque "Risque de perte de l’efficacité de la quinine par augmentation de son métabolisme hépatique par l’inducteur."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b207400, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b207394 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b207395 .

_:79f295ad32df4ce8a18a92539c6e8a3b207395 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207396;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b207397 .

_:79f295ad32df4ce8a18a92539c6e8a3b207396 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10777 .

_:79f295ad32df4ce8a18a92539c6e8a3b207397 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207398;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b207398 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:79f295ad32df4ce8a18a92539c6e8a3b207400 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11400-1 a owl:Class;
  rdfs:label "RALTÉGRAVIR <-> RIFAMPICINE"@fr;
  dct:identifier "IAM_11400";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b207402;
  r:natureDuRisque "Diminution des concentrations du raltégravir par la rifampicine."@fr;
  r:conduiteATenir "Si l’association ne peut être évitée, un doublement de la dose de raltégravir peut être envisagé."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b207408, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b207402 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b207403 .

_:79f295ad32df4ce8a18a92539c6e8a3b207403 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207404;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b207405 .

_:79f295ad32df4ce8a18a92539c6e8a3b207404 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10781 .

_:79f295ad32df4ce8a18a92539c6e8a3b207405 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207406;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b207406 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:79f295ad32df4ce8a18a92539c6e8a3b207408 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11401-1 a owl:Class;
  rdfs:label "RANOLAZINE <-> RIFAMPICINE"@fr;
  dct:identifier "IAM_11401";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b207410;
  r:natureDuRisque "Diminution très importante des concentrations de ranolazine."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b207416, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b207410 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b207411 .

_:79f295ad32df4ce8a18a92539c6e8a3b207411 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207412;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b207413 .

_:79f295ad32df4ce8a18a92539c6e8a3b207412 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10786 .

_:79f295ad32df4ce8a18a92539c6e8a3b207413 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207414;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b207414 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:79f295ad32df4ce8a18a92539c6e8a3b207416 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11402-1 a owl:Class;
  rdfs:label "RANOLAZINE <-> SIMVASTATINE"@fr;
  dct:identifier "IAM_11402";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b207418;
  r:natureDuRisque "Risque majoré d'effets indésirables (concentration-dépendants) à type de rhabdomyolyse par inhibition du métabolisme de la simvastatine par la ranolazine."@fr;
  r:conduiteATenir "Ne pas dépasser la posologie de 20 mg/j de simvastatine ou utiliser une autre statine non concernée par ce type d’interaction."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b207424, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b207418 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b207419 .

_:79f295ad32df4ce8a18a92539c6e8a3b207419 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207420;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b207421 .

_:79f295ad32df4ce8a18a92539c6e8a3b207420 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10786 .

_:79f295ad32df4ce8a18a92539c6e8a3b207421 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207422;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b207422 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10838 .

_:79f295ad32df4ce8a18a92539c6e8a3b207424 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11393-1 a owl:Class;
  rdfs:label "QUINIDINE <-> STIRIPENTOL"@fr;
  dct:identifier "IAM_11393";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b207426;
  r:natureDuRisque "Risque majoré de troubles du rythme ventriculaire, notamment de torsades de pointes."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b207432, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b207426 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b207427 .

_:79f295ad32df4ce8a18a92539c6e8a3b207427 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207428;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b207429 .

_:79f295ad32df4ce8a18a92539c6e8a3b207428 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10776 .

_:79f295ad32df4ce8a18a92539c6e8a3b207429 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207430;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b207430 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10859 .

_:79f295ad32df4ce8a18a92539c6e8a3b207432 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11256-1 a owl:Class;
  rdfs:label "MÉDICAMENTS ADMINISTRÉS PAR VOIE ORALE <-> RÉSINES CHÉLATRICES"@fr;
  dct:identifier "IAM_11256";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b207434;
  r:natureDuRisque "La prise de résine chélatrice peut diminuer l’absorption intestinale et, potentiellement, l’efficacité d’autres médicaments pris simultanément."@fr;
  r:conduiteATenir "D’une façon générale, la prise de la résine doit se faire à distance de celle des autres médicaments, en respectant un intervalle de plus de 2 heures, si possible."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b207440, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b207434 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b207435 .

_:79f295ad32df4ce8a18a92539c6e8a3b207435 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207436;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b207437 .

_:79f295ad32df4ce8a18a92539c6e8a3b207436 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10140 .

_:79f295ad32df4ce8a18a92539c6e8a3b207437 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207438;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b207438 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10166 .

_:79f295ad32df4ce8a18a92539c6e8a3b207440 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11392-1 a owl:Class;
  rdfs:label "QUETIAPINE <-> RIFAMPICINE"@fr;
  dct:identifier "IAM_11392";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b207442;
  r:natureDuRisque "Diminution très importante des concentrations plasmatiques de quétiapine par augmentation de son métabolisme hépatique par l'inducteur, avec risque d’inefficacité."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b207448, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b207442 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b207443 .

_:79f295ad32df4ce8a18a92539c6e8a3b207443 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207444;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b207445 .

_:79f295ad32df4ce8a18a92539c6e8a3b207444 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10773 .

_:79f295ad32df4ce8a18a92539c6e8a3b207445 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207446;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b207446 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:79f295ad32df4ce8a18a92539c6e8a3b207448 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11404-1 a owl:Class;
  rdfs:label "RÉTINOÏDES <-> VITAMINE A"@fr;
  dct:identifier "IAM_11404";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b207450;
  r:natureDuRisque "Risque de symptômes évocateurs d’une hypervitaminose A."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b207456, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b207450 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b207451 .

_:79f295ad32df4ce8a18a92539c6e8a3b207451 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207452;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b207453 .

_:79f295ad32df4ce8a18a92539c6e8a3b207452 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10141 .

_:79f295ad32df4ce8a18a92539c6e8a3b207453 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207454;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b207454 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10997 .

_:79f295ad32df4ce8a18a92539c6e8a3b207456 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11405-1 a owl:Class;
  rdfs:label "RIBAVIRINE <-> STAVUDINE"@fr;
  dct:identifier "IAM_11405";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b207458;
  r:natureDuRisque "Risque de diminution de l'efficacité de chaque antiviral, par antagonisme compétitif de la réaction de phosphorylation à l'origine des métabolites actifs."@fr;
  r:conduiteATenir "Surveillance clinique et biologique régulière, notamment en début d'association."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b207464, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b207458 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b207459 .

_:79f295ad32df4ce8a18a92539c6e8a3b207459 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207460;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b207461 .

_:79f295ad32df4ce8a18a92539c6e8a3b207460 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10797 .

_:79f295ad32df4ce8a18a92539c6e8a3b207461 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207462;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b207462 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10858 .

_:79f295ad32df4ce8a18a92539c6e8a3b207464 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11406-1 a owl:Class;
  rdfs:label "RIBAVIRINE <-> ZIDOVUDINE"@fr;
  dct:identifier "IAM_11406";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b207466;
  r:natureDuRisque "Risque de diminution de l'efficacité de chaque antiviral, par antagonisme compétitif de la réaction de phosphorylation à l'origine des métabolites actifs."@fr;
  r:conduiteATenir "Surveillance clinique et biologique régulière, notamment en début d'association."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b207472, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b207466 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b207467 .

_:79f295ad32df4ce8a18a92539c6e8a3b207467 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207468;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b207469 .

_:79f295ad32df4ce8a18a92539c6e8a3b207468 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10797 .

_:79f295ad32df4ce8a18a92539c6e8a3b207469 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207470;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b207470 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_11004 .

_:79f295ad32df4ce8a18a92539c6e8a3b207472 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11407-1 a owl:Class;
  rdfs:label "RIFABUTINE <-> VORICONAZOLE"@fr;
  dct:identifier "IAM_11407";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b207474;
  r:natureDuRisque "Diminution des concentrations plasmatiques du voriconazole avec risque de perte d'efficacité, par augmentation de son métabolisme hépatique par la rifabutine d'une part, et risque d'augmentation des effets indésirables (uvéites) de la rifabutine d'autre p"@fr;
  r:conduiteATenir "Si l'association est jugée néccessaire, surveillance clinique et adaptation de la posologie du voriconazole (en général doublée) pendant le traitement par la rifabutine."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b207480, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b207474 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b207475 .

_:79f295ad32df4ce8a18a92539c6e8a3b207475 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207476;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b207477 .

_:79f295ad32df4ce8a18a92539c6e8a3b207476 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10800 .

_:79f295ad32df4ce8a18a92539c6e8a3b207477 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207478;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b207478 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10998 .

_:79f295ad32df4ce8a18a92539c6e8a3b207480 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11408-1 a owl:Class;
  rdfs:label "RIFAMPICINE <-> RIVAROXABAN"@fr;
  dct:identifier "IAM_11408";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b207482;
  r:natureDuRisque "Diminution des concentrations plasmatiques de rivaroxaban, avec risque de diminution de l'effet thérapeutique."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b207488, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b207482 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b207483 .

_:79f295ad32df4ce8a18a92539c6e8a3b207483 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207484;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b207485 .

_:79f295ad32df4ce8a18a92539c6e8a3b207484 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:79f295ad32df4ce8a18a92539c6e8a3b207485 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207486;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b207486 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10808 .

_:79f295ad32df4ce8a18a92539c6e8a3b207488 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11409-1 a owl:Class;
  rdfs:label "RIFAMPICINE <-> SIMVASTATINE"@fr;
  dct:identifier "IAM_11409";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b207490;
  r:natureDuRisque "Diminution très importante des concentrations plasmatiques de simvastatine, par augmentation de son métabolisme hépatique par la rifampicine."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b207496, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b207490 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b207491 .

_:79f295ad32df4ce8a18a92539c6e8a3b207491 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207492;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b207493 .

_:79f295ad32df4ce8a18a92539c6e8a3b207492 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:79f295ad32df4ce8a18a92539c6e8a3b207493 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207494;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b207494 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10838 .

_:79f295ad32df4ce8a18a92539c6e8a3b207496 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11410-1 a owl:Class;
  rdfs:label "RIFAMPICINE <-> TELAPREVIR"@fr;
  dct:identifier "IAM_11410";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b207498;
  r:natureDuRisque "Diminution très importante des concentrations de télaprévir."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b207504, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b207498 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b207499 .

_:79f295ad32df4ce8a18a92539c6e8a3b207499 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207500;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b207501 .

_:79f295ad32df4ce8a18a92539c6e8a3b207500 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:79f295ad32df4ce8a18a92539c6e8a3b207501 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207502;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b207502 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10887 .

_:79f295ad32df4ce8a18a92539c6e8a3b207504 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11411-1 a owl:Class;
  rdfs:label "RIFAMPICINE <-> TELITHROMYCINE"@fr;
  dct:identifier "IAM_11411";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b207506;
  r:natureDuRisque "Diminution très importante des concentrations plasmatiques de la télithromycine, avec risque d'échec du traitement anti-infectieux, par augmentation du métabolisme hépatique de la télithromycine par la rifampicine."@fr;
  rdfs:comment """La rifampicine est l'un des inducteurs enzymatiques les plus puissants. Administrée avec la télithromycine, elle diminue ses concentrations de 80%.
Le risque important d'échec de l'antibiothérapie justifie une association déconseillée."""@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b207512, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b207506 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b207507 .

_:79f295ad32df4ce8a18a92539c6e8a3b207507 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207508;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b207509 .

_:79f295ad32df4ce8a18a92539c6e8a3b207508 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:79f295ad32df4ce8a18a92539c6e8a3b207509 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207510;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b207510 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10889 .

_:79f295ad32df4ce8a18a92539c6e8a3b207512 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11412-1 a owl:Class;
  rdfs:label "RIFAMPICINE <-> TÉNOFOVIR ALAFÉNAMIDE"@fr;
  dct:identifier "IAM_11412";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b207514;
  r:natureDuRisque "Diminution des concentrations plasmatiques du ténofovir alafénamide par diminution de son absorption par la rifampicine."@fr;
  r:conduiteATenir "Surveillance clinique pendant l’association et 1 à 2 semaines après l’arrêt de la rifampicine."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b207520, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b207514 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b207515 .

_:79f295ad32df4ce8a18a92539c6e8a3b207515 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207516;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b207517 .

_:79f295ad32df4ce8a18a92539c6e8a3b207516 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:79f295ad32df4ce8a18a92539c6e8a3b207517 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207518;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b207518 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10895 .

_:79f295ad32df4ce8a18a92539c6e8a3b207520 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11413-1 a owl:Class;
  rdfs:label "RIFAMPICINE <-> TERBINAFINE"@fr;
  dct:identifier "IAM_11413";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b207522;
  r:natureDuRisque "Diminution des concentrations plasmatiques et de l'efficacité de la terbinafine, par augmentation de son métabolisme hépatique par la rifampicine."@fr;
  r:conduiteATenir "Surveillance clinique. Si besoin, adaptation de la posologie de la terbinafine pendant le traitement par la rifampicine."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b207528, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b207522 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b207523 .

_:79f295ad32df4ce8a18a92539c6e8a3b207523 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207524;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b207525 .

_:79f295ad32df4ce8a18a92539c6e8a3b207524 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:79f295ad32df4ce8a18a92539c6e8a3b207525 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207526;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b207526 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10900 .

_:79f295ad32df4ce8a18a92539c6e8a3b207528 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11403-1 a owl:Class;
  rdfs:label "REPAGLINIDE <-> TRIMETHOPRIME"@fr;
  dct:identifier "IAM_11403";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b207530;
  r:natureDuRisque "Risque d’augmentation des concentrations plasmatiques de répaglinide par inhibition de son métabolisme hépatique par le triméthoprime."@fr;
  r:conduiteATenir "Si l’association ne peut être évitée, surveillance clinique et biologique étroite."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b207536, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b207530 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b207531 .

_:79f295ad32df4ce8a18a92539c6e8a3b207531 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207532;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b207533 .

_:79f295ad32df4ce8a18a92539c6e8a3b207532 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10791 .

_:79f295ad32df4ce8a18a92539c6e8a3b207533 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207534;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b207534 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10955 .

_:79f295ad32df4ce8a18a92539c6e8a3b207536 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11379-1 a owl:Class;
  rdfs:label "POSACONAZOLE <-> RIFAMPICINE"@fr;
  dct:identifier "IAM_11379";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b207538;
  r:natureDuRisque "Diminution des concentrations plasmatiques et de l'efficacité des deux anti-infectieux (induction enzymatique par la rifampicine et diminution de l'absorption intestinale par l’azolé antifongique)."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b207544, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b207538 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b207539 .

_:79f295ad32df4ce8a18a92539c6e8a3b207539 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207540;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b207541 .

_:79f295ad32df4ce8a18a92539c6e8a3b207540 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10741 .

_:79f295ad32df4ce8a18a92539c6e8a3b207541 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207542;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b207542 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:79f295ad32df4ce8a18a92539c6e8a3b207544 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11095-1 a owl:Class;
  rdfs:label "INDUCTEURS ENZYMATIQUES <-> METHADONE"@fr;
  dct:identifier "IAM_11095";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b207546;
  r:natureDuRisque "Diminution des concentrations plasmatiques de méthadone avec risque d'apparition d'un syndrome de sevrage, par augmentation de son métabolisme hépatique."@fr;
  r:conduiteATenir "Augmenter la fréquence des prises de méthadone (2 à 3 fois par jour au lieu d'une fois par jour)."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b207552, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b207546 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b207547 .

_:79f295ad32df4ce8a18a92539c6e8a3b207547 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207548;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b207549 .

_:79f295ad32df4ce8a18a92539c6e8a3b207548 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10094 .

_:79f295ad32df4ce8a18a92539c6e8a3b207549 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207550;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b207550 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10567 .

_:79f295ad32df4ce8a18a92539c6e8a3b207552 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11370-1 a owl:Class;
  rdfs:label "PHÉNYTOÏNE (ET, PAR EXTRAPOLATION, FOSPHÉNYTOÏNE) <-> SULFAMETHOXAZOLE"@fr;
  dct:identifier "IAM_11370";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b207554;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de phénytoïne jusqu'à des valeurs toxiques (inhibition de son métabolisme)."@fr;
  r:conduiteATenir "Utiliser de préférence une autre classe d'anti-infectieux, sinon surveillance clinique étroite, dosage des concentrations de phénytoïne et adaptation éventuelle de sa posologie pendant le traitement par le sulfamide anti-infectieux et après son arrêt."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b207560, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b207554 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b207555 .

_:79f295ad32df4ce8a18a92539c6e8a3b207555 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207556;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b207557 .

_:79f295ad32df4ce8a18a92539c6e8a3b207556 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10132 .

_:79f295ad32df4ce8a18a92539c6e8a3b207557 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207558;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b207558 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10871 .

_:79f295ad32df4ce8a18a92539c6e8a3b207560 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11371-1 a owl:Class;
  rdfs:label "PHÉNYTOÏNE (ET, PAR EXTRAPOLATION, FOSPHÉNYTOÏNE) <-> TICLOPIDINE"@fr;
  dct:identifier "IAM_11371";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b207562;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de phénytoïne avec signes de surdosage (inhibition du métabolisme de la phénytoïne)."@fr;
  r:conduiteATenir "Surveillance clinique et contrôle des concentrations plasmatiques de phénytoïne."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b207568, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b207562 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b207563 .

_:79f295ad32df4ce8a18a92539c6e8a3b207563 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207564;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b207565 .

_:79f295ad32df4ce8a18a92539c6e8a3b207564 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10132 .

_:79f295ad32df4ce8a18a92539c6e8a3b207565 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207566;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b207566 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10928 .

_:79f295ad32df4ce8a18a92539c6e8a3b207568 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11372-1 a owl:Class;
  rdfs:label "PHÉNYTOÏNE (ET, PAR EXTRAPOLATION, FOSPHÉNYTOÏNE) <-> VALPROÏQUE (ACIDE) ET, PAR EXTRAPOLATION, VALPROMIDE"@fr;
  dct:identifier "IAM_11372";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b207570;
  r:natureDuRisque "Augmentation de l'hyperammoniémie, avec risque accru d'encéphalopathie."@fr;
  r:conduiteATenir "Surveillance clinique et biologique régulière."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b207576, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b207570 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b207571 .

_:79f295ad32df4ce8a18a92539c6e8a3b207571 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207572;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b207573 .

_:79f295ad32df4ce8a18a92539c6e8a3b207572 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10132 .

_:79f295ad32df4ce8a18a92539c6e8a3b207573 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207574;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b207574 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10160 .

_:79f295ad32df4ce8a18a92539c6e8a3b207576 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11373-1 a owl:Class;
  rdfs:label "PIMOZIDE <-> QUINUPRISTINE"@fr;
  dct:identifier "IAM_11373";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b207578;
  r:natureDuRisque "Risque majoré de troubles du rythme ventriculaire, notamment de torsades de pointes."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b207584, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b207578 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b207579 .

_:79f295ad32df4ce8a18a92539c6e8a3b207579 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207580;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b207581 .

_:79f295ad32df4ce8a18a92539c6e8a3b207580 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10721 .

_:79f295ad32df4ce8a18a92539c6e8a3b207581 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207582;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b207582 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10778 .

_:79f295ad32df4ce8a18a92539c6e8a3b207584 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11374-1 a owl:Class;
  rdfs:label "PIMOZIDE <-> SERTRALINE"@fr;
  dct:identifier "IAM_11374";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b207586;
  r:natureDuRisque "Risque majoré de troubles du rythme ventriculaire, notamment de torsades de pointes."@fr;
  rdfs:comment """Le pimozide est un neuroleptique métabolisé par le CYP3A4 et à marge thérapeutique étroite. Il peut entraîner des torsades de pointes en cas de surdosage.
Une étude d’interaction pharmacocinétique entre la sertraline et le pimozide a été réalisée chez 15"""@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b207592, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b207586 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b207587 .

_:79f295ad32df4ce8a18a92539c6e8a3b207587 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207588;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b207589 .

_:79f295ad32df4ce8a18a92539c6e8a3b207588 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10721 .

_:79f295ad32df4ce8a18a92539c6e8a3b207589 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207590;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b207590 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10831 .

_:79f295ad32df4ce8a18a92539c6e8a3b207592 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11375-1 a owl:Class;
  rdfs:label "PIMOZIDE <-> STIRIPENTOL"@fr;
  dct:identifier "IAM_11375";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b207594;
  r:natureDuRisque "Risque majoré de troubles du rythme ventriculaire, notamment de torsades de pointes."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b207600, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b207594 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b207595 .

_:79f295ad32df4ce8a18a92539c6e8a3b207595 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207596;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b207597 .

_:79f295ad32df4ce8a18a92539c6e8a3b207596 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10721 .

_:79f295ad32df4ce8a18a92539c6e8a3b207597 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207598;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b207598 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10859 .

_:79f295ad32df4ce8a18a92539c6e8a3b207600 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11376-1 a owl:Class;
  rdfs:label "PIMOZIDE <-> TRICLABENDAZOLE"@fr;
  dct:identifier "IAM_11376";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b207602;
  r:natureDuRisque "Risque majoré de troubles du rythme ventriculaire, notamment de torsades de pointes (inhibition du métabolisme hépatique du médicament torsadogène)."@fr;
  r:conduiteATenir "Respecter un délai de 24 heures entre l’arrêt du triclabendazole et la prise du médicament torsadogène, et inversement."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b207608, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b207602 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b207603 .

_:79f295ad32df4ce8a18a92539c6e8a3b207603 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207604;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b207605 .

_:79f295ad32df4ce8a18a92539c6e8a3b207604 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10721 .

_:79f295ad32df4ce8a18a92539c6e8a3b207605 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207606;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b207606 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10953 .

_:79f295ad32df4ce8a18a92539c6e8a3b207608 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11377-1 a owl:Class;
  rdfs:label "PIOGLITAZONE <-> RIFAMPICINE"@fr;
  dct:identifier "IAM_11377";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b207610;
  r:natureDuRisque """Diminution des concentrations plasmatiques de la glitazone par
augmentation de son métabolisme par la rifampicine."""@fr;
  r:conduiteATenir """Surveillance clinique et biologique ; adaptation de la posologie de la
glitazone pendant le traitement par la rifampicine et après son arrêt."""@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b207616, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b207610 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b207611 .

_:79f295ad32df4ce8a18a92539c6e8a3b207611 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207612;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b207613 .

_:79f295ad32df4ce8a18a92539c6e8a3b207612 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10723 .

_:79f295ad32df4ce8a18a92539c6e8a3b207613 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207614;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b207614 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:79f295ad32df4ce8a18a92539c6e8a3b207616 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11394-1 a owl:Class;
  rdfs:label "QUINIDINE <-> TAMOXIFENE"@fr;
  dct:identifier "IAM_11394";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b207618;
  r:natureDuRisque "Risque de baisse de l'efficacité du tamoxifène, par inhibition de la formation de son métabolite actif par la quinidine."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b207624, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b207618 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b207619 .

_:79f295ad32df4ce8a18a92539c6e8a3b207619 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207620;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b207621 .

_:79f295ad32df4ce8a18a92539c6e8a3b207620 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10776 .

_:79f295ad32df4ce8a18a92539c6e8a3b207621 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207622;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b207622 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10882 .

_:79f295ad32df4ce8a18a92539c6e8a3b207624 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11378-1 a owl:Class;
  rdfs:label "POSACONAZOLE <-> RIFABUTINE"@fr;
  dct:identifier "IAM_11378";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b207626;
  r:natureDuRisque "Risque d'accroissement des effets indésirables de la rifabutine (uvéites), par augmentation de ses concentrations et de celles de son métabolite actif."@fr;
  r:conduiteATenir "Surveillance clinique et biologique régulière, notamment en début d'association."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b207632, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b207626 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b207627 .

_:79f295ad32df4ce8a18a92539c6e8a3b207627 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207628;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b207629 .

_:79f295ad32df4ce8a18a92539c6e8a3b207628 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10741 .

_:79f295ad32df4ce8a18a92539c6e8a3b207629 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207630;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b207630 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10800 .

_:79f295ad32df4ce8a18a92539c6e8a3b207632 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11368-1 a owl:Class;
  rdfs:label "PHÉNYTOÏNE (ET, PAR EXTRAPOLATION, FOSPHÉNYTOÏNE) <-> SULFAFURAZOL"@fr;
  dct:identifier "IAM_11368";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b207634;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de phénytoïne jusqu'à des valeurs toxiques (inhibition de son métabolisme)."@fr;
  r:conduiteATenir "Utiliser de préférence une autre classe d'anti-infectieux, sinon surveillance clinique étroite, dosage des concentrations de phénytoïne et adaptation éventuelle de sa posologie pendant le traitement par le sulfamide anti-infectieux et après son arrêt."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b207640, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b207634 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b207635 .

_:79f295ad32df4ce8a18a92539c6e8a3b207635 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207636;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b207637 .

_:79f295ad32df4ce8a18a92539c6e8a3b207636 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10132 .

_:79f295ad32df4ce8a18a92539c6e8a3b207637 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207638;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b207638 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10868 .

_:79f295ad32df4ce8a18a92539c6e8a3b207640 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11380-1 a owl:Class;
  rdfs:label "POSACONAZOLE <-> SIMVASTATINE"@fr;
  dct:identifier "IAM_11380";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b207642;
  r:natureDuRisque "Risque majoré d'effets indésirables (concentration-dépendants) à type de rhabdomyolyse (diminution du métabolisme hépatique de l’inhibiteur de l’HMG-CoA reductase)."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b207648, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b207642 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b207643 .

_:79f295ad32df4ce8a18a92539c6e8a3b207643 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207644;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b207645 .

_:79f295ad32df4ce8a18a92539c6e8a3b207644 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10741 .

_:79f295ad32df4ce8a18a92539c6e8a3b207645 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207646;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b207646 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10838 .

_:79f295ad32df4ce8a18a92539c6e8a3b207648 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11382-1 a owl:Class;
  rdfs:label "POTASSIUM <-> TACROLIMUS"@fr;
  dct:identifier "IAM_11382";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b207650;
  r:natureDuRisque "Hyperkaliémie essentiellement létale, surtout lors d'une insuffisance rénale (addition des effets hyperkaliémiants)."@fr;
  r:conduiteATenir "Eviter cette association sauf s'il existe une hypokaliémie préalable."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b207656, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b207650 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b207651 .

_:79f295ad32df4ce8a18a92539c6e8a3b207651 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207652;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b207653 .

_:79f295ad32df4ce8a18a92539c6e8a3b207652 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10742 .

_:79f295ad32df4ce8a18a92539c6e8a3b207653 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207654;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b207654 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10880 .

_:79f295ad32df4ce8a18a92539c6e8a3b207656 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11383-1 a owl:Class;
  rdfs:label "PRAZIQUANTEL <-> RIFAMPICINE"@fr;
  dct:identifier "IAM_11383";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b207658;
  r:natureDuRisque "Diminution très importante des concentrations plasmatiques du praziquantel, avec risque d'échec du traitement, par augmentation du métabolisme hépatique du praziquantel par la rifampicine."@fr;
  rdfs:comment """Une étude montre que l'effet inducteur puissant de la rifampicine retentit de façon majeure sur le métabolisme du praziquantel, avec une diminution de l'AUC de 90%.
Bien que la durée du traitement antiparasitaire soit brève, une association déconseillée s"""@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b207664, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b207658 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b207659 .

_:79f295ad32df4ce8a18a92539c6e8a3b207659 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207660;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b207661 .

_:79f295ad32df4ce8a18a92539c6e8a3b207660 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10750 .

_:79f295ad32df4ce8a18a92539c6e8a3b207661 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207662;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b207662 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:79f295ad32df4ce8a18a92539c6e8a3b207664 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11385-1 a owl:Class;
  rdfs:label "PROGESTATIFS CONTRACEPTIFS <-> ULIPRISTAL"@fr;
  dct:identifier "IAM_11385";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b207666;
  r:natureDuRisque "Risque d'antagonisme des effets du progestatif."@fr;
  r:conduiteATenir "Utiliser une méthode contraceptive additionnelle de type mécanique pendant quelques jours après l’arrêt de l’ulipristal."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b207672, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b207666 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b207667 .

_:79f295ad32df4ce8a18a92539c6e8a3b207667 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207668;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b207669 .

_:79f295ad32df4ce8a18a92539c6e8a3b207668 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10134 .

_:79f295ad32df4ce8a18a92539c6e8a3b207669 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207670;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b207670 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10964 .

_:79f295ad32df4ce8a18a92539c6e8a3b207672 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11386-1 a owl:Class;
  rdfs:label "PROGESTATIFS NON CONTRACEPTIFS, ASSOCIÉS OU NON À UN ESTROGÈNE <-> ULIPRISTAL"@fr;
  dct:identifier "IAM_11386";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b207674;
  r:natureDuRisque "Risque d'antagonisme des effets du progestatif."@fr;
  r:conduiteATenir "Utiliser une méthode contraceptive additionnelle de type mécanique pendant quelques jours après l’arrêt de l’ulipristal."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b207680, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b207674 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b207675 .

_:79f295ad32df4ce8a18a92539c6e8a3b207675 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207676;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b207677 .

_:79f295ad32df4ce8a18a92539c6e8a3b207676 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10135 .

_:79f295ad32df4ce8a18a92539c6e8a3b207677 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207678;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b207678 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10964 .

_:79f295ad32df4ce8a18a92539c6e8a3b207680 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11387-1 a owl:Class;
  rdfs:label "PROPAFENONE <-> RIFAMPICINE"@fr;
  dct:identifier "IAM_11387";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b207682;
  r:natureDuRisque "Diminution des concentrations plasmatiques de la propafénone, par augmentation de son métabolisme hépatique par la rifampicine."@fr;
  r:conduiteATenir "Surveillance clinique et ECG. S'il y a lieu, adaptation de la posologie de la propafénone pendant l'association et après l'arrêt de la rifampicine."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b207688, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b207682 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b207683 .

_:79f295ad32df4ce8a18a92539c6e8a3b207683 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207684;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b207685 .

_:79f295ad32df4ce8a18a92539c6e8a3b207684 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10765 .

_:79f295ad32df4ce8a18a92539c6e8a3b207685 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207686;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b207686 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:79f295ad32df4ce8a18a92539c6e8a3b207688 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11388-1 a owl:Class;
  rdfs:label "PROPAFENONE <-> TERBINAFINE"@fr;
  dct:identifier "IAM_11388";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b207690;
  r:natureDuRisque "Risque d'augmentation des effets indésirables de la propafénone, par diminution de son métabolisme hépatique par la terbinafine."@fr;
  r:conduiteATenir "Surveillance clinique. Si besoin, adaptation de la posologie de la propafénone pendant le traitement par la terbinafine."@fr;
  rdfs:comment """L’effet inhibiteur enzymatique de la terbinafine sur le CYP2D6 a été suggéré sur l’observation chez 12 volontaires sains d’une diminution du métabolisme hépatique de la désipramine, marqueur de l’activité de ce cytochrome.
Afin de prendre acte de cet effe"""@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b207696, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b207690 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b207691 .

_:79f295ad32df4ce8a18a92539c6e8a3b207691 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207692;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b207693 .

_:79f295ad32df4ce8a18a92539c6e8a3b207692 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10765 .

_:79f295ad32df4ce8a18a92539c6e8a3b207693 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207694;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b207694 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10900 .

_:79f295ad32df4ce8a18a92539c6e8a3b207696 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11389-1 a owl:Class;
  rdfs:label "PROPAFENONE <-> THEOPHYLLINE"@fr;
  dct:identifier "IAM_11389";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b207698;
  r:natureDuRisque "Risque d’augmentation de la théophyllinémie par diminution de son métabolisme hépatique par la propafénone."@fr;
  r:conduiteATenir "Surveillance clinique et éventuellement de la théophyllinémie."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b207704, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b207698 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b207699 .

_:79f295ad32df4ce8a18a92539c6e8a3b207699 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207700;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b207701 .

_:79f295ad32df4ce8a18a92539c6e8a3b207700 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10765 .

_:79f295ad32df4ce8a18a92539c6e8a3b207701 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207702;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b207702 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10915 .

_:79f295ad32df4ce8a18a92539c6e8a3b207704 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11390-1 a owl:Class;
  rdfs:label "PROPRANOLOL <-> RIFAMPICINE"@fr;
  dct:identifier "IAM_11390";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b207706;
  r:natureDuRisque "Diminution des concentrations plasmatiques et de l'efficacité du bêta-bloquant (augmentation de son métabolisme hépatique)."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b207712, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b207706 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b207707 .

_:79f295ad32df4ce8a18a92539c6e8a3b207707 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207708;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b207709 .

_:79f295ad32df4ce8a18a92539c6e8a3b207708 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10767 .

_:79f295ad32df4ce8a18a92539c6e8a3b207709 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207710;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b207710 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:79f295ad32df4ce8a18a92539c6e8a3b207712 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11391-1 a owl:Class;
  rdfs:label "PYRIMETHAMINE <-> TRIMETHOPRIME"@fr;
  dct:identifier "IAM_11391";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b207714;
  r:natureDuRisque "Anémie mégaloblastique, plus particulièrement à fortes doses des deux produits (déficit en acide folique par l'association de deux 2-4 diaminopyrimidines)."@fr;
  r:conduiteATenir "Contrôle régulier de l'hémogramme et association d'un traitement par l'acide folique (injections IM régulières)."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b207720, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b207714 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b207715 .

_:79f295ad32df4ce8a18a92539c6e8a3b207715 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207716;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b207717 .

_:79f295ad32df4ce8a18a92539c6e8a3b207716 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10772 .

_:79f295ad32df4ce8a18a92539c6e8a3b207717 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207718;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b207718 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10955 .

_:79f295ad32df4ce8a18a92539c6e8a3b207720 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11381-1 a owl:Class;
  rdfs:label "POSACONAZOLE <-> VINCA-ALCALOÏDES CYTOTOXIQUES"@fr;
  dct:identifier "IAM_11381";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b207722;
  r:natureDuRisque "Majoration de la neurotoxicité de l'antimitotique, par diminution de son métabolisme hépatique par le posaconazole."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b207728, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b207722 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b207723 .

_:79f295ad32df4ce8a18a92539c6e8a3b207723 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207724;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b207725 .

_:79f295ad32df4ce8a18a92539c6e8a3b207724 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10161 .

_:79f295ad32df4ce8a18a92539c6e8a3b207725 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207726;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b207726 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10741 .

_:79f295ad32df4ce8a18a92539c6e8a3b207728 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10823-1 a owl:Class;
  rdfs:label "DIURÉTIQUES DE L'ANSE <-> LITHIUM"@fr;
  dct:identifier "IAM_10823";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b207730;
  r:natureDuRisque "Augmentation de la lithémie avec signes de surdosage en lithium, comme lors d’un régime désodé (diminution de l’excrétion urinaire du lithium)."@fr;
  r:conduiteATenir "Si l'association ne peut être évitée, surveillance stricte de la lithémie et adaptation de la posologie du lithium."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b207736, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b207730 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b207731 .

_:79f295ad32df4ce8a18a92539c6e8a3b207731 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207732;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b207733 .

_:79f295ad32df4ce8a18a92539c6e8a3b207732 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10064 .

_:79f295ad32df4ce8a18a92539c6e8a3b207733 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207734;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b207734 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10530 .

_:79f295ad32df4ce8a18a92539c6e8a3b207736 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10812-1 a owl:Class;
  rdfs:label "DIMÉTHYLE ( FUMARATE DE) <-> VACCINS VIVANTS ATTÉNUÉS"@fr;
  dct:identifier "IAM_10812";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b207738;
  r:natureDuRisque "Possible augmentation du risque infectieux."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b207744, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b207738 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b207739 .

_:79f295ad32df4ce8a18a92539c6e8a3b207739 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207740;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b207741 .

_:79f295ad32df4ce8a18a92539c6e8a3b207740 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10159 .

_:79f295ad32df4ce8a18a92539c6e8a3b207741 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207742;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b207742 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10292 .

_:79f295ad32df4ce8a18a92539c6e8a3b207744 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10813-1 a owl:Class;
  rdfs:label "DIPROPHYLLINE <-> PROBENECIDE"@fr;
  dct:identifier "IAM_10813";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b207746;
  r:natureDuRisque "Risque de surdosage par augmentation des concentrations plasmatiques de diprophylline (inhibition de sa sécrétion tubulaire rénale)."@fr;
  r:conduiteATenir "Réduire la posologie de diprophylline pendant le traitement par le probénécide."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b207752, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b207746 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b207747 .

_:79f295ad32df4ce8a18a92539c6e8a3b207747 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207748;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b207749 .

_:79f295ad32df4ce8a18a92539c6e8a3b207748 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10296 .

_:79f295ad32df4ce8a18a92539c6e8a3b207749 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207750;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b207750 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10758 .

_:79f295ad32df4ce8a18a92539c6e8a3b207752 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10814-1 a owl:Class;
  rdfs:label "DIPYRIDAMOLE <-> THÉINE"@fr;
  dct:identifier "IAM_10814";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b207754;
  r:natureDuRisque "Avec le dipyridamole par voie injectable : réduction de l’effet vasodilatateur du dipyridamole par la théine."@fr;
  r:conduiteATenir "Eviter la consommation de produits à base de théine dans les 24 heures qui précèdent une imagerie myocardique avec le dipyridamole."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b207760, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b207754 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b207755 .

_:79f295ad32df4ce8a18a92539c6e8a3b207755 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207756;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b207757 .

_:79f295ad32df4ce8a18a92539c6e8a3b207756 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10297 .

_:79f295ad32df4ce8a18a92539c6e8a3b207757 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207758;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b207758 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_11014 .

_:79f295ad32df4ce8a18a92539c6e8a3b207760 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10815-1 a owl:Class;
  rdfs:label "DIPYRIDAMOLE <-> THÉOPHYLLINE (ET, PAR EXTRAPOLATION, AMINOPHYLLINE)"@fr;
  dct:identifier "IAM_10815";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b207762;
  r:natureDuRisque "Avec le dipyridamole par voie injectable : réduction de l’effet vasodilatateur du dipyridamole par la théophylline."@fr;
  r:conduiteATenir "Interrompre un traitement par théophylline au moins 5 jours avant une imagerie myocardique avec le dipyridamole."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b207768, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b207762 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b207763 .

_:79f295ad32df4ce8a18a92539c6e8a3b207763 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207764;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b207765 .

_:79f295ad32df4ce8a18a92539c6e8a3b207764 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10152 .

_:79f295ad32df4ce8a18a92539c6e8a3b207765 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207766;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b207766 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10297 .

_:79f295ad32df4ce8a18a92539c6e8a3b207768 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10816-1 a owl:Class;
  rdfs:label "DISOPYRAMIDE <-> INDUCTEURS ENZYMATIQUES"@fr;
  dct:identifier "IAM_10816";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b207770;
  r:natureDuRisque "Risque de diminution des concentrations du disopyramide par l’inducteur."@fr;
  r:conduiteATenir "Surveillance clinique et éventuellement adaptation de la posologie du disopyramide pendant l’associaiton et 1 à 2 semaines après l’arrêt de l’inducteur."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b207776, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b207770 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b207771 .

_:79f295ad32df4ce8a18a92539c6e8a3b207771 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207772;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b207773 .

_:79f295ad32df4ce8a18a92539c6e8a3b207772 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10094 .

_:79f295ad32df4ce8a18a92539c6e8a3b207773 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207774;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b207774 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10298 .

_:79f295ad32df4ce8a18a92539c6e8a3b207776 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10817-1 a owl:Class;
  rdfs:label "DISOPYRAMIDE <-> INHIBITEURS PUISSANTS DU CYP3A4"@fr;
  dct:identifier "IAM_10817";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b207778;
  r:natureDuRisque "Risque d’augmentation des effets indésirables du disopyramide par diminution de son métabolisme."@fr;
  r:conduiteATenir "Surveillance clinique et adaptation éventuelle de la posologie du disopyramide."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b207784, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b207778 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b207779 .

_:79f295ad32df4ce8a18a92539c6e8a3b207779 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207780;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b207781 .

_:79f295ad32df4ce8a18a92539c6e8a3b207780 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10103 .

_:79f295ad32df4ce8a18a92539c6e8a3b207781 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207782;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b207782 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10298 .

_:79f295ad32df4ce8a18a92539c6e8a3b207784 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10818-1 a owl:Class;
  rdfs:label "DISOPYRAMIDE <-> JOSAMYCINE"@fr;
  dct:identifier "IAM_10818";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b207786;
  r:natureDuRisque "Risque de majoration des effets indésirables du disopyramide : hypoglycémies sévères, allongement de l’intervalle QT et troubles du rythme ventriculaire graves, notamment à type de torsades de pointes."@fr;
  r:conduiteATenir "Surveillance clinique, biologique et électrocardiographique régulière."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b207792, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b207786 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b207787 .

_:79f295ad32df4ce8a18a92539c6e8a3b207787 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207788;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b207789 .

_:79f295ad32df4ce8a18a92539c6e8a3b207788 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10298 .

_:79f295ad32df4ce8a18a92539c6e8a3b207789 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207790;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b207790 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10499 .

_:79f295ad32df4ce8a18a92539c6e8a3b207792 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10819-1 a owl:Class;
  rdfs:label "DISULFIRAME <-> ISONIAZIDE"@fr;
  dct:identifier "IAM_10819";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b207794;
  r:natureDuRisque "Troubles du comportement et de la coordination."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b207800, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b207794 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b207795 .

_:79f295ad32df4ce8a18a92539c6e8a3b207795 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207796;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b207797 .

_:79f295ad32df4ce8a18a92539c6e8a3b207796 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10299 .

_:79f295ad32df4ce8a18a92539c6e8a3b207797 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207798;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b207798 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10490 .

_:79f295ad32df4ce8a18a92539c6e8a3b207800 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10820-1 a owl:Class;
  rdfs:label "DISULFIRAME <-> METRONIDAZOLE"@fr;
  dct:identifier "IAM_10820";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b207802;
  r:natureDuRisque "Risque d’épisodes de psychose aiguë ou d’état confusionnel, réversibles à l’arrêt de l’association."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b207808, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b207802 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b207803 .

_:79f295ad32df4ce8a18a92539c6e8a3b207803 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207804;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b207805 .

_:79f295ad32df4ce8a18a92539c6e8a3b207804 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10299 .

_:79f295ad32df4ce8a18a92539c6e8a3b207805 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207806;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b207806 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10580 .

_:79f295ad32df4ce8a18a92539c6e8a3b207808 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10786-1 a owl:Class;
  rdfs:label "DIGOXINE <-> RANOLAZINE"@fr;
  dct:identifier "IAM_10786";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b207810;
  r:natureDuRisque "Augmentation de la digoxinémie."@fr;
  r:conduiteATenir "Surveillance clinique, biologique et éventuellement ECG. Adaptation de la posologie de la digoxine, si besoin."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b207816, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b207810 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b207811 .

_:79f295ad32df4ce8a18a92539c6e8a3b207811 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207812;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b207813 .

_:79f295ad32df4ce8a18a92539c6e8a3b207812 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10286 .

_:79f295ad32df4ce8a18a92539c6e8a3b207813 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207814;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b207814 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10786 .

_:79f295ad32df4ce8a18a92539c6e8a3b207816 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10822-1 a owl:Class;
  rdfs:label "DIURÉTIQUES <-> PRODUITS DE CONTRASTE IODÉS"@fr;
  dct:identifier "IAM_10822";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b207818;
  r:natureDuRisque "En cas de déshydratation provoquée par les diurétiques, risque majoré d'insuffisance rénale fonctionnelle aiguë, en particulier lors d'utilisation de doses importantes de produits de contraste iodés."@fr;
  r:conduiteATenir "Réhydratation avant administration du produit iodé."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b207824, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b207818 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b207819 .

_:79f295ad32df4ce8a18a92539c6e8a3b207819 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207820;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b207821 .

_:79f295ad32df4ce8a18a92539c6e8a3b207820 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10063 .

_:79f295ad32df4ce8a18a92539c6e8a3b207821 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207822;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b207822 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10133 .

_:79f295ad32df4ce8a18a92539c6e8a3b207824 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10809-1 a owl:Class;
  rdfs:label "DILTIAZEM <-> SIMVASTATINE"@fr;
  dct:identifier "IAM_10809";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b207826;
  r:natureDuRisque "Risque majoré d'effets indésirables (concentration-dépendants) à type de rhabdomyolyse, par diminution du métabolisme hépatique de l'hypocholestérolémiant."@fr;
  r:conduiteATenir "Ne pas dépasser la posologie de 20 mg/jour de simvastatine. Si l'objectif thérapeutique n'est pas atteint à cette posologie, utiliser une autre statine non concernée par ce type d'interaction."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b207832, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b207826 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b207827 .

_:79f295ad32df4ce8a18a92539c6e8a3b207827 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207828;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b207829 .

_:79f295ad32df4ce8a18a92539c6e8a3b207828 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10290 .

_:79f295ad32df4ce8a18a92539c6e8a3b207829 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207830;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b207830 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10838 .

_:79f295ad32df4ce8a18a92539c6e8a3b207832 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10824-1 a owl:Class;
  rdfs:label "DIURÉTIQUES DE L'ANSE <-> METFORMINE"@fr;
  dct:identifier "IAM_10824";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b207834;
  r:natureDuRisque "Acidose lactique due à la metformine, déclenchée par une éventuelle insuffisance rénale fonctionnelle, liée aux diurétiques de l'anse."@fr;
  r:conduiteATenir "Ne pas utiliser la metformine lorsque la créatininémie dépasse 15 mg/l (135 µmol/l) chez l'homme, et 12 mg/l (110 µmol/l) chez la femme."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b207840, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b207834 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b207835 .

_:79f295ad32df4ce8a18a92539c6e8a3b207835 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207836;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b207837 .

_:79f295ad32df4ce8a18a92539c6e8a3b207836 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10064 .

_:79f295ad32df4ce8a18a92539c6e8a3b207837 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207838;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b207838 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10566 .

_:79f295ad32df4ce8a18a92539c6e8a3b207840 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10825-1 a owl:Class;
  rdfs:label "DIURÉTIQUES DE L'ANSE <-> ORGANOPLATINES"@fr;
  dct:identifier "IAM_10825";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b207842;
  r:natureDuRisque "Risque d’addition des effets ototoxiques et/ou néphrotoxiques."@fr;
  rdfs:comment """La néphrotoxicité et l’ototoxicité des organoplatines, cytotoxiques majoritairement éliminés par voie rénale, sont bien documentées. L’administration concomitante avec un médicament diminuant leur élimination rénale peut majorer ce risque.
En favorisant l"""@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b207848, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b207842 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b207843 .

_:79f295ad32df4ce8a18a92539c6e8a3b207843 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207844;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b207845 .

_:79f295ad32df4ce8a18a92539c6e8a3b207844 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10064 .

_:79f295ad32df4ce8a18a92539c6e8a3b207845 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207846;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b207846 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10129 .

_:79f295ad32df4ce8a18a92539c6e8a3b207848 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10413-1 a owl:Class;
  rdfs:label "AUTRES DIURÉTIQUES ÉPARGNEURS DE POTASSIUM (SEULS OU ASSOCIÉS) <-> DIURÉTIQUES ÉPARGNEURS DE POTASSIUM (SEULS OU ASSOCIÉS)"@fr;
  dct:identifier "IAM_10413";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b207850;
  r:natureDuRisque "Hyperkaliémie potentiellement létale, notamment chez l'insuffisant rénal (addition des effets hyperkaliémiants)."@fr;
  r:conduiteATenir "Contre-indiqué sauf s'il existe une hypokaliémie."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b207852, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b207850 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10067 .

_:79f295ad32df4ce8a18a92539c6e8a3b207852 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10830-1 a owl:Class;
  rdfs:label "DIURÉTIQUES HYPOKALIÉMIANTS <-> DIURÉTIQUES ÉPARGNEURS DE POTASSIUM (SEULS OU ASSOCIÉS)"@fr;
  dct:identifier "IAM_10830";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b207854;
  r:natureDuRisque "L'association rationnelle, utile pour certains patients, n'exclut pas la survenue d'hypokaliémie ou, en particulier chez l'insuffisant rénal et le diabétique, d'hyperkaliémie."@fr;
  r:conduiteATenir "Surveiller la kaliémie, éventuellement l'ECG et, s'il y a lieu, reconsidérer le traitement."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b207860, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b207854 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b207855 .

_:79f295ad32df4ce8a18a92539c6e8a3b207855 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207856;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b207857 .

_:79f295ad32df4ce8a18a92539c6e8a3b207856 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10065 .

_:79f295ad32df4ce8a18a92539c6e8a3b207857 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207858;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b207858 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10067 .

_:79f295ad32df4ce8a18a92539c6e8a3b207860 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10826-1 a owl:Class;
  rdfs:label "DIURÉTIQUES ÉPARGNEURS DE POTASSIUM (SEULS OU ASSOCIÉS) <-> INHIBITEURS DE L'ENZYME DE CONVERSION"@fr;
  dct:identifier "IAM_10826";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b207862;
  r:natureDuRisque "Risque d'hyperkaliémie (potentiellement létale) surtout en cas d'insuffisance rénale (addition des effets hyperkaliémiants)."@fr;
  r:conduiteATenir """Précaution d'emploi :
- pour la spironolactone à des doses comprises entre 12,5 mg et 50 mg/jour, et pour l’éplérénone utilisées dans le traitement de l'insuffisance cardiaque, ainsi qu'en cas d'hypokaliémie : contrôle strict de la kaliémie et de la fonct"""@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b207868, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b207862 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b207863 .

_:79f295ad32df4ce8a18a92539c6e8a3b207863 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207864;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b207865 .

_:79f295ad32df4ce8a18a92539c6e8a3b207864 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10067 .

_:79f295ad32df4ce8a18a92539c6e8a3b207865 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207866;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b207866 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10096 .

_:79f295ad32df4ce8a18a92539c6e8a3b207868 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10827-1 a owl:Class;
  rdfs:label "DIURÉTIQUES ÉPARGNEURS DE POTASSIUM (SEULS OU ASSOCIÉS) <-> LITHIUM"@fr;
  dct:identifier "IAM_10827";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b207870;
  r:natureDuRisque "Augmentation de la lithémie avec signes de surdosage en lithium, comme lors d’un régime désodé (diminution de l’excrétion urinaire du lithium)."@fr;
  r:conduiteATenir "Surveillance stricte de la lithémie et adaptation éventuelle de la posologie du lithium."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b207876, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b207870 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b207871 .

_:79f295ad32df4ce8a18a92539c6e8a3b207871 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207872;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b207873 .

_:79f295ad32df4ce8a18a92539c6e8a3b207872 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10067 .

_:79f295ad32df4ce8a18a92539c6e8a3b207873 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207874;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b207874 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10530 .

_:79f295ad32df4ce8a18a92539c6e8a3b207876 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10828-1 a owl:Class;
  rdfs:label "DIURÉTIQUES ÉPARGNEURS DE POTASSIUM (SEULS OU ASSOCIÉS) <-> POTASSIUM"@fr;
  dct:identifier "IAM_10828";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b207878;
  r:natureDuRisque "Hyperkaliémie potentiellement létale, notamment chez l'insuffisant rénal (addition des effets hyperkaliémiants)."@fr;
  r:conduiteATenir "Association déconseillée:-en cas d'hypokaliémie ou d'utilisation parentérale des sels de potassium"@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b207884, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b207878 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b207879 .

_:79f295ad32df4ce8a18a92539c6e8a3b207879 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207880;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b207881 .

_:79f295ad32df4ce8a18a92539c6e8a3b207880 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10067 .

_:79f295ad32df4ce8a18a92539c6e8a3b207881 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207882;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b207882 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10742 .

_:79f295ad32df4ce8a18a92539c6e8a3b207884 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10829-1 a owl:Class;
  rdfs:label "DIURÉTIQUES ÉPARGNEURS DE POTASSIUM (SEULS OU ASSOCIÉS) <-> TACROLIMUS"@fr;
  dct:identifier "IAM_10829";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b207886;
  r:natureDuRisque "Hyperkaliémie potentiellement létale, surtout lors d'une insuffisance rénale (addition des effets hyperkaliémiants)."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b207892, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b207886 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b207887 .

_:79f295ad32df4ce8a18a92539c6e8a3b207887 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207888;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b207889 .

_:79f295ad32df4ce8a18a92539c6e8a3b207888 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10067 .

_:79f295ad32df4ce8a18a92539c6e8a3b207889 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207890;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b207890 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10880 .

_:79f295ad32df4ce8a18a92539c6e8a3b207892 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10831-1 a owl:Class;
  rdfs:label "DIURÉTIQUES HYPOKALIÉMIANTS <-> INHIBITEURS DE L'ENZYME DE CONVERSION"@fr;
  dct:identifier "IAM_10831";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b207894;
  r:natureDuRisque "Risque d'hypotension artérielle brutale et/ou d'insuffisance rénale aiguë lors de l'instauration ou de l'augmentation de la posologie d'un traitement par un inhibiteur de l'enzyme de conversion en cas de déplétion hydrosodée préexistante."@fr;
  r:conduiteATenir """Dans l'hypertension artérielle, lorsqu'un traitement diurétique préalable a pu entraîner une déplétion hydrosodée, il faut : 
- soit arrêter le diurétique avant de débuter le traitement par l'IEC, et réintroduire un diurétique hypokaliémiant si nécessaire"""@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b207900, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b207894 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b207895 .

_:79f295ad32df4ce8a18a92539c6e8a3b207895 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207896;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b207897 .

_:79f295ad32df4ce8a18a92539c6e8a3b207896 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10065 .

_:79f295ad32df4ce8a18a92539c6e8a3b207897 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207898;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b207898 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10096 .

_:79f295ad32df4ce8a18a92539c6e8a3b207900 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10821-1 a owl:Class;
  rdfs:label "DISULFIRAME <-> PHÉNYTOÏNE (ET, PAR EXTRAPOLATION, FOSPHÉNYTOÏNE)"@fr;
  dct:identifier "IAM_10821";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b207902;
  r:natureDuRisque "Augmentation importante et rapide des concentrations plasmatiques de phénytoïne avec signes toxiques (inhibition de son métabolisme)."@fr;
  r:conduiteATenir "Si elle ne peut être évitée, contrôle clinique et des concentrations plasmatiques de phénytoïne pendant le traitement par le disulfirame et après son arrêt."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b207908, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b207902 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b207903 .

_:79f295ad32df4ce8a18a92539c6e8a3b207903 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207904;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b207905 .

_:79f295ad32df4ce8a18a92539c6e8a3b207904 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10132 .

_:79f295ad32df4ce8a18a92539c6e8a3b207905 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207906;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b207906 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10299 .

_:79f295ad32df4ce8a18a92539c6e8a3b207908 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10799-1 a owl:Class;
  rdfs:label "DILTIAZEM <-> DRONEDARONE"@fr;
  dct:identifier "IAM_10799";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b207910;
  r:natureDuRisque "Risque de bradycardie ou de bloc auriculo-ventriculaire, notamment chez le sujet âgé. Par ailleurs, légère augmentation des concentrations de dronédarone par diminution de son métabolisme par l’antagoniste des canaux calciques."@fr;
  r:conduiteATenir "Débuter le traitement par l’antagoniste calcique aux posologies minimales recommandées, et ajuster les doses en fonction de l’ECG."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b207916, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b207910 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b207911 .

_:79f295ad32df4ce8a18a92539c6e8a3b207911 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207912;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b207913 .

_:79f295ad32df4ce8a18a92539c6e8a3b207912 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10290 .

_:79f295ad32df4ce8a18a92539c6e8a3b207913 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207914;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b207914 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10311 .

_:79f295ad32df4ce8a18a92539c6e8a3b207916 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11097-1 a owl:Class;
  rdfs:label "INDUCTEURS ENZYMATIQUES <-> OLAPARIB"@fr;
  dct:identifier "IAM_11097";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b207918;
  r:natureDuRisque "Diminution, éventuellement très importante selon l’inducteur, des concentrations plasmatiques de l’olaparib par augmentation de son métabolisme hépatique par l’inducteur."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b207924, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b207918 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b207919 .

_:79f295ad32df4ce8a18a92539c6e8a3b207919 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207920;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b207921 .

_:79f295ad32df4ce8a18a92539c6e8a3b207920 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10094 .

_:79f295ad32df4ce8a18a92539c6e8a3b207921 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207922;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b207922 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10659 .

_:79f295ad32df4ce8a18a92539c6e8a3b207924 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10788-1 a owl:Class;
  rdfs:label "DIGOXINE <-> SULFASALAZINE"@fr;
  dct:identifier "IAM_10788";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b207926;
  r:natureDuRisque "Diminution de la digoxinémie pouvant atteindre 50 %."@fr;
  r:conduiteATenir "Surveillance clinique, ECG et, éventuellement, de la digoxinémie. S'il y a lieu, adaptation de la posologie de la digoxine pendant le traitement par la sulfasalazine et après son arrêt."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b207932, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b207926 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b207927 .

_:79f295ad32df4ce8a18a92539c6e8a3b207927 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207928;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b207929 .

_:79f295ad32df4ce8a18a92539c6e8a3b207928 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10286 .

_:79f295ad32df4ce8a18a92539c6e8a3b207929 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207930;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b207930 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10872 .

_:79f295ad32df4ce8a18a92539c6e8a3b207932 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10790-1 a owl:Class;
  rdfs:label "DIGOXINE <-> TELITHROMYCINE"@fr;
  dct:identifier "IAM_10790";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b207934;
  r:natureDuRisque "Augmentation de la digoxinémie par augmentation de son absorption."@fr;
  r:conduiteATenir "Surveillance clinique et éventuellement de la digoxinémie pendant le traitement par la télithromycine et après son arrêt."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b207940, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b207934 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b207935 .

_:79f295ad32df4ce8a18a92539c6e8a3b207935 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207936;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b207937 .

_:79f295ad32df4ce8a18a92539c6e8a3b207936 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10286 .

_:79f295ad32df4ce8a18a92539c6e8a3b207937 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207938;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b207938 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10889 .

_:79f295ad32df4ce8a18a92539c6e8a3b207940 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10791-1 a owl:Class;
  rdfs:label "DIGOXINE <-> VERAPAMIL"@fr;
  dct:identifier "IAM_10791";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b207942;
  r:natureDuRisque "Bradycardie excessive et bloc auriculo-ventriculaire par majoration des effets de la digoxine sur l'automatisme et la conduction et par diminution de l'élimination rénale et extrarénale de la digoxine."@fr;
  r:conduiteATenir "Surveillance clinique, ECG et, éventuellement, contrôle de la digoxinémie. S'il y a lieu, adaptation de la posologie de la digoxine pendant le traitement par le vérapamil et après son arrêt."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b207948, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b207942 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b207943 .

_:79f295ad32df4ce8a18a92539c6e8a3b207943 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207944;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b207945 .

_:79f295ad32df4ce8a18a92539c6e8a3b207944 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10286 .

_:79f295ad32df4ce8a18a92539c6e8a3b207945 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207946;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b207946 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10980 .

_:79f295ad32df4ce8a18a92539c6e8a3b207948 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10792-1 a owl:Class;
  rdfs:label "DIHYDROERGOTAMINE <-> DILTIAZEM"@fr;
  dct:identifier "IAM_10792";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b207950;
  r:natureDuRisque "Ergotisme avec possibilité de nécrose des extrémités (inhibition du métabolisme hépatique de l'alcaloïde de l'ergot de seigle)."@fr;
  rdfs:comment "Le diltiazem est un un inhibiteur du CYP3A4. Même si elle est modeste, son activité inhibitrice doit être prise en compte, notamment lorsqu'il est associé à des médicaments à marge thérapeutique étroite comme la dihydroergotamine. Une faible augmentation"@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b207956, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b207950 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b207951 .

_:79f295ad32df4ce8a18a92539c6e8a3b207951 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207952;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b207953 .

_:79f295ad32df4ce8a18a92539c6e8a3b207952 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10289 .

_:79f295ad32df4ce8a18a92539c6e8a3b207953 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207954;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b207954 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10290 .

_:79f295ad32df4ce8a18a92539c6e8a3b207956 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10793-1 a owl:Class;
  rdfs:label "DIHYDROERGOTAMINE <-> EFAVIRENZ"@fr;
  dct:identifier "IAM_10793";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b207958;
  r:natureDuRisque "Ergotisme avec possibilité de nécrose des extrémités (inhibition du métabolisme hépatique de l'alcaloïde de l'ergot de seigle)."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b207964, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b207958 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b207959 .

_:79f295ad32df4ce8a18a92539c6e8a3b207959 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207960;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b207961 .

_:79f295ad32df4ce8a18a92539c6e8a3b207960 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10289 .

_:79f295ad32df4ce8a18a92539c6e8a3b207961 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207962;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b207962 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10318 .

_:79f295ad32df4ce8a18a92539c6e8a3b207964 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10794-1 a owl:Class;
  rdfs:label "DIHYDROERGOTAMINE <-> MACROLIDES (SAUF SPIRAMYCINE)"@fr;
  dct:identifier "IAM_10794";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b207966;
  r:natureDuRisque "Ergotisme avec possibilité de nécrose des extrémités (inhibition de l’élimination hépatique de l'alcaloïde de l’ergot de seigle)."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b207972, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b207966 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b207967 .

_:79f295ad32df4ce8a18a92539c6e8a3b207967 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207968;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b207969 .

_:79f295ad32df4ce8a18a92539c6e8a3b207968 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10107 .

_:79f295ad32df4ce8a18a92539c6e8a3b207969 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207970;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b207970 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10289 .

_:79f295ad32df4ce8a18a92539c6e8a3b207972 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10795-1 a owl:Class;
  rdfs:label "DIHYDROERGOTAMINE <-> QUINUPRISTINE"@fr;
  dct:identifier "IAM_10795";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b207974;
  r:natureDuRisque "Ergotisme avec possibilité de nécrose des extrémités (inhibition du métabolisme hépatique de l'alcaloïde de l'ergot de seigle)."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b207980, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b207974 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b207975 .

_:79f295ad32df4ce8a18a92539c6e8a3b207975 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207976;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b207977 .

_:79f295ad32df4ce8a18a92539c6e8a3b207976 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10289 .

_:79f295ad32df4ce8a18a92539c6e8a3b207977 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207978;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b207978 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10778 .

_:79f295ad32df4ce8a18a92539c6e8a3b207980 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10796-1 a owl:Class;
  rdfs:label "DIHYDROERGOTAMINE <-> STIRIPENTOL"@fr;
  dct:identifier "IAM_10796";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b207982;
  r:natureDuRisque "Ergotisme avec possibilité de nécrose des extrémités (inhibition de l’élimination hépatique de l'alcaloïde de l’ergot de seigle)."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b207988, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b207982 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b207983 .

_:79f295ad32df4ce8a18a92539c6e8a3b207983 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207984;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b207985 .

_:79f295ad32df4ce8a18a92539c6e8a3b207984 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10289 .

_:79f295ad32df4ce8a18a92539c6e8a3b207985 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207986;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b207986 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10859 .

_:79f295ad32df4ce8a18a92539c6e8a3b207988 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10811-1 a owl:Class;
  rdfs:label "DILTIAZEM <-> TICAGRELOR"@fr;
  dct:identifier "IAM_10811";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b207990;
  r:natureDuRisque "Risque d’augmentation des concentrations plasmatiques de ticagrelor par diminution de son métabolisme hépatique."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b207996, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b207990 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b207991 .

_:79f295ad32df4ce8a18a92539c6e8a3b207991 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207992;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b207993 .

_:79f295ad32df4ce8a18a92539c6e8a3b207992 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10290 .

_:79f295ad32df4ce8a18a92539c6e8a3b207993 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b207994;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b207994 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10926 .

_:79f295ad32df4ce8a18a92539c6e8a3b207996 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10798-1 a owl:Class;
  rdfs:label "DIHYDROERGOTAMINE <-> VORICONAZOLE"@fr;
  dct:identifier "IAM_10798";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b207998;
  r:natureDuRisque "Ergotisme avec possibilité de nécrose des extrémités (inhibition du métabolisme hépatique de l'alcaloïde de l’ergot de seigle)."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b208004, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b207998 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b207999 .

_:79f295ad32df4ce8a18a92539c6e8a3b207999 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208000;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b208001 .

_:79f295ad32df4ce8a18a92539c6e8a3b208000 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10289 .

_:79f295ad32df4ce8a18a92539c6e8a3b208001 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208002;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b208002 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10998 .

_:79f295ad32df4ce8a18a92539c6e8a3b208004 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10810-1 a owl:Class;
  rdfs:label "DILTIAZEM <-> TAMSULOSINE"@fr;
  dct:identifier "IAM_10810";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b208006;
  r:natureDuRisque "Risque de majoration des effets indésirables de la tamsulosine, par inhibition de son métabolisme hépatique."@fr;
  r:conduiteATenir "Surveillance clinique et adaptation de la posologie de la tamsulosine pensant le traitement par l’inhibiteur enzymatique et après son arrêt, le cas échéant."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b208012, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b208006 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b208007 .

_:79f295ad32df4ce8a18a92539c6e8a3b208007 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208008;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b208009 .

_:79f295ad32df4ce8a18a92539c6e8a3b208008 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10290 .

_:79f295ad32df4ce8a18a92539c6e8a3b208009 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208010;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b208010 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10883 .

_:79f295ad32df4ce8a18a92539c6e8a3b208012 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10800-1 a owl:Class;
  rdfs:label "DILTIAZEM <-> ERGOTAMINE"@fr;
  dct:identifier "IAM_10800";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b208014;
  r:natureDuRisque "Ergotisme avec possibilité de nécrose des extrémités (inhibition du métabolisme hépatique de l'alcaloïde de l'ergot de seigle)."@fr;
  rdfs:comment "Le diltiazem est un inhibiteur du CYP3A4. Même si elle est modeste, son activité inhibitrice doit être prise en compte, notamment lorsqu'il est associé à des médicaments à marge thérapeutique étroite comme l'ergotamine. Une faible augmentation des concent"@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b208020, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b208014 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b208015 .

_:79f295ad32df4ce8a18a92539c6e8a3b208015 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208016;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b208017 .

_:79f295ad32df4ce8a18a92539c6e8a3b208016 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10290 .

_:79f295ad32df4ce8a18a92539c6e8a3b208017 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208018;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b208018 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10334 .

_:79f295ad32df4ce8a18a92539c6e8a3b208020 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10801-1 a owl:Class;
  rdfs:label "DILTIAZEM <-> ESMOLOL"@fr;
  dct:identifier "IAM_10801";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b208022;
  r:natureDuRisque "Troubles de l'automatisme (bradycardie excessive, arrêt sinusal), troubles de la conduction sino-auriculaire et auriculo-ventriculaire et défaillance cardiaque."@fr;
  r:conduiteATenir """Précaution d'emploi :
- si la fonction ventriculaire gauche est normale.
Surveillance clinique et ECG."""@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b208028, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b208022 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b208023 .

_:79f295ad32df4ce8a18a92539c6e8a3b208023 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208024;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b208025 .

_:79f295ad32df4ce8a18a92539c6e8a3b208024 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10290 .

_:79f295ad32df4ce8a18a92539c6e8a3b208025 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208026;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b208026 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10341 .

_:79f295ad32df4ce8a18a92539c6e8a3b208028 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10802-1 a owl:Class;
  rdfs:label "DILTIAZEM <-> IBRUTINIB"@fr;
  dct:identifier "IAM_10802";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b208030;
  r:natureDuRisque "Risque d'augmentation des concentrations plasmatiques d’ibrutinib par diminution de son métabolisme hépatique par le diltiazem."@fr;
  r:conduiteATenir "Si l’association ne peut être évitée, surveillance clinique étroite et réduction de la dose d’ibrutinib à 140 mg par jour pendant la durée de l’association."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b208036, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b208030 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b208031 .

_:79f295ad32df4ce8a18a92539c6e8a3b208031 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208032;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b208033 .

_:79f295ad32df4ce8a18a92539c6e8a3b208032 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10290 .

_:79f295ad32df4ce8a18a92539c6e8a3b208033 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208034;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b208034 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10441 .

_:79f295ad32df4ce8a18a92539c6e8a3b208036 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10803-1 a owl:Class;
  rdfs:label "DILTIAZEM <-> IMMUNOSUPPRESSEURS"@fr;
  dct:identifier "IAM_10803";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b208038;
  r:natureDuRisque "Augmentation des concentrations sanguines de l'immunosuppresseur par diminution de son métabolisme."@fr;
  r:conduiteATenir "Dosage des concentrations sanguines de l'immunosuppresseur, contrôle de la fonction rénale et adaptation de la posologie pendant l'association et après son arrêt."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b208044, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b208038 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b208039 .

_:79f295ad32df4ce8a18a92539c6e8a3b208039 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208040;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b208041 .

_:79f295ad32df4ce8a18a92539c6e8a3b208040 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10093 .

_:79f295ad32df4ce8a18a92539c6e8a3b208041 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208042;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b208042 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10290 .

_:79f295ad32df4ce8a18a92539c6e8a3b208044 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10804-1 a owl:Class;
  rdfs:label "DILTIAZEM <-> IVABRADINE"@fr;
  dct:identifier "IAM_10804";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b208046;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de l’ivabradine et de ses effets indésirables, notamment cardiaques (inhibition de son métabolisme hépatique par le diltiazem), qui s’ajoutent aux effets bradycardisants de ces molécules."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b208052, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b208046 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b208047 .

_:79f295ad32df4ce8a18a92539c6e8a3b208047 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208048;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b208049 .

_:79f295ad32df4ce8a18a92539c6e8a3b208048 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10290 .

_:79f295ad32df4ce8a18a92539c6e8a3b208049 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208050;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b208050 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10497 .

_:79f295ad32df4ce8a18a92539c6e8a3b208052 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10805-1 a owl:Class;
  rdfs:label "DILTIAZEM <-> MIDAZOLAM"@fr;
  dct:identifier "IAM_10805";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b208054;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de midazolam par diminution de son métabolisme hépatique, avec majoration de la sédation."@fr;
  r:conduiteATenir "Surveillance clinique et réduction de la posologie pendant le traitement par le diltiazem."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b208060, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b208054 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b208055 .

_:79f295ad32df4ce8a18a92539c6e8a3b208055 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208056;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b208057 .

_:79f295ad32df4ce8a18a92539c6e8a3b208056 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10290 .

_:79f295ad32df4ce8a18a92539c6e8a3b208057 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208058;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b208058 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10585 .

_:79f295ad32df4ce8a18a92539c6e8a3b208060 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10806-1 a owl:Class;
  rdfs:label "DILTIAZEM <-> NIFEDIPINE"@fr;
  dct:identifier "IAM_10806";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b208062;
  r:natureDuRisque "Augmentation importantes des concentrations de nifédipine par diminution de son métabolisme hépatique par le diltiazem, avec risque d'hypotension sévère."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b208068, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b208062 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b208063 .

_:79f295ad32df4ce8a18a92539c6e8a3b208063 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208064;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b208065 .

_:79f295ad32df4ce8a18a92539c6e8a3b208064 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10290 .

_:79f295ad32df4ce8a18a92539c6e8a3b208065 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208066;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b208066 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10633 .

_:79f295ad32df4ce8a18a92539c6e8a3b208068 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10807-1 a owl:Class;
  rdfs:label "DILTIAZEM <-> OLAPARIB"@fr;
  dct:identifier "IAM_10807";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b208070;
  r:natureDuRisque "Augmentation des concentrations plasmatiques d’olaparib par le diltiazem."@fr;
  r:conduiteATenir "Si l’association ne peut être évitée, limiter la dose d’olaparib à 200 mg deux fois par jour."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b208076, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b208070 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b208071 .

_:79f295ad32df4ce8a18a92539c6e8a3b208071 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208072;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b208073 .

_:79f295ad32df4ce8a18a92539c6e8a3b208072 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10290 .

_:79f295ad32df4ce8a18a92539c6e8a3b208073 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208074;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b208074 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10659 .

_:79f295ad32df4ce8a18a92539c6e8a3b208076 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10808-1 a owl:Class;
  rdfs:label "DILTIAZEM <-> PIMOZIDE"@fr;
  dct:identifier "IAM_10808";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b208078;
  r:natureDuRisque "Risque majoré de troubles du rythme ventriculaire, notamment de torsades de pointes."@fr;
  rdfs:comment "Le diltiazem est un inhibiteur du CYP3A4. Même si elle est modeste, son activité inhibitrice doit être prise en compte, notamment lorsqu'il est associé à des médicaments à marge thérapeutique étroite comme le pimozide. Une faible augmentation des concentr"@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b208084, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b208078 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b208079 .

_:79f295ad32df4ce8a18a92539c6e8a3b208079 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208080;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b208081 .

_:79f295ad32df4ce8a18a92539c6e8a3b208080 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10290 .

_:79f295ad32df4ce8a18a92539c6e8a3b208081 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208082;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b208082 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10721 .

_:79f295ad32df4ce8a18a92539c6e8a3b208084 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10834-1 a owl:Class;
  rdfs:label "DOCETAXEL <-> INDUCTEURS ENZYMATIQUES"@fr;
  dct:identifier "IAM_10834";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b208086;
  r:natureDuRisque "Diminution des concentrations du cytotoxique par augmentation de son métabolisme par l’inducteur, avec risque de moindre efficacité."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b208092, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b208086 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b208087 .

_:79f295ad32df4ce8a18a92539c6e8a3b208087 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208088;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b208089 .

_:79f295ad32df4ce8a18a92539c6e8a3b208088 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10094 .

_:79f295ad32df4ce8a18a92539c6e8a3b208089 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208090;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b208090 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10300 .

_:79f295ad32df4ce8a18a92539c6e8a3b208092 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10797-1 a owl:Class;
  rdfs:label "DIHYDROERGOTAMINE <-> TRICLABENDAZOLE"@fr;
  dct:identifier "IAM_10797";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b208094;
  r:natureDuRisque "Ergotisme avec possibilité de nécrose des extrémités (inhibition du métabolisme hépatique de l’alcaloïde de l’ergot de seigle)."@fr;
  r:conduiteATenir "Respecter un délai de 24 heures entre l’arrêt du triclabendazole et la prise du médicament dérivé de l’ergot, et inversement."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b208100, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b208094 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b208095 .

_:79f295ad32df4ce8a18a92539c6e8a3b208095 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208096;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b208097 .

_:79f295ad32df4ce8a18a92539c6e8a3b208096 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10289 .

_:79f295ad32df4ce8a18a92539c6e8a3b208097 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208098;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b208098 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10953 .

_:79f295ad32df4ce8a18a92539c6e8a3b208100 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11054-1 a owl:Class;
  rdfs:label "IMAO-A RÉVERSIBLES, Y COMPRIS LINEZOLIDE ET BLEU DE MÉTHYLÈNE <-> INHIBITEURS SÉLECTIFS DE LA RECAPTURE DE LA SÉROTONINE"@fr;
  dct:identifier "IAM_11054";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b208102;
  r:natureDuRisque "Risque d'apparition d'un syndrome sérotoninergique : diarrhée, tachycardie, sueurs, tremblements, confusion voire coma."@fr;
  r:conduiteATenir "Si l'association ne peut être évitée, surveillance clinique très étroite. Débuter l'association aux posologies minimales recommandées."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b208108, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b208102 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b208103 .

_:79f295ad32df4ce8a18a92539c6e8a3b208103 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208104;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b208105 .

_:79f295ad32df4ce8a18a92539c6e8a3b208104 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10003 .

_:79f295ad32df4ce8a18a92539c6e8a3b208105 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208106;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b208106 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10104 .

_:79f295ad32df4ce8a18a92539c6e8a3b208108 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10832-1 a owl:Class;
  rdfs:label "DIURÉTIQUES THIAZIDIQUES ET APPARENTÉS <-> LITHIUM"@fr;
  dct:identifier "IAM_10832";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b208110;
  r:natureDuRisque "Augmentation de la lithémie avec signes de surdosage en lithium, comme lors d’un régime désodé (diminution de l’excrétion urinaire du lithium)."@fr;
  r:conduiteATenir "Si l'association ne peut être évitée, surveillance stricte de la lithémie et adaptation de la posologie du lithium."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b208116, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b208110 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b208111 .

_:79f295ad32df4ce8a18a92539c6e8a3b208111 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208112;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b208113 .

_:79f295ad32df4ce8a18a92539c6e8a3b208112 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10066 .

_:79f295ad32df4ce8a18a92539c6e8a3b208113 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208114;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b208114 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10530 .

_:79f295ad32df4ce8a18a92539c6e8a3b208116 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10859-1 a owl:Class;
  rdfs:label "DULOXETINE <-> PROPAFENONE"@fr;
  dct:identifier "IAM_10859";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b208118;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de propafénone avec risque de surdosage, par diminution de son métabolisme hépatique par la duloxétine."@fr;
  r:conduiteATenir "Surveillance clinique et réduction de la posologie de la propafénone pendant le traitement par la duloxétine et après son arrêt."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b208124, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b208118 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b208119 .

_:79f295ad32df4ce8a18a92539c6e8a3b208119 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208120;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b208121 .

_:79f295ad32df4ce8a18a92539c6e8a3b208120 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10314 .

_:79f295ad32df4ce8a18a92539c6e8a3b208121 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208122;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b208122 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10765 .

_:79f295ad32df4ce8a18a92539c6e8a3b208124 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11046-1 a owl:Class;
  rdfs:label "IMAO IRRÉVERSIBLES <-> SYMPATHOMIMÉTIQUES ALPHA ET BÊTA (VOIE IM ET IV)"@fr;
  dct:identifier "IAM_11046";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b208126;
  r:natureDuRisque "Augmentation de l'action pressive du sympathomimétique, le plus souvent modérée."@fr;
  r:conduiteATenir "A n'utiliser que sous contrôle médical strict."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b208132, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b208126 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b208127 .

_:79f295ad32df4ce8a18a92539c6e8a3b208127 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208128;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b208129 .

_:79f295ad32df4ce8a18a92539c6e8a3b208128 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10002 .

_:79f295ad32df4ce8a18a92539c6e8a3b208129 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208130;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b208130 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10149 .

_:79f295ad32df4ce8a18a92539c6e8a3b208132 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11045-1 a owl:Class;
  rdfs:label "IMAO IRRÉVERSIBLES <-> SYMPATHOMIMÉTIQUES ALPHA (VOIES ORALE ET/OU NASALE)"@fr;
  dct:identifier "IAM_11045";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b208134;
  r:natureDuRisque "Crises hypertensives (inhibition du métabolisme des amines pressives). Du fait de la durée d'action de l'IMAO, cette interaction est encore possible 15 jours après l'arrêt de l'IMAO."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b208140, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b208134 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b208135 .

_:79f295ad32df4ce8a18a92539c6e8a3b208135 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208136;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b208137 .

_:79f295ad32df4ce8a18a92539c6e8a3b208136 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10002 .

_:79f295ad32df4ce8a18a92539c6e8a3b208137 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208138;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b208138 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10148 .

_:79f295ad32df4ce8a18a92539c6e8a3b208140 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11047-1 a owl:Class;
  rdfs:label "IMAO IRRÉVERSIBLES <-> SYMPATHOMIMÉTIQUES INDIRECTS"@fr;
  dct:identifier "IAM_11047";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b208142;
  r:natureDuRisque "Hypertension paroxystique, hyperthermie pouvant être fatale. Du fait de la durée d'action de l'IMAO, cette interaction est encore possible 15 jours après l'arrêt de l'IMAO."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b208148, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b208142 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b208143 .

_:79f295ad32df4ce8a18a92539c6e8a3b208143 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208144;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b208145 .

_:79f295ad32df4ce8a18a92539c6e8a3b208144 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10002 .

_:79f295ad32df4ce8a18a92539c6e8a3b208145 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208146;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b208146 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10150 .

_:79f295ad32df4ce8a18a92539c6e8a3b208148 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11048-1 a owl:Class;
  rdfs:label "IMAO IRRÉVERSIBLES <-> TETRABENAZINE"@fr;
  dct:identifier "IAM_11048";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b208150;
  r:natureDuRisque "Risque de crises hypertensives. Du fait de la durée d'action de l'IMAO, cette interaction est encore théoriquement possible 15 jours après son arrêt."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b208156, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b208150 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b208151 .

_:79f295ad32df4ce8a18a92539c6e8a3b208151 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208152;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b208153 .

_:79f295ad32df4ce8a18a92539c6e8a3b208152 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10002 .

_:79f295ad32df4ce8a18a92539c6e8a3b208153 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208154;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b208154 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10908 .

_:79f295ad32df4ce8a18a92539c6e8a3b208156 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11049-1 a owl:Class;
  rdfs:label "IMAO IRRÉVERSIBLES <-> TIANEPTINE"@fr;
  dct:identifier "IAM_11049";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b208158;
  r:natureDuRisque "Risque de collapsus, hypertension paroxystique, hyperthermie, convulsions, décès."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b208164, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b208158 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b208159 .

_:79f295ad32df4ce8a18a92539c6e8a3b208159 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208160;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b208161 .

_:79f295ad32df4ce8a18a92539c6e8a3b208160 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10002 .

_:79f295ad32df4ce8a18a92539c6e8a3b208161 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208162;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b208162 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10923 .

_:79f295ad32df4ce8a18a92539c6e8a3b208164 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11050-1 a owl:Class;
  rdfs:label "IMAO IRRÉVERSIBLES <-> TRAMADOL"@fr;
  dct:identifier "IAM_11050";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b208166;
  r:natureDuRisque "Risque d'apparition d'un syndrome sérotoninergique : diarrhée, sueurs, tremblements, confusion, voire coma."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b208172, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b208166 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b208167 .

_:79f295ad32df4ce8a18a92539c6e8a3b208167 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208168;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b208169 .

_:79f295ad32df4ce8a18a92539c6e8a3b208168 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10002 .

_:79f295ad32df4ce8a18a92539c6e8a3b208169 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208170;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b208170 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10945 .

_:79f295ad32df4ce8a18a92539c6e8a3b208172 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11052-1 a owl:Class;
  rdfs:label "IMAO IRRÉVERSIBLES <-> TRIPTANS NON MÉTABOLISÉS PAR LA MAO"@fr;
  dct:identifier "IAM_11052";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b208174;
  r:natureDuRisque "Risque d'hypertension artérielle, de vasoconstriction artérielle coronaire."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b208180, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b208174 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b208175 .

_:79f295ad32df4ce8a18a92539c6e8a3b208175 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208176;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b208177 .

_:79f295ad32df4ce8a18a92539c6e8a3b208176 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10002 .

_:79f295ad32df4ce8a18a92539c6e8a3b208177 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208178;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b208178 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10158 .

_:79f295ad32df4ce8a18a92539c6e8a3b208180 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10858-1 a owl:Class;
  rdfs:label "DULOXETINE <-> METOPROLOL"@fr;
  dct:identifier "IAM_10858";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b208182;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de métoprolol avec risque de surdosage, par diminution de son métabolisme hépatique par la duloxétine."@fr;
  r:conduiteATenir "Surveillance clinique et réduction de la posologie du métoprolol pendant le traitement par la duloxétine et après son arrêt."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b208188, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b208182 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b208183 .

_:79f295ad32df4ce8a18a92539c6e8a3b208183 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208184;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b208185 .

_:79f295ad32df4ce8a18a92539c6e8a3b208184 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10314 .

_:79f295ad32df4ce8a18a92539c6e8a3b208185 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208186;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b208186 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10579 .

_:79f295ad32df4ce8a18a92539c6e8a3b208188 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11053-1 a owl:Class;
  rdfs:label "IMAO-A RÉVERSIBLES, Y COMPRIS LINEZOLIDE ET BLEU DE MÉTHYLÈNE <-> IMAO-B"@fr;
  dct:identifier "IAM_11053";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b208190;
  r:natureDuRisque "Risque de poussée hypertensive, par perte de sélectivité sur la monoamine oxydase, notamment en cas d’alimentation riche en tyramine (fromage, bière,…)."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b208196, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b208190 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b208191 .

_:79f295ad32df4ce8a18a92539c6e8a3b208191 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208192;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b208193 .

_:79f295ad32df4ce8a18a92539c6e8a3b208192 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10003 .

_:79f295ad32df4ce8a18a92539c6e8a3b208193 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208194;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b208194 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10004 .

_:79f295ad32df4ce8a18a92539c6e8a3b208196 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10856-1 a owl:Class;
  rdfs:label "DULOXETINE <-> FLUVOXAMINE"@fr;
  dct:identifier "IAM_10856";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b208198;
  r:natureDuRisque "Risque d’augmentation des effets indésirables de la duloxétine par diminution de son métabolisme hépatique par la fluvoxamine."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b208204, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b208198 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b208199 .

_:79f295ad32df4ce8a18a92539c6e8a3b208199 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208200;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b208201 .

_:79f295ad32df4ce8a18a92539c6e8a3b208200 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10314 .

_:79f295ad32df4ce8a18a92539c6e8a3b208201 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208202;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b208202 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10398 .

_:79f295ad32df4ce8a18a92539c6e8a3b208204 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11055-1 a owl:Class;
  rdfs:label "IMAO-A RÉVERSIBLES, Y COMPRIS LINEZOLIDE ET BLEU DE MÉTHYLÈNE <-> MÉDICAMENTS MIXTES ADRÉNERGIQUES-SÉROTONINERGIQUES"@fr;
  dct:identifier "IAM_11055";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b208206;
  r:natureDuRisque "Risque d'apparition d'un syndrome sérotoninergique : diarrhée, tachycardie, sueur, confusion voire coma."@fr;
  r:conduiteATenir "Si l'association ne peut être évitée, surveillance clinique très étroite. Débuter l'association aux posologies minimales recommandées."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b208212, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b208206 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b208207 .

_:79f295ad32df4ce8a18a92539c6e8a3b208207 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208208;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b208209 .

_:79f295ad32df4ce8a18a92539c6e8a3b208208 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10003 .

_:79f295ad32df4ce8a18a92539c6e8a3b208209 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208210;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b208210 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10116 .

_:79f295ad32df4ce8a18a92539c6e8a3b208212 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11194-1 a owl:Class;
  rdfs:label "ITRACONAZOLE <-> MIZOLASTINE"@fr;
  dct:identifier "IAM_11194";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b208214;
  r:natureDuRisque "Risque de troubles du rythme ventriculaire, notamment de torsades de pointes."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b208220, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b208214 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b208215 .

_:79f295ad32df4ce8a18a92539c6e8a3b208215 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208216;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b208217 .

_:79f295ad32df4ce8a18a92539c6e8a3b208216 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10496 .

_:79f295ad32df4ce8a18a92539c6e8a3b208217 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208218;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b208218 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10597 .

_:79f295ad32df4ce8a18a92539c6e8a3b208220 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11195-1 a owl:Class;
  rdfs:label "ITRACONAZOLE <-> NINTÉDANIB"@fr;
  dct:identifier "IAM_11195";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b208222;
  r:natureDuRisque "Augmentation des concentrations plasmatiques du nintédanib par augmentation de son absorption par l'itraconazole."@fr;
  r:conduiteATenir "Surveillance clinique pendant l’association."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b208228, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b208222 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b208223 .

_:79f295ad32df4ce8a18a92539c6e8a3b208223 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208224;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b208225 .

_:79f295ad32df4ce8a18a92539c6e8a3b208224 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10496 .

_:79f295ad32df4ce8a18a92539c6e8a3b208225 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208226;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b208226 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10637 .

_:79f295ad32df4ce8a18a92539c6e8a3b208228 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11196-1 a owl:Class;
  rdfs:label "ITRACONAZOLE <-> QUINIDINE"@fr;
  dct:identifier "IAM_11196";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b208230;
  r:natureDuRisque """Risque majoré de troubles du rythme ventriculaire, notamment de
torsades de pointes, ainsi que d'acouphènes et/ou de diminution de l'acuité auditive (cinchonisme), par diminution du métabolisme
hépatique de la quinidine."""@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b208236, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b208230 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b208231 .

_:79f295ad32df4ce8a18a92539c6e8a3b208231 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208232;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b208233 .

_:79f295ad32df4ce8a18a92539c6e8a3b208232 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10496 .

_:79f295ad32df4ce8a18a92539c6e8a3b208233 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208234;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b208234 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10776 .

_:79f295ad32df4ce8a18a92539c6e8a3b208236 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11197-1 a owl:Class;
  rdfs:label "ITRACONAZOLE <-> SALMETEROL"@fr;
  dct:identifier "IAM_11197";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b208238;
  r:natureDuRisque "Augmentation importante des concentrations de salmétérol par diminution de son métabolisme hépatique par l'itraconazole."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b208244, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b208238 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b208239 .

_:79f295ad32df4ce8a18a92539c6e8a3b208239 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208240;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b208241 .

_:79f295ad32df4ce8a18a92539c6e8a3b208240 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10496 .

_:79f295ad32df4ce8a18a92539c6e8a3b208241 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208242;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b208242 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10823 .

_:79f295ad32df4ce8a18a92539c6e8a3b208244 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11198-1 a owl:Class;
  rdfs:label "ITRACONAZOLE <-> SIMVASTATINE"@fr;
  dct:identifier "IAM_11198";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b208246;
  r:natureDuRisque "Risque majoré d'effets indésirables (concentration-dépendants) à type de rhabdomyolyse (diminution du métabolisme hépatique de la simvastatine)."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b208252, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b208246 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b208247 .

_:79f295ad32df4ce8a18a92539c6e8a3b208247 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208248;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b208249 .

_:79f295ad32df4ce8a18a92539c6e8a3b208248 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10496 .

_:79f295ad32df4ce8a18a92539c6e8a3b208249 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208250;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b208250 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10838 .

_:79f295ad32df4ce8a18a92539c6e8a3b208252 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11200-1 a owl:Class;
  rdfs:label "ITRACONAZOLE <-> TÉNOFOVIR ALAFÉNAMIDE"@fr;
  dct:identifier "IAM_11200";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b208254;
  r:natureDuRisque "Augmentation des concentrations plasmatiques du ténofovir alafénamide par augmentation de son absorption."@fr;
  r:conduiteATenir "En cas de co-administration avec l’itraconazole, la dose de ténofovir alafénamide doit être limitée à 10 mg par jour."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b208260, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b208254 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b208255 .

_:79f295ad32df4ce8a18a92539c6e8a3b208255 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208256;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b208257 .

_:79f295ad32df4ce8a18a92539c6e8a3b208256 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10496 .

_:79f295ad32df4ce8a18a92539c6e8a3b208257 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208258;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b208258 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10895 .

_:79f295ad32df4ce8a18a92539c6e8a3b208260 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11201-1 a owl:Class;
  rdfs:label "ITRACONAZOLE <-> TRABECTÉDINE"@fr;
  dct:identifier "IAM_11201";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b208262;
  r:natureDuRisque "Risque d’augmentation des concentrations plasmatiques de la trabectedine par l’itraconazole."@fr;
  r:conduiteATenir "Si l’association est nécessaire, surveillance clinique et adaptation éventuelle de la posologie de la trabectedine pendant la durée du traitement par l’itraconazole."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b208268, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b208262 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b208263 .

_:79f295ad32df4ce8a18a92539c6e8a3b208263 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208264;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b208265 .

_:79f295ad32df4ce8a18a92539c6e8a3b208264 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10496 .

_:79f295ad32df4ce8a18a92539c6e8a3b208265 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208266;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b208266 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10944 .

_:79f295ad32df4ce8a18a92539c6e8a3b208268 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11202-1 a owl:Class;
  rdfs:label "ITRACONAZOLE <-> VENLAFAXINE"@fr;
  dct:identifier "IAM_11202";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b208270;
  r:natureDuRisque "Augmentation des concentrations de venlafaxine avec risque de surdosage."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b208276, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b208270 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b208271 .

_:79f295ad32df4ce8a18a92539c6e8a3b208271 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208272;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b208273 .

_:79f295ad32df4ce8a18a92539c6e8a3b208272 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10496 .

_:79f295ad32df4ce8a18a92539c6e8a3b208273 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208274;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b208274 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10979 .

_:79f295ad32df4ce8a18a92539c6e8a3b208276 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11204-1 a owl:Class;
  rdfs:label "IVABRADINE <-> JOSAMYCINE"@fr;
  dct:identifier "IAM_11204";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b208278;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de l'ivabradine et par conséquent de ses effets indésirables (inhibition de son métabolisme hépatique par la josamycine)."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b208284, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b208278 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b208279 .

_:79f295ad32df4ce8a18a92539c6e8a3b208279 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208280;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b208281 .

_:79f295ad32df4ce8a18a92539c6e8a3b208280 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10497 .

_:79f295ad32df4ce8a18a92539c6e8a3b208281 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208282;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b208282 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10499 .

_:79f295ad32df4ce8a18a92539c6e8a3b208284 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11051-1 a owl:Class;
  rdfs:label "IMAO IRRÉVERSIBLES <-> TRIPTANS MÉTABOLISÉS PAR LA MAO"@fr;
  dct:identifier "IAM_11051";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b208286;
  r:natureDuRisque "Risque d'hypertension artérielle, de vasoconstriction artérielle coronaire."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b208292, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b208286 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b208287 .

_:79f295ad32df4ce8a18a92539c6e8a3b208287 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208288;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b208289 .

_:79f295ad32df4ce8a18a92539c6e8a3b208288 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10002 .

_:79f295ad32df4ce8a18a92539c6e8a3b208289 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208290;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b208290 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10157 .

_:79f295ad32df4ce8a18a92539c6e8a3b208292 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10845-1 a owl:Class;
  rdfs:label "DRONEDARONE <-> FIDAXOMICINE"@fr;
  dct:identifier "IAM_10845";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b208294;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de la fidaxomicine."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b208300, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b208294 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b208295 .

_:79f295ad32df4ce8a18a92539c6e8a3b208295 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208296;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b208297 .

_:79f295ad32df4ce8a18a92539c6e8a3b208296 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10311 .

_:79f295ad32df4ce8a18a92539c6e8a3b208297 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208298;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b208298 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10378 .

_:79f295ad32df4ce8a18a92539c6e8a3b208300 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10785-1 a owl:Class;
  rdfs:label "DIGOXINE <-> QUININE"@fr;
  dct:identifier "IAM_10785";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b208302;
  r:natureDuRisque "Augmentation modérée de la digoxinémie."@fr;
  r:conduiteATenir "Surveillance clinique et ECG, si besoin, avec adaptation éventuelle des doses de digoxine."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b208308, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b208302 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b208303 .

_:79f295ad32df4ce8a18a92539c6e8a3b208303 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208304;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b208305 .

_:79f295ad32df4ce8a18a92539c6e8a3b208304 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10286 .

_:79f295ad32df4ce8a18a92539c6e8a3b208305 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208306;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b208306 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10777 .

_:79f295ad32df4ce8a18a92539c6e8a3b208308 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10835-1 a owl:Class;
  rdfs:label "DOCETAXEL <-> INHIBITEURS PUISSANTS DU CYP3A4"@fr;
  dct:identifier "IAM_10835";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b208310;
  r:natureDuRisque "Risque de majoration des effets indésirables dose-dépendants du docétaxel par inhibition de son métabolisme par l’inhibiteur enzymatique."@fr;
  r:conduiteATenir "Surveillance clinique et adaptation éventuelle de la posologie du docétaxel pendant le traitement par l’inhibiteur enzymatique."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b208316, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b208310 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b208311 .

_:79f295ad32df4ce8a18a92539c6e8a3b208311 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208312;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b208313 .

_:79f295ad32df4ce8a18a92539c6e8a3b208312 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10103 .

_:79f295ad32df4ce8a18a92539c6e8a3b208313 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208314;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b208314 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10300 .

_:79f295ad32df4ce8a18a92539c6e8a3b208316 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10836-1 a owl:Class;
  rdfs:label "DOLUTÉGRAVIR <-> INDUCTEURS ENZYMATIQUES"@fr;
  dct:identifier "IAM_10836";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b208318;
  r:natureDuRisque "Diminution des concentrations plasmatiques de dolutégravir par augmentation de son métabolisme par l’inducteur."@fr;
  r:conduiteATenir """Association déconseillée :
- en cas de résistance à la classe des inhibiteurs d'intégrase

Précaution d'emploi :
- en l'absence de résistance à la classe des inhibiteurs d'intégrase
Adaptation de la posologie de dolutégravir à 50 mg 2 fois par jour penda"""@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b208324, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b208318 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b208319 .

_:79f295ad32df4ce8a18a92539c6e8a3b208319 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208320;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b208321 .

_:79f295ad32df4ce8a18a92539c6e8a3b208320 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10094 .

_:79f295ad32df4ce8a18a92539c6e8a3b208321 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208322;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b208322 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10301 .

_:79f295ad32df4ce8a18a92539c6e8a3b208324 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10837-1 a owl:Class;
  rdfs:label "DOLUTÉGRAVIR <-> METFORMINE"@fr;
  dct:identifier "IAM_10837";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b208326;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de metformine par le dolutegravir et de ses effets indésirables à type d’acidose lactique."@fr;
  r:conduiteATenir "Chez le patient avec une insuffisance rénale modérée (stade 3a, clairance de la créatinine comprise entre 45 et 59 ml/min), surveillance clinique et biologique, et adaptation éventuelle de la posologie de metformine."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b208332, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b208326 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b208327 .

_:79f295ad32df4ce8a18a92539c6e8a3b208327 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208328;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b208329 .

_:79f295ad32df4ce8a18a92539c6e8a3b208328 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10301 .

_:79f295ad32df4ce8a18a92539c6e8a3b208329 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208330;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b208330 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10566 .

_:79f295ad32df4ce8a18a92539c6e8a3b208332 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10838-1 a owl:Class;
  rdfs:label "DOLUTÉGRAVIR <-> MILLEPERTUIS"@fr;
  dct:identifier "IAM_10838";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b208334;
  r:natureDuRisque "Risque de diminution des concentrations plasmatiques de dolutégravir par augmentation de son métabolisme par le millepertuis."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b208340, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b208334 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b208335 .

_:79f295ad32df4ce8a18a92539c6e8a3b208335 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208336;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b208337 .

_:79f295ad32df4ce8a18a92539c6e8a3b208336 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10301 .

_:79f295ad32df4ce8a18a92539c6e8a3b208337 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208338;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b208338 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10588 .

_:79f295ad32df4ce8a18a92539c6e8a3b208340 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10839-1 a owl:Class;
  rdfs:label "DOMPERIDONE <-> FLUCONAZOLE"@fr;
  dct:identifier "IAM_10839";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b208342;
  r:natureDuRisque "Risque de troubles du rythme ventriculaire, notamment de torsades de pointes."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b208348, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b208342 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b208343 .

_:79f295ad32df4ce8a18a92539c6e8a3b208343 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208344;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b208345 .

_:79f295ad32df4ce8a18a92539c6e8a3b208344 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10302 .

_:79f295ad32df4ce8a18a92539c6e8a3b208345 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208346;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b208346 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10381 .

_:79f295ad32df4ce8a18a92539c6e8a3b208348 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10840-1 a owl:Class;
  rdfs:label "DOMPERIDONE <-> INHIBITEURS PUISSANTS DU CYP3A4"@fr;
  dct:identifier "IAM_10840";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b208350;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de dompéridone par diminution de son métabolisme hépatique par l’inhibiteur."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b208356, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b208350 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b208351 .

_:79f295ad32df4ce8a18a92539c6e8a3b208351 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208352;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b208353 .

_:79f295ad32df4ce8a18a92539c6e8a3b208352 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10103 .

_:79f295ad32df4ce8a18a92539c6e8a3b208353 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208354;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b208354 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10302 .

_:79f295ad32df4ce8a18a92539c6e8a3b208356 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10841-1 a owl:Class;
  rdfs:label "DOPAMINERGIQUES <-> NEUROLEPTIQUES ANTIÉMÉTIQUES"@fr;
  dct:identifier "IAM_10841";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b208358;
  r:natureDuRisque "Antagonisme réciproque entre le dopaminergique et le neuroleptique."@fr;
  r:conduiteATenir "Utiliser un antiémétique dénué d'effets extrapyramidaux."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b208364, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b208358 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b208359 .

_:79f295ad32df4ce8a18a92539c6e8a3b208359 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208360;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b208361 .

_:79f295ad32df4ce8a18a92539c6e8a3b208360 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10068 .

_:79f295ad32df4ce8a18a92539c6e8a3b208361 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208362;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b208362 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10126 .

_:79f295ad32df4ce8a18a92539c6e8a3b208364 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10842-1 a owl:Class;
  rdfs:label "DOPAMINERGIQUES <-> TETRABENAZINE"@fr;
  dct:identifier "IAM_10842";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b208366;
  r:natureDuRisque "Antagonisme réciproque entre le dopaminergique et la tétrabénazine."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b208372, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b208366 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b208367 .

_:79f295ad32df4ce8a18a92539c6e8a3b208367 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208368;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b208369 .

_:79f295ad32df4ce8a18a92539c6e8a3b208368 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10068 .

_:79f295ad32df4ce8a18a92539c6e8a3b208369 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208370;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b208370 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10908 .

_:79f295ad32df4ce8a18a92539c6e8a3b208372 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10857-1 a owl:Class;
  rdfs:label "DULOXETINE <-> MEQUITAZINE"@fr;
  dct:identifier "IAM_10857";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b208374;
  r:natureDuRisque "Risque de majoration des effets indésirables de la méquitazine, par inhibition de son métabolisme par l’inhibiteur enzymatique."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b208380, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b208374 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b208375 .

_:79f295ad32df4ce8a18a92539c6e8a3b208375 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208376;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b208377 .

_:79f295ad32df4ce8a18a92539c6e8a3b208376 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10314 .

_:79f295ad32df4ce8a18a92539c6e8a3b208377 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208378;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b208378 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10561 .

_:79f295ad32df4ce8a18a92539c6e8a3b208380 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10844-1 a owl:Class;
  rdfs:label "DOXORUBICINE <-> VERAPAMIL"@fr;
  dct:identifier "IAM_10844";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b208382;
  r:natureDuRisque "Risque de majoration de la toxicité de la doxorubicine par augmentation de ses concentrations plasmatiques."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b208388, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b208382 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b208383 .

_:79f295ad32df4ce8a18a92539c6e8a3b208383 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208384;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b208385 .

_:79f295ad32df4ce8a18a92539c6e8a3b208384 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10308 .

_:79f295ad32df4ce8a18a92539c6e8a3b208385 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208386;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b208386 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10980 .

_:79f295ad32df4ce8a18a92539c6e8a3b208388 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10833-1 a owl:Class;
  rdfs:label "DOCETAXEL <-> DRONEDARONE"@fr;
  dct:identifier "IAM_10833";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b208390;
  r:natureDuRisque "Risque de majoration de la toxicité du docétaxel par diminution de son métabolisme."@fr;
  r:conduiteATenir "Surveillance clinique et adaptation éventuelle de la posologie du docétaxel pendant le traitement par l’inhibiteur enzymatique."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b208396, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b208390 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b208391 .

_:79f295ad32df4ce8a18a92539c6e8a3b208391 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208392;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b208393 .

_:79f295ad32df4ce8a18a92539c6e8a3b208392 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10300 .

_:79f295ad32df4ce8a18a92539c6e8a3b208393 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208394;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b208394 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10311 .

_:79f295ad32df4ce8a18a92539c6e8a3b208396 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10846-1 a owl:Class;
  rdfs:label "DRONEDARONE <-> IMMUNOSUPPRESSEURS"@fr;
  dct:identifier "IAM_10846";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b208398;
  r:natureDuRisque "Augmentation importante des concentrations sanguines de l’immunosuppresseur par diminution de son métabolisme."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b208404, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b208398 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b208399 .

_:79f295ad32df4ce8a18a92539c6e8a3b208399 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208400;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b208401 .

_:79f295ad32df4ce8a18a92539c6e8a3b208400 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10093 .

_:79f295ad32df4ce8a18a92539c6e8a3b208401 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208402;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b208402 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10311 .

_:79f295ad32df4ce8a18a92539c6e8a3b208404 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10847-1 a owl:Class;
  rdfs:label "DRONEDARONE <-> INHIBITEURS PUISSANTS DU CYP3A4"@fr;
  dct:identifier "IAM_10847";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b208406;
  r:natureDuRisque "Augmentation importante des concentrations de dronédarone par diminution de son métabolisme."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b208412, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b208406 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b208407 .

_:79f295ad32df4ce8a18a92539c6e8a3b208407 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208408;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b208409 .

_:79f295ad32df4ce8a18a92539c6e8a3b208408 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10103 .

_:79f295ad32df4ce8a18a92539c6e8a3b208409 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208410;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b208410 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10311 .

_:79f295ad32df4ce8a18a92539c6e8a3b208412 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10848-1 a owl:Class;
  rdfs:label "DRONEDARONE <-> MILLEPERTUIS"@fr;
  dct:identifier "IAM_10848";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b208414;
  r:natureDuRisque "Diminution importante des concentrations de dronédarone par augmentation de son métabolisme, sans modification notable du métabolite actif."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b208420, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b208414 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b208415 .

_:79f295ad32df4ce8a18a92539c6e8a3b208415 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208416;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b208417 .

_:79f295ad32df4ce8a18a92539c6e8a3b208416 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10311 .

_:79f295ad32df4ce8a18a92539c6e8a3b208417 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208418;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b208418 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10588 .

_:79f295ad32df4ce8a18a92539c6e8a3b208420 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10849-1 a owl:Class;
  rdfs:label "DRONEDARONE <-> PAMPLEMOUSSE (JUS ET FRUIT)"@fr;
  dct:identifier "IAM_10849";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b208422;
  r:natureDuRisque "Augmentation des concentrations de dronédarone par inhibition de son métabolisme par le pamplemousse."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b208428, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b208422 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b208423 .

_:79f295ad32df4ce8a18a92539c6e8a3b208423 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208424;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b208425 .

_:79f295ad32df4ce8a18a92539c6e8a3b208424 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10130 .

_:79f295ad32df4ce8a18a92539c6e8a3b208425 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208426;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b208426 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10311 .

_:79f295ad32df4ce8a18a92539c6e8a3b208428 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10850-1 a owl:Class;
  rdfs:label "DRONEDARONE <-> QUINIDINE"@fr;
  dct:identifier "IAM_10850";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b208430;
  r:natureDuRisque "Risque de bradycardie ou de bloc auriculo-ventriculaire, notamment chez le sujet âgé. Par ailleurs, légère augmentation des concentrations de dronédarone par diminution de son métabolisme par la quinidine."@fr;
  r:conduiteATenir "Débuter le traitement par la quinidine aux posologies minimales recommandées, et ajuster les doses en fonction de l’ECG."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b208436, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b208430 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b208431 .

_:79f295ad32df4ce8a18a92539c6e8a3b208431 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208432;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b208433 .

_:79f295ad32df4ce8a18a92539c6e8a3b208432 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10311 .

_:79f295ad32df4ce8a18a92539c6e8a3b208433 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208434;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b208434 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10776 .

_:79f295ad32df4ce8a18a92539c6e8a3b208436 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10851-1 a owl:Class;
  rdfs:label "DRONEDARONE <-> RIFAMPICINE"@fr;
  dct:identifier "IAM_10851";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b208438;
  r:natureDuRisque "Diminution importante des concentrations de dronédarone par augmentation de son métabolisme, sans modification notable du métabolite actif."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b208444, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b208438 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b208439 .

_:79f295ad32df4ce8a18a92539c6e8a3b208439 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208440;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b208441 .

_:79f295ad32df4ce8a18a92539c6e8a3b208440 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10311 .

_:79f295ad32df4ce8a18a92539c6e8a3b208441 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208442;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b208442 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:79f295ad32df4ce8a18a92539c6e8a3b208444 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10852-1 a owl:Class;
  rdfs:label "DRONEDARONE <-> SIMVASTATINE"@fr;
  dct:identifier "IAM_10852";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b208446;
  r:natureDuRisque "Risque majoré d'effets indésirables (concentration-dépendants) à type de rhabdomyolyse (diminution du métabolisme hépatique de la simvastatine)."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b208452, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b208446 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b208447 .

_:79f295ad32df4ce8a18a92539c6e8a3b208447 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208448;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b208449 .

_:79f295ad32df4ce8a18a92539c6e8a3b208448 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10311 .

_:79f295ad32df4ce8a18a92539c6e8a3b208449 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208450;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b208450 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10838 .

_:79f295ad32df4ce8a18a92539c6e8a3b208452 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10853-1 a owl:Class;
  rdfs:label "DRONEDARONE <-> VERAPAMIL"@fr;
  dct:identifier "IAM_10853";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b208454;
  r:natureDuRisque "Risque de bradycardie ou de bloc auriculo-ventriculaire, notamment chez le sujet âgé. Par ailleurs, légère augmentation des concentrations de dronédarone par diminution de son métabolisme par l’antagoniste des canaux calciques."@fr;
  r:conduiteATenir "Débuter le traitement par l’antagoniste calcique aux posologies minimales recommandées, et ajuster les doses en fonction de l’ECG."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b208460, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b208454 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b208455 .

_:79f295ad32df4ce8a18a92539c6e8a3b208455 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208456;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b208457 .

_:79f295ad32df4ce8a18a92539c6e8a3b208456 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10311 .

_:79f295ad32df4ce8a18a92539c6e8a3b208457 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208458;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b208458 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10980 .

_:79f295ad32df4ce8a18a92539c6e8a3b208460 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10854-1 a owl:Class;
  rdfs:label "DULOXETINE <-> ENOXACINE"@fr;
  dct:identifier "IAM_10854";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b208462;
  r:natureDuRisque "Risque d’augmentation des effets indésirables de la duloxétine par diminution de son métabolisme hépatique par l'énoxacine."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b208468, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b208462 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b208463 .

_:79f295ad32df4ce8a18a92539c6e8a3b208463 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208464;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b208465 .

_:79f295ad32df4ce8a18a92539c6e8a3b208464 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10314 .

_:79f295ad32df4ce8a18a92539c6e8a3b208465 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208466;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b208466 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10323 .

_:79f295ad32df4ce8a18a92539c6e8a3b208468 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10855-1 a owl:Class;
  rdfs:label "DULOXETINE <-> FLECAINIDE"@fr;
  dct:identifier "IAM_10855";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b208470;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de flecainide avec risque de surdosage, par diminution de son métabolisme hépatique par la duloxétine."@fr;
  r:conduiteATenir "Surveillance clinique et réduction de la posologie du flecainide pendant le traitement par la duloxétine et après son arrêt."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b208476, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b208470 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b208471 .

_:79f295ad32df4ce8a18a92539c6e8a3b208471 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208472;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b208473 .

_:79f295ad32df4ce8a18a92539c6e8a3b208472 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10314 .

_:79f295ad32df4ce8a18a92539c6e8a3b208473 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208474;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b208474 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10380 .

_:79f295ad32df4ce8a18a92539c6e8a3b208476 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10843-1 a owl:Class;
  rdfs:label "DOPAMINERGIQUES, HORS PARKINSON <-> NEUROLEPTIQUES ANTIPSYCHOTIQUES (SAUF CLOZAPINE)"@fr;
  dct:identifier "IAM_10843";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b208478;
  r:natureDuRisque "Antagonisme réciproque de l'agoniste dopaminergique et des neuroleptiques."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b208484, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b208478 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b208479 .

_:79f295ad32df4ce8a18a92539c6e8a3b208479 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208480;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b208481 .

_:79f295ad32df4ce8a18a92539c6e8a3b208480 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10069 .

_:79f295ad32df4ce8a18a92539c6e8a3b208481 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208482;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b208482 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10125 .

_:79f295ad32df4ce8a18a92539c6e8a3b208484 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10751-1 a owl:Class;
  rdfs:label "DEXAMETHASONE <-> ERYTHROMYCINE"@fr;
  dct:identifier "IAM_10751";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b208486;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de la dexaméthasone par diminution de son métabolisme hépatique par l'inhibiteur enzymatique, avec risque d’apparition d’un syndrome cushingoïde."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b208492, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b208486 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b208487 .

_:79f295ad32df4ce8a18a92539c6e8a3b208487 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208488;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b208489 .

_:79f295ad32df4ce8a18a92539c6e8a3b208488 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10272 .

_:79f295ad32df4ce8a18a92539c6e8a3b208489 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208490;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b208490 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10338 .

_:79f295ad32df4ce8a18a92539c6e8a3b208492 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10740-1 a owl:Class;
  rdfs:label "DASABUVIR <-> MITOTANE"@fr;
  dct:identifier "IAM_10740";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b208494;
  r:natureDuRisque "Risque de diminution des concentrations plasmatiques du dasabuvir par le mitotane."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b208500, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b208494 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b208495 .

_:79f295ad32df4ce8a18a92539c6e8a3b208495 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208496;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b208497 .

_:79f295ad32df4ce8a18a92539c6e8a3b208496 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10255 .

_:79f295ad32df4ce8a18a92539c6e8a3b208497 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208498;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b208498 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10594 .

_:79f295ad32df4ce8a18a92539c6e8a3b208500 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10741-1 a owl:Class;
  rdfs:label "DEFERASIROX <-> DÉFÉRIPRONE"@fr;
  dct:identifier "IAM_10741";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b208502;
  r:natureDuRisque "Risque d'hyperchélation."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b208508, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b208502 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b208503 .

_:79f295ad32df4ce8a18a92539c6e8a3b208503 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208504;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b208505 .

_:79f295ad32df4ce8a18a92539c6e8a3b208504 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10259 .

_:79f295ad32df4ce8a18a92539c6e8a3b208505 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208506;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b208506 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10260 .

_:79f295ad32df4ce8a18a92539c6e8a3b208508 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10742-1 a owl:Class;
  rdfs:label "DEFERASIROX <-> DÉFÉROXAMINE"@fr;
  dct:identifier "IAM_10742";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b208510;
  r:natureDuRisque "Risque d'hyperchélation."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b208516, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b208510 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b208511 .

_:79f295ad32df4ce8a18a92539c6e8a3b208511 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208512;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b208513 .

_:79f295ad32df4ce8a18a92539c6e8a3b208512 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10259 .

_:79f295ad32df4ce8a18a92539c6e8a3b208513 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208514;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b208514 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10261 .

_:79f295ad32df4ce8a18a92539c6e8a3b208516 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10743-1 a owl:Class;
  rdfs:label "DEFERASIROX <-> REPAGLINIDE"@fr;
  dct:identifier "IAM_10743";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b208518;
  r:natureDuRisque "Risque d’augmentation des concentrations plasmatique de répaglinide, par inhibition de son métabolisme hépatique par le deferasirox."@fr;
  r:conduiteATenir "Si l’association ne peut être évitée, surveillance clinique et biologique étroite."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b208524, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b208518 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b208519 .

_:79f295ad32df4ce8a18a92539c6e8a3b208519 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208520;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b208521 .

_:79f295ad32df4ce8a18a92539c6e8a3b208520 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10259 .

_:79f295ad32df4ce8a18a92539c6e8a3b208521 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208522;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b208522 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10791 .

_:79f295ad32df4ce8a18a92539c6e8a3b208524 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10744-1 a owl:Class;
  rdfs:label "DEFERASIROX <-> RIFAMPICINE"@fr;
  dct:identifier "IAM_10744";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b208526;
  r:natureDuRisque "Risque de diminution des concentrations plasmatiques de déférasirox."@fr;
  r:conduiteATenir "Surveiller la ferritinémie pendant et après le traitement par l’inducteur enzymatique. Si besoin, adaptation de la posologie de déférasirox."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b208532, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b208526 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b208527 .

_:79f295ad32df4ce8a18a92539c6e8a3b208527 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208528;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b208529 .

_:79f295ad32df4ce8a18a92539c6e8a3b208528 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10259 .

_:79f295ad32df4ce8a18a92539c6e8a3b208529 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208530;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b208530 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:79f295ad32df4ce8a18a92539c6e8a3b208532 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10745-1 a owl:Class;
  rdfs:label "DÉFIBROTIDE <-> HÉPARINES"@fr;
  dct:identifier "IAM_10745";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b208534;
  r:natureDuRisque "Risque hémorragique accru."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b208540, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b208534 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b208535 .

_:79f295ad32df4ce8a18a92539c6e8a3b208535 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208536;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b208537 .

_:79f295ad32df4ce8a18a92539c6e8a3b208536 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10088 .

_:79f295ad32df4ce8a18a92539c6e8a3b208537 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208538;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b208538 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10262 .

_:79f295ad32df4ce8a18a92539c6e8a3b208540 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10746-1 a owl:Class;
  rdfs:label "DÉFIBROTIDE <-> THROMBOLYTIQUES"@fr;
  dct:identifier "IAM_10746";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b208542;
  r:natureDuRisque "Risque hémorragique accru."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b208548, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b208542 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b208543 .

_:79f295ad32df4ce8a18a92539c6e8a3b208543 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208544;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b208545 .

_:79f295ad32df4ce8a18a92539c6e8a3b208544 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10151 .

_:79f295ad32df4ce8a18a92539c6e8a3b208545 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208546;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b208546 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10262 .

_:79f295ad32df4ce8a18a92539c6e8a3b208548 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10747-1 a owl:Class;
  rdfs:label "DÉLAMANID <-> RIFAMPICINE"@fr;
  dct:identifier "IAM_10747";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b208550;
  r:natureDuRisque "Diminution des concentrations plasmatiques de delamanid par augmentation de son métabolisme hépatique par l’inducteur."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b208556, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b208550 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b208551 .

_:79f295ad32df4ce8a18a92539c6e8a3b208551 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208552;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b208553 .

_:79f295ad32df4ce8a18a92539c6e8a3b208552 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10263 .

_:79f295ad32df4ce8a18a92539c6e8a3b208553 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208554;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b208554 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:79f295ad32df4ce8a18a92539c6e8a3b208556 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10748-1 a owl:Class;
  rdfs:label "DÉRIVÉS NITRÉS ET APPARENTÉS <-> INHIBITEURS DE LA PHOSPHODIESTERASE DE TYPE 5"@fr;
  dct:identifier "IAM_10748";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b208558;
  r:natureDuRisque "Risque d'hypotension importante (effet synergique) pouvant aggraver l'état d'ischémie myocardique et provoquer notamment un accident coronarien aigu."@fr;
  rdfs:comment "Les dérivés nitrés sont des donneurs de monoxyde d'azote (NO). A ce titre, ils sont contre-indiqués avec le sildénafil, le vardénafil et le tadalafil, en raison du risque de vasodilatation majeure, pouvant être à l'origine d'un collapsus."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b208564, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b208558 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b208559 .

_:79f295ad32df4ce8a18a92539c6e8a3b208559 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208560;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b208561 .

_:79f295ad32df4ce8a18a92539c6e8a3b208560 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10071 .

_:79f295ad32df4ce8a18a92539c6e8a3b208561 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208562;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b208562 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10098 .

_:79f295ad32df4ce8a18a92539c6e8a3b208564 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10787-1 a owl:Class;
  rdfs:label "DIGOXINE <-> SUCRALFATE"@fr;
  dct:identifier "IAM_10787";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b208566;
  r:natureDuRisque "Diminution de l'absorption digestive de la digoxine."@fr;
  r:conduiteATenir "Prendre le sucralfate à distance de la digoxine (plus de 2 heures, si possible)."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b208572, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b208566 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b208567 .

_:79f295ad32df4ce8a18a92539c6e8a3b208567 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208568;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b208569 .

_:79f295ad32df4ce8a18a92539c6e8a3b208568 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10286 .

_:79f295ad32df4ce8a18a92539c6e8a3b208569 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208570;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b208570 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10864 .

_:79f295ad32df4ce8a18a92539c6e8a3b208572 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10750-1 a owl:Class;
  rdfs:label "DÉRIVÉS NITRÉS ET APPARENTÉS <-> RIOCIGUAT"@fr;
  dct:identifier "IAM_10750";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b208574;
  r:natureDuRisque "Risque d'hypotension importante (effet synergique)."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b208580, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b208574 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b208575 .

_:79f295ad32df4ce8a18a92539c6e8a3b208575 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208576;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b208577 .

_:79f295ad32df4ce8a18a92539c6e8a3b208576 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10071 .

_:79f295ad32df4ce8a18a92539c6e8a3b208577 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208578;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b208578 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10804 .

_:79f295ad32df4ce8a18a92539c6e8a3b208580 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10737-1 a owl:Class;
  rdfs:label "DASABUVIR <-> GEMFIBROZIL"@fr;
  dct:identifier "IAM_10737";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b208582;
  r:natureDuRisque "Risque d’augmentation des concentrations plasmatiques du dasabuvir par le gemfibrozil."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b208588, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b208582 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b208583 .

_:79f295ad32df4ce8a18a92539c6e8a3b208583 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208584;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b208585 .

_:79f295ad32df4ce8a18a92539c6e8a3b208584 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10255 .

_:79f295ad32df4ce8a18a92539c6e8a3b208585 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208586;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b208586 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10411 .

_:79f295ad32df4ce8a18a92539c6e8a3b208588 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10752-1 a owl:Class;
  rdfs:label "DEXAMETHASONE <-> INHIBITEURS DE PROTÉASES BOOSTÉS PAR RITONAVIR"@fr;
  dct:identifier "IAM_10752";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b208590;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de la dexaméthasone par diminution de son métabolisme hépatique par l'inhibiteur de protéases, avec risque d’apparition d’un syndrome cushingoïde."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b208596, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b208590 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b208591 .

_:79f295ad32df4ce8a18a92539c6e8a3b208591 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208592;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b208593 .

_:79f295ad32df4ce8a18a92539c6e8a3b208592 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10100 .

_:79f295ad32df4ce8a18a92539c6e8a3b208593 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208594;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b208594 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10272 .

_:79f295ad32df4ce8a18a92539c6e8a3b208596 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10753-1 a owl:Class;
  rdfs:label "DEXAMETHASONE <-> ITRACONAZOLE"@fr;
  dct:identifier "IAM_10753";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b208598;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de la dexaméthasone par diminution de son métabolisme hépatique par l'inhibiteur enzymatique, avec risque d’apparition d’un syndrome cushingoïde."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b208604, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b208598 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b208599 .

_:79f295ad32df4ce8a18a92539c6e8a3b208599 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208600;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b208601 .

_:79f295ad32df4ce8a18a92539c6e8a3b208600 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10272 .

_:79f295ad32df4ce8a18a92539c6e8a3b208601 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208602;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b208602 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10496 .

_:79f295ad32df4ce8a18a92539c6e8a3b208604 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10754-1 a owl:Class;
  rdfs:label "DEXAMETHASONE <-> KETOCONAZOLE"@fr;
  dct:identifier "IAM_10754";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b208606;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de la dexaméthasone par diminution de son métabolisme hépatique par l'inhibiteur enzymatique, avec risque d’apparition d’un syndrome cushingoïde."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b208612, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b208606 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b208607 .

_:79f295ad32df4ce8a18a92539c6e8a3b208607 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208608;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b208609 .

_:79f295ad32df4ce8a18a92539c6e8a3b208608 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10272 .

_:79f295ad32df4ce8a18a92539c6e8a3b208609 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208610;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b208610 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10501 .

_:79f295ad32df4ce8a18a92539c6e8a3b208612 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10755-1 a owl:Class;
  rdfs:label "DEXAMETHASONE <-> POSACONAZOLE"@fr;
  dct:identifier "IAM_10755";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b208614;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de la dexaméthasone par diminution de son métabolisme hépatique par l'inhibiteur enzymatique, avec risque d’apparition d’un syndrome cushingoïde."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b208620, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b208614 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b208615 .

_:79f295ad32df4ce8a18a92539c6e8a3b208615 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208616;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b208617 .

_:79f295ad32df4ce8a18a92539c6e8a3b208616 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10272 .

_:79f295ad32df4ce8a18a92539c6e8a3b208617 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208618;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b208618 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10741 .

_:79f295ad32df4ce8a18a92539c6e8a3b208620 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10756-1 a owl:Class;
  rdfs:label "DEXAMETHASONE <-> PRAZIQUANTEL"@fr;
  dct:identifier "IAM_10756";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b208622;
  r:natureDuRisque "Diminution des concentrations plasmatiques du praziquantel, avec risque d'échec du traitement, par augmentation du métabolisme hépatique du praziquantel par la dexaméthasone."@fr;
  r:conduiteATenir "Décaler l'administration des deux médicaments d'au moins une semaine."@fr;
  rdfs:comment "La dexamethasone diminue les concentrations de praziquantel en cas d'administration simultanée. Compte tenu du mode d'utilisation du praziquantel, sur une période courte, il est préférable de différer l'administration de la dexaméthasone, utilisée dans ce"@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b208628, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b208622 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b208623 .

_:79f295ad32df4ce8a18a92539c6e8a3b208623 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208624;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b208625 .

_:79f295ad32df4ce8a18a92539c6e8a3b208624 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10272 .

_:79f295ad32df4ce8a18a92539c6e8a3b208625 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208626;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b208626 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10750 .

_:79f295ad32df4ce8a18a92539c6e8a3b208628 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10757-1 a owl:Class;
  rdfs:label "DEXAMETHASONE <-> RILPIVIRINE"@fr;
  dct:identifier "IAM_10757";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b208630;
  r:natureDuRisque "Avec la dexaméthasone par voie systémique (sauf en cas de prise unique), risque de diminution des concentrations plasmatiques de rilpivirine par augmentation de son métabolisme hépatique par la dexamethasone."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b208636, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b208630 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b208631 .

_:79f295ad32df4ce8a18a92539c6e8a3b208631 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208632;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b208633 .

_:79f295ad32df4ce8a18a92539c6e8a3b208632 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10272 .

_:79f295ad32df4ce8a18a92539c6e8a3b208633 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208634;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b208634 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10803 .

_:79f295ad32df4ce8a18a92539c6e8a3b208636 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10945-1 a owl:Class;
  rdfs:label "FLUCONAZOLE <-> IMMUNOSUPPRESSEURS"@fr;
  dct:identifier "IAM_10945";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b208638;
  r:natureDuRisque "Risque d'augmentation des concentrations sanguines de l'immunosuppresseur par inhibition de son métabolisme et de la créatininémie."@fr;
  r:conduiteATenir "Dosage des concentrations sanguines de l'immunosuppresseur, contrôle de la fonction rénale et adaptation de sa posologie pendant l'association et après son arrêt."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b208644, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b208638 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b208639 .

_:79f295ad32df4ce8a18a92539c6e8a3b208639 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208640;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b208641 .

_:79f295ad32df4ce8a18a92539c6e8a3b208640 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10093 .

_:79f295ad32df4ce8a18a92539c6e8a3b208641 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208642;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b208642 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10381 .

_:79f295ad32df4ce8a18a92539c6e8a3b208644 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10946-1 a owl:Class;
  rdfs:label "FLUCONAZOLE <-> IVACAFTOR"@fr;
  dct:identifier "IAM_10946";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b208646;
  r:natureDuRisque "Augmentation des concentrations d’ivacaftor, avec risques de majoration des effets indésirables."@fr;
  r:conduiteATenir "Réduire la dose de moitié, soit 150 mg/j."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b208652, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b208646 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b208647 .

_:79f295ad32df4ce8a18a92539c6e8a3b208647 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208648;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b208649 .

_:79f295ad32df4ce8a18a92539c6e8a3b208648 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10381 .

_:79f295ad32df4ce8a18a92539c6e8a3b208649 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208650;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b208650 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10498 .

_:79f295ad32df4ce8a18a92539c6e8a3b208652 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10947-1 a owl:Class;
  rdfs:label "FLUCONAZOLE <-> LOSARTAN"@fr;
  dct:identifier "IAM_10947";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b208654;
  r:natureDuRisque "Risque de diminution de l’efficacité du losartan, par inhibition de la formation de son métabolite actif par le fluconazole."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b208660, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b208654 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b208655 .

_:79f295ad32df4ce8a18a92539c6e8a3b208655 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208656;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b208657 .

_:79f295ad32df4ce8a18a92539c6e8a3b208656 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10381 .

_:79f295ad32df4ce8a18a92539c6e8a3b208657 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208658;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b208658 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10539 .

_:79f295ad32df4ce8a18a92539c6e8a3b208660 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10749-1 a owl:Class;
  rdfs:label "DÉRIVÉS NITRÉS ET APPARENTÉS <-> MÉDICAMENTS ABAISSANT LA PRESSION ARTÉRIELLE"@fr;
  dct:identifier "IAM_10749";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b208662;
  r:natureDuRisque "Majoration du risque d’hypotension, notamment orthostatique."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b208668, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b208662 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b208663 .

_:79f295ad32df4ce8a18a92539c6e8a3b208663 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208664;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b208665 .

_:79f295ad32df4ce8a18a92539c6e8a3b208664 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10071 .

_:79f295ad32df4ce8a18a92539c6e8a3b208665 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208666;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b208666 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10113 .

_:79f295ad32df4ce8a18a92539c6e8a3b208668 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10727-1 a owl:Class;
  rdfs:label "DANTROLENE <-> DILTIAZEM"@fr;
  dct:identifier "IAM_10727";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b208670;
  r:natureDuRisque "Avec le dantrolène administré par perfusion : chez l'animal, des cas de fibrillations ventriculaires mortelles sont constamment observés lors de l'administration de vérapamil et de dantrolène par voie IV. L'association d'un antagoniste du calcium et de da"@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b208676, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b208670 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b208671 .

_:79f295ad32df4ce8a18a92539c6e8a3b208671 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208672;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b208673 .

_:79f295ad32df4ce8a18a92539c6e8a3b208672 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10249 .

_:79f295ad32df4ce8a18a92539c6e8a3b208673 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208674;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b208674 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10290 .

_:79f295ad32df4ce8a18a92539c6e8a3b208676 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10716-1 a owl:Class;
  rdfs:label "DACLATASVIR <-> INHIBITEURS PUISSANTS DU CYP3A4"@fr;
  dct:identifier "IAM_10716";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b208678;
  r:natureDuRisque "Augmentation des concentrations de daclatasvir par l’inhibiteur."@fr;
  r:conduiteATenir "La dose de daclatasvir doit être diminuée à 30 mg 1 fois par jour en cas de co-administration avec l'inhibiteur."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b208684, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b208678 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b208679 .

_:79f295ad32df4ce8a18a92539c6e8a3b208679 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208680;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b208681 .

_:79f295ad32df4ce8a18a92539c6e8a3b208680 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10103 .

_:79f295ad32df4ce8a18a92539c6e8a3b208681 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208682;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b208682 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10243 .

_:79f295ad32df4ce8a18a92539c6e8a3b208684 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10717-1 a owl:Class;
  rdfs:label "DACLATASVIR <-> MILLEPERTUIS"@fr;
  dct:identifier "IAM_10717";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b208686;
  r:natureDuRisque "Risque de diminution significative des concentrations plasmatiques de daclatasvir par augmentation de son métabolisme hépatique par le millepertuis."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b208692, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b208686 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b208687 .

_:79f295ad32df4ce8a18a92539c6e8a3b208687 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208688;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b208689 .

_:79f295ad32df4ce8a18a92539c6e8a3b208688 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10243 .

_:79f295ad32df4ce8a18a92539c6e8a3b208689 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208690;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b208690 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10588 .

_:79f295ad32df4ce8a18a92539c6e8a3b208692 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10718-1 a owl:Class;
  rdfs:label "DALFOPRISTINE <-> DIHYDROERGOTAMINE"@fr;
  dct:identifier "IAM_10718";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b208694;
  r:natureDuRisque "Ergotisme avec possibilité de nécrose des extrémités (inhibition du métabolisme hépatique de l'alcaloïde de l'ergot de seigle)."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b208700, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b208694 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b208695 .

_:79f295ad32df4ce8a18a92539c6e8a3b208695 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208696;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b208697 .

_:79f295ad32df4ce8a18a92539c6e8a3b208696 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10245 .

_:79f295ad32df4ce8a18a92539c6e8a3b208697 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208698;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b208698 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10289 .

_:79f295ad32df4ce8a18a92539c6e8a3b208700 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10719-1 a owl:Class;
  rdfs:label "DALFOPRISTINE <-> ERGOTAMINE"@fr;
  dct:identifier "IAM_10719";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b208702;
  r:natureDuRisque "Ergotisme avec possibilité de nécrose des extrémités (inhibition du métabolisme hépatique de l'alcaloïde de l'ergot de seigle)."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b208708, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b208702 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b208703 .

_:79f295ad32df4ce8a18a92539c6e8a3b208703 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208704;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b208705 .

_:79f295ad32df4ce8a18a92539c6e8a3b208704 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10245 .

_:79f295ad32df4ce8a18a92539c6e8a3b208705 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208706;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b208706 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10334 .

_:79f295ad32df4ce8a18a92539c6e8a3b208708 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10720-1 a owl:Class;
  rdfs:label "DALFOPRISTINE <-> IMMUNOSUPPRESSEURS"@fr;
  dct:identifier "IAM_10720";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b208710;
  r:natureDuRisque "Augmentation des concentrations sanguines de l'immunosuppresseur par inhibition de son métabolisme hépatique."@fr;
  r:conduiteATenir "Dosage des concentrations sanguines de l'immunosuppresseur, contrôle de la fonction rénale et adaptation de la posologie pendant l'association et après son arrêt."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b208716, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b208710 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b208711 .

_:79f295ad32df4ce8a18a92539c6e8a3b208711 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208712;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b208713 .

_:79f295ad32df4ce8a18a92539c6e8a3b208712 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10093 .

_:79f295ad32df4ce8a18a92539c6e8a3b208713 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208714;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b208714 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10245 .

_:79f295ad32df4ce8a18a92539c6e8a3b208716 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10721-1 a owl:Class;
  rdfs:label "DALFOPRISTINE <-> PIMOZIDE"@fr;
  dct:identifier "IAM_10721";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b208718;
  r:natureDuRisque "Risque majoré de troubles du rythme ventriculaire, notamment de torsades de pointes."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b208724, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b208718 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b208719 .

_:79f295ad32df4ce8a18a92539c6e8a3b208719 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208720;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b208721 .

_:79f295ad32df4ce8a18a92539c6e8a3b208720 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10245 .

_:79f295ad32df4ce8a18a92539c6e8a3b208721 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208722;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b208722 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10721 .

_:79f295ad32df4ce8a18a92539c6e8a3b208724 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10722-1 a owl:Class;
  rdfs:label "DANAZOL <-> INSULINE"@fr;
  dct:identifier "IAM_10722";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b208726;
  r:natureDuRisque "Effet diabétogène du danazol."@fr;
  r:conduiteATenir "Si l'association ne peut être évitée, prévenir le patient et renforcer l'autosurveillance glycémique. Adapter éventuellement la posologie de l'insuline pendant le traitement par le danazol et après son arrêt."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b208732, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b208726 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b208727 .

_:79f295ad32df4ce8a18a92539c6e8a3b208727 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208728;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b208729 .

_:79f295ad32df4ce8a18a92539c6e8a3b208728 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10248 .

_:79f295ad32df4ce8a18a92539c6e8a3b208729 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208730;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b208730 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10458 .

_:79f295ad32df4ce8a18a92539c6e8a3b208732 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10723-1 a owl:Class;
  rdfs:label "DANAZOL <-> SIMVASTATINE"@fr;
  dct:identifier "IAM_10723";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b208734;
  r:natureDuRisque "Risque majoré d'effets indésirables (concentration-dépendants) à type de rhabdomyolyse par diminution du métabolisme de la simvastatine."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b208740, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b208734 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b208735 .

_:79f295ad32df4ce8a18a92539c6e8a3b208735 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208736;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b208737 .

_:79f295ad32df4ce8a18a92539c6e8a3b208736 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10248 .

_:79f295ad32df4ce8a18a92539c6e8a3b208737 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208738;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b208738 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10838 .

_:79f295ad32df4ce8a18a92539c6e8a3b208740 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10724-1 a owl:Class;
  rdfs:label "DANAZOL <-> SULFAMIDES HYPOGLYCÉMIANTS"@fr;
  dct:identifier "IAM_10724";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b208742;
  r:natureDuRisque "Effet diabétogène du danazol."@fr;
  r:conduiteATenir "Si l'association ne peut être évitée, prévenir le patient et renforcer l'autosurveillance glycémique. Adapter éventuellement la posologie de l'antidiabétique pendant le traitement par le danazol et après son arrêt."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b208748, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b208742 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b208743 .

_:79f295ad32df4ce8a18a92539c6e8a3b208743 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208744;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b208745 .

_:79f295ad32df4ce8a18a92539c6e8a3b208744 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10147 .

_:79f295ad32df4ce8a18a92539c6e8a3b208745 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208746;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b208746 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10248 .

_:79f295ad32df4ce8a18a92539c6e8a3b208748 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10739-1 a owl:Class;
  rdfs:label "DASABUVIR <-> MILLEPERTUIS"@fr;
  dct:identifier "IAM_10739";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b208750;
  r:natureDuRisque "Risque de diminution des concentrations plasmatiques du dasabuvir par le millepertuis."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b208756, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b208750 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b208751 .

_:79f295ad32df4ce8a18a92539c6e8a3b208751 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208752;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b208753 .

_:79f295ad32df4ce8a18a92539c6e8a3b208752 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10255 .

_:79f295ad32df4ce8a18a92539c6e8a3b208753 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208754;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b208754 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10588 .

_:79f295ad32df4ce8a18a92539c6e8a3b208756 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10726-1 a owl:Class;
  rdfs:label "DANTROLENE <-> DIHYDROPYRIDINES"@fr;
  dct:identifier "IAM_10726";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b208758;
  r:natureDuRisque "Avec le dantrolène administré par perfusion : chez l'animal des cas de fibrillations ventriculaires mortelles sont constamment observés lors de l'administration de vérapamil et de dantrolène IV. L'association d'un antagoniste du calcium et de dantrolène e"@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b208764, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b208758 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b208759 .

_:79f295ad32df4ce8a18a92539c6e8a3b208759 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208760;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b208761 .

_:79f295ad32df4ce8a18a92539c6e8a3b208760 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10062 .

_:79f295ad32df4ce8a18a92539c6e8a3b208761 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208762;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b208762 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10249 .

_:79f295ad32df4ce8a18a92539c6e8a3b208764 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10738-1 a owl:Class;
  rdfs:label "DASABUVIR <-> INDUCTEURS ENZYMATIQUES"@fr;
  dct:identifier "IAM_10738";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b208766;
  r:natureDuRisque "Risque de diminution des concentrations plasmatiques du dasabuvir par l’inducteur."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b208772, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b208766 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b208767 .

_:79f295ad32df4ce8a18a92539c6e8a3b208767 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208768;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b208769 .

_:79f295ad32df4ce8a18a92539c6e8a3b208768 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10094 .

_:79f295ad32df4ce8a18a92539c6e8a3b208769 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208770;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b208770 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10255 .

_:79f295ad32df4ce8a18a92539c6e8a3b208772 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10728-1 a owl:Class;
  rdfs:label "DANTROLENE <-> VERAPAMIL"@fr;
  dct:identifier "IAM_10728";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b208774;
  r:natureDuRisque "Avec le dantrolène administré par perfusion : chez l'animal, des cas de fibrillations ventriculaires mortelles sont constamment observés lors de l'administration de vérapamil et de dantrolène par voie IV. L'association d'un antagoniste du calcium et de da"@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b208780, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b208774 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b208775 .

_:79f295ad32df4ce8a18a92539c6e8a3b208775 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208776;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b208777 .

_:79f295ad32df4ce8a18a92539c6e8a3b208776 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10249 .

_:79f295ad32df4ce8a18a92539c6e8a3b208777 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208778;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b208778 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10980 .

_:79f295ad32df4ce8a18a92539c6e8a3b208780 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10729-1 a owl:Class;
  rdfs:label "DAPOXÉTINE <-> INHIBITEURS PUISSANTS DU CYP3A4"@fr;
  dct:identifier "IAM_10729";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b208782;
  r:natureDuRisque "Risque de majoration des effets indésirables, notamment à type de vertiges ou de syncopes."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b208788, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b208782 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b208783 .

_:79f295ad32df4ce8a18a92539c6e8a3b208783 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208784;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b208785 .

_:79f295ad32df4ce8a18a92539c6e8a3b208784 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10103 .

_:79f295ad32df4ce8a18a92539c6e8a3b208785 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208786;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b208786 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10250 .

_:79f295ad32df4ce8a18a92539c6e8a3b208788 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10730-1 a owl:Class;
  rdfs:label "DAPOXÉTINE <-> MÉDICAMENTS À L'ORIGINE D'UNE HYPOTENSION ORTHOSTATIQUE"@fr;
  dct:identifier "IAM_10730";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b208790;
  r:natureDuRisque "Risque de majoration des effets indésirables, notamment à type de vertiges ou de syncopes."@fr;
  r:conduiteATenir """Association déconseillée
- avec les inhibiteurs de la phosphodiestérase de type 5

A prendre en compte 
- avec les autres classes thérapeutiques"""@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b208796, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b208790 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b208791 .

_:79f295ad32df4ce8a18a92539c6e8a3b208791 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208792;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b208793 .

_:79f295ad32df4ce8a18a92539c6e8a3b208792 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10122 .

_:79f295ad32df4ce8a18a92539c6e8a3b208793 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208794;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b208794 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10250 .

_:79f295ad32df4ce8a18a92539c6e8a3b208796 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10731-1 a owl:Class;
  rdfs:label "DAPSONE <-> ZIDOVUDINE"@fr;
  dct:identifier "IAM_10731";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b208798;
  r:natureDuRisque "Augmentation de la toxicité hématologique (addition d'effets de toxicité médullaire)."@fr;
  r:conduiteATenir "Contrôle plus fréquent de l'hémogramme."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b208804, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b208798 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b208799 .

_:79f295ad32df4ce8a18a92539c6e8a3b208799 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208800;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b208801 .

_:79f295ad32df4ce8a18a92539c6e8a3b208800 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10251 .

_:79f295ad32df4ce8a18a92539c6e8a3b208801 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208802;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b208802 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_11004 .

_:79f295ad32df4ce8a18a92539c6e8a3b208804 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10732-1 a owl:Class;
  rdfs:label "DAPTOMYCINE <-> INHIBITEURS DE L'HMG-COA RÉDUCTASE (STATINES)"@fr;
  dct:identifier "IAM_10732";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b208806;
  r:natureDuRisque "Risque d’addition des effets indésirables (dose-dépendant) à type de rhabdomyolyse."@fr;
  r:conduiteATenir "Si l’association ne peut être évitée, renforcer la surveillance biologique (dosage des CPK plus d’une fois par semaine) et surveillance clinique étroite."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b208812, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b208806 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b208807 .

_:79f295ad32df4ce8a18a92539c6e8a3b208807 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208808;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b208809 .

_:79f295ad32df4ce8a18a92539c6e8a3b208808 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10095 .

_:79f295ad32df4ce8a18a92539c6e8a3b208809 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208810;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b208810 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10252 .

_:79f295ad32df4ce8a18a92539c6e8a3b208812 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10733-1 a owl:Class;
  rdfs:label "DARIFENACINE <-> FLECAINIDE"@fr;
  dct:identifier "IAM_10733";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b208814;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de flécaïnide, avec risque de surdosage, par diminution de son métabolisme hépatique par la darifénacine."@fr;
  r:conduiteATenir "Surveillance clinique et réduction de la posologie du flécaïnide pendant le traitement par darifénacine."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b208820, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b208814 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b208815 .

_:79f295ad32df4ce8a18a92539c6e8a3b208815 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208816;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b208817 .

_:79f295ad32df4ce8a18a92539c6e8a3b208816 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10253 .

_:79f295ad32df4ce8a18a92539c6e8a3b208817 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208818;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b208818 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10380 .

_:79f295ad32df4ce8a18a92539c6e8a3b208820 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10734-1 a owl:Class;
  rdfs:label "DARIFENACINE <-> METOPROLOL"@fr;
  dct:identifier "IAM_10734";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b208822;
  r:natureDuRisque "Augmentation des concentrations plasmatiques du métoprolol, avec risque de surdosage, par diminution de son métabolisme hépatique par la darifénacine."@fr;
  r:conduiteATenir "Surveillance clinique et réduction de la posologie du métoprolol pendant le traitement par darifénacine."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b208828, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b208822 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b208823 .

_:79f295ad32df4ce8a18a92539c6e8a3b208823 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208824;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b208825 .

_:79f295ad32df4ce8a18a92539c6e8a3b208824 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10253 .

_:79f295ad32df4ce8a18a92539c6e8a3b208825 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208826;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b208826 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10579 .

_:79f295ad32df4ce8a18a92539c6e8a3b208828 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10735-1 a owl:Class;
  rdfs:label "DARIFENACINE <-> PROPAFENONE"@fr;
  dct:identifier "IAM_10735";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b208830;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de propafénone, avec risque de surdosage, par diminution de son métabolisme hépatique par la darifénacine."@fr;
  r:conduiteATenir "Surveillance clinique et réduction de la posologie de la propafénone pendant le traitement par darifénacine."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b208836, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b208830 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b208831 .

_:79f295ad32df4ce8a18a92539c6e8a3b208831 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208832;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b208833 .

_:79f295ad32df4ce8a18a92539c6e8a3b208832 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10253 .

_:79f295ad32df4ce8a18a92539c6e8a3b208833 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208834;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b208834 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10765 .

_:79f295ad32df4ce8a18a92539c6e8a3b208836 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10736-1 a owl:Class;
  rdfs:label "DASABUVIR <-> ETHINYLESTRADIOL"@fr;
  dct:identifier "IAM_10736";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b208838;
  r:natureDuRisque "Augmentation de l’hépatotoxicité."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b208844, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b208838 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b208839 .

_:79f295ad32df4ce8a18a92539c6e8a3b208839 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208840;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b208841 .

_:79f295ad32df4ce8a18a92539c6e8a3b208840 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10255 .

_:79f295ad32df4ce8a18a92539c6e8a3b208841 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208842;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b208842 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10351 .

_:79f295ad32df4ce8a18a92539c6e8a3b208844 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10950-1 a owl:Class;
  rdfs:label "FLUCONAZOLE <-> OLAPARIB"@fr;
  dct:identifier "IAM_10950";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b208846;
  r:natureDuRisque "Augmentation des concentrations plasmatiques d’olaparib par le fluconazole."@fr;
  r:conduiteATenir "Si l’association ne peut être évitée, limiter la dose d’olaparib à 200 mg deux fois par jour."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b208852, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b208846 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b208847 .

_:79f295ad32df4ce8a18a92539c6e8a3b208847 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208848;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b208849 .

_:79f295ad32df4ce8a18a92539c6e8a3b208848 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10381 .

_:79f295ad32df4ce8a18a92539c6e8a3b208849 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208850;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b208850 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10659 .

_:79f295ad32df4ce8a18a92539c6e8a3b208852 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10725-1 a owl:Class;
  rdfs:label "DANAZOL <-> TACROLIMUS"@fr;
  dct:identifier "IAM_10725";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b208854;
  r:natureDuRisque "Augmentation des concentrations sanguines du tacrolimus par inhibition de son métabolisme hépatique."@fr;
  r:conduiteATenir "Dosage des concentrations sanguines du tacrolimus et adaptation de sa posologie pendant l'association et après son arrêt, avec contrôle de la fonction rénale."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b208860, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b208854 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b208855 .

_:79f295ad32df4ce8a18a92539c6e8a3b208855 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208856;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b208857 .

_:79f295ad32df4ce8a18a92539c6e8a3b208856 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10248 .

_:79f295ad32df4ce8a18a92539c6e8a3b208857 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208858;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b208858 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10880 .

_:79f295ad32df4ce8a18a92539c6e8a3b208860 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10774-1 a owl:Class;
  rdfs:label "DIGOXINE <-> ERYTHROMYCINE"@fr;
  dct:identifier "IAM_10774";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b208862;
  r:natureDuRisque "Augmentation de la digoxinémie par augmentation de son absorption."@fr;
  r:conduiteATenir "Surveillance clinique et éventuellement de la digoxinémie pendant le traitement par l'érythromycine et après son arrêt."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b208868, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b208862 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b208863 .

_:79f295ad32df4ce8a18a92539c6e8a3b208863 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208864;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b208865 .

_:79f295ad32df4ce8a18a92539c6e8a3b208864 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10286 .

_:79f295ad32df4ce8a18a92539c6e8a3b208865 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208866;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b208866 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10338 .

_:79f295ad32df4ce8a18a92539c6e8a3b208868 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10948-1 a owl:Class;
  rdfs:label "FLUCONAZOLE <-> MIDAZOLAM"@fr;
  dct:identifier "IAM_10948";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b208870;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de midazolam par diminution de son métabolisme hépatique, avec majoration de la sédation."@fr;
  r:conduiteATenir "Surveillance clinique et réduction de la posologie de midazolam en cas de traitement par le fluconazole."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b208876, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b208870 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b208871 .

_:79f295ad32df4ce8a18a92539c6e8a3b208871 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208872;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b208873 .

_:79f295ad32df4ce8a18a92539c6e8a3b208872 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10381 .

_:79f295ad32df4ce8a18a92539c6e8a3b208873 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208874;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b208874 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10585 .

_:79f295ad32df4ce8a18a92539c6e8a3b208876 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10765-1 a owl:Class;
  rdfs:label "DIAZEPAM <-> PHÉNYTOÏNE (ET, PAR EXTRAPOLATION, FOSPHÉNYTOÏNE)"@fr;
  dct:identifier "IAM_10765";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b208878;
  r:natureDuRisque "Variations imprévisibles : les concentrations plasmatiques de phénytoïne peuvent augmenter, avec signes de surdosage, mais aussi diminuer ou rester stables."@fr;
  r:conduiteATenir "Surveillance clinique et contrôle des concentrations plasmatiques de phénytoïne."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b208884, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b208878 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b208879 .

_:79f295ad32df4ce8a18a92539c6e8a3b208879 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208880;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b208881 .

_:79f295ad32df4ce8a18a92539c6e8a3b208880 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10132 .

_:79f295ad32df4ce8a18a92539c6e8a3b208881 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208882;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b208882 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10280 .

_:79f295ad32df4ce8a18a92539c6e8a3b208884 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10766-1 a owl:Class;
  rdfs:label "DIAZEPAM <-> STIRIPENTOL"@fr;
  dct:identifier "IAM_10766";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b208886;
  r:natureDuRisque "Augmentation des concentrations plasmatiques du diazépam, avec risque de surdosage, par inhibition de son métabolisme hépatique."@fr;
  r:conduiteATenir "Surveillance clinique et dosage plasmatique, lorsque cela est possible, de l'anticonvulsivant associé au stiripentol et éventuelle adaptation posologique de l'anticonvulsivant associé."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b208892, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b208886 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b208887 .

_:79f295ad32df4ce8a18a92539c6e8a3b208887 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208888;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b208889 .

_:79f295ad32df4ce8a18a92539c6e8a3b208888 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10280 .

_:79f295ad32df4ce8a18a92539c6e8a3b208889 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208890;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b208890 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10859 .

_:79f295ad32df4ce8a18a92539c6e8a3b208892 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10772-1 a owl:Class;
  rdfs:label "DIDANOSINE <-> ZALCITABINE"@fr;
  dct:identifier "IAM_10772";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b208894;
  r:natureDuRisque "Risque majoré de survenue de pancréatite et de neuropathies périphériques par addition d'effets indésirables."@fr;
  r:conduiteATenir "Surveillance clinique régulière et surveillance de l'amylasémie. Ne pas associer si l'amylasémie est à la limite supérieure de la normale."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b208900, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b208894 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b208895 .

_:79f295ad32df4ce8a18a92539c6e8a3b208895 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208896;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b208897 .

_:79f295ad32df4ce8a18a92539c6e8a3b208896 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10283 .

_:79f295ad32df4ce8a18a92539c6e8a3b208897 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208898;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b208898 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_11002 .

_:79f295ad32df4ce8a18a92539c6e8a3b208900 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10767-1 a owl:Class;
  rdfs:label "DIDANOSINE <-> GANCICLOVIR"@fr;
  dct:identifier "IAM_10767";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b208902;
  r:natureDuRisque "Risque d'augmentation des effets indésirables de la didanosine, et notamment la toxicité mitochondriale, par augmentation importante de ses concentrations. De plus risque de diminution de l'efficacité du ganciclovir par diminution de ses concentrations, s"@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b208908, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b208902 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b208903 .

_:79f295ad32df4ce8a18a92539c6e8a3b208903 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208904;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b208905 .

_:79f295ad32df4ce8a18a92539c6e8a3b208904 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10283 .

_:79f295ad32df4ce8a18a92539c6e8a3b208905 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208906;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b208906 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10408 .

_:79f295ad32df4ce8a18a92539c6e8a3b208908 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10768-1 a owl:Class;
  rdfs:label "DIDANOSINE <-> PENTAMIDINE"@fr;
  dct:identifier "IAM_10768";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b208910;
  r:natureDuRisque "Risque majoré de survenue de pancréatite par addition d'effets indésirables."@fr;
  r:conduiteATenir "Surveillance de l'amylasémie. Ne pas associer si l'amylasémie est à la limite supérieure de la normale."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b208916, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b208910 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b208911 .

_:79f295ad32df4ce8a18a92539c6e8a3b208911 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208912;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b208913 .

_:79f295ad32df4ce8a18a92539c6e8a3b208912 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10283 .

_:79f295ad32df4ce8a18a92539c6e8a3b208913 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208914;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b208914 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10703 .

_:79f295ad32df4ce8a18a92539c6e8a3b208916 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10769-1 a owl:Class;
  rdfs:label "DIDANOSINE <-> RIBAVIRINE"@fr;
  dct:identifier "IAM_10769";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b208918;
  r:natureDuRisque "Risque de majoration de la toxicité mitochondriale de la didanosine par augmentation de son métabolite actif."@fr;
  rdfs:comment "La ribavirine, antiviral inhibant la synthèse des acides nucléiques du virus de l’hépatite C, augmente la concentration intra-cellulaire en inosine 5’ monophosphate (IMP) en inhibant l’IMP déhydrogénase. Cette augmentation entraîne une élévation de la con"@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b208924, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b208918 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b208919 .

_:79f295ad32df4ce8a18a92539c6e8a3b208919 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208920;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b208921 .

_:79f295ad32df4ce8a18a92539c6e8a3b208920 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10283 .

_:79f295ad32df4ce8a18a92539c6e8a3b208921 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208922;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b208922 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10797 .

_:79f295ad32df4ce8a18a92539c6e8a3b208924 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10770-1 a owl:Class;
  rdfs:label "DIDANOSINE <-> TENOFOVIR DISOPROXIL"@fr;
  dct:identifier "IAM_10770";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b208926;
  r:natureDuRisque "Risque d'échec du traitement antirétroviral, voire émergence de résistances. De plus, majoration du risque de la toxicité mitochondriale de la didanosine."@fr;
  rdfs:comment "Il existe une augmentation de 60% de l'AUC de la didanosine (DDI), administrée sous forme de comprimé tamponné, lorsqu’elle est associée avec le ténofovir. Si un ajustement posologique n'est pas toujours justifié, compte tenu d'une sensibilité individuell"@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b208932, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b208926 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b208927 .

_:79f295ad32df4ce8a18a92539c6e8a3b208927 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208928;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b208929 .

_:79f295ad32df4ce8a18a92539c6e8a3b208928 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10283 .

_:79f295ad32df4ce8a18a92539c6e8a3b208929 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208930;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b208930 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10896 .

_:79f295ad32df4ce8a18a92539c6e8a3b208932 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10771-1 a owl:Class;
  rdfs:label "DIDANOSINE <-> THALIDOMIDE"@fr;
  dct:identifier "IAM_10771";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b208934;
  r:natureDuRisque "Risque majoré de survenue de neuropathies périphériques par addition d'effets indésirables."@fr;
  r:conduiteATenir "Surveillance clinique et biologique régulière, notamment en début d'association."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b208940, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b208934 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b208935 .

_:79f295ad32df4ce8a18a92539c6e8a3b208935 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208936;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b208937 .

_:79f295ad32df4ce8a18a92539c6e8a3b208936 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10283 .

_:79f295ad32df4ce8a18a92539c6e8a3b208937 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208938;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b208938 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10913 .

_:79f295ad32df4ce8a18a92539c6e8a3b208940 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10763-1 a owl:Class;
  rdfs:label "DEXTROMETHORPHANE <-> IMAO IRRÉVERSIBLES"@fr;
  dct:identifier "IAM_10763";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b208942;
  r:natureDuRisque "Risque d'apparition d'un syndrome sérotoninergique : diarrhée, tachycardie, sueurs, tremblements, confusion voire coma."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b208948, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b208942 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b208943 .

_:79f295ad32df4ce8a18a92539c6e8a3b208943 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208944;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b208945 .

_:79f295ad32df4ce8a18a92539c6e8a3b208944 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10002 .

_:79f295ad32df4ce8a18a92539c6e8a3b208945 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208946;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b208946 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10278 .

_:79f295ad32df4ce8a18a92539c6e8a3b208948 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10773-1 a owl:Class;
  rdfs:label "DIGOXINE <-> DRONEDARONE"@fr;
  dct:identifier "IAM_10773";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b208950;
  r:natureDuRisque "Dépression de l'automatisme (bradycardie excessive) et troubles de la conduction auriculo-ventriculaire. En outre, augmentation de la digoxinémie par diminution du métabolisme de la digoxine. Surveillance clinique et ECG."@fr;
  r:conduiteATenir "Réduire de moitié les doses de digoxine."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b208956, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b208950 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b208951 .

_:79f295ad32df4ce8a18a92539c6e8a3b208951 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208952;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b208953 .

_:79f295ad32df4ce8a18a92539c6e8a3b208952 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10286 .

_:79f295ad32df4ce8a18a92539c6e8a3b208953 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208954;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b208954 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10311 .

_:79f295ad32df4ce8a18a92539c6e8a3b208956 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10762-1 a owl:Class;
  rdfs:label "DEXTRAN 40 <-> HÉPARINES NON FRACTIONNÉES (DOSES CURATIVES ET/OU SUJET ÂGÉ)"@fr;
  dct:identifier "IAM_10762";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b208958;
  r:natureDuRisque "Augmentation du risque hémorragique (inhibition de la fonction plaquettaire par le dextran 40)."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b208964, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b208958 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b208959 .

_:79f295ad32df4ce8a18a92539c6e8a3b208959 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208960;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b208961 .

_:79f295ad32df4ce8a18a92539c6e8a3b208960 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10061 .

_:79f295ad32df4ce8a18a92539c6e8a3b208961 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208962;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b208962 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10091 .

_:79f295ad32df4ce8a18a92539c6e8a3b208964 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10775-1 a owl:Class;
  rdfs:label "DIGOXINE <-> HYDROQUINIDINE"@fr;
  dct:identifier "IAM_10775";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b208966;
  r:natureDuRisque "Augmentation de la digoxinémie par diminution de la clairance rénale de la digoxine. De plus, troubles de l'automatisme (bradycardie excessive et troubles de la conduction auriculo-ventriculaire)."@fr;
  r:conduiteATenir "Surveillance clinique et ECG. En cas de réponse inattendue, contrôler la digoxinémie et adapter la posologie."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b208972, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b208966 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b208967 .

_:79f295ad32df4ce8a18a92539c6e8a3b208967 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208968;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b208969 .

_:79f295ad32df4ce8a18a92539c6e8a3b208968 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10286 .

_:79f295ad32df4ce8a18a92539c6e8a3b208969 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208970;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b208970 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10434 .

_:79f295ad32df4ce8a18a92539c6e8a3b208972 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10776-1 a owl:Class;
  rdfs:label "DIGOXINE <-> HYPOKALIÉMIANTS"@fr;
  dct:identifier "IAM_10776";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b208974;
  r:natureDuRisque "Hypokaliémie favorisant les effets toxiques des digitaliques."@fr;
  r:conduiteATenir "Corriger auparavant toute hypokaliémie et réaliser une surveillance clinique, électrolytique et électrocardiographique."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b208980, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b208974 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b208975 .

_:79f295ad32df4ce8a18a92539c6e8a3b208975 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208976;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b208977 .

_:79f295ad32df4ce8a18a92539c6e8a3b208976 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10086 .

_:79f295ad32df4ce8a18a92539c6e8a3b208977 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208978;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b208978 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10286 .

_:79f295ad32df4ce8a18a92539c6e8a3b208980 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10777-1 a owl:Class;
  rdfs:label "DIGOXINE <-> INHIBITEURS DE PROTÉASES BOOSTÉS PAR RITONAVIR"@fr;
  dct:identifier "IAM_10777";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b208982;
  r:chapeau "Le ritonavir est désormais utilisé à la dose de 100 mg 2 fois par jour en association à un autre inhibiteur de protéase, dans le but d'augmenter de façon très significative la biodisponibilité de l'inhibiteur de protéase associé (ou boosté), ce qui permet"@fr;
  r:natureDuRisque "Augmentation de la digoxinémie, plus marquée pour la voie intraveineuse, par augmentation de l’absorption de la digoxine ou diminution de sa clairance rénale."@fr;
  r:conduiteATenir "Surveillance clinique et, s’il y a lieu, de l’ECG et de la digoxinémie, avec adaptation éventuelle de la posologie de digoxine."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b208988, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b208982 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b208983 .

_:79f295ad32df4ce8a18a92539c6e8a3b208983 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208984;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b208985 .

_:79f295ad32df4ce8a18a92539c6e8a3b208984 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10100 .

_:79f295ad32df4ce8a18a92539c6e8a3b208985 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208986;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b208986 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10286 .

_:79f295ad32df4ce8a18a92539c6e8a3b208988 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10778-1 a owl:Class;
  rdfs:label "DIGOXINE <-> ITRACONAZOLE"@fr;
  dct:identifier "IAM_10778";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b208990;
  r:natureDuRisque "Augmentation de la digoxinémie avec nausées, vomissements, troubles du rythme."@fr;
  r:conduiteATenir "Surveillance clinique et, s'il y a lieu, de l'ECG et de la digoxinémie avec adaptation de la posologie de la digoxine pendant le traitement par l'itraconazole et après son arrêt."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b208996, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b208990 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b208991 .

_:79f295ad32df4ce8a18a92539c6e8a3b208991 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208992;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b208993 .

_:79f295ad32df4ce8a18a92539c6e8a3b208992 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10286 .

_:79f295ad32df4ce8a18a92539c6e8a3b208993 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b208994;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b208994 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10496 .

_:79f295ad32df4ce8a18a92539c6e8a3b208996 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10779-1 a owl:Class;
  rdfs:label "DIGOXINE <-> MIDODRINE"@fr;
  dct:identifier "IAM_10779";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b208998;
  r:natureDuRisque "Troubles de l'automatisme (majoration de l'effet bradycardisant de la midodrine) et troubles de la conduction auriculo-ventriculaire."@fr;
  r:conduiteATenir "Si cette association ne peut être évitée, renforcer la surveillance clinique et ECG."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b209004, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b208998 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b208999 .

_:79f295ad32df4ce8a18a92539c6e8a3b208999 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209000;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b209001 .

_:79f295ad32df4ce8a18a92539c6e8a3b209000 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10286 .

_:79f295ad32df4ce8a18a92539c6e8a3b209001 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209002;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b209002 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10587 .

_:79f295ad32df4ce8a18a92539c6e8a3b209004 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10780-1 a owl:Class;
  rdfs:label "DIGOXINE <-> MILLEPERTUIS"@fr;
  dct:identifier "IAM_10780";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b209006;
  r:natureDuRisque "Diminution de la digoxinémie, en raison de l'effet inducteur enzymatique du millepertuis, avec risque de baisse d'efficacité voire d'annulation de l'effet, dont les conséquences peuvent être éventuellement graves (décompensation d'une insuffisance cardiaq"@fr;
  r:conduiteATenir "En cas d'association fortuite, ne pas interrompre brutalement la prise de millepertuis mais contrôler les concentrations plasmatiques (ou l'efficacité) de la digoxine avant puis après l'arrêt du millepertuis."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b209012, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b209006 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b209007 .

_:79f295ad32df4ce8a18a92539c6e8a3b209007 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209008;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b209009 .

_:79f295ad32df4ce8a18a92539c6e8a3b209008 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10286 .

_:79f295ad32df4ce8a18a92539c6e8a3b209009 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209010;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b209010 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10588 .

_:79f295ad32df4ce8a18a92539c6e8a3b209012 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10781-1 a owl:Class;
  rdfs:label "DIGOXINE <-> OMEPRAZOLE"@fr;
  dct:identifier "IAM_10781";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b209014;
  r:natureDuRisque "Augmentation modérée de la digoxinémie par majoration de son absorption par l'oméprazole."@fr;
  r:conduiteATenir "Surveillance clinique, ECG et de la digoxinémie, particulièrement chez le sujet âgé."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b209020, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b209014 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b209015 .

_:79f295ad32df4ce8a18a92539c6e8a3b209015 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209016;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b209017 .

_:79f295ad32df4ce8a18a92539c6e8a3b209016 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10286 .

_:79f295ad32df4ce8a18a92539c6e8a3b209017 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209018;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b209018 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10664 .

_:79f295ad32df4ce8a18a92539c6e8a3b209020 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10782-1 a owl:Class;
  rdfs:label "DIGOXINE <-> POSACONAZOLE"@fr;
  dct:identifier "IAM_10782";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b209022;
  r:natureDuRisque "Augmentation de la digoxinémie avec nausées, vomissements, troubles du rythme."@fr;
  r:conduiteATenir "Surveillance clinique et, s'il y a lieu, de l'ECG et de la digoxinémie, avec adaptation de la posologie de la digoxine pendant le traitement par le posaconazole et après son arrêt."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b209028, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b209022 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b209023 .

_:79f295ad32df4ce8a18a92539c6e8a3b209023 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209024;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b209025 .

_:79f295ad32df4ce8a18a92539c6e8a3b209024 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10286 .

_:79f295ad32df4ce8a18a92539c6e8a3b209025 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209026;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b209026 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10741 .

_:79f295ad32df4ce8a18a92539c6e8a3b209028 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10783-1 a owl:Class;
  rdfs:label "DIGOXINE <-> PROPAFENONE"@fr;
  dct:identifier "IAM_10783";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b209030;
  r:natureDuRisque "Risque d’augmentation de la digoxinémie, notamment chez le sujet âgé."@fr;
  r:conduiteATenir "Surveillance clinique et éventuellement de la digoxinémie pendant le traitement par propafénone et après son arrêt."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b209036, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b209030 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b209031 .

_:79f295ad32df4ce8a18a92539c6e8a3b209031 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209032;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b209033 .

_:79f295ad32df4ce8a18a92539c6e8a3b209032 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10286 .

_:79f295ad32df4ce8a18a92539c6e8a3b209033 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209034;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b209034 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10765 .

_:79f295ad32df4ce8a18a92539c6e8a3b209036 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10784-1 a owl:Class;
  rdfs:label "DIGOXINE <-> QUINIDINE"@fr;
  dct:identifier "IAM_10784";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b209038;
  r:natureDuRisque "Augmentation de la digoxinémie par diminution de la clairance rénale de la digoxine. De plus, troubles de l'automatisme (bradycardie excessive et troubles de la conduction auriculo-ventriculaire)."@fr;
  r:conduiteATenir "Surveillance clinique et ECG. En cas de réponse inattendue, contrôler la digoxinémie et adapter la posologie."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b209044, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b209038 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b209039 .

_:79f295ad32df4ce8a18a92539c6e8a3b209039 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209040;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b209041 .

_:79f295ad32df4ce8a18a92539c6e8a3b209040 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10286 .

_:79f295ad32df4ce8a18a92539c6e8a3b209041 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209042;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b209042 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10776 .

_:79f295ad32df4ce8a18a92539c6e8a3b209044 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10789-1 a owl:Class;
  rdfs:label "DIGOXINE <-> TELAPREVIR"@fr;
  dct:identifier "IAM_10789";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b209046;
  r:natureDuRisque "Augmentation de la digoxinémie."@fr;
  r:conduiteATenir "Surveillance clinique et biologique et adaptation, si besoin, de la posologie de la digoxine pendant le traitement par le télaprévir et après son arrêt."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b209052, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b209046 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b209047 .

_:79f295ad32df4ce8a18a92539c6e8a3b209047 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209048;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b209049 .

_:79f295ad32df4ce8a18a92539c6e8a3b209048 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10286 .

_:79f295ad32df4ce8a18a92539c6e8a3b209049 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209050;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b209050 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10887 .

_:79f295ad32df4ce8a18a92539c6e8a3b209052 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11125-1 a owl:Class;
  rdfs:label "INHIBITEURS DE PROTÉASES BOOSTÉS PAR RITONAVIR <-> INHIBITEURS PUISSANTS DU CYP3A4"@fr;
  dct:identifier "IAM_11125";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b209054;
  r:chapeau "Le ritonavir est désormais utilisé à la dose de 100 mg 2 fois par jour en association à un autre inhibiteur de protéase, dans le but d'augmenter de façon très significative la biodisponibilité de l'inhibiteur de protéase associé (ou boosté), ce qui permet"@fr;
  r:natureDuRisque "Risque d’augmentation des concentrations plasmatiques de l’inhibiteur de protéase boosté par le ritonavir ou de l’inhibiteur du CYP3A4."@fr;
  r:conduiteATenir "Pour connaître les risques et les niveaux de contrainte de chaque inhibiteur de protéase boosté par le ritonavir avec les inhibiteurs puissants du CYP3A4, il convient de se reporter aux AMM spécifiques à chacun d'eux."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b209060, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b209054 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b209055 .

_:79f295ad32df4ce8a18a92539c6e8a3b209055 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209056;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b209057 .

_:79f295ad32df4ce8a18a92539c6e8a3b209056 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10100 .

_:79f295ad32df4ce8a18a92539c6e8a3b209057 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209058;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b209058 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10103 .

_:79f295ad32df4ce8a18a92539c6e8a3b209060 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11207-1 a owl:Class;
  rdfs:label "IVABRADINE <-> RIFAMPICINE"@fr;
  dct:identifier "IAM_11207";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b209062;
  r:natureDuRisque "Risque de diminution de l'efficacité de l’ivabradine, par augmentation de son métabolisme par la rifampicine."@fr;
  r:conduiteATenir "Surveillance clinique et adaptation de la posologie de l’ivabradine pendant l’association et après l’arrêt de la rifampicine."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b209068, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b209062 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b209063 .

_:79f295ad32df4ce8a18a92539c6e8a3b209063 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209064;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b209065 .

_:79f295ad32df4ce8a18a92539c6e8a3b209064 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10497 .

_:79f295ad32df4ce8a18a92539c6e8a3b209065 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209066;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b209066 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:79f295ad32df4ce8a18a92539c6e8a3b209068 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10951-1 a owl:Class;
  rdfs:label "FLUCONAZOLE <-> OXYCODONE"@fr;
  dct:identifier "IAM_10951";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b209070;
  r:natureDuRisque "Majoration des effets indésirables, notamment respiratoires, de l’oxycodone par diminution de son métabolisme hépatique par le fluconazole."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b209076, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b209070 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b209071 .

_:79f295ad32df4ce8a18a92539c6e8a3b209071 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209072;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b209073 .

_:79f295ad32df4ce8a18a92539c6e8a3b209072 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10381 .

_:79f295ad32df4ce8a18a92539c6e8a3b209073 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209074;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b209074 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10681 .

_:79f295ad32df4ce8a18a92539c6e8a3b209076 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10952-1 a owl:Class;
  rdfs:label "FLUCONAZOLE <-> PHÉNYTOÏNE (ET, PAR EXTRAPOLATION, FOSPHÉNYTOÏNE)"@fr;
  dct:identifier "IAM_10952";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b209078;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de phénytoïne pouvant atteindre des valeurs toxiques. Mécanisme invoqué : inhibition du métabolisme hépatique de la phénytoïne."@fr;
  r:conduiteATenir "Surveillance clinique et biologique étroite."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b209084, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b209078 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b209079 .

_:79f295ad32df4ce8a18a92539c6e8a3b209079 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209080;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b209081 .

_:79f295ad32df4ce8a18a92539c6e8a3b209080 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10132 .

_:79f295ad32df4ce8a18a92539c6e8a3b209081 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209082;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b209082 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10381 .

_:79f295ad32df4ce8a18a92539c6e8a3b209084 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10953-1 a owl:Class;
  rdfs:label "FLUCONAZOLE <-> PIMOZIDE"@fr;
  dct:identifier "IAM_10953";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b209086;
  r:natureDuRisque "Risque majoré de troubles du rythme ventriculaire, notamment de torsades de pointes."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b209092, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b209086 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b209087 .

_:79f295ad32df4ce8a18a92539c6e8a3b209087 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209088;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b209089 .

_:79f295ad32df4ce8a18a92539c6e8a3b209088 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10381 .

_:79f295ad32df4ce8a18a92539c6e8a3b209089 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209090;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b209090 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10721 .

_:79f295ad32df4ce8a18a92539c6e8a3b209092 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11120-1 a owl:Class;
  rdfs:label "INHIBITEURS DE L'ENZYME DE CONVERSION <-> SPIRONOLACTONE"@fr;
  dct:identifier "IAM_11120";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b209094;
  r:natureDuRisque """Avec la spironolactone à la posologie de 12,5 à 50 mg par jour, et avec des doses faibles d’IEC.

Dans le traitement de l’insuffisance cardiaque de classe III ou IV (NYHA) avec fraction d’éjection <35 % et préalablement traitée par l’association inhibiteu"""@fr;
  r:conduiteATenir "Vérifier au préalable l’absence d’hyperkaliémie et d’insuffisance rénale. Surveillance biologique étroite de la kaliémie et de la créatininémie (1 fois par semaine pendant le premier mois, puis une fois par mois ensuite)."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b209100, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b209094 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b209095 .

_:79f295ad32df4ce8a18a92539c6e8a3b209095 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209096;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b209097 .

_:79f295ad32df4ce8a18a92539c6e8a3b209096 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10096 .

_:79f295ad32df4ce8a18a92539c6e8a3b209097 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209098;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b209098 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10857 .

_:79f295ad32df4ce8a18a92539c6e8a3b209100 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11121-1 a owl:Class;
  rdfs:label "INHIBITEURS DE L'ENZYME DE CONVERSION <-> SULFAMIDES HYPOGLYCÉMIANTS"@fr;
  dct:identifier "IAM_11121";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b209102;
  r:natureDuRisque "L'utilisation des IEC peut entraîner une majoration de l'effet hypoglycémiant chez le diabétique traité par sulfamides hypoglycémiants. La survenue de malaises hypoglycémiques semble exceptionnelle (amélioration de la tolérance au glucose qui aurait pour"@fr;
  r:conduiteATenir "Renforcer l'autosurveillance glycémique."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b209108, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b209102 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b209103 .

_:79f295ad32df4ce8a18a92539c6e8a3b209103 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209104;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b209105 .

_:79f295ad32df4ce8a18a92539c6e8a3b209104 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10096 .

_:79f295ad32df4ce8a18a92539c6e8a3b209105 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209106;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b209106 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10147 .

_:79f295ad32df4ce8a18a92539c6e8a3b209108 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11122-1 a owl:Class;
  rdfs:label "INHIBITEURS DE L'HMG-COA RÉDUCTASE (STATINES) <-> LÉDIPASVIR"@fr;
  dct:identifier "IAM_11122";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b209110;
  r:natureDuRisque "Risque d’augmentation des concentrations plasmatiques de la statine et de ses effets indésirables à type de rhabdomyolyse."@fr;
  r:conduiteATenir """Contre-indication :
- avec la rosuvastatine.

Précaution d'emploi :
- avec les autres inhibiteurs de l'HMG Co-A réductase.
Surveillance clinique et biologique. Adaptation éventuelle de la posologie de la statine."""@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b209116, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b209110 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b209111 .

_:79f295ad32df4ce8a18a92539c6e8a3b209111 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209112;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b209113 .

_:79f295ad32df4ce8a18a92539c6e8a3b209112 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10095 .

_:79f295ad32df4ce8a18a92539c6e8a3b209113 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209114;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b209114 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10512 .

_:79f295ad32df4ce8a18a92539c6e8a3b209116 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11123-1 a owl:Class;
  rdfs:label "INHIBITEURS DE L'HMG-COA RÉDUCTASE (STATINES) <-> LENALIDOMIDE"@fr;
  dct:identifier "IAM_11123";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b209118;
  r:natureDuRisque "Risque majoré de survenue de rhabdomyolyses."@fr;
  r:conduiteATenir "Renforcer le contrôle clinique et biologique, notamment durant les premières semaines de traitement."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b209124, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b209118 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b209119 .

_:79f295ad32df4ce8a18a92539c6e8a3b209119 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209120;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b209121 .

_:79f295ad32df4ce8a18a92539c6e8a3b209120 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10095 .

_:79f295ad32df4ce8a18a92539c6e8a3b209121 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209122;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b209122 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10513 .

_:79f295ad32df4ce8a18a92539c6e8a3b209124 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11128-1 a owl:Class;
  rdfs:label "INHIBITEURS DE PROTÉASES BOOSTÉS PAR RITONAVIR <-> LUMEFANTRINE"@fr;
  dct:identifier "IAM_11128";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b209126;
  r:natureDuRisque "Risque majoré de troubles du rythme ventriculaire, notamment de torsades de pointes."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b209132, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b209126 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b209127 .

_:79f295ad32df4ce8a18a92539c6e8a3b209127 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209128;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b209129 .

_:79f295ad32df4ce8a18a92539c6e8a3b209128 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10100 .

_:79f295ad32df4ce8a18a92539c6e8a3b209129 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209130;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b209130 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10541 .

_:79f295ad32df4ce8a18a92539c6e8a3b209132 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10764-1 a owl:Class;
  rdfs:label "DEXTROMETHORPHANE <-> IMAO-A RÉVERSIBLES, Y COMPRIS LINEZOLIDE ET BLEU DE MÉTHYLÈNE"@fr;
  dct:identifier "IAM_10764";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b209134;
  r:natureDuRisque "Risque d'apparition d'un syndrome sérotoninergique : diarrhée, tachycardie, sueurs, tremblements, confusion voire coma."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b209140, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b209134 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b209135 .

_:79f295ad32df4ce8a18a92539c6e8a3b209135 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209136;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b209137 .

_:79f295ad32df4ce8a18a92539c6e8a3b209136 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10003 .

_:79f295ad32df4ce8a18a92539c6e8a3b209137 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209138;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b209138 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10278 .

_:79f295ad32df4ce8a18a92539c6e8a3b209140 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11144-1 a owl:Class;
  rdfs:label "INHIBITEURS DE PROTÉASES BOOSTÉS PAR RITONAVIR <-> VINCA-ALCALOÏDES CYTOTOXIQUES"@fr;
  dct:identifier "IAM_11144";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b209142;
  r:natureDuRisque "Majoration de la toxicité de l’antimitotique, par diminution de son métabolisme hépatique par l’inhibiteur de protéases."@fr;
  r:conduiteATenir "Surveillance clinique étroite et adaptation éventuelle de la posologie de l’antimitotique."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b209148, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b209142 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b209143 .

_:79f295ad32df4ce8a18a92539c6e8a3b209143 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209144;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b209145 .

_:79f295ad32df4ce8a18a92539c6e8a3b209144 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10100 .

_:79f295ad32df4ce8a18a92539c6e8a3b209145 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209146;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b209146 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10161 .

_:79f295ad32df4ce8a18a92539c6e8a3b209148 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10949-1 a owl:Class;
  rdfs:label "FLUCONAZOLE <-> NEVIRAPINE"@fr;
  dct:identifier "IAM_10949";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b209150;
  r:natureDuRisque "Doublement des concentrations de névirapine avec risque d'augmentation de ses effets indésirables."@fr;
  r:conduiteATenir "Surveillance clinique et adaptation éventuelle de la posologie de la névirapine."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b209156, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b209150 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b209151 .

_:79f295ad32df4ce8a18a92539c6e8a3b209151 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209152;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b209153 .

_:79f295ad32df4ce8a18a92539c6e8a3b209152 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10381 .

_:79f295ad32df4ce8a18a92539c6e8a3b209153 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209154;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b209154 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10628 .

_:79f295ad32df4ce8a18a92539c6e8a3b209156 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11126-1 a owl:Class;
  rdfs:label "INHIBITEURS DE PROTÉASES BOOSTÉS PAR RITONAVIR <-> ITRACONAZOLE"@fr;
  dct:identifier "IAM_11126";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b209158;
  r:natureDuRisque "Risque d’augmentation des concentrations d’itraconazole par l’inhibiteur de protéases."@fr;
  r:conduiteATenir "Surveillance clinique lors de l’association. L’administration de doses élevées d’itraconazole (>200 mg par jour) n’est pas recommandée."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b209164, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b209158 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b209159 .

_:79f295ad32df4ce8a18a92539c6e8a3b209159 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209160;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b209161 .

_:79f295ad32df4ce8a18a92539c6e8a3b209160 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10100 .

_:79f295ad32df4ce8a18a92539c6e8a3b209161 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209162;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b209162 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10496 .

_:79f295ad32df4ce8a18a92539c6e8a3b209164 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11127-1 a owl:Class;
  rdfs:label "INHIBITEURS DE PROTÉASES BOOSTÉS PAR RITONAVIR <-> LAMOTRIGINE"@fr;
  dct:identifier "IAM_11127";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b209166;
  r:chapeau "Le ritonavir est désormais utilisé à la dose de 100 mg 2 fois par jour en association à un autre inhibiteur de protéase, dans le but d'augmenter de façon très significative la biodisponibilité de l'inhibiteur de protéase associé (ou boosté), ce qui permet"@fr;
  r:natureDuRisque "Risque de diminution des concentrations et de l’efficacité de la lamotrigine par augmentation de son métabolisme hépatique par le ritonavir."@fr;
  r:conduiteATenir """Association déconseillée 
- Eviter de mettre en route le traitement par ritonavir pendant la période d’ajustement posologique de la lamotrigine.

Précaution d'emploi
- Surveillance clinique et adaptation de la posologie de la lamotrigine lors de la mise e"""@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b209172, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b209166 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b209167 .

_:79f295ad32df4ce8a18a92539c6e8a3b209167 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209168;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b209169 .

_:79f295ad32df4ce8a18a92539c6e8a3b209168 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10100 .

_:79f295ad32df4ce8a18a92539c6e8a3b209169 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209170;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b209170 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10507 .

_:79f295ad32df4ce8a18a92539c6e8a3b209172 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11129-1 a owl:Class;
  rdfs:label "INHIBITEURS DE PROTÉASES BOOSTÉS PAR RITONAVIR <-> METHADONE"@fr;
  dct:identifier "IAM_11129";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b209174;
  r:natureDuRisque "Diminution des concentrations plasmatiques de méthadone avec risque d'apparition d'un syndrome de sevrage par augmentation de son métabolisme hépatique par le ritonavir."@fr;
  r:conduiteATenir "Surveillance clinique régulière et adaptation éventuelle de la posologie de méthadone."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b209180, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b209174 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b209175 .

_:79f295ad32df4ce8a18a92539c6e8a3b209175 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209176;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b209177 .

_:79f295ad32df4ce8a18a92539c6e8a3b209176 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10100 .

_:79f295ad32df4ce8a18a92539c6e8a3b209177 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209178;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b209178 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10567 .

_:79f295ad32df4ce8a18a92539c6e8a3b209180 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11130-1 a owl:Class;
  rdfs:label "INHIBITEURS DE PROTÉASES BOOSTÉS PAR RITONAVIR <-> MILLEPERTUIS"@fr;
  dct:identifier "IAM_11130";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b209182;
  r:natureDuRisque "Diminution des concentrations plasmatiques de l'inhibiteur de protéases, en raison de l'effet inducteur enzymatique du millepertuis, avec risque de baisse d'efficacité voire d'annulation de l'effet dont les conséquences peuvent être éventuellement graves"@fr;
  r:conduiteATenir "En cas d'association fortuite, ne pas interrompre brutalement la prise de millepertuis mais contrôler les concentrations plasmatiques (ou l'efficacité) de l'inhibiteur de protéases avant puis après l'arrêt du millepertuis."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b209188, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b209182 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b209183 .

_:79f295ad32df4ce8a18a92539c6e8a3b209183 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209184;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b209185 .

_:79f295ad32df4ce8a18a92539c6e8a3b209184 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10100 .

_:79f295ad32df4ce8a18a92539c6e8a3b209185 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209186;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b209186 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10588 .

_:79f295ad32df4ce8a18a92539c6e8a3b209188 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11131-1 a owl:Class;
  rdfs:label "INHIBITEURS DE PROTÉASES BOOSTÉS PAR RITONAVIR <-> MIZOLASTINE"@fr;
  dct:identifier "IAM_11131";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b209190;
  r:chapeau "Le ritonavir est désormais utilisé à la dose de 100 mg 2 fois par jour en association à un autre inhibiteur de protéase, dans le but d'augmenter de façon très significative la biodisponibilité de l'inhibiteur de protéase associé (ou boosté), ce qui permet"@fr;
  r:natureDuRisque "Risque de troubles du rythme ventriculaire, notamment de torsades de pointes."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b209196, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b209190 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b209191 .

_:79f295ad32df4ce8a18a92539c6e8a3b209191 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209192;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b209193 .

_:79f295ad32df4ce8a18a92539c6e8a3b209192 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10100 .

_:79f295ad32df4ce8a18a92539c6e8a3b209193 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209194;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b209194 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10597 .

_:79f295ad32df4ce8a18a92539c6e8a3b209196 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11132-1 a owl:Class;
  rdfs:label "INHIBITEURS DE PROTÉASES BOOSTÉS PAR RITONAVIR <-> NINTÉDANIB"@fr;
  dct:identifier "IAM_11132";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b209198;
  r:natureDuRisque "Augmentation des concentrations plasmatiques du nintédanib par augmentation de son absorption par l'inhibiteur de protéases boosté par ritonavir."@fr;
  r:conduiteATenir "Surveillance clinique pendant l’association."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b209204, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b209198 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b209199 .

_:79f295ad32df4ce8a18a92539c6e8a3b209199 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209200;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b209201 .

_:79f295ad32df4ce8a18a92539c6e8a3b209200 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10100 .

_:79f295ad32df4ce8a18a92539c6e8a3b209201 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209202;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b209202 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10637 .

_:79f295ad32df4ce8a18a92539c6e8a3b209204 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10758-1 a owl:Class;
  rdfs:label "DEXAMETHASONE <-> SIMÉPRÉVIR"@fr;
  dct:identifier "IAM_10758";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b209206;
  r:natureDuRisque "Avec la dexaméthasone à usage systémique, risque de diminution des concentrations plasmatiques de simeprevir par augmentation de son métabolisme hépatique par la dexamethasone."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b209212, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b209206 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b209207 .

_:79f295ad32df4ce8a18a92539c6e8a3b209207 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209208;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b209209 .

_:79f295ad32df4ce8a18a92539c6e8a3b209208 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10272 .

_:79f295ad32df4ce8a18a92539c6e8a3b209209 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209210;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b209210 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10837 .

_:79f295ad32df4ce8a18a92539c6e8a3b209212 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10759-1 a owl:Class;
  rdfs:label "DEXAMETHASONE <-> TELITHROMYCINE"@fr;
  dct:identifier "IAM_10759";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b209214;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de la dexaméthasone par diminution de son métabolisme hépatique par l'inhibiteur enzymatique, avec risque d’apparition d’un syndrome cushingoïde."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b209220, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b209214 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b209215 .

_:79f295ad32df4ce8a18a92539c6e8a3b209215 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209216;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b209217 .

_:79f295ad32df4ce8a18a92539c6e8a3b209216 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10272 .

_:79f295ad32df4ce8a18a92539c6e8a3b209217 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209218;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b209218 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10889 .

_:79f295ad32df4ce8a18a92539c6e8a3b209220 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10760-1 a owl:Class;
  rdfs:label "DEXAMETHASONE <-> VORICONAZOLE"@fr;
  dct:identifier "IAM_10760";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b209222;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de la dexaméthasone par diminution de son métabolisme hépatique par l'inhibiteur enzymatique, avec risque d’apparition d’un syndrome cushingoïde."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b209228, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b209222 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b209223 .

_:79f295ad32df4ce8a18a92539c6e8a3b209223 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209224;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b209225 .

_:79f295ad32df4ce8a18a92539c6e8a3b209224 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10272 .

_:79f295ad32df4ce8a18a92539c6e8a3b209225 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209226;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b209226 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10998 .

_:79f295ad32df4ce8a18a92539c6e8a3b209228 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10761-1 a owl:Class;
  rdfs:label "DEXTRAN 40 <-> HÉPARINES DE BAS POIDS MOLÉCULAIRE ET APPARENTÉS (DOSES CURATIVES ET/OU SUJET ÂGÉ)"@fr;
  dct:identifier "IAM_10761";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b209230;
  r:natureDuRisque "Augmentation du risque hémorragique (inhibition de la fonction plaquettaire par le dextran 40)."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b209236, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b209230 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b209231 .

_:79f295ad32df4ce8a18a92539c6e8a3b209231 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209232;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b209233 .

_:79f295ad32df4ce8a18a92539c6e8a3b209232 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10061 .

_:79f295ad32df4ce8a18a92539c6e8a3b209233 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209234;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b209234 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10089 .

_:79f295ad32df4ce8a18a92539c6e8a3b209236 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11139-1 a owl:Class;
  rdfs:label "INHIBITEURS DE PROTÉASES BOOSTÉS PAR RITONAVIR <-> TELAPREVIR"@fr;
  dct:identifier "IAM_11139";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b209238;
  r:natureDuRisque "Diminution des concentrations du télaprévir et du darunavir ou du fosamprénavir, avec risque d’échec thérapeutique."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b209244, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b209238 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b209239 .

_:79f295ad32df4ce8a18a92539c6e8a3b209239 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209240;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b209241 .

_:79f295ad32df4ce8a18a92539c6e8a3b209240 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10100 .

_:79f295ad32df4ce8a18a92539c6e8a3b209241 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209242;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b209242 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10887 .

_:79f295ad32df4ce8a18a92539c6e8a3b209244 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10992-1 a owl:Class;
  rdfs:label "GANCICLOVIR <-> ZALCITABINE"@fr;
  dct:identifier "IAM_10992";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b209246;
  r:natureDuRisque "Risque accru de survenue de neuropathies périphériques par addition d'effets indésirables."@fr;
  r:conduiteATenir "Surveillance clinique et biologique régulière, notamment en début d'association."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b209252, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b209246 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b209247 .

_:79f295ad32df4ce8a18a92539c6e8a3b209247 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209248;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b209249 .

_:79f295ad32df4ce8a18a92539c6e8a3b209248 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10408 .

_:79f295ad32df4ce8a18a92539c6e8a3b209249 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209250;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b209250 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_11002 .

_:79f295ad32df4ce8a18a92539c6e8a3b209252 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10981-1 a owl:Class;
  rdfs:label "FLUVOXAMINE <-> PIRFENIDONE"@fr;
  dct:identifier "IAM_10981";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b209254;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de pirfenidone avec signes de surdosage."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b209260, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b209254 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b209255 .

_:79f295ad32df4ce8a18a92539c6e8a3b209255 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209256;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b209257 .

_:79f295ad32df4ce8a18a92539c6e8a3b209256 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10398 .

_:79f295ad32df4ce8a18a92539c6e8a3b209257 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209258;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b209258 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10731 .

_:79f295ad32df4ce8a18a92539c6e8a3b209260 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10982-1 a owl:Class;
  rdfs:label "FLUVOXAMINE <-> PROPRANOLOL"@fr;
  dct:identifier "IAM_10982";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b209262;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de propranolol par inhibition de son métabolisme hépatique, avec majoration de l'activité et des effets indésirables, par exemple : bradycardie importante."@fr;
  r:conduiteATenir "Surveillance clinique accrue et, si besoin, adaptation de la posologie du propranolol pendant le traitement par la fluvoxamine et après son arrêt."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b209268, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b209262 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b209263 .

_:79f295ad32df4ce8a18a92539c6e8a3b209263 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209264;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b209265 .

_:79f295ad32df4ce8a18a92539c6e8a3b209264 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10398 .

_:79f295ad32df4ce8a18a92539c6e8a3b209265 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209266;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b209266 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10767 .

_:79f295ad32df4ce8a18a92539c6e8a3b209268 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10983-1 a owl:Class;
  rdfs:label "FLUVOXAMINE <-> ROPINIROLE"@fr;
  dct:identifier "IAM_10983";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b209270;
  r:natureDuRisque "Augmentation des concentrations de ropinirole, avec risque de surdosage, par diminution de son métabolisme hépatique par la fluvoxamine."@fr;
  r:conduiteATenir "Surveillance clinique et réduction de la posologie du ropinirole pendant le traitement par fluvoxamine et après son arrêt."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b209276, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b209270 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b209271 .

_:79f295ad32df4ce8a18a92539c6e8a3b209271 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209272;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b209273 .

_:79f295ad32df4ce8a18a92539c6e8a3b209272 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10398 .

_:79f295ad32df4ce8a18a92539c6e8a3b209273 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209274;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b209274 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10813 .

_:79f295ad32df4ce8a18a92539c6e8a3b209276 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10984-1 a owl:Class;
  rdfs:label "FLUVOXAMINE <-> THÉOPHYLLINE (ET, PAR EXTRAPOLATION, AMINOPHYLLINE)"@fr;
  dct:identifier "IAM_10984";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b209278;
  r:natureDuRisque "Augmentation de la théophyllinémie avec signes de surdosage (diminution du métabolisme hépatique de la théophylline)."@fr;
  r:conduiteATenir "Surveillance clinique et éventuellement de la théophyllinémie ; si besoin, adaptation de la posologie de la théophylline pendant le traitement par la fluvoxamine et après son arrêt."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b209284, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b209278 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b209279 .

_:79f295ad32df4ce8a18a92539c6e8a3b209279 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209280;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b209281 .

_:79f295ad32df4ce8a18a92539c6e8a3b209280 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10152 .

_:79f295ad32df4ce8a18a92539c6e8a3b209281 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209282;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b209282 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10398 .

_:79f295ad32df4ce8a18a92539c6e8a3b209284 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10985-1 a owl:Class;
  rdfs:label "FOLATES <-> PHÉNOBARBITAL (ET, PAR EXTRAPOLATION, PRIMIDONE)"@fr;
  dct:identifier "IAM_10985";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b209286;
  r:natureDuRisque "Diminution des concentrations plasmatiques du phénobarbital, par augmentation de son métabolisme dont les folates représentent un des cofacteurs."@fr;
  r:conduiteATenir "Surveillance clinique, contrôle des concentrations plasmatiques, et adaptation, s'il y a lieu, de la posologie du phénobarbital pendant la supplémentation folique et après son arrêt."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b209292, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b209286 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b209287 .

_:79f295ad32df4ce8a18a92539c6e8a3b209287 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209288;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b209289 .

_:79f295ad32df4ce8a18a92539c6e8a3b209288 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10077 .

_:79f295ad32df4ce8a18a92539c6e8a3b209289 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209290;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b209290 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10131 .

_:79f295ad32df4ce8a18a92539c6e8a3b209292 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10986-1 a owl:Class;
  rdfs:label "FOLATES <-> PHÉNYTOÏNE (ET, PAR EXTRAPOLATION, FOSPHÉNYTOÏNE)"@fr;
  dct:identifier "IAM_10986";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b209294;
  r:natureDuRisque "Diminution des concentrations plasmatiques de phénytoïne par augmentation de son métabolisme dont les folates représentent un des cofacteurs."@fr;
  r:conduiteATenir "Surveillance clinique et contrôle des concentrations plasmatiques de phénytoïne. Adaptation éventuelle de la posologie de la phénytoïne pendant la supplémentation folique et après son arrêt."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b209300, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b209294 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b209295 .

_:79f295ad32df4ce8a18a92539c6e8a3b209295 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209296;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b209297 .

_:79f295ad32df4ce8a18a92539c6e8a3b209296 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10077 .

_:79f295ad32df4ce8a18a92539c6e8a3b209297 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209298;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b209298 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10132 .

_:79f295ad32df4ce8a18a92539c6e8a3b209300 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10987-1 a owl:Class;
  rdfs:label "FOSAMPRENAVIR <-> MARAVIROC"@fr;
  dct:identifier "IAM_10987";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b209302;
  r:natureDuRisque "Diminution significative des concentrations d’amprénavir pouvant conduire à une perte de la réponse virologique."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b209308, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b209302 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b209303 .

_:79f295ad32df4ce8a18a92539c6e8a3b209303 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209304;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b209305 .

_:79f295ad32df4ce8a18a92539c6e8a3b209304 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10400 .

_:79f295ad32df4ce8a18a92539c6e8a3b209305 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209306;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b209306 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10551 .

_:79f295ad32df4ce8a18a92539c6e8a3b209308 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10988-1 a owl:Class;
  rdfs:label "FOSAMPRENAVIR <-> METHADONE"@fr;
  dct:identifier "IAM_10988";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b209310;
  r:natureDuRisque """Diminution des concentrations plasmatiques de méthadone avec
risque d'apparition d'un syndrome de sevrage par augmentation de son métabolisme hépatique par l'amprénavir."""@fr;
  r:conduiteATenir "Surveillance clinique régulière et adaptation éventuelle de la posologie de méthadone."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b209316, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b209310 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b209311 .

_:79f295ad32df4ce8a18a92539c6e8a3b209311 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209312;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b209313 .

_:79f295ad32df4ce8a18a92539c6e8a3b209312 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10400 .

_:79f295ad32df4ce8a18a92539c6e8a3b209313 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209314;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b209314 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10567 .

_:79f295ad32df4ce8a18a92539c6e8a3b209316 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10989-1 a owl:Class;
  rdfs:label "FOSAMPRENAVIR <-> NEVIRAPINE"@fr;
  dct:identifier "IAM_10989";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b209318;
  r:natureDuRisque "Risque de baisse de l'efficacité de l'amprénavir."@fr;
  r:conduiteATenir """Surveillance clinique et biologique régulière, notamment en début
d'association."""@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b209324, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b209318 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b209319 .

_:79f295ad32df4ce8a18a92539c6e8a3b209319 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209320;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b209321 .

_:79f295ad32df4ce8a18a92539c6e8a3b209320 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10400 .

_:79f295ad32df4ce8a18a92539c6e8a3b209321 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209322;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b209322 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10628 .

_:79f295ad32df4ce8a18a92539c6e8a3b209324 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11205-1 a owl:Class;
  rdfs:label "IVABRADINE <-> MILLEPERTUIS"@fr;
  dct:identifier "IAM_11205";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b209326;
  r:natureDuRisque "Risque de diminution de l'efficacité de l’ivabradine, par augmentation de son métabolisme par le millepertuis."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b209332, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b209326 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b209327 .

_:79f295ad32df4ce8a18a92539c6e8a3b209327 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209328;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b209329 .

_:79f295ad32df4ce8a18a92539c6e8a3b209328 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10497 .

_:79f295ad32df4ce8a18a92539c6e8a3b209329 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209330;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b209330 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10588 .

_:79f295ad32df4ce8a18a92539c6e8a3b209332 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10991-1 a owl:Class;
  rdfs:label "FUROSEMIDE <-> PHÉNYTOÏNE (ET, PAR EXTRAPOLATION, FOSPHÉNYTOÏNE)"@fr;
  dct:identifier "IAM_10991";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b209334;
  r:natureDuRisque "Diminution de l'effet diurétique pouvant atteindre 50 %."@fr;
  r:conduiteATenir "Utiliser éventuellement des doses plus élevées de furosémide."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b209340, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b209334 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b209335 .

_:79f295ad32df4ce8a18a92539c6e8a3b209335 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209336;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b209337 .

_:79f295ad32df4ce8a18a92539c6e8a3b209336 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10132 .

_:79f295ad32df4ce8a18a92539c6e8a3b209337 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209338;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b209338 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10406 .

_:79f295ad32df4ce8a18a92539c6e8a3b209340 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10978-1 a owl:Class;
  rdfs:label "FLUVOXAMINE <-> MEXILETINE"@fr;
  dct:identifier "IAM_10978";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b209342;
  r:natureDuRisque "Risque de majoration des effets indésirables de la méxilétine, par inhibition de son métabolisme par la fluvoxamine."@fr;
  r:conduiteATenir "Surveillance clinique et ECG. Adaptation de la posologie de la méxilétine pendant le traitement par la fluvoxamine et après son arrêt."@fr;
  rdfs:comment "La méxilétine est un anti-arythmique de la classe Ib de la classification de Vaughan-Williams, indiquée dans le traitement et la prévention des arythmies ventriculaires mettant en jeu le pronostic vital. Son métabolisme dépend principalement du CYP2D6, et"@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b209348, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b209342 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b209343 .

_:79f295ad32df4ce8a18a92539c6e8a3b209343 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209344;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b209345 .

_:79f295ad32df4ce8a18a92539c6e8a3b209344 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10398 .

_:79f295ad32df4ce8a18a92539c6e8a3b209345 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209346;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b209346 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10582 .

_:79f295ad32df4ce8a18a92539c6e8a3b209348 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10993-1 a owl:Class;
  rdfs:label "GANCICLOVIR <-> ZIDOVUDINE"@fr;
  dct:identifier "IAM_10993";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b209350;
  r:natureDuRisque "Augmentation de la toxicité hématologique (addition d'effets de toxicité médullaire)."@fr;
  r:conduiteATenir "Arrêter de façon transitoire la zidovudine ; contrôler la NFS et réintroduire, si possible, la zidovudine à doses faibles."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b209356, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b209350 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b209351 .

_:79f295ad32df4ce8a18a92539c6e8a3b209351 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209352;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b209353 .

_:79f295ad32df4ce8a18a92539c6e8a3b209352 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10408 .

_:79f295ad32df4ce8a18a92539c6e8a3b209353 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209354;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b209354 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_11004 .

_:79f295ad32df4ce8a18a92539c6e8a3b209356 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10994-1 a owl:Class;
  rdfs:label "GEMFIBROZIL <-> PIOGLITAZONE"@fr;
  dct:identifier "IAM_10994";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b209358;
  r:natureDuRisque """Risque d’augmentation des effets indésirables de la glitazone par
diminution de son métabolisme hépatique par le gemfibrozil."""@fr;
  r:conduiteATenir "Si l’association ne peut être évitée, surveillance clinique étroite."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b209364, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b209358 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b209359 .

_:79f295ad32df4ce8a18a92539c6e8a3b209359 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209360;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b209361 .

_:79f295ad32df4ce8a18a92539c6e8a3b209360 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10411 .

_:79f295ad32df4ce8a18a92539c6e8a3b209361 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209362;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b209362 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10723 .

_:79f295ad32df4ce8a18a92539c6e8a3b209364 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10995-1 a owl:Class;
  rdfs:label "GEMFIBROZIL <-> REPAGLINIDE"@fr;
  dct:identifier "IAM_10995";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b209366;
  r:natureDuRisque "Risque d'hypoglycémie sévère voire de coma, par augmentation importante des concentrations plasmatiques de repaglinide par le gemfibrozil."@fr;
  rdfs:comment "Une publication montre que le gemfibrozil augmente d'environ huit fois les concentrations plasmatiques du répaglinide. Les auteurs attribuent cet effet à une inhibition du CYP2C8 par le gemfibrozil. Cette isoenzyme est en effet largement impliquée dans le"@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b209372, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b209366 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b209367 .

_:79f295ad32df4ce8a18a92539c6e8a3b209367 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209368;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b209369 .

_:79f295ad32df4ce8a18a92539c6e8a3b209368 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10411 .

_:79f295ad32df4ce8a18a92539c6e8a3b209369 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209370;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b209370 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10791 .

_:79f295ad32df4ce8a18a92539c6e8a3b209372 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10996-1 a owl:Class;
  rdfs:label "GLIPIZIDE <-> VORICONAZOLE"@fr;
  dct:identifier "IAM_10996";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b209374;
  r:natureDuRisque "Risque d’augmentation des concentrations plasmatiques du glipizide à l’origine d’hypoglycémies potentiellement sévères."@fr;
  r:conduiteATenir "Prévenir le patient, renforcer l'autosurveillance glycémique et adapter éventuellement la posologie du sulfamide pendant et après le traitement par voriconazole."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b209380, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b209374 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b209375 .

_:79f295ad32df4ce8a18a92539c6e8a3b209375 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209376;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b209377 .

_:79f295ad32df4ce8a18a92539c6e8a3b209376 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10417 .

_:79f295ad32df4ce8a18a92539c6e8a3b209377 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209378;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b209378 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10998 .

_:79f295ad32df4ce8a18a92539c6e8a3b209380 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10997-1 a owl:Class;
  rdfs:label "GLIPTINES <-> INHIBITEURS DE L'ENZYME DE CONVERSION"@fr;
  dct:identifier "IAM_10997";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b209382;
  r:natureDuRisque "Majoration du risque de la survenue d’angio-oedèmes, par réduction de l’activité de l’enzyme dipeptidyl peptidase IV (DPP-IV) par la gliptine, chez les patients traités par inhibiteur de l’enzyme de conversion."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b209388, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b209382 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b209383 .

_:79f295ad32df4ce8a18a92539c6e8a3b209383 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209384;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b209385 .

_:79f295ad32df4ce8a18a92539c6e8a3b209384 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10079 .

_:79f295ad32df4ce8a18a92539c6e8a3b209385 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209386;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b209386 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10096 .

_:79f295ad32df4ce8a18a92539c6e8a3b209388 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11011-1 a owl:Class;
  rdfs:label "HALOTHANE <-> THÉOPHYLLINE (ET, PAR EXTRAPOLATION, AMINOPHYLLINE)"@fr;
  dct:identifier "IAM_11011";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b209390;
  r:natureDuRisque "Troubles du rythme ventriculaire graves par augmentation de l'excitabilité cardiaque."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b209396, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b209390 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b209391 .

_:79f295ad32df4ce8a18a92539c6e8a3b209391 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209392;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b209393 .

_:79f295ad32df4ce8a18a92539c6e8a3b209392 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10152 .

_:79f295ad32df4ce8a18a92539c6e8a3b209393 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209394;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b209394 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10427 .

_:79f295ad32df4ce8a18a92539c6e8a3b209396 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11012-1 a owl:Class;
  rdfs:label "HÉPARINES DE BAS POIDS MOLÉCULAIRE ET APPARENTÉS (DOSES CURATIVES ET/OU SUJET ÂGÉ) <-> THROMBOLYTIQUES"@fr;
  dct:identifier "IAM_11012";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b209398;
  r:natureDuRisque "Augmentation du risque hémorragique."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b209404, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b209398 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b209399 .

_:79f295ad32df4ce8a18a92539c6e8a3b209399 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209400;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b209401 .

_:79f295ad32df4ce8a18a92539c6e8a3b209400 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10089 .

_:79f295ad32df4ce8a18a92539c6e8a3b209401 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209402;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b209402 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10151 .

_:79f295ad32df4ce8a18a92539c6e8a3b209404 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11013-1 a owl:Class;
  rdfs:label "HÉPARINES NON FRACTIONNÉES (DOSES CURATIVES ET/OU SUJET ÂGÉ) <-> THROMBOLYTIQUES"@fr;
  dct:identifier "IAM_11013";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b209406;
  r:natureDuRisque "Augmentation du risque hémorragique."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b209412, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b209406 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b209407 .

_:79f295ad32df4ce8a18a92539c6e8a3b209407 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209408;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b209409 .

_:79f295ad32df4ce8a18a92539c6e8a3b209408 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10091 .

_:79f295ad32df4ce8a18a92539c6e8a3b209409 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209410;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b209410 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10151 .

_:79f295ad32df4ce8a18a92539c6e8a3b209412 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11014-1 a owl:Class;
  rdfs:label "HORMONES THYROÏDIENNES <-> IMATINIB"@fr;
  dct:identifier "IAM_11014";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b209414;
  r:natureDuRisque "Risque de baisse de l’efficacité des hormones thyroïdiennes."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b209420, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b209414 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b209415 .

_:79f295ad32df4ce8a18a92539c6e8a3b209415 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209416;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b209417 .

_:79f295ad32df4ce8a18a92539c6e8a3b209416 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10082 .

_:79f295ad32df4ce8a18a92539c6e8a3b209417 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209418;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b209418 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10448 .

_:79f295ad32df4ce8a18a92539c6e8a3b209420 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10990-1 a owl:Class;
  rdfs:label "FOSCARNET <-> PENTAMIDINE"@fr;
  dct:identifier "IAM_10990";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b209422;
  r:natureDuRisque "Risque d'hypocalcémie sévère."@fr;
  r:conduiteATenir "Surveillance de la calcémie et supplémentation si nécessaire."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b209428, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b209422 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b209423 .

_:79f295ad32df4ce8a18a92539c6e8a3b209423 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209424;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b209425 .

_:79f295ad32df4ce8a18a92539c6e8a3b209424 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10401 .

_:79f295ad32df4ce8a18a92539c6e8a3b209425 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209426;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b209426 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10703 .

_:79f295ad32df4ce8a18a92539c6e8a3b209428 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10968-1 a owl:Class;
  rdfs:label "FLUOROURACILE (ET, PAR EXTRAPOLATION, AUTRES FLUOROPYRIMIDINES) <-> ORNIDAZOLE"@fr;
  dct:identifier "IAM_10968";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b209430;
  r:natureDuRisque "Augmentation de la toxicité du fluoro-uracile par diminution de sa clairance."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b209436, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b209430 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b209431 .

_:79f295ad32df4ce8a18a92539c6e8a3b209431 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209432;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b209433 .

_:79f295ad32df4ce8a18a92539c6e8a3b209432 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10076 .

_:79f295ad32df4ce8a18a92539c6e8a3b209433 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209434;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b209434 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10668 .

_:79f295ad32df4ce8a18a92539c6e8a3b209436 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10957-1 a owl:Class;
  rdfs:label "FLUCONAZOLE <-> SULFAMIDES HYPOGLYCÉMIANTS"@fr;
  dct:identifier "IAM_10957";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b209438;
  r:natureDuRisque "Augmentation du temps de demi-vie du sulfamide avec survenue possible de manifestations d'hypoglycémie."@fr;
  r:conduiteATenir "Prévenir le patient, renforcer l'autosurveillance glycémique et adapter éventuellement la posologie du sulfamide pendant le traitement par le fluconazole."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b209444, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b209438 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b209439 .

_:79f295ad32df4ce8a18a92539c6e8a3b209439 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209440;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b209441 .

_:79f295ad32df4ce8a18a92539c6e8a3b209440 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10147 .

_:79f295ad32df4ce8a18a92539c6e8a3b209441 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209442;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b209442 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10381 .

_:79f295ad32df4ce8a18a92539c6e8a3b209444 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10958-1 a owl:Class;
  rdfs:label "FLUCONAZOLE <-> THÉOPHYLLINE (ET, PAR EXTRAPOLATION, AMINOPHYLLINE)"@fr;
  dct:identifier "IAM_10958";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b209446;
  r:natureDuRisque "Augmentation de la théophyllinémie avec risque de surdosage (diminution de la clairance de la théophylline)."@fr;
  r:conduiteATenir "Surveillance clinique et éventuellement de la théophyllinémie ; s'il y a lieu, adaptation de la posologie de la théophylline pendant le traitement par le fluconazole et après son arrêt."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b209452, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b209446 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b209447 .

_:79f295ad32df4ce8a18a92539c6e8a3b209447 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209448;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b209449 .

_:79f295ad32df4ce8a18a92539c6e8a3b209448 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10152 .

_:79f295ad32df4ce8a18a92539c6e8a3b209449 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209450;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b209450 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10381 .

_:79f295ad32df4ce8a18a92539c6e8a3b209452 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10959-1 a owl:Class;
  rdfs:label "FLUCYTOSINE <-> ZIDOVUDINE"@fr;
  dct:identifier "IAM_10959";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b209454;
  r:natureDuRisque "Augmentation de la toxicité hématologique (addition d'effets de toxicité médullaire)."@fr;
  r:conduiteATenir "Contrôle plus fréquent de l'hémogramme."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b209460, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b209454 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b209455 .

_:79f295ad32df4ce8a18a92539c6e8a3b209455 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209456;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b209457 .

_:79f295ad32df4ce8a18a92539c6e8a3b209456 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10382 .

_:79f295ad32df4ce8a18a92539c6e8a3b209457 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209458;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b209458 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_11004 .

_:79f295ad32df4ce8a18a92539c6e8a3b209460 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10960-1 a owl:Class;
  rdfs:label "FLUDARABINE <-> PENTOSTATINE"@fr;
  dct:identifier "IAM_10960";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b209462;
  r:natureDuRisque "Majoration du risque de toxicité pulmonaire pouvant être fatale."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b209468, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b209462 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b209463 .

_:79f295ad32df4ce8a18a92539c6e8a3b209463 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209464;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b209465 .

_:79f295ad32df4ce8a18a92539c6e8a3b209464 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10383 .

_:79f295ad32df4ce8a18a92539c6e8a3b209465 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209466;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b209466 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10704 .

_:79f295ad32df4ce8a18a92539c6e8a3b209468 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10961-1 a owl:Class;
  rdfs:label "FLUOROQUINOLONES <-> GLUCOCORTICOÏDES (SAUF HYDROCORTISONE)"@fr;
  dct:identifier "IAM_10961";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b209470;
  r:natureDuRisque "Possible majoration du risque de tendinopathie, voire de rupture tendineuse (exceptionnelle), particulièrement chez les patients recevant une corticothérapie prolongée."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b209476, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b209470 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b209471 .

_:79f295ad32df4ce8a18a92539c6e8a3b209471 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209472;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b209473 .

_:79f295ad32df4ce8a18a92539c6e8a3b209472 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10075 .

_:79f295ad32df4ce8a18a92539c6e8a3b209473 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209474;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b209474 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10081 .

_:79f295ad32df4ce8a18a92539c6e8a3b209476 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10962-1 a owl:Class;
  rdfs:label "FLUOROQUINOLONES <-> MYCOPHENOLATE MOFETIL"@fr;
  dct:identifier "IAM_10962";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b209478;
  r:natureDuRisque "Diminution des concentrations de l’acide mycophénolique d’environ un tiers, avec risque potentiel de baisse d’efficacité."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b209484, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b209478 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b209479 .

_:79f295ad32df4ce8a18a92539c6e8a3b209479 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209480;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b209481 .

_:79f295ad32df4ce8a18a92539c6e8a3b209480 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10075 .

_:79f295ad32df4ce8a18a92539c6e8a3b209481 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209482;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b209482 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10609 .

_:79f295ad32df4ce8a18a92539c6e8a3b209484 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10963-1 a owl:Class;
  rdfs:label "FLUOROQUINOLONES <-> STRONTIUM"@fr;
  dct:identifier "IAM_10963";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b209486;
  r:natureDuRisque "Diminution de l'absorption digestive du strontium."@fr;
  r:conduiteATenir "Prendre le strontium à distance des fluoroquinolones (plus de deux heures, si possible)."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b209492, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b209486 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b209487 .

_:79f295ad32df4ce8a18a92539c6e8a3b209487 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209488;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b209489 .

_:79f295ad32df4ce8a18a92539c6e8a3b209488 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10075 .

_:79f295ad32df4ce8a18a92539c6e8a3b209489 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209490;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b209490 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10863 .

_:79f295ad32df4ce8a18a92539c6e8a3b209492 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10964-1 a owl:Class;
  rdfs:label "FLUOROQUINOLONES <-> SUCRALFATE"@fr;
  dct:identifier "IAM_10964";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b209494;
  r:natureDuRisque "Diminution de l'absorption digestive des fluoroquinolones."@fr;
  r:conduiteATenir "Prendre le sucralfate à distance des fluoroquinolones (plus de 2 heures, si possible)."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b209500, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b209494 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b209495 .

_:79f295ad32df4ce8a18a92539c6e8a3b209495 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209496;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b209497 .

_:79f295ad32df4ce8a18a92539c6e8a3b209496 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10075 .

_:79f295ad32df4ce8a18a92539c6e8a3b209497 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209498;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b209498 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10864 .

_:79f295ad32df4ce8a18a92539c6e8a3b209500 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10965-1 a owl:Class;
  rdfs:label "FLUOROQUINOLONES <-> ZINC"@fr;
  dct:identifier "IAM_10965";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b209502;
  r:natureDuRisque "Diminution de l'absorption digestives des fluoroquinolones."@fr;
  r:conduiteATenir "Prendre les sels de zinc à distance des fluoroquinolones (plus de 2 heures, si possible)."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b209508, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b209502 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b209503 .

_:79f295ad32df4ce8a18a92539c6e8a3b209503 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209504;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b209505 .

_:79f295ad32df4ce8a18a92539c6e8a3b209504 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10075 .

_:79f295ad32df4ce8a18a92539c6e8a3b209505 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209506;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b209506 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_11005 .

_:79f295ad32df4ce8a18a92539c6e8a3b209508 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10980-1 a owl:Class;
  rdfs:label "FLUVOXAMINE <-> PHÉNYTOÏNE (ET, PAR EXTRAPOLATION, FOSPHÉNYTOÏNE)"@fr;
  dct:identifier "IAM_10980";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b209510;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de phénytoïne avec signes de surdosage, par inhibition du métabolisme hépatique de la phénytoïne."@fr;
  r:conduiteATenir "Surveillance clinique et éventuellement contröle des concentrations plamatiques de phénytoïne. Si besoin, adaptation posologique de la phénytoïne pendant le traitement par la fluvoxamine et après son arrët."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b209516, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b209510 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b209511 .

_:79f295ad32df4ce8a18a92539c6e8a3b209511 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209512;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b209513 .

_:79f295ad32df4ce8a18a92539c6e8a3b209512 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10132 .

_:79f295ad32df4ce8a18a92539c6e8a3b209513 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209514;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b209514 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10398 .

_:79f295ad32df4ce8a18a92539c6e8a3b209516 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10967-1 a owl:Class;
  rdfs:label "FLUOROURACILE (ET, PAR EXTRAPOLATION, AUTRES FLUOROPYRIMIDINES) <-> METRONIDAZOLE"@fr;
  dct:identifier "IAM_10967";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b209518;
  r:natureDuRisque "Augmentation de la toxicité du fluoro-uracile par diminution de sa clairance."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b209524, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b209518 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b209519 .

_:79f295ad32df4ce8a18a92539c6e8a3b209519 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209520;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b209521 .

_:79f295ad32df4ce8a18a92539c6e8a3b209520 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10076 .

_:79f295ad32df4ce8a18a92539c6e8a3b209521 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209522;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b209522 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10580 .

_:79f295ad32df4ce8a18a92539c6e8a3b209524 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10979-1 a owl:Class;
  rdfs:label "FLUVOXAMINE <-> OLANZAPINE"@fr;
  dct:identifier "IAM_10979";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b209526;
  r:natureDuRisque "Augmentation des concentrations de l’olanzapine, avec risque de majoration des effets indésirables, par diminution de son métabolisme hépatique par la fluvoxamine."@fr;
  r:conduiteATenir "Surveillance clinique et réduction éventuelle de la posologie de l’olanzapine pendant le traitement par fluvoxamine."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b209532, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b209526 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b209527 .

_:79f295ad32df4ce8a18a92539c6e8a3b209527 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209528;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b209529 .

_:79f295ad32df4ce8a18a92539c6e8a3b209528 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10398 .

_:79f295ad32df4ce8a18a92539c6e8a3b209529 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209530;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b209530 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10658 .

_:79f295ad32df4ce8a18a92539c6e8a3b209532 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10970-1 a owl:Class;
  rdfs:label "FLUOXETINE <-> METOPROLOL"@fr;
  dct:identifier "IAM_10970";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b209534;
  r:natureDuRisque "Risque de majoration des effets indésirables du métoprolol, avec notamment bradycardie excessive, par inhibition de son métabolisme par la fluoxétine."@fr;
  r:conduiteATenir "Surveillance clinique accrue ; si besoin, adaptation de la posologie du métoprolol pendant la durée du traitement par la fluoxétine et après son arrêt."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b209540, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b209534 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b209535 .

_:79f295ad32df4ce8a18a92539c6e8a3b209535 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209536;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b209537 .

_:79f295ad32df4ce8a18a92539c6e8a3b209536 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10390 .

_:79f295ad32df4ce8a18a92539c6e8a3b209537 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209538;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b209538 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10579 .

_:79f295ad32df4ce8a18a92539c6e8a3b209540 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10971-1 a owl:Class;
  rdfs:label "FLUOXETINE <-> NEBIVOLOL"@fr;
  dct:identifier "IAM_10971";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b209542;
  r:natureDuRisque "Risque de majoration des effets indésirables du nébivolol avec notamment bradycardie excessive, par inhibition de son métabolisme par l’antidépresseur."@fr;
  r:conduiteATenir "Surveillance clinique accrue ; si besoin, adaptation de la posologie du nébivolol pendant la durée du traitement par l’antidépresseur et après son arrêt."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b209548, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b209542 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b209543 .

_:79f295ad32df4ce8a18a92539c6e8a3b209543 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209544;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b209545 .

_:79f295ad32df4ce8a18a92539c6e8a3b209544 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10390 .

_:79f295ad32df4ce8a18a92539c6e8a3b209545 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209546;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b209546 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10623 .

_:79f295ad32df4ce8a18a92539c6e8a3b209548 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10969-1 a owl:Class;
  rdfs:label "FLUOXETINE <-> MEQUITAZINE"@fr;
  dct:identifier "IAM_10969";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b209550;
  r:natureDuRisque "Risque de majoration des effets indésirables de la méquitazine, par inhibition de son métabolisme par l’inhibiteur enzymatique."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b209556, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b209550 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b209551 .

_:79f295ad32df4ce8a18a92539c6e8a3b209551 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209552;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b209553 .

_:79f295ad32df4ce8a18a92539c6e8a3b209552 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10390 .

_:79f295ad32df4ce8a18a92539c6e8a3b209553 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209554;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b209554 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10561 .

_:79f295ad32df4ce8a18a92539c6e8a3b209556 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10972-1 a owl:Class;
  rdfs:label "FLUOXETINE <-> PHÉNYTOÏNE (ET, PAR EXTRAPOLATION, FOSPHÉNYTOÏNE)"@fr;
  dct:identifier "IAM_10972";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b209558;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de phénytoïne avec signes de surdosage, par inhibition du métabolisme de la phénytoïne."@fr;
  r:conduiteATenir "Surveillance clinique et éventuellement contrôle des concentrations plasmatiques de phénytoïne. Si besoin, adaptation posologique pendant le traitement par la fluoxétine et après son arrêt."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b209564, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b209558 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b209559 .

_:79f295ad32df4ce8a18a92539c6e8a3b209559 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209560;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b209561 .

_:79f295ad32df4ce8a18a92539c6e8a3b209560 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10132 .

_:79f295ad32df4ce8a18a92539c6e8a3b209561 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209562;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b209562 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10390 .

_:79f295ad32df4ce8a18a92539c6e8a3b209564 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10973-1 a owl:Class;
  rdfs:label "FLUOXETINE <-> RISPERIDONE"@fr;
  dct:identifier "IAM_10973";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b209566;
  r:natureDuRisque "Augmentation de la fraction active de la rispéridone par diminution de son métabolisme hépatique par la fluoxétine, avec risque de majoration des effets indésirables."@fr;
  r:conduiteATenir "Surveillance clinique et, si besoin, adaptation posologique de la rispéridone."@fr;
  rdfs:comment "La rispéridone est majoritairement métabolisée par le CYP2D6 en 9-OH-rispéridone, métabolite actif. La fraction pharmacologiquement active de la rispéridone est ainsi constituée par la molécule mère et son métabolite hydroxylé. La fluoxétine est un inhibi"@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b209572, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b209566 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b209567 .

_:79f295ad32df4ce8a18a92539c6e8a3b209567 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209568;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b209569 .

_:79f295ad32df4ce8a18a92539c6e8a3b209568 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10390 .

_:79f295ad32df4ce8a18a92539c6e8a3b209569 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209570;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b209570 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10805 .

_:79f295ad32df4ce8a18a92539c6e8a3b209572 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10974-1 a owl:Class;
  rdfs:label "FLUOXETINE <-> TAMOXIFENE"@fr;
  dct:identifier "IAM_10974";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b209574;
  r:natureDuRisque "Baisse de l’efficacité du tamoxifène, par inhibition de la formation de son métabolite actif par la fluoxétine."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b209580, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b209574 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b209575 .

_:79f295ad32df4ce8a18a92539c6e8a3b209575 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209576;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b209577 .

_:79f295ad32df4ce8a18a92539c6e8a3b209576 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10390 .

_:79f295ad32df4ce8a18a92539c6e8a3b209577 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209578;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b209578 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10882 .

_:79f295ad32df4ce8a18a92539c6e8a3b209580 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10975-1 a owl:Class;
  rdfs:label "FLUOXETINE <-> VORTIOXÉTINE"@fr;
  dct:identifier "IAM_10975";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b209582;
  r:natureDuRisque "Risque d’augmentation des effets indésirables de la vortioxétine par diminution de son métabolisme hépatique."@fr;
  r:conduiteATenir "Surveillance clinique et adaptation éventuelle de la posologie de la vortioxétine pendant le traitement par la fluoxétine et après son arrêt."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b209588, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b209582 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b209583 .

_:79f295ad32df4ce8a18a92539c6e8a3b209583 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209584;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b209585 .

_:79f295ad32df4ce8a18a92539c6e8a3b209584 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10390 .

_:79f295ad32df4ce8a18a92539c6e8a3b209585 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209586;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b209586 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10999 .

_:79f295ad32df4ce8a18a92539c6e8a3b209588 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10976-1 a owl:Class;
  rdfs:label "FLUVOXAMINE <-> LIDOCAINE"@fr;
  dct:identifier "IAM_10976";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b209590;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de la lidocaïne avec possibilités d’effets indésirables neurologiques et cardiaques (diminution de la clairance hépatique de la lidocaïne)."@fr;
  r:conduiteATenir "Surveillance clinique, ECG et éventuellement contrôle des concentrations plasmatiques de la lidocaïne pendant et après l’arrêt de l’association. Adaptation, si besoin, de la posologie de la lidocaïne."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b209596, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b209590 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b209591 .

_:79f295ad32df4ce8a18a92539c6e8a3b209591 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209592;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b209593 .

_:79f295ad32df4ce8a18a92539c6e8a3b209592 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10398 .

_:79f295ad32df4ce8a18a92539c6e8a3b209593 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209594;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b209594 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10523 .

_:79f295ad32df4ce8a18a92539c6e8a3b209596 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10977-1 a owl:Class;
  rdfs:label "FLUVOXAMINE <-> METHADONE"@fr;
  dct:identifier "IAM_10977";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b209598;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de méthadone avec surdosage et risque majoré d’allongement de l’intervalle QT et de troubles du rythme ventriculaire, notamment de torsades de pointes."@fr;
  r:conduiteATenir "Surveillance clinique et électrocardiographique renforcée ; si besoin, adaptation de la posologie de la méthadone pendant le traitement par la fluvoxamine et après son arrêt."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b209604, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b209598 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b209599 .

_:79f295ad32df4ce8a18a92539c6e8a3b209599 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209600;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b209601 .

_:79f295ad32df4ce8a18a92539c6e8a3b209600 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10398 .

_:79f295ad32df4ce8a18a92539c6e8a3b209601 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209602;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b209602 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10567 .

_:79f295ad32df4ce8a18a92539c6e8a3b209604 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11017-1 a owl:Class;
  rdfs:label "HORMONES THYROÏDIENNES <-> PROGUANIL"@fr;
  dct:identifier "IAM_11017";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b209606;
  r:natureDuRisque "Risque d’hypothyroïdie clinique chez les patients substitués par hormones thyroïdiennes."@fr;
  r:conduiteATenir "Surveillance des concentrations sériques de T3 et de T4 et adaptation, si besoin, de la posologie de l'hormone thyroïdienne pendant le traitement par l’antipaludique et après son arrêt."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b209612, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b209606 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b209607 .

_:79f295ad32df4ce8a18a92539c6e8a3b209607 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209608;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b209609 .

_:79f295ad32df4ce8a18a92539c6e8a3b209608 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10082 .

_:79f295ad32df4ce8a18a92539c6e8a3b209609 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209610;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b209610 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10761 .

_:79f295ad32df4ce8a18a92539c6e8a3b209612 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10966-1 a owl:Class;
  rdfs:label "FLUOROURACILE (ET, PAR EXTRAPOLATION, AUTRES FLUOROPYRIMIDINES) <-> INTERFERON ALFA"@fr;
  dct:identifier "IAM_10966";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b209614;
  r:natureDuRisque "Augmentation de la toxicité gastro-intestinale du fluorouracile."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b209620, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b209614 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b209615 .

_:79f295ad32df4ce8a18a92539c6e8a3b209615 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209616;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b209617 .

_:79f295ad32df4ce8a18a92539c6e8a3b209616 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10076 .

_:79f295ad32df4ce8a18a92539c6e8a3b209617 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209618;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b209618 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10474 .

_:79f295ad32df4ce8a18a92539c6e8a3b209620 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11070-1 a owl:Class;
  rdfs:label "IMMUNOSUPPRESSEURS <-> INHIBITEURS DE PROTÉASES BOOSTÉS PAR RITONAVIR"@fr;
  dct:identifier "IAM_11070";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b209622;
  r:chapeau "Le ritonavir est désormais utilisé à la dose de 100 mg 2 fois par jour en association à un autre inhibiteur de protéase, dans le but d'augmenter de façon très significative la biodisponibilité de l'inhibiteur de protéase associé (ou boosté), ce qui permet"@fr;
  r:natureDuRisque "Augmentation très importante des concentrations sanguines de l'immunosuppresseur par inhibition de son métabolisme hépatique."@fr;
  r:conduiteATenir "En cas d’association, contrôle strict de la fonction rénale, dosage des concentrations sanguines de l'immunosuppresseur et adaptation de sa posologie."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b209628, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b209622 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b209623 .

_:79f295ad32df4ce8a18a92539c6e8a3b209623 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209624;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b209625 .

_:79f295ad32df4ce8a18a92539c6e8a3b209624 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10093 .

_:79f295ad32df4ce8a18a92539c6e8a3b209625 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209626;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b209626 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10100 .

_:79f295ad32df4ce8a18a92539c6e8a3b209628 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11015-1 a owl:Class;
  rdfs:label "HORMONES THYROÏDIENNES <-> INHIBITEURS DE PROTÉASES BOOSTÉS PAR RITONAVIR"@fr;
  dct:identifier "IAM_11015";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b209630;
  r:chapeau "Le ritonavir est désormais utilisé à la dose de 100 mg 2 fois par jour en association à un autre inhibiteur de protéase, dans le but d'augmenter de façon très significative la biodisponibilité de l'inhibiteur de protéase associé (ou boosté), ce qui permet"@fr;
  r:natureDuRisque "Risque de baisse de l’efficacité des hormones thyroïdiennes par augmentation de leur métabolisme hépatique par le ritonavir."@fr;
  r:conduiteATenir "Surveillance clinique et biologique et adaptation éventuelle de la posologie des hormones thyroïdiennes."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b209636, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b209630 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b209631 .

_:79f295ad32df4ce8a18a92539c6e8a3b209631 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209632;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b209633 .

_:79f295ad32df4ce8a18a92539c6e8a3b209632 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10082 .

_:79f295ad32df4ce8a18a92539c6e8a3b209633 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209634;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b209634 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10100 .

_:79f295ad32df4ce8a18a92539c6e8a3b209636 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11062-1 a owl:Class;
  rdfs:label "IMAO-A RÉVERSIBLES, Y COMPRIS LINEZOLIDE ET BLEU DE MÉTHYLÈNE <-> TRIPTANS NON MÉTABOLISÉS PAR LA MAO"@fr;
  dct:identifier "IAM_11062";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b209638;
  r:natureDuRisque "Risque d'hypertension artérielle, de vasoconstriction artérielle coronaire."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b209644, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b209638 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b209639 .

_:79f295ad32df4ce8a18a92539c6e8a3b209639 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209640;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b209641 .

_:79f295ad32df4ce8a18a92539c6e8a3b209640 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10003 .

_:79f295ad32df4ce8a18a92539c6e8a3b209641 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209642;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b209642 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10158 .

_:79f295ad32df4ce8a18a92539c6e8a3b209644 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11061-1 a owl:Class;
  rdfs:label "IMAO-A RÉVERSIBLES, Y COMPRIS LINEZOLIDE ET BLEU DE MÉTHYLÈNE <-> TRIPTANS MÉTABOLISÉS PAR LA MAO"@fr;
  dct:identifier "IAM_11061";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b209646;
  r:natureDuRisque "Risque d'hypertension artérielle, de vasoconstriction artérielle coronaire."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b209652, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b209646 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b209647 .

_:79f295ad32df4ce8a18a92539c6e8a3b209647 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209648;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b209649 .

_:79f295ad32df4ce8a18a92539c6e8a3b209648 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10003 .

_:79f295ad32df4ce8a18a92539c6e8a3b209649 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209650;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b209650 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10157 .

_:79f295ad32df4ce8a18a92539c6e8a3b209652 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11063-1 a owl:Class;
  rdfs:label "IMAO-B <-> INHIBITEURS SÉLECTIFS DE LA RECAPTURE DE LA SÉROTONINE"@fr;
  dct:identifier "IAM_11063";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b209654;
  r:natureDuRisque "Risque d'apparition d'un syndrome sérotoninergique."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b209660, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b209654 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b209655 .

_:79f295ad32df4ce8a18a92539c6e8a3b209655 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209656;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b209657 .

_:79f295ad32df4ce8a18a92539c6e8a3b209656 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10004 .

_:79f295ad32df4ce8a18a92539c6e8a3b209657 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209658;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b209658 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10104 .

_:79f295ad32df4ce8a18a92539c6e8a3b209660 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11064-1 a owl:Class;
  rdfs:label "IMAO-B <-> LEVODOPA"@fr;
  dct:identifier "IAM_11064";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b209662;
  r:natureDuRisque "Augmentation du risque d'hypotension orthostatique."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b209668, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b209662 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b209663 .

_:79f295ad32df4ce8a18a92539c6e8a3b209663 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209664;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b209665 .

_:79f295ad32df4ce8a18a92539c6e8a3b209664 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10004 .

_:79f295ad32df4ce8a18a92539c6e8a3b209665 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209666;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b209666 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10517 .

_:79f295ad32df4ce8a18a92539c6e8a3b209668 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11065-1 a owl:Class;
  rdfs:label "IMAO-B <-> PETHIDINE"@fr;
  dct:identifier "IAM_11065";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b209670;
  r:natureDuRisque "Manifestations d'excitation centrale évoquant un syndrome sérotoninergique : diarrhée, tachycardie, sueurs, tremblements, confusion voire coma."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b209676, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b209670 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b209671 .

_:79f295ad32df4ce8a18a92539c6e8a3b209671 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209672;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b209673 .

_:79f295ad32df4ce8a18a92539c6e8a3b209672 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10004 .

_:79f295ad32df4ce8a18a92539c6e8a3b209673 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209674;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b209674 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10709 .

_:79f295ad32df4ce8a18a92539c6e8a3b209676 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11066-1 a owl:Class;
  rdfs:label "IMAO-B <-> TRAMADOL"@fr;
  dct:identifier "IAM_11066";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b209678;
  r:natureDuRisque "Risque d’apparition d’un syndrome sérotoninergique."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b209684, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b209678 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b209679 .

_:79f295ad32df4ce8a18a92539c6e8a3b209679 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209680;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b209681 .

_:79f295ad32df4ce8a18a92539c6e8a3b209680 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10004 .

_:79f295ad32df4ce8a18a92539c6e8a3b209681 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209682;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b209682 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10945 .

_:79f295ad32df4ce8a18a92539c6e8a3b209684 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11068-1 a owl:Class;
  rdfs:label "IMAO-B <-> TRIPTANS NON MÉTABOLISÉS PAR LA MAO"@fr;
  dct:identifier "IAM_11068";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b209686;
  r:natureDuRisque "Risque d'hypertension artérielle, de vasoconstriction artérielle coronaire."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b209692, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b209686 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b209687 .

_:79f295ad32df4ce8a18a92539c6e8a3b209687 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209688;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b209689 .

_:79f295ad32df4ce8a18a92539c6e8a3b209688 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10004 .

_:79f295ad32df4ce8a18a92539c6e8a3b209689 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209690;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b209690 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10158 .

_:79f295ad32df4ce8a18a92539c6e8a3b209692 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11067-1 a owl:Class;
  rdfs:label "IMAO-B <-> TRIPTANS MÉTABOLISÉS PAR LA MAO"@fr;
  dct:identifier "IAM_11067";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b209694;
  r:natureDuRisque "Risque d'hypertension artérielle, de vasoconstriction artérielle coronaire."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b209700, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b209694 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b209695 .

_:79f295ad32df4ce8a18a92539c6e8a3b209695 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209696;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b209697 .

_:79f295ad32df4ce8a18a92539c6e8a3b209696 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10004 .

_:79f295ad32df4ce8a18a92539c6e8a3b209697 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209698;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b209698 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10157 .

_:79f295ad32df4ce8a18a92539c6e8a3b209700 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11059-1 a owl:Class;
  rdfs:label "IMAO-A RÉVERSIBLES, Y COMPRIS LINEZOLIDE ET BLEU DE MÉTHYLÈNE <-> SYMPATHOMIMÉTIQUES INDIRECTS"@fr;
  dct:identifier "IAM_11059";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b209702;
  r:natureDuRisque "Risque de vasoconstriction et/ou de poussées hypertensives."@fr;
  r:conduiteATenir """Contre-indication :
avec le bupropion

Association déconseillée :
avec les autres sympathomimétiques indirects"""@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b209708, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b209702 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b209703 .

_:79f295ad32df4ce8a18a92539c6e8a3b209703 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209704;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b209705 .

_:79f295ad32df4ce8a18a92539c6e8a3b209704 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10003 .

_:79f295ad32df4ce8a18a92539c6e8a3b209705 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209706;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b209706 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10150 .

_:79f295ad32df4ce8a18a92539c6e8a3b209708 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11069-1 a owl:Class;
  rdfs:label "IMMUNOSUPPRESSEURS <-> INDUCTEURS ENZYMATIQUES"@fr;
  dct:identifier "IAM_11069";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b209710;
  r:chapeau "Certains médicaments ont la propriété d'activer considérablement certaines voies métaboliques hépatiques par induction enzymatique. Associés à des médicaments fortement métabolisés au niveau du foie, ils sont, de ce fait, en mesure d'en modifier les conce"@fr;
  r:natureDuRisque "Diminution des concentrations sanguines et de l'efficacité de l'immunosuppresseur, par augmentation de son métabolisme hépatique par l'inducteur."@fr;
  r:conduiteATenir "Augmentation de la posologie de l'immunosuppresseur sous contrôle des concentrations sanguines. Réduction de la posologie après l'arrêt de l'inducteur."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b209716, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b209710 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b209711 .

_:79f295ad32df4ce8a18a92539c6e8a3b209711 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209712;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b209713 .

_:79f295ad32df4ce8a18a92539c6e8a3b209712 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10093 .

_:79f295ad32df4ce8a18a92539c6e8a3b209713 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209714;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b209714 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10094 .

_:79f295ad32df4ce8a18a92539c6e8a3b209716 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11058-1 a owl:Class;
  rdfs:label "IMAO-A RÉVERSIBLES, Y COMPRIS LINEZOLIDE ET BLEU DE MÉTHYLÈNE <-> SYMPATHOMIMÉTIQUES ALPHA ET BÊTA (VOIE IM ET IV)"@fr;
  dct:identifier "IAM_11058";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b209718;
  r:natureDuRisque "Par extrapolation à partir des IMAO non sélectifs : risque d'augmentation de l'action pressive."@fr;
  r:conduiteATenir "A n'utiliser que sous contrôle médical strict."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b209724, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b209718 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b209719 .

_:79f295ad32df4ce8a18a92539c6e8a3b209719 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209720;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b209721 .

_:79f295ad32df4ce8a18a92539c6e8a3b209720 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10003 .

_:79f295ad32df4ce8a18a92539c6e8a3b209721 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209722;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b209722 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10149 .

_:79f295ad32df4ce8a18a92539c6e8a3b209724 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11071-1 a owl:Class;
  rdfs:label "IMMUNOSUPPRESSEURS <-> ITRACONAZOLE"@fr;
  dct:identifier "IAM_11071";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b209726;
  r:natureDuRisque "Augmentation très importante des concentrations sanguines de l'immunosuppresseur par inhibition de son métabolisme hépatique."@fr;
  r:conduiteATenir "En cas d’association, contrôle strict de la fonction rénale, dosage des concentrations sanguines de l'immunosuppresseur et adaptation éventuelle de la posologie."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b209732, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b209726 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b209727 .

_:79f295ad32df4ce8a18a92539c6e8a3b209727 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209728;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b209729 .

_:79f295ad32df4ce8a18a92539c6e8a3b209728 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10093 .

_:79f295ad32df4ce8a18a92539c6e8a3b209729 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209730;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b209730 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10496 .

_:79f295ad32df4ce8a18a92539c6e8a3b209732 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11072-1 a owl:Class;
  rdfs:label "IMMUNOSUPPRESSEURS <-> KETOCONAZOLE"@fr;
  dct:identifier "IAM_11072";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b209734;
  r:natureDuRisque "Augmentation très importante des concentrations sanguines de l'immunosuppresseur par inhibition de son métabolisme hépatique."@fr;
  r:conduiteATenir "En cas d’association, contrôle strict de la fonction rénale, dosage des concentrations sanguines de l'immunosuppresseur et adaptation éventuelle de la posologie."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b209740, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b209734 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b209735 .

_:79f295ad32df4ce8a18a92539c6e8a3b209735 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209736;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b209737 .

_:79f295ad32df4ce8a18a92539c6e8a3b209736 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10093 .

_:79f295ad32df4ce8a18a92539c6e8a3b209737 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209738;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b209738 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10501 .

_:79f295ad32df4ce8a18a92539c6e8a3b209740 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11073-1 a owl:Class;
  rdfs:label "IMMUNOSUPPRESSEURS <-> MILLEPERTUIS"@fr;
  dct:identifier "IAM_11073";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b209742;
  r:natureDuRisque "Diminution des concentrations sanguines de l'immunosuppresseur, en raison de l'effet inducteur enzymatique du millepertuis, avec risque de baisse d'efficacité voire d'annulation de l'effet dont les conséquences peuvent être éventuellement graves (rejet de"@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b209748, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b209742 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b209743 .

_:79f295ad32df4ce8a18a92539c6e8a3b209743 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209744;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b209745 .

_:79f295ad32df4ce8a18a92539c6e8a3b209744 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10093 .

_:79f295ad32df4ce8a18a92539c6e8a3b209745 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209746;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b209746 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10588 .

_:79f295ad32df4ce8a18a92539c6e8a3b209748 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11074-1 a owl:Class;
  rdfs:label "IMMUNOSUPPRESSEURS <-> NICARDIPINE"@fr;
  dct:identifier "IAM_11074";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b209750;
  r:natureDuRisque "Augmentation des concentrations sanguines de l'immunodépresseur, par inhibition de son métabolisme."@fr;
  r:conduiteATenir "Dosage des concentrations sanguines de l'immunosuppresseur, contrôle de la fonction rénale et adaptation de sa posologie pendant le traitement et après l'arrêt."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b209756, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b209750 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b209751 .

_:79f295ad32df4ce8a18a92539c6e8a3b209751 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209752;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b209753 .

_:79f295ad32df4ce8a18a92539c6e8a3b209752 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10093 .

_:79f295ad32df4ce8a18a92539c6e8a3b209753 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209754;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b209754 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10630 .

_:79f295ad32df4ce8a18a92539c6e8a3b209756 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11075-1 a owl:Class;
  rdfs:label "IMMUNOSUPPRESSEURS <-> PAMPLEMOUSSE (JUS ET FRUIT)"@fr;
  dct:identifier "IAM_11075";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b209758;
  r:chapeau "Le jus de pamplemousse peut augmenter la biodisponibilité de quelques médicaments, notamment certains immunosuppresseurs (ciclosporine, tacrolimus, sirolimus), les dihydropyridines, certaines statines et le cisapride. Les conséquences cliniques de ces int"@fr;
  r:natureDuRisque "Augmentation de la biodisponibilité de l’immunosuppresseur et par conséquent de ses effets indésirables."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b209764, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b209758 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b209759 .

_:79f295ad32df4ce8a18a92539c6e8a3b209759 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209760;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b209761 .

_:79f295ad32df4ce8a18a92539c6e8a3b209760 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10093 .

_:79f295ad32df4ce8a18a92539c6e8a3b209761 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209762;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b209762 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10130 .

_:79f295ad32df4ce8a18a92539c6e8a3b209764 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11076-1 a owl:Class;
  rdfs:label "IMMUNOSUPPRESSEURS <-> POSACONAZOLE"@fr;
  dct:identifier "IAM_11076";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b209766;
  r:natureDuRisque "Augmentation très importante des concentrations sanguines de l'immunosuppresseur par inhibition de son métabolisme hépatique."@fr;
  r:conduiteATenir "En cas d’association, contrôle strict de la fonction rénale, dosage des concentrations sanguines de l'immunosuppresseur et adaptation éventuelle de la posologie."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b209772, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b209766 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b209767 .

_:79f295ad32df4ce8a18a92539c6e8a3b209767 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209768;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b209769 .

_:79f295ad32df4ce8a18a92539c6e8a3b209768 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10093 .

_:79f295ad32df4ce8a18a92539c6e8a3b209769 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209770;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b209770 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10741 .

_:79f295ad32df4ce8a18a92539c6e8a3b209772 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11077-1 a owl:Class;
  rdfs:label "IMMUNOSUPPRESSEURS <-> PRISTINAMYCINE"@fr;
  dct:identifier "IAM_11077";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b209774;
  r:natureDuRisque "Augmentation des concentrations sanguines de l'immunosuppresseur par inhibition de son métabolisme hépatique."@fr;
  r:conduiteATenir "Dosage des concentrations sanguines de l'immunosuppresseur, contrôle de la fonction rénale et adaptation de sa posologie pendant l'association et après son arrêt."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b209780, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b209774 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b209775 .

_:79f295ad32df4ce8a18a92539c6e8a3b209775 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209776;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b209777 .

_:79f295ad32df4ce8a18a92539c6e8a3b209776 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10093 .

_:79f295ad32df4ce8a18a92539c6e8a3b209777 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209778;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b209778 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10757 .

_:79f295ad32df4ce8a18a92539c6e8a3b209780 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11093-1 a owl:Class;
  rdfs:label "INDUCTEURS ENZYMATIQUES <-> MACITENTAN"@fr;
  dct:identifier "IAM_11093";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b209782;
  r:natureDuRisque "Diminution des concentrations plasmatiques de macitentan par augmentation de son métabolisme par l’inducteur."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b209788, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b209782 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b209783 .

_:79f295ad32df4ce8a18a92539c6e8a3b209783 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209784;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b209785 .

_:79f295ad32df4ce8a18a92539c6e8a3b209784 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10094 .

_:79f295ad32df4ce8a18a92539c6e8a3b209785 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209786;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b209786 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10544 .

_:79f295ad32df4ce8a18a92539c6e8a3b209788 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11094-1 a owl:Class;
  rdfs:label "INDUCTEURS ENZYMATIQUES <-> MARAVIROC"@fr;
  dct:identifier "IAM_11094";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b209790;
  r:natureDuRisque "En l’absence de co-administration avec un inhibiteur puissant du CYP3A4, diminution des concentrations de maraviroc par l’inducteur."@fr;
  r:conduiteATenir "La dose de maraviroc doit être augmentée à 600 mg deux fois par jour dans cette situation."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b209796, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b209790 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b209791 .

_:79f295ad32df4ce8a18a92539c6e8a3b209791 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209792;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b209793 .

_:79f295ad32df4ce8a18a92539c6e8a3b209792 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10094 .

_:79f295ad32df4ce8a18a92539c6e8a3b209793 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209794;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b209794 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10551 .

_:79f295ad32df4ce8a18a92539c6e8a3b209796 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10425-2 a owl:Class;
  rdfs:label "AUTRES MÉDICAMENTS SÉDATIFS <-> MÉDICAMENTS SÉDATIFS"@fr;
  dct:identifier "IAM_10425";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b209798;
  r:natureDuRisque """Majoration de la dépression centrale.
L'altération de la vigilance peut rendre dangereuses la conduite de véhicules et l'utilisation de machines."""@fr;
  r:conduiteATenir """Association déconseillée:
- avec l'oxybate de sodium.

A prendre en compte:
- avec les autres médicaments sédatifs."""@fr;
  rdfs:comment "A"@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b209800, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b209798 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10120 .

_:79f295ad32df4ce8a18a92539c6e8a3b209800 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11081-1 a owl:Class;
  rdfs:label "IMMUNOSUPPRESSEURS <-> TELAPREVIR"@fr;
  dct:identifier "IAM_11081";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b209802;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de l'immunosuppresseur par inhibition de son métabolisme hépatique par le télaprévir."@fr;
  r:conduiteATenir "Dosage des concentrations sanguines de l'immunosuppresseur, contrôle de la fonction rénale et adaptation de sa posologie pendant l'association et après son arrêt."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b209808, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b209802 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b209803 .

_:79f295ad32df4ce8a18a92539c6e8a3b209803 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209804;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b209805 .

_:79f295ad32df4ce8a18a92539c6e8a3b209804 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10093 .

_:79f295ad32df4ce8a18a92539c6e8a3b209805 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209806;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b209806 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10887 .

_:79f295ad32df4ce8a18a92539c6e8a3b209808 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11028-1 a owl:Class;
  rdfs:label "HYDROXYCHLOROQUINE <-> RIFAMPICINE"@fr;
  dct:identifier "IAM_11028";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b209810;
  r:natureDuRisque "Risque de diminution de l'effet thérapeutique. de l’hydroxychloroquine, par augmentation de son métabolisme par la rifampicine."@fr;
  r:conduiteATenir "Surveillance clinique et adaptation éventuelle de la posologie de l’hydroxychloroquine pendant le traitement par rifampicine et après son arrêt."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b209816, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b209810 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b209811 .

_:79f295ad32df4ce8a18a92539c6e8a3b209811 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209812;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b209813 .

_:79f295ad32df4ce8a18a92539c6e8a3b209812 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10437 .

_:79f295ad32df4ce8a18a92539c6e8a3b209813 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209814;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b209814 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:79f295ad32df4ce8a18a92539c6e8a3b209816 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10954-1 a owl:Class;
  rdfs:label "FLUCONAZOLE <-> RIFABUTINE"@fr;
  dct:identifier "IAM_10954";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b209818;
  r:natureDuRisque "Risque d'accroissement des effets indésirables de la rifabutine (uvéites), par augmentation de ses concentrations et de celles de son métabolite actif."@fr;
  r:conduiteATenir "Surveillance clinique et biologique régulière, notamment en début d'association."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b209824, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b209818 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b209819 .

_:79f295ad32df4ce8a18a92539c6e8a3b209819 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209820;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b209821 .

_:79f295ad32df4ce8a18a92539c6e8a3b209820 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10381 .

_:79f295ad32df4ce8a18a92539c6e8a3b209821 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209822;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b209822 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10800 .

_:79f295ad32df4ce8a18a92539c6e8a3b209824 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11018-1 a owl:Class;
  rdfs:label "HORMONES THYROÏDIENNES <-> RÉSINES CHÉLATRICES"@fr;
  dct:identifier "IAM_11018";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b209826;
  r:natureDuRisque "Diminution de l'absorption digestive des hormones thyroïdiennes."@fr;
  r:conduiteATenir "Prendre les hormones thyroïdiennes à distance de la résine (plus de 2 heures, si possible)."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b209832, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b209826 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b209827 .

_:79f295ad32df4ce8a18a92539c6e8a3b209827 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209828;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b209829 .

_:79f295ad32df4ce8a18a92539c6e8a3b209828 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10082 .

_:79f295ad32df4ce8a18a92539c6e8a3b209829 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209830;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b209830 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10140 .

_:79f295ad32df4ce8a18a92539c6e8a3b209832 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11019-1 a owl:Class;
  rdfs:label "HORMONES THYROÏDIENNES <-> RIFABUTINE"@fr;
  dct:identifier "IAM_11019";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b209834;
  r:natureDuRisque "Décrit pour la phénytoïne, la rifampicine, la carbamazépine. Risque d'hypothyroïdie clinique chez les patients hypothyroïdiens, par augmentation du métabolisme de la T3 et de la T4."@fr;
  r:conduiteATenir "Surveillance des concentrations sériques de T3 et de T4 et adaptation, si besoin, de la posologie des hormones thyroïdiennes pendant le traitement par la rifabutine et après son arrêt."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b209840, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b209834 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b209835 .

_:79f295ad32df4ce8a18a92539c6e8a3b209835 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209836;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b209837 .

_:79f295ad32df4ce8a18a92539c6e8a3b209836 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10082 .

_:79f295ad32df4ce8a18a92539c6e8a3b209837 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209838;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b209838 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10800 .

_:79f295ad32df4ce8a18a92539c6e8a3b209840 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11020-1 a owl:Class;
  rdfs:label "HORMONES THYROÏDIENNES <-> RIFAMPICINE"@fr;
  dct:identifier "IAM_11020";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b209842;
  r:natureDuRisque "Risque d'hypothyroïdie clinique chez les patients hypothyroïdiens, par augmentation du métabolisme de la T3 et de la T4."@fr;
  r:conduiteATenir "Surveillance des concentrations sériques de T3 et de T4 et adaptation, si besoin, de la posologie des hormones thyroïdiennes pendant le traitement par la rifampicine et après son arrêt."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b209848, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b209842 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b209843 .

_:79f295ad32df4ce8a18a92539c6e8a3b209843 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209844;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b209845 .

_:79f295ad32df4ce8a18a92539c6e8a3b209844 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10082 .

_:79f295ad32df4ce8a18a92539c6e8a3b209845 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209846;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b209846 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:79f295ad32df4ce8a18a92539c6e8a3b209848 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11021-1 a owl:Class;
  rdfs:label "HORMONES THYROÏDIENNES <-> SUCRALFATE"@fr;
  dct:identifier "IAM_11021";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b209850;
  r:natureDuRisque "Diminution de l'absorption digestive des hormones thyroïdiennes."@fr;
  r:conduiteATenir "Prendre les hormones thyroïdiennes à distance du sucralfate (plus de 2 heures, si possible)."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b209856, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b209850 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b209851 .

_:79f295ad32df4ce8a18a92539c6e8a3b209851 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209852;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b209853 .

_:79f295ad32df4ce8a18a92539c6e8a3b209852 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10082 .

_:79f295ad32df4ce8a18a92539c6e8a3b209853 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209854;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b209854 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10864 .

_:79f295ad32df4ce8a18a92539c6e8a3b209856 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11022-1 a owl:Class;
  rdfs:label "HORMONES THYROÏDIENNES <-> SUNITINIB"@fr;
  dct:identifier "IAM_11022";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b209858;
  r:natureDuRisque "Risque de baisse de l’efficacité des hormones thyroïdiennes."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b209864, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b209858 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b209859 .

_:79f295ad32df4ce8a18a92539c6e8a3b209859 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209860;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b209861 .

_:79f295ad32df4ce8a18a92539c6e8a3b209860 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10082 .

_:79f295ad32df4ce8a18a92539c6e8a3b209861 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209862;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b209862 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10877 .

_:79f295ad32df4ce8a18a92539c6e8a3b209864 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11023-1 a owl:Class;
  rdfs:label "HUILES MINÉRALES <-> PRÉSERVATIFS EN LATEX"@fr;
  dct:identifier "IAM_11023";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b209866;
  r:natureDuRisque "Risque de rupture du préservatif lors de l'utilisation avec des corps gras ou des lubrifiants contenant des huiles minérales (huile de paraffine, huile de silicone, etc...)."@fr;
  r:conduiteATenir "Utiliser un lubrifiant hydrosoluble (glycérine, polyacrylamide...)."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b209872, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b209866 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b209867 .

_:79f295ad32df4ce8a18a92539c6e8a3b209867 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209868;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b209869 .

_:79f295ad32df4ce8a18a92539c6e8a3b209868 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10083 .

_:79f295ad32df4ce8a18a92539c6e8a3b209869 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209870;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b209870 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10136 .

_:79f295ad32df4ce8a18a92539c6e8a3b209872 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11024-1 a owl:Class;
  rdfs:label "HYDROCORTISONE <-> INDUCTEURS ENZYMATIQUES"@fr;
  dct:identifier "IAM_11024";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b209874;
  r:natureDuRisque "Risque de diminution de l'efficacité de l'hydrocortisone (augmentation de son métabolisme) ; les conséquences sont graves lorsque l'hydrocortisone est administrée en traitement substitutif ou en cas de transplantation."@fr;
  r:conduiteATenir "Surveillance clinique et biologique ; adaptation de la posologie de l'hydrocortisone pendant l'association et après l'arrêt de l'inducteur enzymatique."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b209880, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b209874 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b209875 .

_:79f295ad32df4ce8a18a92539c6e8a3b209875 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209876;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b209877 .

_:79f295ad32df4ce8a18a92539c6e8a3b209876 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10094 .

_:79f295ad32df4ce8a18a92539c6e8a3b209877 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209878;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b209878 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10432 .

_:79f295ad32df4ce8a18a92539c6e8a3b209880 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11025-1 a owl:Class;
  rdfs:label "HYDROQUINIDINE <-> ITRACONAZOLE"@fr;
  dct:identifier "IAM_11025";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b209882;
  r:natureDuRisque "Risque d'acouphènes et/ou de diminution de l'acuité auditive : cinchonisme lié à une diminution du métabolisme hépatique de l'antiarythmique par l'itraconazole."@fr;
  r:conduiteATenir "Surveillance des concentrations plasmatiques de l'antiarythmique et diminution éventuelle de sa posologie si nécessaire."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b209888, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b209882 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b209883 .

_:79f295ad32df4ce8a18a92539c6e8a3b209883 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209884;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b209885 .

_:79f295ad32df4ce8a18a92539c6e8a3b209884 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10434 .

_:79f295ad32df4ce8a18a92539c6e8a3b209885 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209886;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b209886 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10496 .

_:79f295ad32df4ce8a18a92539c6e8a3b209888 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11060-1 a owl:Class;
  rdfs:label "IMAO-A RÉVERSIBLES, Y COMPRIS LINEZOLIDE ET BLEU DE MÉTHYLÈNE <-> TRAMADOL"@fr;
  dct:identifier "IAM_11060";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b209890;
  r:natureDuRisque "Risque d'apparition d'un syndrome sérotoninergique : diarrhée, tachycardie, sueurs, tremblements, confusion voire coma."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b209896, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b209890 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b209891 .

_:79f295ad32df4ce8a18a92539c6e8a3b209891 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209892;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b209893 .

_:79f295ad32df4ce8a18a92539c6e8a3b209892 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10003 .

_:79f295ad32df4ce8a18a92539c6e8a3b209893 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209894;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b209894 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10945 .

_:79f295ad32df4ce8a18a92539c6e8a3b209896 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11027-1 a owl:Class;
  rdfs:label "HYDROXYCHLOROQUINE <-> METOPROLOL"@fr;
  dct:identifier "IAM_11027";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b209898;
  r:natureDuRisque "Avec le métoprolol utilisé dans l'insuffisance cardiaque : risque d'augmentation des effets indésirables du métoprolol par diminution de son métabolisme hépatique par l’hydroxychloroquine."@fr;
  r:conduiteATenir "Surveillance clinique. Si besoin, adaptation de la posologie du métoprolol pendant le traitement par l’hydroxychloroquine."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b209904, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b209898 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b209899 .

_:79f295ad32df4ce8a18a92539c6e8a3b209899 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209900;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b209901 .

_:79f295ad32df4ce8a18a92539c6e8a3b209900 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10437 .

_:79f295ad32df4ce8a18a92539c6e8a3b209901 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209902;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b209902 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10579 .

_:79f295ad32df4ce8a18a92539c6e8a3b209904 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11016-1 a owl:Class;
  rdfs:label "HORMONES THYROÏDIENNES <-> ORLISTAT"@fr;
  dct:identifier "IAM_11016";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b209906;
  r:natureDuRisque "Risque de déséquilibre du traitement thyroïdien substitutif en cas de traitement par orlistat."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b209912, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b209906 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b209907 .

_:79f295ad32df4ce8a18a92539c6e8a3b209907 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209908;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b209909 .

_:79f295ad32df4ce8a18a92539c6e8a3b209908 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10082 .

_:79f295ad32df4ce8a18a92539c6e8a3b209909 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209910;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b209910 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10667 .

_:79f295ad32df4ce8a18a92539c6e8a3b209912 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11029-1 a owl:Class;
  rdfs:label "HYDROXYCHLOROQUINE <-> SUBSTANCES SUSCEPTIBLES DE DONNER DES TORSADES DE POINTES"@fr;
  dct:identifier "IAM_11029";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b209914;
  r:natureDuRisque "Risque majoré de troubles du rythme ventriculaire, notamment de torsades de pointes."@fr;
  r:conduiteATenir """Contre-indication :
- avec le citalopram, la dompéridone, l'escitalopram, l'hydroxyzine et la pipéraquine.

Association déconseillée:
- avec les autres médicaments susceptibles de donner des torsades de pointes."""@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b209920, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b209914 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b209915 .

_:79f295ad32df4ce8a18a92539c6e8a3b209915 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209916;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b209917 .

_:79f295ad32df4ce8a18a92539c6e8a3b209916 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10143 .

_:79f295ad32df4ce8a18a92539c6e8a3b209917 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209918;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b209918 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10437 .

_:79f295ad32df4ce8a18a92539c6e8a3b209920 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10414-1 a owl:Class;
  rdfs:label "AUTRES HYPERKALIÉMIANTS <-> HYPERKALIÉMIANTS"@fr;
  dct:identifier "IAM_10414";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b209922;
  r:natureDuRisque "Risque de majoration de l’hyperkaliémie, potentiellement létale."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b209924, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b209922 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10084 .

_:79f295ad32df4ce8a18a92539c6e8a3b209924 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10415-1 a owl:Class;
  rdfs:label "AUTRES HYPNOTIQUES <-> HYPNOTIQUES"@fr;
  dct:identifier "IAM_10415";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b209926;
  r:natureDuRisque "Majoration de la dépression centrale."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b209928, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b209926 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10085 .

_:79f295ad32df4ce8a18a92539c6e8a3b209928 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10416-1 a owl:Class;
  rdfs:label "AUTRES HYPOKALIÉMIANTS <-> HYPOKALIÉMIANTS"@fr;
  dct:identifier "IAM_10416";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b209930;
  r:natureDuRisque "Risque majoré d'hypokaliémie."@fr;
  r:conduiteATenir "Surveillance de la kaliémie avec si besoin correction."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b209932, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b209930 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10086 .

_:79f295ad32df4ce8a18a92539c6e8a3b209932 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11030-1 a owl:Class;
  rdfs:label "HYPOKALIÉMIANTS <-> SUBSTANCES SUSCEPTIBLES DE DONNER DES TORSADES DE POINTES"@fr;
  dct:identifier "IAM_11030";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b209934;
  r:chapeau "Ce trouble du rythme cardiaque grave peut être provoqué par un certain nombre de médicaments, antiarythmiques ou non. L'hypokaliémie (cf. médicaments hypokaliémiants) est un facteur favorisant, de même que la bradycardie (cf. médicaments bradycardisants)"@fr;
  r:natureDuRisque "Risque majoré de troubles du rythme ventriculaire, notamment de torsades de pointes."@fr;
  r:conduiteATenir "Corriger toute hypokaliémie avant d’administrer le produit et réaliser une surveillance clinique, électrolytique et électrocardiographique."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b209940, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b209934 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b209935 .

_:79f295ad32df4ce8a18a92539c6e8a3b209935 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209936;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b209937 .

_:79f295ad32df4ce8a18a92539c6e8a3b209936 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10086 .

_:79f295ad32df4ce8a18a92539c6e8a3b209937 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209938;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b209938 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10143 .

_:79f295ad32df4ce8a18a92539c6e8a3b209940 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11042-1 a owl:Class;
  rdfs:label "IMAO IRRÉVERSIBLES <-> MILLEPERTUIS"@fr;
  dct:identifier "IAM_11042";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b209942;
  r:natureDuRisque "Risque d'apparition d'un syndrome sérotoninergique."@fr;
  r:conduiteATenir "Surveillance clinique et biologique régulière, notamment en début d'association."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b209948, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b209942 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b209943 .

_:79f295ad32df4ce8a18a92539c6e8a3b209943 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209944;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b209945 .

_:79f295ad32df4ce8a18a92539c6e8a3b209944 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10002 .

_:79f295ad32df4ce8a18a92539c6e8a3b209945 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209946;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b209946 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10588 .

_:79f295ad32df4ce8a18a92539c6e8a3b209948 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11043-1 a owl:Class;
  rdfs:label "IMAO IRRÉVERSIBLES <-> PETHIDINE"@fr;
  dct:identifier "IAM_11043";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b209950;
  r:natureDuRisque "Risque d'apparition d'un syndrome sérotoninergique : diarrhée, tachycardie, sueurs, tremblements, confusion voire coma."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b209956, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b209950 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b209951 .

_:79f295ad32df4ce8a18a92539c6e8a3b209951 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209952;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b209953 .

_:79f295ad32df4ce8a18a92539c6e8a3b209952 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10002 .

_:79f295ad32df4ce8a18a92539c6e8a3b209953 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209954;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b209954 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10709 .

_:79f295ad32df4ce8a18a92539c6e8a3b209956 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11044-1 a owl:Class;
  rdfs:label "IMAO IRRÉVERSIBLES <-> RESERPINE"@fr;
  dct:identifier "IAM_11044";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b209958;
  r:natureDuRisque "Agitation psychomotrice, convulsions, hypertension."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b209964, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b209958 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b209959 .

_:79f295ad32df4ce8a18a92539c6e8a3b209959 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209960;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b209961 .

_:79f295ad32df4ce8a18a92539c6e8a3b209960 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10002 .

_:79f295ad32df4ce8a18a92539c6e8a3b209961 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209962;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b209962 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10792 .

_:79f295ad32df4ce8a18a92539c6e8a3b209964 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11056-1 a owl:Class;
  rdfs:label "IMAO-A RÉVERSIBLES, Y COMPRIS LINEZOLIDE ET BLEU DE MÉTHYLÈNE <-> MILLEPERTUIS"@fr;
  dct:identifier "IAM_11056";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b209966;
  r:natureDuRisque "Risque d'apparition d'un syndrome sérotoninergique."@fr;
  r:conduiteATenir "Surveillance clinique et biologique régulière, notamment en début d'association."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b209972, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b209966 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b209967 .

_:79f295ad32df4ce8a18a92539c6e8a3b209967 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209968;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b209969 .

_:79f295ad32df4ce8a18a92539c6e8a3b209968 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10003 .

_:79f295ad32df4ce8a18a92539c6e8a3b209969 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209970;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b209970 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10588 .

_:79f295ad32df4ce8a18a92539c6e8a3b209972 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11057-1 a owl:Class;
  rdfs:label "IMAO-A RÉVERSIBLES, Y COMPRIS LINEZOLIDE ET BLEU DE MÉTHYLÈNE <-> PETHIDINE"@fr;
  dct:identifier "IAM_11057";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b209974;
  r:natureDuRisque "Risque d'apparition d'un syndrome sérotoninergique : diarrhée, tachycardie, sueurs, tremblements, confusion voire coma."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b209980, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b209974 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b209975 .

_:79f295ad32df4ce8a18a92539c6e8a3b209975 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209976;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b209977 .

_:79f295ad32df4ce8a18a92539c6e8a3b209976 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10003 .

_:79f295ad32df4ce8a18a92539c6e8a3b209977 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209978;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b209978 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10709 .

_:79f295ad32df4ce8a18a92539c6e8a3b209980 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11026-1 a owl:Class;
  rdfs:label "HYDROXYCARBAMIDE <-> VACCINS VIVANTS ATTÉNUÉS"@fr;
  dct:identifier "IAM_11026";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b209982;
  r:natureDuRisque "Dans son indication chez le patient drépanocytaire, risque théorique de maladie vaccinale généralisée."@fr;
  r:conduiteATenir """L'association ne devra être envisagée que si les bénéfices sont estimés comme étant supérieurs à ce risque. 
S'il est décidé d’interrompre le traitement par hydroxycarbamide pour effectuer la vaccination, un délai de 3 mois après l’arrêt est recommandé."""@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b209988, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b209982 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b209983 .

_:79f295ad32df4ce8a18a92539c6e8a3b209983 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209984;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b209985 .

_:79f295ad32df4ce8a18a92539c6e8a3b209984 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10159 .

_:79f295ad32df4ce8a18a92539c6e8a3b209985 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209986;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b209986 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10436 .

_:79f295ad32df4ce8a18a92539c6e8a3b209988 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10876-1 a owl:Class;
  rdfs:label "ELVITÉGRAVIR <-> RIFABUTINE"@fr;
  dct:identifier "IAM_10876";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b209990;
  r:natureDuRisque "Diminution des concentrations minimales d’elvitégravir."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b209996, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b209990 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b209991 .

_:79f295ad32df4ce8a18a92539c6e8a3b209991 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209992;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b209993 .

_:79f295ad32df4ce8a18a92539c6e8a3b209992 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10321 .

_:79f295ad32df4ce8a18a92539c6e8a3b209993 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b209994;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b209994 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10800 .

_:79f295ad32df4ce8a18a92539c6e8a3b209996 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10897-1 a owl:Class;
  rdfs:label "ERYTHROMYCINE <-> SIMVASTATINE"@fr;
  dct:identifier "IAM_10897";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b209998;
  r:natureDuRisque "Risque majoré d'effets indésirables (concentration-dépendants) à type de rhabdomyolyse (diminution du métabolisme hépatique de l'hypocholestérolémiant."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b210004, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b209998 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b209999 .

_:79f295ad32df4ce8a18a92539c6e8a3b209999 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b210000;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b210001 .

_:79f295ad32df4ce8a18a92539c6e8a3b210000 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10338 .

_:79f295ad32df4ce8a18a92539c6e8a3b210001 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b210002;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b210002 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10838 .

_:79f295ad32df4ce8a18a92539c6e8a3b210004 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10866-1 a owl:Class;
  rdfs:label "EFAVIRENZ <-> FOSAMPRENAVIR"@fr;
  dct:identifier "IAM_10866";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b210006;
  r:natureDuRisque "Risque de baisse de l'efficacité de l'amprénavir."@fr;
  r:conduiteATenir """Surveillance clinique et biologique régulière, notamment en début
d'association."""@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b210012, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b210006 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b210007 .

_:79f295ad32df4ce8a18a92539c6e8a3b210007 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b210008;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b210009 .

_:79f295ad32df4ce8a18a92539c6e8a3b210008 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10318 .

_:79f295ad32df4ce8a18a92539c6e8a3b210009 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b210010;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b210010 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10400 .

_:79f295ad32df4ce8a18a92539c6e8a3b210012 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10867-1 a owl:Class;
  rdfs:label "EFAVIRENZ <-> INDINAVIR"@fr;
  dct:identifier "IAM_10867";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b210014;
  r:natureDuRisque "Risque de baisse de l'efficacité de l'indinavir."@fr;
  r:conduiteATenir "Surveillance clinique et biologique régulière, notamment en début d'association."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b210020, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b210014 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b210015 .

_:79f295ad32df4ce8a18a92539c6e8a3b210015 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b210016;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b210017 .

_:79f295ad32df4ce8a18a92539c6e8a3b210016 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10318 .

_:79f295ad32df4ce8a18a92539c6e8a3b210017 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b210018;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b210018 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10455 .

_:79f295ad32df4ce8a18a92539c6e8a3b210020 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10868-1 a owl:Class;
  rdfs:label "EFAVIRENZ <-> PIMOZIDE"@fr;
  dct:identifier "IAM_10868";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b210022;
  r:natureDuRisque "Risque majoré de troubles du rythme ventriculaire, notamment de torsades de pointes."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b210028, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b210022 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b210023 .

_:79f295ad32df4ce8a18a92539c6e8a3b210023 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b210024;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b210025 .

_:79f295ad32df4ce8a18a92539c6e8a3b210024 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10318 .

_:79f295ad32df4ce8a18a92539c6e8a3b210025 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b210026;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b210026 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10721 .

_:79f295ad32df4ce8a18a92539c6e8a3b210028 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10869-1 a owl:Class;
  rdfs:label "EFAVIRENZ <-> RIFABUTINE"@fr;
  dct:identifier "IAM_10869";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b210030;
  r:natureDuRisque "Diminution d’environ la moitié des concentrations de rifabutine, par augmentation de son métabolisme hépatique par l’éfavirenz."@fr;
  r:conduiteATenir "Adaptation de la posologie de la rifabutine pendant le traitement par efavirenz."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b210036, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b210030 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b210031 .

_:79f295ad32df4ce8a18a92539c6e8a3b210031 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b210032;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b210033 .

_:79f295ad32df4ce8a18a92539c6e8a3b210032 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10318 .

_:79f295ad32df4ce8a18a92539c6e8a3b210033 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b210034;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b210034 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10800 .

_:79f295ad32df4ce8a18a92539c6e8a3b210036 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10870-1 a owl:Class;
  rdfs:label "EFAVIRENZ <-> RIFAMPICINE"@fr;
  dct:identifier "IAM_10870";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b210038;
  r:natureDuRisque "Diminution des concentrations plasmatiques et de l'efficacité de l'éfavirenz par augmentation de son métabolisme hépatique par la rifampicine."@fr;
  r:conduiteATenir "Surveillance clinique et biologique régulière, notamment en début d'association."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b210044, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b210038 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b210039 .

_:79f295ad32df4ce8a18a92539c6e8a3b210039 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b210040;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b210041 .

_:79f295ad32df4ce8a18a92539c6e8a3b210040 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10318 .

_:79f295ad32df4ce8a18a92539c6e8a3b210041 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b210042;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b210042 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:79f295ad32df4ce8a18a92539c6e8a3b210044 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10871-1 a owl:Class;
  rdfs:label "EFAVIRENZ <-> VORICONAZOLE"@fr;
  dct:identifier "IAM_10871";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b210046;
  r:natureDuRisque "Risque de baisse de l'efficacité du voriconazole par augmentation de son métabolisme hépatique par l'efavirenz."@fr;
  r:conduiteATenir "Si l'association ne peut être évitée, surveillance clinique étroite et adaptation de la posologie du voriconazole et de l'éfavirenz pendant l'association."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b210052, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b210046 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b210047 .

_:79f295ad32df4ce8a18a92539c6e8a3b210047 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b210048;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b210049 .

_:79f295ad32df4ce8a18a92539c6e8a3b210048 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10318 .

_:79f295ad32df4ce8a18a92539c6e8a3b210049 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b210050;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b210050 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10998 .

_:79f295ad32df4ce8a18a92539c6e8a3b210052 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10872-1 a owl:Class;
  rdfs:label "ELTROMBOPAG <-> INHIBITEURS DE L'HMG-COA RÉDUCTASE (STATINES)"@fr;
  dct:identifier "IAM_10872";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b210054;
  r:natureDuRisque "Risque de majoration de la toxicité des statines, par inhibition de leur recapture hépatique."@fr;
  r:conduiteATenir "Surveillance clinique et adaptation éventuelle de la posologie de la statine."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b210060, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b210054 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b210055 .

_:79f295ad32df4ce8a18a92539c6e8a3b210055 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b210056;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b210057 .

_:79f295ad32df4ce8a18a92539c6e8a3b210056 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10095 .

_:79f295ad32df4ce8a18a92539c6e8a3b210057 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b210058;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b210058 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10320 .

_:79f295ad32df4ce8a18a92539c6e8a3b210060 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10873-1 a owl:Class;
  rdfs:label "ELVITÉGRAVIR <-> ESTROPROGESTATIFS CONTRACEPTIFS"@fr;
  dct:identifier "IAM_10873";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b210062;
  r:natureDuRisque "Diminution des concentrations d’éthinylestradiol, avec risque de moindre efficacité contraceptive. De plus, augmentation des concentrations du progestatif."@fr;
  r:conduiteATenir "Utiliser un estroprogestatif contraceptif avec au moins 30 µg d’éthinylestradiol."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b210068, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b210062 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b210063 .

_:79f295ad32df4ce8a18a92539c6e8a3b210063 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b210064;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b210065 .

_:79f295ad32df4ce8a18a92539c6e8a3b210064 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10073 .

_:79f295ad32df4ce8a18a92539c6e8a3b210065 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b210066;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b210066 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10321 .

_:79f295ad32df4ce8a18a92539c6e8a3b210068 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10864-1 a owl:Class;
  rdfs:label "EBASTINE <-> KETOCONAZOLE"@fr;
  dct:identifier "IAM_10864";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b210070;
  r:natureDuRisque "Risque majoré de troubles du rythme ventriculaire chez les sujets prédisposés (syndrome du QT long congénital)."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b210076, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b210070 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b210071 .

_:79f295ad32df4ce8a18a92539c6e8a3b210071 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b210072;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b210073 .

_:79f295ad32df4ce8a18a92539c6e8a3b210072 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10316 .

_:79f295ad32df4ce8a18a92539c6e8a3b210073 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b210074;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b210074 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10501 .

_:79f295ad32df4ce8a18a92539c6e8a3b210076 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10875-1 a owl:Class;
  rdfs:label "ELVITÉGRAVIR <-> KETOCONAZOLE"@fr;
  dct:identifier "IAM_10875";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b210078;
  r:natureDuRisque "Augmentation des concentrations plasmatiques d’elvitegravir par diminution de son métabolisme par le kétoconazole."@fr;
  r:conduiteATenir "Avec l’elvitegravir co-administré avec le cobicistat, surveillance clinique. Limiter la dose maximale de kétoconazole à 200 mg/j."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b210084, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b210078 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b210079 .

_:79f295ad32df4ce8a18a92539c6e8a3b210079 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b210080;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b210081 .

_:79f295ad32df4ce8a18a92539c6e8a3b210080 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10321 .

_:79f295ad32df4ce8a18a92539c6e8a3b210081 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b210082;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b210082 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10501 .

_:79f295ad32df4ce8a18a92539c6e8a3b210084 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10863-1 a owl:Class;
  rdfs:label "EBASTINE <-> JOSAMYCINE"@fr;
  dct:identifier "IAM_10863";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b210086;
  r:natureDuRisque "Risque majoré de troubles du rythme ventriculaire chez les sujets prédisposés (syndrome du QT long, congénital)."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b210092, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b210086 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b210087 .

_:79f295ad32df4ce8a18a92539c6e8a3b210087 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b210088;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b210089 .

_:79f295ad32df4ce8a18a92539c6e8a3b210088 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10316 .

_:79f295ad32df4ce8a18a92539c6e8a3b210089 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b210090;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b210090 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10499 .

_:79f295ad32df4ce8a18a92539c6e8a3b210092 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10877-1 a owl:Class;
  rdfs:label "ENOXACINE <-> ROPINIROLE"@fr;
  dct:identifier "IAM_10877";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b210094;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de ropinirole avec signes de surdosage par diminution de son métabolisme hépatique."@fr;
  r:conduiteATenir "Surveillance clinique et réduction de la posologie du ropinirole pendant le traitement par l'énoxacine et après son arrêt."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b210100, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b210094 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b210095 .

_:79f295ad32df4ce8a18a92539c6e8a3b210095 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b210096;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b210097 .

_:79f295ad32df4ce8a18a92539c6e8a3b210096 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10323 .

_:79f295ad32df4ce8a18a92539c6e8a3b210097 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b210098;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b210098 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10813 .

_:79f295ad32df4ce8a18a92539c6e8a3b210100 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10878-1 a owl:Class;
  rdfs:label "ENOXACINE <-> THÉOPHYLLINE (ET, PAR EXTRAPOLATION, AMINOPHYLLINE)"@fr;
  dct:identifier "IAM_10878";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b210102;
  r:natureDuRisque "Surdosage en théophylline par diminution importante de son métabolisme."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b210108, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b210102 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b210103 .

_:79f295ad32df4ce8a18a92539c6e8a3b210103 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b210104;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b210105 .

_:79f295ad32df4ce8a18a92539c6e8a3b210104 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10152 .

_:79f295ad32df4ce8a18a92539c6e8a3b210105 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b210106;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b210106 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10323 .

_:79f295ad32df4ce8a18a92539c6e8a3b210108 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10879-1 a owl:Class;
  rdfs:label "ENTACAPONE <-> FER"@fr;
  dct:identifier "IAM_10879";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b210110;
  r:natureDuRisque "Diminution de l'absorption digestive de l'entacapone et du fer par chélation de celui-ci par l'entacapone."@fr;
  r:conduiteATenir "Prendre les sels de fer à distance de l'entacapone (plus de 2 heures si possible)."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b210116, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b210110 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b210111 .

_:79f295ad32df4ce8a18a92539c6e8a3b210111 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b210112;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b210113 .

_:79f295ad32df4ce8a18a92539c6e8a3b210112 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10325 .

_:79f295ad32df4ce8a18a92539c6e8a3b210113 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b210114;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b210114 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10375 .

_:79f295ad32df4ce8a18a92539c6e8a3b210116 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10880-1 a owl:Class;
  rdfs:label "ENZALUTAMIDE <-> GEMFIBROZIL"@fr;
  dct:identifier "IAM_10880";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b210118;
  r:natureDuRisque "Majoration de la fraction active de l’enzalutamide."@fr;
  r:conduiteATenir "Réduire la dose d’enzalutamide par deux en cas d’association au gemfibrozil."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b210124, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b210118 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b210119 .

_:79f295ad32df4ce8a18a92539c6e8a3b210119 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b210120;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b210121 .

_:79f295ad32df4ce8a18a92539c6e8a3b210120 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10326 .

_:79f295ad32df4ce8a18a92539c6e8a3b210121 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b210122;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b210122 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10411 .

_:79f295ad32df4ce8a18a92539c6e8a3b210124 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10881-1 a owl:Class;
  rdfs:label "EPLERENONE <-> INHIBITEURS DE L'ENZYME DE CONVERSION"@fr;
  dct:identifier "IAM_10881";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b210126;
  r:natureDuRisque "Majoration du risque d’hyperkaliémie, notamment chez le sujet âgé."@fr;
  r:conduiteATenir "Contrôle strict de la kaliémie et de la fonction rénale pendant l’association."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b210132, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b210126 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b210127 .

_:79f295ad32df4ce8a18a92539c6e8a3b210127 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b210128;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b210129 .

_:79f295ad32df4ce8a18a92539c6e8a3b210128 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10096 .

_:79f295ad32df4ce8a18a92539c6e8a3b210129 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b210130;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b210130 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10329 .

_:79f295ad32df4ce8a18a92539c6e8a3b210132 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10891-1 a owl:Class;
  rdfs:label "ERYTHROMYCINE <-> GLIMEPIRIDE"@fr;
  dct:identifier "IAM_10891";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b210134;
  r:natureDuRisque "Risque d'hypoglycémie par augmentation de l’absorption et des concentrations plasmatiques de l’antidiabétique."@fr;
  r:conduiteATenir "Prévenir le patient, renforcer l'autosurveillance glycémique et adapter éventuellement la posologie du sulfamide hypoglycémiant pendant le traitement par l’érythromycine."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b210140, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b210134 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b210135 .

_:79f295ad32df4ce8a18a92539c6e8a3b210135 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b210136;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b210137 .

_:79f295ad32df4ce8a18a92539c6e8a3b210136 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10338 .

_:79f295ad32df4ce8a18a92539c6e8a3b210137 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b210138;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b210138 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10416 .

_:79f295ad32df4ce8a18a92539c6e8a3b210140 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10892-1 a owl:Class;
  rdfs:label "ERYTHROMYCINE <-> IMMUNOSUPPRESSEURS"@fr;
  dct:identifier "IAM_10892";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b210142;
  r:natureDuRisque "Augmentation très importante des concentrations sanguines de l'immunosuppresseur par inhibition de son métabolisme hépatique."@fr;
  r:conduiteATenir "En cas d’association, contrôle strict de la fonction rénale, dosage des concentrations sanguines de l'immunosuppresseur et adaptation éventuelle de la posologie."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b210148, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b210142 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b210143 .

_:79f295ad32df4ce8a18a92539c6e8a3b210143 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b210144;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b210145 .

_:79f295ad32df4ce8a18a92539c6e8a3b210144 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10093 .

_:79f295ad32df4ce8a18a92539c6e8a3b210145 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b210146;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b210146 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10338 .

_:79f295ad32df4ce8a18a92539c6e8a3b210148 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10894-1 a owl:Class;
  rdfs:label "ERYTHROMYCINE <-> MIZOLASTINE"@fr;
  dct:identifier "IAM_10894";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b210150;
  r:natureDuRisque "Risque de troubles du rythme ventriculaire, notamment de torsades de pointes."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b210156, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b210150 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b210151 .

_:79f295ad32df4ce8a18a92539c6e8a3b210151 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b210152;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b210153 .

_:79f295ad32df4ce8a18a92539c6e8a3b210152 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10338 .

_:79f295ad32df4ce8a18a92539c6e8a3b210153 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b210154;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b210154 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10597 .

_:79f295ad32df4ce8a18a92539c6e8a3b210156 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10895-1 a owl:Class;
  rdfs:label "ERYTHROMYCINE <-> NINTÉDANIB"@fr;
  dct:identifier "IAM_10895";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b210158;
  r:natureDuRisque "Augmentation des concentrations plasmatiques du nintédanib par augmentation de son absorption par l'érythromycine."@fr;
  r:conduiteATenir "Surveillance clinique pendant l’association."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b210164, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b210158 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b210159 .

_:79f295ad32df4ce8a18a92539c6e8a3b210159 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b210160;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b210161 .

_:79f295ad32df4ce8a18a92539c6e8a3b210160 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10338 .

_:79f295ad32df4ce8a18a92539c6e8a3b210161 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b210162;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b210162 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10637 .

_:79f295ad32df4ce8a18a92539c6e8a3b210164 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10956-1 a owl:Class;
  rdfs:label "FLUCONAZOLE <-> RIVAROXABAN"@fr;
  dct:identifier "IAM_10956";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b210166;
  r:natureDuRisque "Augmentation des concentrations plasmatiques du rivaroxaban par le fluconazole, avec majoration du risque de saignement."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b210172, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b210166 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b210167 .

_:79f295ad32df4ce8a18a92539c6e8a3b210167 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b210168;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b210169 .

_:79f295ad32df4ce8a18a92539c6e8a3b210168 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10381 .

_:79f295ad32df4ce8a18a92539c6e8a3b210169 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b210170;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b210170 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10808 .

_:79f295ad32df4ce8a18a92539c6e8a3b210172 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10874-1 a owl:Class;
  rdfs:label "ELVITÉGRAVIR <-> ITRACONAZOLE"@fr;
  dct:identifier "IAM_10874";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b210174;
  r:natureDuRisque "Augmentation des concentrations plasmatiques d’elvitegravir par diminution de son métabolisme par l'itraconazole."@fr;
  r:conduiteATenir "Avec l’elvitegravir co-administré avec le cobicistat, surveillance clinique. Limiter la dose maximale d’itraconazole à 200 mg/j."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b210180, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b210174 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b210175 .

_:79f295ad32df4ce8a18a92539c6e8a3b210175 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b210176;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b210177 .

_:79f295ad32df4ce8a18a92539c6e8a3b210176 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10321 .

_:79f295ad32df4ce8a18a92539c6e8a3b210177 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b210178;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b210178 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10496 .

_:79f295ad32df4ce8a18a92539c6e8a3b210180 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10177-2 a owl:Class;
  rdfs:label "ANTAGONISTES DES CANAUX CALCIQUES <-> ANTICONVULSIVANTS INDUCTEURS ENZYMATIQUES"@fr;
  dct:identifier "IAM_10177";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b210182;
  r:natureDuRisque "Diminution des concentrations plasmatiques de l'antagoniste du calcium par augmentation de son métabolisme hépatique."@fr;
  r:conduiteATenir "Association déconseillée avec la nimodipine"@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b210188, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b210182 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b210183 .

_:79f295ad32df4ce8a18a92539c6e8a3b210183 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b210184;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b210185 .

_:79f295ad32df4ce8a18a92539c6e8a3b210184 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10019 .

_:79f295ad32df4ce8a18a92539c6e8a3b210185 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b210186;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b210186 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10029 .

_:79f295ad32df4ce8a18a92539c6e8a3b210188 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11096-1 a owl:Class;
  rdfs:label "INDUCTEURS ENZYMATIQUES <-> MIANSERINE"@fr;
  dct:identifier "IAM_11096";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b210190;
  r:natureDuRisque "Risque d’inefficacité de la miansérine."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b210196, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b210190 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b210191 .

_:79f295ad32df4ce8a18a92539c6e8a3b210191 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b210192;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b210193 .

_:79f295ad32df4ce8a18a92539c6e8a3b210192 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10094 .

_:79f295ad32df4ce8a18a92539c6e8a3b210193 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b210194;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b210194 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10583 .

_:79f295ad32df4ce8a18a92539c6e8a3b210196 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11208-1 a owl:Class;
  rdfs:label "IVABRADINE <-> VERAPAMIL"@fr;
  dct:identifier "IAM_11208";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b210198;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de l’ivabradine et de ses effets indésirables, notamment cardiaques (inhibition de son métabolisme hépatique par le vérapamil), qui s’ajoutent aux effets bradycardisants de ces substances."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b210204, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b210198 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b210199 .

_:79f295ad32df4ce8a18a92539c6e8a3b210199 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b210200;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b210201 .

_:79f295ad32df4ce8a18a92539c6e8a3b210200 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10497 .

_:79f295ad32df4ce8a18a92539c6e8a3b210201 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b210202;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b210202 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10980 .

_:79f295ad32df4ce8a18a92539c6e8a3b210204 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11209-1 a owl:Class;
  rdfs:label "JOSAMYCINE <-> PIMOZIDE"@fr;
  dct:identifier "IAM_11209";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b210206;
  r:natureDuRisque "Risque majoré de troubles du rythme ventriculaire, notamment de torsades de pointes."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b210212, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b210206 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b210207 .

_:79f295ad32df4ce8a18a92539c6e8a3b210207 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b210208;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b210209 .

_:79f295ad32df4ce8a18a92539c6e8a3b210208 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10499 .

_:79f295ad32df4ce8a18a92539c6e8a3b210209 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b210210;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b210210 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10721 .

_:79f295ad32df4ce8a18a92539c6e8a3b210212 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10017-2 a owl:Class;
  rdfs:label "ACIDE ACETYLSALICYLIQUE <-> CLOPIDOGREL"@fr;
  dct:identifier "IAM_10017";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b210214;
  r:natureDuRisque "Majoration du risque hémorragique par addition des activités antiagrégantes plaquettaires."@fr;
  r:conduiteATenir """Association déconseillée :
- en dehors des indications validées pour cette association dans les syndromes coronariens aigus.

Précaution d'emploi :
- dans les indications validées pour cette association dans les syndromes coronariens aigus. Surveillance c"""@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b210220, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b210214 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b210215 .

_:79f295ad32df4ce8a18a92539c6e8a3b210215 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b210216;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b210217 .

_:79f295ad32df4ce8a18a92539c6e8a3b210216 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10012 .

_:79f295ad32df4ce8a18a92539c6e8a3b210217 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b210218;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b210218 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10216 .

_:79f295ad32df4ce8a18a92539c6e8a3b210220 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10279-2 a owl:Class;
  rdfs:label "ANTI-INFLAMMATOIRES NON STÉROÏDIENS <-> PEMETREXED"@fr;
  dct:identifier "IAM_10279";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b210222;
  r:natureDuRisque "Risque de majoration de la toxicité du pemetrexed (diminution de sa clairance rénale par les AINS)."@fr;
  r:conduiteATenir """Association déconseillée : 
- en cas de fonction rénale faible à modérée.

Précaution d'emploi :
- en cas de fonction rénale normale. Surveillance biologique de la fonction rénale."""@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b210228, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b210222 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b210223 .

_:79f295ad32df4ce8a18a92539c6e8a3b210223 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b210224;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b210225 .

_:79f295ad32df4ce8a18a92539c6e8a3b210224 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10022 .

_:79f295ad32df4ce8a18a92539c6e8a3b210225 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b210226;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b210226 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10700 .

_:79f295ad32df4ce8a18a92539c6e8a3b210228 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11164-2 a owl:Class;
  rdfs:label "INHIBITEURS PUISSANTS DU CYP3A4 <-> QUININE"@fr;
  dct:identifier "IAM_11164";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b210230;
  r:natureDuRisque "Risque de majoration des effets indésirables de la quinine, notamment troubles du rythme ventriculaire et troubles neurosensoriels (cinchonisme)."@fr;
  r:conduiteATenir """Association déconseillée : 
- avec les inhibiteurs de protéases

Précaution d’emploi : 
- avec les azolés antifongiques et certains macrolides.
Surveillance clinique et ECG. Adaptation éventuelle de la posologie de la quinine pendant le traitement par l’i"""@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b210236, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b210230 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b210231 .

_:79f295ad32df4ce8a18a92539c6e8a3b210231 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b210232;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b210233 .

_:79f295ad32df4ce8a18a92539c6e8a3b210232 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10103 .

_:79f295ad32df4ce8a18a92539c6e8a3b210233 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b210234;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b210234 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10777 .

_:79f295ad32df4ce8a18a92539c6e8a3b210236 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10130-2 a owl:Class;
  rdfs:label "AMIODARONE <-> DILTIAZEM"@fr;
  dct:identifier "IAM_10130";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b210238;
  r:natureDuRisque """Pour diltiazem voie injectable : risque de bradycardie et de bloc auriculo-ventriculaire

Pour diltiazem per os : risque de bradycardie ou de bloc auriculo-ventriculaire, notamment chez les personnes âgées."""@fr;
  r:conduiteATenir """Association déconseillée avec :
- le diltiazem IV
Si l'association ne peut être évitée, surveillance clinique et ECG continu."""@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b210244, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b210238 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b210239 .

_:79f295ad32df4ce8a18a92539c6e8a3b210239 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b210240;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b210241 .

_:79f295ad32df4ce8a18a92539c6e8a3b210240 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10066 .

_:79f295ad32df4ce8a18a92539c6e8a3b210241 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b210242;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b210242 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10290 .

_:79f295ad32df4ce8a18a92539c6e8a3b210244 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10698-2 a owl:Class;
  rdfs:label "CYPROTERONE <-> INHIBITEURS DE PROTÉASES BOOSTÉS PAR RITONAVIR"@fr;
  dct:identifier "IAM_10698";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b210246;
  r:natureDuRisque "Risque de diminution de l'efficacité de la cyprotérone."@fr;
  r:conduiteATenir """Association déconseillée
- dans son utilisation comme contraceptif hormonal: utiliser de préférence une autre méthode de contraception en particulier de type mécanique, pendant la durée de l'association et un cycle suivant.

Précaution d'emploi
- dans ses"""@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b210252, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b210246 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b210247 .

_:79f295ad32df4ce8a18a92539c6e8a3b210247 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b210248;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b210249 .

_:79f295ad32df4ce8a18a92539c6e8a3b210248 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10100 .

_:79f295ad32df4ce8a18a92539c6e8a3b210249 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b210250;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b210250 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10238 .

_:79f295ad32df4ce8a18a92539c6e8a3b210252 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10911-2 a owl:Class;
  rdfs:label "ESTROPROGESTATIFS CONTRACEPTIFS <-> LAMOTRIGINE"@fr;
  dct:identifier "IAM_10911";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b210254;
  r:natureDuRisque "Risque de diminution des concentrations et de l’efficacité de la lamotrigine par augmentation de son métabolisme hépatique."@fr;
  r:conduiteATenir """Association déconseillée :
- éviter de mettre en route une contraception orale pendant la période d’ajustement posologique de la lamotrigine."""@fr;
  rdfs:comment """Deux publications d'une même équipe montrent que les contraceptifs oraux (COs) diminuent de près de moitié les concentrations plasmatiques de la lamotrigine. Le mécanisme passerait par une induction de la glucuronidation de la lamotrigine par les COs.
Dan"""@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b210260, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b210254 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b210255 .

_:79f295ad32df4ce8a18a92539c6e8a3b210255 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b210256;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b210257 .

_:79f295ad32df4ce8a18a92539c6e8a3b210256 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10073 .

_:79f295ad32df4ce8a18a92539c6e8a3b210257 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b210258;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b210258 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10507 .

_:79f295ad32df4ce8a18a92539c6e8a3b210260 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10865-1 a owl:Class;
  rdfs:label "EFAVIRENZ <-> ERGOTAMINE"@fr;
  dct:identifier "IAM_10865";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b210262;
  r:natureDuRisque "Ergotisme avec possibilité de nécrose des extrémités (inhibition du métabolisme hépatique de l'alcaloïde de l'ergot de seigle)."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b210268, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b210262 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b210263 .

_:79f295ad32df4ce8a18a92539c6e8a3b210263 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b210264;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b210265 .

_:79f295ad32df4ce8a18a92539c6e8a3b210264 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10318 .

_:79f295ad32df4ce8a18a92539c6e8a3b210265 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b210266;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b210266 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10334 .

_:79f295ad32df4ce8a18a92539c6e8a3b210268 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10836-2 a owl:Class;
  rdfs:label "DOLUTÉGRAVIR <-> INDUCTEURS ENZYMATIQUES"@fr;
  dct:identifier "IAM_10836";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b210270;
  r:natureDuRisque "Diminution des concentrations plasmatiques de dolutégravir par augmentation de son métabolisme par l’inducteur."@fr;
  r:conduiteATenir """Association déconseillée :
- en cas de résistance à la classe des inhibiteurs d'intégrase

Précaution d'emploi :
- en l'absence de résistance à la classe des inhibiteurs d'intégrase
Adaptation de la posologie de dolutégravir à 50 mg 2 fois par jour penda"""@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b210276, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b210270 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b210271 .

_:79f295ad32df4ce8a18a92539c6e8a3b210271 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b210272;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b210273 .

_:79f295ad32df4ce8a18a92539c6e8a3b210272 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10094 .

_:79f295ad32df4ce8a18a92539c6e8a3b210273 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b210274;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b210274 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10301 .

_:79f295ad32df4ce8a18a92539c6e8a3b210276 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10898-1 a owl:Class;
  rdfs:label "ERYTHROMYCINE <-> THÉOPHYLLINE (ET, PAR EXTRAPOLATION, AMINOPHYLLINE)"@fr;
  dct:identifier "IAM_10898";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b210278;
  r:natureDuRisque "Surdosage en théophylline par diminution de son élimination hépatique, plus particulièrement à risque chez l'enfant."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b210284, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b210278 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b210279 .

_:79f295ad32df4ce8a18a92539c6e8a3b210279 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b210280;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b210281 .

_:79f295ad32df4ce8a18a92539c6e8a3b210280 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10152 .

_:79f295ad32df4ce8a18a92539c6e8a3b210281 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b210282;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b210282 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10338 .

_:79f295ad32df4ce8a18a92539c6e8a3b210284 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10031-2 a owl:Class;
  rdfs:label "ACIDE ACETYLSALICYLIQUE <-> TICAGRELOR"@fr;
  dct:identifier "IAM_10031";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b210286;
  r:natureDuRisque """Majoration du risque hémorragique par addition des activités
antiagrégantes plaquettaires."""@fr;
  r:conduiteATenir """Association déconseillée :
- en dehors des indications validées pour cette association dans les syndromes coronariens aigus.

Précaution d'emploi :
- dans les indications validées pour cette association dans les syndromes coronariens aigus. Surveillance c"""@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b210292, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b210286 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b210287 .

_:79f295ad32df4ce8a18a92539c6e8a3b210287 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b210288;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b210289 .

_:79f295ad32df4ce8a18a92539c6e8a3b210288 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10012 .

_:79f295ad32df4ce8a18a92539c6e8a3b210289 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b210290;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b210290 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10926 .

_:79f295ad32df4ce8a18a92539c6e8a3b210292 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10801-2 a owl:Class;
  rdfs:label "DILTIAZEM <-> ESMOLOL"@fr;
  dct:identifier "IAM_10801";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b210294;
  r:natureDuRisque "Troubles de l'automatisme (bradycardie excessive, arrêt sinusal), troubles de la conduction sino-auriculaire et auriculo-ventriculaire et défaillance cardiaque."@fr;
  r:conduiteATenir """Association déconseillée :
- en cas d'altération de la fonction ventriculaire gauche."""@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b210300, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b210294 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b210295 .

_:79f295ad32df4ce8a18a92539c6e8a3b210295 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b210296;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b210297 .

_:79f295ad32df4ce8a18a92539c6e8a3b210296 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10290 .

_:79f295ad32df4ce8a18a92539c6e8a3b210297 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b210298;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b210298 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10341 .

_:79f295ad32df4ce8a18a92539c6e8a3b210300 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10028-2 a owl:Class;
  rdfs:label "ACIDE ACETYLSALICYLIQUE <-> PEMETREXED"@fr;
  dct:identifier "IAM_10028";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b210302;
  r:natureDuRisque "Risque de majoration de la toxicité du pemetrexed (diminution de sa clairance rénale par l’acide acétylsalicylique à doses anti-inflammatoires)."@fr;
  r:conduiteATenir """Association déconseillée : 
- en cas de fonction rénale faible à modérée .

Précaution d'emploi :
- en cas de fonction rénale normale. Surveillance biologique de la fonction rénale."""@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b210308, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b210302 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b210303 .

_:79f295ad32df4ce8a18a92539c6e8a3b210303 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b210304;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b210305 .

_:79f295ad32df4ce8a18a92539c6e8a3b210304 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10012 .

_:79f295ad32df4ce8a18a92539c6e8a3b210305 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b210306;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b210306 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10700 .

_:79f295ad32df4ce8a18a92539c6e8a3b210308 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10016-2 a owl:Class;
  rdfs:label "ACIDE ACETYLSALICYLIQUE <-> ANTI-INFLAMMATOIRES NON STÉROÏDIENS"@fr;
  dct:identifier "IAM_10016";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b210310;
  r:natureDuRisque "Majoration du risque ulcérogène et hémorragique digestif."@fr;
  r:conduiteATenir """Association déconseillée avec :
- des doses anti-inflammatoires d'acide acétylsalicylique (>=1g par prise et/ou >=3g par jour)
- des doses antalgiques ou antipyrétiques (>=500 mg par prise et/ou <3g par jour)"""@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b210316, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b210310 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b210311 .

_:79f295ad32df4ce8a18a92539c6e8a3b210311 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b210312;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b210313 .

_:79f295ad32df4ce8a18a92539c6e8a3b210312 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10022 .

_:79f295ad32df4ce8a18a92539c6e8a3b210313 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b210314;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b210314 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10012 .

_:79f295ad32df4ce8a18a92539c6e8a3b210316 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10253-2 a owl:Class;
  rdfs:label "ANTICORPS MONOCLONAUX (HORS ANTI-TNF ALPHA) <-> VACCINS VIVANTS ATTÉNUÉS"@fr;
  dct:identifier "IAM_10253";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b210318;
  r:natureDuRisque "Risque de maladie vaccinale généralisée, éventuellement mortelle."@fr;
  r:conduiteATenir """Association déconseillée avec :
- bélimumab, blinatumomab, canakinumab, obinutuzumab, ofatumumab, rituximab, tocilizumab, ustékinumab 

A prendre en compte avec :
- alemtuzumab, bevacizumab, brentuximab, cetuximab, daratumumab, dénosumab, ibritumomab, ipi"""@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b210324, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b210318 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b210319 .

_:79f295ad32df4ce8a18a92539c6e8a3b210319 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b210320;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b210321 .

_:79f295ad32df4ce8a18a92539c6e8a3b210320 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10031 .

_:79f295ad32df4ce8a18a92539c6e8a3b210321 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b210322;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b210322 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10159 .

_:79f295ad32df4ce8a18a92539c6e8a3b210324 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10730-2 a owl:Class;
  rdfs:label "DAPOXÉTINE <-> MÉDICAMENTS À L'ORIGINE D'UNE HYPOTENSION ORTHOSTATIQUE"@fr;
  dct:identifier "IAM_10730";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b210326;
  r:natureDuRisque "Risque de majoration des effets indésirables, notamment à type de vertiges ou de syncopes."@fr;
  r:conduiteATenir """Association déconseillée
- avec les inhibiteurs de la phosphodiestérase de type 5

A prendre en compte 
- avec les autres classes thérapeutiques"""@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b210332, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b210326 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b210327 .

_:79f295ad32df4ce8a18a92539c6e8a3b210327 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b210328;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b210329 .

_:79f295ad32df4ce8a18a92539c6e8a3b210328 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10122 .

_:79f295ad32df4ce8a18a92539c6e8a3b210329 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b210330;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b210330 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10250 .

_:79f295ad32df4ce8a18a92539c6e8a3b210332 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10701-2 a owl:Class;
  rdfs:label "CYPROTERONE <-> ULIPRISTAL"@fr;
  dct:identifier "IAM_10701";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b210334;
  r:natureDuRisque """Dans l'indication contraception d'urgence de l'ulipristal :
Antagonisme des effets de l’ulipristal en cas de reprise d’un contraceptif hormonal moins de 5 jours après la prise de la contraception d’urgence.

Dans l’indication fibrome de l'ulipristal :
Ant"""@fr;
  r:conduiteATenir """Association déconseillée 
Dans l'utilisation à visée contraceptive de la cyprotérone

- Dans l'indication contraception d'urgence de l'ulipristal
Dans le cas où la (re)prise d’une contraception hormonale est envisagée, utiliser une contraception additionn"""@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b210340, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b210334 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b210335 .

_:79f295ad32df4ce8a18a92539c6e8a3b210335 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b210336;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b210337 .

_:79f295ad32df4ce8a18a92539c6e8a3b210336 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10238 .

_:79f295ad32df4ce8a18a92539c6e8a3b210337 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b210338;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b210338 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10964 .

_:79f295ad32df4ce8a18a92539c6e8a3b210340 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10860-1 a owl:Class;
  rdfs:label "DULOXETINE <-> TAMOXIFENE"@fr;
  dct:identifier "IAM_10860";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b210342;
  r:natureDuRisque "Risque de baisse de l'efficacité du tamoxifène, par inhibition de la formation de son métabolite actif par la duloxetine."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b210348, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b210342 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b210343 .

_:79f295ad32df4ce8a18a92539c6e8a3b210343 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b210344;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b210345 .

_:79f295ad32df4ce8a18a92539c6e8a3b210344 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10314 .

_:79f295ad32df4ce8a18a92539c6e8a3b210345 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b210346;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b210346 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10882 .

_:79f295ad32df4ce8a18a92539c6e8a3b210348 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10861-1 a owl:Class;
  rdfs:label "EBASTINE <-> ERYTHROMYCINE"@fr;
  dct:identifier "IAM_10861";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b210350;
  r:natureDuRisque "Risque majoré de troubles du rythme ventriculaire chez les sujets prédisposés (syndrome du QT long congénital)."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b210356, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b210350 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b210351 .

_:79f295ad32df4ce8a18a92539c6e8a3b210351 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b210352;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b210353 .

_:79f295ad32df4ce8a18a92539c6e8a3b210352 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10316 .

_:79f295ad32df4ce8a18a92539c6e8a3b210353 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b210354;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b210354 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10338 .

_:79f295ad32df4ce8a18a92539c6e8a3b210356 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10862-1 a owl:Class;
  rdfs:label "EBASTINE <-> ITRACONAZOLE"@fr;
  dct:identifier "IAM_10862";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b210358;
  r:natureDuRisque "Risque majoré de troubles du rythme ventriculaire chez les sujets prédisposés (syndrome du QT long congénital)."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b210364, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b210358 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b210359 .

_:79f295ad32df4ce8a18a92539c6e8a3b210359 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b210360;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b210361 .

_:79f295ad32df4ce8a18a92539c6e8a3b210360 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10316 .

_:79f295ad32df4ce8a18a92539c6e8a3b210361 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b210362;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b210362 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10496 .

_:79f295ad32df4ce8a18a92539c6e8a3b210364 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10147-2 a owl:Class;
  rdfs:label "AMIODARONE <-> VERAPAMIL"@fr;
  dct:identifier "IAM_10147";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b210366;
  r:natureDuRisque """Pour vérapamil voie injectable :
-risque de bradycardie ou de bloc auriculo-ventriculaire.

Pour vérapamil per os :
-risque de bradycardie ou de bloc auriculo-ventriculaire, notamment chez les personnes âgées."""@fr;
  r:conduiteATenir """Association déconseillée avec :
- le vérapamil IV
Si l'association ne peut être évitée, surveillance clinique et ECG continu.

Précaution d'emploi avec :
- le vérapamil per os
Surveillance clinique et ECG."""@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b210372, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b210366 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b210367 .

_:79f295ad32df4ce8a18a92539c6e8a3b210367 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b210368;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b210369 .

_:79f295ad32df4ce8a18a92539c6e8a3b210368 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10066 .

_:79f295ad32df4ce8a18a92539c6e8a3b210369 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b210370;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b210370 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10980 .

_:79f295ad32df4ce8a18a92539c6e8a3b210372 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10934-1 a owl:Class;
  rdfs:label "FER <-> PENICILLAMINE"@fr;
  dct:identifier "IAM_10934";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b210374;
  r:natureDuRisque "Diminution de l'absorption digestive de la pénicillamine."@fr;
  r:conduiteATenir "Prendre les sels de fer à distance de la pénicillamine (plus de 2 heures, si possible)."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b210380, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b210374 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b210375 .

_:79f295ad32df4ce8a18a92539c6e8a3b210375 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b210376;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b210377 .

_:79f295ad32df4ce8a18a92539c6e8a3b210376 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10375 .

_:79f295ad32df4ce8a18a92539c6e8a3b210377 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b210378;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b210378 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10702 .

_:79f295ad32df4ce8a18a92539c6e8a3b210380 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10896-1 a owl:Class;
  rdfs:label "ERYTHROMYCINE <-> PRAVASTATINE"@fr;
  dct:identifier "IAM_10896";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b210382;
  r:natureDuRisque "Avec l'érythromycine utilisée par voie orale : augmentation de la concentration plasmatique de la pravastatine par l' érythromycine."@fr;
  r:conduiteATenir "Surveillance clinique et biologique pendant le traitement par l'antibiotique."@fr;
  rdfs:comment "La clarithromycine et l’érythromycine sont des inhibiteurs puissants du CYP3A4 et de la P-gp intestinale, transporteur qui intervient dans l’efflux de nombreux médicaments au niveau de la lumière intestinale et qui limite donc leur absorption digestive. L"@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b210388, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b210382 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b210383 .

_:79f295ad32df4ce8a18a92539c6e8a3b210383 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b210384;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b210385 .

_:79f295ad32df4ce8a18a92539c6e8a3b210384 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10338 .

_:79f295ad32df4ce8a18a92539c6e8a3b210385 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b210386;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b210386 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10748 .

_:79f295ad32df4ce8a18a92539c6e8a3b210388 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10925-1 a owl:Class;
  rdfs:label "FELBAMATE <-> PHÉNOBARBITAL (ET, PAR EXTRAPOLATION, PRIMIDONE)"@fr;
  dct:identifier "IAM_10925";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b210390;
  r:natureDuRisque "Diminution des concentrations plasmatiques et de l'efficacité du felbamate et augmentation des concentrations plasmatiques du phénobarbital, avec risque de surdosage."@fr;
  r:conduiteATenir "Surveillance clinique et contrôle des concentrations plasmatiques de phénobarbital avec adaptation de la posologie si besoin."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b210396, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b210390 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b210391 .

_:79f295ad32df4ce8a18a92539c6e8a3b210391 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b210392;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b210393 .

_:79f295ad32df4ce8a18a92539c6e8a3b210392 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10131 .

_:79f295ad32df4ce8a18a92539c6e8a3b210393 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b210394;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b210394 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10369 .

_:79f295ad32df4ce8a18a92539c6e8a3b210396 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10926-1 a owl:Class;
  rdfs:label "FELBAMATE <-> PHÉNYTOÏNE (ET, PAR EXTRAPOLATION, FOSPHÉNYTOÏNE)"@fr;
  dct:identifier "IAM_10926";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b210398;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de phénytoïne avec risque de surdosage, par inhibition de son métabolisme par le felbamate."@fr;
  r:conduiteATenir "Surveillance clinique, contrôle des concentrations plasmatiques de phénytoïne et si besoin, adaptation de sa posologie pendant le traitement par le felbamate."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b210404, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b210398 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b210399 .

_:79f295ad32df4ce8a18a92539c6e8a3b210399 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b210400;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b210401 .

_:79f295ad32df4ce8a18a92539c6e8a3b210400 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10132 .

_:79f295ad32df4ce8a18a92539c6e8a3b210401 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b210402;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b210402 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10369 .

_:79f295ad32df4ce8a18a92539c6e8a3b210404 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10927-1 a owl:Class;
  rdfs:label "FELBAMATE <-> VALPROÏQUE (ACIDE) ET, PAR EXTRAPOLATION, VALPROMIDE"@fr;
  dct:identifier "IAM_10927";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b210406;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de l'acide valproïque, avec risque de surdosage."@fr;
  r:conduiteATenir "Surveillance clinique, contrôle biologique et adaptation éventuelle de la posologie du valproate ou du valpromide pendant le traitement par le felbamate et après son arrêt."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b210412, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b210406 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b210407 .

_:79f295ad32df4ce8a18a92539c6e8a3b210407 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b210408;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b210409 .

_:79f295ad32df4ce8a18a92539c6e8a3b210408 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10160 .

_:79f295ad32df4ce8a18a92539c6e8a3b210409 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b210410;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b210410 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10369 .

_:79f295ad32df4ce8a18a92539c6e8a3b210412 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10928-1 a owl:Class;
  rdfs:label "FENTANYL <-> INHIBITEURS PUISSANTS DU CYP3A4"@fr;
  dct:identifier "IAM_10928";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b210414;
  r:natureDuRisque "Risque d'augmentation de l’effet dépresseur respiratoire de l’analgésique opiacé par légère diminution de son métabolisme hépatique."@fr;
  r:conduiteATenir "Surveillance clinique et adaptation éventuelle de la posologie de l’analgésique opiacé en cas de traitement par un inhibiteur puissant du CYP3A4."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b210420, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b210414 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b210415 .

_:79f295ad32df4ce8a18a92539c6e8a3b210415 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b210416;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b210417 .

_:79f295ad32df4ce8a18a92539c6e8a3b210416 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10103 .

_:79f295ad32df4ce8a18a92539c6e8a3b210417 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b210418;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b210418 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10374 .

_:79f295ad32df4ce8a18a92539c6e8a3b210420 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10929-1 a owl:Class;
  rdfs:label "FENTANYL <-> RIFAMPICINE"@fr;
  dct:identifier "IAM_10929";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b210422;
  r:natureDuRisque "Diminution des concentrations plasmatiques de fentanyl par augmentation de son métabolisme hépatique par la rifampicine."@fr;
  r:conduiteATenir "Préférer un autre morphinique."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b210428, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b210422 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b210423 .

_:79f295ad32df4ce8a18a92539c6e8a3b210423 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b210424;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b210425 .

_:79f295ad32df4ce8a18a92539c6e8a3b210424 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10374 .

_:79f295ad32df4ce8a18a92539c6e8a3b210425 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b210426;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b210426 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:79f295ad32df4ce8a18a92539c6e8a3b210428 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10935-1 a owl:Class;
  rdfs:label "FER <-> SELS DE FER PAR VOIE INJECTABLE"@fr;
  dct:identifier "IAM_10935";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b210430;
  r:natureDuRisque "Lipothymie, voire choc attribué à la libération rapide du fer de sa forme complexe et à la saturation de la sidérophiline."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b210436, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b210430 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b210431 .

_:79f295ad32df4ce8a18a92539c6e8a3b210431 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b210432;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b210433 .

_:79f295ad32df4ce8a18a92539c6e8a3b210432 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10164 .

_:79f295ad32df4ce8a18a92539c6e8a3b210433 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b210434;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b210434 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10375 .

_:79f295ad32df4ce8a18a92539c6e8a3b210436 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10930-1 a owl:Class;
  rdfs:label "FER <-> FLUOROQUINOLONES"@fr;
  dct:identifier "IAM_10930";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b210438;
  r:natureDuRisque "Diminution de l'absorption digestive des fluoroquinolones."@fr;
  r:conduiteATenir "Prendre les sels de fer à distance des fluoroquinolones (plus de 2 heures, si possible)."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b210444, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b210438 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b210439 .

_:79f295ad32df4ce8a18a92539c6e8a3b210439 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b210440;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b210441 .

_:79f295ad32df4ce8a18a92539c6e8a3b210440 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10075 .

_:79f295ad32df4ce8a18a92539c6e8a3b210441 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b210442;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b210442 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10375 .

_:79f295ad32df4ce8a18a92539c6e8a3b210444 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10931-1 a owl:Class;
  rdfs:label "FER <-> HORMONES THYROÏDIENNES"@fr;
  dct:identifier "IAM_10931";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b210446;
  r:natureDuRisque "Diminution de l'absorption digestive des hormones thyroïdiennes."@fr;
  r:conduiteATenir "Prendre les hormones thyroïdiennes à distance du fer (plus de 2 heures, si possible)."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b210452, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b210446 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b210447 .

_:79f295ad32df4ce8a18a92539c6e8a3b210447 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b210448;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b210449 .

_:79f295ad32df4ce8a18a92539c6e8a3b210448 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10082 .

_:79f295ad32df4ce8a18a92539c6e8a3b210449 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b210450;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b210450 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10375 .

_:79f295ad32df4ce8a18a92539c6e8a3b210452 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10923-1 a owl:Class;
  rdfs:label "EXEMESTANE <-> RIFAMPICINE"@fr;
  dct:identifier "IAM_10923";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b210454;
  r:natureDuRisque "Risque de diminution de l'efficacité de l'exemestane par augmentation de son métabolisme hépatique par l'inducteur enzymatique."@fr;
  rdfs:comment "L’exémestane est un inhibiteur de l’aromatase de structure stéroïdienne. Les résultats d'une étude d'interaction avec la rifampicine, un des plus puissants inducteurs enzymatiques, ont montré une diminution de plus de 40 % des concentrations de l'exémesta"@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b210460, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b210454 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b210455 .

_:79f295ad32df4ce8a18a92539c6e8a3b210455 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b210456;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b210457 .

_:79f295ad32df4ce8a18a92539c6e8a3b210456 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10364 .

_:79f295ad32df4ce8a18a92539c6e8a3b210457 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b210458;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b210458 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:79f295ad32df4ce8a18a92539c6e8a3b210460 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10933-1 a owl:Class;
  rdfs:label "FER <-> METHYLDOPA"@fr;
  dct:identifier "IAM_10933";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b210462;
  r:natureDuRisque "Diminution de l'absorption digestive de la méthyldopa (formation de complexes)."@fr;
  r:conduiteATenir "Prendre les sels de fer à distance de la méthyldopa (plus de deux heures, si possible)."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b210468, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b210462 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b210463 .

_:79f295ad32df4ce8a18a92539c6e8a3b210463 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b210464;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b210465 .

_:79f295ad32df4ce8a18a92539c6e8a3b210464 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10375 .

_:79f295ad32df4ce8a18a92539c6e8a3b210465 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b210466;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b210466 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10572 .

_:79f295ad32df4ce8a18a92539c6e8a3b210468 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10922-1 a owl:Class;
  rdfs:label "EVEROLIMUS <-> VERAPAMIL"@fr;
  dct:identifier "IAM_10922";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b210470;
  r:natureDuRisque "Augmentation des concentrations sanguines de l'évérolimus par diminution de son métabolisme hépatique par le vérapamil."@fr;
  r:conduiteATenir "Dosage des concentrations sanguines de l’immunosuppresseur, contrôle de la fonction rénale et adaptation de la posologie pendant l’association et après son arrêt."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b210476, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b210470 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b210471 .

_:79f295ad32df4ce8a18a92539c6e8a3b210471 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b210472;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b210473 .

_:79f295ad32df4ce8a18a92539c6e8a3b210472 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10363 .

_:79f295ad32df4ce8a18a92539c6e8a3b210473 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b210474;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b210474 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10980 .

_:79f295ad32df4ce8a18a92539c6e8a3b210476 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10936-1 a owl:Class;
  rdfs:label "FER <-> STRONTIUM"@fr;
  dct:identifier "IAM_10936";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b210478;
  r:natureDuRisque "Diminution de l'absorption digestive du strontium."@fr;
  r:conduiteATenir "Prendre le strontium à distance des sels de fer (plus de deux heures, si possible)."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b210484, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b210478 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b210479 .

_:79f295ad32df4ce8a18a92539c6e8a3b210479 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b210480;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b210481 .

_:79f295ad32df4ce8a18a92539c6e8a3b210480 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10375 .

_:79f295ad32df4ce8a18a92539c6e8a3b210481 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b210482;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b210482 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10863 .

_:79f295ad32df4ce8a18a92539c6e8a3b210484 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10937-1 a owl:Class;
  rdfs:label "FER <-> ZINC"@fr;
  dct:identifier "IAM_10937";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b210486;
  r:natureDuRisque "Diminution de l’absorption digestive du zinc par le fer."@fr;
  r:conduiteATenir "Prendre les sels de fer à distance du zinc (plus de 2 heures si possible)."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b210492, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b210486 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b210487 .

_:79f295ad32df4ce8a18a92539c6e8a3b210487 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b210488;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b210489 .

_:79f295ad32df4ce8a18a92539c6e8a3b210488 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10375 .

_:79f295ad32df4ce8a18a92539c6e8a3b210489 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b210490;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b210490 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_11005 .

_:79f295ad32df4ce8a18a92539c6e8a3b210492 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10938-1 a owl:Class;
  rdfs:label "FIBRATES <-> FIBRATES (AUTRES)"@fr;
  dct:identifier "IAM_10938";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b210494;
  r:natureDuRisque "Risque majoré d'effets indésirables à type de rhabdomyolyse et d'antagonisme pharmacodynamique entre les deux molécules."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b210496, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b210494 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10074 .

_:79f295ad32df4ce8a18a92539c6e8a3b210496 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10939-1 a owl:Class;
  rdfs:label "FIBRATES <-> INHIBITEURS DE L'HMG-COA RÉDUCTASE (STATINES)"@fr;
  dct:identifier "IAM_10939";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b210498;
  r:natureDuRisque "Risque d'addition d'effets indésirables (dose-dépendants) à type de rhabdomyolyse. En outre, avec le gemfibrozil, diminution du métabolisme de la simvastatine et de la rosuvastatine, ce qui majore le risque musculaire, ainsi que la néphrotoxicité de la ro"@fr;
  r:conduiteATenir """Contre-indication 
- entre le gemfibrozil et la simvastatine
- pour des doses de rosuvastatine de 40 mg

Association déconseillée 
- entre les autres fibrates et les autres statines 
- ne pas dépasser 10 mg de simvastatine (cette restriction de doses ne"""@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b210504, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b210498 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b210499 .

_:79f295ad32df4ce8a18a92539c6e8a3b210499 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b210500;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b210501 .

_:79f295ad32df4ce8a18a92539c6e8a3b210500 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10074 .

_:79f295ad32df4ce8a18a92539c6e8a3b210501 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b210502;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b210502 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10095 .

_:79f295ad32df4ce8a18a92539c6e8a3b210504 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10940-1 a owl:Class;
  rdfs:label "FIDAXOMICINE <-> KETOCONAZOLE"@fr;
  dct:identifier "IAM_10940";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b210506;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de la fidaxomicine."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b210512, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b210506 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b210507 .

_:79f295ad32df4ce8a18a92539c6e8a3b210507 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b210508;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b210509 .

_:79f295ad32df4ce8a18a92539c6e8a3b210508 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10378 .

_:79f295ad32df4ce8a18a92539c6e8a3b210509 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b210510;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b210510 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10501 .

_:79f295ad32df4ce8a18a92539c6e8a3b210512 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10941-1 a owl:Class;
  rdfs:label "FIDAXOMICINE <-> VERAPAMIL"@fr;
  dct:identifier "IAM_10941";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b210514;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de la fidaxomicine."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b210520, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b210514 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b210515 .

_:79f295ad32df4ce8a18a92539c6e8a3b210515 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b210516;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b210517 .

_:79f295ad32df4ce8a18a92539c6e8a3b210516 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10378 .

_:79f295ad32df4ce8a18a92539c6e8a3b210517 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b210518;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b210518 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10980 .

_:79f295ad32df4ce8a18a92539c6e8a3b210520 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10942-1 a owl:Class;
  rdfs:label "FLECAINIDE <-> MIRABÉGRON"@fr;
  dct:identifier "IAM_10942";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b210522;
  r:natureDuRisque "Augmentation des concentrations plasmatiques du flécaïnide par diminution de son métabolisme par le mirabégron."@fr;
  r:conduiteATenir "Surveillance clinique et réduction éventuelle de la posologie du flécaïnide pendant l'association."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b210528, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b210522 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b210523 .

_:79f295ad32df4ce8a18a92539c6e8a3b210523 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b210524;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b210525 .

_:79f295ad32df4ce8a18a92539c6e8a3b210524 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10380 .

_:79f295ad32df4ce8a18a92539c6e8a3b210525 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b210526;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b210526 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10591 .

_:79f295ad32df4ce8a18a92539c6e8a3b210528 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10943-1 a owl:Class;
  rdfs:label "FLECAINIDE <-> TERBINAFINE"@fr;
  dct:identifier "IAM_10943";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b210530;
  r:natureDuRisque "Risque d'augmentation des effets indésirables du flécaïnide, par diminution de son métabolisme hépatique par la terbinafine."@fr;
  r:conduiteATenir "Surveillance clinique. Si besoin, adaptation de la posologie du flécaïnide pendant le traitement par la terbinafine."@fr;
  rdfs:comment """L’effet inhibiteur enzymatique de la terbinafine sur le CYP2D6 a été suggéré sur l’observation chez 12 volontaires sains d’une diminution du métabolisme hépatique de la désipramine, marqueur de l’activité de ce cytochrome.
Afin de prendre acte de cet effe"""@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b210536, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b210530 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b210531 .

_:79f295ad32df4ce8a18a92539c6e8a3b210531 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b210532;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b210533 .

_:79f295ad32df4ce8a18a92539c6e8a3b210532 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10380 .

_:79f295ad32df4ce8a18a92539c6e8a3b210533 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b210534;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b210534 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10900 .

_:79f295ad32df4ce8a18a92539c6e8a3b210536 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10944-1 a owl:Class;
  rdfs:label "FLUCONAZOLE <-> HALOFANTRINE"@fr;
  dct:identifier "IAM_10944";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b210538;
  r:natureDuRisque "Risque majoré de troubles du rythme ventriculaires, notamment de torsades de pointes."@fr;
  r:conduiteATenir "Si cela est possible, interrompre le fluconazole. Si l'association ne peut être évitée, contrôle préalable du QT et surveillance ECG monitorée."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b210544, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b210538 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b210539 .

_:79f295ad32df4ce8a18a92539c6e8a3b210539 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b210540;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b210541 .

_:79f295ad32df4ce8a18a92539c6e8a3b210540 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10381 .

_:79f295ad32df4ce8a18a92539c6e8a3b210541 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b210542;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b210542 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10425 .

_:79f295ad32df4ce8a18a92539c6e8a3b210544 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11206-1 a owl:Class;
  rdfs:label "IVABRADINE <-> PAMPLEMOUSSE (JUS ET FRUIT)"@fr;
  dct:identifier "IAM_11206";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b210546;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de l’ivabradine et de ses effets indésirables (inhibition de son métabolisme intestinal par le pamplemousse)."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b210552, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b210546 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b210547 .

_:79f295ad32df4ce8a18a92539c6e8a3b210547 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b210548;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b210549 .

_:79f295ad32df4ce8a18a92539c6e8a3b210548 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10130 .

_:79f295ad32df4ce8a18a92539c6e8a3b210549 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b210550;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b210550 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10497 .

_:79f295ad32df4ce8a18a92539c6e8a3b210552 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10932-1 a owl:Class;
  rdfs:label "FER <-> LEVODOPA"@fr;
  dct:identifier "IAM_10932";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b210554;
  r:natureDuRisque "Diminution de l'absorption digestive de la lévodopa."@fr;
  r:conduiteATenir "Prendre les sels de fer à distance de la lévodopa (plus de 2 heures si possible)."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b210560, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b210554 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b210555 .

_:79f295ad32df4ce8a18a92539c6e8a3b210555 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b210556;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b210557 .

_:79f295ad32df4ce8a18a92539c6e8a3b210556 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10375 .

_:79f295ad32df4ce8a18a92539c6e8a3b210557 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b210558;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b210558 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10517 .

_:79f295ad32df4ce8a18a92539c6e8a3b210560 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10910-1 a owl:Class;
  rdfs:label "ESTROPROGESTATIFS CONTRACEPTIFS <-> INHIBITEURS DE PROTÉASES BOOSTÉS PAR RITONAVIR"@fr;
  dct:identifier "IAM_10910";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b210562;
  r:chapeau "Le ritonavir est désormais utilisé à la dose de 100 mg 2 fois par jour en association à un autre inhibiteur de protéase, dans le but d'augmenter de façon très significative la biodisponibilité de l'inhibiteur de protéase associé (ou boosté), ce qui permet"@fr;
  r:natureDuRisque "Risque de diminution de l'efficacité contraceptive par diminution des concentrations en contraceptif hormonal, dûe à l'augmentation de son métabolisme hépatique par le ritonavir."@fr;
  r:conduiteATenir "Utiliser de préférence une autre méthode contraceptive, en particulier de type mécanique (préservatif ou stérilet), pendant la durée de l'association et un cycle suivant."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b210568, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b210562 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b210563 .

_:79f295ad32df4ce8a18a92539c6e8a3b210563 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b210564;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b210565 .

_:79f295ad32df4ce8a18a92539c6e8a3b210564 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10073 .

_:79f295ad32df4ce8a18a92539c6e8a3b210565 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b210566;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b210566 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10100 .

_:79f295ad32df4ce8a18a92539c6e8a3b210568 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10899-1 a owl:Class;
  rdfs:label "ERYTHROMYCINE <-> VENLAFAXINE"@fr;
  dct:identifier "IAM_10899";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b210570;
  r:natureDuRisque "Augmentation des concentrations de venlafaxine avec risque de surdosage."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b210576, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b210570 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b210571 .

_:79f295ad32df4ce8a18a92539c6e8a3b210571 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b210572;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b210573 .

_:79f295ad32df4ce8a18a92539c6e8a3b210572 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10338 .

_:79f295ad32df4ce8a18a92539c6e8a3b210573 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b210574;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b210574 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10979 .

_:79f295ad32df4ce8a18a92539c6e8a3b210576 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10900-1 a owl:Class;
  rdfs:label "ERYTHROMYCINE <-> VERAPAMIL"@fr;
  dct:identifier "IAM_10900";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b210578;
  r:natureDuRisque "Bradycardie et/ou troubles de la conduction auriculo-ventriculaire, par diminution du métabolisme hépatique du vérapamil par l'érythromycine."@fr;
  r:conduiteATenir "Surveillance clinique et ECG ; s'il y a lieu, adaptation de la posologie du vérapamil pendant le traitement par l'érythromycine et après son arrêt."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b210584, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b210578 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b210579 .

_:79f295ad32df4ce8a18a92539c6e8a3b210579 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b210580;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b210581 .

_:79f295ad32df4ce8a18a92539c6e8a3b210580 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10338 .

_:79f295ad32df4ce8a18a92539c6e8a3b210581 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b210582;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b210582 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10980 .

_:79f295ad32df4ce8a18a92539c6e8a3b210584 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10902-1 a owl:Class;
  rdfs:label "ESMOLOL <-> PROPAFENONE"@fr;
  dct:identifier "IAM_10902";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b210586;
  r:natureDuRisque "Troubles de la contractilité, de l'automatisme et de la conduction (suppression des mécanismes sympathiques compensateurs)."@fr;
  r:conduiteATenir "Surveillance clinique et ECG."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b210592, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b210586 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b210587 .

_:79f295ad32df4ce8a18a92539c6e8a3b210587 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b210588;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b210589 .

_:79f295ad32df4ce8a18a92539c6e8a3b210588 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10341 .

_:79f295ad32df4ce8a18a92539c6e8a3b210589 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b210590;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b210590 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10765 .

_:79f295ad32df4ce8a18a92539c6e8a3b210592 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10903-1 a owl:Class;
  rdfs:label "ESMOLOL <-> VERAPAMIL"@fr;
  dct:identifier "IAM_10903";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b210594;
  r:natureDuRisque "Troubles de l'automatisme (bradycardie excessive, arrêt sinusal), troubles de la conduction sino-auriculaire et auriculo-ventriculaire et défaillance cardiaque."@fr;
  r:conduiteATenir """Précaution d'emploi :
- si la fonction ventriculaire gauche est normale.
Surveillance clinique et ECG."""@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b210600, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b210594 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b210595 .

_:79f295ad32df4ce8a18a92539c6e8a3b210595 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b210596;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b210597 .

_:79f295ad32df4ce8a18a92539c6e8a3b210596 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10341 .

_:79f295ad32df4ce8a18a92539c6e8a3b210597 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b210598;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b210598 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10980 .

_:79f295ad32df4ce8a18a92539c6e8a3b210600 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10904-1 a owl:Class;
  rdfs:label "ESTRAMUSTINE <-> INHIBITEURS DE L'ENZYME DE CONVERSION"@fr;
  dct:identifier "IAM_10904";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b210602;
  r:natureDuRisque "Risque de majoration des effets indésirables à type d'oedème angio-neurotique (angio-oedème)."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b210608, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b210602 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b210603 .

_:79f295ad32df4ce8a18a92539c6e8a3b210603 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b210604;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b210605 .

_:79f295ad32df4ce8a18a92539c6e8a3b210604 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10096 .

_:79f295ad32df4ce8a18a92539c6e8a3b210605 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b210606;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b210606 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10345 .

_:79f295ad32df4ce8a18a92539c6e8a3b210608 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10907-1 a owl:Class;
  rdfs:label "ESTROGÈNES NON CONTRACEPTIFS <-> TELAPREVIR"@fr;
  dct:identifier "IAM_10907";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b210610;
  r:natureDuRisque "Diminution de l'efficacité de l'estrogène."@fr;
  r:conduiteATenir "Surveillance clinique et adaptation éventuelle de la posologie du traitement hormonal pendant l'administration du télaprévir et après son arrêt."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b210616, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b210610 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b210611 .

_:79f295ad32df4ce8a18a92539c6e8a3b210611 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b210612;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b210613 .

_:79f295ad32df4ce8a18a92539c6e8a3b210612 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10072 .

_:79f295ad32df4ce8a18a92539c6e8a3b210613 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b210614;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b210614 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10887 .

_:79f295ad32df4ce8a18a92539c6e8a3b210616 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10905-1 a owl:Class;
  rdfs:label "ESTROGÈNES NON CONTRACEPTIFS <-> HORMONES THYROÏDIENNES"@fr;
  dct:identifier "IAM_10905";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b210618;
  r:natureDuRisque "Risque d'hypothyroïdie clinique en cas d'estrogénothérapie substitutive."@fr;
  r:conduiteATenir "Surveillance clinique et biologique ; adaptation éventuelle des doses de l'hormone thyroïdienne chez les femmes ménopausées prenant des estrogènes."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b210624, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b210618 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b210619 .

_:79f295ad32df4ce8a18a92539c6e8a3b210619 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b210620;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b210621 .

_:79f295ad32df4ce8a18a92539c6e8a3b210620 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10072 .

_:79f295ad32df4ce8a18a92539c6e8a3b210621 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b210622;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b210622 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10082 .

_:79f295ad32df4ce8a18a92539c6e8a3b210624 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10906-1 a owl:Class;
  rdfs:label "ESTROGÈNES NON CONTRACEPTIFS <-> OXCARBAZEPINE"@fr;
  dct:identifier "IAM_10906";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b210626;
  r:natureDuRisque "Risque de diminution de l'efficacité du traitement hormonal, par augmentation de son métabolisme hépatique par l'oxcarbazépine."@fr;
  r:conduiteATenir "Surveillance clinique et adaptation éventuelle de la posologie du traitement hormonal pendant le traitement par l'oxcarbazépine et après son arrêt."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b210632, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b210626 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b210627 .

_:79f295ad32df4ce8a18a92539c6e8a3b210627 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b210628;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b210629 .

_:79f295ad32df4ce8a18a92539c6e8a3b210628 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10072 .

_:79f295ad32df4ce8a18a92539c6e8a3b210629 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b210630;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b210630 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10674 .

_:79f295ad32df4ce8a18a92539c6e8a3b210632 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10915-1 a owl:Class;
  rdfs:label "ESTROPROGESTATIFS CONTRACEPTIFS <-> TELAPREVIR"@fr;
  dct:identifier "IAM_10915";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b210634;
  r:natureDuRisque "Risque de diminution de l'efficacité contraceptive par augmentation du métabolisme hépatique du contraceptif hormonal par le télaprévir."@fr;
  r:conduiteATenir "Utiliser une méthode contraceptive fiable, additionnelle ou alternative, pendant la durée de l'association et deux cycles suivants."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b210640, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b210634 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b210635 .

_:79f295ad32df4ce8a18a92539c6e8a3b210635 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b210636;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b210637 .

_:79f295ad32df4ce8a18a92539c6e8a3b210636 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10073 .

_:79f295ad32df4ce8a18a92539c6e8a3b210637 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b210638;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b210638 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10887 .

_:79f295ad32df4ce8a18a92539c6e8a3b210640 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10924-1 a owl:Class;
  rdfs:label "EZETIMIBE <-> FENOFIBRATE"@fr;
  dct:identifier "IAM_10924";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b210642;
  r:natureDuRisque "Risque de lithiase biliaire par augmentation de l’excrétion biliaire du cholestérol."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b210648, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b210642 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b210643 .

_:79f295ad32df4ce8a18a92539c6e8a3b210643 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b210644;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b210645 .

_:79f295ad32df4ce8a18a92539c6e8a3b210644 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10365 .

_:79f295ad32df4ce8a18a92539c6e8a3b210645 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b210646;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b210646 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10371 .

_:79f295ad32df4ce8a18a92539c6e8a3b210648 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10909-1 a owl:Class;
  rdfs:label "ESTROPROGESTATIFS CONTRACEPTIFS <-> INDUCTEURS ENZYMATIQUES"@fr;
  dct:identifier "IAM_10909";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b210650;
  r:natureDuRisque "Diminution de l'efficacité contraceptive, par augmentation du métabolisme hépatique du contraceptif hormonal par l'inducteur."@fr;
  r:conduiteATenir "Utiliser de préférence une autre méthode contraceptive, en particulier de type mécanique, pendant la durée de l'association et un cycle suivant."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b210656, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b210650 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b210651 .

_:79f295ad32df4ce8a18a92539c6e8a3b210651 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b210652;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b210653 .

_:79f295ad32df4ce8a18a92539c6e8a3b210652 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10073 .

_:79f295ad32df4ce8a18a92539c6e8a3b210653 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b210654;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b210654 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10094 .

_:79f295ad32df4ce8a18a92539c6e8a3b210656 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10955-1 a owl:Class;
  rdfs:label "FLUCONAZOLE <-> RIFAMPICINE"@fr;
  dct:identifier "IAM_10955";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b210658;
  r:natureDuRisque "Diminution des concentrations plasmatiques et de l'efficacité du fluconazole par augmentation de son métabolisme par la rifampicine."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b210664, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b210658 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b210659 .

_:79f295ad32df4ce8a18a92539c6e8a3b210659 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b210660;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b210661 .

_:79f295ad32df4ce8a18a92539c6e8a3b210660 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10381 .

_:79f295ad32df4ce8a18a92539c6e8a3b210661 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b210662;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b210662 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:79f295ad32df4ce8a18a92539c6e8a3b210664 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10911-1 a owl:Class;
  rdfs:label "ESTROPROGESTATIFS CONTRACEPTIFS <-> LAMOTRIGINE"@fr;
  dct:identifier "IAM_10911";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b210666;
  r:natureDuRisque "Risque de diminution des concentrations et de l’efficacité de la lamotrigine par augmentation de son métabolisme hépatique."@fr;
  r:conduiteATenir """Précaution d'emploi :
- surveillance clinique et adaptation de la posologie de la lamotrigine lors de la mise en route d’une contraception orale et après son arrêt."""@fr;
  rdfs:comment """Deux publications d'une même équipe montrent que les contraceptifs oraux (COs) diminuent de près de moitié les concentrations plasmatiques de la lamotrigine. Le mécanisme passerait par une induction de la glucuronidation de la lamotrigine par les COs.
Dan"""@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b210672, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b210666 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b210667 .

_:79f295ad32df4ce8a18a92539c6e8a3b210667 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b210668;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b210669 .

_:79f295ad32df4ce8a18a92539c6e8a3b210668 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10073 .

_:79f295ad32df4ce8a18a92539c6e8a3b210669 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b210670;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b210670 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10507 .

_:79f295ad32df4ce8a18a92539c6e8a3b210672 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10912-1 a owl:Class;
  rdfs:label "ESTROPROGESTATIFS CONTRACEPTIFS <-> MILLEPERTUIS"@fr;
  dct:identifier "IAM_10912";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b210674;
  r:natureDuRisque "Diminution des concentrations plasmatiques du contraceptif hormonal, en raison de l'effet inducteur enzymatique du millepertuis, avec risque de baisse d'efficacité voire d'annulation de l'effet dont les conséquences peuvent être éventuellement graves (sur"@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b210680, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b210674 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b210675 .

_:79f295ad32df4ce8a18a92539c6e8a3b210675 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b210676;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b210677 .

_:79f295ad32df4ce8a18a92539c6e8a3b210676 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10073 .

_:79f295ad32df4ce8a18a92539c6e8a3b210677 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b210678;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b210678 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10588 .

_:79f295ad32df4ce8a18a92539c6e8a3b210680 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10913-1 a owl:Class;
  rdfs:label "ESTROPROGESTATIFS CONTRACEPTIFS <-> MODAFINIL"@fr;
  dct:identifier "IAM_10913";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b210682;
  r:natureDuRisque "Risque de diminution de l’efficacité contraceptive, pendant le traitement et un cycle après l’arrêt du traitement par le modafinil, en raison de son potentiel inducteur enzymatique."@fr;
  r:conduiteATenir "Utiliser des contraceptifs oraux normodosés ou une autre méthode contraceptive."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b210688, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b210682 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b210683 .

_:79f295ad32df4ce8a18a92539c6e8a3b210683 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b210684;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b210685 .

_:79f295ad32df4ce8a18a92539c6e8a3b210684 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10073 .

_:79f295ad32df4ce8a18a92539c6e8a3b210685 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b210686;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b210686 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10599 .

_:79f295ad32df4ce8a18a92539c6e8a3b210688 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10914-1 a owl:Class;
  rdfs:label "ESTROPROGESTATIFS CONTRACEPTIFS <-> RUFINAMIDE"@fr;
  dct:identifier "IAM_10914";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b210690;
  r:natureDuRisque "Diminution modérée des concentrations d’éthinylestradiol."@fr;
  r:conduiteATenir "Utiliser de préférence une autre méthode contraceptive, en particulier de type mécanique."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b210696, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b210690 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b210691 .

_:79f295ad32df4ce8a18a92539c6e8a3b210691 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b210692;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b210693 .

_:79f295ad32df4ce8a18a92539c6e8a3b210692 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10073 .

_:79f295ad32df4ce8a18a92539c6e8a3b210693 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b210694;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b210694 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10818 .

_:79f295ad32df4ce8a18a92539c6e8a3b210696 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10916-1 a owl:Class;
  rdfs:label "ESTROPROGESTATIFS CONTRACEPTIFS <-> TOPIRAMATE"@fr;
  dct:identifier "IAM_10916";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b210698;
  r:natureDuRisque "Pour des doses de topiramate >= 200 mg/jour : Risque de diminution de l’efficacité contraceptive par diminution des concentrations en estrogène."@fr;
  r:conduiteATenir "Utiliser de préférence une autre méthode contraceptive, en particulier de type mécanique."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b210704, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b210698 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b210699 .

_:79f295ad32df4ce8a18a92539c6e8a3b210699 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b210700;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b210701 .

_:79f295ad32df4ce8a18a92539c6e8a3b210700 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10073 .

_:79f295ad32df4ce8a18a92539c6e8a3b210701 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b210702;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b210702 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10941 .

_:79f295ad32df4ce8a18a92539c6e8a3b210704 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10917-1 a owl:Class;
  rdfs:label "ESTROPROGESTATIFS CONTRACEPTIFS <-> ULIPRISTAL"@fr;
  dct:identifier "IAM_10917";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b210706;
  r:natureDuRisque "Risque d'antagonisme des effets du progestatif."@fr;
  r:conduiteATenir "Utiliser une méthode contraceptive additionnelle de type mécanique pendant quelques jours après l’arrêt de l’ulipristal."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b210712, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b210706 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b210707 .

_:79f295ad32df4ce8a18a92539c6e8a3b210707 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b210708;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b210709 .

_:79f295ad32df4ce8a18a92539c6e8a3b210708 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10073 .

_:79f295ad32df4ce8a18a92539c6e8a3b210709 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b210710;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b210710 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10964 .

_:79f295ad32df4ce8a18a92539c6e8a3b210712 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10918-1 a owl:Class;
  rdfs:label "ESTROPROGESTATIFS CONTRACEPTIFS <-> VÉMURAFÉNIB"@fr;
  dct:identifier "IAM_10918";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b210714;
  r:natureDuRisque "Risque de diminution des concentrations des estroprogestatifs, avec pour conséquence un risque d’inefficacité."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b210720, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b210714 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b210715 .

_:79f295ad32df4ce8a18a92539c6e8a3b210715 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b210716;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b210717 .

_:79f295ad32df4ce8a18a92539c6e8a3b210716 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10073 .

_:79f295ad32df4ce8a18a92539c6e8a3b210717 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b210718;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b210718 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10978 .

_:79f295ad32df4ce8a18a92539c6e8a3b210720 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10919-1 a owl:Class;
  rdfs:label "ETHINYLESTRADIOL <-> ÉTORICOXIB"@fr;
  dct:identifier "IAM_10919";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b210722;
  r:natureDuRisque "Augmentation des concentrations d’éthinylestradiol par l’étoricoxib."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b210728, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b210722 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b210723 .

_:79f295ad32df4ce8a18a92539c6e8a3b210723 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b210724;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b210725 .

_:79f295ad32df4ce8a18a92539c6e8a3b210724 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10351 .

_:79f295ad32df4ce8a18a92539c6e8a3b210725 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b210726;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b210726 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10359 .

_:79f295ad32df4ce8a18a92539c6e8a3b210728 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10920-1 a owl:Class;
  rdfs:label "ETHINYLESTRADIOL <-> OMBITASVIR + PARITAPRÉVIR"@fr;
  dct:identifier "IAM_10920";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b210730;
  r:natureDuRisque "Augmentation de l’hépatotoxicité."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b210736, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b210730 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b210731 .

_:79f295ad32df4ce8a18a92539c6e8a3b210731 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b210732;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b210733 .

_:79f295ad32df4ce8a18a92539c6e8a3b210732 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10128 .

_:79f295ad32df4ce8a18a92539c6e8a3b210733 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b210734;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b210734 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10351 .

_:79f295ad32df4ce8a18a92539c6e8a3b210736 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10921-1 a owl:Class;
  rdfs:label "EVEROLIMUS <-> INHIBITEURS DE L'ENZYME DE CONVERSION"@fr;
  dct:identifier "IAM_10921";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b210738;
  r:natureDuRisque "Majoration du risque d’angio-oedème"@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b210744, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b210738 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b210739 .

_:79f295ad32df4ce8a18a92539c6e8a3b210739 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b210740;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b210741 .

_:79f295ad32df4ce8a18a92539c6e8a3b210740 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10096 .

_:79f295ad32df4ce8a18a92539c6e8a3b210741 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b210742;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b210742 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10363 .

_:79f295ad32df4ce8a18a92539c6e8a3b210744 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10908-1 a owl:Class;
  rdfs:label "ESTROPROGESTATIFS CONTRACEPTIFS <-> GRISEOFULVINE"@fr;
  dct:identifier "IAM_10908";
  owl:equivalentClass _:79f295ad32df4ce8a18a92539c6e8a3b210746;
  r:natureDuRisque "Risque de diminution de l'efficacité contraceptive par augmentation de son métabolisme hépatique."@fr;
  r:conduiteATenir "Utiliser de préférence une autre méthode contraceptive, en particulier de type mécanique, pendant la durée de l'association et un cycle suivant."@fr;
  rdfs:subClassOf _:79f295ad32df4ce8a18a92539c6e8a3b210752, r:Interaction .

_:79f295ad32df4ce8a18a92539c6e8a3b210746 a owl:Class;
  owl:intersectionOf _:79f295ad32df4ce8a18a92539c6e8a3b210747 .

_:79f295ad32df4ce8a18a92539c6e8a3b210747 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b210748;
  rdf:rest _:79f295ad32df4ce8a18a92539c6e8a3b210749 .

_:79f295ad32df4ce8a18a92539c6e8a3b210748 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10073 .

_:79f295ad32df4ce8a18a92539c6e8a3b210749 rdf:first _:79f295ad32df4ce8a18a92539c6e8a3b210750;
  rdf:rest rdf:nil .

_:79f295ad32df4ce8a18a92539c6e8a3b210750 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10422 .

_:79f295ad32df4ce8a18a92539c6e8a3b210752 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .
